<SEC-DOCUMENT>0001558370-23-004468.txt : 20230323
<SEC-HEADER>0001558370-23-004468.hdr.sgml : 20230323
<ACCEPTANCE-DATETIME>20230323165027
ACCESSION NUMBER:		0001558370-23-004468
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230323
DATE AS OF CHANGE:		20230323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TELA Bio, Inc.
		CENTRAL INDEX KEY:			0001561921
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				455320061
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39130
		FILM NUMBER:		23756852

	BUSINESS ADDRESS:	
		STREET 1:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-320-2930

	MAIL ADDRESS:	
		STREET 1:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tela-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/23/2023 8:23:32 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: 17693f42-4241-4bac-8b7c-ab704c2aad24 -->

  <html xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:tela="http://www.telabio.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" xs:nil="true" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" name="us-gaap:PreferredStockValue" id="Hidden_zB0Ls2B_l0i5ZHo4irGruQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" xs:nil="true" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" name="us-gaap:PreferredStockValue" id="Hidden_jSt6V58rQUeFCid3YD_e2Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Dui_H_slDEazZiYT0YHI6Q">2.72</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_a3N_SAKM90S-ydoFe7MfqQ">2.30</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_YJBwTeTqC02MfB4Us1UtcA">2.23</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_jUVfzJ5Sc0ip__me3EABkg">16267678</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_ybHydbmMGk2ngdR2CI-iww">14473213</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_8VqSOiw77EycX_RI-uX-cQ">12934421</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" xs:nil="true" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Hidden__Xg7yEHRTkaf1AHzKKzaFA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Hidden_9o4WxlJ-z0CC9U7RFAF0Vg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" xs:nil="true" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Hidden_B8cBHWhtUUWKXvY0U7DfHQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" id="Hidden_N7lFaWJk4UioTzyN62omEA">400000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" id="Hidden_KtzSWTvEJkCOw76-3Skdsg">400000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" id="Hidden_M4WVaq1GFEm8sYjSSs7jbA">400000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" id="Hidden_BsVw2TEmt0uc2rx2gi65UA">400000</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_vMwv7HGAZk6VxBh2MfXhWQ" name="tela:ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" id="Hidden_aX4OvrC5tUqVcgWeJXKlnQ">P60D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityCentralIndexKey" id="Tc_rKXQMDmP00aRa18PBVAa8w_2_1">0001561921</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:DocumentFiscalYearFocus" id="Tc_hzB1q1YSYEiJDEroT_bU-Q_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:DocumentFiscalPeriodFocus" id="Tc_5iMlW-_WEEa-Jp8pcy0Mcg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:AmendmentFlag" id="Tc_P3vhrBSqnEuXqVS43nuKhA_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_tmVXD74xzkigULe3TP8B-Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_m5PUSyBzVUWzcfWCUvycBQ">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_O-RcgO7O50aNxn4SsWFhrQ">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_XxtxzYXVGkCewipeasalog">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tela-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__0NqwDOnU069qrqDweDq7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6jS7FaWS5k2vBIexrI3UwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cMdTTyP7gEeGyUNTqvLRNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Joj3v_81eEyOiZcwVgt7eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8Dc-5nKCK0aFZB4G6pHLtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v61EXnBz5UOMTIqvTTVxlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GnrH2KSZPUexCDzLyVUgWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N7ZqSLBpBkC2dB9n5qsheQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BALcPEf8f06_ByU0A3la0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__z1HrlyAiEeZoN2ntN1wdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mI1Et8gIm0OdOoNeRu_ZkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6I5vqtHVrke8eqs2gI250A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZbaHak272kytCiOj7lO8ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-N1PP0dpzE6v3HICXjB5NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ngCQpjdcvk-SsVBsAtLEbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w6UDjR_eTEagY1f1G_onNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_e7ixSa7Av0qDAVrov1S1Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lJzbq-J-nEOX--0ZNtWiug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:SecondUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_apjFPhUEQUmSn47rVbBhIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_YKvVJdoCfU6XG4kpRDTKPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_P49kb58aeUOwJ9BHNFx0Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_5nSnl9FMqkyjoV_-oqlcRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_0ySqKDuji0e0ER6NBbeSnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_L9eLKsRNw0CRO-mST_AJQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OvitexPrsMember_L3BIDNF6OES8ZPhVA4kbNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexPrsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OvitexMember_EdbT9Stg4kukXsfXOaqw7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OtherCustomersMember_jNrO6oj7BUi2tHp_zIcW1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tela_OvitexPrsMember_65VAhesxikuTOSd3VYTV5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexPrsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tela_OvitexMember_KoD1LsmYCUi3vu5Gf7IEhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tela_OvitexPrsMember_633JkzTN7k-JMFLDXqSR6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexPrsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tela_OvitexMember_g62SfrjEtkKrRkIEyjjV_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_CollagenMatrixInc.Member_1Pkcz42t1Ey6xw6VGMm4YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:CollagenMatrixInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_L6OtipUKj0WBTkfRIZ9BCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_hqviTa-18kW6leCDSegk5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_dMZmT2GGWEeog6Ay7w1DVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_OELAYKjFM02OmAHs-BXhFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mPjPPo5jm0CMb8H3SqPEdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_kFCoP67BGk6_GGyzDE7erQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_1rGYh_LT7ki_OPiUFup5XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_4PvHI75_kUy1koIiD7H3FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_jpLtYA4OHkmQ_qtVIb5JZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_T7ZsTtnwJUu8lL-B2AMf1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_T-vzareBQk2hQt3aejgflA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_BaYfUZMFFkC1bk-Vne9zAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lQEEIhyvLUeG6RwD_4RFTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:SecondUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IVbed4JzJkGCxrAyFbPuzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_loDUZPMImEmoouzBKpBYYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SOs1kkyXi0abe8ZkOi1Ztg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_v9zeKR1og0GICgO2UBJLYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_nh_rYZ3xKUOudm_jXKbwPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_A9GP45d3REOrEZcQtCpqQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_rkR5ymX8o0ef8OoHXSVS1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gvnas9QAp02vVM237t3iyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qV52jkzrGkyM3BjDcW7aFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__lbPSe6rPkKCFW4tp1NNww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_kMDohVy_8EGHSodUA1iG_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_8Fc2PFOc2keKSCoCf2k64w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_KxwryCVlz0irzGqrcf7T9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_ijh9r7V11UmJJurC5JZr8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_pOKNe1MZo0aFsxEbEdiunQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheTwoMember_b-6HOZChpUeQzYJXQLel8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoansTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheOneMember_yI91ExdwXUG56squ0fq2vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoansTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_Kaoof9Egs0ivKLTiFF4Y9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_jCqHr9goH0iWw09Jjit7ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheTwoMember_UJdzkLGJCk6Gx_nvGHVbIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoanTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheOneMember_HRhYP45vYUW4DEuuKEzNbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoanTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_h_H8pqMUMUyTw6VdKGsnwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_tela_OrbimedTermLoanMember_pkFbA7Mc-UqsKDpK3kA_6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_BMBZkylIyUmOoB5qEBh2iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_QykfsvRGv0WxqJJfvminqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_CHZHq7ZTvEK6xqdLmH_vew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tela:CommonStockWarrantsExpiringIn2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member_TigqdE4b6kOc3r-MRIqDcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tela:CommonStockWarrantsExpiringIn2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_PGJ1GKO4r0m8-XWNlJhlug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Aei9Npet1Ea_GR9b8r2LiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_tv04xB9wqEaTQH96wyjNIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_rqhtk_S59EqxwFA-juI72g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_E9meB2rtA0C78Kyfm-g3Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tela:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_pRF4sUzZHkaM1gci9cPj_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cI7QGTXY5USeztjg0obgqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_sM9LuqJ1i0q0bgc5PtaRTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tela:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_UGImw1N6L0mZ0fnBk-7tDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_0cVBhli_GUqVg00WCdCr8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tela:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_YSX6qeqpOEafTWL95y7zgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_9qJHl78Mt0qRtojolu34eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_qb-xC0ZM6EmvUL8LzpWnCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wDi4dsqi-EqOxKJ9dizz-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_idpfOALz2UiyklGl9EYKzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_8-eGjFS6uU6hiVBVgeYbig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7uFgx_FdS0ODpYTmtHXo-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qXTrNzsEgEG6lcTM1Mz12g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_9XvGvd6jPkaCSiqkj9Sjcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZOR2THAP1EyzyW3OgaAWLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_L98p-_WvLky1L5Gl_Pz7mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_xGKYdmhTDE2zwVT9engEmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_5WQ0HWHJy0GEHABnWD88Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_DFSh0vmZ7ES3xBh8RnpMfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_bNi-UjogoEuFoyrMYtfZFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_WrQWz5vLr0aUSSjLYF2vLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_X-lkTg0yAk6A3AzjollXfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_OtherSuppliersForExclusivityRightsMember_nti7PndlCEqpmp9aOi8sDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:OtherSuppliersForExclusivityRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2012_To_8_31_2012_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_5TQp0DFf-kq_QSMl5v0gog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-08-01</xbrli:startDate><xbrli:endDate>2012-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_EuropeMember_P4ROvIxkZ0GJPalY78p2MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_vMwv7HGAZk6VxBh2MfXhWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_SecondYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_z5Xo6mvHC0uadpbBdDSOsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tela:SecondYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_ThirdYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_LQmV-QrJjEGKWrU-HuZaaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tela:ThirdYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_FirstYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Fa-0d26vSUuUMMIob5eqFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tela:FirstYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_NextScienceMember_LkcT3sf4w0qZZyV6NqpeQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:NextScienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_CollagenMatrixInc.Member_dYLoJZtTSE2udKKQ9CsaEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:CollagenMatrixInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_5UcmEJq_IkSYYQljqHnZxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2019_To_11_30_2019_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_2L7PdrGMqki5LBBGmf_Rew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_26_2022_To_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_7alFNq9WVkudCwmmXa7QyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-26</xbrli:startDate><xbrli:endDate>2022-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_0PuV96OlxUKqwMyunu8Gaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_pbxz9JD2tEuMD0Bp4A1EmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_SAt9gqyaqUqRNPZ9FC6LyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tela:CommonStockWarrantsExpiringIn2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member__U-R7Y6xF0uM61E9PpKfaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tela:CommonStockWarrantsExpiringIn2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_QT0qfYviYU6Qkgg2H5pTKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_pYoDsd8Lak-sf5zkcqJ-0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_iop3vfvQHEOwxPOcSV8riA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2023_0OZ9Jh7WtUahPhIJykFOTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561921</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item__TJFBDNbO0SDXs4XkYl9ag"><xbrli:measure>tela:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_taD5b-wNNkeDwJocY19qDA"><xbrli:measure>tela:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_I8CJGHwyyEWw2nQXigOSaQ"><xbrli:measure>tela:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:7.2pt;min-height:43.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5991476c_bd2d_4166_b99a_9282adaaddf2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">UNITED STATES</b><b style="font-size:12pt;font-weight:bold;"><br /></b><b style="font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Washington,&#160;D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:DocumentType" id="Narr_D4p_0D7tkEqfWz50dW_x_A"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><a id="_81d732e2_57a9_49ba_a21b_30ae564fbb3f"></a><a id="Tc_iHWgIHf6qEG4Sb7gbpQfFg_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:DocumentAnnualReport" id="Tc_EiPPGKvZGEqrL7kRblQ2CA_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:DocumentPeriodEndDate" id="Narr_OAsSO_D0g0-WzzFZbtVfkw"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:CurrentFiscalYearEndDate" id="Narr_z8xdw1CDxkq8gXjqOYnIVA"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_88a09155_0373_4925_8ac7_700fbc2e83e7"></a><a id="Tc_Mmm_t42G00SIVDo5-sSf7Q_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:DocumentTransitionReport" id="Tc_iGIFd_OALk2n9XKicb52EA_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">For the transition period from to </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityFileNumber" id="Narr_8_K1qUorrEObamIxtfzSrg"><b style="font-size:8pt;font-weight:bold;">001-39130</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityRegistrantName" id="Narr_wvqyyMw6-k2xQmdMxLrs3Q"><b style="font-weight:bold;">TELA Bio, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Exact name of registrant as specified in its charter)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityIncorporationStateCountryCode" id="Narr_kcnoPXK2zU2Ejed2okjPPA"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">(State or other jurisdiction of<br />incorporation or organization)</p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityTaxIdentificationNumber" id="Narr_EqryBgsORUWtHKdeahj4BA"><b style="font-size:8pt;font-weight:bold;">45-5320061</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer<br />Identification Number)&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityAddressAddressLine1" id="Narr_EPQfRe2Ju0O-J_4E50F0Dw"><b style="font-size:8pt;font-weight:bold;">1 Great Valley Parkway, Suite 24</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityAddressCityOrTown" id="Narr_g79tsNxr3k2eMmCgt1QypQ"><b style="font-size:8pt;font-weight:bold;">Malvern</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityAddressStateOrProvince" id="Narr_EU7-gKkW7kmq8pEd1evGnQ"><b style="font-size:8pt;font-weight:bold;">Pennsylvania</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityAddressPostalZipCode" id="Narr_P6IgoVyJDE-f3kQnCYggXA"><b style="font-size:8pt;font-weight:bold;">19355</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Zip Code)&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:CityAreaCode" id="Narr_nyMYUr7OrE6-FZL92X-GFA"><b style="font-size:8pt;font-weight:bold;">484</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:LocalPhoneNumber" id="Narr_-Gys4a0rDUCOxyTgglFmIw"><b style="font-size:8pt;font-weight:bold;">320-2930</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"><br /></b><span style="font-size:8pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_485bb2cd_8785_49b4_8545_6c131b9f5beb"></a><a id="Tc_eo_qi_ZoHEWzbn1IA1aPIQ_1_0"></a><a id="Tc_d1-_Y9_SkE2JogBv9PgMOg_1_2"></a><a id="Tc_nhE1pKs1e0m4ikJcO1Y_-Q_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:28.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:31.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:37.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class:</b></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:28.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:Security12bTitle" id="Tc_g7uIua4pwEyy7KjlL9f7uw_2_0"><span style="font-size:8pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:28.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:TradingSymbol" id="Tc_YCANGCFP20WAnoLeOBeINQ_2_2"><span style="font-size:8pt;">TELA</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:31.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:SecurityExchangeName" id="Tc_sGe2Hj_sRkuBDkjI_nuZ4Q_2_4"><span style="font-size:8pt;">The Nasdaq Global Market </span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act: None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> Yes </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_FxnUvJvebEO_Sxer2KNUew"><span style="font-size:8pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> Yes </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityVoluntaryFilers" id="Narr_n2jcBvsWc0yKNtP6K4E6pQ"><span style="font-size:8pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityCurrentReportingStatus" id="Narr_otlHf5r8lU-YdKAld9k_0w"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityInteractiveDataCurrent" id="Narr_kU64A6lBWka8_MBQUDBptQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> No</span><span style="font-family:'Wingdings';font-size:8pt;"> </span><span style="font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Large accelerated filer <span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Accelerated filer <span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company </span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntitySmallBusiness" id="Narr_IDH56jibz0yGDLX_-doeWg"><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityFilerCategory" id="Narr_9xbIZ3e1TEeJHYmvDbXcoQ"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityEmergingGrowthCompany" id="Narr_rhq-_hN2BEyOPvULcmaczw"><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityExTransitionPeriod" id="Narr_O3YPqZo1A0e6UR-9YrTPQg"><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:IcfrAuditorAttestationFlag" id="Narr_R5Yvmpi74UqlFHO-zbhnrw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-indent:36pt;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-indent:36pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:EntityShellCompany" id="Narr_b3p4s00BKU-6fTaKI6Di9g"><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-indent:36pt;margin:0pt;">As of June 30, 2022 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2022_iop3vfvQHEOwxPOcSV8riA" decimals="-5" name="dei:EntityPublicFloat" id="Narr_gKxQVkFfBUCMrSnaD9XR6w">54.4</ix:nonFraction> million based on the closing price of the common stock as reported on the NASDAQ Global Market on June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">As of March 16, 2023, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_16_2023_0OZ9Jh7WtUahPhIJykFOTA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_ouQdZNFZFE2FAbMPGuQRZw">19,216,821</ix:nonFraction> shares of Common Stock, $0.001 par value per share, outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8pt;text-align:center;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Portions of the definitive proxy statement to be filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) for TELA Bio&#8217;s 2023 annual meeting of stockholders are incorporated by reference into Part III of this Form 10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e9e744f2_6a5e_4e7f_8fe5_445f3ee767a0"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Item No.</b></p></td><td style="vertical-align:bottom;width:78.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page No.</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><a href="#PARTI_291637"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM1BUSINESS_796317"><span style="font-style:normal;font-weight:normal;">ITEM 1.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM1BUSINESS_796317"><span style="font-style:normal;font-weight:normal;">BUSINESS</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM1ARISKFACTORS_798482"><span style="font-style:normal;font-weight:normal;">ITEM 1A.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM1ARISKFACTORS_798482"><span style="font-style:normal;font-weight:normal;">RISK FACTORS</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_265117"><span style="font-style:normal;font-weight:normal;">ITEM 1B.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_265117"><span style="font-style:normal;font-weight:normal;">UNRESOLVED STAFF COMMENTS</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM2PROPERTIES_264380"><span style="font-style:normal;font-weight:normal;">ITEM 2.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM2PROPERTIES_264380"><span style="font-style:normal;font-weight:normal;">PROPERTIES</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM3LEGALPROCEEDINGS_49550"><span style="font-style:normal;font-weight:normal;">ITEM 3.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM3LEGALPROCEEDINGS_49550"><span style="font-style:normal;font-weight:normal;">LEGAL PROCEEDINGS</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_57184"><span style="font-style:normal;font-weight:normal;">ITEM 4.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_57184"><span style="font-style:normal;font-weight:normal;">MINE SAFETY DISCLOSURES</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><a href="#PARTII_672268"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM5MARKETFORREGISTRANTSSCOMMONEQUITY_9"><span style="font-style:normal;font-weight:normal;">ITEM 5.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM5MARKETFORREGISTRANTSSCOMMONEQUITY_9"><span style="font-style:normal;font-weight:normal;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM6SELECTEDCONSOLIDATEDFINANCIALDATA_6"><span style="font-style:normal;font-weight:normal;">ITEM 6.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM6SELECTEDCONSOLIDATEDFINANCIALDATA_6"><span style="font-style:normal;font-weight:normal;">[RESERVED]</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSIS_41"><span style="font-style:normal;font-weight:normal;">ITEM 7.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSIS_41"><span style="font-style:normal;font-weight:normal;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">ITEM 7A.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">ITEM 8.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">ITEM 9.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_737107"><span style="font-style:normal;font-weight:normal;">ITEM 9A.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_737107"><span style="font-style:normal;font-weight:normal;">CONTROLS AND PROCEDURES</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM9BOTHERINFORMATION_654168"><span style="font-style:normal;font-weight:normal;">ITEM 9B.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM9BOTHERINFORMATION_654168"><span style="font-style:normal;font-weight:normal;">OTHER INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM9CDISCLOSUREREGARDING_316875"><span style="font-style:normal;font-weight:normal;">ITEM 9C.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM9CDISCLOSUREREGARDING_316875"><span style="font-style:normal;font-weight:normal;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><a href="#PARTIII_936646"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">ITEM 10.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_214372"><span style="font-style:normal;font-weight:normal;">ITEM 11.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_214372"><span style="font-style:normal;font-weight:normal;">EXECUTIVE COMPENSATION</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">ITEM 12.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">ITEM 13.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">ITEM 14.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><a href="#PARTIV_994849"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-style:normal;font-weight:normal;">ITEM 15.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-style:normal;font-weight:normal;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">94</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item16Form10kSummary"><span style="font-style:normal;font-weight:normal;">ITEM 16.</span></a></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item16Form10kSummary"><span style="font-style:normal;font-weight:normal;">FORM 10-K SUMMARY</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">94</p></td></tr><tr><td style="vertical-align:top;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:78.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#EXHIBITINDEX_560009"><span style="font-style:normal;font-weight:normal;">EXHIBIT INDEX</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">95</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#SIGNATURES_181481"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">98</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3134aba_7b43_4c6d_a16c_81fd80437eb9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) and the documents incorporated by reference herein contain &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, we may, through our officers and other authorized representatives, make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our communications with our stockholders.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forward-looking statements are neither statements of historical facts nor assurances of future performance, but instead discuss the future of our business, operations, future financial performance, future financial condition, plans, anticipated growth strategies, anticipated or perceived trends in our business, the industry in which we operate or the broader economy, and other objectives of management. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; the negative of such terms, and other similar expressions although not all forward-looking statements contain these identifying words.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ongoing and possible future effects arising from the COVID-19 pandemic, or other pandemics, epidemics or outbreaks of a contagious illness, and associated economic disruptions, including the frequency of surgical procedures using our products, labor and hospital staffing shortages, supply chain integrity, and inflation, impacting our business, financial condition, results of operations and cash flows;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates regarding future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commercial success and the degree of market acceptance of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to expand, manage and maintain our direct sales and marketing organization and to market and sell our products in the U.S. and Europe;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance of our exclusive contract manufacturer for our OviTex portfolio products, Aroa Biosurgery Ltd. (&#8220;Aroa&#8221;), in connection with the supply of product and in the development of additional products and product configurations within these product lines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain our supply chain integrity and expand our supply chain to manage increased demand for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete successfully with larger competitors in our highly competitive industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve and maintain adequate levels of coverage or reimbursement for our current products and any future products we may seek to commercialize; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enhance our products, expand our indications and develop and commercialize additional products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development, regulatory approval, efficacy and commercialization of competing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our business model and strategic plans for our products, technologies and business, including our implementation thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the markets for our current and future products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain senior management and other highly qualified personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain additional capital to finance our planned operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain regulatory approval for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreasing selling prices and pricing pressures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the U.S. and European markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential impact of healthcare reform in the United States, including the Inflation Reduction Act of 2022, and measures being taken worldwide designed to reduce healthcare costs;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the volatility of capital markets and other adverse macroeconomic factors, including due to inflationary pressures, economic slowdown or recession, banking instability, geopolitical tensions or the outbreak of hostilities or war;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop and maintain our corporate infrastructure, including our internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the use of proceeds from recent and any future financings, if any; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of adverse safety events, restrictions on use with our products or product liability claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These forward-looking statements are based on management&#39;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management&#39;s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events.&#160;Although we believe the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements may not be achieved or occur at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">You should refer to the section titled &#8220;Risk Factors&#8221; in this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUMMARY RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; in this Annual Report. The below summary is qualified in its entirety by those more complete discussions of such risks and uncertainties.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Achieving or Sustaining Profitability, Financial Position and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant operating losses since inception, we expect to incur operating losses in the future, and we may not be able to achieve or sustain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our indebtedness may limit our flexibility in operating our business and adversely affect our financial health and competitive position.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to expand, manage and maintain our direct sales and marketing organizations, we may not be able to generate anticipated revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Macroeconomic conditions, including the ongoing response to the COVID-19 pandemic may negatively impact certain aspects of our business, our prospects, results of operations and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rising inflation rates could negatively impact our revenues and profitability if increases in the prices of our product or a decrease in consumer spending results in lower volumes of elective surgeries. In addition, if our costs increase and we are not able to pass along these price increases, our profitability would be adversely affected, and the adverse impact may be material.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to the Commercialization of our Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To date, the vast majority of our revenue has been generated from sales of our OviTex products, and we therefore are highly dependent on the commercial success of our OviTex product line.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The commercial success of our products will largely depend upon attaining significant market acceptance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we are able to attain significant market acceptance of our products, the commercial success of our products is not guaranteed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of our products for these uses.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our OviTex, OviTex PRS or other products we may commercialize in the future, our commercial success may be hindered.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our long-term growth may depend on our ability to enhance our product offerings.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the future our products may become obsolete, which would negatively affect operations and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To successfully market and sell our products in markets outside of the U.S., we must address many international business risks with which we have limited experience.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent upon Aroa as the exclusive contract manufacturer of our OviTex portfolio products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We, or our partners, may experience development or manufacturing problems, capacity constraints, or delays in the production of our products that could limit the potential growth of our revenue or increase our losses.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products contain materials derived from animal sources and may become subject to additional regulation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our supply of ovine rumen for use in manufacturing our products may be vulnerable to disruption due to natural disaster, disease or other events.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to comply with our obligations under any license, collaboration or other agreements, we could lose intellectual property rights that are necessary for developing and protecting our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to adequately protect our intellectual property rights, or if we are accused of infringing on the intellectual property rights of others, our competitive position could be harmed, or we could be required to incur significant expenses to enforce or defend our rights.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money, enter into license agreements for disputed intellectual property and could prevent us from selling our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products and operations are subject to extensive government regulation and oversight both in the U.S. and internationally.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not receive, or may be significantly delayed in receiving, the necessary clearances or approvals for our future products and modifications to our current products may require new 510(k)&#160;clearances or premarket approval (&#8220;PMA&#8221;), and may require us to cease marketing or recall the modified products until clearances or approvals are obtained.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Although we have obtained regulatory clearance for our products, they will remain subject to extensive regulatory scrutiny.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If guidelines for soft-tissue reconstruction surgery change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for our OviTex and OviTex PRS products or other products we may commercialize in the future.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Products</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our financial results may fluctuate significantly and may not fully reflect the underlying performance of our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to renew existing or obtain additional contract positions with major group purchasing organizations (&#8220;GPOs&#8221;) and integrated delivery networks (&#8220;IDNs&#8221;) for our products, and even if we are able to do so, such contracts may not generate sufficient sales of our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited data and experience regarding the safety and efficacy of certain of our products. Results of earlier studies may not be predictive of future clinical trial results, or the safety or efficacy profile for such products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interim or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Securities</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The trading price of the shares of our common stock has been and could in the future be highly volatile.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Provisions in our corporate charter documents and under Delaware law could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_291637"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I</p><a id="ITEM1BUSINESS_796317"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 1.</b></span>BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient&#8217;s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient&#8217;s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements. We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our first portfolio of products, the OviTex Reinforced Tissue Matrix (&#8220;OviTex&#8221;), which we first commercialized in the U.S. in July 2016, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hernia repair is one of the most common surgeries performed in the U.S., representing approximately 1.1&#160;million procedures annually. Based on the volume weighted average selling price of our OviTex products, we estimate the annual U.S. total addressable market opportunity for our OviTex products to be approximately $1.5&#160;billion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Our OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.  In addition, we have also designed an OviTex product specifically for use in laparoscopic and robotic-assisted hernia repair, which we market as OviTex LPR and began commercializing this product in November&#160;2018. We recently launched two new, larger configurations of OviTex LPR, designed for ventral and incisional hernias.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">We have also focused on evaluating and publishing clinical data on the effectiveness and safety of our OviTex products.  To date, there have been thirty published or presented works relating to these clinical findings, either by us or a third-party evaluating the OviTex product.  Recently in October 2022, the 24-month results of our single arm, multicenter post-market clinical study, which we refer to as our BRAVO study, were published in the </span><i style="font-style:italic;">Annals of Medicine and Surgery</i>. The BRAVO study was designed to evaluate the clinical performance of OviTex for primary or recurrent ventral hernias using open, laparoscopic, or robotic techniques in 92 enrolled patients. The recurrence rate at the 24-month time point was 2.6%, and surgical site occurrences (&#8220;SSOs&#8221;) were observed in 38% of the study population. Of the enrolled patients, 78% were characterized as high risk for experiencing an SSO based on at least one known risk factor, which included obesity, active smoking, COPD, diabetes mellitus, coronary artery disease, or advanced age (&#8805;75 years). The results also indicated that BRAVO patients experienced statistically significant and clinically meaningful improvements in their quality of life and perceived health based on patient responses to the EuroQol-5 Dimension (EQ-5D) health assessment and the validated 12-question Hernia-Related Quality of Life survey (HerQLes). In addition to the BRAVO study and other current clinical initiatives, we also commenced enrollment in May 2021 for our BRAVO II study, a prospective study evaluating the use of OviTex in robot-assisted ventral and inguinal hernia repairs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (&#8220;OviTex PRS&#8221;), which we first commercialized in the U.S. in May 2019, addresses unmet needs in plastic and reconstructive surgery. OviTex&#160;PRS is indicated for use in implantation to reinforce soft-tissue where weakness exists in patients requiring soft-tissue repair or reinforcement in plastic and reconstructive surgery. Our OviTex&#160;PRS portfolio is supported by non-human primate data that demonstrated more rapid tissue integration and tissue remodeling compared to the market leading biologic matrix used in this indication. Based on the current sales of biologic matrices in the U.S., we estimate the annual U.S. current addressable market opportunity for our OviTex&#160;PRS products to be approximately $700&#160;million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our OviTex products have received 510(k)&#160;<span style="white-space:pre-wrap;">clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), which clearance was obtained and is currently held by our exclusive contract manufacturer of these products, Aroa. In April 2019, our OviTex PRS products received 510(k) clearance from the FDA, which clearance was obtained by Aroa and is currently held by us.  We have also engaged in discussions with the FDA regarding an Investigational Device Exemption (&#8220;IDE&#8221;) protocol to study the safety and effectiveness of our OviTex&#160;PRS product for an indication in breast reconstruction surgery. The FDA has stated that a PMA, rather than 510(k) clearance will be required for such an indication. We have also commenced a retrospective clinical study evaluating the effectiveness and safety of our OviTex PRS products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We also continue to expand our service offerings and diversify our supplier base as we continue to create a soft tissue restoration portfolio, including through the development of complimentary solutions targeting surgical wound management and infection control. In January 2023, we announced an exclusive development and distribution partnership with Collagen Matrix, Inc. (&#8220;CMI&#8221;), pursuant to which we launched the commercialization of our NIVIS Fibrillar Collagen Pack, an absorbent matrix of Type I and Type III bovine collagen designed to manage moderately to heavily exudating wounds and to control minor bleeding. We also previously commercialized through a distribution agreement with Next Science Technologies Pty Limited (&#8220;Next Science&#8221;), a proprietary antimicrobial surgical wash in the U.S. plastic reconstructive market. We are assessing additional strategic partnerships with medical device companies whereby we may enter into distribution, product development and/or licensing agreements for new products complimentary to, or related to, existing and future products in our distribution channel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have a broad portfolio of intellectual property protecting our products that we believe, when combined with the proprietary manufacturing processes associated with our products and our know-how, provides significant barriers to entry. Our intellectual property applies to our differentiated product construction and materials. In addition, we believe our exclusive manufacturing and long-term supply and license agreement (the &#8220;Aroa License&#8221;) with Aroa creates a competitive advantage by allowing us to secure an exclusive supply of ovine rumen at a low cost. Ovine rumen, the forestomach of a sheep, is the source of the biologic material used in our OviTex portfolio products. In manufacturing the product, we use biologic material from ovine rumen because of its plentiful supply, optimal biomechanical profile and open collagen architecture that allows for rapid cellular infiltration. We purchase product from Aroa at a fixed cost equal to 27% of our net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We market our products through a single direct sales force, predominantly in the U.S., as augmented by a smaller number of sales representatives and distributors in certain European countries. We have invested in our direct sales and marketing infrastructure to expand our presence and to promote awareness and adoption of our products. As of December 31, 2022, we had 67 sales territories in the U.S. As part of our commercial strategy, we plan to continue to invest in our commercial organization by hiring additional territory managers and administrative and field-based support employees to support and service new accounts for soft-tissue reconstruction procedures. We believe we can enhance the productivity of our sales force by improving customer segmentation and targeting, implementing and further refining our proprietary training programs leveraging support from our medical education and clinical development functions to drive physician awareness and education on our products, and utilizing engagement analytics to support product development.  Additionally, we have contracted with three national GPOs covering our OviTex portfolio and plan to continue to contract with additional GPOs and other integrated delivery networks (&#8220;IDNs&#8221;) to increase access to and penetration of hospital accounts. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business was directly impacted by the COVID-19 pandemic. We experienced volatility in demand for our products which primarily resulted from government and hospital restrictions, as well as patient health and safety concerns, decreasing the volume of elective procedures using our products. We saw improvement in our business during the second half of 2022 and anticipate that procedure volumes will continue to normalize to pre-pandemic levels; however, we continue to monitor the potential impact of COVID-19 on labor and hospital staffing levels, procedural volumes and ultimately on our financial results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our revenue for the&#160;years ended December 31, 2022 and 2021 was $41.4&#160;million and $29.5&#160;million, respectively, which represents an increase of $12.0&#160;million, or 41% for the year ended December 31, 2022. Our net loss for the same time periods was $44.3&#160;million and $33.3&#160;million, respectively, which represents an increase of $11.0&#160;million, or 33% for the year ended December 31, 2022. As of December 31, 2022, we had an accumulated deficit of $274.2&#160;million. The vast </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">majority of our revenue to date has been generated from sales of our OviTex and OviTex&#160;PRS products in the U.S., with the remainder generated from sales of our OviTex products in Europe and the sale of other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Opportunity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OviTex</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Hernia repair is one of the most common surgeries performed in the U.S. There are an estimated 1.1&#160;million hernia repairs annually in the U.S. including recurrences, which we categorize as approximately (i)&#160;60,000 complex/moderate ventral hernia repairs and abdominal wall reconstructions, (ii)&#160;345,000 simple ventral hernia repairs and (iii)&#160;665,000 inguinal hernia repairs, and (iv) 40,000 hiatal hernia repairs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The healthcare burden of hernia disease to patients, insurers and employers is significant. For the patient, a hernia may cause an increasing level of pain when lifting, straining during urination or a bowel movement, or sitting or standing for long periods of time. Increased pain from the hernia is the most common reason that a patient who is deferring surgical hernia repair will ultimately elect repair surgery. Following surgical hernia repair, convalescence has a significant socioeconomic impact. Absence from work during this period can range from approximately five to 14&#160;days according to one study. Pain is the most common cause of delay in returning to work, followed by wound problems. Long-term pain or discomfort at the hernia repair site is one of the most serious complications of hernia surgery and may, in some cases, persist for&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Given the limitations of and lack of innovation in existing hernia repair products, we believe a significant market opportunity exists for our portfolio of OviTex products. Based on the volume weighted average selling price of our OviTex products, we estimate the annual U.S. total addressable market opportunity for our OviTex products to be approximately $1.5&#160;billion.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Approximate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;Hernia</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Procedures</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Using</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tissue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Addressable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Traditional</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reinforcement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Market</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Products</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Material</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Opportunity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Utilized</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Complex/Moderate Ventral Repair /Abdominal Wall Reconstruction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 360</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">million&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biologic Matrices and Resorbable Synthetic Mesh</p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Simple Ventral Hernia Repair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 345,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 515</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">million&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent Synthetic Mesh</p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inguinal Hernia Repair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 665,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 600</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">million&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent Synthetic Mesh</p></td></tr><tr><td style="vertical-align:top;width:40.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hiatal Hernia Repair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">million&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biologic Matrices and Resorbable Synthetic Mesh</p></td></tr><tr><td style="vertical-align:bottom;width:40.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,110,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1.5</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">billion&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OviTex&#160;PRS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Modern advances in tissue engineering have transformed the plastic and reconstructive surgeon&#8217;s management strategies across a wide variety of applications. Because biologic matrices incorporate into host tissues and enable revascularization and functional tissue remodeling, surgeons have realized multiple applications for their use, with techniques tailored to the specific requirements of the surgery. There is growing clinical literature validating the use of biologic matrices in head and neck surgery and reconstructions of the chest wall, pelvic region, extremities and breast.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In head and neck surgery, biologic matrices are used for both aesthetic and reconstructive purposes that include: surgery of the nose to change its shape or improve its function, referred to as rhinoplasty; lip augmentation; repair of perforations of the cartilage and thin bone separating the nostrils referred to as the nasal septum; complex reconstruction of the oral and oropharynx cavities after oncologic resection; cleft palate repair; upper and lower eyelid reconstruction; scalp defects and defects of the fibrous membrane covering the brain and spinal cord referred to as dura. In chest wall </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reconstruction, biologic matrices are used to repair defects from oncologic resections. In pelvic reconstruction, biologic matrices are utilized as an adjunct in the reconstruction of acquired pelvic defects caused by resections for colorectal, gynecologic and urologic malignancies. In extremities reconstruction, biologic matrices are used in the upper extremity for repair of the donor site following the harvest of a radial forearm free flap, a procedure used to harvest tissue and replace it in the head and neck after cancer has been resected. In breast reconstruction, biologic matrices are utilized for prosthetic based reconstruction following the removal of cancerous breast tissue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Based on the current sales of biologic matrices in the U.S., we estimate the annual U.S. current addressable market opportunity for our OviTex&#160;PRS products to be approximately $700&#160;million. Given the limitations of and lack of innovation in existing biologic matrices for plastic and reconstructive surgical procedures, we believe a significant market opportunity exists for our OviTex&#160;PRS portfolio products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Current Materials Used in Hernia Repair and Abdominal Wall Reconstruction and Their Limitations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Hernia Repair and Abdominal Wall Reconstruction</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The vast majority of hernias are treated with surgical repair. Surgical hernia repair is performed either through open repair, which uses a single incision to open the abdomen or groin across the hernia, or minimally invasive repair, which involves laparoscopic or robotic-assisted techniques. Laparoscopic surgery is a minimally invasive surgical technique performed in the abdomen or groin through small incisions. Surgical instruments and devices, such as mesh products, are then delivered to the surgical site through a trocar, which is an access port to the patient&#8217;s abdomen or groin. Robotic-assisted surgery is also performed using small incisions in the patient&#8217;s abdomen or groin and a trocar, but the surgeon sits at a console in the operating room and operates the robotic instruments remotely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the advent of hernia repair, all procedures were performed using an open surgical technique in which an incision is made through the body to access and repair the hernia. Due to the amount of healthy soft-tissue disruption required for an open procedure, there is a high risk of wound-related complications and seroma formation. In the early 1990s, surgeons began using a laparoscopic approach for hernia repair because it provided the benefits of lower wound complication rates, lower patient morbidity and decreased length of stay for patients. Despite these benefits, laparoscopic surgery presents surgeons with challenges, primarily due to restricted instrument dexterity that makes it difficult to achieve primary closure of the hernia defect, in which the connective tissue layer is sutured close, and leads to a bridged repair. In a bridged repair, the tissue reinforcement material spans a portion of the hernia defect without any connective tissue layer above it to provide additional reinforcement. This leads to increased risk of bulging of the material or hernia recurrence. Robotic-assisted hernia repair addresses this issue while still providing the benefits of a laparoscopic repair. In robotic-assisted repair, the surgeon enjoys greater instrument dexterity and precision, and is able to achieve primary closure of the hernia defect. This has contributed to a significant increase in the number of robotic-assisted hernia repairs over the last several&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">It is estimated that about 90% of hernia repairs today use a form of reconstruction material to provide long-term support at the repair site. Reconstruction materials include synthetic mesh, which can be either permanent or resorbable, and biologic matrices made from tissue material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In October 2020, we surveyed a group of 71 surgeons to better understand their receptivity to natural repair solutions, their technique preferences across their hernia practice and their views on the risks associated with plastic mesh.&#160;Feedback was gathered across inguinal hernia, simple ventral, moderate-to-complex ventral and hiatal hernia repair. Included in the group were 43 general surgeons (61%), 19 plastic reconstructive surgeons (27%) and the remainder were colorectal and trauma surgeons. These surgeons indicated they believe there is a role for natural repair products across all hernia segments and they expect to increase their usage of those products in the next 24 months. Almost 60% of surgeons stated that they are aware of the risks associated with plastic mesh and reported approximately 20% of their hernia patients have voiced concern about the use of plastic mesh within the past 12 months.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Permanent Synthetic Mesh</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Permanent synthetic mesh, the oldest category of hernia repair materials, is made of plastic materials that are also used in industrial and consumer products. These products have gained popularity with surgeons because they are relatively inert, can be readily sterilized, exhibit biomechanical strength and durability and are available at relatively low upfront cost. Limitations of permanent synthetic mesh products may include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant persistent foreign body inflammatory response that can result in encapsulation of the implant by fibrotic tissue or contraction of the mesh;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">chronic post-operative pain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scar tissue formation and lack of regeneration of soft-tissue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permanent susceptibility to mesh infection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant cost associated with subsequent repairs or failed and infected mesh;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compromised abdominal wall anatomy due to damaged and eroded tissue rendering subsequent surgical repairs challenging; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">migration of the permanent synthetic mesh which can result in organ erosion or perforation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of these complications caused by permanent synthetic mesh require additional surgical intervention, including, explantation of the mesh or repair of hernia recurrence or of the abdominal wall. Based on longitudinal data from the Danish Hernia Database, in an analysis of approximately 2,900 patients who received a hernia repair using a permanent synthetic mesh, the observed rate of surgical intervention due to either recurrence or mesh-related complications at five&#160;years post operatively was approximately 17%. As a result of these complications and litigation involving these complications, the number of adverse events reported to the FDA for permanent synthetic mesh hernia repairs has risen from 1,484 in 2016, 3,220 in 2017, 9,887 in 2018 to 18,072 in 2019. Synthetic mesh products have been the subject of an increasing number of lawsuits with over 24,000 cases filed in federal and state courts across the U.S. as of September 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biologic Matrices</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The complications associated with permanent synthetic mesh prompted the development of biologic matrices as a second category of hernia repair materials. Biologic matrices are derived from human or animal dermis, pericardium or intestinal submucosa, which allows them to become replaced entirely by the patient&#8217;s own tissue over time, a process known as remodeling. The goal behind these biologic materials was to lower the foreign body inflammatory response and biomechanical requirements of the repair, while providing a matrix upon which tissue remodeling could occur. Compared to permanent synthetic mesh, biologic matrices are less likely to induce this inflammatory response and become infected; however, they may have the following limitations:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack strength or durability as compared to synthetic mesh products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prone to laxity and stretching;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficult to handle, leading to longer operating times as compared to synthetic mesh products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to be placed in a patient through a trocar in laparoscopic or robotic-assisted surgery; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">considerably more expensive upfront costs than permanent synthetic mesh, typically limiting their use to complex hernia repairs or abdominal wall reconstructions.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Though hernia recurrence occurs with the use of all types of soft-tissue reconstruction, biologic matrices have the highest rates of recurrence, partly due to common use in complex hernia repairs or abdominal wall reconstructions. The RICH study, a multicenter, prospective study sponsored by LifeCell Corporation (&#8220;LifeCell&#8221;) that evaluated the performance of Strattice, the industry leader for biological tissue matrices in complex abdominal wall reconstruction, in open ventral incisional hernia repair in contaminated abdominal wall defects, demonstrated post-operative hernia recurrence rates of 19% and 28% at 12-months and 24-months follow-up, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Resorbable Synthetic Mesh</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Resorbable synthetic mesh was introduced as a third category of hernia repair materials and as an alternative to permanent synthetic mesh and biologic matrices. Resorbable synthetic mesh was designed with the intended benefits of full degradation over several&#160;months, a moderately lower cost than biologic matrices and gradual transfer of strength from synthetic mesh to native tissue over time. Resorbable synthetic mesh is polymer-based and does not include biologic material to promote tissue remodeling and healing. Despite improvements compared to the use of permanent synthetic mesh or biologic matrices, limitations of resorbable synthetic mesh may include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant foreign body inflammatory response that can result in encapsulation or contraction of the mesh until resorbed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scar tissue formation and lack of remodeling of soft-tissue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mesh infection until resorbed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">migration of the mesh until resorbed which can result in organ erosion or perforation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of mid-term and long-term soft-tissue reinforcement as resorption progresses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of these complications can require additional surgical intervention including explantation of the resorbable synthetic mesh or repair of hernia recurrence or the abdominal wall. Data from a published, multicenter, prospective study sponsored by C.R. Bard,&#160;Inc. (now a subsidiary of Becton, Dickinson and Company) that evaluated the performance of Phasix, the current market-leading resorbable synthetic mesh, in CDC Class&#160;I, high risk ventral and incisional hernia repair, showed a post-operative hernia recurrence rate of 9% at 18-months follow-up and 18% at 36-month follow-up.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Current Materials Used in Plastic and Reconstructive Surgery and Their Limitations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Biologic matrices are most commonly used in plastic and reconstructive surgery, including surgery of the nose to change its shape or improve its function, referred to as rhinoplasty, lip augmentation, repair of perforations of cartilage and thin bone separating the nostrils, complex reconstruction of the oral and oropharynx cavities after oncologic resection, cleft palate repair, upper and lower eyelid reconstruction, scalp defects, and defects of the fibrous membrane covering the brain and spinal cord, called the dura, because of their ability to define shape and position, improve tissue quality, reinforce existing soft-tissue and reduce the rate of complications associated with a foreign body inflammatory response, however they are prone to excessive stretching over time and difficult for surgeons to handle. These limitations may lead to undesirable results requiring additional surgical intervention. Additionally, biologic matrices are typically expensive to source.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Solution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have created a new category of tissue reinforcement materials that were purposefully designed in close collaboration with more than 100 surgeons to address the unmet clinical needs in soft-tissue reconstruction. Our portfolio of products, designed with over 95% biologic material, combines the benefits of both biologic and polymer materials while addressing their limitations by interweaving polymer fibers through layers of a minimally-processed biologic material. These products are priced competitively and designed for use with a range of surgical techniques, allowing the benefits </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:253.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of an advanced biologic repair to be available to more patients for use in accordance with the products&#8217; 510(k) clearances and instructions for use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The biologic material serves as the natural building block from which we can fabricate devices that meet specific clinical and surgical handling requirements. This material consists of an intact, minimally-processed extracellular matrix derived from ovine rumen, which is the forestomach of a sheep. Polymer fibers are interwoven through the layers of biologic material in unique embroidered patterns and contribute to approximately 5% of the overall device by mass. The interwoven polymer utilized can be either permanent, made from polypropylene, or resorbable, made from polyglycolic acid (&#8220;PGA&#8221;). The embroidering pattern varies between our OviTex and OviTex&#160;PRS portfolios to impart different biomechanical properties tailored for their respective intended clinical applications. Our OviTex products are designed with a lockstitch embroidery pattern that is sewn in a grid pattern to create a ripstop effect and minimize unraveling (when cut). Our OviTex&#160;PRS products are designed with a patented corner-lock stitch pattern designed to resist deformation and to control the degree and direction of stretching of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our capabilities in polymer science, biologics, textile engineering and analytical testing enable us to quickly design innovative products for development and manufacture. These competencies also allow our technical team to tailor the degree of stretch, direction of stretch, overall strength, handling properties, permeability, thickness, texture, size and shape of each reinforced tissue matrix to suit the needs of particular clinical applications and surgical techniques. This expertise has been utilized in the development of our OviTex and OviTex&#160;PRS products and is currently being leveraged in the development of our additional OviTex product pipeline seeking to enhance product features for various applications within our indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our reinforced tissue matrices are designed to improve the outcomes of soft-tissue reconstructions by reinforcing tissue while allowing rapid tissue integration, revascularization and biomechanical control. In addition to overall strength, a key property that we engineer into our products is the degree to which they stretch, known as compliance. Each of our products is designed to exhibit&#160;a degree of compliance appropriate for its intended clinical application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The graphics below illustrate the key features of our OviTex and OviTex&#160;PRS products:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OviTex</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tela-20221231x10k001.jpg" alt="Graphic" style="display:inline-block;height:253.69pt;width:437.18pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:273.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OviTex&#160;PRS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tela-20221231x10k002.jpg" alt="Graphic" style="display:inline-block;height:273.12pt;width:432.65pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe the principal benefits of our reinforced tissue matrices are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Reduced foreign body inflammatory response. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The biologic material utilized in our reinforced tissue matrices is designed to minimize the body&#8217;s inflammatory response to the device. Our unique embroidered patterns create a macroporous grid within the biologic material. In our non-human primate study in which we compared our OviTex products to several commercially available synthetic mesh and biologic matrix products, at 24 weeks, our OviTex products demonstrated a minimal foreign body inflammatory response similar to that of biologic matrices, and less foreign body inflammatory response than all of the synthetic mesh tested.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Enhanced remodeling of soft-tissue and rate of healing. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our reinforced tissue matrices are constructed to provide increased surface area and permeability, allowing for rapid absorption of wound fluids and blood during implantation and enabling oxygen supply, cellular infiltration, migration, and repopulation for revascularization and functional tissue remodeling during healing. In our non-human primate comparative study, at 24&#160;weeks the pattern of collagen formation in our OviTex products resembled connective tissue as opposed to the random fibers typical of scar tissue that were seen adjacent to the synthetic mesh. By contrast, the synthetic mesh showed no signs of remodeling of soft-tissue and exhibited a high level of mesh contraction.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Highly engineered biomechanical properties supported by clinical evidence. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our reinforced tissue matrices are reinforced with interwoven polymer fibers to provide mid-term and long-term support. The interwoven polymer increases the strength of our OviTex products by approximately 25% compared to the biologic material alone. When tensile forces are applied, this design allows for load sharing between the biologic material and the polymer during the remodeling process. Data from our strength testing demonstrated that our OviTex products meet or exceed that of published data from market-leading permanent and resorbable synthetic mesh. In our BRAVO study, the recurrence rate at the 24-month time point was 2.6%, and SSOs were observed in 38% of the study population. Of the enrolled patients, 78% </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">were characterized as high risk for experiencing an SSO based on at least one known risk factor, which included obesity, active smoking, COPD, diabetes mellitus, coronary artery disease, or advanced age (&#8805;75 years). Based on this data, we believe that this recurrence rate is the lowest reported rate in any published study, including our biologic or resorbable synthetic mesh competitors. The addition of polymer to our reinforced tissue matrices allows each product to maintain its physiologic compliance properties, while resisting stretching and elongation. In our non-human primate comparative study, our OviTex devices best preserved their original shape, experiencing less contraction compared to biologic and synthetic mesh.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Enhanced surgeon handling and satisfaction. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Each of our embroidery patterns was designed specifically to allow the surgeon to trim and shape the product while minimizing the potential for unraveling of the polymer. Based upon our survey of approximately 50 surgeons, our OviTex products conform readily to the contours of surgical sites and are easy to handle, trim, suture and tack in all surgical approaches. In addition, in our BRAVO study, 32 of the 92 enrolled subjects received minimally invasive surgery, of whom 12 received laparoscopic repair and 20 received robotic repair. Of the surgeons who performed minimally invasive surgery, all reported at the time of surgery that the product was easy or very easy to place. The average surgeon satisfaction with the product was 9.7/10 at 30 days for the minimally invasive cohort and remained consistent over 24 months of follow-up. We are also actively enrolling patients in our BRAVO II study, a prospective study evaluating robot-assisted ventral and inguinal hernia repairs with OviTex, including our OviTex LPR, OviTex Core Permanent and OviTex 1S Permanent configurations. During the fourth quarter of 2022, 40% of reported cases using OviTex were performed robotically and 20% were completed laparoscopically, showing growing use of our OviTex product in these minimally invasive settings.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Lower upfront cost products. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our reinforced tissue matrices provide our customers with meaningful cost savings over leading competitive products across a range of clinical uses so that more patients can experience the benefits of an advanced biologic repair solution. We price our OviTex products competitively, and on average, our customers realize 20% to 40% cost savings over leading biologic matrices and resorbable synthetic mesh. Our OviTex&#160;PRS portfolio is priced below leading biologic matrices.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strengths</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are focused on developing and commercializing a new category of tissue reinforcement materials for surgeons and patients that aim to address the shortcomings of existing products. We believe the following strengths will allow us to build our business and potentially increase our market penetration:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Innovative and broad portfolio of products. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our OviTex and OviTex PRS products are the only FDA-cleared products to incorporate polymer fibers interwoven through layers of biologic material in a lockstitch pattern creating an embroidered construction. The biologic matrix is derived from ovine rumen and utilizes a patented process to create a reinforced tissue matrix that is optimized for soft-tissue reconstruction. Our OviTex and OviTex PRS products are available in resorbable and permanent polymer versions in a variety of configurations and sizes. For example, our OviTex devices are currently available in sizes ranging from 4&#160;&#215;&#160;8 cm to 25&#160;&#215;&#160;40 cm, and our OviTex&#160;LPR devices are designed with specific thickness, handling properties and shapes optimized for use in laparoscopic and robotic-assisted surgery.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Disruptive technology supported by compelling pre-clinical and clinical evidence. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OviTex product technology is supported by extensive pre-clinical research, including bench testing, in-vitro and in-vivo studies. These studies have demonstrated appropriate physiologic strength for the repair, compliance within the physiologic range of the human abdominal wall, retention of extracellular matrix proteins which may aid in tissue remodeling and porosity and permeability to promote fluid transfer. Our in-vivo non-human primate data demonstrated that use of our OviTex products resulted in more rapid tissue integration and revascularization compared to pure biologic matrices, as well as lower inflammatory response and better functional tissue remodeling compared to permanent and resorbable synthetic mesh. This preclinical data is </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supported by our compelling clinical evidence showing the safety and efficacy of our OviTex products in published data on over 1,000 hernia patients. </span><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Long-term supply agreement that provides pricing flexibility. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our Aroa License provides for the exclusive supply of ovine rumen and manufacture of our OviTex and OviTex PRS products, which gives us a low and fixed cost of raw materials. We purchase product from Aroa at a fixed cost equal to 27% of our net sales of licensed products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Potential cost savings to healthcare systems and hospitals. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our pricing flexibility allows us to sell our OviTex and OviTex PRS products to hospitals and healthcare systems at prices substantially below competitive products based on national average competitive pricing. Our OviTex products are sold at prices approximately 20% to 40% lower than other biologic matrices and resorbable synthetic mesh. We believe our pricing flexibility will continue to drive greater adoption of our products. Our OviTex PRS products are priced below leading biologic matrices, and as we further commercialize our OviTex PRS portfolio, we anticipate that our customers will realize cost savings over biologic matrices based on national average competitive pricing. We believe that the average selling prices across our products will provide financial benefits to our customers in addition to improving clinical outcomes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Established reimbursement pathway for hernia repair. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The implantation of biologic matrices and synthetic mesh for hernia repair is coded using an established fixed procedure payment system known as a MS-DRG that consists of a lump sum payment rate that varies based on the degree of complications and comorbidities of each hernia. In addition, surgeons receive payment for their services depending on the coding associated with the procedure. The MS-DRG-based reimbursement system encourages hospitals to become more efficient in treating patients due to its fixed per-patient reimbursement nature.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Broad intellectual property portfolio. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products are covered by intellectual property that broadly covers changing a biologic matrix&#8217;s biomechanical properties by interweaving a polymer thread through the biologic matrix. Specifically, our patents claim the ability to tailor stretch resistance. The ability to predictably control the biomechanical properties of a biologic matrix is the cornerstone of our product portfolio. Our intellectual property also covers the development of extracellular matrix scaffolds derived from ovine rumen, methods for isolating these scaffolds from ovine rumen, layering multiple sheets of these ovine rumen scaffolds together, sewing in an anti-adhesive layer into a scaffold, and adding unique patterns sewn or embroidered into these scaffolds using different polymers to impart reinforcing strength. Our portfolio also includes patents covering implants with gripping strands, and implants with multivesicular liposomes that may be used to deliver drugs. Through the Aroa License and our issued or allowed patents and patent applications, we have a broad portfolio of intellectual property that is leveraged in all of our reinforced tissue matrix products. In addition, we believe that the trade secrets developed with Aroa create additional barriers to entry.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Highly accomplished executive team with proven track record. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our executive team consists of seasoned medical device professionals with deep industry experience, and a broad network of relationships within the industry and the medical community. Our executive team has led and managed companies through significant growth and introduction and commercialization of multiple new products, including driving surgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical technology companies such as Orthovita&#160;Inc., Stryker Corporation, OraSure Technologies, Inc., LifeCell and Medtronic&#160;plc. We believe this team is well-positioned to lead us through the commercial expansion of our products and development and launch of future products.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Growth Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our goal is to become the leading provider of soft-tissue reconstruction products. The key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand our U.S. commercial organization to support our growth. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We sell our products through a single direct sales organization in the U.S. As of December 31, 2022, we had 67 sales territories in the U.S. which are supported by 123 employees in our U.S. based commercial organization. We plan to continue to invest in our commercial organization by hiring additional territory managers and administrative and field-based support employees to support and service new accounts for soft-tissue reconstruction procedures. We believe we can also enhance the productivity of our sales force by improving customer segmentation and targeting, implementing and further refining our proprietary training programs, leveraging support from our medical education and clinical development functions to drive physician awareness and education on our products, and utilizing engagement analytics to support product development. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Promote awareness of our products to drive surgeon use. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We educate surgeons regarding the value proposition of our products through presentations and exhibits at industry conferences, medical education symposia, direct training and education, webinars and publishing additional clinical data demonstrating the benefits of our products and establishing online peer-to-peer communities. We plan to continue to drive awareness of our products through in-person and virtual versions of these programs, while expanding their geographic reach and increasing the number of surgeon interactions. We will continue to increase our digital marketing efforts as well to build brand awareness with event marketing engagement, targeted ads and emails, various social media efforts and patient education and outreach efforts. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Drive utilization through existing GPO and IDN contracts and secure additional contracts. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are focused on partnering with our existing GPO- and IDN-contracted customers to promote implementation of our contracts, increase our access to surgeon customers, broaden awareness of products and help drive utilization of our products within associated hospitals and healthcare systems. To date, we have contracted with three national GPOs covering our OviTex and OviTex PRS products. In addition, we continue to pursue contracts with additional GPOs and IDNs. GPO and IDN contracts enable greater access to geographies with high procedural volumes and provide prioritized status within hospital procurement systems. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to build upon clinical evidence of the effectiveness and safety of our products. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are committed to evidence-based medicine and investing in clinical data to support the use of our products. In our BRAVO study, the recurrence rate at the 24-month time point was 2.6%, and SSOs were observed in 38% of the study population. 78% of all enrolled patients were characterized as high risk for experiencing an SSO based on at least one known risk factor, which included obesity, active smoking, COPD, diabetes mellitus, coronary artery disease, or advanced age (&#8805;75 years). Our analysis of patients in the BRAVO study reaching 24-month follow-up was published in the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Annals of Medicine and Surgery</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in October 2022. We have begun our next post-market prospective study, BRAVO II, which evaluates OviTex LPR, OviTex Core Permanent and OviTex 1S Permanent in the robotic repair of ventral and inguinal hernias over 24 months. </span><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance our portfolio of reinforced tissue matrices with the introduction of new product features and designs. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We plan to continue to expand our product offerings and the treatment capabilities of our products to address a broader patient base within soft-tissue reconstruction. As we innovate and develop our products, the new features and improved surgical techniques expand the clinical applications for soft-tissue reinforcement. Areas of focus include enhanced surgical handling, increased permeability, and longer-acting resorbable polymers. Improving the surgical handling and implementation of our devices benefits both the clinician and patient. Increasing product permeability encourages a more-natural healing response. Longer-acting polymers can provide additional support for patients that need more time to heal. We believe these technology enhancements will continue to bolster our portfolio and expand the successful use of our products.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand our service offerings and diversify our supplier base to create a broader soft tissue preservation and restoration portfolio. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">We plan to continue assessing internal development strategies and strategic partnerships with medical device companies whereby we may enter into distribution, product development and/or licensing agreements for new soft tissue preservation and restoration products complimentary to, or related to, existing and future products in our distribution channel.  For example, in January 2023, we announced the commercial launch of our NIVIS Fibrillar Collagen Pack, an absorbent matrix of Type I and Type III bovine collagen designed to manage moderately to heavily exudating wounds and to control minor bleeding.  Similarly, we continue to evaluate additional product opportunities that address patient health and unmet needs within the indications in which we operate. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Technology Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our advanced reinforced tissue matrix technology consists of multiple layers of minimally-processed, decellularized extracellular matrix derived from ovine rumen with interwoven polymer fibers in a unique embroidered pattern. The extracellular matrix is the collagen component of the rumen that is retained following removal of the epithelium, muscle and cellular content, and has an optimal biomechanical profile and open collagen architecture that allows for rapid cellular infiltration. These thin, strong layers of ovine rumen are plentiful in supply and serve as building blocks from which we can construct multilayered devices to customize products to adapt to clinical needs and surgeon preferences. The layers of extracellular matrix provide a high degree of surface area for tissue remodeling. We strengthen these reinforced tissue matrix layers with interwoven polymers, that are either permanent (polypropylene), or resorbable (PGA). These polymers were selected because they are well characterized suture materials with a history of significant clinical use and recognized safety profiles. Polypropylene has a high tensile strength and a low inflammatory response in small quantities. PGA is the fastest resorbing polymer and within three&#160;months it tends to be fully absorbed into the body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our highly specialized and customizable textile engineering capability allows us to tailor the degree and direction of stretch, overall strength, handling properties, permeability, thickness, texture, size and shape of each reinforced tissue matrix to suit the needs of particular clinical applications and surgical techniques. Our textile engineering utilizes a computer-controlled fabrication method that is scalable, reproducible, efficient and customizable. This embroidery process creates hundreds of micro-channels to allow the multi-directional passage of the patients&#8217; native cells and fluids throughout the product. The interwoven polymers are embroidered using a lockstitch pattern, which allows for the device to be trimmed while minimizing unraveling (when cut), and we use a patented corner-lock pattern, which creates a stable polymer fabric within the biologic material. We manipulate the polymer thread patterns to control the degree and stretch of our products. Denser grid patterns increase the amount of reinforcement and less dense patterns of different geometry allow for greater stretch. We are also able to manufacture products with smooth external layers that minimize the amount of exposed polymer such that the product can be placed in contact with the viscera. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OviTex Reinforced Tissue Matrix</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our OviTex Reinforced Tissue Matrix has received 510(k)&#160;clearance from the FDA, which clearance was obtained and is currently held by Aroa and is intended for use as a surgical mesh to reinforce and/or repair soft-tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome. Our OviTex products can be used in a variety of hernia repairs, including simple and complex ventral, inguinal and hiatal hernias, as well as abdominal wall reconstructions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our OviTex products are sterile reinforced tissue matrices derived from ovine rumen with either polypropylene or PGA. The product is provided in a dry, hydratable form and packaged in a double pouched configuration. The product can be stored at room temperature and only needs five minutes of rehydration for use. To be used in surgery our OviTex product is placed in a sterile dish, rehydrated with sterile saline for five minutes, trimmed to fit the site, if needed, and then positioned to achieve maximum contact between the device and the surrounding tissue. The device may be sutured, stapled or tacked into place.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:55.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All of our OviTex products were designed to minimize the amount of polymer material implanted in patients. The synthetic material in our OviTex products comprise less than 5% of our final product. Depending on the configuration selected, the amount of polymer is approximately 75% less than the polymer content of the most widely implanted permanent synthetic mesh, thereby reducing the patient&#8217;s foreign body inflammatory response to the polymer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We market a variety of OviTex products in a range of sizes, thicknesses and degrees of reinforcement in order to suit surgeon preference and desired surgical technique. Our OviTex portfolio is designed to allow surgeons to select a device appropriate for any abdominal tissue plane. Generally, surgeons may place the reinforced tissue matrix in direct contact with internal organs, known as intraperitoneal placement, or away from these internal organs in a variety of tissue planes, known as pre-peritoneal placement. When selecting a product for intraperitoneal placement, surgeons require a surface that minimizes the risk of tissue attachment, whereas when selecting a product for pre-peritoneal placement, surgeons are able to use a product with polymer exposure on both sides. Surgeons may select the most appropriate product from our OviTex portfolio based on the size of the defect, necessity or surgeon preference for internal organ contact, use of a minimally invasive or open surgical technique and risk of infection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OviTex Laparoscopic&#160;and Robotic Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our OviTex&#160;LPR product was specifically designed for use in laparoscopic and robotic-assisted hernia surgical repairs. OviTex&#160;LPR was designed for use with a trocar and requires the same rehydration and fixation as our other OviTex products. This product includes design elements to improve surgical handling, including two extra embroidered lines of blue colored polypropylene fibers to enhance endoscopic orientation and alignment. This product can be introduced into the patient&#8217;s body through various sized trocar ports. Based on surgeon feedback, OviTex&#160;LPR was designed in an elliptical or circular shape to minimize trimming.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OviTex Portfolio</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:17.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:17.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">OviTex</b></p></td><td style="vertical-align:bottom;width:1.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:19.3%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">OviTex 1S</b></p></td><td style="vertical-align:bottom;width:1.23%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:19%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">OviTex 2S</b></p></td><td style="vertical-align:bottom;width:1.23%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:19.31%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">OviTex&#160;LPR</b></p></td></tr><tr><td style="vertical-align:top;width:17.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><img src="tela-20221231x10k003.jpg" alt="Graphic" style="display:inline-block;height:48.75pt;width:90pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><img src="tela-20221231x10k004.jpg" alt="Graphic" style="display:inline-block;height:42pt;width:92.25pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><img src="tela-20221231x10k004.jpg" alt="Graphic" style="display:inline-block;height:42pt;width:92.25pt;" /></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><img src="tela-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:55.5pt;width:93.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:17.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Size and Shape</b></p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">4&#160;&#215;&#160;8 cm to 25&#160;&#215;&#160;40 cm* (Rectangle or Square)</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">4&#160;&#215;&#160;8 cm to 25&#160;&#215;&#160;40 cm* (Rectangle or Square)</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">4&#160;&#215;&#160;8 cm to 25&#160;&#215;&#160;40 cm* (Rectangle or Square)</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">12&#160;&#215;&#160;18 cm to 15 x 25 cm <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#708;</sup> (Ellipse); 9 cm to 15 cm (Round)</p></td></tr><tr><td style="vertical-align:top;width:17.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Strength</b></p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">++</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+++</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+</p></td></tr><tr><td style="vertical-align:top;width:17.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Layers of Ovine Rumen</b></p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Four</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Six</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Eight</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Four</p></td></tr><tr><td style="vertical-align:top;width:17.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Common Procedures</b></p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Moderate ventral hernia (pre-peritoneal placement), inguinal hernia, hiatal hernia</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Moderate to complex ventral hernia, can be placed intraperitoneally</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Complex ventral hernia and abdominal wall reconstruction and can be used for bridging, can be placed intraperitoneally</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Laparoscopic or Robotic-assisted surgery</p></td></tr><tr><td style="vertical-align:top;width:17.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Polymer</b></p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Resorbable (PGA) or Permanent (Polypropylene)</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Resorbable (PGA) or Permanent (Polypropylene)</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Resorbable (PGA) or Permanent (Polypropylene)</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Permanent (Polypropylene)</p></td></tr><tr><td style="vertical-align:top;width:17.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Shelf Life</b></p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Resorbable-18&#160;months<br />Permanent-36&#160;months</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Resorbable-18&#160;months<br />Permanent-36&#160;months</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Resorbable-18&#160;months<br />Permanent-36&#160;months</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">36&#160;months</p></td></tr><tr><td style="vertical-align:top;width:17.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Configuration</b></p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exposed polymer on both sides</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exposed polymer on one side, and one smooth side</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Two smooth sides</p></td><td style="vertical-align:top;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exposed polymer on one side, and one smooth side</p></td></tr><tr><td style="vertical-align:top;width:17.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Commercial Availability</b></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.22%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;border:0;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';font-size:8pt;">&#183;</span></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">U.S.</span></p></div></div></div><div style="border-collapse:collapse;display:table;border:0;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';font-size:8pt;">&#183;</span></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Europe</span></p></div></div></div></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.3%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;border:0;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';font-size:8pt;">&#183;</span></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">U.S.</span></p></div></div></div><div style="border-collapse:collapse;display:table;border:0;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';font-size:8pt;">&#183;</span></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Europe</span></p></div></div></div></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;border:0;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';font-size:8pt;">&#183;</span></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">U.S.</span></p></div></div></div><div style="border-collapse:collapse;display:table;border:0;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';font-size:8pt;">&#183;</span></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Europe</span></p></div></div></div></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.31%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;border:0;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';font-size:8pt;">&#183;</span></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">U.S.</span></p></div></div></div><div style="border-collapse:collapse;display:table;border:0;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';font-size:8pt;">&#183;</span></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Europe</span></p></div></div></div></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">25&#160;x&#160;30&#160;cm and 25&#160;x&#160;40&#160;cm sizes currently only available with permanent (polypropylene) polymer.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#708;</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">15 x 20 cm and 15 x 25 cm sizes currently only available in the U.S.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Denotes relative level of strength</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:169.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OviTex Plastic and Reconstructive Surgery&#160;&#8212; OviTex PRS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">OviTex PRS, has received 510(k)&#160;clearance from the FDA, which clearance was obtained by Aroa and is held by us, and is indicated for use in implantation to reinforce soft-tissue where weakness exists in patients requiring soft-tissue repair or reinforcement in plastic and reconstructive surgery. Our OviTex PRS product can be stored at room temperature and comes in the same packaging and requires the same rehydration and fixation as our OviTex products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our OviTex PRS product is a sterile reconstructive reinforced tissue matrix composed of three layers of ovine rumen joined by a patented corner-lock embroidered diamond patterned polymer (PGA or polypropylene) that allows the product to stretch while also maintaining its shape. Machine punched regularly spaced fenestrations, or holes, and die-cut slits in the product facilitate fluid management, allow for rapid cellular infiltration and create a directional bias to the stretch. Our OviTex PRS product is available in arced rectangle and half-moon shapes in a range of sizes (4&#160;&#215;&#160;16 cm through 20&#160;&#215;&#160;20 cm) to suit surgeon preference and nature of the soft-tissue repair in plastic and reconstructive surgery. The device may be trimmed to a desired shape to further accommodate individual anatomy. The current shelf life of permanent OviTex PRS is 36&#160;months and the current shelf life of resorbable OviTex PRS is 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OviTex PRS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="tela-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:169.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:450.72pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product Pipeline and Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We continue to advance our product pipeline to broaden our treatment capabilities for soft-tissue reinforcement. As we innovate and develop our products, the new features and improved surgical techniques expand the clinical applications for soft-tissue reinforcement. Areas of focus include enhanced surgical handling, increased permeability, and longer-acting resorbable polymers. Improving the surgical handling and implementation of our devices benefits both the clinician and patient. Increasing product permeability encourages a more-natural healing response. Longer-acting polymers can provide additional support for patients that need more time to heal. We believe these technology enhancements will continue to bolster our portfolio and expand the successful use of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Scientific Evidence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview of Preclinical and Clinical Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">One of our key strategies is to continuously obtain evidence to support the safety and effectiveness of our products, which we believe will differentiate us from our competitors. As part of our strategy to gather and analyze high-quality data, we seek to ensure rigorous and reliable data collection and reporting. The data from our preclinical and clinical studies strengthens our ability to raise surgeon awareness and drive adoption of our products as a new category of soft-tissue reconstruction products. We expect our clinical evidence will provide surgeons with safety and efficacy data on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the appropriate use of our products and we plan to obtain further clinical evidence to support additional regulatory clearances or approvals of our reinforced tissue matrices for additional indications for use in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our pre-clinical program is paramount in the design of our products. Our program starts with bench performance characterization to ensure proper strength and compliance for the indication, followed by in-vitro and in-vivo studies to ensure proper biological performance to help promote remodeling of the repair site. We have developed an extensive pre-clinical research library on our devices, as well as on competitor devices. We continue to evaluate new and existing technologies for safety and biocompatibility as part of our product development process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We believe we have completed the largest collection of non-human primate preclinical studies conducted in soft-tissue reconstruction surgery. In these studies, we compared our OviTex and OviTex PRS products to market leading competitive materials. The results showed our reinforced tissue matrices exhibited a minimal inflammatory response, rapid cellular infiltration and revascularization and demonstrated early and complete remodeling into functional tissue. The OviTex results have been published in the peer-reviewed journal Hernia (https://doi.org/10.1007/s10029-019-02119-z). The OviTex PRS results have been published in  the peer-reviewed journal ePlasty (ePlasty 2022;22:e43).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are committed to obtaining evidence to support the safety and efficacy of our products across their indications. Clinical data has been published on over 1,000 patients treated with OviTex in ventral hernia, inguinal hernia, hiatal hernia, and abdominal wall reconstruction. As part of our clinical research program, we have developed two post-market studies, BRAVO and BRAVO II. This commitment to generating clinical data through controlled prospective studies with 24-month follow-up will allow us to understand the short- and long-term benefits of using OviTex in hernia repair.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In October 2022, the 24-month results of our BRAVO study were published in the <i style="font-style:italic;">Annals of Medicine and Surgery</i>. The BRAVO study was designed to evaluate the clinical performance of OviTex for primary or recurrent ventral hernias using open, laparoscopic, or robotic techniques in 92 enrolled patients. The recurrence rate at the 24-month time point was 2.6%, and SSOs were observed in 38% of the study population. 78% of all enrolled patients were characterized as high risk for experiencing an SSO based on at least one known risk factor, which included obesity, active smoking, COPD, diabetes mellitus, coronary artery disease, or advanced age (&#8805;75 years). The results also indicated that BRAVO patients experienced statistically significant and clinically meaningful improvements in their quality of life and perceived health.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Surgeons continue to use our OviTex PRS reinforced tissue matrices in their surgeries and, in addition to a potential IDE study, we have also commenced a retrospective clinical study evaluating the effectiveness and safety of our OviTex PRS products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our ability to obtain, maintain, protect and enforce our proprietary technology and intellectual property rights, in particular, our patent and trademark rights, preserving the confidentiality of our trade secrets, and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We rely on a combination of patent, trademark, trade secret and other intellectual property rights and measures to protect the intellectual property rights that we consider important to our business. We also rely on know-how and continuing technological innovation to develop and maintain our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Aroa License</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August&#160;2012, we entered into the Aroa License, which was amended and restated in July&#160;2015, pursuant to which we obtained an exclusive license to certain patents and know-how to develop, commercialize and sell bovine and ovine extracellular matrix products for hernia repair, abdominal wall and breast reconstruction in North America and Europe, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which we refer to as the Licensed Territory. In addition, under the Aroa License, Aroa is our exclusive manufacturer and supplier for the development of our bovine and ovine extracellular matrix products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Aroa License, we made upfront payments to Aroa totaling $2.3&#160;million and granted Aroa 74,316 newly issued shares of our restricted common stock. We have made additional payments in the aggregate of $2.0&#160;million to Aroa following the achievement of certain regulatory and operational milestones, including FDA 510(k)&#160;clearance of our OviTex products, which clearance was obtained and is currently held by Aroa, for use in surgical soft-tissue reinforcement and the receipt of the first CE mark for sale of our products in the European Economic Area for use in abdominal wall reconstruction and hernia repair and our acceptance of certain supply quantities manufactured by Aroa for our commercial launch in Europe. In addition, we paid Aroa $4.0&#160;million in revenue-based milestone payments upon our achievement of certain net sales thresholds for sales of our products within the Licensed Territory. As of December 31, 2022, we have satisfied all milestone payment obligations under the Aroa License.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are responsible for commercializing the products manufactured for us by Aroa. We pay Aroa for the supply and manufacturing of our products through a revenue sharing agreement. Pursuant to the Aroa License, we retain 73% of the net sales of all of our products and pay Aroa the remaining 27%. If at any point during the term of the Aroa License we and Aroa determine that our anticipated product needs exceed Aroa&#8217;s manufacturing capabilities, we and Aroa will mutually approve an expansion and equally share the cost of such expansion. Our share of such expansion costs may be offset by us against future revenue share payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The initial term of the Aroa License terminates on the expiration of the last patent covering the OviTex and OviTex PRS products, currently March&#160;9, 2031, with an option to extend for an additional ten-year period. Either party may terminate the Aroa License upon the other party&#8217;s material breach, subject to a ninety-day notice and cure period or upon thirty-days written notice in the event of bankruptcy. We may terminate manufacture and production of a specific product upon thirty-days prior written notice upon (i)&#160;a reasonable determination that such product infringes the intellectual property rights of a third party, (ii)&#160;an uncured supply failure by Aroa or (iii)&#160;such product proves unfeasible, and immediately upon written notice from a regulatory authority that such product must be withdrawn from the market. If we materially breach the Aroa License in one of the Licensed Territories, Aroa may terminate the Aroa License solely with respect to the Licensed Territory in which the breach occurred. Upon termination of the Aroa License, we have the right to purchase all or any part of the unsold portion of any completed products from Aroa and the right to continue to sell all products remaining in our inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Aroa License also contains customary representations and warranties, confidentiality, insurance, audit, indemnification and non-competition provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we exclusively license two issued U.S. patents that will expire in 2029 and 2031. We own fifteen U.S. issued or allowed patents which will expire between 2035 and 2038 and nine pending U.S. patent applications, which subject to issuance, are projected to expire between 2035 and 2042, without taking into account potential patent term extensions or adjustments. In addition to our U.S. intellectual property, we also own three issued non-U.S. patents and four pending non-U.S. patent applications, which, subject to issuance, would be projected to expire between 2036 and 2037 and have exclusively licensed issued patents in Europe and Canada that will expire in 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our patents and patent applications cover, among other things, our corner-lock embroidery pattern, the use of adhesion barriers sewn into soft-tissue and compliance associated with stretching.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although the term of individual patents varies depending upon the country in which they were granted, in most countries, including the U.S., the patent term is 20&#160;years from the earliest claimed filing date of a non-provisional patent application in the applicable country. In the U.S., a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cannot be sure that our pending patent applications that we have filed or may file in the future will result in issued patents, and we can give no assurance that any patents that have been issued or might issue in the future will protect our current or future products, will provide us with any competitive advantage, and will not be challenged, invalidated, or circumvented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Secrets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to our proprietary information. However, trade secrets and proprietary information can be difficult to protect. While we have confidence in the measures we take to protect and preserve our trade secrets and proprietary information, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets and proprietary information may otherwise become known or be independently discovered by competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also rely on trademarks and trade designs to develop and maintain our competitive position. TELA Bio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, OviTex<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Minimize the Foreign Body Footprint<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and A More Natural Hernia Repair<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> are registered trademarks of ours in the U.S. and TELA Bio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and OviTex<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> are registered trademarks in the foreign jurisdictions in which we conduct our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For more information regarding the risks related to our intellectual property, please see the section titled &#8220;Risk Factors&#160;&#8212; Risks Related to Intellectual Property Matters.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We invest in research and development to advance our reinforced tissue matrix products and to develop complimentary soft tissue preservation and restoration products, with the goal of improving upon and supplementing our existing product offerings. We believe our ability to rapidly develop new products and product configurations is attributable to the dynamic product innovation process that we have implemented, the versatility and leveragability of our core technology and the management philosophy behind that process. We have recruited and retained engineers and scientists with significant experience in the development of polymer science, biologics, textile engineering and analytical testing. We have a number of design improvements for our reinforced tissue matrices in various stages of development that are expected to enhance our current products and increase surgeon adoption of our products. In addition, we have engaged in discussions with the FDA regarding an IDE protocol to study the safety and effectiveness of our OviTex PRS portfolio for an indication in breast reconstruction surgery. The FDA has stated that a PMA, rather than 510(k) clearance, will be required for such an indication. Our research and development efforts are based at our facility in Malvern, Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Commercial Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial efforts are predominantly focused on the U.S. market where we have established strong relationships with key constituencies, including hospitals, ambulatory surgery centers, GPOs, IDN, third-party payors and other key clinical and economic decision makers by offering a unique high quality, cost-effective product. As part of our overall commercial strategy, we intend to contract with&#160;GPOs and IDNs to increase access and penetration with hospital accounts. To date, we have contracted with three national GPOs for coverage of our OviTex and OviTex PRS products. We have invested in our direct sales and marketing infrastructure in order to expand our presence to promote awareness and adoption of our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We market our products to hospitals, ambulatory surgery centers, surgeons,&#160;GPOs, IDNs and medical device supply chain participants primarily through our direct sales force. Our sales representatives and sales managers have substantial medical device experience. As of December 31, 2022, we had 123 employees in our U.S. based commercial organization in 67 sales territories, which includes sales management, territory managers, marketing and administrative and field-based support staff. We plan to continue to invest in our commercial organization by hiring additional territory managers and administrative and field-based support employees to support and service new accounts for soft-tissue reconstruction procedures.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All our raw materials are sourced through and manufactured by Aroa in their Auckland, New Zealand facility under the terms of the Aroa License. Aroa&#8217;s facility is approximately 40,000 square feet of which approximately 25,000 square feet is dedicated to manufacturing, including an additional 15,000 square feet of additional manufacturing space in a neighboring facility. The Auckland facility is FDA registered and ISO&#160;13485 certified. We believe that Aroa will be capable of providing sufficient quantities of our products to meet anticipated customer demands. In the event of an uncured supply failure by Aroa, we have the right to, directly or through a third-party, step in and operate the Aroa Auckland facility to manufacture our products on behalf of Aroa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The proprietary ovine rumen used in the manufacturing of our products is obtained from sheep raised for human consumption in New Zealand and is currently sourced by Aroa from two abattoirs, or slaughterhouses. Although only two abattoirs are currently used, there are more than 30 additional abattoirs in New Zealand that could be used to source the ovine rumen. New Zealand cattle and sheep are considered by the USDA to be free of prion disease (progressive neurodegenerative disorders, including scrapie). The sheep receive veterinary inspection prior to slaughter and then each carcass is inspected post-mortem for the presence of disease according to USDA approved standards. Only sheep which pass full inspection can be used as a raw tissue source for our products and all the ovine rumen is processed in compliance with the FDA&#8217;s regulations for Medical Devices Containing Materials Derived from Animal Sources. Once the ovine rumen is procured, our reinforced tissue matrix products are then manufactured by Aroa at its facility in Auckland, New Zealand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The majority of our products are shipped directly from Auckland, New Zealand to our headquarters in Malvern, Pennsylvania. We sell our products directly to our customers, which are hospitals and ambulatory surgery centers. Except for our stocking distributors in Europe, we do not use distributors to sell our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The medical device industry is intensely competitive, subject to change and significantly affected by new product introductions and other market activities of industry participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the hernia repair market, our primary competitors are Bard, a subsidiary of Becton, Dickinson and Company, which produces Phasix and Ventralight ST, and LifeCell, a subsidiary of AbbVie, which produces Strattice. In the plastic and reconstructive surgery market, our primary competitor is LifeCell, a subsidiary of AbbVie, which produces AlloDerm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of these competitors are large, well-capitalized companies with significantly greater market share and resources than we have, selling products that have been on the market prior to the commercialization of our products. As a consequence, they are able to spend more on product development, marketing, sales and other product initiatives than we can, while also benefiting from greater brand awareness. We also compete with smaller medical device companies that have single products or a limited range of products. Some of our competitors have:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significantly greater name recognition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">broader or deeper relations with healthcare professionals, customers and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">more established distribution networks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval for products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater financial and human resources for product development, sales and marketing and patent prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that our continued ability to compete favorably depends on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully expanding our commercial operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing to innovate and maintain scientifically-advanced technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting and retaining skilled personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining and obtaining intellectual property protection for our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting clinical studies and obtaining and maintaining regulatory approvals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our products and operations are subject to extensive and rigorous regulation by the FDA and other federal, state and local authorities, as well as foreign regulatory authorities. The FDA regulates, among other things, the research, development, testing, design, manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion and marketing, distribution, post-approval monitoring and reporting and import and export of medical devices in the U.S. to assure the safety and effectiveness of medical products for their intended use. The Federal Trade Commission also regulates the advertising of our products in the U.S. Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training and other practices to government scrutiny.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory System for Medical Devices in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All of our medical devices sold in the U.S. are subject to the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) as implemented and enforced by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the U.S. will require either a premarket notification to the FDA requesting permission for commercial distribution under Section&#160;510(k)&#160;of the FDCA also referred to as a 510(k)&#160;clearance, or approval from the FDA of a PMA application. Both the 510(k)&#160;clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees, unless an exemption is available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Device Classification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the FDCA, medical devices are classified into one of three classes&#160;&#8212; Class&#160;I, Class&#160;II or Class&#160;III&#160;&#8212; depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the Quality Systems Regulations, or QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices, also called Class I reserved devices, also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Class II devices are those that are subject to the General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Class III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent to a medical device cleared through the 510(k) process. The safety and effectiveness of Class III devices cannot be reasonably assured solely by the General Controls and special controls described above. Therefore, these devices are subject to the PMA application process, which is generally more costly and time consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, preclinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">510(k)&#160;Clearance Pathway</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our current products are subject to premarket notification and clearance under section&#160;510(k)&#160;of the FDCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">When a 510(k)&#160;clearance is required, we must submit a premarket notification to the FDA demonstrating that our proposed device is substantially equivalent to a predicate device, which is a previously cleared and legally marketed 510(k)&#160;device or a device that was in commercial distribution before May&#160;28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class&#160;III to Class&#160;II or I, or a device that was found substantially equivalent through the 510(k)&#160;process. By regulation, a premarket notification must be submitted to the FDA at least 90&#160;days before we intend to distribute a device. As a practical matter, clearance often takes nine to twelve&#160;months, but may take significantly longer. To demonstrate substantial equivalence, the manufacturer must show that the proposed device has the same intended use as the predicate device, and it either has the same technological characteristics, or different technological characteristics and the information in the premarket notification demonstrates that the device is as safe and effective as the predicate device and does not raise different questions of safety and effectiveness. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k)&#160;clearance to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is automatically designated as a Class&#160;III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the <i style="font-style:italic;">de novo</i> classification procedure, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After a device receives 510(k)&#160;marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k)&#160;marketing clearance or, depending on the modification, a <i style="font-style:italic;">de novo</i> classification or PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires a premarket submission in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many minor modifications today are accomplished by a manufacturer documenting the change in an internal letter-to-file. The letter-to-file is in lieu of submitting a new 510(k)&#160;to obtain clearance for every change. The FDA can always review these letters-to-file in an inspection. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until marketing authorization is obtained. Also, in these circumstances, we may be subject to significant regulatory fines or penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">De Novo Classification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Medical device types that the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997, or FDAMA, established a new route to market for low to moderate risk medical devices that are automatically placed into </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the <i style="font-style:italic;">de novo </i>classification procedure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, a medical device could only be eligible for <i style="font-style:italic;">de novo </i>classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent to a predicate device. FDASIA streamlined the <i style="font-style:italic;">de novo </i>classification pathway by permitting manufacturers to request <i style="font-style:italic;">de novo </i>classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. Under FDASIA, the FDA is required to classify the device within 120 days following receipt of the <i style="font-style:italic;">de novo </i>application, although the review of an application can occur over a significantly longer period of time. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would support a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The PMA Approval Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Class III devices require PMA approval before they can be marketed although some pre-amendment Class III devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed labeling. While our current products are subject to the 510(k) clearance pathway, any future products or modifications to our existing products that we plan to develop for a breast reconstruction indication would be subject to the PMA approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Following receipt of a PMA application, the FDA determines whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA has 180 days to review a filed PMA application, although the review of an application can occur over a significantly longer period of time, and can take up to several years. During this review period, the FDA may request additional information or clarification of information already provided, or the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an applicant fails to respond to an FDA request for information (e.g., a major deficiency letter) within 360 days. Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years, but may take significantly longer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">New PMA applications or PMA supplements are required for changes to an approved device, such as modifications to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require extensive technical or clinical data or the convening of an advisory committee, depending on the nature of the proposed change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In approving a PMA application, as a condition of approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device. The FDA may also require post-market surveillance for certain devices cleared under a 510(k) notification, such as implants or life-supporting or life-sustaining devices. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Investigational Device Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s IDE regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Some types of studies deemed to present a &#8220;non-significant risk&#8221; are deemed to have an approved IDE once certain requirements are addressed and Institutional Review Board, or IRB approval is obtained. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under an approval with conditions. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by an appropriate IRB. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials, and although the FDA&#8217;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and efficacy, even if the trial meets its intended success criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA good clinical practice regulations and must obtain patient informed consent, rigorously follow the investigational plan and study </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. The results of clinical testing may be unfavorable, or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pervasive and Continuing FDA Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After the FDA permits a device to enter commercial distribution, numerous and pervasive regulatory requirements continue to apply to our business operations, products and technologies. These include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s Quality Systems Regulations (&#8220;QSR&#8221;), which requires manufacturers, including third party manufacturers, to follow stringent design, testing, production, control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling and marketing regulations which require that promotion is truthful, not misleading, fairly balanced and provides adequate directions for use and that all claims are substantiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complying with requirements for Unique Device Identifiers on devices and also requiring the submission of certain information about each device to the FDA&#8217;s Global Unique Device Identification Database;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advertising and promotion requirements, including FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses and FDA guidance on off-label dissemination of information and responding to unsolicited requests for information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on sale, distribution or use of a device;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">device establishment, registration and listing requirements and annual reporting requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval or clearance of modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">medical device correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall requirements, including a mandatory recall if there is a reasonable probability that the device would cause serious adverse health consequences or death;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an order of repair, replacement or refund;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">device tracking requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance activities and regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA has broad post-market and regulatory enforcement powers. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, untitled letters, Form&#160;483s, fines, injunctions, consent decrees and civil penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall or seizure of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions, partial suspension or total shutdown of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s refusal of requests for 510(k)&#160;clearance or premarket approval of new products, new intended uses or modifications to existing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawing 510(k)&#160;clearance or premarket approvals that have already been granted; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory System for Medical Devices in Europe</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The European Union (&#8220;EU&#8221;) and the European Economic Area (&#8220;EEA&#8221;) (which is comprised of the 27 Member States of the EU plus Norway, Liechtenstein and Iceland) has a coordinated system for the authorization of medical devices. <span style="background:#ffffff;"> Until May 25, 2021, medical devices were regulated by the Council Directive 93/42/EEC, or the Medical Devices Directive (&#8220;MDD&#8221;), which has been repealed and replaced by Regulation (EU) No 2017/745, or the Medical Devices Regulation (&#8220;MDR&#8221;). There is a transition period during which certificates issued under the MDD remain valid, however, when such certificates expire (or, if earlier, by 27 May 2024) the devices must be certified under the new regime set forth in the MDR. However, in response to concerns raised about notified body capacity and the ability for devices to be re-certified within such time period, the European Commission has adopted a proposal to extend the transition period by some years, depending on the risk class of the device. Such proposal is currently being considered for adoption by the European Parliament and Council.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The MDR went into effect on May 26, 2021, and it:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthens the rules&#160;on placing devices on the market and reinforces surveillance once they are available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improves the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sets up a central database (Eudamed) to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthens rules&#160;for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the MDR, the system of regulating medical devices operates by way of a certification for each medical device, which confirms that the device meets the relevant general safety and performance requirements laid down in Annex I of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the MDR. Each certificated device is marked with a CE mark which shows that the device has a certificat de conformit&#233;, also referred to as a certificate of conformity. The means for achieving the requirements for a CE mark varies according to the nature of the device. Devices are classified in accordance with their perceived risks, similarly to the U.S. system. The class of a product determines the requirements to be fulfilled in accordance with the MDR before a CE mark can be placed on a product. The procedure by which a device is assessed to confirm if it complies with the applicable safety and performance requirements is known as a conformity assessment. Conformity assessment procedures require an assessment of available clinical evidence, literature data for the product, and post-market experience in respect of similar products already marketed. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. Except for low-risk medical devices (Class&#160;I non-sterile, non-measuring devices), where the manufacturer can self-certify compliance with the MDR based on a self-assessment of the conformity of its products with the applicable requirements of the MDR, a conformity assessment procedure requires the intervention of an independent organization accredited by a member state of the EEA to conduct conformity assessments, known as a notified body. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EEA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The MDR requires that before placing a device, other than a custom-made device, on the market, manufacturers (as well as other economic operators such as authorized representatives and importers) must register by submitting identification information to the electronic system (Eudamed), unless they have already registered, and manufacturers must assign a unique identifier to the device and provide it along with other core data to the unique device identifier, or UDI, database. These new requirements aim at ensuring better identification and traceability of the devices. Manufacturers are responsible for entering the necessary data on Eudamed, which includes the UDI database, and for keeping it up to date. Eudamed is not yet fully functional, however the European Commission is aiming to have a fully functional version of the Eudamed medical device database available in the second quarter of 2024. The Medical Device Coordination Group (MDCG) has published guidance on administrative practices for manufacturers until Eudamed is fully functional.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Post-Brexit, the MDR does not apply in the United Kingdom (except for Northern Ireland, which under the Northern Ireland Protocol is bound by certain EU laws). &#160;The medical device legislative framework in the United Kingdom is set out in the Medical Devices Regulations 2002. &#160;These Regulations are based on the previous medical device directives of the EU but have been amended so that they function properly now the United Kingdom is no longer part of the EU. &#160;The amended Medical Devices Regulations 2002 have introduced several changes including (but not limited to) replacing the CE mark with a UKCA marking, requiring manufacturers outside of the United Kingdom to appoint a &#8220;UK Responsible Person&#8221; if they place devices on the market in the United Kingdom and more wide-ranging device registration requirements. Manufacturers can continue placing CE marked medical devices on the Great Britain market for the time being, however from July 2024, transitional arrangements will apply for CE marked medical devices placed on the Great Britain market. These transitional arrangements have not yet been brought into force through the UK medical devices regulations, but the UK Government intends to introduce legislation by Spring 2023 that will bring these into force.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Privacy and Security Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information, including health information. Among others, the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations (collectively referred to as &#8220;HIPAA&#8221;) establish privacy and security standards that limit the use and disclosure of protected health information (&#8220;PHI&#8221;) and require covered entities and business associates to implement administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form, among other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Violations of HIPAA may result in civil and criminal penalties. Companies subject to HIPAA must also comply with HIPAA&#8217;s breach notification rule&#160;which requires notification of affected patients and the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and in certain cases of media outlets, in the case of a breach of unsecured PHI. The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">regulations also require business associates of covered entities to notify the covered entity of breaches by the business associate. State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states, and HIPAA standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business associates for compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many states have laws that protect the privacy and security of sensitive and personal information, including health information, to which we are subject. These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, California enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;) which creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA went into effect on January&#160;1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July&#160;1, 2020. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. And the CPRA, which will take effect in most material respects on January 1, 2023, modifies the CCPA significantly, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses to comply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security, laws that place specific requirements on certain types of activities, such as data security and texting, and laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Foreign data protection laws, including the General Data Protection Regulation, (&#8220;GDPR&#8221;) may also apply to health-related and other personal information belonging to individuals who reside outside of the U.S. The GDPR went into effect in the European Union in May 2018 and introduced strict requirements for processing the personal data of data subjects residing in the European Economic Area.  Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates cross-border transfers of personal data and requires transferee countries to have protections equivalent to protections available in the EU.  Because of the uncertainty created by the Court of Justice of the European Union&#8217;s decision invalidating the EU/US Privacy Shield (the primary mechanism to effectuate the flow of data from the EU to the United States), there continues to be uncertainty as to appropriate transfer mechanism for the transfer of data from the EU to the United States.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Further, the United Kingdom&#8217;s exit from the European Union, referred to as Brexit, has created uncertainty regarding data protection regulation in the United Kingdom. The United Kingdom has transposed the GDPR into domestic law with a United Kingdom version of the GDPR that took effect in January 2021 (&#8220;UK GDPR&#8221;). Currently, the GDPR and UK GDPR remain largely aligned, but the United Kingdom has announced plans to reform the country&#8217;s data protection legal framework in its Data Reform Bill, which will introduce significant changes from the GDPR. This may lead to divergence between the GDPR and UK GDPR.<span style="white-space:pre-wrap;">   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">EU member states have introduced national laws implementing the GDPR which impose additional requirements; this  adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-Kickback Statutes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute prohibits persons from (among other things) knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce the referral of an individual, or the recommending, furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Courts have interpreted the Anti-Kickback Statute quite broadly, holding that the statute will be violated if even one purpose of a payment&#160;&#8212; though not its sole or primary purpose&#160;&#8212; is to induce an act prohibited by the statute with a willful intent to act improperly. The statute prohibits many arrangements and practices that are otherwise lawful in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">businesses outside of the healthcare industry. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Prosecutors may infer intent from the surrounding circumstances and, because courts have interpreted the statute to be violated if even one purpose of a payment is to induce the purchase of items or services paid for by federal healthcare programs, prosecutors have broad discretion in choosing arrangements to prosecute under the statute. There are statutory exceptions and regulatory &#8220;safe harbors&#8221; available to protect certain appropriately structured arrangements that otherwise would implicate the Anti-Kickback Statute and those who structure their business arrangements to satisfy all of the criteria of a safe harbor are protected from liability under the statute. Our business is subject to these laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many states have adopted anti-kickback and self-referral laws similar to the Anti-Kickback Statute; however, some of these state prohibitions are broader in scope and apply to arrangements involving healthcare items or services reimbursed by any source, and not only by Medicare, Medicaid or another federal healthcare program. These state laws do not always have the same exceptions or safe harbors as the federal Anti-Kickback Statute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">False Claims Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The federal False Claims Act imposes liability on any individual or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The qui tam or &#8220;whistleblower&#8221; provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has violated the False Claims Act and to share in any monetary recovery. In recent&#160;years, the number of lawsuits brought against healthcare industry participants by private individuals has increased dramatically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government, but also may arise when an entity knowingly makes a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the federal government. Various states have also enacted false claims and insurance fraud laws that are analogous to the federal False Claims Act. Many of these state laws apply to claims submitted to any third-party payor and are not limited to claims submitted to a federal healthcare program. The scope of these laws and the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. A determination of liability under such laws could result in fines and penalties and restrictions on a company&#8217;s ability to operate in these jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Transparency Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The federal Physician Payments Sunshine Act (&#8220;Sunshine Act&#8221;) which was enacted as part of the Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;) generally requires certain manufacturers of a drug, device, biologic or other medical supply that is covered by Medicare, Medicaid or the Children&#8217;s Health Insurance Program and applicable GPOs to report on an annual basis: (i)&#160;certain payments and other transfers of value given to certain healthcare professionals and teaching hospitals and (ii)&#160;any ownership or investment interest that certain healthcare professionals, or their immediate family members, have in their company. The payments required to be reported include the cost of meals provided to a healthcare professional, travel reimbursements and other transfers of value, including those provided as part of contracted services such as speaker programs, advisory boards, consultation services and clinical trial services. Under the statute, the federal government makes reported information available to the public. Failure to comply with the reporting requirements can result in significant civil monetary penalties or criminal penalties if an entity intentionally makes false statements in the reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There has been a recent trend of separate state regulation of payments and transfers of value by manufacturers of medical devices to healthcare professionals and entities, however, and some state transparency laws apply more broadly than the federal Sunshine Act. There are also an increasing number of analogous state laws that require manufacturers to file reports with states on pricing and marketing information. Many of these laws contain ambiguities as to what is required to comply with the laws. For example, several states have enacted legislation requiring manufacturers to, among other things, establish and implement commercial compliance programs, file periodic reports with the state, make periodic </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">public disclosures on sales, marketing, pricing, clinical trials and other activities and/or register their sales representatives. Certain state laws also regulate manufacturers&#8217; use of physician and patient identifiable data. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance burdens. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities. All of our activities are also potentially subject to federal and state consumer protection and unfair competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Federal Healthcare Fraud and Abuse Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may also be subject to other federal healthcare fraud and abuse laws, including provisions of HIPAA, which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and recklessly executing a scheme or artifice to defraud any healthcare benefit program, including private payors, as well as knowingly and willfully falsifying, concealing or covering up a material fact by any trick, scheme or device or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government-sponsored programs. As with the federal Anti-Kickback Statute, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Corrupt Practices Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits U.S. businesses and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with accounting provisions requiring us to maintain books and records, which in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the corporation, including international subsidiaries, if any, and to devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements. Our industry is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Enforcement actions may be brought by the Department of Justice or the SEC, and recent enacted legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in SEC enforcement actions in intent-based claims such as those under the FCPA from five years to ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">International Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In Europe, and throughout the world, other countries have enacted anti-bribery laws and/or regulations similar to the FCPA. Violations of any of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are also international privacy laws that impose restrictions on the access, use, and disclosure of health information. All of these laws may impact our business. Our failure to comply with these privacy laws or significant changes in the laws restricting our ability to obtain required patient information could significantly impact our business and our future business plans.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S. Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls and restrictions on reimbursement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the U.S., the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the &#8220;Affordable Care Act&#8221;, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the healthcare industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There have been significant ongoing judicial, administrative, executive and legislative efforts to modify or eliminate the Affordable Care Act. For example, the Tax Act enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code, commonly referred to as the individual mandate. Other legislative changes have been proposed and adopted since passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent litigation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or the &#8220;CARES Act&#8221;, which was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 to December 31, 2021, which was further extended through March 31, 2022. Following the suspension, a 1% payment reduction began April 1, 2022 and remained through June 30, 2022. The 2% payment reduction resumed on July 1, 2022. The sequester will remain in place through 2030. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Affordable Care Act has been subject to challenges in the courts. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct.&#160; As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further changes to and under the Affordable Care Act remain possible, but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control healthcare costs, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pricing and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third party payors. Third party payors include government health administrative authorities, managed care providers, private health insurers, and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products, and there are continuing legislative and regulatory efforts by the federal government and the states to reduce the cost of medical products and services overall. We may need to conduct expensive studies in order to demonstrate the cost-effectiveness of our products. Our product candidates may not be considered cost-effective. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product or procedure using the product does not ensure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate revenue levels. Future legislation could limit payments for medical devices, including our products and our future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of less costly products. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our products. The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the U.S. has increased and will continue to increase the pressure on medical product and service pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had 173 employees worldwide. None of our employees are represented by a collective bargaining agreement and we have never experienced a work stoppage. We believe we have good relationships with our employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The success of our business is fundamentally connected to the well-being of our employees. Accordingly, we are committed to their health, safety and wellness. We provide our employees and their families with access to a variety of flexible and convenient health and wellness programs, including benefits that provide protection and security so they can have peace of mind concerning events that may require time away from work or that impact their financial well-being; that support their physical and mental health by providing tools and resources to help them improve or maintain their health status and encourage engagement in healthy behaviors; and that offer choice where possible so they can customize their benefits to meet their needs and the needs of their families. In response to the COVID-19 pandemic, we implemented significant changes that we determined were in the best interest of our employees, as well as the communities in which we operate, and which comply with government regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We strive to provide a competitive mix of pay, benefits and services that help meet the needs of our employees. In addition to salaries, these programs include variable incentive compensation plans, potential annual discretionary bonuses, stock awards, a 401(k) Plan, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and flexible work schedules, among others. In addition to our broad-based equity award programs, we have used targeted equity-based grants with vesting conditions to enhance retention of personnel.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We were incorporated on April 17, 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our primary executive offices are located at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355 and our telephone number is (484) 320-2930. Our website address is www.telabio.com. The information contained in, or that can be accessed through, our website is not part of this Annual Report. <span style="background:#ffffff;">We make available, free of charge and through our website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after they are electronically filed with or furnished to the SEC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_41e867e2_ee9c_42cf_89f9_36e15ec1bdf7"></a><a id="ITEM1ARISKFACTORS_798482"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 1A.</b></span>RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should carefully consider the following risks described below, together with all of the other information in this Annual Report, including our consolidated financial statements and related notes. While we believe that the risks and uncertainties described below are the material risks facing our business, additional risks that we do not know of or that we currently think are immaterial may also arise and materially affect our business. The realization of any of these risks could have a material adverse effect on our business, financial condition, results of operations, and our ability to accomplish our strategic objectives.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Achieving or Sustaining Profitability, Financial Position and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant operating losses since inception, we expect to incur operating losses in the future, and we may not be able to achieve or sustain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have incurred net losses since our incorporation on April&#160;17, 2012. For the&#160;years ended December&#160;31, 2022, 2021 and 2020, we had net losses of $44.3 million, $33.3&#160;million and $28.8&#160;million, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $274.2&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant sales and marketing, research and clinical development, regulatory and other expenses as we expand our sales and marketing efforts to increase adoption of our products, expand existing relationships with our customers, obtain regulatory clearances or approvals for our planned or future products, conduct clinical trials on our existing and planned or future products, develop, acquire or license complimentary products for our product portfolio, or add new features to our existing products. As a result, we expect to continue to incur operating losses for the foreseeable future and may never achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on an ongoing basis. If we do not achieve or sustain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of which would have a material adverse effect on our business, financial condition and results of operations and may cause the market price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our indebtedness may limit our flexibility in operating our business and adversely affect our financial health and competitive position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had $40.0&#160;million of indebtedness outstanding under our credit facility with MidCap Financial Trust (&#8220;MidCap&#8221;) that matures in May&#160;2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To service this indebtedness and any additional indebtedness we may incur in the future, we need to generate cash from our operating activities. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory, and other factors beyond our control. We cannot assure you that our business will be able to generate sufficient cash flow from operations or that future borrowings or other financings will be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use cash from operations or the proceeds of any future financing to service our indebtedness, our ability to plan for, or react to, changes in our business, industry and the economy generally will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the MidCap credit facility contains certain covenants that limit our ability to engage in certain transactions that may be in our long-term best interests, including the incurrence of additional indebtedness, effecting certain corporate changes, making certain investments, acquisitions or dispositions and paying dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have not previously breached and are not currently in breach of these or any of the other covenants; however, there can be no guarantee that we will not breach these covenants in the future. In the event that we breach one or more covenants, our lender may choose to declare an event of default and require that we immediately repay all amounts outstanding, terminate any commitment to extend further credit and foreclose on the collateral granted to it to collateralize such indebtedness. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If needed, any future funding requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">surgeon and market acceptance of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of our research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of obtaining regulatory clearances or approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of establishing additional sales and marketing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of clinical trials that we are currently conducting or may conduct in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with any product recall that may occur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing products in our markets or competing technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or invest in products, technologies and businesses, although we currently have no commitments or agreements relating to any of these types of transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of filing and prosecuting patent applications and defending and enforcing our patent or other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of defending, in litigation or otherwise, any claims that we infringe third-party patents or other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any additional equity or debt financing that we raise may contain terms that are not favorable to us or our stockholders. In addition, any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. If we raise additional funds through collaboration and licensing arrangements with third-parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we cannot be certain that additional funding will be available on acceptable terms, if at all. If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or commercialization of our products or license to third-parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to reduce marketing, customer support or other resources devoted to our products or cease operations. Any of these factors could harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to expand, manage and maintain our direct sales and marketing organizations, we may not be able to generate anticipated revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Building the requisite sales, marketing and distribution capabilities to successfully market and sell our products continues to be expensive and time-consuming and requires significant attention from our leadership team to manage. Any failure or delay in the expansion of our sales, marketing or distribution capabilities would adversely impact the commercialization of our products. Additionally, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties on the commercialization of our products. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2022, our commercial organization consisted of 123&#160;employees in the U.S. and 9 employees in Europe. To generate future revenue growth, we plan to expand the size and geographic scope of our direct sales </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">organization. This growth may require us to split or adjust existing sales territories, which may adversely affect our ability to retain customers in those territories. Additionally, our future success will depend largely on our ability to continue to hire, train, retain and motivate skilled sales and marketing personnel with significant industry experience and technical knowledge of medical devices and related products. The competition for talented individuals experienced in selling and marketing medical device products is intense, and we cannot assure you that we can assemble or maintain an effective team. We cannot assure you that we will be able to hire and retain additional personnel on favorable or commercially reasonable terms, if at all. Our operating results are directly dependent upon the sales and marketing efforts of our employees. Failure to hire or retain qualified sales and marketing personnel would prevent us from expanding our business and generating revenue. If we are unable to expand our sales and marketing capabilities, we may not be able to effectively commercialize our products, which could have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Macroeconomic conditions, including the ongoing response to the COVID-19 pandemic, may negatively impact certain aspects of our business, our prospects, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Macroeconomic conditions, including the COVID-19&#160;pandemic, have negatively impacted our business, results of operations and financial condition, and, if continued or exacerbated by inflationary pressures, geopolitical conflict or other macroeconomic events, may adversely impact our business, financial condition and prospects. In the first quarter of 2022, regional surges of the COVID-19 Omicron variant resulted in some government restrictions on elective procedures and surgical staffing challenges leading to the deferral of elective surgeries. While the initial challenges from COVID-19 and its variants have begun to subside, we cannot predict the severity of any long-term impact stemming from strains on the healthcare system, labor and staffing in the hospital sector, fatigue on healthcare workers, and hospital capacity for elective procedures, that resulted from measures taken to address the COVID-19 pandemic. We do not know when, and how, hospitals will return to normal surgical procedural volumes and also reduce the substantial backlog in elective procedures deferred in response to the COVID-19 pandemic. Any prolonged delays in normalized levels of elective surgeries by governmental, hospital or payor actions would continue to impair net sales of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">General supply chain disruptions, initially arising from COVID-19, have also continued to interrupt trade globally and weakened supply systems.&#160;We currently rely on Aroa, which is headquartered in New Zealand, for supply of our products. While there have been minimal disruptions to our supply chain to date, there is a risk that in the future supplies of our products could be disrupted or delayed based on competition within a tightening supply chain or otherwise affected by substantial inflationary pressures due to macroeconomic conditions.&#160;There can be no assurance that we would be able to timely implement any mitigation plans relating to our supply chain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Continued concerns about the systemic impact of potential long-term and wide-spread recession, liquidity constraints, failures and instability in the U.S. and international financial banking systems, and geopolitical issues, including the war in Ukraine, have contributed to increased market volatility and diminished expectations for economic growth in the world. &#160;These conditions may lead to continued volatility in the future, which could result in a decline in our stock price, high inflation, increase our cost of capital and adversely affect our ability to access the capital markets in the future even after local conditions improve. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Market acceptance of our medical products in the U.S. and other countries is dependent upon the procurement practices of our customers, patient need for our products and procedures and the reimbursement of patients&#8217; medical expenses by government healthcare programs and third-party payors. The continuing uncertainty surrounding global economic conditions and financial markets, including the lingering economic impact of the COVID-19 pandemic on our customers, may adversely affect demand for our products and procedures and result in lower reimbursement rates or coverage for our products, resulting in lower sales volume and downward pricing pressure on our products and slower adoption of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The full extent to which the global economic forces, including the COVID-19 pandemic, will further, directly or indirectly, impact our business, results of operations and financial condition, including our sales, expenses, manufacturing capability, supply chain integrity, research and development activities, and employee-related matters, will depend on future developments that are highly uncertain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Information pertaining to the impact of the COVID-19 pandemic and these macroeconomic pressures on our operations to date can be found in &#8220;Management&#39;s Discussion and Analysis of Financial Position and Results of Operations&#8221; in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">Rising inflation rates could negatively impact our revenues and profitability if increases in the prices of our product  or a decrease in consumer spending results in lower volumes of elective surgeries.  In addition, if our costs increase and we are not able to pass along these price increases, our profitability would be adversely affected, and the adverse impact may be material.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inflation rates, particularly in the U.S., have increased recently to levels not seen in years. Increased inflation may result in decreased demand for our products, increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks. In an inflationary environment, we may be unable to raise the prices of our products at or above the rate at which our costs increase, which could/would reduce our profit margins and have a material adverse effect on our financial results. We also may experience lower than expected sales and potential adverse impacts on our competitive position if there is a decrease in consumer spending or a negative reaction to our pricing. A reduction in our revenue would be detrimental to our profitability and financial condition and could also have an adverse impact on our future growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;">Events involving limited liquidity, defaults, non-performance, or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Most recently, on March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (&#8220;SVB&#8221;) and appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although a statement by the Department of the Treasury, the Federal Reserve and the FDIC indicated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, Signature Bank or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder. Even though we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations.  These factors could include, but may not be limited to, the following:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Loss of access to working capital sources and/or the inability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potential or actual breach of financial covenants in our credit agreements or credit arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potential or actual cross-defaults in other credit agreements, credit arrangements or operating or financing agreements; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all.  Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws.  Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Commercialization of our Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">To date, the vast majority of our revenue has been generated from sales of our OviTex products, and we therefore are highly dependent on the commercial success of OviTex product line.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sales of our OviTex products accounted for 70%, 78% and 83% of total revenue for the years ended December 31, 2022, 2021 and 2020, respectively. We first commercialized OviTex products in the U.S. in 2016 and have introduced our larger sized OviTex products, our OviTex&#160;LPR product for use in laparoscopic and robotic-assisted hernia surgical repairs, larger configurations of our LPR product, OviTex PRS products for use in surgery for soft-tissue repair or reinforcement in plastic and reconstructive procedures and recently our NIVIS Fibrillar Collagen Pack for the management of surgical wounds. We expect that sales of our OviTex products and our OviTex PRS products, will account for the majority of our revenue for the foreseeable future. Our failure to successfully increase sales of these products or any other event impeding our ability to sell these products would result in a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The commercial success of our products will largely depend upon attaining significant market acceptance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our ability to execute our growth strategy, achieve commercial success and become profitable will depend upon the adoption by inpatient and outpatient hospitals, surgeons, and medical device supply chain participants of our reinforced tissue matrix products. We cannot predict how quickly, if at all, surgeons will accept our products or, if accepted, how frequently they will be used. Our products and planned or future products we may develop or market may never gain broad market acceptance among surgeons and the medical community for some or all of our indications. Some surgeons may have prior history with or a preference for other soft-tissue reinforcement products, such as permanent synthetic mesh, resorbable synthetic mesh, or other biologic matrices, or may be reluctant to alter their practice patterns to treat patients with our reinforced tissue matrix products. The degree of market acceptance of any of our products will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether surgeons and others in the medical community consider our products to be safe, effective and cost effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived advantages of our products over alternative products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any complications associated with using our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of use of our products relative to competing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements by regulatory authorities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the competitive pricing of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality of our products meeting patient and surgeon expectations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials and post-market clinical studies relating to the use of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing pressure, including from&#160;GPOs and government payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage and adequate reimbursement for procedures using our products from third-party payors, including government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to pay out-of-pocket for our products in the absence of coverage and adequate reimbursement by third-party payors, including government authorities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to provide incremental clinical and economic data that show the safety, clinical efficacy and cost effectiveness, and patient benefits from, our products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, even if our products achieve market acceptance, they may not maintain that market acceptance over time if competing products or technologies, which are more cost effective or received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to attain significant market acceptance of our products, the commercial success of our products is not guaranteed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future financial success will depend substantially on our ability to effectively and profitably market and sell our products. Even if we are able to attain significant market acceptance of our products, the commercial success of our products and any of our planned or future products is dependent on a number of additional factors, including the results of clinical trials relating to the use of our products and our ability to obtain and maintain regulatory approval or clearance to market our products and maintain compliance with applicable regulatory requirements. Successful growth of our sales and marketing efforts will depend on the strength of our marketing and distribution infrastructure and the effectiveness of our marketing and sales efforts, including our efforts to expand our direct sales force, while our ability to satisfy demand for our products driven by our sales and marketing efforts will be largely dependent on the ability of Aroa to maintain a commercially viable manufacturing process that is compliant with regulatory standards. If we fail to successfully market and sell our products, we will not be able to achieve profitability, which will have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our ability to grow our revenue in future periods will depend on our ability to increase sales of our OviTex and OviTex PRS products and any new product or product indications that we introduce, which will, in turn, depend in part on our success in expanding our customer base and driving increased use of our products. New products or product indications may also need to be approved or cleared by the FDA and comparable non-U.S. regulatory agencies to drive revenue growth. If we cannot achieve revenue growth, it could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of our products for these uses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Surgeons and other medical professionals may misuse our reinforced tissue matrix products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our products are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and result in sizeable damage awards against us that may not be covered by insurance. In addition, any of the events described above could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The products we commercialize have been cleared by the FDA and other regulatory authorities for specific indications. Our OviTex products are reinforced tissue matrices designed for use as a surgical mesh to reinforce and/or repair soft-tissue where weakness exists and indications for use of our OviTex products include the repair of hernia and/or abdominal wall defects which require the use of reinforcing or bridging material to obtain the desired surgical outcome. Our OviTex PRS products are reconstructive reinforced tissue matrices designed for implantation to reinforce soft-tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. In connection with the March&#160;2019 meeting of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee, the FDA stated that no surgical mesh device has been cleared or approved for use in breast surgery, and that to obtain such indication, the product sponsor must obtain an approved PMA. This statement applies to our OviTex PRS products as they are not cleared or approved for use in breast surgery and thus, we are prohibited from marketing them for that use. OviTex PRS or any other product we may develop for use in breast surgery will need to be approved specifically for that indication and there can be no guarantee that it will be approved. We have engaged in discussions with the FDA regarding an IDE protocol to study the safety and effectiveness of our OviTex PRS product for an indication in breast reconstruction surgery. There can be no assurance that we will be able to secure a PMA approval in a timely manner, or at all. Any marketing for OviTex PRS or any other product for a use in breast reconstruction surgery would be deemed off-label promotion of that product if it has been cleared for a general indication of use to reinforce or repair soft-tissue and has not received an approval specifically for use in breast surgery. We train our marketing personnel and direct sales force to not promote our OviTex or OviTex PRS products for uses outside of the FDA-cleared indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a surgeon or medical professional from using our OviTex or OviTex PRS products or other products we may commercialize in the future for off-label uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we train our direct sales force not to promote our products for off-label uses, and our instructions for use in all markets specify that our products are not intended for use outside of those indications cleared or approved for use, the FDA or another regulatory authority could conclude that we have engaged in off-label promotion. If the FDA determines that our promotional or training materials constitute promotion of an off-label use, or make claims that are not supported by the available clinical data, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions. It is also possible that other federal, state or non-U.S. enforcement authorities might take action under other regulatory authority if they consider our business activities to constitute promotion of an off-label use, or are otherwise objectionable, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if surgeons or medical professionals use our OviTex products only for their approved indications, a failure by such surgeons and medical professionals to use our products in accordance with the processes and procedures established to properly utilize our OviTex products could result in product liability lawsuits, costly investigations and potentially affect our ability to achieve sufficient market penetration for our OviTex products. In those possible events, our reputation could be damaged and adoption of the products would be impaired. We may also be required to reassess the training, written instructions and product warnings or other labeling information we provide our customers. This process could require us to expend significant time and capital and could have a material adverse effect on our business, financial condition and results of operations and impair our ability to grow our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our OviTex, OviTex PRS or other products we may commercialize in the future, our commercial success may be hindered.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our ability to successfully commercialize and achieve market acceptance of our products depends, in significant part, on the availability of adequate financial coverage and reimbursement from third-party payors, including governmental payors (such as the Medicare and Medicaid programs in the U.S.), managed care organizations and private health insurers. The primary customers for our products are hospitals and ambulatory surgery centers who will then seek reimbursement from third-party payors for the procedures performed using our products. While some third-party payors currently cover and provide reimbursement for procedures using our currently cleared or approved products, we can give </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">no assurance that these third-party payors will continue to provide coverage and adequate reimbursement for the procedures using our products, to permit hospitals and surgeons to offer procedures using our products to patients requiring treatment, or that current reimbursement levels for procedures using our products will continue. Additionally, no uniform policy for coverage and reimbursement exists in the U.S. and coverage and reimbursement can differ significantly from payor to payor. If third-party payors reverse or limit their coverage for the procedures using our currently cleared or approved products in the future, this could have a material adverse effect on our business. If we are forced to lower the price we charge for our products, this could have a material adverse effect on our business, financial condition and results of operations and impair our ability to grow our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Healthcare costs have risen significantly over the past decade, which has resulted in or led to numerous cost reform initiatives. Third-party payors, whether U.S. or non-U.S., or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs, including examining the cost effectiveness of procedures, in addition to their safety and efficacy, when making coverage and payment decisions. Payors continually review new and existing technologies for possible coverage and can, without notice, deny or reverse coverage or alter pre-authorization requirements for new or existing procedures. We cannot provide assurance that we will be successful in any efforts we may potentially undertake to reverse such non-coverage decisions. If we are not successful in reversing non-coverage policies, or if third-party payors that currently cover or reimburse certain procedures reverse or limit their coverage of such procedures in the future, or if other third-party payors issue similar policies, our business could be adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our long-term growth may depend on our ability to enhance our product offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">It is important to our business that we continue to enhance our OviTex and OviTex PRS products and develop and introduce new reinforced tissue matrix products. Developing products is expensive and time-consuming and could divert management&#8217;s attention away from other aspects of our business. The success of any new reinforced tissue matrix product offering or product enhancements to our OviTex and OviTex PRS products will depend on several factors, including our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">properly identify and anticipate surgeon and patient needs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and introduce new products and product enhancements in a timely manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">avoid infringing upon the intellectual property rights of third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ensure the quality, manufacture and supply of new products by Aroa;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrate, if required, the safety and efficacy of new products with data from preclinical studies, clinical trials and post-market clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain the necessary regulatory clearances or approvals for expanded indications, new products or product modifications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be fully FDA-compliant with marketing of new devices or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide adequate training to potential users of our new products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receive adequate coverage and reimbursement for procedures performed with our new products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and expand an effective and dedicated sales and marketing team.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we are not successful in introducing new product indications and developing and commercializing new products and product enhancements, our ability to increase our revenue may be impaired, which could have a material adverse effect on our business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In the future our products may become obsolete, which would negatively affect operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The medical device industry is characterized by rapid and significant change. There can be no assurance that other companies will not succeed in developing or marketing devices and products that are more effective than our reinforced tissue matrix products or that would render our reinforced tissue matrix products obsolete or noncompetitive. Additionally, new surgical procedures, medications and other therapies could be developed that replace or reduce the importance of our products. Accordingly, our success will depend in part on our ability to respond quickly to medical and other changes through the development and introduction of new products. Our reinforced tissue matrix products have a limited shelf life and will expire if not timely used. Product development involves a high degree of risk, and there can be no assurance that our new product development efforts will result in any commercially successful products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">To successfully market and sell our products in markets outside of the U.S., we must address many international business risks with which we have limited experience.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Approximately 8%, 5% and 4% of our revenue for the years ended December 31, 2022, 2021 and 2020, respectively, came from sales in markets outside of the U.S. Part&#160;of our sales strategy is to maintain our European presence. European sales are subject to a number of risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing international operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased competition as a result of more products and procedures receiving regulatory approval in international markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">longer accounts receivable payment cycles and difficulties in collecting accounts receivable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in currency exchange rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">non-U.S. certification and regulatory clearance or approval requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in developing effective marketing campaigns in unfamiliar countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">customs clearance and shipping delays;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">political, social, and economic instability abroad, terrorist attacks, and security concerns in general;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the macroeconomic factors, including COVID-19 pandemic, inflationary pressures and geopolitical conflicts like the war in Ukraine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters and global pandemics like COVID-19, which result in lock-downs, travel restrictions and other restrictions on our ability to operate internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preference for locally produced products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potentially adverse tax consequences, including the complexities of non-U.S. value-added tax systems, tax inefficiencies related to our corporate structure, and restrictions on the repatriation of earnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the burdens of complying with a wide variety of non-U.S. laws and different legal standards; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased financial accounting and reporting burdens and complexities.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If one or more of these risks are realized, our business, financial condition and results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are highly dependent upon Aroa, as the exclusive manufacturer and supplier of our OviTex portfolio products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2012, we entered into our Aroa License which was amended and restated in July&#160;2015. The Aroa License grants us an exclusive license in North America, the EU, United Kingdom, Norway, Switzerland, Russia and former Soviet satellite countries to certain intellectual property rights, including patents relating to the use of bovine and ovine rumen as a source of extracellular matrix. Under the Aroa License, Aroa is our exclusive manufacturer and supplier of our OviTex portfolio products, consisting of OviTex, OviTex LPR and OviTex PRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are reliant upon the intellectual property we license from Aroa for the development and commercialization of our products. Under the Aroa License, we hold an exclusive license to certain intellectual and technology rights to develop, commercialize and sell certain endoform regenerative template products derived from cows and sheep. The Aroa License also provides for cooperative development of our products utilizing the licensed intellectual property and all of our products rely on intellectual property owned by Aroa and licensed to us under the Aroa License. The Aroa License imposes various developmental and regulatory requirements upon us along with requiring us to make milestone payments upon the achievement of certain commercial and regulatory milestones. If we fail to comply with our obligations under the Aroa License, Aroa will have the right to terminate the Aroa License, in which event we would not be able to develop and market our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aroa is required under the Aroa License to manufacture all of our OviTex portfolio products at its manufacturing and warehousing facility in Auckland, New Zealand. The production of all of our OviTex portfolio products in a single location exposes us to the risk of Aroa&#8217;s facility being harmed or rendered inoperable by natural or man-made disasters or pandemics, which may render it difficult or impossible for Aroa to perform its manufacturing and assembly activities for some time. Although we and Aroa intend to establish redundant production facilities to lessen the risk of production disruptions, we will need to ensure that any manufacturing facility complies with our quality expectations and applicable regulatory requirements. If we are unable to establish redundant manufacturing facilities in a timely manner, any disruption in the manufacture of our OviTex portfolio products at Aroa&#8217;s manufacturing and warehouse facility, the continued commercialization of our OviTex portfolio products, the supply of our OviTex portfolio products to customers and the development of any new reinforced tissue matrix products will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Aroa License, Aroa is responsible for supplying all of the raw materials and components used in the manufacture and assembly of our OviTex portfolio products. If Aroa is unable to supply the raw materials and components or to manufacture and assemble our OviTex portfolio products reliably and at the levels we anticipate or that are required by the market, we may be unable to acquire a substitute supply of raw materials and components on a timely basis, if at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Aroa License Aroa also holds the FDA clearances under which we commercialize our OviTex and OviTex LPR products, and maintains ultimate responsibility for all regulatory interactions with FDA relating to our OviTex and OviTex LPR products and decisions made with respect to changing or updating those clearances. If Aroa fails to comply with all applicable regulatory requirements and maintain the FDA clearances related to our OviTex and OviTex LPR products, we may be unable to commercialize our OviTex and OviTex LPR products on a timely basis, or at all. Our ability to supply our OviTex portfolio products commercially and to develop any future products depends, in part, on our ability to obtain these materials, components and products in accordance with regulatory requirements and in sufficient quantities for commercialization and clinical testing. While Aroa has historically met our demand for its products and services on a timely basis in the past, we cannot guarantee that it will always be able to meet our demand for its products. If Aroa fails to meet demand or notifies us that it believes it will fail to meet demand for our OviTex portfolio products, we are required under the Aroa License to work with Aroa to cure its supply failure and may, only in certain circumstances and on a temporary basis, engage a replacement contract manufacturer to mitigate a failure by Aroa to meet demand for our OviTex portfolio products. As such, we are highly dependent upon Aroa&#8217;s continued ability to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">supply our OviTex portfolio products at the levels we require and any production shortfall that impairs the supply of our OviTex portfolio products could have a material adverse effect on our business, financial condition and results of operations and adversely affect our ability to satisfy demand for our OviTex portfolio products, which could adversely affect our product sales and operating results materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We, or our partners, may experience development or manufacturing problems, capacity constraints, or delays in the production of our products that could limit the potential growth of our revenue or increase our losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may encounter unforeseen situations in Aroa&#8217;s manufacturing and assembly of our OviTex portfolio products that would result in delays or shortfalls in its production. For example, Aroa was unable to supply us with our products from September&#160;2017 to December&#160;2017 due to a quality testing process failure identified by Aroa. Personnel shortages and reduced manufacturing capacity due to the COVID-19 pandemic may also result in a disruption in production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Based upon our current planned market adoption we believe we will reach our capacity limitations in the Aroa facility. Aroa expanded its manufacturing capacity, with approximately 15,000 square feet of additional manufacturing space being constructed in a neighboring facility, in 2022. If we are unable to successfully expand capacity, we may not be able to meet the demand for our products. In addition, Aroa&#8217;s production processes and assembly methods may have to change in order to accommodate any significant future expansion of its manufacturing capacity, which may increase our manufacturing costs, delay production of our products and adversely impact our business. Conversely, if demand for our OviTex portfolio products shifts such that Aroa&#8217;s manufacturing facility is operated below its capacity for an extended period, it may adjust its manufacturing operations to reduce fixed costs, which could lead to uncertainty and delays in manufacturing times and quality during any transition period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If Aroa&#8217;s manufacturing activities are adversely impacted or if it is otherwise unable to keep up with demand for our OviTex portfolio products by successfully manufacturing, assembling, testing and shipping our OviTex portfolio products in a timely manner, our revenue could be impaired, market acceptance for our products could be adversely affected and our customers might instead purchase our competitors&#8217; products, which would have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;margin:0pt;">Our products contain materials derived from&#160;animal&#160;sources&#160;and may become subject to additional regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our products are manufactured using ovine rumen. Products that contain materials derived from&#160;animal&#160;sources&#160;are increasingly subject to scrutiny in the media and by regulatory authorities. Regulatory authorities are concerned about the potential for the transmission of disease, particularly progressive neurodegenerative disorders, from animals to humans via those materials. In addition, the COVID-19 pandemic has heightened public awareness of animals and animal products as a disease vector. Products that contain materials derived from animals, including our products, may become subject to additional regulation, or even be banned in certain countries, because of concern over the potential for the transmission of infectious agents. Significant new regulation, or a ban of our products, could impair our current business or our ability to expand our business, and in the case of a ban or suspension, could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our supply of ovine rumen for use in manufacturing our products may be vulnerable to disruption due to natural disaster, disease or other events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ovine rumen used in the manufacturing of our products is sourced through Aroa in New Zealand. Although Aroa obtains its supply of ovine rumen from jurisdictions with sheep that are not currently known to carry any prion disease (progressive neurodegenerative disorders, including scrapie disease), there can be no assurance that these flocks will remain prion disease-free or that a future outbreak or presence of other unintended and potentially hazardous agents would not adversely affect our products or patients that may receive them. The geographic concentration of our supply chain increases our vulnerability to disruption due to natural disasters, disease or other events. If there is a disruption in the supply of ovine rumen to our manufacturer and supplier, we may be unable to fulfill customer orders or delay the commercialization of new products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may also be prohibited from importing our products into the U.S. in the event of disease outbreak or other event impacting the sheep population in New Zealand. Any disruption in our supply lines could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Performance issues, service interruptions or price increases by our shipping carriers could adversely affect our business and harm our reputation and ability to provide our products on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expedited, reliable shipping is essential to our operations. We rely heavily on providers of transport services for reliable and secure point-to-point transport of our OviTex portfolio products (and would rely heavily on such providers for any other products we may commercialize and ship in the future) to our customers and for tracking of these shipments. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any of our products, it would be costly to replace such products in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our OviTex portfolio products (or any other products we commercialize in the future) and increased cost and expense to our business. In addition, any significant increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters, disease or other service interruptions affecting delivery services we use would adversely affect our ability to deliver our OviTex portfolio products (or any other products we commercialize in the future) on a timely basis. For example, disruptions to transportation infrastructure as a result of macroeconomic conditions, including COVID-19 pandemic, may impact our ability to provide our products to our customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Intellectual Property Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our products, and we cannot provide any assurances that third-party patents do not exist which might be enforced against our products in the absence of such a license. The licensing and acquisition of third-party intellectual property rights is a competitive practice and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our products. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected products, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected products, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to comply with our obligations under any license, collaboration or other agreements, we could lose intellectual property rights that are necessary for developing and protecting our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have licensed certain intellectual property rights covering our current products from third parties, including Aroa. We are heavily dependent on our agreements with such third parties for our current products. If, for any reason, one or more of our agreements is terminated or we otherwise lose those rights, it could harm our business. Our license and other agreements impose, and any future collaboration agreements or license agreements we enter into are likely to impose various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">covered by the licensed technology, having to negotiate new or reinstated licenses on less favorable terms, or enabling a competitor to gain access to the licensed technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to adequately protect our intellectual property rights, or if we are accused of infringing on the intellectual property rights of others, our competitive position could be harmed or we could be required to incur significant expenses to enforce or defend our rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in part on our success in obtaining and maintaining issued patents, trademarks and other intellectual property rights in the U.S. and elsewhere and protecting our proprietary technology. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We own fifteen issued or allowed U.S. patents and have nine pending U.S. patent applications. As of December 31, 2022, we had rights, whether through ownership or licensing, to seventeen issued or allowed U.S. patents, nine pending U.S. patent applications, three issued non-U.S. patents and four pending non-U.S. patent applications. Our issued U.S. patents will expire between 2035 and 2042. The licensed patents will expire between 2029 and 2031.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We cannot provide any assurances that any of our patents, or patents to which we have ownership rights through licensing agreements, have, or that any of our pending patent applications that mature into issued patents will include, claims with a scope sufficient to protect our OviTex portfolio products, any additional features we develop for our OviTex portfolio products or any new products we seek to develop in the future. Other parties may have developed technologies that may be related or competitive to our OviTex portfolio products, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position. The patent positions of medical device companies, including our patent position, may involve complex legal, scientific and factual questions, and, therefore, the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated or circumvented. Proceedings challenging our patents could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be costly. Thus, any patents that we may own, or to which we have ownership rights through licensing agreements, may not provide any protection against competitors. Furthermore, an adverse decision in a judicial or administrative proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents covering our products could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors could purchase our OviTex or OviTex PRS products and attempt to replicate the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around the relevant patents, or develop and obtain patent protection for more effective technologies, designs or methods. We may be unable to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, suppliers, vendors, former employees and current employees. The laws of some non-U.S. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">countries do not protect our proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary rights in these countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, proceedings to enforce or defend our patents, or patents to which we have ownership rights through licensing agreements, could put those patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of those patents are invalid or otherwise unenforceable. If any of the patents covering our OviTex portfolio products are invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our products, our competitive position could be harmed or we could be required to incur significant expenses to enforce or defend our rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third parties may assert ownership or commercial rights to inventions we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. In addition, we may face claims by third parties that our agreements with employees, contractors or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property or may lose our exclusive rights in such intellectual property. Either outcome could harm our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money, enter into license agreements for disputed intellectual property and could prevent us from selling our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in part on not infringing the patents or violating other proprietary rights of others. Significant litigation regarding patent rights occurs in our industry. Our competitors may have applied for or obtained, or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. We do not always conduct independent reviews of patents issued to third parties. In addition, patent applications in the U.S. and elsewhere can be pending for many&#160;years before issuance, or unintentionally abandoned patents or applications can be revived, so there may be applications of others now pending or recently revived patents of which we are unaware. Patent applications in the U.S., the EU and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to develop and market our products. Third parties may assert claims that we are employing their proprietary technology without authorization, including claims from competitors or from nonpracticing entities that have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As we continue to commercialize our products in their current or updated forms, launch new products and enter new markets, we expect competitors may claim that one or more of our products infringe their intellectual property rights as a strategy to impede our commercialization and entry into new markets. The large number of patents, the rapid rate of new patent applications and issuances, the complexities of the technologies involved, and the uncertainty of litigation may increase the risk of business resources and management&#8217;s attention being diverted to patent litigation. We have received, and we may in the future receive, letters or other threats or claims from third parties inviting us to take licenses under, or alleging that we infringe, their patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Moreover, we may become party to adversarial proceedings regarding our or third-party patent portfolios. Such proceedings could include supplemental examination or contested post-grant proceedings such as review, reexamination, inter partes review, interference or derivation proceedings before the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and challenges in U.S. District Courts. Patents may be subjected to opposition, post-grant review or comparable proceedings lodged in various foreign, both national and regional, patent offices. The legal threshold for initiating litigation or contested proceedings may be low, so that even lawsuits or proceedings with a low probability of success might be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">initiated. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. We may also occasionally use these proceedings to challenge the patent rights of others. We cannot be certain that any particular challenge will be successful in limiting or eliminating the challenged patent rights of the third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any lawsuits resulting from such allegations could subject us to significant liability for damages and/ or invalidate our proprietary rights. Any potential intellectual property litigation also could force us to do one or more of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stop making, selling or using products or technologies that allegedly infringe the asserted intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lose the opportunity to license our technology to others or to collect royalty payments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur significant legal expenses, including, in some cases, the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pay substantial damages (possibly treble damages) or royalties to the party whose intellectual property rights on which we may be found to be infringing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">redesign products that contain the allegedly infringing intellectual property; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attempt to obtain a license to the relevant intellectual property from third parties, which may not be available on reasonable terms or at all.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any litigation or claim against us, even those without merit, may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our business and harm our reputation. If we are found to infringe the intellectual property rights of third parties, we could be required to pay substantial damages (which may be increased up to three times of awarded damages) and/or substantial royalties and could be prevented from selling our products unless we obtain a license or are able to redesign our products to avoid infringement. In addition, we may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give any competitors access to the same technology or intellectual property rights license to us. Any such license may not be available on reasonable terms, if at all, and there can be no assurance that we would be able to redesign our products in a technically feasible way that would not infringe the intellectual property rights of others. We could encounter delays in product introductions while we attempt to develop alternative methods or products. If we fail to obtain a required license, the holders of any such patents may be able to block us, our licenses or our collaborators from marketing products based on the disputed technology until such patents expire, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. Intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, importing, marketing or otherwise commercializing our products, services and technology. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, we generally indemnify our customers with respect to infringement by our products of the proprietary rights of third parties. Third parties may assert infringement claims against our customers. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, regardless of the merits of these claims. If any of these claims succeed or settle, we may be forced to pay damages or settlement payments on behalf of our customers or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also rely upon copyright and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Such measures may not provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome of any such claim is unpredictable. Trade secret violations are often a matter of state law, and the criteria for protection of trade secrets can vary among different jurisdictions. In addition, trade secrets may be independently developed or reverse engineered by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our business and competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our target markets and our business may be adversely affected. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity, possibly leading to market confusion and potentially requiring us to pursue legal action. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. If we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to enforce our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Filing, prosecuting and defending patents covering our products in all countries throughout the world would be prohibitively expensive, and the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This could make it difficult for us to stop infringement of our foreign patents, if obtained, or the misappropriation of our other intellectual property rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. Additionally, in the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Proceedings to enforce our patent or trademark rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We employ individuals who previously worked with other companies, including our competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property or personal data, including trade secrets or other proprietary information, of a former employer or other third party. Litigation may be necessary to defend against these claims. If we fail in defending any such claims or settling those claims, in addition to paying monetary damages or a settlement payment, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent changes in U.S. patent laws may limit our ability to obtain, defend and/or enforce our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The U.S. has recently enacted and implemented wide ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent&#160;years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the U.S. federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The USPTO and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and other patent agencies over the lifetime of the patent. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by additional payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance with such provisions will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, it can create opportunities for competitors to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the U.S., provided all maintenance fees are timely paid, a patent generally has a term of 20&#160;years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Even if we or our licensors obtain patents covering our products, when the terms of all patents covering a product expire, our business may become subject to competition from products identical or similar to ours. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to obtain a patent term extension in the U.S. under the Hatch-Waxman Act and in foreign countries under similar legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the U.S., a patent that covers a drug product or medical device approved by the FDA may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our products, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five&#160;years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, and only claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. In the European Union, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of&#160;years of revenue from applicable products could be substantial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to our products or utilize similar technology but that are not covered by the claims of our patents or that incorporate certain technology in our products that is in the public domain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by the applicable issued patent or pending patent application that we own now or may own or license in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to successfully commercialize our products before our relevant patents we may have, or to which we have ownership rights through licensing agreements, expire;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our current or future pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may harm our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file&#160;a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our products and operations are subject to extensive government regulation and oversight both in the U.S. and internationally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our products are regulated as medical devices. We and our products are subject to extensive regulation in the U.S. and internationally including by the FDA and competent authorities of the EU member states. The FDA and other foreign equivalents regulate, among other things, with respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; premarket clearance and approval; record keeping procedures; advertising and promotion; recalls and field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; post-market approval studies; and product import and export.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The regulations to which we are subject are complex, have become more stringent over time and are subject to further change. Failure to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as: warning letters; untitled letters; Form 483s; fines; injunctions; civil penalties; termination of distribution; recalls or seizures of products; delays in the introduction of products into the market; total or partial suspension of production; refusal to grant future clearances or approvals; withdrawals or suspensions of current approvals, resulting in prohibitions on sales of our products; and in the most serious cases, criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not receive, or may be significantly delayed in receiving, the necessary clearances or approvals for our future products and modifications to our current products may require new 510(k)&#160;clearances or PMA approvals, and may require us to cease marketing or recall the modified products until clearances or approvals are obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">An element of our strategy is to continue to add new features and expand the indications and uses for our current products. In the U.S., before we can market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive marketing authorization, such as either clearance under Section&#160;510(k)&#160;of the FDCA or approval of a PMA from the FDA, unless an exemption applies. Our products are cleared with the FDA, through clearances obtained and, with the exception of the clearances relating to our OviTex PRS products, held by Aroa, under Section&#160;510(k)&#160;of the FDCA, which permits marketing of a device if it is &#8220;substantially equivalent&#8221; to an already legally-marketed &#8220;predicate&#8221; device, which includes a device that has been previously cleared through the 510(k)&#160;process, a device that was legally marketed prior to May&#160;28, 1976 (preamendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later downclassified, or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and either have the same technological characteristics as the predicate device or have different technological characteristics and the information in the premarket notification demonstrates that the device is as safe and effective and does not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence. In the PMA process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. To date, our products have been the subject of cleared 510(k)s, obtained and, with the exception of the clearances relating to our OviTex PRS products, held by Aroa. For more information regarding the regulation of our products, see &#8220;Business&#160;&#8212; Government Regulation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Modifications to products that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared through a 510(k)&#160;may require a new 510(k)&#160;clearance. Both the PMA approval and the 510(k)&#160;clearance process can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k)&#160;clearance process usually takes from three to 12&#160;months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k)&#160;clearance process and generally takes from one to three&#160;years, or even longer, from the time the application is filed with the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, we cannot assure you that any particular device will be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the U.S., Aroa has obtained and holds 510(k)&#160;clearances from the FDA to market our OviTex products and obtained the 501(k) clearances from the FDA held by us for our OviTex PRS products. An element of our strategy is to continue to upgrade our reinforced tissue matrix products. We expect that any such modifications may require new 510(k)&#160;clearances; however, future modifications may be subject to the substantially more costly, time-consuming and uncertain PMA process. The FDA will require a PMA, rather than a 510(k) clearance for the use if OviTex PRS in breast surgery. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, product introductions or modifications could be delayed or canceled, which could cause our sales to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to demonstrate to the FDA&#8217;s satisfaction that the product or modification is substantially equivalent to the proposed predicate device or safe and effective for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data from our preclinical studies and clinical trials may be insufficient to support clearance or approval, where required; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the manufacturing process or facilities we use may not meet applicable requirements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our future products under development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even after we have obtained the proper regulatory clearance or approval to market a product, we have ongoing responsibilities under FDA regulations. The failure to comply with applicable regulations could jeopardize our ability to sell our reinforced tissue matrix products and result in enforcement actions such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, untitled letters or Form 483s;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">civil penalties;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination of distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls or seizures of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the introduction of products into the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">total or partial suspension of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to grant future clearances or approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawals or suspensions of current clearances or approvals, resulting in prohibitions on sales of our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the most serious cases, criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and harm our reputation, business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, regulators may determine that our financial relationships with our principal investigators resulted in a perceived or actual conflict of interest that may have affected the interpretation of a study. Principal investigators for our clinical trials may serve as speakers or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authority. The FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To sell our products in member countries of the EEA our products must comply with the general safety and performance requirements of the EU Medical Devices Regulation (Regulation 2017/745) (&#8220;MDR&#8221;), which was passed by the EU Parliament on April 5, 2017, and became effective on May 26, 2021. The MDR repeals and replaces the former Medical Devices Directive (Council Directive 93/42/EEC) and the Active Implantable Medical Devices Directive (Council Directive 90/385/EEC). Compliance with the new MDR requirements is a prerequisite to be able to affix the Conformit&#233; Europ&#233;enne, or CE, mark to our products, without which they cannot be sold or marketed in the EEA. In the EEA, we have obtained the CE mark for our OviTex products. For more information regarding regulation of our products, see &#8220;Business&#8212;Government Regulation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">An element of our strategy is to continue to add new features and expand the indications and uses for our current products. Any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k)&#160;clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. Such modifications can be expensive and uncertain in time and outcome. We may not be able to obtain additional 510(k)&#160;clearances or PMAs for new products or for modifications to, or additional indications for, our products in a timely fashion, or at all. Delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. We have made modifications to our products in the past and expect to make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for these modifications, we may be required to recall and to stop selling or marketing such products as modified until we obtain clearance or approval, which could harm our operating results and require us to redesign such products. In these circumstances, we may be subject to significant enforcement actions, including significant fines or penalties.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">International regulatory approval processes may take more or less time than the FDA clearance or approval process. If we fail to comply with applicable FDA and comparable non-U.S. regulatory requirements, we may not receive regulatory clearances or approvals or may be subject to FDA or comparable non-U.S. enforcement actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may be unable to obtain future regulatory clearance or approval in a timely manner, or at all, especially if existing regulations are changed or new regulations are adopted. For example, the FDA clearance or approval process can take longer than anticipated due to requests for additional clinical data and changes in regulatory requirements. A failure or delay in obtaining necessary regulatory clearances or approvals would materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Although we have obtained regulatory clearance for our products, they will remain subject to extensive regulatory scrutiny.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to ongoing and pervasive regulatory requirements governing, among other things, the manufacturing, marketing, advertising, medical device reporting, selling and promoting our products. For example, we must submit periodic reports to the FDA as a condition of our clearance under Section&#160;510(k). These reports include safety and effectiveness information about the device after its clearance. Failure to submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even after we have obtained the proper regulatory approval to market our products, they will be subject to ongoing regulatory requirements for design, development, manufacturing, testing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, recalls and field safety corrective actions, conduct of post-marketing studies and submission of safety, effectiveness and other post-market information, including both federal and state requirements in the U.S. and requirements of comparable non-U.S. regulatory authorities. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA and applicable state regulatory authorities, which may include any of the following sanctions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning or untitled letters that would result in adverse publicity or may require corrective advertising;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, injunctions, consent decrees and civil penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls, termination of distribution, administrative detention, or seizure of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">customer notifications or repair, replacement or refunds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions or partial suspension or total shutdown of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or refusal to grant our requests for future clearances under Section&#160;510(k)&#160;or premarket approvals or EU regulatory approvals of new products, new intended uses, or modifications to existing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal or suspension of regulatory clearances or approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA refusal to issue certificates to non-U.S. governments needed to export products for sale in other countries; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory clearance or approval is withdrawn, it would have a material adverse effect on our business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our products must be manufactured in accordance with federal and state regulations, and we could be forced to recall our products or terminate production if we fail to comply with these regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The methods used in, and the facilities used for, the manufacture of our products must comply with the FDA&#8217;s QSR which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. Furthermore, Aroa must maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations and various EU laws and regulations governing manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aroa may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. For example, following an inspection in March&#160;2017, Aroa received an FDA Form&#160;483 that contained multiple observations related to its manufacturing processes and procedures. In addition, failure to comply with applicable FDA requirements or later discovery of previously unknown problems with our products or manufacturing processes could result in, among other things: untitled letters or warning letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us or our employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these actions could significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If guidelines for soft-tissue reconstruction surgery change or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for our OviTex and OviTex PRS products or other products we may commercialize in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If guidelines for soft-tissue reconstruction surgery change or the standard of care for reconstructing tissue evolves, we may need to redesign the applicable product and seek new approvals from the FDA. Our clearances under Section&#160;510(k)&#160;of the FDCA are based on current soft-tissue reconstruction surgery guidelines. If the guidelines change so that different surgeries or products become desirable, the clinical utility of one or more of our OviTex portfolio products or other products we may commercialize in the future could be diminished and our business could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If any of our products cause or contribute to a death, serious injury, or other adverse medical events, or malfunction in certain ways, we will be required to report these events to FDA and other comparable regulatory authorities under applicable medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions. If we fail to comply with our reporting obligations, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are subject to the FDA&#8217;s medical device reporting regulations and similar EU and other foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including untitled letters, warning letters, administrative actions, criminal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">prosecution, imposition of civil monetary penalties, revocation of related approvals, seizure of our products or delay in clearance or approval of future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA and foreign regulatory agencies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#8217;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. For example, in April&#160;2018, Aroa, as the product manufacturer, issued a voluntary recall of our resorbable OviTex products due to a reduction in the labeled shelf life of such products from 24&#160;months to 18&#160;months. The recall included a total of 1,974 units from 48 manufacturing lots and was ultimately terminated in April&#160;2019. A government-mandated or voluntary recall by us could also occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device. Seeking such approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices, or the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our future products under development. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance of or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April&#160;5, 2017, the European Parliament passed the Medical Devices Regulation (Regulation&#160;2017/745), which repeals and replaces the EU Medical Devices Directive and the Active Implantable Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable, i.e.,&#160;without the need for adoption of EEA member state laws implementing them, in all EEA member states and are intended to eliminate current differences in the regulation of medical devices among EEA member states. The Medical Devices Regulation is intended to, among other things, establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The MDR became fully effective on May 26, 2021. It includes new regulations which, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthen the rules&#160;on placing devices on the market and reinforce surveillance once they are available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthen rules&#160;for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with these regulations may harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent&#160;years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new devices to be reviewed and/or approved or cleared by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our relationships with surgeons, patients and payors in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our current and future operations with respect to the commercialization of our products are subject to various U.S. federal and state healthcare laws and regulations. These laws impact, among other things, our proposed sales, marketing, support and education programs and constrain our business and financial arrangements and relationships with third-party </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">payors, surgeons and other healthcare professionals. The laws are described in greater detail in the section below under &#8220;Business&#160;&#8212; Government Regulation,&#8221; and include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal false claims laws, including the civil False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), which prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Health Insurance Portability and Accountability Act of 1996 which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare and Medicare Services, or CMS, information related to certain payments made in the preceding calendar&#160;year and other transfers of value to physicians, certain other licensed healthcare practitioners and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require medical device companies to comply with the medical device industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug and device manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance or reporting requirements in multiple jurisdictions increase the possibility that a healthcare or medical device company may fail to comply fully with one or more of these requirements. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. Certain physicians who influence the ordering or use of our products in procedures they perform have ownership interests in us and/or receive compensation for consulting services provided to us. It is possible that governmental authorities will conclude that our business practices do not comply with applicable fraud and abuse or other healthcare laws and regulations or guidance.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To enforce compliance with healthcare regulatory laws, certain enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time- and resource-consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these investigations, healthcare providers and entities may also have to agree to additional compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlements could increase our costs or otherwise have an adverse effect on our business. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to respond to.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight and reporting requirements if we become subject to a corporate integrity agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to the same criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to anti-bribery, anti-corruption, and anti-money laundering laws, including the U.S. Foreign Corrupt Practices Act, in which violations of these laws could result in substantial penalties and prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are exposed to trade and economic sanctions and other restrictions imposed by the U.S. and other governments and organizations. The U.S. Departments of Justice, Commerce, State and Treasury and other federal agencies and authorities have a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of economic sanctions laws, export control laws, the U.S. Foreign Corrupt Practices Act, or the FCPA, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control. In addition, the U.K. Bribery Act of 2010 (&#8220;Bribery Act&#8221;), prohibits both domestic and international bribery, as well as bribery across both private and public sectors. An organization that &#8220;fails to prevent bribery&#8221; by anyone associated with the organization can be charged under the Bribery Act unless the organization can establish the defense of having implemented &#8220;adequate procedures&#8221; to prevent bribery. Under these laws and regulations, as well as other anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other laws governing our operations, various government agencies may require export licenses, may seek to impose modifications to business practices, including cessation of business activities in sanctioned countries or with sanctioned persons or entities and modifications to compliance programs, which may increase compliance costs, and may subject us to fines, penalties and other sanctions. A violation of these laws or regulations would negatively affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face risks related to our collection and use of data, which could result in investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about our privacy and data protection practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business processes personal data, including some data related to health. When conducting clinical trials, we face risks associated with collecting trial participants&#8217; data, especially health data, in a manner consistent with applicable laws and regulations. We also face risks inherent in handling large volumes of data and in protecting the security of such data. We could be subject to attacks on our systems by outside parties or fraudulent or inappropriate behavior by our service providers or employees. Third parties may also gain access to users&#8217; accounts using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks or other means, and may use such access to obtain users&#8217; personal data or prevent use of their accounts. Further, our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability that may be imposed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, California enacted the CCPA on June&#160;28, 2018, which took effect on January&#160;1, 2020. The CCPA created individual privacy rights for California consumers and increased the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches in certain instances that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Additionally, a new privacy law, the California Privacy Rights Act, or the CPRA, was approved by California voters in the election of November 3, 2020. The CPRA, which took effect in most material respects on January 1, 2023, modifies the CCPA significantly, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses to comply. A failure to comply with these current or future federal and state laws and regulations and industry standards relating to data privacy and security could lead to investigatory or regulatory action, private litigation or class actions that could result in exposure to civil or criminal penalties, monetary or statutory damages, attorney fee awards and/or exposure to adverse publicity that could negatively affect our operating results and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This risk is enhanced in certain jurisdictions as we expand our operations internationally. The EU&#8217;s GDPR became effective in May&#160;2018. The GDPR applies extraterritorially and imposes several stringent requirements for controllers and processors of personal data, of data subjects residing in the European Economic Area. For example, the GDPR imposes higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of personal data and pseudonymised (i.e.,&#160;key-coded) data and additional obligations when we contract third-party processors in connection with the processing of the personal data. This risk is increased because EU member states have made their own laws and regulations limiting the processing of personal data, including special categories of data (e.g.,&#160;racial or ethnic origin, political opinions, religious or philosophical beliefs) and profiling and automated individual decision-making of individuals, which limits our ability to process personal data or other data and could cause our compliance costs and liability risks to increase, harming our business and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Further, the United Kingdom&#8217;s exit from the European Union, referred to as Brexit, has created uncertainty regarding data protection regulation in the United Kingdom.   The United Kingdom has transposed the GDPR into domestic law with a United Kingdom version of the GDPR that took effect in January 2021 (UK GDPR).  </span>Currently, the EU GDPR and UK GDPR remain largely aligned, but the UK has announced plans to reform the country&#8217;s data protection legal framework in its Data Reform Bill, which will introduce significant changes from the EU GDPR. This may lead to additional compliance costs and could increase our overall risk exposure as we may no longer be able to take a unified approach across the EEA and the UK, and we will need to amend our processes and procedures to align with the new framework. Non-compliance with GDPR, and UK GDPR, is subject to significant penalties, including fines of up to &#8364;20.0&#160;million (&#163;17.5 million under UK GDPR) or 4% of total worldwide revenue, whichever is greater. The implementation and enforcement of the GDPR (and UK GDPR) may subject us to enforcement risk and requirements to change certain of our data collection, processing and other policies and practices. We could incur significant costs investigating and defending such claims and, if we are found liable, significant damages. If any of these events were to occur, our business and financial results could be adversely affected. Other jurisdictions outside the EU and the United Kingdom are similarly introducing or enhancing laws and regulations relating to privacy and data security, which enhances risks relating to compliance with such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The GDPR also regulates cross-border transfers of personal data and requires transferee countries to have protections equivalent to protections available in the EU.  </span>The GDPR imposes strict rules on the transfer of personal data to countries outside the EEA, Switzerland or the United Kingdom, including the United States,<span style="color:#231f20;font-size:11pt;"> </span>to other countries in respect of which the European Commission or the United Kingdom government has not issued a so-called &#8220;adequacy decision&#8221; or &#8220; adequacy regulation&#8221; (known as &#8220;third countries&#8221;), unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data.<span style="color:#231f20;font-size:11pt;"> </span><span style="white-space:pre-wrap;">This includes putting in place the European Commission&#8217;s Standard Contractual Clauses (SCCs) for transfers outside of the EEA and a similar transfer mechanism for transfers of personal data outside of the United Kingdom, the International Data Transfer Agreement or Addendum (IDTA). Under both the GDPR and the UK GDPR,  exporters are also required to assess the risk of the data transfer on a case-by-case basis, </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">including conducting an analysis of the laws in the destination country. The SCCs had to be in place by December 27, 2022, whereas the IDTA must be implemented in all existing contracts by March 21, 2024.  Finalizing the implementation of the updated SCCs and UK IDTA, and conducting the required risk assessments, may continue to necessitate significant contractual overhaul of our data transfer arrangements with customers, sub-processors and vendors.  On June 28, 2021, the European Commission published its decision recognizing the United Kingdom as having adequate laws to the protect the rights and freedoms of data subjects such that personal data may transfer to from the EU to the United Kingdom without an approved transfer mechanism.  The decision is effective for four years and its continuing effect is dependent on United Kingdom and regulation on data privacy not diverging materially from the GDPR. The United Kingdom Government also confirmed that data transfers to the EU remain free flowing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compliance with U.S. federal and state laws and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with United States and foreign data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. And claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Toc63927383"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Affordable Care Act and any changes in healthcare law may increase the difficulty and cost for us to successfully commercialize our products and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the U.S., the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the healthcare industry. The Affordable Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">There have been significant ongoing judicial, administrative, executive and legislative efforts to modify or eliminate the Affordable Care Act. For example, the Tax Act enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code, commonly referred to as the individual mandate. Other legislative changes have been proposed and adopted since passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent litigation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, which was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 to December 31, 2021 , later extended through March 31, 2022.  Following the suspension, a 1% payment reduction began April 1, 2022, and remained through June 30, 2022. The 2% payment reduction resumed on July 1, 2022. The sequester will remain in place through 2030. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Affordable Care Act has been subject to challenges in the courts. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Affordable Care Act. An appeal was taken to the U.S. Supreme Court.  On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct.&#160; As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further changes to and under the Affordable Care Act remain possible, but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control healthcare costs, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures. and could seriously harm our future revenues. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain and maintain profitability of our product and product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business involves the use of hazardous materials and we and Aroa must comply with environmental laws and regulations, which may be expensive and restrict how we do business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aroa&#8217;s activities in manufacturing our products may involve the controlled storage, use and disposal of hazardous materials. Aroa is or may be subject to federal, state, local and non-U.S. laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials. We currently carry no insurance specifically covering environmental claims relating to the use of hazardous materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we believe that Aroa&#8217;s safety procedures for handling and disposing of these materials and waste products comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental injury or contamination from the use, storage, handling or disposal of hazardous materials. In the event of an accident, federal, state or other applicable authorities may curtail Aroa&#8217;s use of these materials and interrupt their business operations which could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Compliance with environmental laws and regulations may be expensive and non-compliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our financial results may fluctuate significantly and may not fully reflect the underlying performance of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our quarterly and annual results of operations may vary significantly in the future, and period-to-period comparisons of our operating results may not be meaningful. Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside our control.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Factors that may cause fluctuations in our quarterly and annual results include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">surgeon and patient adoption of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of new product offerings, acquisitions, licenses or other significant events by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in coverage policies by third-party payors that affect the reimbursement of procedures in which our products are used;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated pricing pressure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory clearance or approval for any products in development or for our current products for additional indications or in additional jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the hiring, retention and continued productivity of our sales representatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to expand the geographic reach of our sales and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical research and trials on our existing products and products in development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in, or failure of, component and raw material deliveries by Aroa;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls or other field safety corrective actions by Aroa; </span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters such as earthquakes, floods or public health emergencies such as the COVID-19 pandemic; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">positive or negative coverage in the media or clinical publications of our products or products of our competitors or our industry.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because our quarterly and annual results may fluctuate, period-to-period comparisons may not be the best indication of the underlying results of our business. In particular, we cannot predict at this time the extent of the impact that the COVID-19 pandemic will have on our sales and financial results. These fluctuations may also increase the likelihood that we will not meet our forecasted performance, which could negatively affect the market price for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to compete successfully with larger competitors in our highly competitive industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, as well as in acquiring technologies complementary to, or necessary for, our products. Because of the complex and technical nature of our products and the dynamic market in which we compete, any failure to attract and retain a sufficient number of qualified employees could materially harm our ability to develop and commercialize our products, which would have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In the U.S., we currently compete with LifeCell Corporation, a subsidiary of AbbVie, and Davol&#160;Inc., a subsidiary of Becton, Dickinson and Company, which produce, among other things, soft-tissue reconstruction surgery products, including Strattice and Phasix, respectively. In the EEA, we compete with Bard, a subsidiary of Becton, Dickinson and Company, who produces other soft-tissue reinforcement products. Many of these competitors are large, well-capitalized companies with significantly greater market share and resources than us, selling products that have been on the market prior to the commercialization of our products. As a consequence, they are able to spend more on product development, marketing, sales and other product initiatives than we can, while benefiting from greater brand awareness. We believe other emerging businesses are in the early stages of developing similar products designed for soft-tissue reconstruction </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">surgery. Although we are the only ovine-derived implantable product designed for soft-tissue reconstruction surgery, there are other soft tissue reconstruction surgery products derived solely, or in part, from other biological sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Most of the other soft-tissue reconstruction surgery products currently have a greater penetration into the soft tissue reconstruction surgery market. Often, other soft-tissue reconstruction surgery products with which our products compete are marketed as part of a bundled product line, which may provide our potential customers a better price-per-product than we could offer. If we are unable to penetrate the soft-tissue reconstruction surgery market or offer competitive pricing on our products compared with products sold as part of a bundled product line, it could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, competitors with greater financial resources could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or products that could effectively compete with our existing products, which may cause our revenue to decline and would harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to renew existing contracts with GPOs or obtain additional contract positions with major GPOs and integrated delivery networks, or IDNs, for our products, and even if we are able to do so, such contracts may not generate sufficient sales of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many existing and potential customers for our products within the U.S. are members of&#160;GPOs and IDNs, including accountable care organizations or public-based purchasing organizations, and our business strategy is focused on entering into major contracts with these organizations. Our products can be contracted under national tenders or with larger hospital&#160;GPOs.&#160;GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. We are currently responding to bids and negotiating a number of&#160;GPO and IDN agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">We may not be able to renew existing contracts with GPOs or IDNs and due to the highly competitive nature of the bidding process and the&#160;GPO and IDN contracting processes in the U.S., we may not be able to obtain additional contract positions with major&#160;GPOs and IDNs for our products. If we are unable to renew existing contracts with GPOs or IDNs, our net sales and results of operations may be materially and adversely affected. In addition, while having a contract with a major purchaser for a given product category can facilitate sales, sales volumes of those products may not be maintained. For example,&#160;GPOs and IDNs are increasingly awarding contracts to multiple suppliers for the same product category. Even if we are the sole contracted supplier of a&#160;GPO or IDN for our product category, members of the&#160;GPO or IDN generally are free to purchase from other suppliers. Furthermore,&#160;GPO and IDN contracts typically are terminable without cause upon 60 to 90&#160;days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Supply chain disruptions could adversely impact our operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Global supply chains have been disrupted because of the COVID-19 pandemic and other factors, and this may impact the availability of raw materials and components used in the manufacture of our products. Additionally, even when we and our suppliers are able to source such materials and components, they may cost more and may only be available on a delayed basis. Higher materials and component costs could adversely affect our margins if we are unable to pass such costs along to customers in the form of price increases. Delays in receipt of materials and components could also interrupt our production and cause us to go into backorder on certain of our products, further exacerbating the effect of the global supply chain disruption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face the risk of product liability claims that could be expensive, divert management&#8217;s attention and harm our reputation and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our business exposes us to the risk of product liability claims that are inherent in the testing, manufacturing and marketing of medical devices. This risk exists even if a product is cleared or approved for commercial sale by the FDA, and manufactured in facilities licensed and regulated by the FDA. Any side effects, manufacturing defects or misuse associated with our products could result in patient injury or death. The industry in which we operate has historically been subject to extensive litigation over product liability claims, and we cannot offer any assurance that we will not face product liability suits. We may be subject to product liability claims if our products cause, or merely appear to have caused, patient injury or death. In addition, an injury that is caused by the activities of Aroa may be the basis for a claim </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">against us. Product liability claims may be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with our products. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in substantial litigation costs, product recalls or market withdrawals, decreased sales and demand for our products and damage to our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We can provide no assurance that we will be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of our products, either of which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we have product liability insurance that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. In addition, our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, coverage may not be adequate to protect us against any future product liability claims. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The continuing development of our products depends upon our maintaining strong working relationships with surgeons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The research, development, marketing and sale of our current and future products and any future product indications for which we receive regulatory clearance or approval depend upon our maintaining working relationships with surgeons. We rely on these professionals to provide us with considerable knowledge and experience regarding the development, marketing and sale of our products. Surgeons assist us in clinical trials and in marketing, and as researchers, product consultants and public speakers. If we cannot maintain our strong working relationships with these professionals and continue to receive their advice and input, the development and marketing of our products could suffer, which could have a material adverse effect on our business, financial condition and results of operations. At the same time, the medical device industry&#8217;s relationship with surgeons is under increasing scrutiny by the U.S. Department of Health and Human Services Office of Inspector General (&#8220;OIG&#8221;), the U.S. Department of Justice (&#8220;DOJ&#8221;), the state attorneys general and other foreign and domestic government agencies. Our failure to comply with requirements governing the industry&#8217;s relationships with surgeons or an investigation into our compliance by the OIG, the DOJ, state attorneys general and other government agencies, could have a material adverse effect on our business, financial condition and results of operations. Additional information regarding the laws impacting our relationships with surgeons and other healthcare professionals can be found above under &#8220;Risks Related to Government Regulation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have limited data and experience regarding the safety and efficacy of certain of our products. Results of earlier studies may not be predictive of future clinical trial results, or the safety or efficacy profile for such products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our single arm multicenter post-market clinical study, which we refer to as our BRAVO study, was fully enrolled at 92 patients. We conducted this study to support the marketing of our OviTex products for their cleared indicated uses, and do not currently have any clinical data for use of our OviTex PRS products in patients. The long-term effects of using certain of our products in a large number of patients have not been studied and the results of short-term clinical use of such products do not necessarily predict long-term clinical benefits or reveal long-term adverse effects. The results of preclinical studies and clinical studies of our products conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials in other patient populations. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in preclinical studies and earlier clinical trials have nonetheless failed to replicate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">results in later clinical trials. Products in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and earlier clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publicly disclose interim or preliminary data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a full analyses of all data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim or preliminary data should be viewed with caution until the final data are available. We may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to use such results to support the marketing of our products may be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our estimates of the annual total addressable markets for our current products and products under development are based on a number of internal and third-party estimates, including, without limitation, the number of hernia and soft-tissue reconstruction surgery patients and overall market and the assumed prices at which we can sell our products. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our products may prove to be incorrect. If the price at which we can sell future products, or the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our reinforced tissue matrix products have a limited shelf life and will expire if not timely used. To ensure adequate inventory supply, we must forecast inventory needs and place orders with Aroa based on our estimates of future demand for our reinforced tissue matrix products. Our ability to accurately forecast demand for such products could be negatively affected by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product introductions by competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase or decrease in surgeon demand for our products or for products of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to accurately manage our expansion strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to accurately forecast surgeon acceptance of new products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to obtain contracts with a significant number of GPOs and IDNs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated changes in general market conditions or regulatory matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity and duration of market disruptions as a result of the COVID-19 outbreak; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">weakening of economic conditions or consumer confidence.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Additionally, we are subject to the risk that a portion of our inventory will expire, which could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory. Conversely, if we underestimate customer demand for our products, Aroa may not be able to deliver products to meet our requirements, and this could result in damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or Aroa may not be able to allocate sufficient capacity to meet our increased requirements, which could have an adverse effect on our ability to meet customer demand for our products and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on our own direct sales force for our products, which may result in higher fixed costs than our competitors and may slow our ability to reduce costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely on our own direct sales force, which as of December 31, 2022 consisted of 61 representatives in the U.S. and 7 representatives in Europe, to market and sell our products. A direct sales force may subject us to higher fixed costs than those of companies that market competing products through independent third parties, due to the costs that we will bear associated with employee benefits, training and managing sales personnel. As a result, we may be at a competitive disadvantage. Additionally, these fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, independent contractors, consultants, commercial partners, distributors and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees, independent contractors, consultants, commercial partners and vendors may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i)&#160;the rules&#160;of the FDA and other similar foreign regulatory bodies; (ii)&#160;manufacturing standards; (iii)&#160;healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws; (iv)&#160;data privacy laws and other similar non-U.S. laws; or (v)&#160;laws that require the true, complete and accurate reporting of financial information or data. These laws may impact, among other things, future sales, marketing and education programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or other sanctions, including the imposition of civil, criminal and administrative penalties, additional integrity reporting and oversight obligations and possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, any of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against any such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We could be adversely affected by any interruption to our ability to conduct business at our current location.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not have redundant facilities. We perform substantially all of our research and development and back-office activity and maintain all our finished goods inventory in a single location in Malvern, Pennsylvania. Our facility, equipment and inventory would be costly to replace and could require substantial lead time to repair or replace. The facility may be harmed or rendered inoperable by natural or man-made disasters, including, but not limited to, tornadoes, flooding, fire, public health emergencies such as pandemics and power outages, which may render it difficult or impossible for us to perform our customer service research, development and commercialization activities for some period of time. The inability to perform those activities, combined with the time it may take to rebuild our inventory of finished product, may result in the loss of customers or harm to our reputation. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and this insurance may not continue to be available to us on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we experience significant disruption or a breach in our information technology systems, our business could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely extensively on information technology systems to conduct our business. These systems affect, among other things, ordering and managing products, shipping products to customers, processing transactions, summarizing and reporting results of operations, complying with regulatory, legal and tax requirements, data security and other processes necessary to manage our business. Our information systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customer information, and changing customer patterns. If our systems are damaged or cease to function properly due to any number of causes, ranging from catastrophic events to power outages to security breaches, and our business continuity plans do not effectively compensate on a timely basis, we may experience interruptions in our operations, which could have an adverse effect on our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we fail to maintain or protect our information systems and data integrity effectively, we could lose existing customers, have difficulty attracting new customers, suffer backlash from negative public relations, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Furthermore, any breach in our information technology systems could lead to the unauthorized access, disclosure and use of non-public information from our patient registry or other patient information which is protected by HIPAA and other laws. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and damage to our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had federal and state net operating loss carry forwards (&#8220;NOLs&#8221;) of approximately $212.3 million and $173.5 million, respectively. The federal carry forwards for losses incurred prior to 2018 will begin expiring in 2032 for federal purposes. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Cut &amp; Jobs Act. The state carry forwards will begin expiring in 2026. A full allowance for the value of the NOLs is provided for in our audited financial statements for the year of December 31, 2022 included in this Annual Report on Form 10-K. We cannot guarantee what the ultimate outcome or amount of the benefit we may receive from the NOLs, if any, will be. If we become profitable in the future, our ability to use net operating loss carryforwards and other tax attributes to offset future taxable income or reduce taxes may be subject to limitations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The trading price of the shares of our common stock has been and could in the future be highly volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The price of our common stock has been and may continue to be volatile. Even though our common stock is listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;), an active trading market for our common stock may not be sustained. The lack of an active trading market may impair the value of your shares and your ability to sell your shares at the time you wish to sell them. An inactive trading market may also impair our ability to raise capital by selling shares of our common stock and enter into strategic partnerships or acquire other complementary products, technologies or businesses by using shares of our common stock as consideration. Furthermore, there can be no guarantee that we will continue to satisfy the continued listing standards of Nasdaq. If we fail to satisfy the continued listing standards, we could be de-listed, which would have a negative effect on the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cannot predict the prices at which our shares of common stock may trade. The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the volume and timing of sales of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of new products or product enhancements by us or others in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments with respect to our or others&#8217; intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop, obtain regulatory clearance for, and market new and enhanced products on a timely basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product liability claims or other litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarterly variations in our results of operations or those of others in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">media exposure of our products or of those of others in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in governmental regulations or in reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in earnings estimates or recommendations by securities analysts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">broad trends impacting companies within the pharmaceutical, biotechnology and medical technology industries; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, including any economic downturn as a result of the COVID-19 pandemic, or macroeconomic factors such as geopolitical tensions or the outbreak of hostilities or war.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In recent&#160;years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance. Further, on March 10, 2023, the FDIC took control and was appointed receiver of SVB. The financing uncertainty pharmaceutical, biotechnology and medical technology companies may now face as a result of SVB&#8217;s entry into receivership may cause significant volatility with respect to pharmaceutical, biotechnology, and medical technology company stocks, which in turn could negatively impact the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">price, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management&#8217;s attention and resources from our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not intend to pay cash dividends on our common stock for the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the agreement governing our credit facility precludes, and any future debt agreements may preclude us from paying cash dividends. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on, among other factors, our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. Any return to stockholders will therefore be limited to the appreciation in the value of their stock, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our officers, directors and principal stockholders each holding more than 5% of our common stock, collectively, control approximately 56% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to significantly influence our management and affairs and most matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could attempt to delay or prevent a change in control, even if such change in control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our capital stock or our assets, and might affect the prevailing market price of our common stock due to investors&#8217; perceptions that conflicts of interest may exist or arise. As a result, this concentration of ownership may not be in the best interests of our other stockholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions and relief from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies.&#8221; In particular, while we are an &#8220;emerging growth company&#8221; (i)&#160;we will not be required to comply with the auditor attestation requirements of Section&#160;404(b)&#160;of the Sarbanes-Oxley Act, (ii)&#160;we will be exempt from any rules&#160;that could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#8217;s report on financial statements, (iii)&#160;we will be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and (iv)&#160;we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may remain an emerging growth company until as late as December&#160;31, 2024, the fiscal&#160;year-end following the fifth anniversary of the completion of our IPO, though we may cease to be an &#8220;emerging growth company&#8221; earlier under certain circumstances, including if (i)&#160;we have more than $1.235&#160;billion in annual revenue in any fiscal&#160;year, (ii)&#160;the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of any June&#160;30 or (iii)&#160;we issue more than $1.0&#160;billion of non-convertible debt over a three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The exact implications of the JOBS Act are still subject to interpretations and guidance by the SEC and other regulatory agencies, and we cannot assure you that we will be able to take advantage of all of the benefits of the JOBS Act. In addition, investors may find our common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or become more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are at risk of securities class action litigation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because medical device companies have experienced significant stock price volatility in recent&#160;years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock depends in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, the price of our stock could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provisions in our corporate charter documents and under Delaware law could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provisions in our fourth amended and restated certificate of incorporation and our second amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. As our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions provide, among other things, that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our board of directors has the exclusive right to expand the size of our board of directors and to elect directors to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our stockholders may not act by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a special meeting of stockholders may be called only by the chair of our board of directors, our chief executive officer (or president, in the absence of a chief executive officer) or a majority of our board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our fourth amended and restated certificate of incorporation prohibits cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our board of directors may alter certain provisions of our second amended and restated bylaws without obtaining stockholder approval;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval of the holders of at least two-thirds of our shares entitled to vote at an election of our board of directors is required to adopt, amend or repeal our second amended and restated bylaws or repeal the provisions of our fourth amended and restated certificate of incorporation regarding the election and removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders must provide advance notice and additional disclosures to nominate individuals for election to the board of directors or to propose matters that can be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain voting control of our shares; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our board of directors is authorized to issue shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;) which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three&#160;years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our fourth amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our fourth amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the United State District Court for the District of Delaware) is the exclusive forum, to the fullest extent permitted by law, for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL or our fourth amended and restated certificate of incorporation or second amended and restated bylaws or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine, except, in each case, (A)&#160;any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10&#160;days following such determination), (B)&#160;which is vested in the exclusive jurisdiction of a court or forum other than such court, or (C)&#160;for which such court does not have subject matter jurisdiction, in all cases subject to the courts having jurisdiction over indispensable parties named as defendants. This provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. For example, stockholders who do bring a claim in the Court of Chancery could face additional litigations costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our fourth amended and restated certificate of incorporation to be inapplicable or unenforceable in such action. Alternatively, if a court were to find the choice of forum provision contained in our fourth amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions. This provision will not apply to actions arising under the Securities Act or Exchange Act. Our fourth amended and restated certificate of incorporation and second amended and restated bylaws further provide that the federal district courts of the U.S. will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Section&#160;22 of the Securities Act, however, creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules&#160;and regulations thereunder. Accordingly, there is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to maintain our competitive position depends on our ability to attract and retain senior management and other highly qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on our senior management and other key personnel. Our success depends in part on our continued ability to attract, retain and motivate highly qualified senior management and attract, retain and motivate qualified employees, including sales and marketing professionals, clinical specialists and other highly skilled personnel. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. If we are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition and results of operations. The loss of highly qualified employees could result in delays in product development and commercialization and harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we have entered into employment agreements with all of our executive officers, each of them may terminate their employment with us at any time. The replacement of any of our key personnel likely would involve significant time and costs and may significantly delay or prevent the achievement of our business objectives and could therefore have an adverse effect on our business. We also do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules&#160;and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well those controls and procedures are conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p><a id="_4f06903d_31b1_4ef2_b72d_1cff1146bf04"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_265117"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 1B.</b></span>UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="ITEM2PROPERTIES_264380"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 2.</b></span>PROPERTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our products are manufactured by our exclusive manufacturer and supplier of our products, Aroa, at their facility in Auckland, New Zealand which currently totals approximately 40,000 square feet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We lease our corporate headquarters in Malvern, Pennsylvania, which houses our research and development operations, controlled environment room, and office space, and currently totals approximately 25,000&#160;square feet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that our current facilities meet our current and future anticipated needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate office space will be readily available on commercially reasonable terms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM3LEGALPROCEEDINGS_49550"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 3.</b></span>LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may be subject to other legal proceedings and claims in the ordinary course of business. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us due to diversion of management time and attention as well as the financial costs related to resolving such disputes.</p><a id="ITEM4MINESAFETYDISCLOSURES_57184"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 4.</b></span><b style="font-weight:bold;">MINE SAFETY DISCLOSURES </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_17048fac_ac56_4583_9856_0714531d252f"></a><a id="PARTII_672268"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-align:center;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">PART II</p><a id="ITEM5MARKETFORREGISTRANTSSCOMMONEQUITY_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">ITEM 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt;"><span style="font-weight:normal;">Our common stock has been publicly traded on the Nasdaq Global Market under the symbol &#8220;TELA&#8221; since November 8,</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">2019. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of March 16, 2023, the Company had approximately 65 record holders of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt;"><span style="font-weight:normal;">The Company has not declared or paid any dividends since its inception nor does it expect to pay dividends in the </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information under the heading &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; will be filed in the Company&#8217;s definitive proxy statement for the 2023 annual meeting of stockholders and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Issuer Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_170896d4_2c07_437b_bd69_13f8bda17775"></a><a id="ITEM6SELECTEDCONSOLIDATEDFINANCIALDATA_6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 6.</b></span>RESERVED</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_99c21dcd_f4aa_45af_b8a5_4dcde78e7881"></a><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSIS_41"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">ITEM 7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations and the consolidated financial statements and the related notes included elsewhere in this Annual Report. In addition to historical financial information, the following discussion contains forward-looking statements based upon our current plans, expectations and beliefs that involve risks, uncertainties and assumptions. Our actual results may differ materially from those described in or implied by these forward-looking statements as a result of many factors, including those set forth under the section titled &#8220;Risk Factors&#8221; and in other parts of this Annual Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient&#8217;s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient&#8217;s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements. We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our first portfolio of products, the OviTex Reinforced Tissue Matrix (&#8220;OviTex&#8221;), which we first commercialized in the U.S. in July 2016, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hernia repair is one of the most common surgeries performed in the U.S., representing approximately 1.1&#160;million procedures annually. Based on the volume weighted average selling price of our OviTex products, we estimate the annual U.S. total addressable market opportunity for our OviTex products to be approximately $1.5&#160;billion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Our OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.  In addition, we have also designed an OviTex product specifically for use in laparoscopic and robotic-assisted hernia repair, which we market as OviTex LPR and began commercializing this product in November&#160;</span><span style="white-space:pre-wrap;">2018.  We recently launched two new, larger configurations of OviTex LPR, designed for ventral and incisional hernias.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">We have also focused on evaluating and publishing clinical data on the effectiveness and safety of our OviTex products.  To date, there have been thirty published or presented works relating to these clinical findings, either by us or a third-party evaluating the OviTex product.  Recently in October 2022, the 24-month results of our single arm, multicenter post-market clinical study, which we refer to as our BRAVO study, were published in the </span><i style="font-style:italic;">Annals of Medicine and Surgery</i>. The BRAVO study was designed to evaluate the clinical performance of OviTex for primary or recurrent ventral hernias using open, laparoscopic, or robotic techniques in 92 enrolled patients. The recurrence rate at the 24-month time point was 2.6%, and surgical site occurrences (&#8220;SSOs&#8221;) were observed in 38% of the study population. Of the enrolled patients, 78% were characterized as high risk for experiencing an SSO based on at least one known risk factor, which included obesity, active smoking, COPD, diabetes mellitus, coronary artery disease, or advanced age (&#8805;75 years). The results also indicated that BRAVO patients experienced statistically significant and clinically meaningful improvements in their quality of life and perceived health based on patient responses to the EuroQol-5 Dimension (EQ-5D) health assessment and the validated 12-question Hernia-Related Quality of Life survey (HerQLes). In addition to the BRAVO study and other current clinical initiatives, we also commenced enrollment in May 2021 for our BRAVO II study, a prospective study evaluating the use of OviTex in robot-assisted ventral and inguinal hernia repairs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (&#8220;OviTex PRS&#8221;), which we first commercialized in the U.S. in May 2019, addresses unmet needs in plastic and reconstructive surgery.  OviTex&#160;PRS is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">indicated for use in implantation to reinforce soft-tissue where weakness exists in patients requiring soft-tissue repair or reinforcement in plastic and reconstructive surgery. Our OviTex&#160;PRS portfolio is supported by non-human primate data that demonstrated more rapid tissue integration and tissue remodeling compared to the market leading biologic matrix used in this indication. Based on the current sales of biologic matrices in the U.S., we estimate the annual U.S. current addressable market opportunity for our OviTex&#160;PRS products to be approximately $700&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our OviTex products have received 510(k)&#160;clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), which clearance was obtained and is currently held by our exclusive contract manufacturer of these products, Aroa. In April 2019, our OviTex PRS products received 510(k) clearance from the FDA, which clearance was obtained by Aroa and is currently held by us. We have also engaged in discussions with the FDA regarding an Investigational Device Exemption (&#8220;IDE&#8221;) protocol to study the safety and effectiveness of our OviTex&#160;PRS product for an indication in breast reconstruction surgery. The FDA has stated that a PMA, rather than 510(k) clearance will be required for such an indication. We have also commenced a retrospective clinical study evaluating the effectiveness and safety of our OviTex PRS products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We also continue to expand our service offerings and diversify our supplier base as we continue to create a soft tissue restoration portfolio, including through the development of complimentary solutions targeting surgical wound management and infection control. In January 2023, we announced an exclusive development and distribution partnership with Collagen Matrix, Inc. (&#8220;CMI&#8221;), pursuant to which we launched the commercialization of our NIVIS Fibrillar Collagen Pack, an absorbent matrix of Type I and Type III bovine collagen designed to manage moderately to heavily exudating wounds and to control minor bleeding. We also previously commercialized through a distribution agreement with Next Science Technologies Pty Limited (&#8220;Next Science&#8221;), a proprietary antimicrobial surgical wash in the U.S. plastic reconstructive market. We are assessing additional strategic partnerships with medical device companies whereby we may enter into distribution, product development and/or licensing agreements for new products complimentary to, or related to, existing and future products in our distribution channel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have a broad portfolio of intellectual property protecting our products that we believe, when combined with the proprietary manufacturing processes associated with our products and our know-how, provides significant barriers to entry. Our intellectual property applies to our differentiated product construction and materials. In addition, we believe our exclusive manufacturing and long-term supply and license agreement (the &#8220;Aroa License&#8221;) with Aroa creates a competitive advantage by allowing us to secure an exclusive supply of ovine rumen at a low cost. Ovine rumen, the forestomach of a sheep, is the source of the biologic material used in our OviTex portfolio products. In manufacturing the product, we use biologic material from ovine rumen because of its plentiful supply, optimal biomechanical profile and open collagen architecture that allows for rapid cellular infiltration. We purchase product from Aroa at a fixed cost equal to 27% of our net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We market our products through a single direct sales force, predominantly in the U.S., as augmented by a smaller number of sales representatives and distributors in certain European countries. We have invested in our direct sales and marketing infrastructure to expand our presence and to promote awareness and adoption of our products. As of December 31, 2022, we had 67 sales territories in the U.S. As part of our commercial strategy, we plan to continue to invest in our commercial organization by hiring additional territory managers and administrative and field-based support employees to support and service new accounts for soft-tissue reconstruction procedures. We believe we can enhance the productivity of our sales force by improving customer segmentation and targeting, implementing and further refining our proprietary training programs, leveraging support from our medical education and clinical development functions to drive physician awareness and education on our products, and utilizing engagement analytics to support product development.  Additionally, we have contracted with three national GPOs covering our OviTex product and plan to continue to contract with additional GPOs and other integrated delivery networks (&#8220;IDNs&#8221;) to increase access to and penetration of hospital accounts. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are currently devoting research and development resources to develop additional versions of our OviTex hernia product lines, including self-adhering technology to further enhance product compatibility in robotic procedures, as well as additional versions of our OviTex PRS product lines. We are also working to develop new product features and designs for both our existing OviTex and OviTex PRS products. Additionally, we are exploring new packaging technology to increase the shelf life of our OviTex and OviTex PRS products. We are also exploring additional </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">technologies that may complement our existing products, or expand the number of our product lines, in each case within the hernia, plastic and reconstruction, and broader soft-tissue reconstruction and preservation market. We intend to continue to make investments in research and development efforts to develop improvements and enhancements. We are also assessing strategic partnerships with medical device companies whereby we may enter into distribution, product development and/or licensing agreements for products complimentary to, or related to, existing and future products in our distribution channel, which could result in the payment of single digit royalties or other product acquisition costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our OviTex products are manufactured by Aroa at their FDA registered and ISO&#160;13485 compliant facility in Auckland, New Zealand. We maintain our Aroa License for the exclusive supply of ovine rumen and manufacture of our reinforced tissue matrices under which we purchase product from Aroa at a fixed cost equal to 27% of our net sales of licensed products. This revenue sharing arrangement allows us to competitively price our products and pass along cost-savings to our customers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business was directly impacted by the COVID-19 pandemic. We experienced volatility in demand for our products which primarily resulted from government and hospital restrictions, as well as patient health and safety concerns, decreasing the volume of elective procedures using our products. We saw improvement in our business during the second half of 2022 and anticipate that procedure volumes will continue to normalize to pre-pandemic levels; we continue to monitor the potential impact of the COVID-19 pandemic on labor and hospital staffing levels, procedural volumes and ultimately on our results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our revenue for the&#160;years ended December 31, 2022 and 2021 was $41.4&#160;million and $29.5&#160;million, respectively, which represents an increase of $12.0&#160;million, or 41% for the year ended December 31, 2022. Our net loss for the same time periods was $44.3&#160;million and $33.3&#160;million, respectively, which represents an increase of $11.0&#160;million, or 33% for the year ended December 31, 2022. As of December 31, 2022, we had an accumulated deficit of $274.2&#160;million. The vast majority of our revenue to date has been generated from sales of our OviTex and OviTex&#160;PRS products in the U.S., with the remainder generated from sales of our OviTex products in Europe and the sale of other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Business Update Regarding Macroeconomic Conditions and COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business, results of operations and commercial operations have been impacted by macroeconomic conditions, including the COVID-19 pandemic, as well as, to a lesser extent, inflationary pressures, fluctuations in foreign currency in the jurisdictions in which we operate, and geopolitical conflicts. These factors have and may continue to impact us in the following ways:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COVID-19</i><span style="white-space:pre-wrap;">:  In the first quarter of 2022, regional surges of the COVID-19 Omicron variant resulted in some government restrictions on elective procedures and surgical staffing challenges leading to the deferral of elective surgeries and lower surgical procedural volumes overall. While we anticipate the normalization of surgical procedures to pre-pandemic levels, the pace of increased procedural volume remains unknown as hospitals allocate to address staffing shortages to prioritize any backlog of non-elective procedures. Additionally, other labor and financial strains on healthcare systems may continue to reduce procedural volumes. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General Economic Uncertainty</i><span style="white-space:pre-wrap;">:  Continued concerns about the systemic impact of potential long-term and wide-spread recession and geopolitical issues, including the war in Ukraine, have contributed to increased market volatility and diminished expectations for economic growth in the world.  As a result, we have experienced high volatility in our stock price over the prior year. Continued uncertainty and perception of worsening market conditions could result in a decline in our stock price, high inflation, increase our cost of capital and adversely affect our ability to access the capital markets in the future.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Financial Strain and Inflationary Pressures</i>:<i style="font-style:italic;white-space:pre-wrap;">  </i>Market acceptance of our medical products in the U.S. and other countries is dependent upon the procurement practices of our customers, patient need for our products and procedures and the reimbursement of patients&#8217; medical expenses by government healthcare programs and third-party payors. The continuing uncertainty surrounding global economic conditions and financial markets, including the financial strain suffered by hospital customers during the COVID-19 pandemic, may adversely affect demand for our products and procedures and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">result in lower reimbursement rates or coverage for our products, resulting in lower sales volume and downward pricing pressure on our products and slower adoption of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Substantially all our revenue consists of direct sales of our products to hospital accounts in the U.S. Depending on the terms of our agreements with our customers, we recognize revenue related to product sales either when control transfers, which generally occurs when the product is shipped to the customer, or when the product is utilized in a surgical procedure in the case of consignment agreements. Fees charged to customers for shipping are recognized as revenue. Recent revenue growth has been driven by increasing revenue from product sales due to our expanding customer base, although it is unclear at this point what long-term effect the COVID-19 pandemic and related macroeconomic pressures will have on our ability to continue to generate revenue and expand our customer base. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of revenue primarily consists of the costs of licensed products, charges related to excess and obsolete inventory adjustments, royalties and costs related to shipping. We purchase product from Aroa at a fixed cost equal to 27% of our net sales of licensed products. The initial term of our Aroa License terminates on the expiration of the last patent covering bovine and ovine products, with an option to extend for an additional ten-year period. We expect our cost of revenue to increase in absolute dollars as, and to the extent, our sales volume grows, although it is unclear at this point what long-term effect, if any, the COVID-19 pandemic and related macroeconomic pressures will have on our product demand which could lead to additional charges to excess and obsolete inventory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Amortization of Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Amortization of intangible assets relates to the amortization of capitalized milestone amounts paid or probable to be paid to Aroa related to license fees or commercialization rights after future economic benefit has been established for a product. These capitalized milestone amounts relate to regulatory clearances, the receipt of certain supply quantities of product, and amounts based upon aggregate net sales thresholds within a specified territory, and are amortized over the remaining useful life of the intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gross Profit and Gross Margin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our gross profit is calculated by subtracting our cost of revenue and amortization of intangible assets from our revenue. We calculate our gross margin&#160;percentage as our gross profit divided by our revenue. Our gross margin has been, and we expect it will continue to be, affected by a variety of factors, including sales volume, royalties and inventory excess and obsolescence costs. Our gross profit may increase to the extent our revenue grows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales and Marketing Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sales and marketing expenses consist of commercial activities related to the sale of our products, along with the salaries and related benefits, including sales commissions and stock-based compensation for employees focused on these efforts. Other significant sales and marketing expenses include costs incurred with post-market clinical studies, conferences and trade shows, promotional and marketing activities, market research, as well as travel and training expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Over time we expect our sales and marketing expenses to increase in absolute dollars as we continue to expand our commercial organization to both drive and support our planned growth in revenue. We expect our sales and marketing expenses to continue to decrease as a&#160;percentage of revenue, as and to the extent, our revenue grows.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation for personnel in executive, finance, information technology and administrative functions. General and administrative expenses also include professional service fees for legal, accounting, consulting, investor and public relations, insurance costs and direct and allocated facility-related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect that our general and administrative expenses will increase in absolute dollars as we execute our growth initiatives and expand our business and headcount to support these initiatives. We expect our general and administrative expenses to decrease as a&#160;percentage of revenue primarily as, and to the extent, our revenue grows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses consist primarily of product research, engineering, product development, regulatory compliance and clinical development. These expenses include salaries and related benefits including stock-based compensation, for employees focused on these efforts, consulting services, costs associated with our preclinical studies, costs incurred with our manufacturing partner under development agreements related to technology transfer, costs incurred from license agreements with no alternative future uses, laboratory materials and supplies and an allocation of related facilities costs. We expense research and development costs as they are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses in absolute dollars to increase in the future as we develop new products and enhance existing products. We expect research and development expenses as a&#160;percentage of revenue to vary over time depending on the level and timing of new product development initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Interest expense consists of cash interest under our credit facilities and non-cash interest attributable to the amortization of final payment fees and the amortization of deferred financing costs related to our indebtedness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loss on Extinguishment of Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Loss on extinguishment of debt consists of the excess consideration paid over the net carrying value of our debt at the time of extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other expense consists primarily of miscellaneous tax expenses and foreign currency exchange gains and losses offset by income earned on our cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the Year Ended December&#160;31, 2022 and 2021</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 41,418</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,463</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,955</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of revenue (excluding amortization of intangible assets)&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,570</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,346</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,224</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 804</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 304</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 164</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27,044</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,813</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 44</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 43,252</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,062</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,190</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 49</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,862</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,459</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,403</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,937</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,743</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,194</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66,051</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48,264</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,787</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (39,007)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (29,451)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (9,556)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,051)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,597)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (454)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,228)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,228)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (228)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 218</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (96)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,289)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,825)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,464)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 38</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (44,296)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,276)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11,020)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue increased by $12.0 million, or 41%, to $41.4 million for the year ended December 31, 2022 from $29.5&#160;million for the year ended December&#160;31, 2021. The increase in revenue was primarily driven by an increase in unit sales of our products due to the expansion of our commercial organization, increased penetration within existing customer accounts and stronger international sales. During the year ended December 31, 2022, we sold 10,083 units of OviTex compared to 7,516 units of OviTex during the year ended December 31, 2021, a 34% increase in unit sales volume. Additionally, we sold 2,385 units of OviTex PRS compared to 1,260 units during the year ended December 31, 2021, an 89% increase in unit sales volume.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of revenue (excluding amortization of intangible assets) increased by $3.2&#160;million to $13.6&#160;million for the year ended December 31, 2022 from $10.3&#160;million for the year ended December&#160;31, 2021. The increase in cost of revenue was primarily the result of an increase in products purchased to support demand from our higher unit sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Amortization of Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Amortization of intangible assets increased by $0.5 million, or 164%, to $0.8 million for the year ended December 31, 2022 from $0.3 million for the year ended December 31, 2021. In June 2022, we determined that our final milestone target under our licensing agreement with Aroa was probable of being met and recorded the payment obligation as an intangible asset, resulting in an additional cumulative amortization charge of $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gross Margin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Gross margin increased to 65% for the year ended December 31, 2022 from 64% for the year ended December&#160;31, 2021. The increase was primarily due to a lower expense recognized for excess and obsolete inventory adjustments as a percentage of revenue which resulted from improved inventory management processes during the year ended December 31, 2022 as compared to the prior&#160;year partially offset by higher amortization of intangible assets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales and Marketing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sales and marketing expenses increased by $14.2&#160;million, or 49%, to $43.3 million for the year ended December 31, 2022 from $29.1&#160;million for the year ended December&#160;31, 2021. The increase was primarily due to higher salaries, benefits and commission costs as a result of our expanded commercial organization, higher travel and consulting expenses and additional employee-related costs due to an increase in headcount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $1.4&#160;million, or 11%, to $13.9 million for the year ended December 31, 2022 from $12.5&#160;million for the year ended December&#160;31, 2021. The increase was primarily due to higher salaries and benefits due to an increase in headcount, higher software related expenses and additional bad debt expense which offset lower insurance expense and recruiting fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by $2.2 million, or 33%, to $8.9 million for the year ended December 31, 2022 from $6.7&#160;million for the year ended December&#160;31, 2021. The increase was primarily due to an in-process research and development charge, higher salaries and benefits due to an increase in headcount and higher study costs, which offset a decrease in stock-based compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense increased by $0.5 million, or 13%, to $4.1 million for the year ended December 31, 2022 from $3.6 million for the year ended December 31, 2021 as our borrowings increased under our MidCap Credit Agreement at higher interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss on Extinguishment of Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded a loss on the extinguishment of debt of $1.2&#160;million during the year ended December 31, 2022 related to the repayment of borrowings of our credit facilities with OrbiMed in May. The losses were primarily comprised of the write-off of unamortized debt discounts and prepayment penalties at the time of extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other expense decreased by $0.2 million, or 96%, primarily due to foreign currency translation adjustments offset by increased interest income.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, we had cash and cash equivalents of $42.0&#160;million, working capital of $50.0 million and an accumulated deficit of $274.2 million. As of December&#160;31, 2021, we had cash and cash equivalents of $43.9&#160;million, working capital of $48.5 million and an accumulated deficit of $229.9&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2022, we completed an underwritten public offering in which we issued and sold 4,600,000 shares of common stock at a public offering price of $8.00 per share. We received net proceeds of $34.4 million after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have incurred operating losses since our inception, and we anticipate that our operating losses will continue in the near term as we seek to invest in our sales and marketing initiatives to support our growth in existing and new markets and in additional research and development activities. As of December 31, 2022, we had $40.0&#160;million of borrowings outstanding under our Credit and Security Agreement (the &#8220;MidCap Credit Agreement&#8221;) with MidCap Financial Trust, as agent and certain lender parties thereto. The MidCap Credit Agreement matures in May 2027 and provides for up to $50.0 million in term loans (the &#8220;MidCap Term Loans&#8221;), consisting of a $40.0 million Tranche 1 (&#8220;Tranche 1&#8221;) and a $10.0 million Tranche 2 (&#8220;Tranche 2&#8221;). Upon closing, we borrowed $40.0 million of Tranche 1 and used a portion of the proceeds to repay borrowings under the OrbiMed Credit Facility and intend to use the remaining proceeds to fund operations and other general corporate purposes. We will be eligible to borrow Tranche 2 at our option upon meeting certain conditions, including, but not limited to, reaching $65.0 million of net product revenue over the preceding four quarters by fiscal year end 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on our current business plan, we believe that our existing cash resources will be sufficient to meet our capital requirements and fund our operations for at least the next 12&#160;months from the issuance of this Annual Report. If these sources are insufficient to satisfy our liquidity requirements, we may seek to sell common or preferred equity or debt securities, or enter into a new credit facility. In December 2020, we entered into an Equity Distribution Agreement (the &#8220;Equity Agreement&#8221;) with Piper Sandler &amp; Co (the &#8220;Agent&#8221;) in connection with the establishment of an at-the-market offering program under which we may sell up to an aggregate of $50.0 million of shares of our common stock, from time to time through the Agent as sales agent. No sales were made under the Equity Agreement during the years ended December 31, 2022, 2021 or 2020. If we raise additional funds by issuing equity or equity-linked securities, our stockholders would experience dilution and any new equity securities could have rights, preferences and privileges superior to those of holders of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. We cannot be assured that additional equity, equity-linked or debt financing will be available on terms favorable to us or our stockholders, or at all, including as a result of market volatility resulting from the COVID-19 pandemic, inflationary pressures, geopolitical conflict or other factors. If we are unable to obtain adequate financing, we may be required to delay or reduce the current development, commercialization and marketing plans for our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes our sources and uses of cash for each of the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (40,748)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30,432)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (24,456)</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,872)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (627)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,122</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,852</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 585</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 44,409</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate change on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (144)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net (decrease) increase in cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,912)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30,463)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,092</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, we used $40.7 million of cash in operating activities, resulting from our net loss of $44.3&#160;million and the change in operating assets and liabilities of $5.3 million offset by non-cash charges of $8.9 million. Our non-cash charges were comprised of stock-based compensation expense of $4.0 million, our excess and obsolete inventory charge of $1.9&#160;million, loss on extinguishment of debt of $1.2 million, depreciation and amortization expense of $1.2&#160;million and interest expense of $0.7&#160;million. The change in our operating assets and liabilities was primarily related to an increase in our inventory and accounts receivable, partially offset by increases in accrued expenses and other current and long-term liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, we used $30.4 million of cash in operating activities, resulting from our net loss of $33.3&#160;million and the change in operating assets and liabilities of $3.5 million offset by non-cash charges of $6.3 million. Our non-cash charges were comprised of stock-based compensation expense of $3.7 million, our excess and obsolete inventory charge of $1.4&#160;million, interest expense of $0.7&#160;million and depreciation and amortization expense of $0.5&#160;million. The change in our operating assets and liabilities was primarily related to an increase in our inventory and prepaid expenses and other assets, partially offset by increases in accrued expenses and other current and long-term liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, we used $24.5 million of cash in operating activities, resulting from our net loss of $28.8&#160;million and the change in operating assets and liabilities of $0.2 million offset by non-cash charges of $4.5 million. Our non-cash charges were comprised of stock-based compensation expense of $2.1 million, our excess and obsolete inventory charge of $1.3&#160;million, interest expense of $0.6&#160;million and depreciation and amortization expense of $0.5&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, cash used in investing activities was $1.9 million consisting of a $1.0 million payment made for our intangible asset and purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, cash used in investing activities was $0.6 million consisting of purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, cash provided by investing activities was $9.1 million consisting primarily of the proceeds from the sale and maturity of short-term investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">During the year ended December 31, 2022, cash provided by financing activities was $40.9 million, consisting primarily of $34.4 million in proceeds from an underwritten public offering, $40.0 million in proceeds received from the issuance of long-term debt, partially offset by $30.0 million in repayments of long-term debt and $3.5 million in payments of issuance costs.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, cash provided by financing activities was $0.6&#160;million, consisting primarily of the proceeds received from the exercise of stock options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, cash provided by financing activities was $44.4&#160;million, consisting primarily of the net proceeds received from a follow-on public offering of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indebtedness</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 26, 2022, we entered into the MidCap Credit Agreement with MidCap Financial Trust, as agent and certain lender parties thereto. The MidCap Credit Agreement provides for up to $50.0 million in MidCap Term Loans, consisting of a $40.0 million Tranche 1 and a $10.0 million Tranche 2. Upon closing, we borrowed $40.0 million of Tranche 1 and used a portion of the proceeds to fully repay borrowings under the OrbiMed Credit Facility and intend to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">use the remaining proceeds to fund operations and other general corporate purposes. We will be eligible to borrow Tranche 2 at our option upon meeting certain conditions, including, but not limited to, reaching $65.0 million of net product revenue over the preceding four quarters by fiscal year end 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the MidCap Credit Agreement, we provided a first priority security interest in all existing and future acquired assets, including intellectual property, owned by us. The MidCap Credit Agreement contains certain covenants that limit our ability to engage in certain transactions that may be in our long-term best interests, including the incurrence of additional indebtedness, effecting certain corporate changes, making certain investments, acquisitions or dispositions and paying dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The MidCap Credit Agreement also contains customary indemnification obligations and customary events of default, including, among other things, (i) non-payment, (ii) breach of warranty, (iii) non-performance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, we must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, we would be required to pay interest on principal and all other due and unpaid obligations at the current rate in effect plus 2%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The MidCap Term Loans mature on May 1, 2027 and bear interest at a rate equal to 6.25% plus the greater of one-month Term SOFR (as defined in the MidCap Credit Agreement) or 1.0%. We are required to make 36 monthly interest payments beginning on June 1, 2022 (the &#8220;Interest-Only Period&#8221;). If we are in covenant compliance at the end of the Interest-Only Period, we will have the option to extend the Interest-Only Period by 12 months to 48 monthly interest payments, followed by 12 months of straight-line amortization, with the entire principal payment due at maturity. If we are not in covenant compliance at the end of the Interest-Only Period, we are required to make 24 months of straight-line amortization payments, with the entire principal amount due at maturity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subject to certain limitations, the MidCap Term Loans have a prepayment fee equal to 3.0% of the prepaid principal amount for the first year following the closing date of the MidCap Term Loans, 2.0% of the prepaid principal amount for the second year following the closing date and 1.0% of the prepaid principal amount for the third year following the closing date and thereafter. We are also required to pay an exit fee at the time of maturity or prepayment event equal to 5% of all principal borrowings (or in the event of a prepayment event, the amount of principal being prepaid).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual Obligations and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our contractual obligations as of December 31, 2022 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:45.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments due by Period</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:53.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1 year</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1 to 3 years</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">3 to 5 years</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal payments on long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and end of term charge on long-term debt<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,147</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,190</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,379</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,578</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease commitments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,039</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 358</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 741</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 775</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 165</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase commitments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21,655</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,275</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,315</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,335</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,730</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,841</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,823</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 52,688</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,895</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interest payable reflects the rate in effect as of December 31, 2022. The interest rate on borrowings under the MidCap Credit Facility is variable and resets&#160;monthly. End of term fee reflects final payment fee due at maturity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects payments due for our lease of office and laboratory space in Malvern, Pennsylvania under an operating lease agreement that expires in 2028.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 7A.</b></span>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our cash is held on deposit in demand accounts at high-credit-quality financial institutions in amounts in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (&#8220;SVB&#8221;) and appointed the FDIC as receiver.  On March 12, 2023, the U.S. Department of the Treasury, the Federal Reserve and the FDIC released a joint statement confirming that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, on March 10, 2023, the Bank of England (the &#8220;BOE&#8221;) announced that it intended to seek the placement of Silicon Valley Bank UK Limited (&#8220;SVBUK&#8221;), an affiliate of SVB, into a Bank Insolvency Procedure, which ultimately results in the acquisition of SVBUK by HSBC UK Bank Plc (&#8220;HSBC&quot;) on March 13, 2023. The BOE confirmed that all depositors&#8217; money with SVBUK is safe and secure as a result of the transaction, and that operations at SVBUK would continue as normal.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the course of these events, a portion of our cash was held in accounts at SVB and SVBUK, with the remainder at another high-credit-quality financial institution. We have recently established additional redundant accounts with another high-credit-quality financial institution to mitigate liquidity risk to our cash and cash equivalents from any further instability in the financial industry. We have reviewed the consolidated financial statements of this financial institution and believe they have sufficient assets and liquidity to conduct their operations in the ordinary course of business with little or no credit risk to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk principally consist of cash equivalents and accounts receivable. We limit our credit risk associated with cash equivalents by placing investments in highly-rated money market funds. We limit our credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but we do not require collateral to secure amounts owed to us by our customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As discussed above in the section of this Annual Report entitled &#8220;Liquidity and Capital Resources&#160;&#8212; Indebtedness,&#8221; the MidCap Credit Facility bears interest at a floating rate of interest, which resets monthly and is equal to 6.25% plus the greater of one-month Term SOFR or 1.0%. As a result, we are exposed to risks from changes in interest rates. A 1% increase in interest rates would have resulted in a $0.2 million increase to our interest expense for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inflationary factors, such as increases in our cost of revenue and operating expenses, may adversely affect our operating results. Although we do not believe inflation has had a material impact on our financial condition, results of operations or cash flows to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin or decrease our operating expenses as a&#160;percentage of our revenue if our selling prices of our products do not increase as much or more than our costs increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not currently have any material exposure to foreign currency fluctuations and do not engage in any hedging activities as part of our normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Significant Judgments and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in Note&#160;3 to our consolidated financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We account for revenue in accordance with Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). Under ASC 606, we recognize revenue when our customer obtains control of our promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventory Valuation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventory, which consists of our OviTex portfolio products held on consignment or held in our warehouse, is considered finished goods and is purchased from a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We evaluate the carrying value of our inventory in relation to the estimated forecast of product demand, which takes into consideration the expiration date of the products. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory. The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. In addition, we continue to introduce new products and sizes, which we believe will increase our revenue. As a result, we may be required to take additional charges for excess and obsolete inventory in the future if the purchased units do not align with sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued and Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;3 to our consolidated financial statements appearing elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">JOBS Act Accounting Election</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of the Securities Act of 1933 for complying with new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Section&#160;107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><a id="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 8.</b></span>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item is set forth on pages F-1 through F-25 hereto.</p><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">ITEM 9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM9ACONTROLSANDPROCEDURES_737107"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 9A.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">CONTROLS AND PROCEDURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:6.05pt;margin:0pt;"><span style="font-size:6.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Operating Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Operating Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that: (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Internal control over financial reporting may not prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of internal control, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our systems of controls to enhance, where necessary, our control policies and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Operating Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">control over financial reporting. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the fourth quarter ended December 31, 2022, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="ITEM9BOTHERINFORMATION_654168"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM</b> <b style="font-weight:bold;">9B.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">OTHER INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="ITEM9CDISCLOSUREREGARDING_316875"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM</b> <b style="font-weight:bold;">9C.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT </b><b style="font-weight:bold;">INSPECTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="PARTIII_936646"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 10.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information concerning directors and compliance with Section 16(a) of the Exchange Act and our Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller called for by Item 10 of Form 10-K will be set forth in our definitive proxy statement for the 2023 annual meeting of stockholders, to be filed within 120 days after the end of the fiscal year covered by this annual report on Form 10-K, and is incorporated herein by reference.</p><a id="ITEM11EXECUTIVECOMPENSATION_214372"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 11.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 11 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2023 annual meeting of stockholders.</p><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">ITEM 12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 12 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2023 annual meeting of stockholders.</p><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">ITEM 13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 13 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2023 annual meeting of stockholders.</p><a id="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 14.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our independent registered public accounting firm is <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:AuditorName" id="Narr_JsUCODzikkmFc_MJA1ofkQ">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:AuditorLocation" id="Narr_kZz3_xcgmUyWVwCiZS-hqA">Philadelphia, PA</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="dei:AuditorFirmId" id="Narr_boMQNbGSEUCVJWpY7ODvoA">185</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 14 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2023 annual meeting of stockholders.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIV_994849"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART IV</b></p><a id="ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 15.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) 1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">See Index to the Consolidated Financial Statements on page F-1 of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2. Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None, as all information required in these schedules is included in the Notes to the Consolidated Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3. Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reference is made to the Exhibit Index on page 95 of this Annual Report for a list of exhibits required by Item 601 of Regulation S-K to be filed as part of this Annual Report.</p><a id="Item16Form10kSummary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM </b><b style="font-weight:bold;">16</b><b style="font-weight:bold;">.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">FORM 10-K SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_306ab988_a107_4762_9f67_83c723e82a41"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Index to Consolidated Financial Statements</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:91.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENT"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BalanceSheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:top;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StockholdersDeficit"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity </span></a></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CashFlows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:91.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidated"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ef0615e5_8220_420f_b451_5257e7389aed"></a><a id="REPORTOFINDEPENDENT"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Opinion on the Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of TELA Bio,&#160;Inc. and subsidiary (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the&#160;years in the three-year period ended December 31, 2022, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the&#160;years in the three-year period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Change in Accounting Principle</i></p><a id="_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 3 to the consolidated financial statements, the Company has changed its method of accounting for leases&#160;as of January 1, 2022 due to the adoption of Accounting Standards Update 2016-02, <i style="font-style:italic;">Leases</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ KPMG&#160;LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2013.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;23, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a2055dc3_b3f3_46f2_a4b8_b058e9891b38"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TELA Bio,&#160;Inc.</b></p><a id="BalanceSheets"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><a id="_7d7b8539_c2ce_4b4e_b4a9_f2fb11e250d3"></a><a id="Tc_wNC0o7KQZ0GuHfu1Ga86OA_1_2"></a><a id="Tc_vtuzncPSxkChaHpmMn7xaQ_2_2"></a><a id="Tc_vUWgd7CWU0esgNeVkcryCA_2_5"></a><a id="Tc_tQanj3VyrECxcUmAGbyNcg_3_0"></a><a id="Tc_McvQ0U8VF0C0wq5Go6uBjw_4_0"></a><a id="Tc_m26UbH55KEucjRbTGOtRAg_5_0"></a><a id="Tc_JkJI7Mcl_E6pJjRodVTQWg_5_2"></a><a id="Tc_CpLhf3fgukGpLA2oX2zROQ_5_5"></a><a id="Tc_JXJrM7Mo_kKAz3caRLcHAg_6_0"></a><a id="Tc_kB4fnnnbzEu7IBWjahArSw_7_0"></a><a id="Tc_1IfE-3yMQUOuMolGNLexoQ_8_0"></a><a id="Tc_JhqEgCb1m0W0VFZ-nXasOQ_9_0"></a><a id="Tc_GSRHY_vrbEujABmwGji_MQ_10_0"></a><a id="Tc_36hUjc6CpUycIlUrRNfZdQ_11_0"></a><a id="Tc_KeZQy81eKUem09PCEXYprA_12_0"></a><a id="Tc_ZM12bkZDIEyVjqG1Gx4Oig_12_6"></a><a id="Tc_UkXbLWRBIUudJ5vkEwRx9Q_13_0"></a><a id="Tc_sqxE1wk1d0qnM45s0FfwqQ_13_2"></a><a id="Tc_XuqvrbA65Ee2NCbTVPhEHQ_13_5"></a><a id="Tc_c5oNPbbgvkua3FwjqEkQgg_15_0"></a><a id="Tc_4XkSo8RnkEu4fO9up9XUiQ_16_0"></a><a id="Tc_gofSSV2TX0ySvpZMVYhpbw_17_0"></a><a id="Tc_Y6dEtCrZcE-WXTiXm63FEg_17_2"></a><a id="Tc_FHPF8lGSmEawNERTXm_eXg_17_5"></a><a id="Tc_OttGqinpCESy_HWkCAt24Q_18_0"></a><a id="Tc_LlPTIg7YeUCiYyIlEyiOCQ_19_0"></a><a id="Tc_tyGnBT2JMk6ok6FbnK-yOA_20_0"></a><a id="Tc_UBrjGgFQTUajdVozqSQfFQ_20_6"></a><a id="Tc_pldRc0x2OkidfjHdIWSIYA_21_0"></a><a id="Tc_OmXvQaZ1CkyEl2YOZp4G5g_21_3"></a><a id="Tc_FJVfOXVUGESlEWtHYv6WWQ_22_0"></a><a id="Tc_eBuzcSos9UqznCf7XTuHDA_23_0"></a><a id="Tc_FHBPH8k9y0OJINFwz9TJhw_25_0"></a><a id="Tc_yBt_mkkUMkuZeJ10xI8fmg_27_0"></a><a id="Tc_UfQt7ZdSY0abgllzYMb3UA_28_0"></a><a id="_0c5a896f_976f_476e_9b54_0de798e3a10d"></a><a id="_0c5a896f_976f_476e_9b54_0de798e3a10d_2"></a><a id="_0c5a896f_976f_476e_9b54_0de798e3a10d_3"></a><a id="Tc_GBjFHKM_y0-8wRk37ENq1w_29_0"></a><a id="Tc_Sm9wx2IRkUq7zJAX-TprfA_30_0"></a><a id="Tc_fUWyDh9Ix0yG9HRtnqbIxw_31_0"></a><a id="Tc_Xt8F2gL6gUW4VV_HZUcW7g_32_0"></a><a id="Tc_zaUHGkEzmkSz7ei6kU7PHw_33_0"></a><a id="Tc_24rcDrvt3kyPa7qMr_Kzjw_34_0"></a><a id="Tc_ya3SGmyT90qYyTaSu4iGJA_34_2"></a><a id="Tc_TSxcXfsoIUuoovD3F34JBA_34_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_KQLiKS2rgE6OQW59NsCm_A_5_3">42,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_YkTkYi6PskSAR6pMv5IaCQ_5_6">43,931</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_y9WJWspkGUGjuNR6BwBeFA_6_3">6,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc__CIgcIYYAkOAdoiXLOBZsw_6_6">4,234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_S24reQo_GUWumsRJCoubTA_7_3">11,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_6sAzQ0x_a0m8OkarLhe4ng_7_6">7,658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_fZmeiSVYmUOcMDBi7lNdfQ_8_3">2,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_CIKaEgA7XEyeVfR6TW41BQ_8_6">3,232</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_-KnFCNzTBUehiGwCO71Uug_9_3">62,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_m4L2ZignCUiMJwf9N0iHbg_9_6">59,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_X2C27JMzAkmKjHyQJcfHWA_10_3">1,682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_7fL_K1QCKUSHVtyqjTzDog_10_6">1,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_jQ2vOV1twkihJ2MSmo5lRg_11_3">2,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_3BgUVjxRSkCecpcc5FLwAg_11_6">2,303</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_h_AdTwqu5UeeILn5Qbjt5g_12_3">1,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_XGU-CVNg7UCsK8CM9SDXrw_13_3">67,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_rriIlLOTUUC-K_NmcmaPdA_13_6">62,544</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_950cSrFmH0KLEDHhD9iIpA_17_3">1,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_FueXeNKV9UyXX4VfxR98rg_17_6">2,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_4cxIZ5htRkOqMWtes3F-nA_18_3">10,869</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_lUAOweL_V0Gvb-3qqdGAdw_18_6">8,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_G8HI3RpLA0agehXjoV5Tmg_19_3">12,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_lwLj9UywlUO1qLZZFI5FhQ_19_6">10,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long&#8209;term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_W-fS5lq1PE-KdCJGRYjDDA_20_3">39,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long&#8209;term debt with related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="3" id="Tc_LIahiltWpUephmlPs6_UKw_21_6">31,491</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other long&#8209;term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_T3J6JmEUfE2nwglw-q5f4Q_22_3">1,231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_YDs6gvveYkqtOKi9lIO58Q_22_6">380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_wVxImSITnU2A50Gz5lg2vA_23_3">53,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_lFVkPdUoFk2HTiz7KUqCCQ_23_6">42,446</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Preferred stock; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_5vV3YZN-NU2W9RXq-ZxTBQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_0-7mOs_g1EGdCPte_obvnA">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_uj8REwIHNkOagTmqDIykGw"><ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_lEnwuIin00OP0Qw2f5QJpA">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_FsCJ0BRpMkGM2B4aUfKAmw"><ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_mqceYozI1UWI8Sopex2puw">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_zB0Ls2B_l0i5ZHo4irGruQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_jSt6V58rQUeFCid3YD_e2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Lm4_BxeVFE29nqTRD4DrQg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Juvp4Mhx7kyGyEjDHRsxpw">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_nVOnWX9eO0u3qQh2ancCNA"><ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_89B7yHYo5kOmddpCOenLYw">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_QO6yHh2PWkq4V2JGBfypSw">19,165,027</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_WatDQZRqAEWEa_Rb0sGEFA">14,529,606</ix:nonFraction> shares issued and <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_qnLFFx5Zz0GqbssUH4TPmA">19,165,027</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_XOkgsEElKkWdooetoNKS5w">14,529,577</ix:nonFraction> shares outstanding at December 31, 2022 and December 31, 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Y_tKMfnHkk-LvJGaFWZnAw_29_3">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_783jIxpBWEuKPcIQkcZKxQ_29_6">15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_ASl-Hffo-EmtDhha1PibOA_30_3">288,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_MjVXwaNfhEmAzFOqGwPQaQ_30_6">250,064</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_qZFylpa0W0Kb50xTmMpmWw_31_3">150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_AIf0K60qnEyMRqDNWKCk4A_31_6">52</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_s4A5_F8nskOuV9GZ9dd1ng_32_3">274,225</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_wPbV89LCkkGWJYReqo0aog_32_6">229,929</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1996ce-S-USlrugtfoNImA_33_3">14,305</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__h0rh-dqiEyjnbXR1FBB2A_33_6">20,098</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_KwTmqybtZkaF_u5bjbOKNA_34_3">67,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_v0u4XBgWg0CromTFHZcV_Q_34_6">62,544</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f923d681_4ec3_432b_ad9d_4f0507bb941b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TELA Bio,&#160;Inc.</p><a id="StatementsofOperations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Consolidated Statements of Operations and Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(In thousands, except share and per share amounts)</p><a id="_a77676ff_5a45_464b_8487_86e61ef18c77"></a><a id="Tc_su79DBOKhkWQUcp-N_9T2w_1_2"></a><a id="Tc_TxXkoIa8nkyuq69aARIQ0A_2_2"></a><a id="Tc_VsnAsnBrhUKB5fslytnreA_2_5"></a><a id="Tc_k393YmcDUU-IcPcmw-eKtA_2_8"></a><a id="Tc_sM6kLq-nA0mcNta6b186GA_3_0"></a><a id="Tc_dNFl1QIhWEuhDfsMRsGpLg_3_2"></a><a id="Tc_kgAP6DPioESs4PCVc7_Zqg_3_5"></a><a id="Tc_RJxdwgz4C0Whn5uXEPJYBg_3_8"></a><a id="Tc_NvCNY4XU80iUJT3nVJ08Pg_4_0"></a><a id="Tc_M8qK5XG4lUq40v6KbENK4g_5_0"></a><a id="Tc_KYdOJSvMs0yT7-kxXWAFbA_6_0"></a><a id="Tc_lEUt_a6NQUqVc4_xLlB8ZQ_7_0"></a><a id="Tc_-BMPHd6TfUyMzw5B6NuUzw_8_0"></a><a id="Tc_BcHaDeke40yR2MfbNxFv_g_9_0"></a><a id="Tc_2_fbM7TjmUmvkJDJwN3uvw_10_0"></a><a id="Tc_N8dJVaXXbEuT_klQjuj9hQ_11_0"></a><a id="Tc_6-ri0JBY8EWwxsHuhZqIhw_12_0"></a><a id="Tc_alZ8fYSiMkWyr9yO7oE2Zw_13_0"></a><a id="Tc_W9QvJEl4a0e9US5OJJsOEw_14_0"></a><a id="Tc_C56p2VKCtUm-UNHdLa1d7w_15_0"></a><a id="Tc_CfzShjiTn0Obu7NjZHqGFA_15_6"></a><a id="Tc_w18NhZMNHkyGttAhPC_5bA_15_9"></a><a id="Tc_VcTyXYtJQ0u1-xFNaVpw9g_16_0"></a><a id="Tc_8x0F8vef20ih7qE4hhcwbA_17_0"></a><a id="Tc_-71JOcyQqkKZuFlIjBeMyA_18_0"></a><a id="Tc_xhPqpQN4SUmsBvicHk0U9g_18_2"></a><a id="Tc_tDMQiuK5mkmiitEC42Iscw_18_5"></a><a id="Tc_Wp4ZeBn1D0y29oAx5_aMxw_18_8"></a><a id="Tc_1Jq27N-cBEChz5JV-YPlVg_19_0"></a><a id="Tc_ds4gdwpEP0-utdhs95fH8g_20_0"></a><a id="Tc_5IEbW9BdPke5zUexXJf5yw_21_0"></a><a id="Tc_Gl6HKS43BUytEyxQ8xb3LA_22_0"></a><a id="Tc_tQY9Vgrp5k-sj3VzhidO8Q_22_2"></a><a id="Tc_UJ10dyTrMUeVugLnziqcbA_22_5"></a><a id="Tc_NBg8o1NEykGhmN5YRARPqw_22_8"></a><a id="Tc_cGRFFuDVqk6hM8s0mKjxoQ_23_0"></a><a id="Tc_7XBIdl8U1ECoNdASElzGyg_24_0"></a><a id="Tc_mN3crpKHhUWsc-yD9HiOAg_24_2"></a><a id="Tc_ynqHy4buQ0uErUeLEbUutA_24_5"></a><a id="Tc_7_0mrzycjkK4JMzNUPTegw_24_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_GB3GtgK5PESi943JKAYbrg_3_3">41,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_XmSmOcRnpU-tf4L2_5MJ5g_3_6">29,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_PZBkhcnEP0-S12Nz2-aTnA_3_9">18,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue (excluding amortization of intangible assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="Tc_KyFcL4A8wUa-gtdoK4jgOQ_4_3">13,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="Tc_Ece-1rdrFEiB2K_LIE-Caw_4_6">10,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="Tc_H3sCb2hWOUmouXwXn-rydA_4_9">6,675</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="Tc_WFBWAOvlgUepTlUo5v_PaQ_5_3">804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="Tc_6VwkmhCGgUijV09ALIf4EQ_5_6">304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="Tc_MIVJj1zZGk-BPo9FrL8OzA_5_9">304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_QhHsW5yd_kaTrmbOdabrFQ_6_3">27,044</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_1gUJOOTj-0mZxyRZTWnw_g_6_6">18,813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_N85ktFx300e5uBh1LBgcPQ_6_9">11,234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_tsnkLahfpUqW8dUPmkjbaw_8_3">43,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_0eZucfuemk6RAb4WYSKxaQ_8_6">29,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_bESURh9L6kif9ZB-4FUzrA_8_9">22,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_nXR1M3xBqE6QZ5zQx4TAFw_9_3">13,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_lBnBxJ6zeESGXelDL8Yx_A_9_6">12,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_re7JavkHD0Wj2YIlSSJ-HQ_9_9">10,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_09BnxFoZK0Kxl4GgaLpMiA_10_3">8,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_J8lTfV2JcUOcovnY6PAWtA_10_6">6,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc__RKa41djQUKwd9CaagO8qg_10_9">4,255</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_38UcK8ApSUCZ7PsKVrwmTQ_11_3">66,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_zRfKJSvHjESZyCpMsYhNYg_11_6">48,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_hM67ektQR0yppY1Ts97vEA_11_9">36,509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_seng4oW-QECxJamc8qhS5A_12_3">39,007</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_lCVYCip_qU-C8dYSkkgUfg_12_6">29,451</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_qeLul1qNY02sZZc_PPFrBg_12_9">25,275</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_bzzAIlacOEKrUMnn62xj7w_14_3">4,051</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_IndTef1cO0qFmkVNeKIUtQ_14_6">3,597</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_B-WNa_zwdUSki6Kk-Sbllw_14_9">3,564</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_ITnnGcIW206uKgjLeSHWuQ_15_3">1,228</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other (expense) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_kTbEpZ3vaE2w_7E7X-QWqQ_16_3">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_NM3siMXDC024bwcAGC7LCg_16_6">228</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_dAw2h7zJ_0Ga3B5oI_eQDg_16_9">45</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_huV9M-u3nkuTn3y-wvHmDw_17_3">5,289</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_bPDuRLorFkarOSU4Gb3NDg_17_6">3,825</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_VsGeFPhlo0e2dbbpVfIoIw_17_9">3,519</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__ApBf7Y5GUCPlxyWJY6RNQ_18_3">44,296</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DUusIHluAEmsC8TuF1B31g_18_6">33,276</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_duTbcvCQdkqtTOP5dhratA_18_9">28,794</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Dui_H_slDEazZiYT0YHI6Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_6Cw4uwdgnECjwPN1GD4XMg_19_3">2.72</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_a3N_SAKM90S-ydoFe7MfqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_GVv23BzlbUq3wbm_-ebR3Q_19_6">2.30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_YJBwTeTqC02MfB4Us1UtcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_DlbrUBcbc0uOPz6-Wrm8kQ_19_9">2.23</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_NdclkHNyaU6lD4TrOSw7Gw_20_3">16,267,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_m2T_Kox13kiLY0FSXmlPDw_20_6">14,473,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Bi9V-yudu0azeBDubAfBNw_20_9">12,934,421</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_otbjIAs6EUOEh4HuPeSQlA_22_3">44,296</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4bbjKuPoAEKTepIOk1hzZg_22_6">33,276</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_BLTcqxbQCkuUYie9fErhng_22_9">28,794</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_qMdV-D-T4kOWz4f2EF-bBg_23_3">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_YfeQl7cb_UuW_SoAeer5cg_23_6">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_qVM3nYCAtkWrVBqnmOK3Kg_23_9">52</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_J2I89XeJPU-0P1wg5e9ViA_24_3">44,094</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Xs19Y-MUbUqJhOfLFAHe0A_24_6">33,257</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Z0TOZ9fsoU2xc6sP1Xme6g_24_9">28,846</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_78285900_b6bb_4eb3_a1b8_3e20fecb8216"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TELA Bio,&#160;Inc.</p><a id="StockholdersDeficit"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Consolidated Statements of Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(In thousands, except share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7638e67f_6ac2_493f_bb43_9aec896d0f5f"></a><a id="Tc_0OWXeJjZ8USqQAmgqcP5Mg_1_10"></a><a id="Tc_wFhhnrplW0ic_uOiK-ndtA_2_7"></a><a id="Tc_bAZ3IQIWUE6pT5KMBTfkWQ_2_10"></a><a id="Tc_3-THZwlGu0-aE_S1J0WBfg_3_2"></a><a id="Tc_CyXRkOoe9UKEx7DOqrYDvw_3_7"></a><a id="Tc_XpSjMWr42ESVfvZ_PYMB8Q_3_10"></a><a id="Tc_h3FtmYNLI0-3A-7v4dNSiQ_3_13"></a><a id="Tc_n2mTti7jTkOppnv72TDJnQ_4_2"></a><a id="Tc_3Et8SuKeuU-PY9_ch9lGCQ_4_4"></a><a id="Tc_hYVG0L1u-UKx8kQfIX67lQ_4_7"></a><a id="Tc_pPYRwFXIwkmn78YtYLuNxw_4_10"></a><a id="Tc_1YhAsHC3g0ql5VZWq324LA_4_13"></a><a id="Tc_ejGaLNzHPk2G50n6hd7Eug_4_16"></a><a id="Tc_YXoBacmfrUqttKD54c5qXQ_5_0"></a><a id="Tc_W3Xeb2lxx0KcXh4G5psiCA_5_4"></a><a id="Tc_5i04jruw2ECgaWl6PO4uTw_5_7"></a><a id="Tc_PJMqqPkzR0itH4e6uIAYpw_5_10"></a><a id="Tc_PiQqmxdD906Q_RuyDVg9ZQ_5_13"></a><a id="Tc_1vlMtgiFOU-WPZNn3lqpvQ_5_16"></a><a id="Tc_O2iXgWB9_E6LmjdIwAxUOw_6_0"></a><a id="Tc_Hs4ksUvEMk6-8aL_2IUmQw_6_5"></a><a id="Tc_GDvByI9M70KQobX1rvq_-w_6_11"></a><a id="Tc_EJ6pEcm2dU681HvmnEnhTw_6_14"></a><a id="Tc_QIEXphK4NUS1m7LqEyc43Q_7_0"></a><a id="Tc_1S9x0hZSDUCWOpKXjMmoxw_7_5"></a><a id="Tc_rrkYmQOcvEKx75-DYWKJNQ_7_11"></a><a id="Tc__JtH0xG5AEu0zH0aVd8Pkg_7_14"></a><a id="Tc_ZhEl30uGt0OSYPB6WfNIKw_8_0"></a><a id="Tc_MBVTGba3UkCx6Mbm0A8JWQ_8_5"></a><a id="Tc_xJ6P5q7wS0Sp2nEgj2qVeg_8_11"></a><a id="Tc_F83yy6T1C0i-ZzE5fYYLAA_8_14"></a><a id="Tc_-uPuU2Bix0WsbBE2DAJARQ_9_0"></a><a id="Tc_w5b2jAaiiE-AhfxIDxmXyg_9_2"></a><a id="Tc_-gveTSVElE2-MxoH1UAGuw_9_5"></a><a id="Tc_tUIciRuBlUGCP5gCdMvPbw_9_8"></a><a id="Tc_OfiR5ZyAP0u0MnND-LecKA_9_14"></a><a id="Tc_P2AnDcasPk6k91fTNNI0wg_10_0"></a><a id="Tc_8yEuEGV8e0mBQbMbeIsSxQ_10_2"></a><a id="Tc_FiQxhoIUbkKsmPDyWfMROw_10_5"></a><a id="Tc_7ETcI8lAGECTKDUTkUtRlg_10_11"></a><a id="Tc_wq-LQ-TZC0-4v6kcrWIegg_10_14"></a><a id="Tc_hLmpDKGG90abHDNPZW2b3Q_11_0"></a><a id="Tc_QwL65BaJKkOIm9jYKSMMXA_11_11"></a><a id="Tc_GD15gFgYdk6qopzaVvKWsg_11_14"></a><a id="Tc_HSZ0KfFooEehpVjjFwzrZA_12_0"></a><a id="Tc_120wVR-7pkOztHs8zDEDnw_12_2"></a><a id="Tc__i2eKk0-T0yVkHLRWV0MhA_12_5"></a><a id="Tc_WHSMM_T6OUST-CM2By_vRA_12_8"></a><a id="Tc_zNLyqB9d0Ua0zFssfvZQFA_12_11"></a><a id="Tc_MsL34_uer0i-FnJsfhjZdw_13_0"></a><a id="Tc_TePTUNFD3k-c-aKDECVCsg_14_0"></a><a id="Tc_jqJsgYL3q06UDkvs4HdXgQ_14_5"></a><a id="Tc_I2EspQ3ZokWXozwlj9uixg_14_11"></a><a id="Tc_iIYR3BW-zUyc7N_LCTOwKw_14_14"></a><a id="Tc_3cQv6cvJW0qAX4_adJEb9g_15_0"></a><a id="Tc_jf77KouhREOG0zS-py4W7w_15_11"></a><a id="Tc_1hr7z46t5EmDpW8cJ25AsQ_15_14"></a><a id="Tc_odiID9qhkUuxxGKy-qlA0Q_16_0"></a><a id="Tc_lsZcs3oAXUqqqpRsnrhd2Q_16_5"></a><a id="Tc_mBjMvsi4yE-p2z_Fj22Xpg_16_11"></a><a id="Tc_ao8OsKZz_kKKu1iOnqGl_Q_16_14"></a><a id="Tc_rNkUpIXWJkClV9Fg8cVvFA_17_0"></a><a id="Tc_8rMWGFmjQEWM3XpScqF7VQ_17_2"></a><a id="Tc_knBYND0FaEqR5c4ds2UTpQ_17_5"></a><a id="Tc_kIa2qG5Hz0-GB62-ZMWZrQ_17_8"></a><a id="Tc_dYTfn2rg9UG71HxW1Bgizg_17_14"></a><a id="Tc_ynAtuWGBREyZuM56MLw3Kw_18_0"></a><a id="Tc_RPbfcjbm_06SX0v3HpfUtA_18_2"></a><a id="Tc_JzuQjDWnx0mKTKDGNMfEgg_18_5"></a><a id="Tc_pefk5MzH7UqK4rY-nsEEZA_18_11"></a><a id="Tc_FokPRDh7oEKHN7fbKtdueQ_18_14"></a><a id="Tc_iu9JYupmMkOiOyBVWRSRmQ_19_0"></a><a id="Tc_fv3e80Bh00qseKTItA0krw_19_2"></a><a id="Tc_8Z12KNoAskKJSPg5pJZLOQ_19_5"></a><a id="Tc_cOE8YspiekKLC6prdMON3Q_19_11"></a><a id="Tc_ADvLWTk_cUCFMtM-q_4K9A_19_14"></a><a id="Tc_nJlQeR6FQ0K32UDqkzf0fg_20_0"></a><a id="Tc_jlKwGrEoykun657wXt0LuQ_20_2"></a><a id="Tc_8mJnzUSjwkiNebuAAJcUaw_20_5"></a><a id="Tc_NPBPr6fDNk-O4Gzk1cHlKA_20_8"></a><a id="Tc_IYbot3k9dEeVVDTRC42Ibw_20_11"></a><a id="Tc_W3N3R-x480q0ENxXVhsFPQ_21_0"></a><a id="Tc_ESyVbNS2vE-S3zEvR0xKbA_22_0"></a><a id="Tc_1cEc8_cWdkCHePoZ2aHnnQ_22_5"></a><a id="Tc_4pEsIxRMIUC0flc5Ue4gBQ_22_8"></a><a id="Tc_V_qlZOOP7kOgOI9Z6QOcUw_22_11"></a><a id="Tc_IE8D4sY5UUW0X8hECt3oCA_22_14"></a><a id="Tc_Gmr5imWurEeYiWcQzkd0YQ_22_17"></a><a id="Tc_orObP4_gVEC1GQUCfsJG6Q_23_0"></a><a id="Tc_QZ15sw7EbUGF2SjQdF2ANQ_23_5"></a><a id="Tc_CxjyRn-HBEupTgLwuJ6ogQ_23_11"></a><a id="Tc_CQ08NwcVHkaIkM8YREYUrA_23_14"></a><a id="Tc_5yui13G00k6r9P1K_bWdpQ_24_0"></a><a id="Tc_nxfNnc3QLUytyVkRkWYUGg_24_5"></a><a id="Tc_2KdmOZPt1UCe1-mcmQCBrw_24_11"></a><a id="Tc_Xv9o_VjmukSDPr9OE2n1Xg_24_14"></a><a id="Tc_20qxyla7eka9e-3j4-1VYg_25_0"></a><a id="Tc_BAjJJUFkbkSIqvCLgoB7OQ_25_5"></a><a id="Tc_v5mJW3tQWUWRqKd-DWUUJQ_25_11"></a><a id="Tc_pJamOebULUyKFlwljAQsPw_25_14"></a><a id="Tc_gN_Va3DpvUOoB-U3KAdAXg_26_0"></a><a id="Tc_mkbOTpKHpkeYPirnyZaOhw_26_2"></a><a id="Tc_xAOiwiyNYEuCiAEJGs8pGA_26_5"></a><a id="Tc_0InUt-znlUOXYLdLjCRbuA_26_8"></a><a id="Tc_twSk9XSmZ06XzQTS0pM0CQ_26_14"></a><a id="Tc_hMVMUVQU4E2Tfink8cmxZg_27_0"></a><a id="Tc_W9sckjX5XEKi6omfLliTbg_27_2"></a><a id="Tc_3iR-qMlWfU-ZzZX1rpy3Uw_27_5"></a><a id="Tc_Cob_U0b38UyCRvSPjddWfg_27_11"></a><a id="Tc_aKp3MpX8akywtqBwz8fYgQ_27_14"></a><a id="Tc_yf9IZTfD-kmQ7xkpRq5-ZA_28_0"></a><a id="Tc_StCn3Y5S_0exf_BnABRk_g_28_11"></a><a id="Tc_e92djrF7w0aXbOBzdwY4Gg_28_14"></a><a id="Tc_HkWBDCm5uUi06vB8M2QTnA_29_0"></a><a id="Tc_MFnz_D3FZEOOm1eMiKb7AA_29_2"></a><a id="Tc_lOTwT5VPdkKyOSw1gHNv1A_29_5"></a><a id="Tc_wvXbF4bqmEOiib6M0XeWsA_29_8"></a><a id="Tc_DbhMevdPgEeLYrt-Jv3q8g_29_11"></a><a id="Tc_EKjE8WqSAESNdZbTEOmoBQ_30_0"></a><a id="Tc_VWkgO1qoekagvpuxRyXPVQ_30_4"></a><a id="Tc_B0M7xCOtLEKVhq8z136H0Q_30_7"></a><a id="Tc_Gxv6AamzZU-s_BUQyqSEDQ_30_10"></a><a id="Tc_AZVXQklkVEOHZmiD9EWZsw_30_13"></a><a id="Tc_dRw-StBRC02cTheL-aS_jQ_30_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.36%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at January 1, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w6UDjR_eTEagY1f1G_onNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_PBLg2sTzSEOVBdsE-uMHBQ_5_2">11,406,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w6UDjR_eTEagY1f1G_onNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_aNgdVbcEYECOJoCMNiT3lw_5_5">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mI1Et8gIm0OdOoNeRu_ZkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EIBl4vO4sE-X6OAGACGIbw_5_8">198,829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6I5vqtHVrke8eqs2gI250A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_enkTGqO9oE-RsjQRJ35NQQ_5_11">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__z1HrlyAiEeZoN2ntN1wdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dT5DeUKa2kyAcyTQDXsjQw_5_14">167,859</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_frbYSs0gA0CMaKwfgKSFIw_5_17">30,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Vesting of common stock previously subject to repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg" decimals="INF" format="ixt:numdotdecimal" name="tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" scale="0" id="Tc_dfROwNrMRkekqRTpPtKVhA_6_2">306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ" decimals="-3" format="ixt:numdotdecimal" name="tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_x7U7vmG3Y0GVGz3KEhnpOQ_6_8">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_F8T7K_V2qkee1C9qzBGkNA_6_17">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_T9J2olmdNUm3VjYM9kuORQ_7_2">27,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_729Y9o9jc06wcn2qPcrLmQ_7_8">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_OWaAETQHHkuJGC8xOYhFzw_7_17">175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_JWbLgl7xs0G2lCI7Fl_VaQ_8_2">2,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_8NvdMkAzLUqTFDB_CuGFXA_8_8">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_yYOUXmoGmEOUndeYg5Fb9g_8_17">34</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SOs1kkyXi0abe8ZkOi1Ztg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_OmT9azKCqkG05i9p6Oh9Cw_9_11">52</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_5sAPas127kaRYC0lgasZ0A_9_17">52</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Stock&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_YtAD9JQjyUyaL9DPBBe-ZQ_10_8">1,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_8WVLcmH7nUmU2Hc0_L3EoQ_10_17">1,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon follow-on offering, net of underwriting discounts, commissions and offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_ry54KxUKB0e--XIK6VIm1g_11_2">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_aFgF09mMLUmYhgx98sU-MA_11_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_iTuum7c0NEi3O4dZYbJmPA_11_8">44,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_zeZ1PM1GQkaqnmscIlYd7g_11_17">44,722</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__lbPSe6rPkKCFW4tp1NNww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7AxoIxhsS0G-klL4QJpH9w_12_14">28,794</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4nrmvqWcv0uKR-FCiUB29Q_12_17">28,794</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ngCQpjdcvk-SsVBsAtLEbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_EU5G3nsMBUKeqIpFF8-9Pg_13_2">14,437,107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ngCQpjdcvk-SsVBsAtLEbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tnRwktmrZEOyVrcXGrcAAQ_13_5">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N7ZqSLBpBkC2dB9n5qsheQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1OPY9lUTck2GDLZgnE_Vcg_13_8">245,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BALcPEf8f06_ByU0A3la0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7SXrzMgQhU22RUgQ8xL8Yw_13_11">71</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GnrH2KSZPUexCDzLyVUgWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_o_cyfGhdH0-2YTkYs94tSA_13_14">196,653</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eQGjdiwFREWpuM0eUORuzQ_13_17">49,026</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Vesting of common stock previously subject to repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew" decimals="INF" format="ixt:numdotdecimal" name="tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" scale="0" id="Tc_O-YNGUGM90CKU4AB5CYEzw_14_2">153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA" decimals="-3" format="ixt:numdotdecimal" name="tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_H_BYrTMDLE-rLkzyv5K43A_14_8">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_STwftRwzk0-_ZN7ZCvTz-Q_14_17">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Vesting of share-based awards and exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_L0IJ-KjQaUSvOcmdar9-rg_15_2">89,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_2yGuWANljkSytB21nyXCQA_15_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Hv1V0EcwZEa5s9u7dgCpPw_15_8">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_h5P38bA8N0a4WMRcfr7i5g_15_17">547</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_dcHzWjP8l0K7srcyt-5o2A_16_2">3,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_WMbf0kJId0CtvsL8ADdsQw_16_8">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_Br2D8Cg0sEigjBUB_Znx6A_16_17">38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_loDUZPMImEmoouzBKpBYYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_CywXa9av80CWyvhhsPmoUg_17_11">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_A8Mhsw97o02x07RLQRqUOQ_17_17">19</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Stock&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CSWeZca2HkerB2orAk626g_18_8">3,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0g_avfBpG0adSW94RpEIQA_18_17">3,661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Reclassification of liability-classified stock-based compensation awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA" decimals="-3" format="ixt:numdotdecimal" name="tela:AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" scale="3" id="Tc_eq_csioqwEGXzAR-uCbpSQ_19_8">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="tela:AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" scale="3" id="Tc_BKdVco8ChEaK8tgt-vBjWw_19_17">82</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qV52jkzrGkyM3BjDcW7aFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_hZ-ohSD0CUWVW6mMjWCp5w_20_14">33,276</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_pJTLcOgyl026Jlr7VcPBmw_20_17">33,276</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-N1PP0dpzE6v3HICXjB5NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_5TAjAShh7kSKeoycinVLeg_21_2">14,529,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-N1PP0dpzE6v3HICXjB5NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_z89SboXQgU2ZU25iHe6gLA_21_5">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8Dc-5nKCK0aFZB4G6pHLtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AIlKYNOp9kO192wpsG-5vQ_21_8">250,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v61EXnBz5UOMTIqvTTVxlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_35UusNAlCkSxOLGyNrlKbA_21_11">52</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Joj3v_81eEyOiZcwVgt7eA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_1r_8zBfeyk2Bh3THpgisqQ_21_14">229,929</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_asiN_uh1yUytyGu0P4vkTQ_21_17">20,098</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Vesting of common stock previously subject to repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg" decimals="INF" format="ixt:numdotdecimal" name="tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" scale="0" id="Tc_vVrxv7GvpUS_VQqzhyNppg_22_2">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Vesting of share-based awards and exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_2KSb6TKozE6vhTd8GY-uuw_23_2">44,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_xe_RA52eUEOhYUuf2zoG3g_23_8">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_zQ3R0vYYO0as1MqyRA7CaA_23_17">19</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_Saw3akBky0qq8BvgsBRYNg_24_2">4,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_onrIFjCqdUWcY3-297Obgw_24_8">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_2I-I0BjC00-nMZBUUcxf4g_24_17">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Shares withheld for employee taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Tc_-mrBGIG7-0Ollo-D0oZnRQ_25_2">13,448</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_zEZPe2h1v06PI5YA6QU01w_25_8">157</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_pthx9wVslk-LKS2Fmzruew_25_17">157</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IVbed4JzJkGCxrAyFbPuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_n19WphwGaECRkQO5dXFRKg_26_11">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_I8T5f6Nm3kigKZCJ96e_Vw_26_17">202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Stock&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_KHiG1PAt70a16subwQDoZw_27_8">3,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0mOxRM51MkK7rQne3hIhug_27_17">3,989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Sale of common stock, net of underwriting discounts, commissions and offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc__-VUI5k37keZ52nNByQ-Yg_28_2">4,600,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_q058P9DdQky5ovhqofrslQ_28_5">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ieyNxeb6GE6Dr6zADTZEgQ_28_8">34,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_JI7NRddnbk2htJU3rVw2gQ_28_17">34,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:38.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gvnas9QAp02vVM237t3iyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jpYmpTOFOE2RGyxHZxao5A_29_14">44,296</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NfMeb0711k-r5jdnmB4xGQ_29_17">44,296</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:38.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZbaHak272kytCiOj7lO8ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_wsUJMZOkDUalQb2-QLiwBA_30_2">19,165,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZbaHak272kytCiOj7lO8ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_n2YsBiEDBkeOlLhigThB5Q_30_5">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6jS7FaWS5k2vBIexrI3UwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_SCiV3-hqUUiBBiKINDoMKQ_30_8">288,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cMdTTyP7gEeGyUNTqvLRNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_y93Ni2qjM0qx6_Qb0IPK_A_30_11">150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__0NqwDOnU069qrqDweDq7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_UBeBbTtDXkeMJ1-FRBfPaA_30_14">274,225</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9rpOPseSNUmAefEw7W6Cdw_30_17">14,305</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3bb3978a_03b6_4ce7_b27e_e008e4eb0ccb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TELA Bio,&#160;Inc.</p><a id="CashFlows"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(In thousands)</p><a id="_bbd57dbb_7d43_4ba3_b4dc_b9a654c86f01"></a><a id="Tc_h8yGqHncgkKtt30TzSINkQ_1_2"></a><a id="Tc_-7SErV4ggEK89OxBM0WN5g_2_2"></a><a id="Tc_BNljJoLAy06zReZ-r7Gqjw_2_5"></a><a id="Tc_dG7BNm540UGhIgD-rECuRQ_2_8"></a><a id="Tc_Cw2H482P0kyXmy7EGlxAAw_3_0"></a><a id="Tc_U6bx6VUS00m5CIobE2wPvA_4_0"></a><a id="Tc_xRPFlaMtWEGIXUsAIDGqdg_4_2"></a><a id="Tc_ml_xXXIsOkSyaJ58P8nmRA_4_5"></a><a id="Tc_OSt7IA78SES3T2k3eODlmQ_4_8"></a><a id="Tc_EcwqEjefvEe9jSFrd4_bJA_5_0"></a><a id="Tc_JdoN3ZqGR0qugz1mBmdxrA_6_0"></a><a id="Tc_6N22GdpTjU-UV4kldz3_ug_7_0"></a><a id="Tc_s3CaxP0eu06yDN-58pt2OA_8_0"></a><a id="Tc_eqYb_mLnvkG4t2mLJ-WLIg_8_6"></a><a id="Tc__AUQepqbXUyMAXKm2P1xPQ_8_9"></a><a id="Tc_OpBtiUwbE0Ol3K_Ps4EeYg_9_0"></a><a id="Tc_91clTJV4w0y8RBgXtnRl8w_10_0"></a><a id="Tc_iDn9YWbZT0Gr5LJTM2JInA_10_6"></a><a id="Tc_UAtXbHKQQk-YniCMA3lAFg_10_9"></a><a id="Tc_CixXOMQz6U2TCosgzNOvrQ_11_0"></a><a id="Tc_1lVaHMVY8kyRVC1ze08Xzg_12_0"></a><a id="Tc_nD289ALMF0SQ29A84pUhog_13_0"></a><a id="Tc_O2zHkZgYt0iD4JJk-kLX6w_13_3"></a><a id="Tc_UJIryykiMU2JwbMfdlFJBQ_13_9"></a><a id="Tc_dC6_CcYoJkq1ImriBS5LEw_14_0"></a><a id="Tc_y976hjR3y0etUJSWoqto0w_15_0"></a><a id="Tc_zI71be1phUWoxZhualUmpQ_16_0"></a><a id="Tc_qSyPbPqF_E6NKXCMRVQEhg_17_0"></a><a id="Tc_8E6uSAbz8kGMHj6EYr63Jg_18_0"></a><a id="Tc_CbXbLMmK3k6TiyOETNL7qw_19_0"></a><a id="Tc_QkiuEI3i90ixFyas92YU0w_20_0"></a><a id="Tc_rDAIv9jb806IH0QLEH3R_w_21_0"></a><a id="Tc_zzGVS_aKLkKdAtf09tY-NA_22_0"></a><a id="Tc_DLnHiDChUEepdMpG1JHdkQ_23_0"></a><a id="Tc_VoshWVVEK0mTCil_YyjTLw_23_3"></a><a id="Tc_LVtveSQQ30GDb_cXEh76Pg_23_6"></a><a id="Tc_xE_4qNEWjUe60pARxYmMBg_24_0"></a><a id="Tc_sQB-fu-U00S0WOCLSe_Pqw_24_6"></a><a id="Tc_7QsBKDu_9ECsV0eTv-HRbw_24_9"></a><a id="Tc_9-f0bUtb_kS7qv1tp4xwyg_25_0"></a><a id="Tc_M-Im1c6VykKgG9BVIh4hUw_26_0"></a><a id="Tc_R99aJGVUyk-Dzap3ZIzTwg_27_0"></a><a id="Tc_czvBXkUtFEKA94GZ-aJEog_28_0"></a><a id="Tc_oLLtmYepRkCifPmXYFrHag_28_6"></a><a id="Tc_dGccoo3Coka5vqo78lVVZQ_29_0"></a><a id="Tc_ravXMh_ZwUGTk74h4YrBZg_29_6"></a><a id="Tc_foQW-o_ivUyRc8HmO6tMbw_29_9"></a><a id="Tc_Q6o4fOkNyEW6hskAHIHgfw_30_0"></a><a id="Tc_LfOB_4T5EkSKZwdnb2j8jQ_30_6"></a><a id="Tc_IF9HkY0tS0KvvH43P8DLlg_30_9"></a><a id="Tc_JmUk0XLtw0qWRp_2aFGNoQ_31_0"></a><a id="Tc_T3tc_vQp-0SSk32taxMDtA_31_6"></a><a id="Tc_EhuAZEdYA0m-4X-RisCfBg_31_9"></a><a id="Tc_jtjcwoG3akeMbbnpRHZ4GQ_32_0"></a><a id="Tc_AI-OUt1H2Eiei7cR-4uXoQ_32_3"></a><a id="Tc_pwYrn4no7EW0YfP95PQUWg_32_6"></a><a id="Tc_1m-X13PIKkCVaTIV8q0-7Q_33_0"></a><a id="Tc_KkMDQ03oJ0yRylMEEc1Cng_34_0"></a><a id="Tc_Db0MRE9jWkiXMXUsFTYlLw_34_6"></a><a id="Tc_Lk4Rzggva0aDK8SQmSVm5g_34_9"></a><a id="Tc_RLsTxLxyPEqIpm-O5fB6SA_35_0"></a><a id="Tc_znVwcYuQQUWjfMHP7cbMeg_36_0"></a><a id="Tc_l93_gj2nREOIauqO2OWdUA_37_0"></a><a id="Tc_Kjr3n-zBdUaFbKwjJyLmrA_38_0"></a><a id="Tc_ErLaWU5zdkmHoEMHu_cK-Q_39_0"></a><a id="Tc_UYdhkqJmKkKWAgb-IZqZFg_40_0"></a><a id="Tc_UQRHdmq3Q0mhLqyPhV9uAg_40_2"></a><a id="Tc_B-WEfYMb5k-p2qmjKnv8aA_40_5"></a><a id="Tc_ENqqponfk02H4DzPYmvo1A_40_8"></a><a id="Tc_mhHZ8lyrpUyrZJZ9I1hWwQ_41_0"></a><a id="Tc__c6l5ilSlUa3IHrH34Fglg_42_0"></a><a id="Tc_8FriGQhl-E6PUzHz6zqPCg_42_2"></a><a id="Tc_RFSX1fHzrU6TcqlOba-2gA_42_5"></a><a id="Tc_Fp9AqVTJ6Eq3OReuUYkMoQ_42_8"></a><a id="Tc_q4ws7AULZ0ObYjIoMCg9AQ_43_0"></a><a id="Tc_neIjRGQOdk6iQim-NaHLrQ_44_0"></a><a id="Tc_dtj5rYg-fUurRfS2JPX1Ew_44_2"></a><a id="Tc_VaFeY5raN0OCrxmkIdBM9w_44_5"></a><a id="Tc_AM2hlliKDUq3Vst56jvPoQ_44_8"></a><a id="Tc_8grT9zSxuku1CaRRa76FZw_45_0"></a><a id="Tc_tmfbAX83p0m5CU0uE1Er-Q_45_2"></a><a id="Tc_4IAWSSJu5E2CbdYsz88C-g_45_3"></a><a id="Tc_6P-m9FBe5UaR1RJv7s_OXA_45_5"></a><a id="Tc_vVrgUMmDy0qk4syXWwwOyg_45_8"></a><a id="Tc_TmvKbWr5XkGt2qDrj_tEYw_46_0"></a><a id="Tc_JcYmhPpsrki8dfdHkJiK-w_46_2"></a><a id="Tc_emauEQjjeEeZ3wKOQnwvuA_46_3"></a><a id="Tc_x3AzQ2Vx6Em3p_zO59aQJA_46_5"></a><a id="Tc_WdGDV-bCZUuRQoOXylAWZw_46_6"></a><a id="Tc_PdtnffO5l0iUhigkr24CRw_46_8"></a><a id="Tc_-vDucyPXo0mZa0JtfejOOA_47_0"></a><a id="Tc_kqa0QnEALEWVb1BBf8FCTA_47_2"></a><a id="Tc_Zage6SA390WXZvbWPM3aYA_47_3"></a><a id="Tc_YxPR2VmAcEyl-FS532wH6Q_47_5"></a><a id="Tc_lzPcdwSTtUOawmknKCKoUg_47_8"></a><a id="Tc_wxLt7RvTU0GtaUbCIJhh6A_47_9"></a><a id="Tc_vw5QRlqqe0SunQr1MpQ9PQ_48_0"></a><a id="Tc_Nw_-Qj0M406ub4h-zzNt8w_48_2"></a><a id="Tc_TsISL8-ziE6_mIC3jHynfg_48_5"></a><a id="Tc_YI6b1JundU-_Xw-wGL3XHg_48_6"></a><a id="Tc_DGcCfcaUrUmZs-_uF-fHZQ_48_8"></a><a id="Tc_4NysSfqwKE-s5pXJOg1WNg_48_9"></a><a id="Tc_byZ8e4R6zk6iNzyfBvMeGA_49_0"></a><a id="Tc_RDTWZnfzy0K5qWrDKiYJFg_49_2"></a><a id="Tc_T0tnxDa2lk2UyLjxmDL_mg_49_5"></a><a id="Tc_hNfUOjwXrEa_AXc7xN82Dw_49_6"></a><a id="Tc_PDjf_3Z52UKro3bOX-v2ZA_49_8"></a><a id="Tc_n1pgaso1CUmcFEJ6eD74bw_49_9"></a><a id="Tc_umWBThW48kujF3susjkDMQ_50_0"></a><a id="Tc_pi28uBYAU0STrbMP-NNfUg_50_2"></a><a id="Tc_mZvixMbDG0SiYWXy82ksLw_50_5"></a><a id="Tc_a566nHwt1kORsmRBe48M6Q_50_6"></a><a id="Tc_5HEoyM2Um0ebLyFXhvVODg_50_8"></a><a id="Tc_OClEgpvB5EWBwW0bqalggg_50_9"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Cash flows from operating activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_05iebgxycUW1A_mIMszfow_4_3">44,296</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_G76JMjOR20-yUc0OvnQ5ng_4_6">33,276</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Y_TN3UG2Lky2Yj_ZE4CQ2w_4_9">28,794</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Depreciation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_cIvpsJA4gkizfHAdtLzaqw_6_3">383</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_3-kR8Inh10Ozv5HLcY7fQA_6_6">231</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_rx-Z0ahVIUGuVBOkTjeVgg_6_9">221</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Noncash interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_61y02Jyal0O3GbDOh1jTBw_7_3">657</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_wKqndEGEkEyHT4sBQwBBNg_7_6">664</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_TR5Va2WI60Ob9Oj7mWE4PA_7_9">584</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Noncash loss on extinguishment of debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="tela:NoncashLossOnExtinguishmentOfDebt" scale="3" id="Tc_qbRmgVY6c0W1_Lx2JxnN0A_8_3">1,228</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Amortization of intangible assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="Tc_oNAuWi3DSEey6KKcv1puBw_9_3">804</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="Tc_lrr_xQLMhUSPBe02QE-Dug_9_6">304</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="Tc_qTp7qyfFi0OIWtej9kvzcg_9_9">304</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Net changes in operating lease ROU assets and liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="tela:NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities" scale="3" id="Tc_rrox9fEf906Jkc4EGQOXEg_10_3">36</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Inventory excess and obsolescence charge</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_0tZfyOxI40m68I-u189_Qw_11_3">1,866</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_JjHoYygC8k6XZCTqY20Baw_11_6">1,439</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_8C6jThV8rkSoWGu9TciLCA_11_9">1,327</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Stock</span><span style="font-size:8.5pt;">&#8209;</span><span style="font-size:8.5pt;">based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_qpeqkBB-AU-_8VHxt13q0Q_12_3">3,989</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_CSwPpcWfs06DdcaSGBNv5Q_12_6">3,661</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_kn3MSpduE0WxfolE7v-HDA_12_9">2,058</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Loss on disposal of fixed assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" sign="-" scale="3" id="Tc_nZ0lR6SIUEi1xXXJoHh3SQ_13_6">2</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8.5pt;">Change in operating assets and liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Accounts receivable, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_eX3TOnkKWUieWLWqiLmNJQ_15_3">2,421</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_K4PVK0jvYkSDn7khISOyKQ_15_6">1,553</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_i5X693J79keHiMoITTwMmA_15_9">149</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_Pw3ohuPjtUea4zpFgpdZ5Q_16_3">6,073</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_tg0PUW1PwEOgGrrMwgO6jA_16_6">5,194</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_ZRhDzMOrckWNkyEmyesLlQ_16_9">620</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Prepaid expenses and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_OuRBXQVwTkyB8Au1uBDNpg_17_3">1,216</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_1XmiyuqH3UenFhgOzvoyRg_17_6">992</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_yj8Fq1354UWvkzyx5CWUhw_17_9">66</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_486DJ3bwtk29snxZkt1Nwg_18_3">884</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_y6DJ6RAvFk-31aov_bx67Q_18_6">1,597</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_7-DJwM4Jf0OVxBhIshwEOA_18_9">2,002</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Accrued expenses and other current and long-term liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_x93rFSLinUuBpJuCOzgzWA_19_3">2,399</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_1a7tEf8StkWXsZSaZGcRrw_19_6">2,673</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_GEGpuU0FdkiCYcK05AQ6_Q_19_9">2,321</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Foreign currency remeasurement loss </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_e8ikf6S9jEu_b936UyzRRw_20_3">420</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_q_lRtu_PZkCCyvXoNW-sdA_20_6">12</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="Tc_XkoCzwx9mEub9YZp5uUJTw_20_9">70</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8.5pt;">Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_rGhCsNkwo0ShZIWrEB2w2A_21_3">40,748</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_GTUmBpkYy0OdoSQWLLZwCA_21_6">30,432</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_T-1D5EcF_06dzhEB5PHRDQ_21_9">24,456</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Cash flows from investing activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Proceeds from the sale and maturity of short-term investments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="Tc_tylGFhq7DEKky3bREK5Q9w_23_9">9,289</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Payment for intangible asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_ZKpQNwhUUU2ok2wyQFgpRw_24_3">1,000</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Purchase of property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_8r7-F8cmgEG7f-Wg53Ax8Q_25_3">872</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_BVur8vedZ022jX8a2YNfEA_25_6">627</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_t2QIoHFjGEeu85I6-a7fNw_25_9">167</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8.5pt;">Net cash (used in) provided by investing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_D0c4EcC5nU6pnbeM5qZ57A_26_3">1,872</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_wbMRWJtxcUS9aUc7I9ZH9g_26_6">627</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_R9bbY_dZLEmObj1Eyni7uA_26_9">9,122</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Cash flows from financing activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Proceeds from sale of common stock, net of underwriting discounts, commissions and offering costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_QGM4WTEhq0iu_LBk2gG4mg_28_3">34,400</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_b9UIu_zBsEGiZRWq8jGBEQ_28_9">44,722</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Proceeds from issuance of long</span><span style="font-size:8.5pt;">&#8209;</span><span style="font-size:8.5pt;">term debt </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="Tc_rN2pFbpDfkGJi0EUZM0zzQ_29_3">40,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Repayment of long</span><span style="font-size:8.5pt;">&#8209;</span><span style="font-size:8.5pt;">term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_qXcwPeh57k2ilvi9F9Jdyw_30_3">30,000</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Payment of debt financing costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_ELFFthW96kudWi4NIKzPqw_31_3">3,460</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Payment of initial public offering costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_SI_QF34qHkCHxr5zQ3-eiQ_32_9">522</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Proceeds from exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_y9PuEZ1AxU-5O9oJygwFqw_33_3">19</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_3zNsb9Up9kWVBpAidFhZ8Q_33_6">547</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc__bQ3xsXUWkKoHqhTv8fOGw_33_9">175</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Payment of withholding taxes related to stock-based compensation to employees</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_oqvWoYQFw0iOSBecRxHKlw_34_3">157</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Proceeds from issuance of common stock under the employee stock purchase plan</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_Kwq8KaTL9km1QqPtmJfpMA_35_3">50</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_oeDvnYkHsECaUsUD_MF7WQ_35_6">38</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_A6NQ7qAl10KODn_mURvswQ_35_9">34</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8.5pt;">Net cash provided by financing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_CYixyJNyqUSxf7myaDlWTQ_36_3">40,852</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_pojd6AfzrUqZ78ojIK5S1A_36_6">585</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Xp2vTgkQUEqeBiOkW2fybw_36_9">44,409</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8.5pt;">Effect of exchange rate on cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_QiEuNawLl0y54YbxSRVwKw_37_3">144</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_cnxxyh2ANkuLeeilduz9HQ_37_6">11</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_oJwEPZZiI0KDGAojlqEjyA_37_9">17</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8.5pt;">Net (decrease) increase in cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_ArgD9_ncyUajM-rrJhW1nA_38_3">1,912</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_MkoIdf9D40CUuHTxOFw9lg_38_6">30,463</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_bFgz_IoqbEi_p6VkGoniYQ_38_9">29,092</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Cash and cash equivalents, beginning of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_CdHn-xxVz0yIvkjpToDIeQ_39_3">43,931</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_0Hz_6LUALUKRbyA8-cSE-w_39_6">74,394</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc__BrJLAnrGU-IPIumLevDUQ_39_9">45,302</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Cash and cash equivalents, end of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_vdD89D7qQE2XgtPnxcogcg_40_3">42,019</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_-QTadml3gkKWu9yjbsM5Pw_40_6">43,931</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_TziFTePXsUOiCcfPFdrgGg_40_9">74,394</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Supplemental disclosure of cash flow information:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Cash paid during the period for interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_dacsK-aOLU2FaEJ6QkIlqQ_42_3">3,394</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_TcanEg3OiU6-ch78-5uBgw_42_6">2,933</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_p3vT35U1dkKhnDp0luSCcQ_42_9">2,980</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Supplemental disclosures of noncash investing and financing activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Property and equipment in accounts payable and accrued expenses and other current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_AI9qZAgw6ECEmPsFB6eleQ_44_3">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_si4Rmm5je0KMWZAqEv27EA_44_6">166</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_0rggLZbJaEuOOcoAWMeTFQ_44_9">3</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Issuance of common stock for early exercised stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="3" id="Tc_kvbdQ94eiUSGXgSZtrkrOA_45_6">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="3" id="Tc_lqCfJphsn0S4PTUAEtU-zg_45_9">3</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Liability-classified stock-based compensation in accrued expenses and other current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="tela:LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_E6M9sY1Yt0q3cukP9D9h2A_46_9">82</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Reclassification of liability-classified stock-based compensation awards to equity-classified</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="tela:ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified" scale="3" id="Tc_9RfQimk-hE2CtTmyE2QcSA_47_6">82</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Operating lease ROU asset exchanged for operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_W7nsunf9rkuMd2USdpG2Hg_48_3">1,376</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Tenant improvement and deferred rent reclassified to operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="tela:TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities" scale="3" id="Tc_YnxteH83JU2pOGzqBQAIwQ_49_3">380</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Operating lease liabilities assumed for operating lease ROU assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="tela:OperatingLeaseObligationAssumed" sign="-" scale="3" id="Tc_vnePwamIdUaNu2j_UeCWRg_50_3">1,756</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f739f0bf_a583_4ff0_817d_3f598b0dfa7c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><a id="NotestoConsolidated"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_ocCM_nkLpUehU9ZsbM8AkA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1)&#160;Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on April&#160;17, 2012 and wholly owns TELA Bio Limited, a company incorporated in the United Kingdom. The Company is commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient&#8217;s own anatomy. OviTex Reinforced Tissue Matrix (&#8220;OviTex&#8221;), the Company&#8217;s first portfolio of products, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. OviTex PRS Reinforced Tissue Matrix (&#8220;OviTex PRS&#8221;), the Company&#8217;s second portfolio of products, addresses unmet needs in plastic and reconstructive surgery. The Company&#8217;s principal corporate office and research facility is located in Malvern, Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has been directly impacted by the COVID-19 pandemic since the onset of the pandemic in 2020. To date, among other impacts on the Company&#8217;s business related to the pandemic, physicians and their patients have been required by state mandates, or have chosen to, defer elective surgery procedures in which the Company&#8217;s products otherwise would be used. There remains uncertainty and lack of visibility regarding the Company&#8217;s near-term revenue growth prospects and product development plans due to the volatility in the frequency of surgical procedures using the Company&#8217;s products, including through labor and hospital staffing shortages and the allocation of hospital resources due to financial strain experienced during the COVID-19 pandemic. Although the Company continues to monitor developments related to hospital capacity and the volume of elective procedures, there is uncertainty regarding the pace to which surgical volumes will normalize to their pre-pandemic levels and the timing to address the backlog of deferred procedures. The full extent of the impact of the COVID-19 pandemic on the Company&#8217;s business, results of operations and financial condition, including revenue, expenses, manufacturing capability, supply chain integrity, staffing availability, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="Tb_sfXXNJrCK0KRmxY1kvpSVg" continuedAt="Tb_sfXXNJrCK0KRmxY1kvpSVg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2)&#160;Risks and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations to date have focused on commercializing products, developing and acquiring technology and assets, business planning, raising capital and organization and staffing. The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_c-7FzdjTbUGRMT-aCaU-zA">274.2</ix:nonFraction> million as of December 31, 2022. The Company anticipates incurring additional losses until such time, if ever, it can generate sufficient revenue from its products to cover its expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2022, the Company completed an underwritten public offering in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YT0-sLIStUSpSV-5HQs3ng">4,600,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_e7ixSa7Av0qDAVrov1S1Rw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_y-IHow0TY0aVsaZnUg_9-Q">8.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_-AH7eGZJUUan3vLcbaxm0A">34.4</ix:nonFraction> million after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The operations of the Company are subject to certain risks and uncertainties including, among others, the uncertainty of product development, the impact of macroeconomic conditions, including the COVID-19 pandemic, general economic uncertainty, including as a result of inflationary pressures and the measures undertaken by various governments to address them, banking instability, geopolitical factors such as the war in Ukraine, technological uncertainty, commercial acceptance of any developed products, alternative competing technologies, dependence on collaborative partners, uncertainty regarding patents and proprietary rights, comprehensive government regulations, and dependence on key personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sfXXNJrCK0KRmxY1kvpSVg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_uIQKdKtx-Uim8_JRTZWqLw" continuedAt="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3)&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_NdhnL46pI0Cavk2dUjlCLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principals of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of TELA Bio,&#160;Inc. and its wholly owned subsidiary TELA Bio Limited. All intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:UseOfEstimates" id="Tb_3D0ep_FRx0eyDmzOwn3n-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company&#8217;s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_K6lpGrU0fkebF8ge78YFTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_I8CJGHwyyEWw2nQXigOSaQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_4CsR91aKx0qBo3I0kLa2ag">one</ix:nonFraction> segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_YMPUaTqSrUqIlJQvaBRqCQ" continuedAt="Tb_YMPUaTqSrUqIlJQvaBRqCQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash with high-credit-quality financial institutions and primarily invests in money market funds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (&#8220;SVB&#8221;) and appointed the FDIC as receiver. On March 12, 2023, the U.S. Department of the Treasury, the Federal Reserve and the FDIC released a joint statement confirming that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, on March 10, 2023, the Bank of England (the &#8220;BOE&#8221;) announced that it intended to seek the placement of Silicon Valley Bank UK Limited (&#8220;SVBUK&#8221;), an affiliate of SVB, into a Bank Insolvency Procedure, which ultimately results in the acquisition of SVBUK by HSBC UK Bank Plc (&#8220;HSBC&quot;) on March 13, 2023. The BOE confirmed that all depositors&#8217; money with SVBUK is safe and secure as a result of the transaction, and that operations at SVBUK would continue as normal.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the course of these events, a portion of the Company&#8217;s cash was held in accounts at SVB and SVBUK, with the remainder held at another high-credit-quality financial institution. We have recently established additional redundant accounts with another high-credit-quality financial institution to mitigate liquidity risk to our cash and cash equivalents from any further instability in the financial industry.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont1" continuedAt="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont2"><ix:continuation id="Tb_YMPUaTqSrUqIlJQvaBRqCQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As described in Note&#160;11, the Company has licensed patents and other intellectual property from Aroa Biosurgery Ltd. (&#8220;Aroa&#8221;). As part of this agreement, Aroa is also the exclusive contract manufacturer of the Company&#8217;s OviTex portfolio of products. The inability of Aroa to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with Aroa, or an adverse change in their business, could materially impact future operating results.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_gHCziumJ4karwV21ZXzVzA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers cash equivalents to be highly liquid investments with maturities of three&#160;months or less from the date of purchase. Cash equivalents consist of investments in a money market fund. The Company&#8217;s cash and cash equivalents are carried at fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:InventoryPolicyTextBlock" id="Tb_ptjRrrD5W0ioI4snh6VcdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory consists of finished goods and is identified and tracked by lot and stated at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. The Company periodically analyzes its inventory levels and writes down inventory that has become obsolete or that has a cost basis in excess of its expected net realizable value based on expected customer demand. As of December 31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="6" id="Narr_PTdvalngxkqRYctF73C9Qw">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="6" id="Narr_t4Qw2DkUW0aVpHs4F8PIwQ">1.7</ix:nonFraction>&#160;million, respectively, in finished goods consigned to others.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_q5-AhCQtME2P_dDt1tvTxA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at the aggregate cost incurred to acquire and place the asset in service. Expenditures for routine maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Depreciation is provided over the estimated useful lives of the assets using the straight-line method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="Tb_XLf21lP4d0-igk5UF_x4dQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and milestone payments due related to licenses or commercialization rights prior to future economic benefit being established are recorded as research and development expenses. Milestone payments due related to licenses or commercialization rights after future economic benefit is established are recorded as intangible assets. In 2022, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="Narr_lyo1qTLgUUGr5XfKrkB6mQ">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="Narr_Vdc-4qPWIUmQ3LTFviQlYQ">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="Narr_ESp0m-5TIEmJ-dd3evkmAg">0.3</ix:nonFraction> million of amortization expense, respectively, related to intangible assets. At December 31, 2022, the remaining life of intangible assets was <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_3Rrjcl0_TEuBaiNgTc6qTw">6.6</ix:nonNumeric>&#160;years. The Company anticipates recognizing amortization expense of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="Narr_tmxXsBIVdEC3JzSPyLUa6w">0.4</ix:nonFraction>&#160;<span style="-sec-ix-hidden:Hidden_N7lFaWJk4UioTzyN62omEA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span></span> in each of the <span style="-sec-ix-hidden:Hidden_KtzSWTvEJkCOw76-3Skdsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">next</span></span> <span style="-sec-ix-hidden:Hidden_M4WVaq1GFEm8sYjSSs7jbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span>&#160;<span style="-sec-ix-hidden:Hidden_BsVw2TEmt0uc2rx2gi65UA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">years</span></span> and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="Narr_aI3FVOGjPUim43k_PvXjLw">0.5</ix:nonFraction>&#160;million thereafter.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_cBespzxVLkqHlWQ6LWvPcA" continuedAt="Tb_cBespzxVLkqHlWQ6LWvPcA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by such asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group exceeds the undiscounted cash flows, an impairment is recognized to the extent the carrying value exceeds its fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="Narr_AqkUH1jEk0-J2U3Wlv4gyQ"><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="Narr_lzPhqlzHqE6w2lNUcd1OAA"><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="Narr_7wT4p6EYk0SkmMnuQL12NA">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses were recognized during the&#160;years ended December 31, 2022, 2021 or 2020.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a0f9e93c_20f8_4dcb_aa1c_911932c1af94"></a><a id="Tc_lu3Lbj9rvEKRLXKTy_e8bA_1_2"></a><a id="Tc_5mYn8BSOY061MESDgz6wSg_2_2"></a><a id="Tc_PPeKel7GJEqc-pOM3EXFFQ_2_5"></a><a id="Tc_bdQgqIwIkkip0I3brj6L3Q_2_8"></a><a id="Tc_slJ7xStGVkyLsGYlCNABTw_3_0"></a><a id="Tc_XPVzeBzX5UquGPWHM5MLMw_3_2"></a><a id="Tc_ihMIrA4yikK9ieJ2kFDbOg_3_5"></a><a id="Tc_OEdH-L-iHEaAzJxp1-87aw_3_8"></a><a id="Tc_Rj8l222beUCDV79IYkYF1A_4_0"></a><a id="Tc_un6tmZg0NkqPgiawALr4Eg_5_0"></a><a id="Tc_6u6iA9EuwEq9XC3yBCqfNA_5_6"></a><a id="Tc_Kk1esWy5W0CTGuph8vNgAA_5_9"></a><a id="Tc_FcAVPf1zbkWSSPwbfSGdsg_6_0"></a><a id="Tc_O1JnygjUqUiRp7tmO-6J5g_6_2"></a><a id="Tc_WjlO5J95bE6OAunLBbARrg_6_5"></a><a id="Tc_JNmoHRU5uESuAZjfzIFBpA_6_8"></a><ix:continuation id="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont2" continuedAt="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont3"><ix:continuation id="Tb_cBespzxVLkqHlWQ6LWvPcA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:DebtPolicyTextBlock" id="Tb_RapPcdp8Ik-B_H4QATNZSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Debt Issuance Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Debt issuance costs incurred in connection with debt (Note&#160;6) are amortized to interest expense over the term of the respective financing arrangement using the effective-interest method. Debt issuance costs, net of related amortization are deducted from the carrying value of the related debt.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_OtCFG1kXJUi9dYosDBlnXg" continuedAt="Tb_OtCFG1kXJUi9dYosDBlnXg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i)&#160;identify the contract(s)&#160;with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Company&#8217;s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Company&#8217;s customer contracts, the only identified performance obligation is providing the product to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue is recognized at the estimated net sales price which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Payment terms with customers do not exceed one&#160;year and, therefore, the Company does not account for a financing component in its arrangements. There are <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt-sec:numwordsen" name="tela:IncrementalCostsOfObtainingContract" scale="3" id="Narr_-nuEigRNHkqZrxtyraP6Gg">no</ix:nonFraction> incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than one&#160;year. Fees charged to customers for shipping are recognized as revenue.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_bSGTtcmmSkWMVy0DXbI_vA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents revenue disaggregated (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OvitexMember_EdbT9Stg4kukXsfXOaqw7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_k75sSUEuIE2JXP7RoOCdzQ_3_3">28,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tela_OvitexMember_KoD1LsmYCUi3vu5Gf7IEhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_8fngu1mqFE6Vz360wU3osg_3_6">22,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tela_OvitexMember_g62SfrjEtkKrRkIEyjjV_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_1sBfa7aTekij6vrPxZPpFg_3_9">15,093</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex PRS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OvitexPrsMember_L3BIDNF6OES8ZPhVA4kbNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_82fUkehlQkmPd-xWD-EeCA_4_3">12,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tela_OvitexPrsMember_65VAhesxikuTOSd3VYTV5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_UjOAQah8nEi00HnnujukAg_4_6">6,473</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tela_OvitexPrsMember_633JkzTN7k-JMFLDXqSR6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_sjGVY2g5BUacVVaIZQayxQ_4_9">3,120</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OtherCustomersMember_jNrO6oj7BUi2tHp_zIcW1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_2RUtwNUg1kquTtcXsxjGTg_5_3">108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_CJNhO_tNlkidxAYfyOu3fA_6_3">41,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_x355mzwxP0WH4LMoLR71LA_6_6">29,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_g5jWg0OFH0uuemYLfYfMFg_6_9">18,213</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Sales outside of the U.S. were $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_X-lkTg0yAk6A3AzjollXfg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_u6oB4p0zWkydo-loo3lo8Q">3.2</ix:nonFraction> million or <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_X-lkTg0yAk6A3AzjollXfg" decimals="2" format="ixt:numdotdecimal" name="tela:RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" scale="-2" id="Narr_UBa6JuXnSk-HG-AzxHu8dA">8</ix:nonFraction>% of total revenue for the year ended December 31, 2022 and immaterial for the years ended December 31, 2021 and 2020.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont3" continuedAt="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont4"><ix:continuation id="Tb_OtCFG1kXJUi9dYosDBlnXg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_yAFpdg3_kk-FEmgEwstfGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred and consist primarily of salaries, benefits, and other related costs, including stock-based compensation for personnel serving in the research and development functions as well as costs incurred with Aroa under development agreements related to technology transfer, laboratory materials and supplies. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. Costs incurred in obtaining patent and other intellectual property licenses or milestone payments from license agreements for which there are no alternative future uses are charged to expense as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_2RpJv08mDUSDQJbrzWs4vg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based awards in accordance with provisions of ASC Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>, under which the Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over the vesting period of the award while awards containing a performance condition are recognized as expense when the achievement of the performance criteria is considered probable. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_RlvTLlq9cEi1IRxzxN7iNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by ASC Topic 740, <i style="font-style:italic;">Income Taxes </i>(&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ASC Subtopic 740-10, <i style="font-style:italic;">Accounting for Uncertainty of Income Taxes </i>(&#8220;ASC 740-10&#8221;), defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in consolidated financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the consolidated financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income tax expense.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_pdBR3EV1qkuRAn4lkZLm5A" continuedAt="Tb_pdBR3EV1qkuRAn4lkZLm5A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bdd5887a_b4e4_4bb9_ad8f_7e2a92f0c595"></a><a id="Tc_Db0RvrzuhUqYhVHEjDsWpw_1_2"></a><a id="Tc_d1FtE2_WcEOeQ4cvlcRgUg_2_2"></a><a id="Tc_KdqiApt2W0O7umHRlpW2EQ_3_2"></a><a id="Tc_1_ObD1nS6k66SMYa-3eRiA_3_5"></a><a id="Tc_Mcc0dSL370OzrAYIhyMC9g_3_8"></a><a id="Tc_CzD4f30uE0OUfNlJpbAipg_4_2"></a><a id="Tc_Qo-fnKeVR0CjBvaizse9PQ_4_5"></a><a id="Tc_kX-DvvlZNEqQ81bcqJ4Fzg_4_8"></a><a id="Tc_LJfa6Rsc2UCHXMID_RcH1A_5_2"></a><a id="Tc_IiwePtySWU-4-gx0J6pXaQ_5_5"></a><a id="Tc_c0DHS6aeTEmtP3yftiZJWA_5_8"></a><a id="Tc_JCwuvERxWk66CfZ5ZATbwA_6_2"></a><a id="Tc_8nsh3GVm3UeaWe-6C5Q8mw_6_5"></a><a id="Tc_jPIOiT3JKk28MSRkcNSKNQ_6_8"></a><a id="Tc_stWdY1j98keCp001JIXUEg_7_0"></a><a id="Tc_B902oXEhQ0umOEn1PEhpWw_8_0"></a><a id="Tc_c-CozuTTvEm-SS8vPUxigw_8_2"></a><a id="Tc_r1omCnj1IEKX3oRZPTKwkA_8_5"></a><a id="Tc_KIPmFMKdAkSAfQx1hLFw9Q_8_6"></a><a id="Tc_EIXXXiKpUEiWt2o_zYV3jA_8_8"></a><a id="Tc_YFXsBQXWmUuEui76eqx50Q_8_9"></a><a id="Tc_oOC_ZSPj9UKf0ikGaosO0g_10_0"></a><a id="Tc_UQpPZ3ZW1Eenubxht4SaBw_11_0"></a><a id="Tc_Qa65vuEikkCftNfyJNVO2A_11_2"></a><a id="Tc_dfzZO6GjyUi27FfhodLpAg_11_5"></a><a id="Tc_e8IeOOYmBkKLnD0dziFUQQ_11_6"></a><a id="Tc_WIvSW8AMK0yzorDPmW3i1g_11_8"></a><a id="Tc_xNQxmd-n5kGpLORQjEgHkw_11_9"></a><ix:continuation id="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont4" continuedAt="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont5"><ix:continuation id="Tb_pdBR3EV1qkuRAn4lkZLm5A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. Due to the related-party relationship of the OrbiMed Credit Facility (Note&#160;6), it was impractical to determine the fair value of the debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company follows the provisions of ASC Topic&#160;820, <i style="font-style:italic;">Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">1:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">2:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">3:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></td></tr></table><div style="margin-top:12pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_gppnzFcql0q0JSLnd0LbBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following fair value hierarchy table presents information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measurement&#160;at&#160;reporting&#160;date&#160;using</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">active&#160;markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents&#160;&#8211; money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_PGJ1GKO4r0m8-XWNlJhlug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_UqJCApn8ukaXUT5GfN34Ng_8_3">39,010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents&#160;&#8211; money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Aei9Npet1Ea_GR9b8r2LiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_5A1O0H8OQ06D2EFS2C2c_A_11_3">41,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_Or1-dqMi6UWX1Qup2vDFIw" continuedAt="Tb_Or1-dqMi6UWX1Qup2vDFIw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:12pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per common share is determined by dividing net loss by the weighted-average shares of common stock outstanding during the reporting period. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share since dilutive shares are not assumed to have been issued if their effect is antidilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as they would be antidilutive.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_nZsBl7s95U-GnRnLyg3JbA" continuedAt="Tb_nZsBl7s95U-GnRnLyg3JbA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_KVlO5ujN7UGDlWVS8uhZjg_1_2"></a><a id="Tc_6lT0LJlIYEqFH5JmP39tAQ_2_2"></a><a id="Tc__l_lU49VqkKDg-dPNgUUWQ_2_4"></a><a id="Tc_dYlEJiaCKEq2ZKXohXoeKQ_2_6"></a><a id="Tc_-pFiinkKxEOZZalvAkADFQ_3_0"></a><a id="Tc__I3phZMqmECRTivuqeTsFA_4_0"></a><a id="Tc_TXSUVzTnS0-d0u5CYxsy5g_4_6"></a><a id="Tc_fubrJMjJsUeAdGxZHJ2Ydg_5_0"></a><a id="Tc_7jOqLHnZJUOoaKQPg1Dc0Q_6_0"></a><ix:continuation id="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont5" continuedAt="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont6"><ix:continuation id="Tb_Or1-dqMi6UWX1Qup2vDFIw_cont1"><ix:continuation id="Tb_nZsBl7s95U-GnRnLyg3JbA_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options (including shares subject to repurchase)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_tv04xB9wqEaTQH96wyjNIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_7LAy9r1ddkqIZ_-w7IEobw_3_2">2,071,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_pRF4sUzZHkaM1gci9cPj_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Zq2gb6orp0u4NxEIuayacw_3_4">1,706,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_UGImw1N6L0mZ0fnBk-7tDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_aCaFurlaFkGHVD3-rh0t1w_3_6">1,498,390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_rqhtk_S59EqxwFA-juI72g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ITvmeKR8lkqqeoOLBCKDqw_4_2">311,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cI7QGTXY5USeztjg0obgqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_MhbjFiFtZ0iZKnH0kKphqg_4_4">163,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_E9meB2rtA0C78Kyfm-g3Bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_WuMeMq5gKkm9hKepSB0q-w_5_2">88,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_sM9LuqJ1i0q0bgc5PtaRTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YN85ALqVWEWz7UiUUvk_Ww_5_4">88,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_0cVBhli_GUqVg00WCdCr8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_fIZVB-cTdUKIrsFux6-olA_5_6">88,556</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Pa5sBIxLVEym12hPZF9mZA_6_2">2,472,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2bNCAo_SKUWun-O4UJT_eg_6_4">1,958,037</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_K-p0HweGG0ameDJG_kxqRw_6_6">1,586,946</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb__76EjmLUJE2g371uWEQyrw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, <i style="font-style:italic;">Leases</i>, (&#8220;ASU 2016-02&#8221;) which requires a lessee to record a right-of-use (&#8220;ROU&#8221;) asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12&#160;months. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&#160;its effective date or (2)&#160;the beginning of the earliest comparative period presented in the consolidated financial statements as its date of initial application. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the transition practical expedients to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the date of application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In June 2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Measurement of Credit Losses on Financial Instruments</i>, which provides guidance for recognizing credit losses on financial instruments based on an estimate of current expected credit losses model. The standard is effective for the Company beginning January&#160;1, 2023, and the adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2020, the FASB issued ASU No.&#160;2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options</i><i style="font-style:italic;"> and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (&#8220;</i>ASU 2020-06&#8221;)<i style="font-style:italic;">.</i> ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. The adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uIQKdKtx-Uim8_JRTZWqLw_cont6"></ix:continuation><a id="_486a1fc0_fb28_44f0_a9d3_a3cfc048cbd7"></a><a id="Tc_U5o5YTEsokCnr0B5I9lxUg_1_4"></a><a id="Tc_at6V7Jc9AUWhn8h0F42e4A_2_0"></a><a id="Tc_su-6mKb1702LbkvRoMT1vA_2_2"></a><a id="Tc_-GelPlGyAk20NGbmyW6MUQ_2_4"></a><a id="Tc_UIbcplRzP0CBXXgF7YZzKQ_2_7"></a><a id="Tc_n8n5KtkCYUGaeTZpYJqv0A_3_0"></a><a id="Tc_jdCyObnuqkuzzqrpKn8_mw_3_4"></a><a id="Tc_e9-i-tj4bUmlxgcvHH-YMA_3_7"></a><a id="Tc_YAy5tZPV20GL8CKW2mkt2A_4_0"></a><a id="Tc_7BbLUlJ2NkihtZbKU0prNw_4_2"></a><a id="Tc_JL7WUD8y7kKVk9I9L57opQ_5_0"></a><a id="Tc_YPp-8fqrUkOsWrGE-w9_Zw_5_2"></a><a id="Tc_mlVdfElWe0mKGV9VozjxnA_6_0"></a><a id="Tc_GomYlAXviUC1mebGApO2IQ_6_2"></a><a id="Tc_ddXdXBBSiEyYX0SOUa25eA_7_0"></a><a id="Tc_lBuzju7AG06HCKycrS2i4g_8_0"></a><a id="Tc_lzpYJIg-gk-O8m3MdGu92Q_9_0"></a><a id="Tc_jv58Dm6a3kKanaPedkD_ww_9_4"></a><a id="Tc_eAwMe-SxE0y2TFvxxismpg_9_7"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_ARCEjlOF_UKP2UYNNjC_Ng" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;Property and Equipment</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_qI3MnDlZxEmCJpFXXctoWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Asset description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated useful lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_hqviTa-18kW6leCDSegk5w" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_lFxcUzqNtEGMXlP8-eUBCw_3_2">5&#160;Years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_kFCoP67BGk6_GGyzDE7erQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Ry5H81YJqEGhjG_8xc6m0A_3_5">2,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_T7ZsTtnwJUu8lL-B2AMf1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Xf3eWZLSYEKQ1mPEi7fZ2Q_3_8">2,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_L6OtipUKj0WBTkfRIZ9BCw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_wO5ptA4XsEOXDLcmP8MJRg">5&#160;Years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mPjPPo5jm0CMb8H3SqPEdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Cj3piFsNsU-mc2fT_GZWyQ_4_5">274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_jpLtYA4OHkmQ_qtVIb5JZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_JjgAlenIZUi-8uMd_KbGZA_4_8">242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_dMZmT2GGWEeog6Ay7w1DVA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_usaHov5Xfkeqe4PbyIxH2w">3&#160;Years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_1rGYh_LT7ki_OPiUFup5XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_nCC1FmdSVESNzaIlbZEdYg_5_5">604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_T-vzareBQk2hQt3aejgflA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_SKhqHQJXNEiYy83OIiXSqg_5_8">468</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of useful life or lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_OELAYKjFM02OmAHs-BXhFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_WMwzSwvdjkO0Dh8wlCo1fg_6_5">2,309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_4PvHI75_kUy1koIiD7H3FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_cm4lT2hdzUuO4mVogY09Vw_6_8">1,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_yi1v9wCzYUaBp69Hyl6upw_7_5">5,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-zUJoCz_s0mSv1tSXyLsUA_7_8">4,943</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_fMwdMGGsy0-ejxPEDJLQSA_8_5">4,140</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_AWvoK4kSO0ygrTsgeaVvhQ_8_8">3,757</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_RmuERawfpke5JkAInytURA_9_5">1,682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Zk1e9JLdwEKdDJjroGEClw_9_8">1,186</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The cost of property and equipment at both December&#160;31, 2022 and 2021 includes $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_BaYfUZMFFkC1bk-Vne9zAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="Narr_FXfytBvdIk-iB_ut6oW4_w"><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="Narr_p64dB5DGB0CYzGjsewAAxQ">0.2</ix:nonFraction></ix:nonFraction>&#160;million of equipment located at Aroa. Depreciation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_4nSFzUiYkk2wRfDmG5Lqvw">0.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_l0TpkhXBR02JtRHUoeDyaA">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_CLOPmaX3K0CXVTVXJzL8cA">0.2</ix:nonFraction> million for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively.</p></ix:nonNumeric><a id="_eae0e4e6_8b0e_4154_ba50_db4a0f25dc2b"></a><a id="Tc_pwWdWFp0T0q0x0r6XliWWA_1_2"></a><a id="Tc_lZuUKWaNTUCVXziiMeGN9Q_1_5"></a><a id="Tc_jkeC5uY43UeZKgym2OGptA_2_2"></a><a id="Tc_1E9rOea_wESczoXutPfcvA_2_5"></a><a id="Tc_RdmG4VPhbUSqmU_VZhgOjg_3_0"></a><a id="Tc_lGlX99dTnU6zfywr703vXg_3_2"></a><a id="Tc_aLXw8Du9LUuFP6v_fkXd5w_3_5"></a><a id="Tc_3-3RuXMCLkSOaClZ02CZDA_4_0"></a><a id="Tc_37Z3VYDIbE6HKyBIkKU9OQ_5_0"></a><a id="Tc_tg_uozQM4EasYHhxeNq1BQ_6_0"></a><a id="Tc_aXZjPJ5KakO2V1tprEOg8w_6_6"></a><a id="Tc_D6HdbCgMmUOYEY63B1ZeBw_7_0"></a><a id="Tc_vE1fkGxhmEWhT1vs4YRtyg_8_0"></a><a id="Tc_aTdhFBcg1UmzwT5p0QkoVQ_9_0"></a><a id="Tc_BFWalz8uEke_FSkNXlTzRw_9_2"></a><a id="Tc_cracspNyWEKpguaijwuWVw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_gfB2Qr_n5UCoDbbc0pPEpA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;Accrued Expenses and Other Current Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_I7-BRo6oeUC3d1NS3m78pw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_GM5lnUvfokyrXiXEE4MbQw_3_3">6,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_8QpGBuLcJ0GT0HkHRlTCDQ_3_6">4,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party and professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_5QZG6cXHdkWLZ49SUHs7ag_4_3">2,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_DX7L3oubfkukN9z6qvVh8g_4_6">2,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amounts due to contract manufacturer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="tela:AccruedExpensesAmountDueToContractManufacturer" scale="3" id="Tc_Tj7_XkiEY0eJprk57zeDRg_5_3">1,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="tela:AccruedExpensesAmountDueToContractManufacturer" scale="3" id="Tc_j8mGeXK8R0CPZVAenZtHWA_5_6">842</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_VRiK9AdXhUqdcIFz6rMPlA_6_3">340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="tela:ResearchAndDevelopmentExpensesPayableCurrent" scale="3" id="Tc_j4i7kiAjikaTo6uJkVjomA_7_3">137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="tela:ResearchAndDevelopmentExpensesPayableCurrent" scale="3" id="Tc_vIFpwKvf8U2Q8kS8fzJ8lQ_7_6">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_0P8Jev8m1E-xrf7DW0znTg_8_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_5NPMMDg-Mkah6m5H7UJTAg_8_6">79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_SomUEBFJSEqlQu9PFcF49w_9_3">10,869</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_biT6OtHfakOYCOvos_YJZw_9_6">8,161</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8fce3ef_642b_4b63_9eb4_003d807870e3"></a><a id="Tc_BSFXc58VSkWel6LY6Lj3xQ_1_2"></a><a id="Tc_4uA6uAjt30SHS11Vxr-C6Q_2_2"></a><a id="Tc_3oghe5EaykCWJRQbhu8XVA_2_5"></a><a id="Tc_2a3J_2RRB0en62o2edLt5g_3_0"></a><a id="Tc_V0AiHI_IcU29qZ2Et1dH3A_3_2"></a><a id="Tc_mDUndce_sEyw5GfoHL0pxw_3_5"></a><a id="Tc_RAUQ5pa2N0qWWrevSRSZZQ_3_6"></a><a id="Tc_d0ob75wTWUO7v8JfijtTxg_4_0"></a><a id="Tc_Yv7nsMH_nku5FDlhJ3WHYQ_4_3"></a><a id="Tc_2laxEmuklE65ZPfim-NH9Q_5_0"></a><a id="Tc_9hWALcDcpEW3ldxM-5qHrw_6_0"></a><a id="Tc_M6Gwtt-5xEqoyd654-83Jg_7_0"></a><a id="Tc_bN78iiADJEKG0Abut0oIfA_7_2"></a><a id="Tc_CHKuapfKQkqfAXHl9aix6w_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:LongTermDebtTextBlock" id="Tb_c1ZqIlySh0mUska7FEZ6jQ" continuedAt="Tb_c1ZqIlySh0mUska7FEZ6jQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;Debt</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfDebtTableTextBlock" id="Tb_t1AZHfTnlEeoOqzxzQZFfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Long-term debt consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">MidCap Term Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_jCqHr9goH0iWw09Jjit7ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_0DjPUFhT6Uykw3ROVsLEUA_3_3">40,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OrbiMed Term Loan (related party)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_tela_OrbimedTermLoanMember_pkFbA7Mc-UqsKDpK3kA_6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_FN58tjG7BUOBUij-UBmxrw_4_6">30,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">End of term charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="Tc_1ckFpIDRrk2IEwD056WHYg_5_3">2,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="Tc_zINiBms2VkCAiTQCNjgjHA_5_6">3,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unamortized end of term charge and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_2hba7St7wUS-oSCvwmYdOQ_6_3">2,084</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_ZCaJZAYfaUqgjU7cNQSSNg_6_6">1,509</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_qjSt5jP--EKtCZzK1aHb4Q_7_3">39,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_lsYjrssfA0C4xgPCWmIAGw_7_6">31,491</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MidCap Term Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 26, 2022, the Company entered into the Credit and Security Agreement (the &#8220;MidCap Credit Agreement&#8221;) with MidCap Financial Trust, as agent (the &#8220;Agent&#8221;), and certain lender parties thereto. The MidCap Credit Agreement provides for up to $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_h_H8pqMUMUyTw6VdKGsnwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_DUys8Z_pI0KmmTZs0pYuRA">50.0</ix:nonFraction> million in term loans (the &#8220;MidCap Term Loans&#8221;), consisting of a $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheOneMember_HRhYP45vYUW4DEuuKEzNbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_zTlIJIbE9kSZyQ_-qTnknQ">40.0</ix:nonFraction> million Tranche 1 (&#8220;Tranche 1&#8221;) and a $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheTwoMember_UJdzkLGJCk6Gx_nvGHVbIA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_HttmDajHmkOzc7xbbTYSAQ">10.0</ix:nonFraction> million Tranche 2 (&#8220;Tranche 2&#8221;). Upon closing, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheOneMember_HRhYP45vYUW4DEuuKEzNbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_cuNPk2bLkEmzKiuCq1Yo0w">40.0</ix:nonFraction> million of Tranche 1 and used a portion of the proceeds to repay borrowings under the OrbiMed Credit Facility (described below) and intends to use the remaining proceeds to fund operations and other general corporate purposes. The Company will be eligible to borrow Tranche 2 at the Company&#8217;s option upon meeting certain conditions, including, but not limited to, reaching $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_5_26_2022_To_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_7alFNq9WVkudCwmmXa7QyA" decimals="-5" format="ixt:numdotdecimal" name="tela:EligibilityRequirementToBorrowTranche2" scale="6" id="Narr_IEEK0kTH3UGksuSMQ7Miog">65.0</ix:nonFraction> million of net product revenue over the preceding four quarters by fiscal year end 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the MidCap Credit Agreement, the Company provided a first priority security interest in all existing and future acquired assets, including intellectual property, owned by the Company. The MidCap Credit Agreement contains certain covenants that limit the Company&#8217;s ability to engage in certain transactions that may be in the Company&#8217;s long-term best interests, including the incurrence of additional indebtedness, effecting certain corporate changes, making certain investments, acquisitions or dispositions and paying dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The MidCap Credit Agreement also contains customary indemnification obligations and customary events of default, including, among other things, (i) non-payment, (ii) breach of warranty, (iii) non-performance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, the Company must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, the Company would be required to pay interest on principal and all other due and unpaid obligations at the current rate in effect plus <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw" decimals="2" format="ixt:numdotdecimal" name="tela:InterestPenaltyPercentage" scale="-2" id="Narr_xCoz_1J7DEycE7M9NbIpxw">2</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The MidCap Term Loans mature on May 1, 2027 and bear interest at a rate equal to <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_jCqHr9goH0iWw09Jjit7ig" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_HQ23RMxfN06TEkVxdx-Qkg">6.25</ix:nonFraction>% plus the greater of one-month Term SOFR (as defined in the MidCap Credit Agreement) or <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_QykfsvRGv0WxqJJfvminqQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_sCQKT-92K0i-l2SFrBMYvQ">1.0</ix:nonFraction>%. The Company is required to make <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw" format="ixt-sec:durmonth" name="tela:DebtInstrumentInterestPaymentTerm" id="Narr_K12gRPLYxU-bVGMwCjFdrQ">36</ix:nonNumeric> monthly interest payments beginning on June 1, 2022 (the &#8220;Interest-Only Period&#8221;). If the Company is in covenant compliance at the end of the Interest-Only Period, the Company will have the option to extend the Interest-Only Period by <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_QT0qfYviYU6Qkgg2H5pTKQ" format="ixt-sec:durwordsen" name="tela:AdditionalExtensionForInterestOnlyPaymentPeriod" id="Narr_6nSgeZPYbUy4TJetQ0SILg">12 months</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_pYoDsd8Lak-sf5zkcqJ-0w" format="ixt-sec:durmonth" name="tela:AdditionalExtensionForInterestOnlyPaymentPeriod" id="Narr_N79DQRZgk02bFOUbLF-t6w">48</ix:nonNumeric> monthly interest payments, followed by 12 months of straight-line amortization, with the entire principal payment due at maturity. If the Company is not in covenant compliance at the end of the Interest-Only Period, the Company is required to make 24 months of straight-line amortization payments, with the entire principal amount due at maturity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subject to certain limitations, the MidCap Term Loans have a prepayment fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_FirstYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Fa-0d26vSUuUMMIob5eqFg" decimals="3" format="ixt:numdotdecimal" name="tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" scale="-2" id="Narr_KHMcv_t890KEuSninHv9Gg">3.0</ix:nonFraction>% of the prepaid principal amount for the first year following the closing date of the MidCap Term Loans, <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_SecondYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_z5Xo6mvHC0uadpbBdDSOsg" decimals="3" format="ixt:numdotdecimal" name="tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" scale="-2" id="Narr_yRPEbZarH0ubcZwxmG7evw">2.0</ix:nonFraction>% of the prepaid principal amount for </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_c1ZqIlySh0mUska7FEZ6jQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the second year following the closing date and <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_ThirdYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_LQmV-QrJjEGKWrU-HuZaaA" decimals="3" format="ixt:numdotdecimal" name="tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" scale="-2" id="Narr_nK0nE3Fg70SDBPZLmz3FkA">1.0</ix:nonFraction>% of the prepaid principal amount for the third year following the closing date and thereafter. The Company is also required to pay an exit fee at the time of maturity or prepayment event equal to <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw" decimals="2" format="ixt:numdotdecimal" name="tela:PercentageOfExitFee" scale="-2" id="Narr_SNIzjiHsDEOckaIg2CRrJQ">5</ix:nonFraction>% of all principal borrowings (the &#8220;End of Term Charge&#8221;) (or in the event of a prepayment event, the amount of principal being prepaid). Interest expense associated with the MidCap Credit Facility recorded for the year ended December 31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_TEhtRGXQEUSK7BWhRlVsmg">2.6</ix:nonFraction> million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="Narr_y9NGTfWDGUCwW0MiVzyNNg">0.4</ix:nonFraction> million was related to the amortization of debt issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OrbiMed Term Loan (Related Party)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2018, the Company entered into the OrbiMed Credit Facility with OrbiMed, a related party as the lender is affiliated with a stockholder of the Company, which consisted of up to $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_Kaoof9Egs0ivKLTiFF4Y9Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_xegINaV3EEib1mCqIFQeJw">35.0</ix:nonFraction> million in term loans (the &#8220;OrbiMed Term Loans&#8221;). The OrbiMed Term Loans consisted of <ix:nonFraction unitRef="Unit_Standard_tranche_taD5b-wNNkeDwJocY19qDA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA" decimals="INF" format="ixt-sec:numwordsen" name="tela:NumberOfTranches" scale="0" id="Narr_lfnEquQKBkqKr4T8GhVQ6Q">two</ix:nonFraction> tranches, a $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheOneMember_yI91ExdwXUG56squ0fq2vQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_4dR4XyVtnEahQ4rDfKSMSw">30.0</ix:nonFraction>&#160;million Tranche&#160;1 (&#8220;First Tranche&#8221;) and a $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheTwoMember_b-6HOZChpUeQzYJXQLel8A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_lIFeBLkowkOgOVvMJUiSuw">5.0</ix:nonFraction>&#160;million Tranche&#160;2 (&#8220;Second Tranche&#8221;). In November&#160;2018, the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheOneMember_yI91ExdwXUG56squ0fq2vQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_Vd5R6BkBy0KID-XO0oDczQ">30.0</ix:nonFraction>&#160;million of the First Tranche. The Company elected not to borrow the Second Tranche&#160;prior to its expiration on December&#160;31, 2019. On May 26, 2022, the Company entered into the MidCap Credit Agreement and upon closing used a portion of the proceeds to repay all borrowings under the OrbiMed Credit Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The OrbiMed Term Loan bore interest at a rate equal to <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_Kaoof9Egs0ivKLTiFF4Y9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_VqEP9CdSGEC08t-c8SFyaQ">7.75</ix:nonFraction>% plus the greater of one-month LIBOR or <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_BMBZkylIyUmOoB5qEBh2iA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_6WvGssFxU0SbsH5Csi8g8A">2.0</ix:nonFraction>% until the aggregate principal, interest and End of Term Charge of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA" decimals="-5" format="ixt:numdotdecimal" name="tela:EndOfTermCharge" scale="6" id="Narr_SGcSBm8RO0WRG2Y46_SKrg">3.0</ix:nonFraction> million were paid with part of the proceeds received from the MidCap Credit Agreement. As a result of these payments, a $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_XPuZeyCGt0O-MJ7KLcdtKQ">1.2</ix:nonFraction> million loss on extinguishment was recorded during the year ended December 31, 2022. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2022, was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_PztRWeYBu0epmNZaApgk_Q">1.5</ix:nonFraction> million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="Narr_Lur4jF0oZUWkLlKDKTAUmQ">0.3</ix:nonFraction> million was related to the amortization of debt issuance costs. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2021, was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_YSX6qeqpOEafTWL95y7zgA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_ZrbRDM1ZXEKPatC9wuMJIw">3.6</ix:nonFraction> million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_YSX6qeqpOEafTWL95y7zgA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="Narr_yV0lGZwMyES3RZ-aL6ipfQ">0.7</ix:nonFraction> million was related to the amortization of debt issuance costs. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2020, was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_9qJHl78Mt0qRtojolu34eA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_v4ZE41VXL0azGJ4awk2vpA">3.6</ix:nonFraction> million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_9qJHl78Mt0qRtojolu34eA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="Narr_xR14MJW4n0mWiV7ZMnnu2Q">0.6</ix:nonFraction> million was related to the amortization of debt issuance costs.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_BBMPzqNNP0GievSAdSpUew" continuedAt="Tb_BBMPzqNNP0GievSAdSpUew_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7)&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Public Stock Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lQEEIhyvLUeG6RwD_4RFTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_F04Qh2L-2UaK6KYdxAHy8Q">3,000,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lJzbq-J-nEOX--0ZNtWiug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_HvjvumMycEeyfvQHLmw7-w">16.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lQEEIhyvLUeG6RwD_4RFTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_agsRfIL6U0Cv0EfpON5RFw">44.7</ix:nonFraction> million after deducting underwriting discounts, commissions and other offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2020, the Company entered into an Equity Distribution Agreement (the &#8220;Equity Agreement&#8221;) with Piper Sandler &amp; Co (&#8220;Piper&#8221;) in connection with the establishment of an at-the-market offering program under which it may sell up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_DFSh0vmZ7ES3xBh8RnpMfw" decimals="-5" format="ixt:numdotdecimal" name="tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" scale="6" id="Narr_rNEwxdR6gEiVd70zbFFRLw">50.0</ix:nonFraction> million of shares of the Company&#8217;s common stock, from time to time through Piper as sales agent. <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_5WQ0HWHJy0GEHABnWD88Bg" decimals="-5" format="ixt-sec:numwordsen" name="tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" scale="6" id="Narr_DNrsMKzv6U-r33KIsdqwIg"><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_xGKYdmhTDE2zwVT9engEmA" decimals="-5" format="ixt-sec:numwordsen" name="tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" scale="6" id="Narr_EsxxnZoSCki4MLms59TfuA">No</ix:nonFraction></ix:nonFraction> sales were made under the Equity Agreement during the years ended December 31, 2022, 2021 or 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2022, the Company completed an underwritten public offering in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_vIJH8TG72EWqRDnrQUMzWA">4,600,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_e7ixSa7Av0qDAVrov1S1Rw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_UKL-8LyxOUONSNSeWX9ong">8.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_EuqZDReuXEaFroZocU_Hqg">34.4</ix:nonFraction> million after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_LfqmjKG_gE-KxvlKu_61nQ_1_5"></a><a id="Tc_P7kZtjL5E0u02D4-2zrEaQ_1_7"></a><a id="Tc_vntuZUd2wkeF7aqkhuXxAA_2_2"></a><a id="Tc_QMywTa32AU-gCO0blpsw_A_2_5"></a><a id="Tc_4CY8xS65B0eOxGXocOs4Zg_2_7"></a><a id="Tc_aAPgAGw0CUWDdfM9b9A55Q_3_0"></a><a id="Tc_8pibAEu_IUyemp6U9xmhmA_3_4"></a><a id="Tc_IB57q3aps0qe1Wa9lI7NBg_4_0"></a><ix:continuation id="Tb_BBMPzqNNP0GievSAdSpUew_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company had the following warrants outstanding at December&#160;31, 2022:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_8YUe00RGT0W89dHq7oTn2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">dates</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_CHZHq7ZTvEK6xqdLmH_vew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_4RL_ndQ5w0esuA-MXhKDwA_3_2">8,379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_CHZHq7ZTvEK6xqdLmH_vew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_ekUVxgeEcUu-7ShPrney1A_3_5">28.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_SAt9gqyaqUqRNPZ9FC6LyQ" name="tela:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" id="Tc_5Qra2PebFE602pQzkJvyfA_3_7">2028</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member_TigqdE4b6kOc3r-MRIqDcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_uGhWPntOlUqJB9Gt-g-wRg_4_2">80,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member_TigqdE4b6kOc3r-MRIqDcQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_IqR8wdLy0UGEP4p-l9PIgg_4_5">28.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member__U-R7Y6xF0uM61E9PpKfaw" name="tela:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" id="Tc_thDcq_-U5Eqzpcb702-R4w_4_7">2027</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_DnQFXmXFYkO0yPuNfYnjxg_5_2">88,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_a91cc7e3_aa69_4fce_996b_d35ed7c62dfd"></a><a id="Tc_Vq85OtmVgUiSrfO52JT5yA_1_2"></a><a id="Tc_SiwPhPZJYU2aNEy0W6yhrA_2_2"></a><a id="Tc_QodyvrOq20ObjjklEdHjcw_2_5"></a><a id="Tc_oF6XtApCAkyAwaLh0lathA_2_8"></a><a id="Tc_hpKW3V6Ri0Kt503XuTmMrw_3_0"></a><a id="Tc_4vtkSPQj9keyeTBl8M7dfQ_3_2"></a><a id="Tc_e211Dbh2zEe_5dlTk67BvQ_3_5"></a><a id="Tc_2pk9pmkdAkGPIRvkweSMpQ_3_8"></a><a id="Tc_as_qbxQTLkCI6JEAV-m3HQ_4_0"></a><a id="Tc_cFD9MQQjl0OFF52O5Zo9EQ_5_0"></a><a id="Tc_cIFKhElApk-Jji_4O8jO_Q_6_0"></a><a id="Tc_7Uh73355IUmNcXvg6JmxYQ_6_2"></a><a id="Tc_oEeMhBAuGkKqkY466EPv9g_6_5"></a><a id="Tc_RYqUF3uJ8U-U4YdrliNclg_6_8"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_cIKczxzKiECF12q-enfxKQ" continuedAt="Tb_cIKczxzKiECF12q-enfxKQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_item__TJFBDNbO0SDXs4XkYl9ag" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt-sec:numwordsen" name="tela:EquityIncentivePlansNumber" scale="0" id="Narr_jM0CFdt0LUGSjzhGp1cG7A">two</ix:nonFraction> equity incentive plans: the 2012 Stock Incentive Plan and the Amended and Restated 2019 Equity Incentive Plan. New awards can only be granted under the Amended and Restated 2019 Equity Incentive Plan (the &#8220;Plan&#8221;). At December 31, 2022,  <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_pbxz9JD2tEuMD0Bp4A1EmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_EkBxPuE1OkmPGFYpYAOBKQ">1,427,772</ix:nonFraction> shares of common stock were available for future issuances under the Plan. The Plan is subject to an annual increase, subject to prior approval by the Company&#8217;s board of directors, equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_pbxz9JD2tEuMD0Bp4A1EmA" decimals="0" format="ixt:numdotdecimal" name="tela:CommonStockCapitalSharesReservedForFutureAnnualIssuance" scale="0" id="Narr_BqH0Kk0U7k2l6uJQwO7xVA">432,442</ix:nonFraction> shares, (ii) <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_pbxz9JD2tEuMD0Bp4A1EmA" decimals="2" format="ixt:numdotdecimal" name="tela:CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" scale="-2" id="Narr_bXUyNG0PNk64gqTekXZR3A">4</ix:nonFraction>% of the shares outstanding on the last day of the immediately preceding fiscal year and (iii) such smaller number of shares as determined by the board of directors. The Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options vest based on the terms in each award agreements and generally vest over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_L9eLKsRNw0CRO-mST_AJQw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_3rH0BXJRCUCG6apRKSE8-A">four&#160;years</ix:nonNumeric> and have a term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_L9eLKsRNw0CRO-mST_AJQw" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="Narr_cVkHEqVfj0evXBNABwHNzA">10&#160;years</ix:nonNumeric>. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense ratably over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations and comprehensive loss (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_SF4zR4CfnkizOihNSRDJIg" continuedAt="Tb_SF4zR4CfnkizOihNSRDJIg_cont1" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_qb-xC0ZM6EmvUL8LzpWnCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_YIwrrCjkbEGDLpISMznEjg_3_3">1,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_8-eGjFS6uU6hiVBVgeYbig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_m-HFmtKphE2Y-3h5iqaTVA_3_6">961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_9XvGvd6jPkaCSiqkj9Sjcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_BSRabVPK3kiBgz-R85SXmQ_3_9">696</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_idpfOALz2UiyklGl9EYKzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9ko4CYKzSk6aBDl1ui19NA_4_3">2,029</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qXTrNzsEgEG6lcTM1Mz12g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fXWsR0oUukeEabue9AfkJQ_4_6">1,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_L98p-_WvLky1L5Gl_Pz7mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uNQNmsyaiUaVtgdlJUBc-w_4_9">1,030</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wDi4dsqi-EqOxKJ9dizz-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9mbA8xodxU2FjYAfzQqi4w_5_3">587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7uFgx_FdS0ODpYTmtHXo-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_JA-7FA3jVkWqtzD3niulsw_5_6">1,158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZOR2THAP1EyzyW3OgaAWLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_suvbXWqbxUu37WpVWGU-Lw_5_9">332</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_pr9Y_j9svk60ggqypbBbEA_6_3">3,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_EzCslsZOL0GooBv_QAP3nQ_6_6">3,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HeYXpz_Uck6o_xqV_zwdiA_6_9">2,058</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_EF17qcknFk6jaczeMfx7hg_1_7"></a><a id="Tc_bHkR6At-dkqLJAUFeTkLPA_2_7"></a><a id="Tc_W3weqS_DgkCqcZgBwe94aA_3_4"></a><a id="Tc_nAfCD1AC00WbnlSFW48TeA_3_7"></a><a id="Tc_HXVlO_QEN06wpuo-3oaCxw_4_2"></a><a id="Tc_fJpAbNPzgUChbgAfKNaXzw_4_4"></a><a id="Tc_qA4va9lLDE61LKQcFo_KCQ_4_7"></a><a id="Tc_r7X-VXjao0yOC58rP--zUg_5_2"></a><a id="Tc_hmlZt9I1_U2dVdLeFdpYIQ_5_4"></a><a id="Tc_-O2QaZ3fS0GsnEgR3vyyLA_5_7"></a><a id="Tc_By8ZXgsjVkW3l83-gb-VkA_6_0"></a><a id="Tc_7e6mBeCuqk2BHZSLOkeacA_6_4"></a><a id="Tc_-28xo1RrMUS4I9sXCsVEsg_7_0"></a><a id="Tc_QZ0OD9zK0EOSr55Zhh3r8w_8_0"></a><a id="Tc_4YCKBlyXCEWM8yXlUBoTHw_9_0"></a><a id="Tc_V6cez45iCUWlr1SWUHxm_g_10_0"></a><a id="Tc_zU4knoZEZ0e-gH9UWEa8tQ_10_4"></a><a id="Tc_XAwdOoJpO02q49mQ4c0Xhg_11_0"></a><a id="Tc_7WqQ9ml97ka2sVUd92S5JQ_12_0"></a><a id="Tc_oOn3Vo4Z5Ea6E8_AE2iFHg_13_0"></a><a id="Tc_jZmdf3FgHEGI3yzKHRk-bg_14_0"></a><a id="Tc_SsH63SwmckKSVoPzLvqhXw_15_0"></a><a id="Tc_8ugRJR_fGkqgfYcTlNkD1A_16_0"></a><a id="Tc_aff84MR1rU21aAwYVggTbw_17_0"></a><a id="Tc_Nc0mYMeEN0m9_fp7dUiVaw_18_0"></a><a id="Tc_P6g7bxG-BkyAOuBGTgo5Uw_18_4"></a><a id="Tc_vZmQlEFaRUGoyB_pdLWqig_19_0"></a><a id="Tc_tIJOeO_HAkG8nI4jLaXaWA_19_4"></a><a id="Tc_6t7PZzioiUGuICb_bGO7Kg_20_0"></a><a id="Tc_34B4EutCF0uTd67e6gXwpA_20_4"></a><a id="Tc_fM-dTCWMFkihJs4RmvQNaw_1_2"></a><a id="Tc_dRUvIgrbkE-9Shjq85YqVw_2_2"></a><a id="Tc__YIkEGYLGEyer_ssM_jL6A_3_0"></a><a id="Tc_6Pwk3RLEYECm9v1AMTCX-g_4_0"></a><a id="Tc_CzSxhqv8L0SXXzTR_J-1SA_5_0"></a><a id="Tc_1qLS6Bvl_0GdoPq_zCeiNg_6_0"></a><a id="Tc_56-hTJJynkqWkfACmCmeGA_7_0"></a><a id="Tc_F3NJJ0Osoki_NqZAkqs-Sw_8_0"></a><a id="Tc_M8yn-WNupUCI4ezZzxGGxw_9_0"></a><a id="Tc_K2FT0uwkSkmfiH0flSskJA_10_0"></a><a id="Tc_QF_N6e_6k0Oqg7H-zT5PHA_10_2"></a><ix:continuation id="Tb_cIKczxzKiECF12q-enfxKQ_cont1" continuedAt="Tb_cIKczxzKiECF12q-enfxKQ_cont2"><ix:continuation id="Tb_SF4zR4CfnkizOihNSRDJIg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity for the Plan:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_4Sx2giwIxEKmgkW3gRetew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average&#160;exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual&#160;term</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price&#160;per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_6ZnepCO0FUK_j9ZJvjVoUA_6_2">1,420,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_sFqTzphmGkKITDLnvqTilQ_6_5">10.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_AEdjn1j-20Ku6TGMBxdl2g_7_2">175,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_f7uxZZ0uh0KPgJs30_Ma_A_7_5">15.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_qtr8ddKH-E2sqhk5dcmIjQ_8_2">27,783</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_TsFNmR3mtUeJMsuexpaXrA_8_5">6.29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_IoRb_HD7HUCws3WmLHwSeQ_9_2">70,037</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_UT25E2roVEWhkQbC9T1hAA_9_5">12.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_S4BKrgciX06yipfAzNXkpQ_10_2">1,498,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_-FtRPSpHb0yrOqvgb_qWug_10_5">10.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_hNWFopowPkqZIRUkorlbTA_11_2">468,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_21FjzAjf0UiEP0XIX1zEmA_11_5">14.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_rGfAcF7eI0yURjnzbPcEKw_12_2">77,154</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_5-qxU6qUHkarIi_sdhgjEA_12_5">7.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_zmw4s_zAmkKn3DtZOKTP6A_13_2">182,645</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__dEm7gh_4kmFclP8UDxGmg_13_5">13.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_b07Cndhuuk2vd14pLdhE2Q_14_2">1,706,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_wn7MsCmF30S0or--ea3KSg_14_5">11.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_6KTH4I6QlEiFAjs_oXAxOw_15_2">450,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_S87fGlV-JEKlPESDb9ZNgw_15_5">10.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_E8qDELzPJ02_biOut_BizQ_16_2">3,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_YAqKJZgtvEOmK5kzfV7GiQ_16_5">5.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_pIJVuP4B6kefgRiayneVVw_17_2">81,408</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_MPrHqYX9nkSTZ0db2gbiwA_17_5">13.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_pMWrct4dlkWmawm6Wxxltw_18_2">2,071,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_U6HVJIzP3kmBBIbA2gxfdw_18_5">11.49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_nYU7wgaEIkOrnuyz2DoSfA_18_7"> 7.16</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_O8lxAVEfCESNgafTEZhGoQ_19_2">2,022,232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_LOE9YC_lm0yzsNmMNFTA3w_19_5">11.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_FctZyyRi6EafcBEMS872QQ_19_7"> 7.12</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_A4AyKRkiukWTW8dKetw79w_20_2">1,237,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_1jHJC3KT6U2_G3RWXXVDaA_20_5">11.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_Kyy54Gipvka3pzXZApI0dg_20_7"> 6.16</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Included in outstanding options at December 31, 2022, were <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA" decimals="INF" format="ixt:numdotdecimal" name="tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" scale="0" id="Narr_sgmalzg7eEaYJydUeS71kQ">381,125</ix:nonFraction> stock options granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). At December 31, 2022, the aggregate intrinsic value of outstanding options and exercisable options was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Narr_Bvn-Rmtzb0yq5WbLVYBFgg">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Narr_4cKd3gkwiUqUo1cJMKASIQ">2.3</ix:nonFraction> million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The 2012 Stock Incentive Plan provided the holders of stock options an election to early exercise prior to vesting. The Company had the right, but not the obligation, to repurchase early exercised options without transferring any appreciation to the employee if the employee terminates employment before the end of the original vesting period. The repurchase price is the lesser of the original exercise price or the then fair value of the common stock. At December&#160;31, 2022, all early exercised options had vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity relating to early exercise of stock options:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" id="Tb_OnFluEuLc0WM2v0VpcRvgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc__yZ3rD8pLky758WTJQ6KNQ_3_2">755</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_17AmFgEqYUG5YS026DY0wA_4_2">306</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="Tc_F1SIoLQ07k-e0Sssk7j37A_5_2">267</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_E0UMu82CnU-JWvxZ_1tS5g_6_2">182</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_OQRYVql6qkyLx-b9VweFyg_7_2">153</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_cFB9XQq26U6YZ4gmM2YMvQ_8_2">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_uv8zoIMQt0uW7Rj1g72ebw_9_2">29</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The weighted average grant-date fair value per share of options granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_tv04xB9wqEaTQH96wyjNIw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_tnPCFOyYdEm-fbuxeTG8rg">6.55</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_pRF4sUzZHkaM1gci9cPj_g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ZMtXecU_ik2hadYSlzLBqA">8.66</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_UGImw1N6L0mZ0fnBk-7tDQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_LLhhwKL4_kmVsjoWCEdx8g">8.13</ix:nonFraction> for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Narr_cTjJ4PZPt0qPDMSNcWKMkA">16,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Narr__mcURQQRwUatxkaY-oUpYA">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Narr_YCIX4yvqWUObtd2acp4IhA">0.2</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December&#160;31, </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_eLyStvvDhEuT0g5HayGHLw_1_2"></a><a id="Tc_CQ4jf3oxLU-JPT2i7PtSQQ_2_2"></a><a id="Tc_g6uIglq1DEyG81SZFVy8YA_2_4"></a><a id="Tc_vidYbsR2I0uC5x_EbBTlTQ_2_6"></a><a id="Tc_Peu3sQiyr0y5RekuIK8BYg_3_0"></a><a id="Tc_I1IraDoUMkGWWf-LhyiaqA_4_0"></a><a id="Tc_8HGS8LmJ80OU8-S9m8sxzA_4_3"></a><a id="Tc_Lrst_ERmwECRSWYPZ1Ovsw_4_5"></a><a id="Tc_nDy5fC_KZUeCTOfRYBlvmw_4_7"></a><a id="Tc_3oRyAt01UE-GE9KGLkbAmQ_5_0"></a><a id="Tc_HP8UXDoG8ECYUPe9iYwYpQ_5_3"></a><a id="Tc_uiHA1e--3kmVgYvVHnzjfw_5_5"></a><a id="Tc_gT2mNKp990KPi9FT7Q16sA_5_7"></a><a id="Tc_jf3RSwcSVk-OrUANTBVXMw_6_0"></a><a id="_7bb89e13_dd7e_46bd_b2c6_7de3aa21052d"></a><a id="Tc_sIVutwn3YEC3kKspNPSCYA_1_2"></a><a id="Tc_SIIvt9JgIU6mq5Y-jQ4e-g_2_2"></a><a id="Tc_IV-Wlvs5nEGk59DwF-AIfg_3_0"></a><a id="Tc_RvFOWndrFEe7zt0BEFoukA_3_2"></a><a id="Tc_Wm3MnVb9kEKyR3O16hetZw_4_0"></a><a id="Tc_ZXe03lhVckGIXh6GPNpBfg_5_0"></a><a id="Tc_WGC_z_4K3kOKCdbXmE04Vg_6_0"></a><a id="Tc_RDSg9O88O0yZVI38HU5a8A_7_0"></a><a id="Tc_RVtRwYe9XkehRcsg0G2P7w_8_0"></a><a id="Tc_77kaG-eA3kauIwzdrxJz7g_9_0"></a><a id="Tc_M2j5I6nA3E2XgKIx6YqEqQ_10_0"></a><a id="Tc_NC88m6HaS0aNeEOkuBU-5Q_11_0"></a><ix:continuation id="Tb_cIKczxzKiECF12q-enfxKQ_cont2" continuedAt="Tb_cIKczxzKiECF12q-enfxKQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2022, the total unrecognized compensation expense related to unvested employee and nonemployee stock option awards was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_PJO7j25WeUCXbH9EasEFSg">5.1</ix:nonFraction>&#160;million, which is expected to be recognized in expense over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_tv04xB9wqEaTQH96wyjNIw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_7xmZK6jyzkWedC9xW9Sg-g">2.5</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Estimating Fair Value of Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected term</i>&#160;&#8211; The expected term of stock options represents the weighted average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time to vesting and the contractual life of the options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility</i>&#160;&#8211; Due to the Company&#8217;s limited operating history and lack of sufficient company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers, including the Company, whose share prices are publicly available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate</i>&#160;&#8211; The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividend</i>&#160;&#8211; The Company has not paid and does not intend to pay dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="Tb_ldPvx1xuukq8QxxcbT1ogQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_dO_YHMkWC0CBHpUWdEpTpg_3_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_OOo2279h0Ua5J81OwgWC1A_3_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_hJ6aKFYcSEanaBERu5vitA_3_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ksA24rshD0mbTbxJF8UT-Q_4_2">69.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_FKbLfW4zqUCwhJvO_JKLZA_4_4">63.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_WysmL8YQvUeqs7u71U1mEw_4_6">59.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Tb3x0ijr9UyarzG7IxgMrg_5_2">2.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_x0gkPAuM4U-jLce0332Jlw_5_4">0.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_LLR9D0EPNkmwoUdszceiVg_5_6">0.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_zT3wg2aItU2MH_bZZXTrJA_6_2"> 6.20</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_MXZpv36t5ECcncuQtZYkbQ_6_4"> 6.15</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_unyHHoPLkkGKwnNeQDeGRg_6_6"> 5.98</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Units</i></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_Oc73JBGjZEe3QbIOHyn8zA" continuedAt="Tb_Oc73JBGjZEe3QbIOHyn8zA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) vest based on the terms in each award agreement and generally vest over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_mUoXkNs1N0aXpesNAElZmw">four years</ix:nonNumeric>. The following table summarizes restricted stock units for the Plan:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_dpnPyxsyg0CxID5TBn_aug_4_2">194,232</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_V3G4yRHySEK_BP_7eA3ieA_5_2">12,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_DT5uCT26-0mPYLD9um4PEQ_6_2">19,189</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_0ySqKDuji0e0ER6NBbeSnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_fjBnTsSxJkyYZRwg9OFmRg_7_2">163,043</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_BRgyFjKry0yt2nJcCyrnaA_8_2">197,950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_xOKkkPfqpkKmRYVzqEzLAg_9_2">40,783</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_Y-AlUtuWuEWO_jffoWC2cQ_10_2">8,219</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_2whHoKdN0ESi5SblPsdAwQ_11_2">311,991</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_cIKczxzKiECF12q-enfxKQ_cont3"><ix:continuation id="Tb_Oc73JBGjZEe3QbIOHyn8zA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Included in outstanding RSUs at December 31, 2022, were <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w" decimals="INF" format="ixt:numdotdecimal" name="tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" scale="0" id="Narr_-LNTtJsbREyaDO2hxxbelg">7,500</ix:nonFraction> RSUs granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). The weighted average grant-date fair value per RSU granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr__LT-VuN1mU6Dm_lA1L2fcw">11.21</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ZKtTTtVUk0WxxEZKGblrEA">16.57</ix:nonFraction> during the year ended December 31, 2022 and 2021, respectively. The aggregate intrinsic value of RSUs outstanding was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="Narr_QOouFJIQzUGUbzU9Dtu2qw">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_0ySqKDuji0e0ER6NBbeSnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="Narr_39yBg9F7xU2eO8Iw_Hr1zw">2.1</ix:nonFraction> million at December 31, 2022 and 2021, respectively. The total unrecognized compensation expense at December 31, 2022 related to RSUs was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_t5rwRiSDgkeP-nLPGVgK8g">2.6</ix:nonFraction>&#160;million, which is expected to be recognized in expense over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_IXsFKd3FV0maYm_Hdoe_EQ">2.6</ix:nonNumeric>&#160;years.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="Tb_DTMUzseynkibNqDCgvXR4g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9)&#160;Employee Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">401(k) Defined Contribution Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a 401(k)&#160;defined-contribution plan covering all employees. Participants are permitted to contribute up to <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_evx4uxp_UU22Gr9oAu-7ZQ">100</ix:nonFraction>% of their eligible annual pretax compensation up to an established federal limit on aggregate participant contributions. Discretionary contributions made by the Company, if any, are determined annually by the board of directors. Effective January 1, 2020, the Company matched <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_tS9PZ2cuNE-Y_fEPGx6pBQ">50</ix:nonFraction>% of employees&#8217; contributions up to <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_w-B6HdkdMk2KS8Two5igkg">6</ix:nonFraction>%, subject to a maximum annual amount. The Company&#8217;s contributions were $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_E5hyO99SgUSN8BTAc5h6Mg">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_X5ifbVZDxUWXpTg-fc4Sfw">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_Ue9MrOdvq0qsodN-srCQCw">0.2</ix:nonFraction> million for the years ended December 31, 2022, 2021 and 2020, respectively. The match was suspended from April to August 2020 due to COVID-19. Participants are immediately vested in their own contributions to the plan and are fully vested in discretionary profit sharing made by the Company after <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" format="ixt-sec:durwordsen" name="us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" id="Narr_i44BUmjsj06JE1J5hHyyRA">three&#160;years</ix:nonNumeric> of service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2019 Employee Stock Purchase</b> <b style="font-weight:bold;">Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). At December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_apjFPhUEQUmSn47rVbBhIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_TbAiMuS6IE62_J0uQGE4Sg">421,065</ix:nonFraction> shares were available for future issuance under the ESPP. The ESPP is subject to an annual increase, subject to prior approval by the Company&#8217;s board of directors, equal to the least of (i) <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_11_1_2019_To_11_30_2019_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_2L7PdrGMqki5LBBGmf_Rew" decimals="INF" format="ixt:numdotdecimal" name="tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" scale="0" id="Narr_R-25KNBX-EKsqhqoT2x4Ig">107,887</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_11_1_2019_To_11_30_2019_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_2L7PdrGMqki5LBBGmf_Rew" decimals="2" format="ixt:numdotdecimal" name="tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" scale="-2" id="Narr_mMikenZ5gUeNky_-xuuiLw">1</ix:nonFraction>% of the shares outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares as determined by the board of directors. The ESPP provides the opportunity to purchase the Company&#8217;s common stock at a <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_11_1_2019_To_11_30_2019_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_2L7PdrGMqki5LBBGmf_Rew" decimals="2" format="ixt:numdotdecimal" name="tela:EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" scale="-2" id="Narr_0emqnAXEwUqK9bL4ddhLsg">15</ix:nonFraction>% discount to the market price through payroll deductions. As of December 31, 2022, 2021 and 2020, <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_YKvVJdoCfU6XG4kpRDTKPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_KWilbjY6uE-VE0N-UvSqwg">4,523</ix:nonFraction>, <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_P49kb58aeUOwJ9BHNFx0Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_6y4jhD-GN02YRgDQR1kAOA">3,163</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_5nSnl9FMqkyjoV_-oqlcRA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_OTOGQ4XU5EW-04j6ch42kQ">2,797</ix:nonFraction> shares, respectively, have been issued under the ESPP. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_OBs6UvZrtky2pKP9I_XsPw" continuedAt="Tb_OBs6UvZrtky2pKP9I_XsPw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10)&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred losses since inception. Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for&#160;years in which differences are expected to reverse.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_iE6pGUnCG0SMu4b-B81bFg_1_2"></a><a id="Tc_E8yJHlWTM0q-46agD3UJtw_2_2"></a><a id="Tc_6ABZLm3bhUWPfPEZ2vsP7Q_2_5"></a><a id="Tc_FXJ1hredSUeE_S4fQPuNZQ_3_0"></a><a id="Tc_yyC9FgamEUGSWpAt_3x7qA_4_0"></a><a id="Tc_SwQWta4e5kWjJB8N1801BQ_4_2"></a><a id="Tc_UdjzjuPr40-QoVrpAGRMxg_4_5"></a><a id="Tc_SRk3bDEC-EqMqY32xmi4yQ_5_0"></a><a id="Tc_V26CPGht3UuU51wIY9BHVQ_6_0"></a><a id="Tc_dmSpUkPEIkmiq_-IegrwKQ_6_6"></a><a id="Tc_SW5ILpHShUiH1PqSUmZtpg_7_0"></a><a id="Tc_RUPq_DyBukm4T3pmhoj9uA_8_0"></a><a id="Tc_QL0HeHptp0-OxLuLRGXMAQ_9_0"></a><a id="Tc_SFUt-gRM4UK5vwaYHVL4DA_10_0"></a><a id="Tc_GeR5-R_UbEaLmuP1WstE9w_11_0"></a><a id="Tc_gW1UmMTTAEKlMWfYkGc_hw_12_0"></a><a id="Tc_mXCGTEoxjk-8HvcUWi3qiA_12_6"></a><a id="Tc_4n5GzVnqL0WPOgnqVZwnrA_13_0"></a><a id="Tc_9fQ8cZbL302wLRlpCbbsCQ_14_0"></a><a id="Tc_iJouxssuOkSY5jLXOF71MA_15_0"></a><a id="Tc_4ZlSlMqGiEGR_bg0tjpZtw_16_0"></a><a id="Tc_RnHcCRZ2zUCQYxNjLYJM7A_16_2"></a><a id="Tc_wJQ13YifHUW4OrjhW9QNeg_16_5"></a><a id="Tc_lAg6G5h950yhntBezUwIkA_1_2"></a><a id="Tc_tQud6FEC30CFyZEQ2H_LVA_2_2"></a><a id="Tc_bm5jiLxmOUO-YF__5OhS5w_2_5"></a><a id="Tc_djkbdUvskEqoTeFhJx76aw_3_0"></a><a id="Tc_vH6qqM50TE6oSX8tGajayg_4_0"></a><a id="Tc_rarRhVtV9kW7GV_fPTlHlw_4_2"></a><a id="Tc_H-ejzU-s80qlaWgZkfQykg_4_5"></a><a id="Tc_JzWV5Sm0CEyHBanBmK5Cnw_5_0"></a><ix:continuation id="Tb_OBs6UvZrtky2pKP9I_XsPw_cont1" continuedAt="Tb_OBs6UvZrtky2pKP9I_XsPw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets for federal income taxes consisted of the following (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_UTPnabPOVEG3xSetzL3E3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_66OLbhOZb0KsLP6pDuYxAQ_4_3">55,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_ZlZzkYDRQEOe_c6UNQMDRQ_4_6">47,737</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_hOA9n_ibkUCsxTMMZpMpig_5_3">623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_wRQ8bpPlz06ZFZuGUVnFYQ_5_6">623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="tela:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_iVQXedWoz0SY4b6JRnfjvQ_6_3">387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_-y-U8ZGrWEmeRit1Qgc7Zw_7_3">4,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_mDp0755SkUG8EKVz0TZjhw_7_6">1,356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_mGAIl3NPhkevO9kO7bOdQg_8_3">372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_VhmWFeh6OEq4zmTSef41bg_8_6">171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_dNVqCveU2U-d_UOwW8ZCVA_9_3">60,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_sOLeP34JzUGQNWZLjEAEAg_9_6">49,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="tela:DeferredTaxLiabilitiesDepreciationAndAmortization" scale="3" id="Tc_QlWmslnmn02tSCh9O4jyhQ_11_3">435</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="tela:DeferredTaxLiabilitiesDepreciationAndAmortization" scale="3" id="Tc_-3jys51fy0m0XWIbrSqFvQ_11_6">89</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="tela:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_WSubGXSGSUWe5cW0uWQesA_12_3">302</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_-1895EPszkyrwreXdnkKfg_13_3">737</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_rwaYQu3zJkG76aF-dXo0dg_13_6">89</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax asset before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="tela:NetDeferredTaxAssetBeforeValuationAllowance" scale="3" id="Tc_kKrqUWtZdkmBFDptHNtQ3Q_14_3">60,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="tela:NetDeferredTaxAssetBeforeValuationAllowance" scale="3" id="Tc_egu_1-4QK0CF7jU_L6TcVw_14_6">49,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_dH22NYwjHUavxt4QdPKQGw_15_3">60,161</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Li1bmJmX2kSQzmlfz9woaA_15_6">49,798</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_6BvC-BNXG02Lk9hzVnVGcA_16_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_bbD_p1F2uES_gRpMqNWCQw_16_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company does <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_xFqUQOyRe0aQzFI6cBYVZw"><ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_5V-iI9WCvUW0Y2FTtXdm1w">no</ix:nonFraction></ix:nonFraction>t have unrecognized tax benefits as of December&#160;31, 2022 and 2021. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss (&#8220;NOL&#8221;) carryforwards for federal and state income tax purposes consisted of the following (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="Tb_95q_Q_-oQ0COriqWLhp9BA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NOL carryforwards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_pOKNe1MZo0aFsxEbEdiunQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_HaHwQHuhbE25G9hMnQ2vpQ_4_3">212,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_A9GP45d3REOrEZcQtCpqQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_8GNRsy5AdEqXBTKyDtLymg_4_6">181,443</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_v9zeKR1og0GICgO2UBJLYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_qHpqVIYhlU2nKJnjfCbvHg_5_3">173,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_nh_rYZ3xKUOudm_jXKbwPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_fbedyIQimESVQsF49K6FKg_5_6">151,488</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The NOL carryforwards begin expiring in 2032 for federal purposes and in 2026 for state income tax purposes yet $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_pOKNe1MZo0aFsxEbEdiunQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="Narr_DwhlqPWJzEql7S4RHr8bsA">100.7</ix:nonFraction> million of the federal NOL carryforwards have no expiration. The Company recorded a valuation allowance on the deferred tax assets as of December&#160;31, 2022 and 2021 because of the uncertainty of their realization. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_zEErOFuUxE6zIO2qmqWqkw">10.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_9fPOhKbrWUm_l2rTc8RFbw">8.1</ix:nonFraction> million for the years ended December 31, 2022 and 2021, respectively, mainly due to losses incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Utilization of the net operating losses and general business tax credits carryforwards may be subject to a substantial limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, if changes in ownership of the company have occurred previously or occur in the future. Ownership changes may limit the amount of net operating losses and general business tax credits carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of 5% shareholders in the stock of a corporation by more than 50&#160;percentage points over a three-year period. If the Company experiences a Section&#160;382 ownership change, the tax benefits related to the NOL carryforwards may be further limited or lost. The Company has not performed an analysis under Section 382 and cannot predict or otherwise determine whether there would be any limitation to the amount of net operating losses and general business tax credits carryforwards that can be utilized.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_gaMIFgxeCkidkNVpdbgXQw_1_2"></a><a id="Tc_m8CMcDpfQUqycxqbaOdPFg_2_2"></a><a id="Tc_hMPHHw1C0Ui7Ck9_CNYtlw_2_4"></a><a id="Tc_XpBsQx3QsUmBSXqI13o44g_2_6"></a><a id="Tc_eRoQdp65hEqubYJZfdVZAQ_3_0"></a><a id="Tc_d19Uf9MHKkqCp-JL2_XOjQ_4_0"></a><a id="Tc_nQVvmMomDk6yJWq0ShgIKg_4_3"></a><a id="Tc_1TBxr4QXMUCbEHzWjz_IWw_4_5"></a><a id="Tc_ckrRKkeqDUOiVLGH48MO2Q_4_7"></a><a id="Tc_7FB3-h2MqEaldnJZbfO33Q_5_0"></a><a id="Tc_qwy0eYKAdEe8_EZijFQ_Rw_6_0"></a><a id="Tc_E_VTjnLIyU-15icpKLBemQ_7_0"></a><a id="Tc_23dtcSbMR0yN1EdUXPs59A_7_2"></a><a id="Tc_d5s5e_U7gEu1Kal_i1bhqw_8_0"></a><a id="Tc_aoDuPkV9S0mfTRi-lnsDQA_9_0"></a><a id="Tc_30_kLAJ7uk62eIIIcTG-Bw_10_0"></a><a id="Tc_8pvBWVM9rkeF1Sv5Cc49AA_10_3"></a><a id="Tc_LWtUPc_33UK3mG99NKQ60A_10_5"></a><a id="Tc_oH8rHwBCekeoqgPKZfdZbw_10_7"></a><ix:continuation id="Tb_OBs6UvZrtky2pKP9I_XsPw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and as reflected in the consolidated financial statements is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_HKj3UCqSYkq2ReuBIqgJJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rate reconciliation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_iVNKvU0M7EmPP1Ll7iYlWw_4_2">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_wSXLnoU7I0uRImtvyZfK0A_4_4">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_OMfdTu3T-EKkhmf7ZUbyAg_4_6">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State rate, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_ObR3o2Eh6kuix43CCN7YHA_5_2">3.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_hCxJMMR3MkeQ6lJudTpVUw_5_4">3.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_TyOtLLC7pEuy_FmHzczEjQ_5_6">4.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="1" format="ixt:numdotdecimal" name="tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="0" id="Tc_41KbQo5d7kKNNL_aP85ong_6_2">0.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="1" format="ixt:numdotdecimal" name="tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="0" id="Tc_tGdJi1MwiUiQQWI_ra1DKA_6_4">0.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="1" format="ixt:numdotdecimal" name="tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="0" id="Tc_xnuL-bEwIUKO1yDAoEHPZQ_6_6">0.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_EkRTxbf-HUKHg1_PKbogPA_7_4">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_MbnR0RZ_QUqpK5rqTs841g_7_6">0.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_UK4Sh2iUYkyMzNkkNPCIFQ_8_2">23.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_1aEUtwidw0mgvQ6mXPV1nQ_8_4">24.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_o61YS5va_k23o9dqZuf3xw_8_6">24.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="Tc_HiSc2pVq9U2TxxAMPJY1Ww_9_2">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_GF9E2GIhvEulY_RmzEWsUw_9_4">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_5wa4HgptYkqVUU5g6oqeLQ_9_6">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__Xg7yEHRTkaf1AHzKKzaFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9o4WxlJ-z0CC9U7RFAF0Vg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_B8cBHWhtUUWKXvY0U7DfHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction, various state jurisdictions and the United Kingdom. Tax years 2019 and forward remain open for examination for federal and the Company&#8217;s more significant state tax jurisdictions. Carryforward attributes from prior years may be adjusted upon examination by taxing authorities if used in an open period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many governments have enacted or are currently contemplating economic stimulus and financial aid measures. Many of these measures include deferring the due dates for tax payments, including both income tax and other taxes. The Coronavirus Aid, Relief, and Economic Security Act (&quot;CARES Act&quot;) was enacted on March 27, 2020 in the United States to address the economic impacts of the COVID-19 pandemic. The CARES Act includes corporate income tax, payroll tax, and other provisions. While the Company may receive financial, tax, or other benefits under the bill, this legislation did not impact the Company during the year ended December 31, 2020. During the year ended December 31, 2021, the Company claimed an employee retention payroll tax credit of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="Narr_QcA3qApAiEyqt85l4fWP4w">0.5</ix:nonFraction> million for certain employment taxes.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_zgUqrppuk0SLbQZyM30cmA" continuedAt="Tb_zgUqrppuk0SLbQZyM30cmA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(11) Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be a party to various other lawsuits, claims, and other legal proceedings that arise in the ordinary course of its business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Agreements with Aroa</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2012, the Company entered into a License, Product Development, and Supply Umbrella Agreement (&#8220;Aroa Agreement&#8221;) with Aroa. The Aroa Agreement provides the Company a license to patent rights and other intellectual property related to Aroa&#8217;s products and technologies for use in certain indications and expires on the expiration of the last patent covering the products (currently March 9, 2031). The Company has the right to extend the term of the agreement by an additional 10 years following the expiration of the last patent covering the products on commercially reasonable terms to be negotiated by the parties. This agreement initially limited the Company&#8217;s license rights to the U.S. but was subsequently amended in March&#160;2013 to include certain countries in Europe including the United Kingdom and members of the European Union and certain former Union of Soviet Socialist Republic satellite nations. The Aroa Agreement required payments aggregating up to $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_8_1_2012_To_8_31_2012_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_5TQp0DFf-kq_QSMl5v0gog" decimals="-5" format="ixt:numdotdecimal" name="tela:RevenueBasedMilestonePayment" scale="6" id="Narr_1XhU1PBMnU6EIBjPHNJqlg">4.0</ix:nonFraction>&#160;million upon the achievement of U.S. and European cumulative product sales targets.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zgUqrppuk0SLbQZyM30cmA_cont1" continuedAt="Tb_zgUqrppuk0SLbQZyM30cmA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_WrQWz5vLr0aUSSjLYF2vLg" decimals="-5" format="ixt:numdotdecimal" name="tela:SalesMilestonePayment" scale="6" id="Narr_VxT3eszry0GIensK-eN5MA">1.0</ix:nonFraction>&#160;million to Aroa in 2018 related to one of the cumulative product sales targets and the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_bNi-UjogoEuFoyrMYtfZFQ" decimals="-5" format="ixt:numdotdecimal" name="tela:SalesMilestonePayment" scale="6" id="Narr_09X3gf2sbEqKWjhBso2SkQ">2.0</ix:nonFraction> million in 2019. The Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_EuropeMember_P4ROvIxkZ0GJPalY78p2MQ" decimals="-5" format="ixt:numdotdecimal" name="tela:SalesMilestonePaymentDue" scale="6" id="Narr_jGqzGb0WkEKG0YEM51oOBQ">1.0</ix:nonFraction>&#160;million in 2022 related to the sales milestone payments in the European territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other key terms of the amended Aroa agreement in addition to those disclosed above are as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The transfer price for product produced by Aroa is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_5UcmEJq_IkSYYQljqHnZxQ" decimals="2" format="ixt:numdotdecimal" name="tela:TransferPriceForProductProduced" scale="-2" id="Narr_HPbfwj4gK0KQxKZfc4ZVOQ">200</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Aroa&#8217;s cost of goods sold. The transfer price and the quarterly true-up amount continued to equal </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_5UcmEJq_IkSYYQljqHnZxQ" decimals="2" format="ixt:numdotdecimal" name="tela:FixedCostOfNetSales" scale="-2" id="Narr_r_yQOYoCS0ayieMPvdObMQ">27</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Company&#8217;s net sales of licensed products. Upon a change in control of the Company (as defined in the amended agreement), the annual minimum amounts will be extended for a sixth&#160;year with a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_5UcmEJq_IkSYYQljqHnZxQ" decimals="-5" format="ixt:numdotdecimal" name="tela:PurchaseObligationDueInSixthYear" scale="6" id="Narr_dJA8m209KkG9SFmpCd-C0w">5.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million minimum amount for the North American territory and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_EuropeMember_P4ROvIxkZ0GJPalY78p2MQ" decimals="-5" format="ixt:numdotdecimal" name="tela:PurchaseObligationDueInSixthYear" scale="6" id="Narr_4zs2EYsjWU-aEUaTnGIqTw">1.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million minimum amount for the European territory. If a change in control of the Company occurs prior to the first product launch in the applicable territory, then the annual minimum requirements shall commence upon such change in control. If the make whole payments, if any, are not made by the Company after a notice and cure period, then the license will convert to a nonexclusive basis in the territory for which the payment was required but not made.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Provisions exist for the Company to step in and operate Aroa&#8217;s plant if a supply failure occurs and is not cured within a set timeframe. Under the amended agreement, the criteria for a supply failure was modified to mean a failure by Aroa to timely supply, during any consecutive </span><span style="-sec-ix-hidden:Hidden_aX4OvrC5tUqVcgWeJXKlnQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60-day</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period, at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_vMwv7HGAZk6VxBh2MfXhWQ" decimals="2" format="ixt:numdotdecimal" name="tela:ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" scale="-2" id="Narr_7WN2KUMJtEWKUSPNmmk2rA">75</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the products ordered by the Company under binding purchase orders. During the period that the Company steps in and assumes manufacturing responsibility, it shall not be required to purchase product from or pay transfer prices to Aroa, the annual minimums shall be proportionately reduced to reflect the lack of supply responsibility by Aroa and the Company shall pay a royalty of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_vMwv7HGAZk6VxBh2MfXhWQ" decimals="2" format="ixt:numdotdecimal" name="tela:PercentageOfRoyaltyOfNetSales" scale="-2" id="Narr_XOF0AFV0PE6i2BwxXxWpQQ">6</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of net sales in lieu of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw" decimals="2" format="ixt:numdotdecimal" name="tela:FixedCostOfNetSales" scale="-2" id="Narr_G6XT7fTQ2UKCF5eQvrfBdw">27</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of net sales of the licensed products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company expects to enter into similar milestone-based agreements with its strategic partner for both product territories and new products in order to expand and extend its product portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="Narr_5SnfMoLfIU6S0pc1iq54bg">1.0</ix:nonFraction> million in purchase commitments with Aroa, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_OtherSuppliersForExclusivityRightsMember_nti7PndlCEqpmp9aOi8sDw" decimals="-5" format="ixt:numdotdecimal" name="tela:RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" scale="6" id="Narr_1TPRMaDWa06s7pxcrYfnNw">20.7</ix:nonFraction> million in commitments with certain other suppliers to maintain exclusivity rights over time and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw" decimals="-5" format="ixt:numdotdecimal" name="tela:MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" scale="6" id="Narr_HISeQS6LyEeRkkHC-Z30IA">2.2</ix:nonFraction> million milestone payments related to certain research and development arrangements which are currently deemed not probable as the timing and likelihood of such payments are not known with certainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2021, the Company entered into an exclusive distribution agreement with Next Science, a medical technology company, granting the Company exclusive rights to sell and market Next Science&#8217;s proprietary antimicrobial surgical wash in the U.S. plastic reconstructive surgery market. To maintain exclusivity, the Company had purchase commitments and annual license fees over a <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_NextScienceMember_LkcT3sf4w0qZZyV6NqpeQA" format="ixt-sec:durwordsen" name="tela:OtherCommitmentsTermOfContract" id="Narr_Oy5KLcEZVEi0vkcC0xCLhA">ten-year</ix:nonNumeric> period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Company entered into an exclusive development and distribution partnership for Collagen Matrix, Inc.&#8217;s proprietary fibrillar collagen pack in the U.S. To maintain exclusivity, the Company has purchase commitments of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_CollagenMatrixInc.Member_1Pkcz42t1Ey6xw6VGMm4YA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="Narr_ADJ9VNIehUO9oAzc4b9W0A">20.7</ix:nonFraction> million over the remaining <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_CollagenMatrixInc.Member_dYLoJZtTSE2udKKQ9CsaEQ" format="ixt-sec:durwordsen" name="tela:OtherCommitmentsTermOfContract" id="Narr_k60mDcda40yGtb5gQhoNow">nine-year</ix:nonNumeric> period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c5a1ac1f_351d_4c62_9dbf_c105d8ddaad1"></a><a id="Tc_7e1Cic_MvEaIIJOKRWB1-w_1_0"></a><a id="Tc_p18XtesbLka9-156bfk4yw_1_1"></a><a id="Tc_64cmu1lNQ06WmLDF7FtX0Q_2_0"></a><a id="Tc_-6zsz2lyxkaHoTtFr-wLcg_3_0"></a><a id="Tc_4CCHblrID0CSSr8pHL9RRA_4_0"></a><a id="Tc_dfwBB8aBmUKXA3olFE98SQ_5_0"></a><a id="Tc_tl3qMr8Fwkmd7Ro9XK8gBg_6_0"></a><a id="Tc_RVJKXDJ_Fk-LZIZnjZUjiA_7_0"></a><a id="Tc_7TMdnlqaZ0aQLd56e6k75Q_7_1"></a><a id="Tc_sksp19leqUWGszPcyVToQQ_8_0"></a><a id="Tc_JLPTluGlx02r-Ehh6pONsA_9_0"></a><a id="Tc_vDSV6SSXqkmZ2hUDSYLKDA_9_1"></a><ix:continuation id="Tb_zgUqrppuk0SLbQZyM30cmA_cont2" continuedAt="Tb_zgUqrppuk0SLbQZyM30cmA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company leases office and laboratory space in Malvern, Pennsylvania under a noncancelable lease (the &#8220;Malvern Lease&#8221;). The Malvern Lease, which was concluded to be an operating lease, was amended in December 2020 to extend the term of the lease from May 2021 to May&#160;2028. The Malvern Lease has annual scheduled payment increases and provides the Company a <ix:nonNumeric contextRef="Duration_12_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_KxwryCVlz0irzGqrcf7T9w" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_hUMdPdzoI0-dgT-6qaiccA">renewal option</ix:nonNumeric> for an additional term of <ix:nonNumeric contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_kMDohVy_8EGHSodUA1iG_A" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_iJbcpZlwmUaK2Dofa9rVig">60 months</ix:nonNumeric> at the end of the lease term. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. As the Company is not reasonably certain to exercise the renewal option, the additional 60-month term has been excluded. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On January 1, 2022 and upon adoption of ASU 2016-02, the Company recorded an operating lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_rkR5ymX8o0ef8OoHXSVS1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_Vbcbmbvdp0q11bb03sewbQ">1.8</ix:nonFraction> million and an operating lease ROU asset of $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_rkR5ymX8o0ef8OoHXSVS1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_5EsIlUJRtU-lEoWY1CTJzQ">1.4</ix:nonFraction> million related to the Malvern Lease. The Company also eliminated approximately $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_0PuV96OlxUKqwMyunu8Gaw" decimals="-5" format="ixt:numdotdecimal" name="tela:DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" scale="6" id="Narr_kJ1pl24l6U61RmaWwsKhCg">0.4</ix:nonFraction><span style="white-space:pre-wrap;"> million of deferred rent and tenant allowance liabilities as of January 1, 2022 as these components are reflected as a reduction in the operating lease ROU asset.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the lease term. The tenant allowance was historically amortized over the initial, non-cancelable term of the Malvern Lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#39;s lease does not provide an implicit rate, and therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company used an incremental borrowing rate of <ix:nonFraction unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ" contextRef="As_Of_1_1_2022_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_ijh9r7V11UmJJurC5JZr8A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_PdhjYsgxbka_re7xWj7v5Q">9.75</ix:nonFraction>% to discount the Malvern Lease payments included in the operating lease liabilities recognized upon adoption of ASU 2016-02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="Narr_-iWq7ED5S0Wov5hdqcM8IA">0.3</ix:nonFraction> million of lease cost during the year ended December 31, 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_beGZKvb9REyk57o4_KRnKQ">0.3</ix:nonFraction> million for the year ended December 31, 2022, and this amount is included in operating activities in the consolidated statements of cash flows. As of December 31, 2022, the remaining lease term for the Malvern Lease is <ix:nonNumeric contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_8Fc2PFOc2keKSCoCf2k64w" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Narr_k3EoZIdklESjVZuz6K6VhA">5.5</ix:nonNumeric> years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_u99WfN4B-kekD48n_ZfU3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_q0UTg6W2D0SNQZ5kha-JFg_1_2">358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_IpMTeOoZJ0SyG2aLeoSkzw_2_2">366</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_GU36ORVe_kK3x7YyUCu4tQ_3_2">375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_0mp2rY1aDU-Tt0w1W11YSw_4_2">383</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_q42N4nFVT0qqHvKBe--C2A_5_2">392</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_NSWdp1BfXEyGWDh3K2Xokw_6_2">165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total undiscounted future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_Qf30vyhVVUqsWUn-pRkB4Q_7_2">2,039</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_4FzEXxhGP0iO-APfqo-Tcg_8_2">468</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_0l-FvnyyWEeVdlLAUMvkPA_9_2">1,571</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2021, the Company&#8217;s future minimum lease payments under non-cancelable operating leases for the five years ending December 31, 2022 through 2026 and thereafter were as follows: $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="Narr_rU91ie9yQkqV3K5Q_XWX0g">0.3</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="Narr_7xWFgiqZ2kuzn46HthRauQ">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="Narr_QVQnofTg4U-36m1ji-NnRA">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="Narr_TQxeAXYE70ia3Jsr3HtLvg">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="Narr_Pf7hAGZ_9E6lZmSi-BJs1A">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="Narr_USe9WUvV2keUwJB-x6ND9g">0.5</ix:nonFraction> million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements (continued)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zgUqrppuk0SLbQZyM30cmA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2022, $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="Narr_rn4HV6-zF06xX30cNAknbg">0.3</ix:nonFraction> million representing the current portion of operating lease liabilities is included in <span style="-sec-ix-hidden:Hidden_O-RcgO7O50aNxn4SsWFhrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accrued expenses and other current liabilities</span></span> in the consolidated balance sheets and $<ix:nonFraction unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ" contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="Narr_flRaP3Wmt060RlQcjHqIIA">1.2</ix:nonFraction> million representing the long-term portion of operating lease liabilities is included in <span style="-sec-ix-hidden:Hidden_XxtxzYXVGkCewipeasalog;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other long-term liabilities</span></span><span style="white-space:pre-wrap;"> in the consolidated balance sheets.  </span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_9x06qfD7PEqxRL4JZQmvPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(12) Related-Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November&#160;16, 2018, the Company entered into a senior secured term loan facility with OrbiMed, an entity affiliated with an owner of a material amount of the Company&#8217;s outstanding voting securities. The terms of the debt and related components are described in more detail in Note&#160;6. On May 26, 2022, the Company entered into the MidCap Credit Agreement and upon closing used a portion of the proceeds to repay all borrowings under the OrbiMed Credit Facility, and terminated the OrbiMed Credit Facility.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7631de46_773a_42ab_a1ed_6caed230380d"></a><a id="Item6_Exhibits"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following exhibits are being filed herewith:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><a id="_d364a4a1_e7c7_4d9e_b38c_a20c2ce5c95a"></a><a id="EXHIBITINDEX_560009"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:87.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:87.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Exhibit</b></p></td></tr><tr><td style="vertical-align:top;width:10.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">3.1</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000110465919065432/a19-23314_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amended and Restated Certificate of Incorporation (incorporated by reference to exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on November 19, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">3.2</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000110465919065432/a19-23314_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws (incorporated by reference to exhibit 3.2 of the Company&#8217;s Current Report on Form 8-K filed on November 19, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">4.1</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005938/a2239923zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Common Stock Certificate of the Company (incorporated by reference to exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">4.2</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="https://www.sec.gov/Archives/edgar/data/1561921/000155837020003346/tela-20191231ex4259bd826.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to exhibit 4.2 to the Company&#8217;s Report on Form 10-K, filed on March 30, 2020)</span></a><span style="font-size:9.5pt;">.</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.1</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement by and between the Company and its individual directors and officers (incorporated by reference to exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.2</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">TELA Bio, Inc. 2012 Stock Incentive Plan (incorporated by reference to exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.3</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the TELA Bio, Inc. 2012 Stock Incentive Plan (incorporated by reference to exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.4</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to the TELA Bio, Inc. 2012 Stock Incentive Plan (incorporated by reference to exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.5</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to the TELA Bio, Inc. 2012 Stock Incentive Plan (incorporated by reference to exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.6</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to the TELA Bio, Inc. 2012 Stock Incentive Plan (incorporated by reference to exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.7</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to the TELA Bio, Inc. 2012 Stock Incentive Plan (incorporated by reference to exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.8</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement pursuant to the 2012 Stock Incentive Plan (incorporated by reference to exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.9</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonstatutory Stock Option Agreement pursuant to 2012 Stock Incentive Plan (incorporated by reference to exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.10</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="https://www.sec.gov/Archives/edgar/data/1561921/000110465920070850/tm2021946d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan (incorporated by reference to exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 8, 2020)</span></a><span style="font-size:9.5pt;">.</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.11</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="https://www.sec.gov/Archives/edgar/data/1561921/000155837022008301/tela-20220331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Stock Option Grant Notice and Stock Option Agreement (incorporated by reference to exhibit 10.1 to the Company&#8217;s Report on Form 10-Q, filed on May 11, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.12</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="https://www.sec.gov/Archives/edgar/data/1561921/000155837022008301/tela-20220331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (time-based vesting) (incorporated by reference to exhibit 10.2 to the Company&#8217;s Report on Form 10-Q, filed on May 11, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.13</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="tela-20221231xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (performance-based vesting) (filed herewith).</span></a><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005938/a2239923zex-10_12.htm"></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.14</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005938/a2239923zex-10_12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">TELA Bio, Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.15</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex10d15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to </span><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">TELA Bio, Inc. 2019 Employee Stock Purchase Plan (fil</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ed herewith</span><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">)</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">.</span></a><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005938/a2239923zex-10_16.htm"></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.16</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of TELA Bio, Inc. Inducement Award Agreement for Non-Qualified Stock Option (filed herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.17</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex10d17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of TELA Bio, Inc. Inducement Award Agreement for Restricted Stock Unit (filed herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.18</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="tela-20221231xex10d18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">TELA Bio, Inc. Amended and Restated Non-Employee Director Compensation Policy (filed herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.19</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005938/a2239923zex-10_16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated October 25, 2019, by and between the Company and Antony Koblish (incorporated by reference to exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.20</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="https://www.sec.gov/Archives/edgar/data/0001561921/000155837020003346/tela-20191231ex10260ad2b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated January 17, 2020, by and between the Company and Peter Murphy (incorporated by reference to exhibit 10.26 to the Company&#8217;s Report on Form 10-K, filed on March 30, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.21</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="https://www.sec.gov/Archives/edgar/data/1561921/000110465921119817/tm2128539d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated August 27, 2021, by and between the Company and Roberto Cuca (incorporated by reference to exhibit 10.1 to the Company&#8217;s Report on Form 8-K, filed on September 27, 2021)</span></a><span style="font-size:9.5pt;">.</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.22</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="https://www.sec.gov/Archives/edgar/data/1561921/000155837022004151/tela-20211231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated September 15, 2020, by and between the Company and Paul Talmo (incorporated by reference to exhibit 10.19 to the Company&#8217;s Report on Form 10-K, filed on March 23, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.23</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1561921/000110465922066225/tm2217085d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit and Security Agreement, dated as of May 26, 2022, by and among TELA Bio, Inc., MidCap Financial Trust and the lenders from time to time party thereto (incorporated by reference to exhibit 10.1 to the Company&#8217;s </span><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Report on Form 8-K, filed on May 31, 2022</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.24*</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9.5pt;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated License, Product Development and Supply Umbrella Agreement, dated July 16, 2015, by and between the Company and Aroa Biosurgery Ltd. (incorporated by reference to exhibit 10.23 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a><span style="font-size:9.5pt;">.</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.25*</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Second Amended and Restated License, Product Development and Supply Umbrella Agreement, dated November 26, 2015, by and between the Company and Aroa Biosurgery Ltd. (incorporated by reference to exhibit 10.24 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.26*</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Second Amended and Restated License, Product Development and Supply Umbrella Agreement, dated January 3, 2019, by and between the Company and Aroa Biosurgery Ltd. (incorporated by reference to exhibit 10.25 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.27*</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1561921/000155837020003346/tela-20191231ex10228386f.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Addendum to the Second Amended and Restated License, Product Development and Supply Umbrella Agreement, dated August 27, 2019, by and between the Company and Aroa Biosurgery Ltd. (incorporated by reference to exhibit 10.22 on the Company&#8217;s Report on Form 10-K filed on March 30, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.28*</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1561921/000155837020006726/tela-20200331ex102802ad7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Addendum to the Second Amended and Restated License, Product Development and Supply Umbrella Agreement, dated February 15, 2020, by and between the Company and Aroa Biosurgery Ltd. (incorporated by reference to exhibit 10.2 on the Company&#8217;s Report on Form 10-Q filed on May 15, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.29</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease between the Company and Liberty Property Limited Partnership, dated January 31, 2013 (incorporated by reference to exhibit 10.26 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.30</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Lease between the Company and Liberty Property Partnership, dated June 19, 2014 (incorporated by reference to exhibit 10.27 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.31</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1561921/000104746919005750/a2239787zex-10_24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Lease between the Company and WPT Land 2 LP (as successor in interest to Liberty Property Limited Partnership), dated January 17, 2018 (incorporated by reference to exhibit 10.28 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-234217), dated November 7, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.32</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1561921/000155837021003483/tela-20201231ex1029d9875.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Lease between the Company and WPT Land 2 LP (as successor in interest to Liberty Property Limited Partnership), dated December 22, 2020 (incorporated by reference to exhibit 10.29 to the Company&#8217;s Report on Form 10-K, filed on March 25, 2021)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">10.33</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1561921/000110465920137462/tm2038728d2_ex1-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Equity Distribution Agreement, dated December 18, 2020 (incorporated by reference to Exhibit 1.2 of the Company&#8217;s Registration Statement on Form S-3 (File No. 333-251505) filed on December 18, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">21.1</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Registrant (filed herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">23.1</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of KPMG LLP (filed herewith)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">31.1</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">31.2</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">32.1</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">32.2</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tela-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">101 INS</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Inline XBRL Instance Document (filed herewith).</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">101 SCH</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Inline XBRL Taxonomy Extension Schema Document (filed herewith).</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">101 CAL</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith).</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">101 DEF</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document (filed herewith).</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">101 LAB</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Inline XBRL Taxonomy Extension Label Linkbase Document (filed herewith).</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">101 PRE</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith).</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">104</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">*</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_17dd9213_3902_4654_9433_f2514f62081c"></a><a id="SIGNATURES_181481"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TELA BIO,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ ANTONY KOBLISH</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Antony Koblish</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President, Chief Executive Officer and Director</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 23, 2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><a id="_Hlk96347177"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:43.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ ANTONY KOBLISH</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director (Principal Executive Officer)</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Antony Koblish</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ ROBERTO CUCA</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operating Officer and Chief Financial Officer<br />(Principal Financial Officer)</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Roberto Cuca</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MEGAN SMEYKAL</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Accounting Officer and Controller (Principal Accounting Officer)</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Megan Smeykal</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ DOUG EVANS</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman, Board of Directors</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Doug Evans</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ KURT AZARBARZIN</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Kurt Azarbarzin</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ VINCE BURGESS</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Vince Burgess</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ LISA COLLERAN</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lisa Colleran</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ JOHN NOSENZO</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">John Nosenzo</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ FEDERICA O&#8217;BRIEN</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;23, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Federica O&#8217;Brien</p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>2
<FILENAME>tela-20221231xex10d13.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:23:26 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.13</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TELA BIO, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">TELA Bio, Inc., a Delaware corporation (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-size:11pt;">&#8221;), pursuant to its Amended and Restated 2019 Equity Incentive Plan (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u><font style="font-size:11pt;">&#8221;), hereby grants to the individual listed below (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participant</u><font style="font-size:11pt;">&#8221;) an award of the target number of Performance Restricted Stock Units set forth below (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock Units</u><font style="font-size:11pt;">&#8221; or &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PSUs</u><font style="font-size:11pt;">&#8221;) listed below (an &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award</u><font style="font-size:11pt;">&#8221; and such number of PSUs, the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Number of PSUs</u><font style="font-size:11pt;">&#8221;). The PSUs&#160;are subject to the terms and conditions set forth in this Performance Restricted Stock Unit Grant Notice (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant Notice</u><font style="font-size:11pt;">&#8221;), the Performance Restricted Stock Unit Award Agreement attached hereto as </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:11pt;"> (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-size:11pt;">&#8221;) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Agreement. Each PSU represents the right to receive one Share at the times and subject to the conditions set forth herein.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100.63%;"><tr><td style="vertical-align:top;width:47.45%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Participant:</b></p></td><td style="vertical-align:top;width:52.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:47.45%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:top;width:52.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:47.45%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Target No. of PSUs:</b></p></td><td style="vertical-align:top;width:52.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:47.45%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:52.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0.5pt;"><font style="font-size:11pt;">By Participant&#8217;s signature below, Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and the Grant Notice. Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">TELA BIO, INC.</b></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-size:12pt;font-weight:bold;">PARTICIPANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">_____________________________</font><font style="display:inline-block;width:6pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">_____________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.5pt;text-indent:-0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Name:</font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">Name:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Title:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">TO PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award of Performance Restricted Stock Units</u><font style="font-size:11pt;">. The Company has granted to the Participant the Target Number of PSUs set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice, the Plan and this Agreement. Each Restricted Stock Unit represents the right to receive one Share at the times and subject to the conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Grant</u><font style="font-size:11pt;">. The Restricted Stock Units were granted on the Grant Date set forth in the Grant Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Transfer of Award</u><font style="font-size:11pt;">. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Participant, and any Shares issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the PSUs have vested as provided in Section 4 of this Agreement and (ii) Shares have been issued to the Participant in accordance with the terms of the Plan and this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting of Restricted Stock Units</u><font style="font-size:11pt;">. Except as otherwise provided below, the restrictions and conditions of Section 3 of this Agreement shall lapse as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number of Restricted Stock Units Earned</u><font style="font-size:11pt;">. The number of PSUs to be earned by the Participant will vary depending upon the Company&#8217;s achievement of the Performance Criteria during the Measurement Period, each as set forth on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-size:11pt;">, attached hereto, and shall equal the Target Number of PSUs multiplied by the Performance Multiplier (as described on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-size:11pt;">) for the Measurement Period. The number of Restricted Stock Units earned for a Performance Period (if any) shall be rounded to the nearest whole Share. &#160;The Performance Multiplier shall be determined as set forth on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-size:11pt;">. The number of PSUs determined to be earned as of the achievement of the Performance Criteria pursuant to this Section 4 and </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-size:11pt;"> shall be referred to herein as &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Earned PSUs</u><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number of Restricted Stock Units Vested</u><font style="font-size:11pt;">. With respect to any Earned PSUs, the restrictions and conditions of Section 3 of this Agreement shall lapse as set forth on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-size:11pt;">, subject to the Grantee&#8217;s continued service or employment with the Company through the Performance Period End Date (as defined in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-size:11pt;">). The number of Earned PSUs that become vested in accordance with the preceding sentence and in accordance with Appendix A shall be referred to herein as &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vested PSUs</u><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discretionary Acceleration Upon Death</u><font style="font-size:11pt;">. If the Participant dies while in service with the Company, any Restricted Stock Units that are outstanding and unvested immediately prior to the Participant&#8217;s death will remain outstanding for sixty (60) days, during which time the Committee may, in its sole discretion, vest all or a portion of such Restricted Stock Units. If the Committee decides to vest any Restricted Stock Units under this Section 4(c), it may condition such vesting on the execution by Participant&#8217;s estate and/or beneficiaries of a general release of claims against the Company and its affiliates in such form as the Company may prescribe (each, a &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</u><font style="font-size:11pt;">&#8221;). Upon conclusion of the sixtieth (60th) day following the Participant&#8217;s death, any portion of the unvested Restricted Stock Units that the Committee has not determined to vest in accordance with this Section 4(c) will then be forfeited automatically.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service with Affiliates</u><font style="font-size:11pt;">. Solely for purposes of this Agreement, service with the Company will be deemed to include service with any Affiliate of the Company (for only so long as such entity remains an Affiliate of the Company).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination of Service</u><font style="font-size:11pt;">. Except as set forth in paragraphs (c) and (d) of this Section 4 or as set forth in any applicable employment agreement between the Participant and the Company, if the Participant&#8217;s service with the Company ceases for any reason, any then unvested Restricted Stock Units will be forfeited automatically.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u><font style="font-size:11pt;">. Notwithstanding anything to the contrary set forth herein or contained in the Plan, in the event the Participant ceases to be employed by the Company as a result of a Qualifying Termination (as such term is defined below) upon the date a Change in Control is consummated (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</u><font style="font-size:11pt;">&#8221;) or within the [_________] period following such Closing, the number of Restricted Stock Units that shall become Vested PSUs on such date (i.e., the later of the Closing or such Qualifying Termination) shall equal [_________]. Notwithstanding the foregoing, in the event that in connection with a Change in Control the acquirer does not agree to assume in writing the Restricted Stock Units, effective upon the Closing, on substantially the same terms and obligations described herein, then the number of Restricted Stock Units that shall become Vested PSUs as of immediately prior to the Closing shall equal [________].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Settlement of Restricted Stock Units.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">Shares will be issued in respect of Vested PSUs within sixty (60) days following the Vesting Date. For avoidance of doubt, this deadline is intended to comply with the &#8220;short-term deferral&#8221; exemption from Section 409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">The Restricted Stock Units will not confer on the Participant any rights as a stockholder of the Company until Shares are actually issued in settlement of such Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">Notwithstanding the foregoing, to the extent provided in Prop. Treas. Reg. &#167; 1.409A-1(b)(4)(ii) or any successor provision, the Company may delay settlement of Restricted Stock Units if it reasonably determines that such settlement would violate federal securities laws or any other applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Transferability of Restricted Stock Units</u><font style="font-size:11pt;">. The Restricted Stock Units may not be sold, pledged, assigned, hypothecated, gifted, transferred or disposed of in any manner, either voluntarily or involuntarily, by operation of law or otherwise, other than by will or by the laws of descent and distribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Representations</u><font style="font-size:11pt;">. The Participant represents and warrants to the Company that the Participant is acquiring the Restricted Stock Units (and upon settlement of the Restricted Stock Units, may be acquiring Shares) for investment for the Participant&#8217;s own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. As a further condition to the settlement of the Restricted Stock Units, the Board may require that certain agreements, undertakings, representations, certificates, legends and/or information or other matters, as the Board may deem necessary or advisable, be executed, agreed to and/or provided to the Company to assure compliance with all such applicable laws or regulations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Consequences</u><font style="font-size:11pt;">. The Participant acknowledges that the Company has not advised the Participant regarding the Participant&#8217;s income tax liability in connection with the grant of the Restricted Stock Units and that the Company does not guarantee any particular tax treatment. The Participant acknowledges that the Participant has reviewed with the Participant&#8217;s own tax advisors the tax treatment of the Restricted Stock Units and is relying solely on those advisors in that regard. The Participant understands that the Participant (and not the Company) will be responsible for the Participant&#8217;s own tax liabilities arising in connection with the Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">10.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Continuation of Service</u><font style="font-size:11pt;">. Neither the Plan nor this Agreement will confer upon the Participant any right to continue in the employment or service of the Company or any of its Affiliates, or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">limit in any respect the right of the Company or its Affiliates to discharge the Participant at any time, with or without Cause and with or without notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u><font style="font-size:11pt;">. &#160;The Company is hereby authorized to withhold from any consideration payable or property transferable to the Participant any taxes required to be withheld in connection with the Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Policies</u><font style="font-size:11pt;">. In consideration for the grant of the PSUs, the Participant agrees to be subject to the policies of the Company regarding clawback, securities trading and hedging or pledging of securities, as in effect from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">13.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Plan</u><font style="font-size:11pt;">. The Participant has received a copy of the Plan, has read the Plan and is familiar with its terms, and hereby accepts the Restricted Stock Units subject to the terms and provisions of the Plan. Pursuant to the Plan, the Board is authorized to interpret the Plan and to adopt rules and regulations not inconsistent with the Plan as it deems appropriate. The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board with respect to questions arising under the Plan, the Grant Notice or this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">14.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u><font style="font-size:11pt;">. The Grant Notice and this Agreement, together with the Plan, represents the entire agreement between the parties with respect to the subject matter hereof and supersedes any prior agreement, written or otherwise, relating to the subject matter hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">15.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="font-size:11pt;">. Except as otherwise provided herein, in the Grant Notice or in the Plan, or as would otherwise not have a material adverse effect on the Participant, this Agreement may only be amended by a writing signed by each of the parties hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">16.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:11pt;">. This Agreement will be construed in accordance with the laws of the State of Delaware, without regard to the application of the principles of conflicts of laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">17.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Execution</u><font style="font-size:11pt;">. The Grant Notice may be executed, including execution by facsimile or electronic signature, in one or more counterparts, each of which will be deemed an original, and all of which together shall be deemed to be one and the same instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Vesting Criteria</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>tela-20221231xex10d15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:23:26 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.15</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">First Amendment to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">TELA Bio, Inc. 2019 Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, TELA Bio, Inc., a Delaware Corporation (the &#8220;Company&#8221;) sponsors the TELA Bio, Inc. 2019 Employee Stock Purchase Plan (the &#8220;Plan&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, pursuant to Section 19.8 of the Plan, the Compensation Committee of the Board of Directors of the Company (the &#8220;Committee&#8221;) may, in its sole discretion, amend the Plan at any time and for any reason; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Committee desires to amend the Plan as set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">NOW THEREFORE, the Plan is hereby amended as follows, effective on the date hereof:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">The definition of &#8220;</font><b style="font-size:12pt;font-weight:bold;">Eligible Employee</b><font style="font-size:12pt;">&#8221; is restated as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Eligible Employee</b><font style="font-size:12pt;">&#8221; means an Employee who (i)&#160;has been continuously employed by the Company or a Participating Subsidiary for at least one (1)&#160;year (or such other period, not to exceed two (2) years, as determined by the Committee prior to a particular Offering Period) and (ii)&#160;is customarily employed for at least twenty (20) hours per week and for more than five (5)&#160;months in any calendar year.&#160; Notwithstanding the foregoing, the Committee may exclude from participation in the Plan or from any Offering, within a manner permitted under Section 423 of the Code, Employees who are (x)&#160;&#8220;highly compensated employees&#8221; (within the meaning of Section&#160;414(q)&#160;of the Code) with compensation above a certain level or who are officers or subject to the disclosure requirements of Section 16(a) of the Exchange Act, or (y)&#160;citizens or residents of a foreign jurisdiction where the grant of an option under the Plan to such Employee would be prohibited under the laws of such foreign jurisdiction or the grant of an option under the Plan to such Employee in compliance with the laws of such foreign jurisdiction would cause the Plan to violate the requirements of Section&#160;423 of the Code, as determined by the Committee in its sole discretion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">The definition of &#8220;</font><b style="font-size:12pt;font-weight:bold;">Offering Period</b><font style="font-size:12pt;">&#8221; is restated as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Offering Period</b><font style="font-size:12pt;">&#8221; means (x) the six (6) month period starting on February 1 of each year and ending on July 31 of such year, and (y) the six (6) month period starting on August 1 of each year and ending on January 31 of the next year; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;"> that, pursuant to Section 5, the Committee may change the duration of future Offering Periods (subject to a maximum Offering Period of twenty-seven (27) months), the frequency of future Offering Periods, the start dates of future Offering Periods, and the end dates of future Offering Periods.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">The definition of &#8220;</font><b style="font-size:12pt;font-weight:bold;">Purchase Price</b><font style="font-size:12pt;">&#8221; is restated as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Purchase Price</b><font style="font-size:12pt;">&#8221; means an amount equal to eighty-five percent (85%) (or such greater percentage, if determined by the Committee prior to a particular Offering</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Period) of the lesser of (i) the Fair Market Value of a share of Common Stock on the Offering Date, and (ii) the Fair Market Value of a share of Common Stock on the Purchase Date; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;"> that, the Purchase Price per share of Common Stock will in no event be less than the par value of the Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Except as set forth in this amendment, all other terms of the&#160;Plan remain unchanged.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, this amendment has been executed by a duly authorized officer of the Company on the 18</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">day of January, 2023.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;padding-left:0pt;padding-right:0pt;width:40%;"><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">TELA BIO, INC.</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:21.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:78.35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">&#160;/s/ Antony Koblish</font></p></td><td style="vertical-align:top;width:0.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Antony Koblish</font></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">President &amp; Chief Executive Officer</font></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">- 2 -</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>4
<FILENAME>tela-20221231xex10d16.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:23:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TELA BIO, INC. INDUCEMENT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">FOR NON-QUALIFIED STOCK OPTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">STOCK OPTION GRANT NOTICE AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">STOCK OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">TELA Bio, Inc.,&#160;a Delaware corporation (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-size:11pt;">&#8221;) hereby grants to the individual listed below (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grantee</u><font style="font-size:11pt;">&#8221;) a non-qualified stock option&#160;to purchase the number of Shares set forth below (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option</u><font style="font-size:11pt;">&#8221;) as an inducement to the Grantee&#8217;s acceptance of the Company&#8217;s offer of employment. The Option&#160;is subject to the terms and conditions set forth in this Stock Option Grant Notice (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant Notice</u><font style="font-size:11pt;">&#8221;) and the Stock Option Agreement attached hereto as&#160;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:11pt;">&#160;(the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-size:11pt;">&#8221;). This Option constitutes a non-plan &#8220;inducement award&#8221; as contemplated by NASDAQ Listing Rule 5635(c)(4) and is therefore not made pursuant to the TELA Bio, Inc. 2019 Equity Incentive Plan (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u><font style="font-size:11pt;">&#8221;). Nonetheless, the terms and provisions of the Plan are hereby incorporated into the Grant Notice and Agreement by this reference, as if this Option was granted pursuant to the Plan. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Grantee:</b></p></td><td style="vertical-align:top;width:41.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:top;width:41.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exercise Price Per Share:</b></p></td><td style="vertical-align:top;width:41.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Total Number of Shares Subject to Option:</b></p></td><td style="vertical-align:top;width:41.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Expiration Date:</b></p></td><td style="vertical-align:top;width:41.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:41.22%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Subject to the continued service of Grantee with the Company though the relevant vesting date or event, the Option will become vested and exercisable as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">25% shall vest on the first anniversary of the Grant Date (the &#8220;Initial Vesting Date&#8221;). The remaining 75% shall vest ratably in equal monthly installments on the last day of each of the thirty-six (36) calendar months immediately following the Initial Vesting Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">[Signature Page to Follow]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">By Grantee&#8217;s signature below, Grantee agrees to be bound by the terms and conditions of the Agreement and this Grant Notice. Grantee has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">TELA BIO, INC.</b></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">GRANTEE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">_____________________________</font><font style="display:inline-block;width:20.5pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">_____________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Name:</font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">Name:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Title:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">TO STOCK OPTION GRANT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">INDUCEMENT AWARD AGREEMENT FOR NON-QUALIFIED STOCK OPTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Grantee an Option to purchase the number of Shares set forth in the Grant Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award of Option</u><font style="font-size:11pt;">. &#160;Effective as of the Grant Date set forth in the Grant Notice, the Company has granted to Grantee the Option to purchase any part or all of the aggregate number of Shares set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice and this Agreement (including the terms and provisions of the Plan, which are incorporated into this Agreement by reference). A copy of the Plan has been provided to the Grantee along with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Grant; Term of Option</u><font style="font-size:11pt;">. &#160;The Option is granted on the Grant Date and may not be exercised later than the Expiration Date, subject to earlier termination in accordance with the terms of the Plan and this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Exercise Price</u><font style="font-size:11pt;">. &#160;The exercise price per Share of the Shares subject to the Option (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</u><font style="font-size:11pt;">&#8221;) shall be as set forth in the Grant Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting and Exercise of Option</u><font style="font-size:11pt;">. &#160;The Option will become vested and exercisable only in accordance with the terms and provisions of this Agreement, as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(i)</font><font style="display:inline-block;width:25.62pt;"></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</u><font style="font-size:11pt;">. &#160;Subject to the continued service of Grantee with the Company through the relevant vesting date or event, the Option shall become vested and exercisable in such amounts and at such times as are set forth in the Grant Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(ii)</font><font style="display:inline-block;width:22.56pt;"></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discretionary Acceleration Upon Death</u><font style="font-size:11pt;">. If Grantee dies while in service with the Company, any portion of the Option that is outstanding and unvested immediately prior to Grantee&#8217;s death will remain outstanding for sixty (60) days, during which time the Committee may, in its sole discretion, vest all or a portion of such Option. &#160;If the Committee decides to vest all or any portion of such Option under this Section 4(a)(ii), it may condition such vesting on the execution by Grantee&#8217;s estate and/or beneficiaries of a general release of claims against the Company and its affiliates in such form as the Company may prescribe (each, a &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</u><font style="font-size:11pt;">&#8221;). &#160;Upon conclusion of the sixtieth (60th) day following Grantee&#8217;s death, any portion of the unvested Option that the Committee has not determined to vest in accordance with this Section 4(a)(ii) will then be forfeited automatically.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service with Affiliates</u><font style="font-size:11pt;">. &#160;Solely for purposes of this Agreement, service with the Company will be deemed to include service with any Affiliate of the Company (for only so long as such entity remains an Affiliate of the Company).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination of Service on the Option</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(i)</font><font style="display:inline-block;width:25.62pt;"></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forfeiture of Unvested Option</u><font style="font-size:11pt;">. &#160;Except as set forth in Section 4(a)(ii) above, if the Grantee&#8217;s service terminates or is terminated for any reason, any then unvested portion of the Option will be forfeited automatically.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(ii)</font><font style="display:inline-block;width:22.56pt;"></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vested Portion of the Option</u><font style="font-size:11pt;">. &#160;If the Grantee&#8217;s service terminates or is terminated for any reason, the vested portion of the Option will remain exercisable for such period as set forth in Section 7 of the Plan. &#160;For avoidance of doubt, to the extent the Committee elects to accelerate an</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">otherwise unvested portion of the Option under Section 4(a)(ii) above (relating to discretionary acceleration upon death), the portion of the Option then vesting will be subject to Section 7(a) of the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Method of Exercise</u><font style="font-size:11pt;">. &#160;The Grantee may exercise the Option only to the extent it is vested. To exercise the Option, the Grantee must deliver payment of the Exercise Price, any required tax withholding and written notice of exercise to the Company as set forth in Section 5(d) of the Plan. Such notice must also be accompanied by:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(i)</font><font style="display:inline-block;width:25.62pt;"></font><font style="font-size:11pt;">a joinder to </font><font style="font-size:11pt;">any shareholder, voting or similar agreement entered into by the stockholders of the Company</font><font style="font-size:11pt;"> (if not already party thereto) agreeing to be bound by the terms thereof</font><font style="font-size:11pt;">; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(ii)</font><font style="display:inline-block;width:22.56pt;"></font><font style="font-size:11pt;">any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Partial Exercise</u><font style="font-size:11pt;">. &#160;The vested portion of the Option may be exercised in whole or in part; </font><i style="font-size:11pt;font-style:italic;">provided</i><font style="font-size:11pt;">, </font><i style="font-size:11pt;font-style:italic;">however</i><font style="font-size:11pt;">, that any exercise may apply only with respect to a whole number of Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Exercise</u><font style="font-size:11pt;">. &#160;The Option may not be exercised, and any purported exercise will be void, if the issuance of Shares upon such exercise would constitute a violation of any law, regulation or exchange listing requirement. &#160;The Board may from time to time modify the terms of the Option or impose additional conditions on the exercise of the Option as it deems necessary or appropriate to facilitate compliance with any law, regulation or exchange listing requirement. &#160;As a further condition to the exercise of the Option, the Company may require the Grantee to make any representation or warranty as may be required by or advisable under any applicable law or regulation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Transferability of Option</u><font style="font-size:11pt;">. &#160;The Option may not be sold, pledged, assigned, hypothecated, gifted, transferred or disposed of in any manner either voluntarily or involuntarily by operation of law or otherwise, other than by will or by the laws of descent and distribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Representations</u><font style="font-size:11pt;">. &#160;The Grantee represents and warrants to the Company that the Grantee is acquiring the Option (and upon exercise of the Option, will be acquiring Shares) for investment for the Grantee&#8217;s own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. As a further condition to the exercise of the Option, the Board may require that certain agreements, undertakings, representations, certificates, legends and/or information or other matters, as the Board may deem necessary or advisable, be executed, agreed to and/or provided to the Company to assure compliance with all such applicable laws or regulations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Consequences</u><font style="font-size:11pt;">. &#160;The Grantee acknowledges that the Company has not advised the Grantee regarding the Grantee&#8217;s income tax liability in connection with the grant of the Option and that the Company does not guarantee any particular tax treatment. &#160;The Grantee acknowledges that the Grantee has reviewed with the Grantee&#8217;s own tax advisors the tax treatment of the Option (including the purchase and sale of Shares subject hereto) and is relying solely on those advisors in that regard. &#160;The Grantee understands that the Grantee (and not the Company) will be responsible for the Grantee&#8217;s own tax liabilities arising in connection with the Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Continuation of Service</u><font style="font-size:11pt;">. &#160;This Agreement will not confer upon the Grantee any right to continue in the employment or service of the Company or any of its Affiliates, or limit in any respect the right of the Company or its Affiliates to discharge the Grantee at any time, with or without Cause and with or without notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u><font style="font-size:11pt;">. &#160;The Company is hereby authorized to withhold from any consideration payable or property transferable to the Grantee any taxes required to be withheld by applicable law in connection with the exercise of the Option or the vesting or disposition of the Shares subject to the Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">10.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration</u><font style="font-size:11pt;">. &#160;The Grantee hereby accepts the Option, subject to the terms and conditions stated in the Grant Notice and this Agreement (including the terms and conditions of the Plan incorporated herein). &#160;The Board, or any committee of the Board designated to administer the Plan, is hereby authorized to interpret the Grant Notice and this Agreement, to administer the Option and to otherwise exercise the same authority with respect to this Option as the Board (or committee thereof) possesses under the Plan with respect to Awards granted thereunder. &#160;By accepting this Award, the Grantee hereby acknowledges and agrees to accept as binding, conclusive and final all decisions or interpretations of the Board or its committee with respect to the Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">11.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u><font style="font-size:11pt;">. &#160;The Grant Notice and this Agreement, including the terms of the Plan incorporated herein, represent the entire agreement between the parties with respect to the subject matter hereof and supersede any prior agreement, written or otherwise, relating to the subject matter hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">12.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="font-size:11pt;">. &#160;Except as otherwise provided herein, in the Grant Notice or in the Plan, or as would otherwise not have a material adverse effect on the Grantee, this Agreement may only be amended by a writing signed by each of the parties hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">13.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:11pt;">. &#160;This Agreement will be construed in accordance with the laws of the State of Delaware, without regard to the application of the principles of conflicts of laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">14.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Execution</u><font style="font-size:11pt;">. &#160;The Grant Notice may be executed, including execution by facsimile or electronic signature, in one or more counterparts, each of which will be deemed an original, and all of which together shall be deemed to be one and the same instrument.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>5
<FILENAME>tela-20221231xex10d17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:23:26 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.17</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TELA BIO, INC. INDUCEMENT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">FOR RESTRICTED STOCK UNIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">RESTRICTED STOCK UNIT GRANT NOTICE AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">RESTRICTED STOCK UNIT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">TELA Bio, Inc., a Delaware corporation (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-size:11pt;">&#8221;), hereby grants to the individual listed below (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participant</u><font style="font-size:11pt;">&#8221;) an award of the number of Restricted Stock Units set forth below (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock Units</u><font style="font-size:11pt;">&#8221;) as an inducement to the Participant&#8217;s acceptance of the Company&#8217;s offer of employment. The Restricted Stock Units&#160;are subject to the terms and conditions set forth in this Restricted Stock Unit Grant Notice (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant Notice</u><font style="font-size:11pt;">&#8221;) and the Restricted Stock Unit Agreement attached hereto as&#160;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:11pt;">&#160;(the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-size:11pt;">&#8221;). The Restricted Stock Units constitute a non-plan &#8220;inducement award&#8221; as contemplated by NASDAQ Listing Rule 5635(c)(4) and is therefore not made pursuant to the TELA Bio, Inc. 2019 Equity Incentive Plan (the &#8220;Plan&#8221;). Nonetheless, the terms and provisions of the Plan are hereby incorporated into the Grant Notice and Agreement by this reference, as if the Restricted Stock Units were granted pursuant to the Plan. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Participant:</b></p></td><td style="vertical-align:top;width:55.63%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:top;width:55.63%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Total Number of Restricted Stock Units:</b></p></td><td style="vertical-align:top;width:55.63%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[_________]</font></p></td></tr><tr><td style="vertical-align:top;width:44.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:55.63%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Subject to Participant&#8217;s continued service with the Company through the applicable vesting date or event, the Restricted Stock Units will vest as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">25% of the Restricted Stock Units shall vest on each of the first four anniversaries of the Grant Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">By Participant&#8217;s signature below, Participant agrees to be bound by the terms and conditions of the Agreement and the Grant Notice. Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p><div style="position:relative;white-space:nowrap;"><div style="display:inline-block;padding-right:3.33%;vertical-align:top;white-space:normal;width:46.67%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">TELA BIO, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">_____________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Name:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Title:</font></p></div><div style="display:inline-block;padding-left:3.33%;vertical-align:top;white-space:normal;width:46.67%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">PARTICIPANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">_____________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Name:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">TO RESTRICTED STOCK UNIT GRANT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">INDUCEMENT AWARD AGREEMENT FOR RESTRICTED STOCK UNIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award of Restricted Stock Units</u><font style="font-size:11pt;">. &#160;The Company has granted to the Participant the number of Restricted Stock Units set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice and this Agreement. &#160;Each Restricted Stock Unit represents the right to receive one Share at the times and subject to the conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Grant</u><font style="font-size:11pt;">. &#160;The Restricted Stock Units were granted on the Grant Date set forth in the Grant Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting of Restricted Stock Units</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</u><font style="font-size:11pt;">. Subject to the continued service of the Participant with the Company through the relevant vesting date or event, the Restricted Stock Units shall become vested in such amounts and at such times as are set forth in the Grant Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discretionary Acceleration Upon Death</u><font style="font-size:11pt;">. If Participant dies while in service with the Company, any Restricted Stock Units that are outstanding and unvested immediately prior to Participant&#8217;s death will remain outstanding for sixty (60) days, during which time the Committee may, in its sole discretion, vest all or a portion of such Restricted Stock Units. If the Committee decides to vest any Restricted Stock Units under this Section 3(a)(ii), it may condition such vesting on the execution by Participant&#8217;s estate and/or beneficiaries of a general release of claims against the Company and its affiliates in such form as the Company may prescribe (each, a &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</u><font style="font-size:11pt;">&#8221;). Upon conclusion of the sixtieth (60th) day following Participant&#8217;s death, any portion of the unvested Restricted Stock Units that the Committee has not determined to vest in accordance with this Section 3(a)(ii) will then be forfeited automatically.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service with Affiliates</u><font style="font-size:11pt;">. &#160;Solely for purposes of this Agreement, service with the Company will be deemed to include service with any Affiliate of the Company (for only so long as such entity remains an Affiliate of the Company).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination of Service</u><font style="font-size:11pt;">. &#160;Except as set forth in Section 3(a)(ii) above, if the Participant&#8217;s service with the Company ceases for any reason, any then unvested Restricted Stock Units will be forfeited automatically.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Settlement of Restricted Stock Units</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">Shares will be issued in respect of vested Restricted Stock Units within sixty (60) days following the applicable vesting date. &#160;For avoidance of doubt, this deadline is intended to comply with the &#8220;short-term deferral&#8221; exemption from Section 409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">The Restricted Stock Units will not confer on the Participant any rights as a stockholder of the Company until Shares are actually issued in settlement of such Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">Notwithstanding the foregoing, to the extent provided in Prop. Treas. Reg. &#167; 1.409A-1(b)(4)(ii) or any successor provision, the Company may delay settlement of Restricted Stock Units if it reasonably determines that such settlement would violate federal securities laws or any other applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Transferability of Restricted Stock Units</u><font style="font-size:11pt;">. &#160;The Restricted Stock Units may not be sold, pledged, assigned, hypothecated, gifted, transferred or disposed of in any manner, either voluntarily or involuntarily, by operation of law or otherwise, other than by will or by the laws of descent and distribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Representations</u><font style="font-size:11pt;">. &#160;The Participant represents and warrants to the Company that the Participant is acquiring the Restricted Stock Units (and upon settlement of the Restricted Stock Units, may be acquiring Shares) for investment for the Participant&#8217;s own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. As a further condition to the settlement of the Restricted Stock Units, the Board may require that certain agreements, undertakings, representations, certificates, legends and/or information or other matters, as the Board may deem necessary or advisable, be executed, agreed to and/or provided to the Company to assure compliance with all such applicable laws or regulations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Consequences</u><font style="font-size:11pt;">. &#160;The Participant acknowledges that the Company has not advised the Participant regarding the Participant&#8217;s income tax liability in connection with the grant of the Restricted Stock Units and that the Company does not guarantee any particular tax treatment. &#160;The Participant acknowledges that the Participant has reviewed with the Participant&#8217;s own tax advisors the tax treatment of the Restricted Stock Units and is relying solely on those advisors in that regard. &#160;The Participant understands that the Participant (and not the Company) will be responsible for the Participant&#8217;s own tax liabilities arising in connection with the Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Continuation of Service</u><font style="font-size:11pt;">. &#160;This Agreement will not confer upon the Participant any right to continue in the employment or service of the Company or any of its Affiliates, or limit in any respect the right of the Company or its Affiliates to discharge the Participant at any time, with or without Cause and with or without notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u><font style="font-size:11pt;">. &#160;The Company is hereby authorized to withhold from any consideration payable or property transferable to the Participant any taxes required to be withheld in connection with the Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">10.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Policies</u><font style="font-size:11pt;">. &#160;In consideration for the grant of the Restricted Stock Units, the Participant agrees to be subject to the policies of the Company regarding clawback, securities trading and hedging or pledging of securities, as in effect from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">11.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration</u><font style="font-size:11pt;">. &#160;The Participant hereby accepts the Restricted Stock Units, subject to the terms and conditions stated in the Grant Notice and this Agreement (including the terms and conditions of the Plan incorporated herein). &#160;The Board, or any committee of the Board designated to administer the Plan, is hereby authorized to interpret the Grant Notice and this Agreement, to administer the Restricted Stock Units and to otherwise exercise the same authority with respect to the Restricted Stock Units as the Board (or committee thereof) possesses under the Plan with respect to Awards granted thereunder. &#160;By accepting this Award, the Participant hereby acknowledges and agrees to accept as binding, conclusive and final all decisions or interpretations of the Board or its committee with respect to the Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">12.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u><font style="font-size:11pt;">. &#160;The Grant Notice and this Agreement, including the terms of the Plan incorporated herein, represents the entire agreement between the parties with respect to the subject matter hereof and supersedes any prior agreement, written or otherwise, relating to the subject matter hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">13.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="font-size:11pt;">. &#160;Except as otherwise provided herein, in the Grant Notice or in the Plan, or as would otherwise not have a material adverse effect on the Participant, this Agreement may only be amended by a writing signed by each of the parties hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">14.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:11pt;">. &#160;This Agreement will be construed in accordance with the laws of the State of Delaware, without regard to the application of the principles of conflicts of laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">15.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Execution</u><font style="font-size:11pt;">. &#160;The Grant Notice may be executed, including execution by facsimile or electronic signature, in one or more counterparts, each of which will be deemed an original, and all of which together shall be deemed to be one and the same instrument.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">A-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>6
<FILENAME>tela-20221231xex10d18.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:23:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.18</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5.84pt 0pt;"><b style="font-size:11pt;font-weight:bold;">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:11pt;">Non-employee members of the board of directors (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Board</font><font style="font-size:11pt;">&#8221;) of TELA Bio, Inc. (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:11pt;">&#8221;) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Policy (this &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-size:11pt;">&#8221;). The cash and equity compensation described in this Policy shall be paid or granted, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-size:11pt;">&#8221;), unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. This Policy shall become effective on January 1, 2023 (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Effective Time</font><font style="font-size:11pt;">&#8221;) and shall remain in effect until it is revised or rescinded by further action of the Board. This Policy may be amended, modified or terminated by the Board at any time in its sole discretion. The terms and conditions of this Policy shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors and between any subsidiary of the Company and any of its non-employee directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">(1)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Cash Compensation</b><font style="font-size:11pt;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:41.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Retainers</u><font style="font-size:11pt;">. Each Non-Employee Director shall receive an annual retainer of $45,000 for service on the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0.5pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:41.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Annual Retainers</u><font style="font-size:11pt;">. In addition, a Non-Employee Director shall receive the following annual retainers:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.55pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chairperson of the Board</u><font style="font-size:11pt;">. A Non-Employee Director serving as Chairperson of the Board shall receive an additional annual retainer of $35,000 for such service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.5pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit Committee</u><font style="font-size:11pt;">. A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $20,000 for such service. A Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $10,000 for such service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation Committee</u><font style="font-size:11pt;">. A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $15,000 for such service. A Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an additional annual retainer of $7,500 for such service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iv)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nominating and Corporate Governance Committee</u><font style="font-size:11pt;">. A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $10,000 for such service. A Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0.05pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:41.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Retainers</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.05pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Timing</u><font style="font-size:11pt;">. The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Form</u><font style="font-size:11pt;">. The annual retainers shall be paid in the form of cash; provided that the Board may, in its discretion, permit a Non-Employee Director to elect to receive any portion of the annual retainer in the form of shares of common stock of the Company (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-size:11pt;">&#8221;) in lieu of cash. If such an election is permitted by the Board and made by a Non-Employee Director, the number of shares of Common Stock to be paid shall be determined by dividing the portion of the annual retainer payable in the form of Common Stock by the Fair Market</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.5pt 0pt;"><font style="font-size:11pt;">Value (as defined in the Company&#8217;s Amended and Restated 2019 Equity Incentive Plan or any other applicable Company equity plan then maintained by the Company (such plan, as may be amended from time to time, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Equity Plan</font><font style="font-size:11pt;">&#8221;)) per share of Common Stock on the date the annual retainer is payable. Shares issued in lieu of cash shall be fully vested and unrestricted shares of Common Stock. Any election by a Non-Employee Director to receive a portion of the annual retainer in shares of Common Stock must be made prior to the applicable payment date for such portion of the annual retainer and pursuant to an election form to be provided by the Company. An election must comply with all rules established from time to time by the Board, including any insider trading policy or similar policy. A Non-Employee Director may not make an election pursuant to this Section 1(c)(ii) during a Company blackout period or when the Non-Employee Director is otherwise in possession of material non-public information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.05pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Service</u><font style="font-size:11pt;">. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, such Non-Employee Director shall receive a prorated portion of the retainer(s) otherwise payable to such Non-Employee Director for such calendar quarter pursuant to Section 1(b), with such prorated portion determined by multiplying such otherwise payable retainer(s) by a fraction, the numerator of which is the number of days during which the Non-Employee Director serves as a Non-Employee Director or in the applicable positions described in Section 1(b) during the applicable calendar quarter and the denominator of which is the number of days in the applicable calendar quarter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(2)</font></font><b style="font-size:11pt;font-weight:bold;">Equity Compensation</b><font style="font-size:11pt;">. Non-Employee Directors shall be granted the equity awards described below (collectively, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Awards</font><font style="font-size:11pt;">&#8221;). The Awards shall be granted under and shall be subject to the terms and provisions of the Equity Plan and shall be granted subject to the execution and delivery of award agreements in substantially the forms approved by the Board. The approval of this Policy by the Board is intended to be effective for all purposes, including for purposes of satisfying Rule 16b-3(d)(1) of the Securities Exchange Act of 1934, as amended, in respect of each award issued hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 5.94pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Awards</u><font style="font-size:11pt;">. Upon a Non-Employee Director&#8217;s initial appointment or election to the Board after the Effective Time, he or she will be granted: (i) an option to purchase 8,040 shares of Common Stock at a per-share exercise price equal to the closing price per share of Common Stock on the date of such appointment or election (or on the last preceding trading day, if the date of such appointment or election is not a trading day), and (ii) a restricted stock unit award with respect to 4,702 shares of Common Stock. The Awards described in this Section 2(a) shall be referred to as &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Initial Awards</font><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Awards</u><font style="font-size:11pt;">. Each Non-Employee Director who serves on the Board as of the date of any annual meeting of the Company&#8217;s stockholders (an &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Annual Meeting</font><font style="font-size:11pt;">&#8221;) after the Effective Time, and will continue to serve as a Non-Employee Director immediately following such Annual Meeting, shall be automatically granted on the date of such Annual Meeting: (i) an option to purchase 5,360 shares of Common Stock at a per-share exercise price equal to the closing price per share of Common Stock on the date of such Annual Meeting (or on the last preceding trading day, if the date of the Annual Meeting is not a trading day), and (ii) a restricted stock unit award with respect to 3,135 shares of Common Stock. The Awards described in this Section 2(b) shall be referred to as &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Annual Awards</font><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting of Awards</u><font style="font-size:11pt;">. Awards will vest as follows, in each case subject to the continued service of the grantee to the Company through the applicable vesting date or event:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 41.75pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:11pt;">Initial Awards described in Section 2(a)(i) will vest in 36 equal monthly installments, on the monthly anniversary of the date of grant over the 36 calendar months commencing after the grantee&#8217;s initial appointment or election to the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3.7pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.5pt 41.95pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:11pt;">Initial Awards described in Section 2(a)(ii) will vest in three equal annual installments, on the first three anniversaries of the grantee&#8217;s initial appointment or election to the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11pt;">Annual Awards will vest on the earlier of (A) the first anniversary of the date of grant, and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 41.95pt;"><font style="font-size:11pt;">(B) the date of the subsequent Annual Meeting following the date of grant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 41.95pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iv)</font></font><font style="font-size:11pt;">In addition, any otherwise unvested Awards will vest and become exercisable in full immediately prior to and contingent upon the occurrence of a Change in Control (as defined in the Equity Plan).</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>tela-20221231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:23:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIST OF SUBSIDIARIES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:37.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction of Incorporation or</b></p></td></tr><tr><td style="vertical-align:bottom;width:20%;border-bottom:1px solid #a5a5a5;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Subsidiary</b></p></td><td style="vertical-align:bottom;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:37.48%;border-bottom:1px solid #a5a5a5;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ownership Percentage</b></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.48%;border-bottom:1px solid #a5a5a5;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Organization</b></p></td></tr><tr><td style="vertical-align:top;width:20%;border-top:1px solid #a5a5a5;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">TELA Bio, Limited</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.48%;border-top:1px solid #a5a5a5;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">100%</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.48%;border-top:1px solid #a5a5a5;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">England and Wales</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>tela-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:23:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 20pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We consent to the incorporation by reference in the registration statements (No. 333-251505) on Form S-3 and (Nos. 333-263797, 333-245707 and 333-235241) on Form S-8 of our report dated March 23, 2023, with respect to the consolidated financial statements of TELA Bio, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">March 23, 2023</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>tela-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:23:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">CERTIFICATION</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Antony Koblish, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-K of TELA Bio, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">4.&#160;&#160;&#160;&#160;The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(a)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(b)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(c)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(d)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5.&#160;&#160;&#160;&#160;The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(a)&#160;&#160;</font>&#160;<font style="font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="font-size:10pt;">(b)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:41.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:56.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:43.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 23, 2023</p></td><td style="vertical-align:bottom;width:56.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:43.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:56.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:43.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:56.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Antony Koblish</p></td><td style="vertical-align:bottom;width:56.03%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Antony Koblish</p></td><td style="vertical-align:bottom;width:56.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td><td style="vertical-align:bottom;width:56.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:bottom;width:56.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>tela-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:24:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">CERTIFICATION</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Roberto Cuca, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-K of TELA Bio, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">4.&#160;&#160;&#160;&#160;The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(a)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(b)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(c)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(d)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5.&#160;&#160;&#160;&#160;The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><font style="font-size:10pt;">(a)&#160;</font>&#160;<font style="font-size:10pt;">&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="font-size:10pt;">(b)&#160;</font>&#160;<font style="font-size:10pt;">&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 23, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Roberto Cuca</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roberto Cuca</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Operating Officer and Chief Financial Officer</i></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>tela-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:24:04 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">CERTIFICATION</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pursuant to 18 U.S.C. Section 1350,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), that: Antony Koblish, Chief Executive Officer of TELA Bio, Inc. (the &#8220;Company&#8221;), hereby certifies that, to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">(1)&#160;&#160;&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">(2)&#160;&#160;&#160;The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 23, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Antony Koblish</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Antony Koblish</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>tela-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/23/2023 08:24:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">CERTIFICATION</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pursuant to 18 U.S.C. Section 1350,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), that: Roberto Cuca, Chief Operating Officer and Chief Financial Officer of TELA Bio, Inc. (the &#8220;Company&#8221;), hereby certifies that, to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-size:10pt;">(1)&#160;</font>&#160;<font style="font-size:10pt;">&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2022, to which this Certification is attached as Exhibit 32.2 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;">(2)&#160;</font>&#160;<font style="font-size:10pt;">&#160;The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 23, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Roberto Cuca</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roberto Cuca</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Operating Officer and Chief Financial Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tela-20221231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tela-20221231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N N4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!8]M_UV3<OYC/\JR;WX=Z5J/W;>PO/]S&[\N#6Q<:,Z?\ +.J7V)XOO1T
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M;J,7PT\-^%WL-"\1_P!FP;)?[2EFMMLH&(Y8)8U9HV&2,@ X/##G.E?> ?$
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M."%RI&0>@TWX>)'\-];\.#3-*T";5H+J*6+1]S0JTD9C#EF56=MNW+%1T Z
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M%'CSQ!>^';BXN=!U?6WB\-ZGI^F7-YJNKJMLTKR0&2#R2I:X=H[@99\<L-C
MK@ 'T36=KFM6/AO1[S5=1G^S6-G&9IYMI;8@Y)P 2?P!KR2UU/4I]#\8>-?[
M>O[S6M)O-5M[;P_#<!+13;M*D%LT(&6:14CE+$[R9 5(4@5Q>I/XMNOAAKFJ
MWEY<WF@ZEX6NKBZN;S5(;M;F<JC12VZ1J!&A#2 JI"X*<9&2 ?1UCK=CJ-]J
M-E;3[[G3I4BN8PI'ELT:NHY&#E74\9ZTFJZ[8Z))8+?3_9WO;E;2W^0MYDK
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M,[V:.OHK$AUF6!)%O+=U>+[S1(65O<>WMU%2V/B'3[]3Y=QMVML_>H8^?^!
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MXA:1X]@O+G1C=SV%L[1?;I+62*&9U=DD$18#?L=&5B!@'H30!?N/"&AWE_\
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M5;J.XD9MCV:K\N]?+D9L\]3T'N <U-;V26<7D16?V:%?N_9GV_D.*JWFJ/\
MO+.SWO<LG_+RA\N->F]B<9Y[ Y/;UJN9R=MR>505]BQI/BS3]8O'MH),S)][
MH5W=T# E2PQD@$D#KBM^N%O_  _;KH\=LUNEXGRJWDRF'<QZOE02&)YW9!]3
MWK,T;6]0\,>(/[#N72:VGB:>UO+AV9MJ8\R.63)#.,Y! &1UY!)V5-33<.G3
M^OR,?:RIR2J+?K^7_#GIM%06UREU%YL;AT/3;4]8'6%%%% '*^.X-5NK*.WL
M= TOQ-82[DO-.U*?RMPX*%<QNC $'*L!V(/&#C?#WX8KX?T/2!JK2?VC923R
MQ0V%_<"TM4>9Y([=4W*LB1*XC4LG(0<* %';7.I6EE<6EM<7<-O<W;&*VBFD
M"M.X0N50$Y8A59B!DX4GH#5V@#Q+P_\ #?QA<>#/#?@S5[?1].T'2Y[>6\O+
M:]DN)[U8)A+'&D9B01AGC3<Q9B%W* 2=PW?B[X+U?Q4\$FAZ5;#58[9XK'Q!
M'JDEE=Z=*W?Y(SYD/"LT9)#%<%2"".DT_P"*/A75=.N;ZVUNV^R6\$MX[OF/
M=;QXWSH& +Q#(_>*"IR,$YKIUD1B55\LO]: /-_#'A_Q?X,O-3TJVM]-O])U
M#49]175WN6BFM_//F3!H/+(=A*9"N' *E0<;23QFB?!OQ5/>6=YJL%@FI0:+
M?Z9>:G+JMQ=SW]Q-'$HE :,+%$61FV#[N5   P?H"J.I:M8:/97-Y?WMO86=
MLN^>YN95CCB7U9B0%'N30!Y1KOP8U77-/-LMY:6SKX9M-+B<AG5;NWG$REEP
M,Q%E4$9!(R,"F>+? OC'XBV^MWFI66EZ+>+H%WH^G6,-Z]PLTMP\3R223>6N
MU,V\2J I/+,0.!7M%% 'BOBCX?\ C&73/'F@Z-::3-8^*I'NEO[R]DC:R>2"
M..6-HUB/F8,>Y6##A@" %!;T7Q9X=N-<U3PI<P21(FEZK]NG#YRZ?9KB+"X!
MYW3*><# //0'I:* /&M%^'7BJ'1_"?A"^BTU/#_AJ\MYUU>&X=I[N&U.;=!!
ML CD)6+>V\C"OM!WC;VWP[\+7?A/P#9Z'=RPO=P+*C/!GR_FD9AC(!Z,.U=?
M5'2M3M-<TNSU#3[A+FQNXEG@FC/RR(PR"/8@YH \HNOAOXEM]#\!Z5Y=MK>E
MZ3HZ:??:;_:4ME$UTJQ*MP61"98U"2C8P'W@<$XQ@>#=%\4_#GQ9H>@:;IFD
MZQ?V'@VUM;E/MTEM"LBW$@#1DQ.3&#D'(# 8P#R*^A*B\I?,W[1OQMW=\>E
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M9?.N4"LJG^!=H  _ D]R<"CSD"[1*B0/J@CEEDFMK-MW^AO\K2*>,2AAE?\
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M@X92&!$:JF01\H Z<59;P;H3>%_^$:_LNS_L'R/LW]G>4/*\OTQ^N>N>>O-
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MAI'P<#&.-HJ]^T[XK\0?%#XJ:?\ "O2M0^TI'=(\Z<[5N"-V)"6.Y8D)8\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM]*@M]MY;PNC?*J.GF;O8+SGZ8K!B\/:KJFE[5N'T&\:=I5N88HVGV@],<J
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M++XJ^#+VWCE_X2S1(=R_ZF;4(59?8@OP1WKSI/V4/@_^[6?P7#9S-_ ][/\
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M<6=I%XD\/3)+N\VY?4H?W*X/(^<9). !D<G/:O/6_95^$6I1_P#$C\'V%_\
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M>XSTX71/V3O@_K<GVR+PO#_9O_+)$N+A6;W;=(& ST! /<UIW7[&_P (I?\
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M^A'MO_ JX_\ CE'_  QC\&O^A'MO_ JX_P#CE.^+_EC][_R'[/A[_G[6_P#
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MHUCIUOY5C;I9PKN_X]OW?S$DD\=22223U/-,BBO;+S&^T?;TW[MCH%95] 0
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M#>H!)R!RT?B26X\4:'Y&H:J+-KKQ'%.DUP&9FAF*C&T!=JD'RPP)5=H))R2
M>T45XYX(^('B+4O$FEZ?::8^I:$WA2PU-;F\OX_MKR2+)RX$85G8HJD[E7.6
M& <5D^(OCYJQT/Q!;:5IFF_\)'I:6$_EV>KQW</E3W/E$-((\)(I5@5*D892
MK'G ![S17C_B;]H"+PK<ZI#=Z99I_8444NM*VKQ1R0LT:RM';HP!G98G5SG8
M#N 4EL@=%X6^)4WBSQAK&DVVF6\-GI=S+:SROJ"?:U90,2-;;<K$^<HQ;+#:
MV "#0!WU%?/7C+4M:;XD>,[EXYK:VTN70K6QO(=2?]VDMY%YJ"  */,#,&8D
MDA0.00!Z<WQ-METS4[[[!,4L-=BT-D##<SO<10^8/]D&8-CK@&@#MZ*\IT_X
MD36<KZ7I&GW_ (AUJ^UK4H(+:_NDCCABMY<32&4(=D*ED55"NV70<\D)X \2
M:X_PY\7ZI/;N^L6VIZMY=G<W8=8RDTFR,2X(V  8., 8X!R  >KT5Y+X3^*/
MB6_TOP+977AI+G7M=TQM1E=+]5MH8(_LPDED;RP0S&X!5%0\@@D#)#S\<EL/
M$&J:3JFEVUM<VVF7FIQ0V>JQ74^VVV^9'/&H'DN1(A7EP?F!(( (!ZO17E2_
M&>_L=/GOM7\(7EA"VA3:_8PVUU'<SSQ1;/,B=% $<H\Z(@ NI!;YOE(K"\<^
M)];\::)X'6+3+"YT[5]?2"=-*\0EH+NW%M-(,3QQJ67?'DJ  3'C)!- &_K'
M[-GP]UW5]0U&YT29'U*4SWUM;:A<P6UVYZO+"D@1B>^1SWS7HNGZ?:Z38V]G
M96\5K:6Z+%%!"@1(T P %'  '&*\MT']H73-9U32TAM[8Z1JLLT&GW*:I%)<
MR,D;R*\MN/FC218I"IR2/DW*FX@=CX#\8ZCXS\&6WB*7P_+I:7MJEY8V,ETC
MW$D3QAU$F %C<YQMW,!QDCD#.-.$&W&*1V5\9B<3&,*]64E'9-MI>E]CKZ*\
M=7]H.*VL_$OVO1X;G4M$MK6\:ST75(KWSDFE:(1[\(J2JZ$%6P,%2&.3C5NO
MBY>Z*FLVVM>&Y+;6+3[#]CL+.]2?[:;R1XK=!(0@1O-B=6W#"@;MQ'(T.,]-
MHKS7P%KFNZC\2_%]MKEA_93VVG:8T=I#?_:X/F>[S)&=JD$X"D% 3L'48->E
M4 %%%% !1110 4444 %%%% !1110 4444 >=^.-':P$ES$F;.3[_ /TS8G^1
M_P#K>Q\VUY[3Q!9R:1XAMWO]*D^\B863;GM)UQ^(/8,3Q7T/-"EQ$\<D:NC?
M*ROT85YAXP^%DJR/>:)^]7[S6;M_Z"21GV!(/8,!Q46<7S1W':,DXR6C,&X3
M3/"GA^.YL=^JZ5 JQ+;37!695Z; 6(RV,85L$GOS5O2?$'AJP^T7S7%G;7+*
MOFHF/,C49(0@#=D>XZ].*Y")WL[C_GC-'\K0S1>G;:1SCKM(^@ ^:M/7+C3_
M !1H?V:73[:VU)=OD7*(%\MLC$D;9^1@>1DE20 &/(JU*,G:?7J9.#CK3Z=#
M>L/$&J^)M8O+:VT^;2M$@B7_ (F5RFV2=S_ D9P0 N,LV.2!@\FK<O@/1WU"
MWU.*WV:K!N\JY=RVUB,$^7D+G'&<9';%8&EZSXE\,QQV.KZ7_H$2?+K;RIM^
MLL2DLK'J6&1GDD9K4M]9EO-8MY5U1'L(XF:5(4"QLS<1X8DGH"<#';\:E&4=
M8[?U_5B8SC)+GW\^G]=S5M]4O;*\DBOK-(;9=OE7B2[ED]MO5/JW7L:OWNJ6
M]A'N:3[W^J3^)F] .IK(_MNZO[BX@@LTL[-=NV_O'VK)GKM4<D#U. >V:JV_
M@6RT;4)-<L8_.UMEVL[N^UDZ[%7)5!GGY1G/7/?&R^UI_7X&]Y?9U7]?>3R^
M'[CQ?I]Q!XEL[9["=MJZ;L\Q63J/-SU/<J.!W)YQ=ET;4-+L]NE20NB[5BMK
ME-JJO0 ,!D #U!]..:=I'B9+^/;<V\VFS?\ /&\0*W'I@D$>F#R/U6_UY+>3
M[-;?Z3?[?EA1_P"?8#W)_/N7;?+85HVO^)%>^*[+P_;R3ZU)_9L*_P"MFF^6
M'GC[QX'XD9S[FHI9[WQ'''_9DCV%FVUFN73YI$Z_NQ[CHS<<YP>:2U\.2ZW'
M'+XECMKR;_GS3]Y;1^G# ;R!W88!Z 8S4LMKJ&C2;M/CAN;/=\]L[^6T:]]O
M!!]E./J!T+16V_X"][KM^/\ 7H<M\1O@%X,^)NC_ &;5]/>&_7_4:K;/MNX_
M^!'.]?\ 98$>@')'SI+\&_C1^SA>27G@+6'\0Z#N9FMK9/,^OF6CD\XZM&2?
M<5]>Q>(]/ECD:6X2V\I/F2;]WM^N>@JM=:IJ=_\ 9XM#MX71F_>WESE8U3OM
M'!=O09 [DCI7GUL'"O+GUC+NM'_P3ZW+.)<9EE'ZMI5H/_EW-<T?EV^3M?5H
M^5M(_;A>*3[#XS\'S6=XORRS::^UMW?,,N"/INKN;#]K+X7ZE;_O]4O]-?\
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MFRLXPF3]Z1OXI'/=F.23_P#6KRW]E3X(?\*M\(#5=5@V>)M6B5IT?[UI#U2
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M/S9EN(<1H-P5G <G;@D@]\<<7X$\.1>$-$^%%[IOV^&\U30IHM1>:XE?SP+
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MQ=Q\R_3T_P#K^U1.25XK7S_KH:0BY)3EIY=/^'+*LC?^A?Y_S_.FR_\ 7/\
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M<SO'9!*IR636K(H/#EKXWUC3]<TC5+]-'@5]L,-T6LKUCQ\R$X9%QU!&3P.
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MFXM;S55A5;J>S@:&"27'S%(V=BJD] 6)'J:TZ "BBB@ HHHH **** "BBB@
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MO<0Z:[,J_OGVJS< !?[Q/  ')SC&:E\0ZN^FV^VQC2YOY?\ 56V_;YC>F><
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M")I6FLT,C,J\GY1ELX' &<UK6]_#=1^:LB.C?QI]0/Q[US.J?:->\01Z8O\
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M;M-6?F%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZU->>5]GD6>-'3^X_P"9KSFR\$6GB/6(]5:XO$L+1F^QV<,I6"=^\K+R& .
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M.,;QO)).TE+EO?WK\K_+[11UO]H'XDWMW\3%\+^&/#\UGX(O)EN;S4KN53-
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M!UKZMTGPT[^)+C7+F/R;F2#[*J;]VU<YR>VXD]0.!QDU\@_'V_E\&_&#PO\
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MU2398:;;/<28ZMCHH_VF;"CW(I-J*<GLC2G3G6G&G35Y2:27=O9'QS\;)/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD>HH Q-"^#GAKP_K5EJ5M'>.^FSS3Z=;S7LLD%@TJNLHAB+;5#"1Q@@X!PN
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M["5X5A]TD>AKO*:K!AQ3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110!4O;^WTVVDGN[B*WA12[RS.$55 R22<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tela-20221231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tela-20221231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &X KD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ$.Y<9R/2EPRCN!7FGP@L(8+W4[FQOH6T]XH8VL(+.Z@6.8%B9'\]F)D((#
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M9%M8"@9HU+-\SA!@?5A6B=P8CG/\Z?M0^KKN?#7CSPO?QSZ7X?\ &)2\U5_
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MCD^5W>"0QRX!ZA6'7W![U;?48H]1AL2TGVF:)Y4 C8J54J&R^-H.77 )R><
MX./$K+3K2/Q?X;O[Z)HG@UCQ#;0S3&5(TN)+S? K;<#YP"1GJ.G:MKXA2^*X
M[.\665X[W_A%M8;.B&81"</:^25SSYH!?;W^]CO0!ZV01U&*2N*\+Z(/#?C[
M6[*R6[32YM,M+L^?-),C7)EN%D8,Y/S%5CW8ZX4FNUH **** "BBB@ HHHH
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MQ'<XHPP/?)H \1MI]:\/6#ZWX>@U*ZTN2]N=+TJTG21SY$R1?9YMC<B)+I7
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MT%CW)KPF\FM=0UNV75;^_F\91>+(%-B)9@D=HER/*98 =GDF(*^\C&YCEMW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$QE3C_9'U%=C\,_@3H7PE-]J]JESXN\:R_\ 'QK.I2+]I=FZ^7O.U 1GG))
M/)Z5ZBS?99G:19IT"X:;G.1CJ"!Q@\$>A]*F\FWFM<Q0[@I'E[2!NQ]TJP/
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MT;9#X6>.M3\(S7%GXF\/16\K6FM:=)!(J2RHJ2^5(%+(REL&A0DP=:"3;?\
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M1S27=K8W@N%C>&XW_NIH2 ^,<A74\]\\^M,@5K=5,K.L2<QO&6/KD-SE@<T
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M4MP47:29)I78A02QW9. !GC';KT%6$$MI:J\$B&:0;H;@D'=NY7I@,.>/44
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M]XN""N<$D@8.<X/K2]I+N/V-/^4\N?\ 9C\.SK$!KWC9F))._P 2S$)QU_\
MU5Y)\5_AO8_"CQG\+=8BO]8O77Q"MM='5-4DO8T#!2I3>!MSSGUP/2OK#[1)
M:W<2QVSI9,I/FDY3/& !@XZGDXZ=*\F_:E\"7GC;X/ZM)IUIC4=)D75+0Q,Q
M)6+YF(4<9P6P/:M(3;DDV8U:,5!N*U6OW:G=21A=P:,*P..:Y+58/%,WB*PO
M+/4-/TSPU;[Q?:?>VN^YNV!(39.)-L2-\O)4GVYP#X?>+H?B+X%T7Q% ^X7M
MNK2A3]R4?+(OU# _I7#_ +1FA>/-0\&Z==^ )%&MZ;JD%\]A-@)?QIG]TV2
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MU!'<4 >#R:3K&NZC!!<PZFOBJ V6JS0QFR@6>U@62)5B,;RQK('G,@\S 8J
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M]0.IX!]JLFYNH+$RFS$LX4'RHV7(/<9)Q^M9VH6K2W-Q%=VZ7VEWB) ;>9U
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MH&34J?>%-'2G)]Z@1)1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_8M061FEN[6ZD/"Q(R(V.&W  @#'?/7K0!:N?"UC+IBVAMUCMSDHA4,JDYY
M/0\GD8//6J=G:(D\$.HPV;:D8-@:$<F)6RN,\X'![C)J3^T;32-+DBU'7?LY
MC39]JOF165CT)R #[<8K*U%V:PMKBPO6>Y\MF2>")660D<$ID YZC! .<9H
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M&@QS77VD>Q!6/I=OM4<5O1+@"@"P@^44M Z4JC+"@;):5.M)3DZF@0^BBB@
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M1C*JGR\)^Z7(.3R>:Z/Q'XTE\.-HUO+I\;7VHAL)+>+#"CJ%S&)6&&<EOE7
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MY'&174QZJ)UY<@CCCH: .0F\.6?B"UETC6]-_M:U1C+!Y[JYD4$X*,N,$#G
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MWESIY%O @B\R5FSP/WP(49)P1[T :<GPTTJXTS3M/GDN)K6RM+FR",P!DCG
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M,4CD)]UF^0,Q/!V  #OV?BGQ);^$]%DU*Z1Y(UDCB"(57+NX1<LQ"J,L,LQ
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M8:U<Q85\=6 A W#&<G@5-X8\=Q^);NUA_LN^TU+VQ&HV<EWY?[^#* G"L2C
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MM3&M!W% ''-H"'M3#X?7^Z#78FP7TIGV(#MBF!Q_]@+_ '*4: @_@_2NO^P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tela-20221231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tela-20221231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !! '@# 2(  A$! Q$!_\0
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@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tela-20221231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tela-20221231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X 'L# 2(  A$! Q$!_\0
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M@2D3-WR?O-]<BOHF.)(5"HH10,!5& !3Z 2L4-&T'3O#MC'9Z99PV-K&,+%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tela-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tela-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !* 'T# 2(  A$! Q$!_\0
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MD'_IH"6[#C/WO_'L^WF#[M6D4@W8;/.3@GCDG_/;KZ T?*5X&W(/3!//7/\
MGCOBE"%0%'R\A#QSDY/3;^F!G^X_6@XVG!7G/;LO7GO^9Q_TSIE" J0 W/JN
M1^'^3P>V:-QW'#'(Y''&?7 &?PZ]R.](^ &8MD#YNO&".N<_KD9_O2=*79E@
MG?\ U?W.I'.,;?\ QW'']Q?O4$#, N<X((Q\Q'3/3_Z^<>^:3.%!+'(.[/OV
M..H^F,], U%-?Q6[94^9)G?D-[^N?U!SVW_PU"EM+=-^^)0YV! /F&>1QCC/
MI@D]=K=:8P:^>0M' &+$D#(SD=S]">_3^5+%8ELM.QD;&-JL.GN>.GX ]LU;
MCACC 6-0JG+8'?:.23@Y^O./6.G>8,%N,=2,[<;AUSD?GGG^])THN @*H5 X
MP,@@< ],XZ_AC([@4C$J5^8XZ'V&>F>GISG'OFE(WN4ZMGR^1W!Z8P?^^=O'
M]Q/O4IDV$R$X ^?<3CC..N?7^+=[>9VI -SAFY.XG).>2?7_ .MC)[ ]:[KP
MY=/<VDRNNT0S-"G^Z ,5PZ@9(((C12'P,X&"3QQCCM@9Q]QOO5Z)IUM]EM44
MJ%D8!GQW; S4R!F;XFU'R;4P1G#2*=S;2<#_ .O@_@#R.M<J&'R %0!R,< '
M_/?//J_2K.LW/VJ[,G(R!@9^[VQ^.!5'+=O<8SW';/J._P"'6A(-B5@"V3D#
M)&2!T],8_3&.,[!UIA9C\Q;DC.2Q)^OWNO\ M9S_ +?:E#,1DL,8SN[?[WT_
M3MQ3P ^0 1ST(Y^GU_7ZTQC%!4$>A P$'3O_  \=OEP,_P!U^IB9B0!Q@YZ8
MP<=.>_Z[>WET^5UB4EG4#IUZ]>?PZ<?EQ5"6XEN24@4X!QO+$$?4X.,^^3Z"
MG8'Y$]S=I"A+MDXR,?SZ_KD9[L_2JQ>XOG('[J'IN*\$<\<#)_W0,#KM'6IH
M=/"L-Q+R<GN!N]NY(]^1^-6&;C[P /S!C@#'K].WI3)(H8$M<E<A]N=Y.#G/
M8AACZ@CTW]JEC / Z,0,;0>._&.![8P?[K=:1< D%6Y(!'4D_P!WZ]\=:8<E
M?O8 ')SG\?H/Z^U $@?*XXSR/7ITR<'^NW_IG32Y=2NX< <YP,]^<C\\\^LG
M2G%=H//(QU;IG_'M353#<$G<3]T\\=A].] (<QWN!D%<D<C/'L"#_P!\XXZ[
M%ZTU6(RRL=Q&[<6[Y]<_^/;O^VG:E88 =GP ,EB<#''/I@_EZ4S3K6Z\4WGD
M:>S0V",1<7ZKG&,C9'GAGSWY"X(/(Q4WL-V-+PW8+KFJ[FVRV-F02VS :4'(
M0< 84C<VT ;@O<-7?5!86$&F6<-K;1B*"% B*.P%6*@D\^U6![>[,;??C&&.
M/ER1].X(';Z-TJDZC9M/IMY]L$CIV[\?54ZUU/BW199T%]9QF6:)<20J<&1,
M'[N?XAD^Q!(.>,<5'K5M.&"%F=28VB*[67;T0@C@J>Q'&#A(^M7'L4:#2#>2
M6R-Q?S">W3=UZ9[Y_P"!GI5.2^+/Y<$9>4C:!C/?IC&3Z]!_N]ZB N+IO-D?
MRXS^]/8DGC?R>_3<3[;CTJY';1P*8ECP"VPJRY)S_"?E_'&.G\!^]5;#W(H;
M1G/F32DD\A0PQMQC.0<<>QQV++TJTJ!(M@  4'"#@#(X_/MTSVWTL<VY2?,S
MGY\Y_NY&[.[G&,9R<8^^G0.RP;'(V=!C&W=U_P"^OH,_]-*5V.PQAN'3((V]
M,].HQCM]#[JG6D+D/G>1@EMS$=^-W7H>F<_\#/2G[>,;>Y7)&?N]!T_A],''
M]U.M()-NYA(%./,WYYR>"_WAUZ9W9_VV^[001!.<;#G&W: <DYSM^[^.,9_V
M/XJ16QSN 4D-D'CCOG/;ZX']]>E3>4-I0QX7/E%2O\/79C;^.-N/]C^*LF?Q
M/8VM^MFD[WFI.-_V:U1IICCH^U#NP/[V>/[Z=* -($L,9"A0?0<D?U_7MYE5
MKS5K?3R(W8O-)\J0Q@O(Y'\(4 DD>@!/'W4J:W\->)O$#+]WP[8[OF,K++<L
M#]X*JG:N[U)S_>5NM=EX>\%:7X:D:>UA:2\=!&]Y<.7E9>NW)X5<\[5 7/:I
M;[ <GI'@K4O$DGVC6O,TVQ#!X[*-\32>I=A]P>RDMTRPY6O1+.TAL+6&VMXD
M@@A01QQ1J%5% P  .@ J:BI$%%%% !6!KO@G3-=E:X=9+2]./]+M6V.<=-PY
M5\8XW X[5OT4 >:S>#O%&F"06]Q9ZP@8LDDS-!,/8@!@S?[65_*J%R=:L$#7
M'AC45B"X_P!',4W?IB-B<=^G_ >]>LT4[L=SQD>)64;7T;Q$C@Y_Y EVW(Z'
M(0\CMS^(IR^()Y/D@\/Z_,PSC=I4T2\]?OJO7OT]\U[)11=A<\JCA\276TQ>
M%;J,LH&^YN;=5]@0'+ #_=^@6K$?@[QE>E/,O=+THCEI(Q)=,3W(4[,-[[C^
M(KTVBB["YQ%K\*K!L-J>HZEJK8QLDN/)C7U 6+;Q[,374Z3H>G:% 8-.L;>Q
>B)R4MX@@)]3@<GW-7J*0@HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tela-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tela-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #[ IT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z8Y(Q@X
MI6SCY>M8?BCQ"F@6@E*33,H)*01&5STZ*.IYJ)SC3BY2V+A"51\L=S5ENEM_
M]8ZJ/?K5"X\2V5K($:X#2,N]8U'S8!P3],UPE_J<K2'4)9KZ])P!;1QJ2N[C
M 3 /'H<X)K)BU/3=1U@3)HUR=3MDV/<- JR1H>W7(S7C5,QL_=CIW9Z,,&_M
M,[^Z^(NB03>0U\HFSM\M"K,"1G&!GG'-/T_X@Z/JEQ+#:W:3/%G>JGI@X.?<
M'BN.AT]D:6]=87FG8,H>U"SH0"/F)8EB >HJ*VT6#29Q=V=K!:AV9;A(;4>9
M,6.221CO@G/I67]IR[(T^I1?5GI U^W<R 2!3&1N&5R/;K52?QII=N9%>\C#
MIC>NY24!Z$C.:\^76-/AN9A]CEM[F9#(Q6US)*@/)R.2/K56^U/2M/OK4R0V
MEM=ZH\=O&[0!9)B>0C<9)QV.1S4_VE4Z1#ZG%=6>F0>,],NF"07'FR'/R*-Q
MQGK@=J>GBRP>[>U%RHN0,^2>' ]<9R1[UY\=+LX9X[Z7"11HT<F+<M.Z'L&&
M,#/4#)/M6<^E^'?M46HV>DA-7MK?[/#=7%G*&1.X9MNX@#CG\ZI9G/JD+ZE'
MNSTR\\<:1I\B)/?PHSC*KOR2,X)P,]R*C@^(&B7;A8;]68G"J!RYSC &.>>.
M*X^33-$TN:T)MK.$R9BMYI(@&((R5#'DD@$D=>*;?Z3H5K'#-=Z7:JMI(&AF
M-LI\LYR&4X^7FFLRG?9!]3CT;.Z7Q;8%DQ<-*&&5\N-GSUXX7K[53'Q(T$*^
M_45C,>0_F1LI!'7J!7G]Y9:596ENMA86UN+>9IE:6T=@FXC>5"G*GIS]:LW&
MD:%=M''/IMO*BLTD8>W#+EN2VT^I.2._.:K^TGV0E@DM[GHMKXOTR]21X;Q&
M6(9D^4_+^E3+XAM'0-YX"E0V[:V,'H>E<*[6UEI2_P!H*+OSH\3M!:D[R/XB
M /K3X]5L6MU6*V=H7C7;M@.S;COQTJ7F3[(?U./F=>/&>C;HP-4MF\S&W$BD
M-VXQ[U,/$EA- L\-_ T.,E]V1SC:3Z=1^=<#:6.F7NE1MIMK:)92 F%X;955
M#DC.W Z,.U5'TGP[H,#V\NGP*\T:)*(;3Y9MNWJ%!'##.#C%']I2[(EX2/=G
MIJ:_8O#-,M] \4>=SJX(7'#9^A%53XRT=3@:K;-A=YRXX7&<\>W->=Z+INF6
M=I<PI86S174CJ(H++R$<$YPX);/.XD]\].*L6FB:*86DM;"QDBD!BD\F%,''
MRD9QSTQ^&*?]I2[(I8./=GHMOXETRZ7,-_!)TX##/.,<?B*2/Q%8N3B^MV41
MB0XD&X+@'./3!ZUYP3X>MM3N!#91R7;1&.X$,&^3:1C:Y /7WS6;8V6@65TO
MFZ=;1R2%K2!Q9-%^Y/ C);/8D9) QQCM1_:<NR(^I>9Z<?'6B*2O]IP.RH'(
M4EOE/1N!WJ>+Q5IUR(##>Q/YX8QJ#\S8ZD ]A7%6FDVNFSF:WAAM(!;K$(D@
M4%%'8..WM4+3:&VKN#8)+JNG )YL=KO>%7 ;&\<X(8$CWH693ZQ0GA(]&ST*
M;6[6UC)FND088@L1G Z]N0,BH6\5Z2D4;R:E;(&<("9 ,L>-O-<+%J^G:CK
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M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[FWN?+Q<PEA'-N^<!L @GN.IP?7C%9__  D6FVVISZ0A,=W9*AEM88B3&C\
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M%CS"Y[D=1\Q')/8TT4G8@1I9;1(+J6&6?RQN?8%C)4[MP4DX' ]^.U<)X_\
MVA/!/PS\::7X;\3:[-8ZQ?%"%AB=HXA(Q57D8*0NX@@8SR#TKO&MK6QL0)8U
MF(C^=XNIR N2O.W/7 / -8?BOX0?#_Q=K6EZEKWA^RUS5=/54M9)59VC4-O
M&#QM;D9]3U'%--:\PG?>)TKV;VML9;27D(6CBE'[MB>06 ]<]C6<=?M4M1]M
MN[6&]1D@G$,N4$K'"CD#K[@'VJ^D]MK5K,UI<^9YA*'>A4J^>NW([^F*C.B6
MKPE)+:.XG?<K2. OFDCYB/3BL]"M;#9]+?4(76:>8B5F/DPR9C*YV@$XZ'K7
MBGQL^#>M:G;6DNGW5W=B'(%HTX=%4] J\ 5[99-;Z7 8V>5H[<,QW@Y51R
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M+>:YC01,[-$)G1BK%21N"[N1QD'@&BQL%TG2(TO;N"XN 3YMT\7EJW]W"[B
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MIS4L%Y<H\9EL_(R2"$D#;!C/)[__ %ZHQB:TG:[C6.YU)RD$FZ4PQ[,\-MY
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MV(JP;:YBMH_LT45TL>Q!'Y^T^7T+;F/! '3+$^M,"1-;GG++;6;[EP<LW'N
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MQQ4AO[F2PAF-E,LLT>7BED3='QC#'//4\?[/:H4U#4%? :P 0D ^5(>#^/\
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M#C\J@>^?>T<=K/*H .Y"OSGN I;/IS6/##>6EK##H<5@;"WMU6"/S)$!3.2
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ME_\ 0KWO_@0O_P 37LW_  IOPW_SY+_WRM'_  IOPW_SY+_WRM'M\'_SY?\
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M3<6=I',A(FE97)2-6VJ20#EN,X)'B$7[#?Q(TSX#^$-&TJ_\*Z?XX\-^-O\
MA+[&Q26Z?0[;#N1:H6S-Y>6#9/S9R.>H]R\+_ /Q'I7Q^\?>.[^\L6T[Q#H5
MCIMLEHY-Q#-$"'8@J%"\_*0Q..H!HDK1M'?7\G;\2K)N[?3\;K]#C/"O[?\
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M93OJT4%O8"-EE=+D[2I^]NX7'U!S43W^H%)8K&UMFLT$8@F%V=S1GEBPVD9
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M"48I(\!MR=V%%%%6(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:A/%9H)5SSM4K% VYB3T5%!8GGD=LJ/2BS(N,O=*M3 8;>1K/RXQ' (0?+3
MPN5!'RCCC-53X@TW2;,PWUZPEMC%#/<>1(L/FOC #-GJ3_>..YJ['#;WUO)'
M(9T1D.=D;I(A*YP.,J1QU-87BCX@>%_A[8::/$>M6VBVLT@BM[C5)=AF? P
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M>6_V% &3CWIH-ANE7-MJ5LMZ+R4VI#QF"1?*7.>K!@",>H)'O6ELA6$*LQ/
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M*VLQ)J:V,31*YE>"5FC"@'GYP,\8ZGMQQ4]G9R01X>4SN.=[QA?R J+4I)1
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M_P #F_\ C%']FXK^5?\ @4?\P^LTN_X/_(^J<T9KY6_X;8U/_HG-W_X'-_\
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M=*_-?XX:MXTTCX??%34_"'C:X\%M9_$LP7!TV!5FNS(UK&H\Y2K*5)W-C.]
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MPM:1DKLP".3@9^@Q5) 9UEX?@T66SAMDO[RW#2/+>7U_YOD#)8%\DD@DX'H
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MK^(H([#4-$_L9D=FR)@P8LNUOE 5@5SMYX.<U[#=V*[4-M:P2.7171Y"F$)
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M6()Y2@'(2%L?F,BFWNL:3-I<Z2!KBTDC=) 5(1DP=V<CTS4MOX@5[78(5D>
MK#*+:,X$NX#'M^?'4XJS!+J\FG;K\QRR@G,03:'3/'5F'3C[Q'L#4E6.;M9;
M-=-A33(+*2Q\A1;IYK*A0<8R%(R 3@C.>^*U+!["."=8(XXG$Q$ABC*KN  _
M$XQS5OS+@1%3I3N4541$"\>P&>/TJ;=/)$K_ &7R-_WXB K#ZD<?UJ7J!")K
M>ZRA82"7Y=A4X_.F.MI'A$MXD7';./3UJO\ :I[&*&":*>\G&]O-AM=B8&2.
MG XXZ\D51M[@ZH!<6MG.UNZD ,OE.'!.3\R@^W/!QP:H5@L6T==4U"33FMWN
MC-&+WRV8G(3 R,'G' '&>Y%3;K6^OPMRD'VQ$9%AAN&(5,@\C"#U_A)_VC7%
M_%GQ;JG@#P%J^NZ=I)NKFRB1XX/+)8[I%3+[,DA=Q)('M2?!KQ+K'C#P#I^O
MZUX;FT?5+AF1[8X)* G+H&PVTX!YK3V<N7FZ&?,KV._-AIP3(B#2 \!6)(/K
MUZ>_2D35M.W,JW\0(X*F0 C'4<UD2W45E.MQ<L8HIF2.UMF"AS)SD \EL@$[
M?8^E+:W,T]RLL<5S'"KNK0RVOEN2<8(9B,#Z U*7<M[#Y9-'GU(S?;8Y;WRO
M)53=E4V[B22JY./< U6U"RM)WC:]LH)EAE#Q;V9PQ Y.WCG\3FI-0N(X$,\]
ME$[X$8F$:JRDG &<?IFJ\.FW.KZM;06=K.V>9(3&&S]6_AK6,+NRW(<DEJ4[
MKQ+I\=Z;))#)<8(9(XV*+QW;! S79>%/A/<>)8!?W%Y+9I(N!L+= 00 I Z<
M\^]=CX3^$MII]M:R:@JSRH586Y9O+3&< @D[L<=:]%C0H ., 8&*]>EA$K2G
MJ<%3%:<L$4]'TB#1;&.UMDV1(!]6/<GW-7P,4M%>DE961P-WU"BBBF(****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II (Z"
MG44 9^I:-9ZHJ"[M(+H+]WS8P^WZ9'%<=JWPHTNXNUNK>WMA<(2T?VB!9"C=
MMK8RO/7'M7H-%85*,*JM-&L*LJ?PL\-UCP)K=C-!*-T<2LWG)$JRQL#W W C
M&#^=<W>2?8=22VM],WB<C==+!N3([$KG;T[@#'>OI*10W4%@>,5C:EX4T_4&
M+-%Y<A_Y:)P:\JKERM^Z.^GC+_Q#Q?2;ZV@O+N.]LX!?1@<6,1E81GE2Q(R"
M0#P*N7VK#^SYDAM;B:Z-N[1H\.1(V#A23P,].?7H>E=SJ'PW5[@75J4EN#%Y
M;F9<%DSDC/U ["N6N?".N:=)(\D+/:JK[1M)YS\O*DD#'JIKS)8:K3UE$ZXU
MZ<]$SPK]F_Q/\5/$LOB1OBAX5L]"@A>(:>HM$MSN.[S(PH)+J $(<]<GENWK
M^HQQB;_0+.V.I1JJK)/:Y B+#<H88(SSQTJK /$]UJ+VTVDV<%I]T2QWZN7'
M^Z8P1^=01^(+"VURZT\0JFI2L// C*F0H!@;B!D 8Y [5F]7V.B*LK7N7TOX
M[?7(;::& B['E6(DM3N$N&9ANR!DKC&-O3J>E;+7441*RK&!S\I3#5G6VJ.Q
M;[*T3RJQ3((P.>>G-9FHPW"7B:@]XRQQAC+:PKE)!CY3RNXL.P7)-3ROJ,U[
MG4U;Y5MY2BX"[(6P?H<\UEZM<VWEM]IMD,^2;4W5L6Q-M)3L3U'..<9J*W%S
MJ4KR.DUCY4B,N8U9)00<@;O;.>A&:WI;VX1D$!CA"Y8*Y.T#M[_G2V$T<_<7
M*CF]TQ9[7"%V:S/R2<= 1PN2?O#/3.*M:JNI7%M<110-%<F)UA9R@V,1\AQN
M[<?X5KMJ-VBJ[/;ARH&</S5'4A-YUL1=-;2"4&2-0,NO]TY4X![G@\"B^MR6
M>,_LU_#KXE_#B_\ $<_C_P 2/K@O?*$$+7DET@D&=SX<?)G/W5Z#GL*]NN[^
M)HR\EN)7^4%(HVD89Z$*.WUKG+K5;V]0VHMI+,3*[-/;2JQA.<*H*G&3V !]
MZO::]PEK&^=SKM5FE^_(<]R.,TYR<W=A'W58LO+>:?HZ_P!I.]^8C))<-;6J
M%9TP<)M5VS@X^89/%:M@]M-:1SI%Y43(&6,Q;& Q]W'7'UYK.;4IHD+1(C'_
M &>:JW=T]V@B\Q[9W 8M;R;7//3GC%-K0+6-2>6)E>8Q*"O("("1^%5+JZMH
MK29KJUFDM?+)E$UMF(KWW=L>HJC;:I>WLNV/39(K=F>-K@&-=HP?F[9'TJWI
M^M&RL5225YY(QL,S*JEQ[A0 ,=/PYYJ;=AW3W*ZK?,DA_P! >,2K]G5K4@+;
MCJI&[&_TP,9J6S-DB[;18UV2%"EE".&(R<@8J*XUMDCFE2V\]$R-JJ6<^ORC
MDU&-9O=4A22.VBA/54FR&!Z<J5X']*M/6U@:2W+CZE;1O^]6;<O!4Q=?J!3+
MJ^M4B,_EJK,3C(^]QSD'GBJNE^$_$7B"5(5B1T*C,D"M&(O^VC<,?HO^!Z[P
M_P# XV6RYO\ 4I9KO;L9L&4$9)Z, N>?[E=E/#U)]+'-*M3AHV>9V&OVNK8N
M=.%S<0J'VQ?8-D,S#(PLI]&!S^5:OAK3M6\0R1I:VRW"Q$K<O((VD&>0 5^5
M0#D<\\9KV>S^&6C0R))(L]YC^&XDRO\ WS@5TMEIUOIT7E6L*6\2]$1<+^%=
M]/ -:N1RRQ2^RCR[2O@Y'.L(U*8; QE9"BM(">H$FWCTXYKO=$\':1H"*MG9
MHI_YZ2#<_P"9K>'2EKT84(4_A1PRJRGNQ@5?2G 8I:*W,@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>tela-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2023 8:23:45 PM-->
<!--Modified on: 3/23/2023 8:23:45 PM-->
<xsd:schema targetNamespace="http://www.telabio.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:tela="http://www.telabio.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
        <link:definition>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40401 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2" id="DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2">
        <link:definition>40402 - Disclosure - Leases - Future minimum lease payments (Details) (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails" id="DisclosureDebtScheduleOfLongTermDebtDetails">
        <link:definition>40601 - Disclosure - Debt - Schedule of long term debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>41001 - Disclosure - Income Taxes - Deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails" id="DisclosureIncomeTaxesRateReconciliationDetails">
        <link:definition>41003 - Disclosure - Income Taxes - Rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeasesDetails">
        <link:definition>41102 - Disclosure - Commitments and Contingencies - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails" id="DisclosureRisksAndLiquidityDetails">
        <link:definition>40201 - Disclosure - Risks and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails">
        <link:definition>40305 - Disclosure - Summary of Significant Accounting Policies - Revenue Disaggregated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails">
        <link:definition>40306 - Disclosure - Summary of Significant Accounting Policies - Fair value of financial instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails">
        <link:definition>40307 - Disclosure - Summary of Significant Accounting Policies - Net loss per share (Potentially dilutive securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails" id="DisclosureDebtMidcapTermLoanDetails">
        <link:definition>40602 - Disclosure - Debt - MidCap Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails" id="DisclosureDebtOrbimedTermLoanRelatedPartyDetails">
        <link:definition>40603 - Disclosure - Debt - OrbiMed Term Loan (related party) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails" id="DisclosureStockholdersEquityPublicStockOfferingsDetails">
        <link:definition>40701 - Disclosure - Stockholders' Equity - Public Stock Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" id="DisclosureStockholdersEquityWarrantsOutstandingDetails">
        <link:definition>40702 - Disclosure - Stockholders' Equity - Warrants outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" id="DisclosureStockBasedCompensationNarrativesDetails">
        <link:definition>40801 - Disclosure - Stock-Based Compensation - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" id="DisclosureStockBasedCompensationExpensesDetails">
        <link:definition>40802 - Disclosure - Stock-Based Compensation - Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" id="DisclosureStockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>40806 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails" id="DisclosureEmployeeBenefitPlansDetails">
        <link:definition>40901 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails" id="DisclosureIncomeTaxesNolCarryforwardsDetails">
        <link:definition>41002 - Disclosure - Income Taxes - NOL carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41101 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureBackground" id="DisclosureBackground">
        <link:definition>10101 - Disclosure - Background</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureRisksAndLiquidity" id="DisclosureRisksAndLiquidity">
        <link:definition>10201 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10401 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>10601 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10701 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10801 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>10901 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11101 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11201 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30403 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>30603 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30703 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30803 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31003 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31103 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails">
        <link:definition>40302 - Disclosure - Summary of Significant Accounting Policies - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>40303 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails">
        <link:definition>40304 - Disclosure - Summary of Significant Accounting Policies - Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>40803 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails" id="DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails">
        <link:definition>40804 - Disclosure - Stock-Based Compensation - Early Exercise Of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" id="DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>40805 - Disclosure - Stock-Based Compensation - Weighted average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesNarrativesDetails" id="DisclosureIncomeTaxesNarrativesDetails">
        <link:definition>41004 - Disclosure - Income Taxes - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tela-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tela-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tela-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tela-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xsd:element id="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" name="StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" name="StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_ResearchAndDevelopmentExpensesPayableCurrent" name="ResearchAndDevelopmentExpensesPayableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tela_OrbimedTermLoanMember" name="OrbimedTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_OrbimedTermLoansTrancheOneMember" name="OrbimedTermLoansTrancheOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_OrbimedTermLoansTrancheTwoMember" name="OrbimedTermLoansTrancheTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_NumberOfTranches" name="NumberOfTranches" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_InterestPenaltyPercentage" name="InterestPenaltyPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_DebtInstrumentInterestPaymentTerm" name="DebtInstrumentInterestPaymentTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" name="PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" />
  <xsd:element id="tela_PercentageOfExitFee" name="PercentageOfExitFee" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" />
  <xsd:element id="tela_NoncashLossOnExtinguishmentOfDebt" name="NoncashLossOnExtinguishmentOfDebt" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="tela_EquityIncentivePlan2019Member" name="EquityIncentivePlan2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_LabEquipmentMember" name="LabEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_AgreementWithAroaMember" name="AgreementWithAroaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" name="RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_MidcapTermLoansMember" name="MidcapTermLoansMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_SalesMilestonePaymentDue" name="SalesMilestonePaymentDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tela_SalesMilestonePayment" name="SalesMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tela_PurchaseObligationDueInSixthYear" name="PurchaseObligationDueInSixthYear" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" name="ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_PercentageOfRoyaltyOfNetSales" name="PercentageOfRoyaltyOfNetSales" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_RevenueBasedMilestonePayment" name="RevenueBasedMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" name="ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_EmployeeStockPurchasePlan2019Member" name="EmployeeStockPurchasePlan2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" name="EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_IncrementalCostsOfObtainingContract" name="IncrementalCostsOfObtainingContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="tela_OvitexMember" name="OvitexMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_OvitexPrsMember" name="OvitexPrsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_AccruedAndOtherLiabilitiesCurrent" name="AccruedAndOtherLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tela_SecondUnderwrittenPublicOfferingMember" name="SecondUnderwrittenPublicOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" name="ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" nillable="true" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tela_EquityIncentivePlansNumber" name="EquityIncentivePlansNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" abstract="false" />
  <xsd:element id="tela_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities" name="LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance" name="CommonStockCapitalSharesReservedForFutureAnnualIssuance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" name="CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="tela_FixedCostOfNetSales" name="FixedCostOfNetSales" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified" name="ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="NextScienceMember" id="tela_NextScienceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TransferPriceForProductProduced" id="tela_TransferPriceForProductProduced" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CommonStockWarrantsExpiringIn2027Member" id="tela_CommonStockWarrantsExpiringIn2027Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockWarrantsExpiringIn2028Member" id="tela_CommonStockWarrantsExpiringIn2028Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherCommitmentsTermOfContract" id="tela_OtherCommitmentsTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities" id="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OperatingLeaseObligationAssumed" id="tela_OperatingLeaseObligationAssumed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherCustomersMember" id="tela_OtherCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeAndLaboratorySpaceLeaseMember" id="tela_OfficeAndLaboratorySpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" id="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" id="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities" id="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MidcapTermLoanTrancheOneMember" id="tela_MidcapTermLoanTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MidcapTermLoanTrancheTwoMember" id="tela_MidcapTermLoanTrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FirstYearMember" id="tela_FirstYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecondYearMember" id="tela_SecondYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThirdYearMember" id="tela_ThirdYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionalExtensionForInterestOnlyPaymentPeriod" id="tela_AdditionalExtensionForInterestOnlyPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedExpensesAmountDueToContractManufacturer" id="tela_AccruedExpensesAmountDueToContractManufacturer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EligibilityRequirementToBorrowTranche2" id="tela_EligibilityRequirementToBorrowTranche2" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAssetsLeaseLiability" id="tela_DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesDepreciationAndAmortization" id="tela_DeferredTaxLiabilitiesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredTaxLiabilitiesRightOfUseAsset" id="tela_DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollagenMatrixInc.Member" id="tela_CollagenMatrixInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetDeferredTaxAssetBeforeValuationAllowance" id="tela_NetDeferredTaxAssetBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" id="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" id="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EndOfTermCharge" id="tela_EndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" id="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherSuppliersForExclusivityRightsMember" id="tela_OtherSuppliersForExclusivityRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" id="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>tela-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2023 8:23:45 PM-->
<!--Modified on: 3/23/2023 8:23:45 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.telabio.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2" roleURI="http://www.telabio.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebtScheduleOfLongTermDebtDetails" roleURI="http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxesRateReconciliationDetails" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" />
  <calculationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638151998237743978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638151998237743978" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151998237743978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638151998237743978" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151998237743978" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638151998237753991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638151998237743978" xlink:to="us-gaap_ReceivablesNetCurrent_638151998237753991" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638151998237753991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638151998237743978" xlink:to="us-gaap_InventoryNet_638151998237753991" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638151998237753991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638151998237743978" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638151998237753991" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638151998237753991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638151998237753991" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638151998237753991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638151998237753991" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638151998237753991" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638151998237753991" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638151998237903984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638151998237903984" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638151998237903984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638151998237903984" xlink:to="us-gaap_LiabilitiesCurrent_638151998237903984" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638151998237903984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638151998237903984" xlink:to="us-gaap_AccountsPayableCurrent_638151998237903984" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638151998237903984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638151998237903984" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638151998237903984" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_638151998237903984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638151998237903984" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_638151998237903984" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638151998237903984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638151998237903984" xlink:to="us-gaap_LongTermDebtNoncurrent_638151998237903984" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638151998237903984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638151998237903984" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638151998237903984" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638151998237913976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638151998237913976" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638151998237913976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151998237913976" xlink:to="us-gaap_CommonStockValue_638151998237913976" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638151998237913976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151998237913976" xlink:to="us-gaap_PreferredStockValue_638151998237913976" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638151998237913976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151998237913976" xlink:to="us-gaap_AdditionalPaidInCapital_638151998237913976" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638151998237913976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151998237913976" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638151998237913976" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638151998237913976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638151998237913976" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638151998237913976" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638151998237923987" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638151998237923987" xlink:to="us-gaap_GrossProfit_638151998237923987" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638151998237923987" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998237923987" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638151998237923987" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_638151998237923987" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638151998237923987" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638151998237923987" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638151998237923987" xlink:to="us-gaap_OperatingExpenses_638151998237923987" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638151998237923987" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638151998237923987" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638151998237923987" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638151998237923987" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638151998237923987" xlink:to="us-gaap_SellingAndMarketingExpense_638151998237923987" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638151998237923987" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_638151998237923987" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151998237933993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638151998237923987" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151998237933993" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638151998237933993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638151998237923987" xlink:to="us-gaap_InterestExpense_638151998237933993" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638151998237933993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638151998237923987" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638151998237933993" order="3" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Calc 2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638151998237933993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638151998237933993" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151998237933993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638151998237933993" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_ProfitLoss_638151998237943983" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638151998237943983" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638151998237943983" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998237943983" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities_638151998237943983" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_Depreciation_638151998237943983" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NoncashLossOnExtinguishmentOfDebt" xlink:label="tela_NoncashLossOnExtinguishmentOfDebt_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="tela_NoncashLossOnExtinguishmentOfDebt_638151998237943983" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638151998237943983" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638151998237943983" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638151998237943983" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638151998237953982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638151998237953982" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638151998237953982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_IncreaseDecreaseInInventories_638151998237953982" order="11" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638151998237953982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638151998237953982" order="12" use="optional" weight="-1" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638151998237953982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_InventoryWriteDown_638151998237953982" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638151998237953982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_PaidInKindInterest_638151998237953982" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638151998237953982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998237933993" xlink:to="us-gaap_ShareBasedCompensation_638151998237953982" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151998237953982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151998237953982" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638151998237953982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151998237953982" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638151998237953982" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638151998237963985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151998237953982" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638151998237963985" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638151998237963985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151998237953982" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638151998237963985" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638151998237963985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638151998237963985" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638151998237963985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638151998237963985" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638151998237963985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" xlink:to="us-gaap_PaymentsOfFinancingCosts_638151998237963985" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638151998237963985" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638151998237963985" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638151998237974001" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638151998237974001" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638151998237974001" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638151998237974001" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638151998237974001" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" xlink:to="us-gaap_ProceedsFromStockPlans_638151998237974001" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638151998237974001" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998237963985" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638151998237974001" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638151998237974001" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638151998237974001" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638151998237983982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638151998237983982" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638151998237983982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638151998237983982" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="extended" xlink:title="40402 - Disclosure - Leases - Future minimum lease payments (Details) (Calc2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638151998237983982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638151998237983982" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638151998237983982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" xlink:to="us-gaap_OperatingLeaseLiability_638151998237983982" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638151998237993986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638151998237993986" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ResearchAndDevelopmentExpensesPayableCurrent" xlink:label="tela_ResearchAndDevelopmentExpensesPayableCurrent_638151998237993986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="tela_ResearchAndDevelopmentExpensesPayableCurrent_638151998237993986" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151998237993986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151998237993986" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AccruedExpensesAmountDueToContractManufacturer" xlink:label="tela_AccruedExpensesAmountDueToContractManufacturer_638151998237993986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="tela_AccruedExpensesAmountDueToContractManufacturer_638151998237993986" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638151998237993986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638151998237993986" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638151998237993986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638151998237993986" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Debt - Schedule of long term debt (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638151998237993986" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638151998237993986" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638151998238003982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentFaceAmount_638151998238003982" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_638151998238003982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_638151998238003982" order="3" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638151998238003982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638151998238003982" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NetDeferredTaxAssetBeforeValuationAllowance" xlink:label="tela_NetDeferredTaxAssetBeforeValuationAllowance_638151998238003982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="tela_NetDeferredTaxAssetBeforeValuationAllowance_638151998238003982" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638151998238003982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tela_NetDeferredTaxAssetBeforeValuationAllowance_638151998238003982" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638151998238003982" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="tela_DeferredTaxLiabilitiesRightOfUseAsset_638151998238003982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638151998238003982" xlink:to="tela_DeferredTaxLiabilitiesRightOfUseAsset_638151998238003982" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="tela_DeferredTaxLiabilitiesDepreciationAndAmortization_638151998238003982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638151998238003982" xlink:to="tela_DeferredTaxLiabilitiesDepreciationAndAmortization_638151998238003982" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638151998238013981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tela_NetDeferredTaxAssetBeforeValuationAllowance_638151998238003982" xlink:to="us-gaap_DeferredTaxAssetsGross_638151998238013981" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638151998238013981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151998238013981" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638151998238013981" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638151998238013981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151998238013981" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638151998238013981" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxAssetsLeaseLiability" xlink:label="tela_DeferredTaxAssetsLeaseLiability_638151998238013981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151998238013981" xlink:to="tela_DeferredTaxAssetsLeaseLiability_638151998238013981" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638151998238013981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151998238013981" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638151998238013981" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_638151998238013981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638151998238013981" xlink:to="us-gaap_DeferredTaxAssetsInventory_638151998238013981" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Rate reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638151998238023982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638151998238023982" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638151998238023982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638151998238023982" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638151998238023982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638151998238023982" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638151998238023982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638151998238023982" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638151998238023982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638151998238023982" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638151998238023982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638151998238023982" order="6" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Commitments and Contingencies - Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638151998238023982" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638151998238023982" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638151998238033988" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638151998238033988" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638151998238033988" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638151998238033988" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638151998238033988" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638151998238033988" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638151998238033988" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638151998238033988" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638151998238033988" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638151998238033988" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>tela-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2023 8:23:45 PM-->
<!--Modified on: 3/23/2023 8:23:45 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureRisksAndLiquidityDetails" roleURI="http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebtScheduleOfLongTermDebtDetails" roleURI="http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebtMidcapTermLoanDetails" roleURI="http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebtOrbimedTermLoanRelatedPartyDetails" roleURI="http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockholdersEquityPublicStockOfferingsDetails" roleURI="http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockholdersEquityWarrantsOutstandingDetails" roleURI="http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationNarrativesDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationExpensesDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureEmployeeBenefitPlansDetails" roleURI="http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxesNolCarryforwardsDetails" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.telabio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tela-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AccruedAndOtherLiabilitiesCurrent" xlink:label="tela_AccruedAndOtherLiabilitiesCurrent_1" xlink:title="tela_AccruedAndOtherLiabilitiesCurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="tela_AccruedAndOtherLiabilitiesCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To tela_AccruedAndOtherLiabilitiesCurrent_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1" xlink:title="us-gaap_AccruedLiabilitiesCurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_AccruedLiabilitiesCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To us-gaap_AccruedLiabilitiesCurrent_1" order="7" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.telabio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:title="us-gaap_DerivativeInstrumentRiskAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1" xlink:title="us-gaap_DerivativeContractTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:to="us-gaap_DerivativeContractTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DerivativeInstrumentRiskAxis_1 To us-gaap_DerivativeContractTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:title="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_1" xlink:title="us-gaap_ConversionOfStockNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:to="us-gaap_ConversionOfStockNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConversionOfStockByUniqueDescriptionAxis_1 To us-gaap_ConversionOfStockNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OptionIndexedToIssuersEquityTypeAxis_1 To us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_1" xlink:title="us-gaap_LitigationStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_1" xlink:title="us-gaap_LitigationStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LitigationStatusAxis_1" xlink:to="us-gaap_LitigationStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LitigationStatusAxis_1 To us-gaap_LitigationStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:to="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" xlink:label="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Risks and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyTable" xlink:label="us-gaap_UnusualRiskOrUncertaintyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_UnusualRiskOrUncertaintyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:label="us-gaap_UnusualRiskOrUncertaintyLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="us-gaap_UnusualRiskOrUncertaintyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Summary of Significant Accounting Policies - Revenue Disaggregated (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OvitexMember" xlink:label="tela_OvitexMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tela_OvitexMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OvitexPrsMember" xlink:label="tela_OvitexPrsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tela_OvitexPrsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherCustomersMember" xlink:label="tela_OtherCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tela_OtherCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_IncrementalCostsOfObtainingContract" xlink:label="tela_IncrementalCostsOfObtainingContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="tela_IncrementalCostsOfObtainingContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" xlink:label="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Summary of Significant Accounting Policies - Fair value of financial instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Summary of Significant Accounting Policies - Net loss per share (Potentially dilutive securities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsMember" xlink:label="tela_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tela_CommonStockWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_LabEquipmentMember" xlink:label="tela_LabEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tela_LabEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ComputerEquipmentAndSoftwareMember" xlink:label="tela_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tela_ComputerEquipmentAndSoftwareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AgreementWithAroaMember" xlink:label="tela_AgreementWithAroaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tela_AgreementWithAroaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Debt - Schedule of long term debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoansMember" xlink:label="tela_MidcapTermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tela_MidcapTermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoanMember" xlink:label="tela_OrbimedTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tela_OrbimedTermLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Debt - MidCap Term Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoansMember" xlink:label="tela_MidcapTermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tela_MidcapTermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoanTrancheOneMember" xlink:label="tela_MidcapTermLoanTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tela_MidcapTermLoansMember" xlink:to="tela_MidcapTermLoanTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoanTrancheTwoMember" xlink:label="tela_MidcapTermLoanTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tela_MidcapTermLoansMember" xlink:to="tela_MidcapTermLoanTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_FirstYearMember" xlink:label="tela_FirstYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tela_FirstYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SecondYearMember" xlink:label="tela_SecondYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tela_SecondYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ThirdYearMember" xlink:label="tela_ThirdYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tela_ThirdYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EligibilityRequirementToBorrowTranche2" xlink:label="tela_EligibilityRequirementToBorrowTranche2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_EligibilityRequirementToBorrowTranche2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_InterestPenaltyPercentage" xlink:label="tela_InterestPenaltyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_InterestPenaltyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DebtInstrumentInterestPaymentTerm" xlink:label="tela_DebtInstrumentInterestPaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_DebtInstrumentInterestPaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AdditionalExtensionForInterestOnlyPaymentPeriod" xlink:label="tela_AdditionalExtensionForInterestOnlyPaymentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_AdditionalExtensionForInterestOnlyPaymentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfExitFee" xlink:label="tela_PercentageOfExitFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_PercentageOfExitFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Debt - OrbiMed Term Loan (related party) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoanMember" xlink:label="tela_OrbimedTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tela_OrbimedTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoansTrancheOneMember" xlink:label="tela_OrbimedTermLoansTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tela_OrbimedTermLoanMember" xlink:to="tela_OrbimedTermLoansTrancheOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoansTrancheTwoMember" xlink:label="tela_OrbimedTermLoansTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tela_OrbimedTermLoanMember" xlink:to="tela_OrbimedTermLoansTrancheTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NumberOfTranches" xlink:label="tela_NumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_NumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_InterestPenaltyPercentage" xlink:label="tela_InterestPenaltyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_InterestPenaltyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DebtInstrumentInterestPaymentTerm" xlink:label="tela_DebtInstrumentInterestPaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_DebtInstrumentInterestPaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfExitFee" xlink:label="tela_PercentageOfExitFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_PercentageOfExitFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EndOfTermCharge" xlink:label="tela_EndOfTermCharge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tela_EndOfTermCharge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders' Equity - Public Stock Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SecondUnderwrittenPublicOfferingMember" xlink:label="tela_SecondUnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tela_SecondUnderwrittenPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityDistributionAgreementMember" xlink:label="tela_EquityDistributionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tela_EquityDistributionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" xlink:label="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stockholders' Equity - Warrants outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsExpiringIn2028Member" xlink:label="tela_CommonStockWarrantsExpiringIn2028Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tela_CommonStockWarrantsExpiringIn2028Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsExpiringIn2027Member" xlink:label="tela_CommonStockWarrantsExpiringIn2027Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tela_CommonStockWarrantsExpiringIn2027Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:label="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stock-Based Compensation - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityIncentivePlan2019Member" xlink:label="tela_EquityIncentivePlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="tela_EquityIncentivePlan2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityIncentivePlansNumber" xlink:label="tela_EquityIncentivePlansNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tela_EquityIncentivePlansNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance" xlink:label="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" xlink:label="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stock-Based Compensation - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="40806 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Employee Benefit Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EmployeeStockPurchasePlan2019Member" xlink:label="tela_EmployeeStockPurchasePlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="tela_EmployeeStockPurchasePlan2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" xlink:label="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - NOL carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AgreementWithAroaMember" xlink:label="tela_AgreementWithAroaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tela_AgreementWithAroaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherSuppliersForExclusivityRightsMember" xlink:label="tela_OtherSuppliersForExclusivityRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tela_OtherSuppliersForExclusivityRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NextScienceMember" xlink:label="tela_NextScienceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tela_NextScienceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CollagenMatrixInc.Member" xlink:label="tela_CollagenMatrixInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tela_CollagenMatrixInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA" xlink:label="stpr_PA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_PA" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OfficeAndLaboratorySpaceLeaseMember" xlink:label="tela_OfficeAndLaboratorySpaceLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tela_OfficeAndLaboratorySpaceLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueBasedMilestonePayment" xlink:label="tela_RevenueBasedMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_RevenueBasedMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" xlink:label="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" xlink:label="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SalesMilestonePayment" xlink:label="tela_SalesMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_SalesMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SalesMilestonePaymentDue" xlink:label="tela_SalesMilestonePaymentDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_SalesMilestonePaymentDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_TransferPriceForProductProduced" xlink:label="tela_TransferPriceForProductProduced" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_TransferPriceForProductProduced" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_FixedCostOfNetSales" xlink:label="tela_FixedCostOfNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_FixedCostOfNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_PurchaseObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PurchaseObligationDueInSixthYear" xlink:label="tela_PurchaseObligationDueInSixthYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_PurchaseObligationDueInSixthYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfRoyaltyOfNetSales" xlink:label="tela_PercentageOfRoyaltyOfNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_PercentageOfRoyaltyOfNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherCommitmentsTermOfContract" xlink:label="tela_OtherCommitmentsTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_OtherCommitmentsTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" xlink:label="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>tela-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2023 8:23:45 PM-->
<!--Modified on: 3/23/2023 8:23:45 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt with related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock; $0.001 par value: 200,000,000 shares authorized; 19,165,027 and 14,529,606 shares issued and 19,165,027 and 14,529,577 shares outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Ending period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, Par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of revenue (excluding amortization of intangible assets)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense related to intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and Marketing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense (income)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Ending period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:to="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of stock vesting of common stock previously subject to repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Vesting Of Common Stock Previously Subject To Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of common stock previously subject to repurchase</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:to="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that have been vesting of common stock previously subject to repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Vesting Of Common Stock Previously Subject To Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of common stock previously subject to repurchase (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of share-based awards and exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of share-based awards and exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under the employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under the employee stock purchase plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares withheld for employee taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares withheld for employee taxes (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" xlink:label="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" xlink:to="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of adjustments to additional paid in capital resulting from reclassification of liability-classified stock based compensation to equity classified.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Reclassification Of Liability Classified Stock Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of liability-classified stock-based compensation awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net of underwriting discounts, commissions and offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued and sold (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash interest expense</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NoncashLossOnExtinguishmentOfDebt" xlink:label="tela_NoncashLossOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_NoncashLossOnExtinguishmentOfDebt" xlink:to="tela_NoncashLossOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_NoncashLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Loss On Extinguishment Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_NoncashLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Loss On Extinguishment Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_NoncashLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash loss on extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:to="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net changes in operating lease right-of-use assets and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Changes in Operating Lease Right-of-use Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net changes in operating lease ROU assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory excess and obsolescence charge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current and long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency remeasurement loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale, Maturity and Collection of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the sale and maturity of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of common stock, net of underwriting discounts, commissions and offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of debt financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of initial public offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment, Tax Withholding, Share-based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of withholding taxes related to stock-based compensation to employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock under the employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid during the period for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of noncash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment in accounts payable and accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for early exercised stock options</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Classified Stock-Based Compensation In Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Classified Stock-Based Compensation In Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability-classified stock-based compensation in accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified" xlink:label="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified" xlink:to="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of liability-classified stock-based compensation to equity-classified.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Of Liability Classified Stock Based Compensation To Equity Classified</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of liability-classified stock-based compensation awards to equity-classified</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease ROU asset exchanged for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities" xlink:label="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities" xlink:to="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of tenant improvement and deferred rent exchanged for operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant Improvements and Deferred Rent Exchanged For Operating lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant improvement and deferred rent reclassified to operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OperatingLeaseObligationAssumed" xlink:label="tela_OperatingLeaseObligationAssumed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OperatingLeaseObligationAssumed" xlink:to="tela_OperatingLeaseObligationAssumed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OperatingLeaseObligationAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in operating lease obligation assumed on exchange of operating lease right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OperatingLeaseObligationAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Obligation Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tela_OperatingLeaseObligationAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities assumed for operating lease ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Background</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Background</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Principals of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of assets and liabilities measured on recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of dilutive securities excluded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of warrants outstanding to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock based compensation expense categories in statement of operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of activity relating to early exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of restricted stock units (RSUs)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant components of the Company's deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Operating Loss Carryforwards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Company's net operating loss (NOL) carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of income tax benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments under non-cancelable operating lease agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyTable" xlink:label="us-gaap_UnusualRiskOrUncertaintyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnusualRiskOrUncertaintyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unusual Risk or Uncertainty [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:label="us-gaap_UnusualRiskOrUncertaintyLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="us-gaap_UnusualRiskOrUncertaintyLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnusualRiskOrUncertaintyLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unusual Risk or Uncertainty [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGrossAbstract" xlink:label="us-gaap_InventoryGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGrossAbstract" xlink:to="us-gaap_InventoryGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory consigned to others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining life of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets future amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 4</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Year 5</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OvitexMember" xlink:label="tela_OvitexMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OvitexMember" xlink:to="tela_OvitexMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OvitexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OviTex [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OvitexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OviTex [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_OvitexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OviTex</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OvitexPrsMember" xlink:label="tela_OvitexPrsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OvitexPrsMember" xlink:to="tela_OvitexPrsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OvitexPrsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OviTex PRS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OvitexPrsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OviTex PRS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_OvitexPrsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OviTex PRS</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherCustomersMember" xlink:label="tela_OtherCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OtherCustomersMember" xlink:to="tela_OtherCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to other customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-US [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_IncrementalCostsOfObtainingContract" xlink:label="tela_IncrementalCostsOfObtainingContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_IncrementalCostsOfObtainingContract" xlink:to="tela_IncrementalCostsOfObtainingContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_IncrementalCostsOfObtainingContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents incremental costs incurred in obtaining a contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_IncrementalCostsOfObtainingContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Costs Of Obtaining A Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_IncrementalCostsOfObtainingContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental costs of obtaining a contract</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" xlink:label="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" xlink:to="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax, as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax, as a Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, as a percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsMember" xlink:label="tela_CommonStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_CommonStockWarrantsMember" xlink:to="tela_CommonStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Contract [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities excluded from computation of diluted weighted average shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_LabEquipmentMember" xlink:label="tela_LabEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_LabEquipmentMember" xlink:to="tela_LabEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Lab equipment .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ComputerEquipmentAndSoftwareMember" xlink:label="tela_ComputerEquipmentAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ComputerEquipmentAndSoftwareMember" xlink:to="tela_ComputerEquipmentAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Computer equipment and software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AgreementWithAroaMember" xlink:label="tela_AgreementWithAroaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_AgreementWithAroaMember" xlink:to="tela_AgreementWithAroaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_AgreementWithAroaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to License, Product Development, and Supply Umbrella Agreement with Aroa.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_AgreementWithAroaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Umbrella Agreement with Aroa</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and related benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third-party and professional fees</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AccruedExpensesAmountDueToContractManufacturer" xlink:label="tela_AccruedExpensesAmountDueToContractManufacturer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_AccruedExpensesAmountDueToContractManufacturer" xlink:to="tela_AccruedExpensesAmountDueToContractManufacturer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_AccruedExpensesAmountDueToContractManufacturer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to contract manufacturer due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_AccruedExpensesAmountDueToContractManufacturer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses, Amount Due To Contract Manufacturer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_AccruedExpensesAmountDueToContractManufacturer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts due to contract manufacturer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ResearchAndDevelopmentExpensesPayableCurrent" xlink:label="tela_ResearchAndDevelopmentExpensesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ResearchAndDevelopmentExpensesPayableCurrent" xlink:to="tela_ResearchAndDevelopmentExpensesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ResearchAndDevelopmentExpensesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value of current portion of obligation payable pertaining to Research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ResearchAndDevelopmentExpensesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expenses Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ResearchAndDevelopmentExpensesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoansMember" xlink:label="tela_MidcapTermLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_MidcapTermLoansMember" xlink:to="tela_MidcapTermLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_MidcapTermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to MidCap Term loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_MidcapTermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MidCap Term Loan</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoanMember" xlink:label="tela_OrbimedTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OrbimedTermLoanMember" xlink:to="tela_OrbimedTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OrbimedTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Information pertaining to OrbiMed Term Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OrbimedTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OrbiMed Term Loans (related party)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">End of term charge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized end of term charge and issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm debt</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoanTrancheOneMember" xlink:label="tela_MidcapTermLoanTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_MidcapTermLoanTrancheOneMember" xlink:to="tela_MidcapTermLoanTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_MidcapTermLoanTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to MidCap term loans tranche one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_MidcapTermLoanTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MidCap Term Loan Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_MidcapTermLoanTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche One</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoanTrancheTwoMember" xlink:label="tela_MidcapTermLoanTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_MidcapTermLoanTrancheTwoMember" xlink:to="tela_MidcapTermLoanTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_MidcapTermLoanTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to MidCap term loans tranche two
..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_MidcapTermLoanTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MidCap Term Loan Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_MidcapTermLoanTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SOFR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_FirstYearMember" xlink:label="tela_FirstYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_FirstYearMember" xlink:to="tela_FirstYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_FirstYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information first year of term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_FirstYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_FirstYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First year</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SecondYearMember" xlink:label="tela_SecondYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_SecondYearMember" xlink:to="tela_SecondYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_SecondYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information second year of term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_SecondYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_SecondYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second year</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ThirdYearMember" xlink:label="tela_ThirdYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ThirdYearMember" xlink:to="tela_ThirdYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ThirdYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information third year of term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ThirdYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ThirdYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EligibilityRequirementToBorrowTranche2" xlink:label="tela_EligibilityRequirementToBorrowTranche2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_EligibilityRequirementToBorrowTranche2" xlink:to="tela_EligibilityRequirementToBorrowTranche2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_EligibilityRequirementToBorrowTranche2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue the company must generate to be eligible to borrow Tranche 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_EligibilityRequirementToBorrowTranche2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligibility Requirement To Borrow Tranche 2</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_InterestPenaltyPercentage" xlink:label="tela_InterestPenaltyPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_InterestPenaltyPercentage" xlink:to="tela_InterestPenaltyPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_InterestPenaltyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of penalty to be paid on the event of default in meeting the obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_InterestPenaltyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Penalty, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_InterestPenaltyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest due to unpaid obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Interest Rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DebtInstrumentInterestPaymentTerm" xlink:label="tela_DebtInstrumentInterestPaymentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_DebtInstrumentInterestPaymentTerm" xlink:to="tela_DebtInstrumentInterestPaymentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_DebtInstrumentInterestPaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term of debt instrument interest payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_DebtInstrumentInterestPaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Payment Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_DebtInstrumentInterestPaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Installment</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AdditionalExtensionForInterestOnlyPaymentPeriod" xlink:label="tela_AdditionalExtensionForInterestOnlyPaymentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_AdditionalExtensionForInterestOnlyPaymentPeriod" xlink:to="tela_AdditionalExtensionForInterestOnlyPaymentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_AdditionalExtensionForInterestOnlyPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional extension for interest only payment period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_AdditionalExtensionForInterestOnlyPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Extension for Interest Only Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_AdditionalExtensionForInterestOnlyPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension for interest only payment period</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" xlink:to="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of penalty to be paid on principal amount of debt for the first year after closing date and thereafter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Prepayment Penalty On Prepaid Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of prepayment penalty on prepaid principal amount</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" xlink:to="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of penalty to be paid on principal amount of debt for the second year after closing date and thereafter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Prepayment Penalty On Prepaid Principal Amount 2</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfExitFee" xlink:label="tela_PercentageOfExitFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_PercentageOfExitFee" xlink:to="tela_PercentageOfExitFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_PercentageOfExitFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the principal amount paid as an exit fee at the time of maturity or prepayment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_PercentageOfExitFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Exit Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_PercentageOfExitFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exit fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoansTrancheOneMember" xlink:label="tela_OrbimedTermLoansTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OrbimedTermLoansTrancheOneMember" xlink:to="tela_OrbimedTermLoansTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OrbimedTermLoansTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Information pertaining to OrbiMed Term Loans Tranche One.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OrbimedTermLoansTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OrbiMed Term Loans - Tranche One</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoansTrancheTwoMember" xlink:label="tela_OrbimedTermLoansTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OrbimedTermLoansTrancheTwoMember" xlink:to="tela_OrbimedTermLoansTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OrbimedTermLoansTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Information pertaining to OrbiMed Term Loans Tranche Two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OrbimedTermLoansTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OrbiMed Term Loans - Tranche Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIBOR</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NumberOfTranches" xlink:label="tela_NumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_NumberOfTranches" xlink:to="tela_NumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches of debt obtained.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Tranches</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EndOfTermCharge" xlink:label="tela_EndOfTermCharge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_EndOfTermCharge" xlink:to="tela_EndOfTermCharge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_EndOfTermCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the principal amount paid as an exit fee at the time
 of maturity or prepayment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_EndOfTermCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">End of Term Charge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SecondUnderwrittenPublicOfferingMember" xlink:label="tela_SecondUnderwrittenPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_SecondUnderwrittenPublicOfferingMember" xlink:to="tela_SecondUnderwrittenPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_SecondUnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Underwritten Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_SecondUnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Underwritten Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_SecondUnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Underwritten Public Offering</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityDistributionAgreementMember" xlink:label="tela_EquityDistributionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_EquityDistributionAgreementMember" xlink:to="tela_EquityDistributionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_EquityDistributionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Distribution Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_EquityDistributionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Distribution Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" xlink:label="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" xlink:to="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Shares Authorized To Be Sold Under Equity Distribution Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Shares Authorized To Be Sold Under Equity Distribution Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsExpiringIn2028Member" xlink:label="tela_CommonStockWarrantsExpiringIn2028Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_CommonStockWarrantsExpiringIn2028Member" xlink:to="tela_CommonStockWarrantsExpiringIn2028Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_CommonStockWarrantsExpiringIn2028Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock warrants expiring in 2028.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_CommonStockWarrantsExpiringIn2028Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrants expiring in 2028</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsExpiringIn2027Member" xlink:label="tela_CommonStockWarrantsExpiringIn2027Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_CommonStockWarrantsExpiringIn2027Member" xlink:to="tela_CommonStockWarrantsExpiringIn2027Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_CommonStockWarrantsExpiringIn2027Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock warrants expiring in 2027.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_CommonStockWarrantsExpiringIn2027Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrants expiring in 2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:label="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:to="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Date from which Warrants or Rights Expire</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Date from which Warrants or Rights Expire</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration dates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityIncentivePlan2019Member" xlink:label="tela_EquityIncentivePlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_EquityIncentivePlan2019Member" xlink:to="tela_EquityIncentivePlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for 2019 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityIncentivePlansNumber" xlink:label="tela_EquityIncentivePlansNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_EquityIncentivePlansNumber" xlink:to="tela_EquityIncentivePlansNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_EquityIncentivePlansNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about number of equity incentive plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_EquityIncentivePlansNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_EquityIncentivePlansNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equity incentive plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future issuance</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance" xlink:label="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance" xlink:to="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Capital Shares Reserved For Future Annual Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Capital Shares Reserved For Future Annual Issuance</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" xlink:label="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" xlink:to="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Capital Shares Reserved For Future Issuance, Percentage Of Shares Outstanding Last Day Of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Capital Shares Reserved For Future Issuance, Percentage Of Shares Outstanding Last Day Of Fiscal Year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Participants vesting period in share based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value, Options (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value, Equity Instruments (per share)</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of inducement restricted stock units outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Inducement Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of outstanding options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of exercisable options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period for recognition of unrecognized expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canceled/forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted ( in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canceled/forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term, Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Early exercised stock options, Unvested balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Early exercised stock options, Unvested balance at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canceled/forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EmployeeStockPurchasePlan2019Member" xlink:label="tela_EmployeeStockPurchasePlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_EmployeeStockPurchasePlan2019Member" xlink:to="tela_EmployeeStockPurchasePlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_EmployeeStockPurchasePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2019 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_EmployeeStockPurchasePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan 2019</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum contribution of participant (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employer's contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employer's contribution to employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of employer's contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Requisite Service Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of conditional annual increase to shares authorized or reserved for issuance under the share based payment arrangement plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Conditional Annual Increase To Number Of Shares Authorized Or Reserved For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in number of shares</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of shares outstanding on the final day of the immediately preceding calendar year, which will be the conditional annual increase to the number of shares authorized or reserved for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Annual Conditional Increase, Percentage Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in percentage of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" xlink:label="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" xlink:to="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the discount on purchase of common stock under the employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Discount On Purchase Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount on purchase of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxAssetsLeaseLiability" xlink:label="tela_DeferredTaxAssetsLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_DeferredTaxAssetsLeaseLiability" xlink:to="tela_DeferredTaxAssetsLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to  lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="tela_DeferredTaxLiabilitiesDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="tela_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to  depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tela_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="tela_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="tela_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to Right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tela_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NetDeferredTaxAssetBeforeValuationAllowance" xlink:label="tela_NetDeferredTaxAssetBeforeValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_NetDeferredTaxAssetBeforeValuationAllowance" xlink:to="tela_NetDeferredTaxAssetBeforeValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_NetDeferredTaxAssetBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_NetDeferredTaxAssetBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Deferred Tax Asset Before Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="tela_NetDeferredTaxAssetBeforeValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset before valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax benefit at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State rate, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee retention payroll tax credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Purchase Commitment [Table]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherSuppliersForExclusivityRightsMember" xlink:label="tela_OtherSuppliersForExclusivityRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OtherSuppliersForExclusivityRightsMember" xlink:to="tela_OtherSuppliersForExclusivityRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OtherSuppliersForExclusivityRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Other Suppliers for Exclusivity Rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OtherSuppliersForExclusivityRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Suppliers for Exclusivity Rights [Member]</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NextScienceMember" xlink:label="tela_NextScienceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_NextScienceMember" xlink:to="tela_NextScienceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_NextScienceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Next Science.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_NextScienceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next Science</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CollagenMatrixInc.Member" xlink:label="tela_CollagenMatrixInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_CollagenMatrixInc.Member" xlink:to="tela_CollagenMatrixInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_CollagenMatrixInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Collagen Matrix, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_CollagenMatrixInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collagen Matrix, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_CollagenMatrixInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collagen Matrix, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">European territory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NorthAmericaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">North American territory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA" xlink:label="stpr_PA" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_PA" xlink:to="stpr_PA_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_PA_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pennsylvania</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OfficeAndLaboratorySpaceLeaseMember" xlink:label="tela_OfficeAndLaboratorySpaceLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OfficeAndLaboratorySpaceLeaseMember" xlink:to="tela_OfficeAndLaboratorySpaceLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OfficeAndLaboratorySpaceLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to office and laboratory space lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OfficeAndLaboratorySpaceLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect, Period of Adoption [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect, Period of Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect, Period of Adoption, Adjustment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASU 2016-02</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Purchase Commitment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingencies and Commitments</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueBasedMilestonePayment" xlink:label="tela_RevenueBasedMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_RevenueBasedMilestonePayment" xlink:to="tela_RevenueBasedMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_RevenueBasedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for agreement under the terms of agreement entered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_RevenueBasedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Based Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_RevenueBasedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for agreement</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" xlink:label="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" xlink:to="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment under the terms of agreement entered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Based Milestone Payment Upon Achievement Of Cumulative Product Sales Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate future payments</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" xlink:label="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" xlink:to="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments related to research and development arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments related to research and development arrangements</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SalesMilestonePayment" xlink:label="tela_SalesMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_SalesMilestonePayment" xlink:to="tela_SalesMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_SalesMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone Payment made.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_SalesMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_SalesMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone payment</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SalesMilestonePaymentDue" xlink:label="tela_SalesMilestonePaymentDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_SalesMilestonePaymentDue" xlink:to="tela_SalesMilestonePaymentDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_SalesMilestonePaymentDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone Payment due when cumulative product sales in the North American territory reach certain amounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_SalesMilestonePaymentDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Milestone Payment Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_SalesMilestonePaymentDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone payments due</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_TransferPriceForProductProduced" xlink:label="tela_TransferPriceForProductProduced" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_TransferPriceForProductProduced" xlink:to="tela_TransferPriceForProductProduced_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_TransferPriceForProductProduced_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage increase above Counterparty's cost of good sold for product purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_TransferPriceForProductProduced_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer Price For Product Produced</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_FixedCostOfNetSales" xlink:label="tela_FixedCostOfNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_FixedCostOfNetSales" xlink:to="tela_FixedCostOfNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_FixedCostOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Cost Of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_FixedCostOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Cost Of Net Sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase commitments</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PurchaseObligationDueInSixthYear" xlink:label="tela_PurchaseObligationDueInSixthYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_PurchaseObligationDueInSixthYear" xlink:to="tela_PurchaseObligationDueInSixthYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_PurchaseObligationDueInSixthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum amount of purchase arrangement maturing in the sixth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_PurchaseObligationDueInSixthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation, Due in Sixth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_PurchaseObligationDueInSixthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase commitments due year Six</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" xlink:to="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days for supply of the products ordered , in case of supply failure occurs, the Company to step in and operate Aroa's plant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision To Step In Plant In Case Of Supply Failure Supply Period Under Binding Purchase Order</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days for product supply</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" xlink:to="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of product ordered to be supplied within specified period, in case of supply failure occurs, the Company to step in and operate Aroa's plant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision To Step In Plant In Case of Supply Failure, Percentage of product supply Under Binding Purchase Order</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of products ordered to be supplied</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfRoyaltyOfNetSales" xlink:label="tela_PercentageOfRoyaltyOfNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_PercentageOfRoyaltyOfNetSales" xlink:to="tela_PercentageOfRoyaltyOfNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_PercentageOfRoyaltyOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Royalty of net sales in lieu of 27% of net sales of the licensed products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_PercentageOfRoyaltyOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Royalty Of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_PercentageOfRoyaltyOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty percentage of net sales</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherCommitmentsTermOfContract" xlink:label="tela_OtherCommitmentsTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_OtherCommitmentsTermOfContract" xlink:to="tela_OtherCommitmentsTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_OtherCommitmentsTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of Contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_OtherCommitmentsTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments, Term Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_OtherCommitmentsTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of Contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term of operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" xlink:label="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" xlink:to="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred rent and tenant allowance netted against operating lease right-of-use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent And Tenant Allowance, Netted Against Operating Lease Right-of-use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent and tenant allowance netted off against right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease payments made</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases, Operating [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022/2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023/2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024/2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025/2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026/2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>tela-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2023 8:23:45 PM-->
<!--Modified on: 3/23/2023 8:23:45 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.telabio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.telabio.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureBackground" roleURI="http://www.telabio.com/role/DisclosureBackground" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureRisksAndLiquidity" roleURI="http://www.telabio.com/role/DisclosureRisksAndLiquidity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.telabio.com/role/DisclosurePropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebt" roleURI="http://www.telabio.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://www.telabio.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.telabio.com/role/DisclosureEmployeeBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.telabio.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.telabio.com/role/DisclosurePropertyAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebtTables" roleURI="http://www.telabio.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.telabio.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureRisksAndLiquidityDetails" roleURI="http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails" roleURI="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebtScheduleOfLongTermDebtDetails" roleURI="http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebtMidcapTermLoanDetails" roleURI="http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureDebtOrbimedTermLoanRelatedPartyDetails" roleURI="http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockholdersEquityPublicStockOfferingsDetails" roleURI="http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockholdersEquityWarrantsOutstandingDetails" roleURI="http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationNarrativesDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationExpensesDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureEmployeeBenefitPlansDetails" roleURI="http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxesNolCarryforwardsDetails" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxesRateReconciliationDetails" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureIncomeTaxesNarrativesDetails" roleURI="http://www.telabio.com/role/DisclosureIncomeTaxesNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tela-20221231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.telabio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638151998238593995" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638151998238593995" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638151998238593995" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638151998238593995" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638151998238593995" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638151998238593995" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638151998238593995" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638151998238593995" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638151998238593995" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638151998238593995" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638151998238593995" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638151998238593995" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638151998238593995" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638151998238603984" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638151998238603984" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638151998238603984" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638151998238603984" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638151998238603984" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638151998238603984" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638151998238603984" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638151998238603984" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638151998238603984" order="21" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638151998238603984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638151998238603984" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638151998238613977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638151998238613977" order="23" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638151998238613977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638151998238613977" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638151998238613977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638151998238613977" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638151998238613977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638151998238613977" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638151998238613977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638151998238613977" order="27" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638151998238613977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638151998238613977" order="28" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638151998238613977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638151998238613977" order="29" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638151998238623980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638151998238623980" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638151998238623980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638151998238623980" order="31" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638151998238623980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638151998238623980" order="32" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638151998238623980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638151998238623980" order="33" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638151998238623980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638151998238623980" order="34" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638151998238623980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638151998238623980" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638151998238623980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638151998238623980" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638151998238623980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638151998238623980" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638151998238633977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151998238633977" xlink:to="us-gaap_AssetsCurrentAbstract_638151998238633977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151998238633977" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638151998238633977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151998238633977" xlink:to="us-gaap_ReceivablesNetCurrent_638151998238633977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151998238633977" xlink:to="us-gaap_InventoryNet_638151998238633977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151998238633977" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638151998238633977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638151998238633977" xlink:to="us-gaap_AssetsCurrent_638151998238633977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151998238633977" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638151998238633977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638151998238633977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151998238633977" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638151998238633977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151998238633977" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638151998238643980" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638151998238633977" xlink:to="us-gaap_Assets_638151998238643980" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151998238643980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151998238643980" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638151998238643980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151998238643980" xlink:to="us-gaap_AccountsPayableCurrent_638151998238643980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151998238643980" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638151998238643980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638151998238643980" xlink:to="us-gaap_LiabilitiesCurrent_638151998238643980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151998238643980" xlink:to="us-gaap_LongTermDebtNoncurrent_638151998238643980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151998238643980" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_638151998238643980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151998238643980" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638151998238643980" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638151998238643980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151998238643980" xlink:to="us-gaap_Liabilities_638151998238643980" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638151998238653977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638151998238643980" xlink:to="us-gaap_StockholdersEquityAbstract_638151998238653977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638151998238653977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151998238653977" xlink:to="us-gaap_PreferredStockValue_638151998238653977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638151998238653977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151998238653977" xlink:to="us-gaap_CommonStockValue_638151998238653977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638151998238653977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151998238653977" xlink:to="us-gaap_AdditionalPaidInCapital_638151998238653977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638151998238653977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151998238653977" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638151998238653977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638151998238653977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151998238653977" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638151998238653977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638151998238653977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151998238653977" xlink:to="us-gaap_StockholdersEquity_638151998238653977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638151998238653977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638151998238653977" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638151998238653977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638151998238663978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638151998238663978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638151998238663978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638151998238663978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638151998238663978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638151998238663978" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638151998238663978" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638151998238663978" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638151998238663978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_638151998238663978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998238663978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998238663978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit_638151998238673979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638151998238673979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638151998238673979" xlink:to="us-gaap_SellingAndMarketingExpense_638151998238673979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638151998238673979" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638151998238673979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638151998238673979" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638151998238673979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638151998238673979" xlink:to="us-gaap_OperatingExpenses_638151998238673979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638151998238673979" xlink:to="us-gaap_OperatingIncomeLoss_638151998238673979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638151998238673979" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638151998238673979" xlink:to="us-gaap_InterestExpense_638151998238673979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638151998238673979" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151998238673979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638151998238673979" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638151998238673979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638151998238673979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638151998238673979" xlink:to="us-gaap_NonoperatingIncomeExpense_638151998238673979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151998238683979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638151998238683979" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638151998238683979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638151998238683979" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638151998238683979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638151998238683979" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638151998238683979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638151998238683979" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638151998238683979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638151998238683979" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638151998238683979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638151998238683979" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6381519982386839791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638151998238683979" xlink:to="us-gaap_NetIncomeLoss_6381519982386839791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638151998238683979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638151998238683979" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638151998238683979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638151998238683979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638151998238683979" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638151998238683979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638151998238693979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151998238693979" xlink:to="us-gaap_StatementEquityComponentsAxis_638151998238693979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151998238693979" xlink:to="us-gaap_CommonStockMember_638151998238693979" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151998238693979" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638151998238693979" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151998238693979" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638151998238693979" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151998238693979" xlink:to="us-gaap_RetainedEarningsMember_638151998238693979" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638151998238693979" xlink:to="us-gaap_EquityComponentDomain_638151998238693979" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638151998238693979" xlink:to="us-gaap_StatementLineItems_638151998238693979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_StockholdersEquity_638151998238693979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_SharesOutstanding_638151998238693979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_638151998238693979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_638151998238693979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_638151998238693979" xlink:to="tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_638151998238703982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638151998238703982" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638151998238703982" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151998238703982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638151998238703982" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638151998238703982" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638151998238703982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638151998238703982" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638151998238703982" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_638151998238703982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638151998238703982" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638151998238703982" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation" xlink:label="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation_638151998238703982" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638151998238703982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638151998238703982" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151998238713978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638151998238703982" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151998238713978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638151998238713978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_NetIncomeLoss_638151998238713978" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638151998238713978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_StockholdersEquity_638151998238713978" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638151998238713978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638151998238693979" xlink:to="us-gaap_SharesOutstanding_638151998238713978" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638151998238713978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_ProfitLoss_638151998238713978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_Depreciation_638151998238723982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_PaidInKindInterest_638151998238723982" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NoncashLossOnExtinguishmentOfDebt" xlink:label="tela_NoncashLossOnExtinguishmentOfDebt_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="tela_NoncashLossOnExtinguishmentOfDebt_638151998238723982" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998238723982" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities_638151998238723982" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_InventoryWriteDown_638151998238723982" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_ShareBasedCompensation_638151998238723982" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638151998238723982" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151998238723982" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151998238723982" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638151998238723982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151998238723982" xlink:to="us-gaap_IncreaseDecreaseInInventories_638151998238723982" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638151998238723982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151998238723982" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638151998238723982" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151998238723982" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638151998238733977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151998238723982" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638151998238733977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638151998238723982" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638151998238733977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638151998238713978" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638151998238733977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151998238733977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_638151998238733977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638151998238733977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638151998238733977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638151998238733977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638151998238743977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638151998238743977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638151998238743977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638151998238743977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638151998238743977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638151998238743977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638151998238743977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_PaymentsOfFinancingCosts_638151998238743977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638151998238743977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638151998238743977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638151998238743977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638151998238743977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638151998238743977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638151998238743977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638151998238743977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_ProceedsFromStockPlans_638151998238743977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998238753978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638151998238733977" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638151998238753978" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638151998238753978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638151998238753978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638151998238753978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638151998238753978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638151998238753978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638151998238753978" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381519982387539781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381519982387539781" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638151998238753978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638151998238753978" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638151998238753978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638151998238753978" xlink:to="us-gaap_InterestPaidNet_638151998238753978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638151998238763976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638151998238763976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_638151998238763976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" xlink:to="us-gaap_StockIssued1_638151998238763976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities_638151998238763976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" xlink:to="tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities_638151998238763976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified" xlink:label="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified_638151998238763976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" xlink:to="tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified_638151998238763976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638151998238763976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638151998238763976" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities" xlink:label="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities_638151998238773977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" xlink:to="tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities_638151998238773977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OperatingLeaseObligationAssumed" xlink:label="tela_OperatingLeaseObligationAssumed_638151998238773977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638151998238763976" xlink:to="tela_OperatingLeaseObligationAssumed_638151998238773977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureBackground" xlink:type="extended" xlink:title="10101 - Disclosure - Background" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638151998238773977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638151998238773977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureRisksAndLiquidity" xlink:type="extended" xlink:title="10201 - Disclosure - Risks and Liquidity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_638151998238773977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_638151998238773977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638151998238783985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638151998238783985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10401 - Disclosure - Property and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638151998238783985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638151998238783985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses and Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638151998238783985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638151998238783985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureDebt" xlink:type="extended" xlink:title="10601 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_638151998238783985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_638151998238783985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10701 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638151998238793984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638151998238793984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10801 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638151998238793984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638151998238793984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="10901 - Disclosure - Employee Benefit Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638151998238793984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638151998238793984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11001 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638151998238793984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638151998238793984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11101 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638151998238803986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11201 - Disclosure - Related-Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638151998238803986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638151998238803986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638151998238803986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638151998238803986" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638151998238803986" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638151998238803986" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638151998238803986" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638151998238803986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638151998238803986" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_638151998238813980" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638151998238813980" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638151998238813980" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638151998238813980" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638151998238813980" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638151998238813980" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638151998238813980" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638151998238813980" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638151998238813980" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638151998238813980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638151998238813980" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638151998238823979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638151998238823979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638151998238823979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638151998238823979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638151998238823979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638151998238823979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30403 - Disclosure - Property and Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638151998238823979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638151998238823979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638151998238823979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638151998238823979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="30603 - Disclosure - Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_638151998238833982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_638151998238833982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638151998238833982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638151998238833982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30803 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638151998238833982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638151998238833982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638151998238833982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638151998238833982" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_638151998238833982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_638151998238833982" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_638151998238833982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_638151998238833982" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638151998238833982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638151998238833982" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638151998238843981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638151998238843981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_638151998238843981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_638151998238843981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638151998238843981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638151998238843981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31103 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638151998238843981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638151998238843981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Risks and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyTable" xlink:label="us-gaap_UnusualRiskOrUncertaintyTable_638151998238843981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_UnusualRiskOrUncertaintyTable_638151998238843981" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638151998238843981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyTable_638151998238843981" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638151998238843981" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638151998238843981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151998238843981" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638151998238843981" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638151998238853983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151998238843981" xlink:to="us-gaap_OverAllotmentOptionMember_638151998238853983" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:label="us-gaap_UnusualRiskOrUncertaintyLineItems_638151998238853983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyTable_638151998238843981" xlink:to="us-gaap_UnusualRiskOrUncertaintyLineItems_638151998238853983" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638151998238853983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems_638151998238853983" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638151998238853983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151998238853983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems_638151998238853983" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151998238853983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638151998238853983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems_638151998238853983" xlink:to="us-gaap_SharesIssuedPricePerShare_638151998238853983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638151998238853983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyLineItems_638151998238853983" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638151998238853983" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies - Segments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_638151998238853983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_638151998238853983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638151998238853983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_638151998238853983" xlink:to="us-gaap_NumberOfOperatingSegments_638151998238853983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGrossAbstract" xlink:label="us-gaap_InventoryGrossAbstract_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryGrossAbstract_638151998238863984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:label="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryGrossAbstract_638151998238863984" xlink:to="us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_638151998238863984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_638151998238863984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_638151998238863984" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_638151998238863984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_638151998238863984" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638151998238863984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_638151998238863984" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638151998238863984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638151998238863984" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638151998238863984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638151998238863984" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638151998238863984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638151998238863984" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638151998238863984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638151998238863984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638151998238863984" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638151998238863984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638151998238873987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638151998238863984" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638151998238873987" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638151998238873987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638151998238863984" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638151998238873987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Summary of Significant Accounting Policies - Long-Lived Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract_638151998238873987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_638151998238873987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638151998238873987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract_638151998238873987" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638151998238873987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Summary of Significant Accounting Policies - Revenue Disaggregated (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638151998238873987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638151998238873987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638151998238873987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638151998238873987" xlink:to="srt_MajorCustomersAxis_638151998238873987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638151998238873987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638151998238873987" xlink:to="srt_NameOfMajorCustomerDomain_638151998238873987" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OvitexMember" xlink:label="tela_OvitexMember_638151998238873987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638151998238873987" xlink:to="tela_OvitexMember_638151998238873987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OvitexPrsMember" xlink:label="tela_OvitexPrsMember_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638151998238873987" xlink:to="tela_OvitexPrsMember_638151998238883983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherCustomersMember" xlink:label="tela_OtherCustomersMember_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638151998238873987" xlink:to="tela_OtherCustomersMember_638151998238883983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638151998238873987" xlink:to="srt_StatementGeographicalAxis_638151998238883983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638151998238883983" xlink:to="srt_SegmentGeographicalDomain_638151998238883983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638151998238883983" xlink:to="us-gaap_NonUsMember_638151998238883983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638151998238873987" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638151998238883983" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638151998238883983" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638151998238883983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_IncrementalCostsOfObtainingContract" xlink:label="tela_IncrementalCostsOfObtainingContract_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638151998238883983" xlink:to="tela_IncrementalCostsOfObtainingContract_638151998238883983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage" xlink:label="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638151998238883983" xlink:to="tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage_638151998238883983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Summary of Significant Accounting Policies - Fair value of financial instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638151998238883983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638151998238883983" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638151998238883983" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638151998238893980" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638151998238893980" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638151998238893980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638151998238893980" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638151998238893980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638151998238883983" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638151998238893980" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638151998238893980" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638151998238893980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638151998238893980" xlink:to="us-gaap_FairValueInputsLevel1Member_638151998238893980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638151998238883983" xlink:to="us-gaap_FinancialInstrumentAxis_638151998238893980" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638151998238893980" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638151998238893980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638151998238893980" xlink:to="us-gaap_MoneyMarketFundsMember_638151998238893980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638151998238883983" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638151998238893980" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638151998238893980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638151998238893980" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638151998238893980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Summary of Significant Accounting Policies - Net loss per share (Potentially dilutive securities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151998238903981" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151998238903981" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638151998238903981" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638151998238903981" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638151998238903981" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638151998238903981" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638151998238903981" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsMember" xlink:label="tela_CommonStockWarrantsMember_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638151998238903981" xlink:to="tela_CommonStockWarrantsMember_638151998238903981" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151998238903981" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638151998238903981" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638151998238903981" xlink:to="us-gaap_DerivativeContractTypeDomain_638151998238903981" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638151998238903981" xlink:to="us-gaap_StockOptionMember_638151998238903981" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638151998238903981" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638151998238903981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638151998238903981" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638151998238903981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151998238903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151998238903981" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151998238903981" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151998238913978" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151998238913978" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998238913978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_LabEquipmentMember" xlink:label="tela_LabEquipmentMember_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998238913978" xlink:to="tela_LabEquipmentMember_638151998238913978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998238913978" xlink:to="us-gaap_FurnitureAndFixturesMember_638151998238913978" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ComputerEquipmentAndSoftwareMember" xlink:label="tela_ComputerEquipmentAndSoftwareMember_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998238913978" xlink:to="tela_ComputerEquipmentAndSoftwareMember_638151998238913978" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998238913978" xlink:to="us-gaap_LeaseholdImprovementsMember_638151998238913978" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151998238903981" xlink:to="srt_CounterpartyNameAxis_638151998238913978" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638151998238913978" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638151998238913978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AgreementWithAroaMember" xlink:label="tela_AgreementWithAroaMember_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638151998238913978" xlink:to="tela_AgreementWithAroaMember_638151998238913978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638151998238903981" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638151998238913978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151998238913978" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638151998238913978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151998238913978" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638151998238913978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638151998238913978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151998238913978" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638151998238913978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151998238913978" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638151998238923979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638151998238913978" xlink:to="us-gaap_Depreciation_638151998238923979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638151998238923979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638151998238923979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AccruedExpensesAmountDueToContractManufacturer" xlink:label="tela_AccruedExpensesAmountDueToContractManufacturer_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tela_AccruedExpensesAmountDueToContractManufacturer_638151998238923979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151998238923979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ResearchAndDevelopmentExpensesPayableCurrent" xlink:label="tela_ResearchAndDevelopmentExpensesPayableCurrent_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tela_ResearchAndDevelopmentExpensesPayableCurrent_638151998238923979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638151998238923979" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638151998238923979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638151998238923979" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Debt - Schedule of long term debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638151998238933981" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238933981" xlink:to="us-gaap_LongtermDebtTypeAxis_638151998238933981" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638151998238933981" xlink:to="us-gaap_LongtermDebtTypeDomain_638151998238933981" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoansMember" xlink:label="tela_MidcapTermLoansMember_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638151998238933981" xlink:to="tela_MidcapTermLoansMember_638151998238933981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoanMember" xlink:label="tela_OrbimedTermLoanMember_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638151998238933981" xlink:to="tela_OrbimedTermLoanMember_638151998238933981" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238933981" xlink:to="us-gaap_DebtInstrumentLineItems_638151998238933981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238933981" xlink:to="us-gaap_DebtInstrumentFaceAmount_638151998238933981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238933981" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_638151998238933981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238933981" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638151998238933981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238933981" xlink:to="us-gaap_LongTermDebt_638151998238933981" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Debt - MidCap Term Loan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638151998238933981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638151998238933981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238933981" xlink:to="us-gaap_LongtermDebtTypeAxis_638151998238943979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638151998238943979" xlink:to="us-gaap_LongtermDebtTypeDomain_638151998238943979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoansMember" xlink:label="tela_MidcapTermLoansMember_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638151998238943979" xlink:to="tela_MidcapTermLoansMember_638151998238943979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoanTrancheOneMember" xlink:label="tela_MidcapTermLoanTrancheOneMember_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tela_MidcapTermLoansMember_638151998238943979" xlink:to="tela_MidcapTermLoanTrancheOneMember_638151998238943979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MidcapTermLoanTrancheTwoMember" xlink:label="tela_MidcapTermLoanTrancheTwoMember_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tela_MidcapTermLoansMember_638151998238943979" xlink:to="tela_MidcapTermLoanTrancheTwoMember_638151998238943979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238933981" xlink:to="us-gaap_VariableRateAxis_638151998238943979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638151998238943979" xlink:to="us-gaap_VariableRateDomain_638151998238943979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638151998238943979" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638151998238943979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238933981" xlink:to="srt_StatementScenarioAxis_638151998238943979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638151998238943979" xlink:to="srt_ScenarioUnspecifiedDomain_638151998238943979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_FirstYearMember" xlink:label="tela_FirstYearMember_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638151998238943979" xlink:to="tela_FirstYearMember_638151998238943979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SecondYearMember" xlink:label="tela_SecondYearMember_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638151998238943979" xlink:to="tela_SecondYearMember_638151998238943979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ThirdYearMember" xlink:label="tela_ThirdYearMember_638151998238943979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638151998238943979" xlink:to="tela_ThirdYearMember_638151998238943979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238933981" xlink:to="srt_RangeAxis_638151998238953978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638151998238953978" xlink:to="srt_RangeMember_638151998238953978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638151998238953978" xlink:to="srt_MaximumMember_638151998238953978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638151998238953978" xlink:to="srt_MinimumMember_638151998238953978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238933981" xlink:to="us-gaap_DebtInstrumentLineItems_638151998238953978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="us-gaap_DebtInstrumentFaceAmount_638151998238953978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EligibilityRequirementToBorrowTranche2" xlink:label="tela_EligibilityRequirementToBorrowTranche2_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="tela_EligibilityRequirementToBorrowTranche2_638151998238953978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_InterestPenaltyPercentage" xlink:label="tela_InterestPenaltyPercentage_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="tela_InterestPenaltyPercentage_638151998238953978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638151998238953978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638151998238953978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638151998238953978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DebtInstrumentInterestPaymentTerm" xlink:label="tela_DebtInstrumentInterestPaymentTerm_638151998238963976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="tela_DebtInstrumentInterestPaymentTerm_638151998238963976" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AdditionalExtensionForInterestOnlyPaymentPeriod" xlink:label="tela_AdditionalExtensionForInterestOnlyPaymentPeriod_638151998238963976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="tela_AdditionalExtensionForInterestOnlyPaymentPeriod_638151998238963976" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount_638151998238963976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount_638151998238963976" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2_638151998238963976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2_638151998238963976" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfExitFee" xlink:label="tela_PercentageOfExitFee_638151998238963976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="tela_PercentageOfExitFee_638151998238963976" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638151998238963976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="us-gaap_InterestExpenseDebt_638151998238963976" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_638151998238963976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238953978" xlink:to="us-gaap_AmortizationOfFinancingCosts_638151998238963976" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Debt - OrbiMed Term Loan (related party) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638151998238973978" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238973978" xlink:to="us-gaap_DebtInstrumentAxis_638151998238973978" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638151998238973978" xlink:to="us-gaap_DebtInstrumentNameDomain_638151998238973978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoanMember" xlink:label="tela_OrbimedTermLoanMember_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638151998238973978" xlink:to="tela_OrbimedTermLoanMember_638151998238973978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoansTrancheOneMember" xlink:label="tela_OrbimedTermLoansTrancheOneMember_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tela_OrbimedTermLoanMember_638151998238973978" xlink:to="tela_OrbimedTermLoansTrancheOneMember_638151998238973978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OrbimedTermLoansTrancheTwoMember" xlink:label="tela_OrbimedTermLoansTrancheTwoMember_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tela_OrbimedTermLoanMember_638151998238973978" xlink:to="tela_OrbimedTermLoansTrancheTwoMember_638151998238973978" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238973978" xlink:to="us-gaap_VariableRateAxis_638151998238973978" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638151998238973978" xlink:to="us-gaap_VariableRateDomain_638151998238973978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638151998238973978" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_638151998238973978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638151998238973978" xlink:to="us-gaap_DebtInstrumentLineItems_638151998238973978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="us-gaap_DebtInstrumentFaceAmount_638151998238973978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NumberOfTranches" xlink:label="tela_NumberOfTranches_638151998238973978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="tela_NumberOfTranches_638151998238973978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_InterestPenaltyPercentage" xlink:label="tela_InterestPenaltyPercentage_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="tela_InterestPenaltyPercentage_638151998238983978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638151998238983978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638151998238983978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DebtInstrumentInterestPaymentTerm" xlink:label="tela_DebtInstrumentInterestPaymentTerm_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="tela_DebtInstrumentInterestPaymentTerm_638151998238983978" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount" xlink:label="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount_638151998238983978" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfExitFee" xlink:label="tela_PercentageOfExitFee_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="tela_PercentageOfExitFee_638151998238983978" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EndOfTermCharge" xlink:label="tela_EndOfTermCharge_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="tela_EndOfTermCharge_638151998238983978" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638151998238983978" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="us-gaap_InterestExpenseDebt_638151998238983978" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_638151998238983978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638151998238973978" xlink:to="us-gaap_AmortizationOfFinancingCosts_638151998238983978" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders' Equity - Public Stock Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638151998238993975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638151998238993975" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638151998239063985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638151998238993975" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638151998239063985" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638151998239063985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638151998239063985" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638151998239063985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638151998239063985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151998239063985" xlink:to="us-gaap_OverAllotmentOptionMember_638151998239063985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SecondUnderwrittenPublicOfferingMember" xlink:label="tela_SecondUnderwrittenPublicOfferingMember_638151998239063985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151998239063985" xlink:to="tela_SecondUnderwrittenPublicOfferingMember_638151998239063985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityDistributionAgreementMember" xlink:label="tela_EquityDistributionAgreementMember_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638151998239063985" xlink:to="tela_EquityDistributionAgreementMember_638151998239074013" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638151998238993975" xlink:to="us-gaap_TemporaryEquityLineItems_638151998239074013" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638151998239074013" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638151998239074013" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638151998239074013" xlink:to="us-gaap_SharesIssuedPricePerShare_638151998239074013" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638151998239074013" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638151998239074013" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement" xlink:label="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638151998239074013" xlink:to="tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement_638151998239074013" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stockholders' Equity - Warrants outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638151998239074013" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638151998239074013" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638151998239074013" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638151998239074013" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638151998239074013" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsExpiringIn2028Member" xlink:label="tela_CommonStockWarrantsExpiringIn2028Member_638151998239074013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638151998239074013" xlink:to="tela_CommonStockWarrantsExpiringIn2028Member_638151998239074013" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockWarrantsExpiringIn2027Member" xlink:label="tela_CommonStockWarrantsExpiringIn2027Member_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638151998239074013" xlink:to="tela_CommonStockWarrantsExpiringIn2027Member_638151998239083983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638151998239074013" xlink:to="us-gaap_TemporaryEquityLineItems_638151998239083983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638151998239083983" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638151998239083983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638151998239083983" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638151998239083983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire" xlink:label="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638151998239083983" xlink:to="tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire_638151998239083983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stock-Based Compensation - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239083983" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239083983" xlink:to="us-gaap_PlanNameAxis_638151998239083983" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638151998239083983" xlink:to="us-gaap_PlanNameDomain_638151998239083983" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityIncentivePlan2019Member" xlink:label="tela_EquityIncentivePlan2019Member_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638151998239083983" xlink:to="tela_EquityIncentivePlan2019Member_638151998239083983" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239083983" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638151998239083983" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638151998239083983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638151998239083983" xlink:to="us-gaap_DerivativeContractTypeDomain_638151998239083983" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638151998239083983" xlink:to="us-gaap_StockOptionMember_638151998239093981" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638151998239083983" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638151998239093981" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239083983" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EquityIncentivePlansNumber" xlink:label="tela_EquityIncentivePlansNumber_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="tela_EquityIncentivePlansNumber_638151998239093981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638151998239093981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance" xlink:label="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance_638151998239093981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear" xlink:label="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear_638151998239093981" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638151998239093981" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_638151998239093981" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638151998239093981" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638151998239093981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638151998239093981" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod_638151998239103979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod_638151998239103979" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638151998239103979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638151998239103979" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638151998239103979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638151998239103979" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_638151998239103979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_638151998239103979" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638151998239103979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638151998239103979" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638151998239103979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239093981" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638151998239103979" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stock-Based Compensation - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239103979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239103979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638151998239103979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239103979" xlink:to="us-gaap_IncomeStatementLocationAxis_638151998239103979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638151998239103979" xlink:to="us-gaap_IncomeStatementLocationDomain_638151998239113980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638151998239113980" xlink:to="us-gaap_SellingAndMarketingExpenseMember_638151998239113980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638151998239113980" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638151998239113980" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638151998239113980" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638151998239113980" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239103979" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239113980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239113980" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638151998239113980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638151998239113980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638151998239113980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151998239113980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638151998239113980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638151998239123983" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638151998239123983" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638151998239123983" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638151998239113980" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638151998239123983" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638151998239123983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638151998239123983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638151998239123983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638151998239123983" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381519982391239831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381519982391239831" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638151998239123983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638151998239123983" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638151998239133978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638151998239123983" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638151998239133978" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151998239133978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151998239133978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638151998239133978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151998239133978" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638151998239133978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638151998239133978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151998239133978" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638151998239133978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638151998239133978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638151998239133978" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638151998239133978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Stock-Based Compensation - Early Exercise Of Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638151998239133978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638151998239133978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638151998239133978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638151998239133978" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638151998239133978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638151998239133978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638151998239133978" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638151998239133978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_638151998239143979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638151998239133978" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_638151998239143979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638151998239143979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638151998239133978" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638151998239143979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Stock-Based Compensation - Weighted average assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638151998239143979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638151998239143979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638151998239143979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638151998239143979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638151998239143979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638151998239143979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638151998239143979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638151998239143979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="40806 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239143979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239143979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_638151998239143979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239143979" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_638151998239143979" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_638151998239143979" xlink:to="us-gaap_DerivativeContractTypeDomain_638151998239153984" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_638151998239153984" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638151998239153984" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638151998239143979" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239153984" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239153984" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638151998239153984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239153984" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638151998239153984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239153984" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638151998239153984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239153984" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638151998239153984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381519982391539841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638151998239153984" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381519982391539841" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Employee Benefit Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638151998239153984" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638151998239153984" xlink:to="us-gaap_PlanNameAxis_638151998239153984" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638151998239153984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638151998239153984" xlink:to="us-gaap_PlanNameDomain_638151998239153984" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EmployeeStockPurchasePlan2019Member" xlink:label="tela_EmployeeStockPurchasePlan2019Member_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638151998239153984" xlink:to="tela_EmployeeStockPurchasePlan2019Member_638151998239163982" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638151998239153984" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638151998239163982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638151998239163982" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638151998239163982" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638151998239163982" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638151998239163982" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_638151998239163982" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638151998239163982" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance_638151998239163982" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding" xlink:label="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding_638151998239163982" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock" xlink:label="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock_638151998239163982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock_638151998239163982" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638151998239163982" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638151998239173978" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638151998239173978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638151998239173978" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638151998239173978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638151998239173978" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638151998239173978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxAssetsLeaseLiability" xlink:label="tela_DeferredTaxAssetsLeaseLiability_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638151998239173978" xlink:to="tela_DeferredTaxAssetsLeaseLiability_638151998239173978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638151998239173978" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638151998239173978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638151998239173978" xlink:to="us-gaap_DeferredTaxAssetsInventory_638151998239173978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638151998239173978" xlink:to="us-gaap_DeferredTaxAssetsGross_638151998239173978" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638151998239173978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="tela_DeferredTaxLiabilitiesDepreciationAndAmortization_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638151998239173978" xlink:to="tela_DeferredTaxLiabilitiesDepreciationAndAmortization_638151998239173978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="tela_DeferredTaxLiabilitiesRightOfUseAsset_638151998239173978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638151998239173978" xlink:to="tela_DeferredTaxLiabilitiesRightOfUseAsset_638151998239173978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638151998239173978" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638151998239183980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NetDeferredTaxAssetBeforeValuationAllowance" xlink:label="tela_NetDeferredTaxAssetBeforeValuationAllowance_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638151998239173978" xlink:to="tela_NetDeferredTaxAssetBeforeValuationAllowance_638151998239183980" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638151998239173978" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638151998239183980" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638151998239183980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - NOL carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637130567891618609" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637130567891618609" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638151998239183980" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638151998239183980" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638151998239183980" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638151998239183980" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638151998239183980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638151998239183980" xlink:to="us-gaap_DomesticCountryMember_638151998239183980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638151998239183980" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638151998239183980" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638151998239183980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638151998239183980" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638151998239183980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151998239183980" xlink:to="us-gaap_OperatingLossCarryforwards_638151998239193979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638151998239183980" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638151998239193979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Rate reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637135839707441451" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637135839707441451" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638151998239193979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638151998239193979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" xlink:to="tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638151998239193979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638151998239193979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638151998239193979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638151998239193979" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638151998239193979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638151998239193979" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638151998239193979" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureIncomeTaxesNarrativesDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Income Taxes - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638151998239203980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638151998239203980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638151998239203980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638151998239203980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_638151998239203980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_638151998239203980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_638151998239203980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTable_638151998239203980" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638151998239203980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable_638151998239203980" xlink:to="srt_CounterpartyNameAxis_638151998239203980" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638151998239203980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638151998239203980" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638151998239203980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_AgreementWithAroaMember" xlink:label="tela_AgreementWithAroaMember_638151998239203980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638151998239203980" xlink:to="tela_AgreementWithAroaMember_638151998239203980" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherSuppliersForExclusivityRightsMember" xlink:label="tela_OtherSuppliersForExclusivityRightsMember_638151998239203980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638151998239203980" xlink:to="tela_OtherSuppliersForExclusivityRightsMember_638151998239203980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_NextScienceMember" xlink:label="tela_NextScienceMember_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638151998239203980" xlink:to="tela_NextScienceMember_638151998239213985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_CollagenMatrixInc.Member" xlink:label="tela_CollagenMatrixInc.Member_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638151998239203980" xlink:to="tela_CollagenMatrixInc.Member_638151998239213985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable_638151998239203980" xlink:to="srt_StatementGeographicalAxis_638151998239213985" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638151998239213985" xlink:to="srt_SegmentGeographicalDomain_638151998239213985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638151998239213985" xlink:to="srt_EuropeMember_638151998239213985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638151998239213985" xlink:to="srt_NorthAmericaMember_638151998239213985" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA" xlink:label="stpr_PA_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638151998239213985" xlink:to="stpr_PA_638151998239213985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable_638151998239203980" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151998239213985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638151998239213985" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998239213985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OfficeAndLaboratorySpaceLeaseMember" xlink:label="tela_OfficeAndLaboratorySpaceLeaseMember_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638151998239213985" xlink:to="tela_OfficeAndLaboratorySpaceLeaseMember_638151998239213985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable_638151998239203980" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638151998239213985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638151998239213985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638151998239213985" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638151998239213985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_638151998239213985" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638151998239223985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable_638151998239203980" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638151998239223985" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638151998239223985" xlink:to="us-gaap_TypeOfAdoptionMember_638151998239223985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638151998239223985" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_638151998239223985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable_638151998239203980" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueBasedMilestonePayment" xlink:label="tela_RevenueBasedMilestonePayment_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_RevenueBasedMilestonePayment_638151998239223985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets" xlink:label="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets_638151998239223985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements" xlink:label="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements_638151998239223985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SalesMilestonePayment" xlink:label="tela_SalesMilestonePayment_638151998239223985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_SalesMilestonePayment_638151998239223985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_SalesMilestonePaymentDue" xlink:label="tela_SalesMilestonePaymentDue_638151998239233979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_SalesMilestonePaymentDue_638151998239233979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_TransferPriceForProductProduced" xlink:label="tela_TransferPriceForProductProduced_638151998239233979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_TransferPriceForProductProduced_638151998239233979" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_FixedCostOfNetSales" xlink:label="tela_FixedCostOfNetSales_638151998239233979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_FixedCostOfNetSales_638151998239233979" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation_638151998239233979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_PurchaseObligation_638151998239233979" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PurchaseObligationDueInSixthYear" xlink:label="tela_PurchaseObligationDueInSixthYear_638151998239233979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_PurchaseObligationDueInSixthYear_638151998239233979" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder_638151998239233979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder_638151998239233979" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder" xlink:label="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder_638151998239233979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder_638151998239233979" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_PercentageOfRoyaltyOfNetSales" xlink:label="tela_PercentageOfRoyaltyOfNetSales_638151998239233979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_PercentageOfRoyaltyOfNetSales_638151998239233979" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_OtherCommitmentsTermOfContract" xlink:label="tela_OtherCommitmentsTermOfContract_638151998239243976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_OtherCommitmentsTermOfContract_638151998239243976" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638151998239243976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638151998239243976" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638151998239243976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638151998239243976" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638151998239243976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_OperatingLeaseLiability_638151998239243976" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638151998239243976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638151998239243976" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tela-20221231.xsd#tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset" xlink:label="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset_638151998239243976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset_638151998239243976" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638151998239243976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638151998239243976" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638151998239253976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_OperatingLeaseCost_638151998239253976" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638151998239253976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_OperatingLeasePayments_638151998239253976" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638151998239253976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638151998239253976" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638151998239253976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638151998239253976" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638151998239253976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_638151998239253976" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638151998239253976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638151998239253976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems_638151998239223985" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638151998239253976" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638151998239253976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent_638151998239253976" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638151998239253976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Commitments and Contingencies - Operating Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract_638151998239263979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_638151998239263979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638151998239263979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638151998239263979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638151998239263979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638151998239263979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638151998239263979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638151998239263979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638151998239263979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638151998239263979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638151998239263979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638151998239263979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638151998239263979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638151998239263979" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638151998239263979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638151998239263979" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638151998239273983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638151998239273983" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638151998239273983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_638151998239263979" xlink:to="us-gaap_OperatingLeaseLiability_638151998239273983" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091286240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 16, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TELA Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-5320061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Great Valley Parkway, Suite 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Malvern<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">320-2930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TELA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,216,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001561921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751093048768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 42,019<span></span>
</td>
<td class="nump">$ 43,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,621<span></span>
</td>
<td class="nump">4,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">11,792<span></span>
</td>
<td class="nump">7,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,015<span></span>
</td>
<td class="nump">3,232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">62,447<span></span>
</td>
<td class="nump">59,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">2,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,855<span></span>
</td>
<td class="nump">62,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">2,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,869<span></span>
</td>
<td class="nump">8,161<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,403<span></span>
</td>
<td class="nump">10,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">39,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Long-term debt with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">53,550<span></span>
</td>
<td class="nump">42,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.001 par value: 200,000,000 shares authorized; 19,165,027 and 14,529,606 shares issued and 19,165,027 and 14,529,577 shares outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">288,361<span></span>
</td>
<td class="nump">250,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">150<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(274,225)<span></span>
</td>
<td class="num">(229,929)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">14,305<span></span>
</td>
<td class="nump">20,098<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 67,855<span></span>
</td>
<td class="nump">$ 62,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091202016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">19,165,027<span></span>
</td>
<td class="nump">14,529,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">19,165,027<span></span>
</td>
<td class="nump">14,529,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090430320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 41,418<span></span>
</td>
<td class="nump">$ 29,463<span></span>
</td>
<td class="nump">$ 18,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue (excluding amortization of intangible assets)</a></td>
<td class="nump">13,570<span></span>
</td>
<td class="nump">10,346<span></span>
</td>
<td class="nump">6,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangible assets</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">27,044<span></span>
</td>
<td class="nump">18,813<span></span>
</td>
<td class="nump">11,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">43,252<span></span>
</td>
<td class="nump">29,062<span></span>
</td>
<td class="nump">22,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,862<span></span>
</td>
<td class="nump">12,459<span></span>
</td>
<td class="nump">10,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,937<span></span>
</td>
<td class="nump">6,743<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">66,051<span></span>
</td>
<td class="nump">48,264<span></span>
</td>
<td class="nump">36,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(39,007)<span></span>
</td>
<td class="num">(29,451)<span></span>
</td>
<td class="num">(25,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,051)<span></span>
</td>
<td class="num">(3,597)<span></span>
</td>
<td class="num">(3,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(1,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(5,289)<span></span>
</td>
<td class="num">(3,825)<span></span>
</td>
<td class="num">(3,519)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,296)<span></span>
</td>
<td class="num">$ (33,276)<span></span>
</td>
<td class="num">$ (28,794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="num">$ (2.30)<span></span>
</td>
<td class="num">$ (2.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="num">$ (2.30)<span></span>
</td>
<td class="num">$ (2.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">16,267,678<span></span>
</td>
<td class="nump">14,473,213<span></span>
</td>
<td class="nump">12,934,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">16,267,678<span></span>
</td>
<td class="nump">14,473,213<span></span>
</td>
<td class="nump">12,934,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,296)<span></span>
</td>
<td class="num">$ (33,276)<span></span>
</td>
<td class="num">$ (28,794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (44,094)<span></span>
</td>
<td class="num">$ (33,257)<span></span>
</td>
<td class="num">$ (28,846)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092769280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 198,829<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (167,859)<span></span>
</td>
<td class="nump">$ 30,962<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">11,406,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of common stock previously subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of common stock previously subject to repurchase (in shares)</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Vesting of share-based awards and exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Vesting of share-based awards and exercise of stock options (in shares)</a></td>
<td class="nump">27,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan (in shares)</a></td>
<td class="nump">2,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">44,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,794)<span></span>
</td>
<td class="num">(28,794)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Ending period at Dec. 31, 2020</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">245,736<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="num">(196,653)<span></span>
</td>
<td class="nump">49,026<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Ending period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">14,437,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of common stock previously subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of common stock previously subject to repurchase (in shares)</a></td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Vesting of share-based awards and exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Vesting of share-based awards and exercise of stock options (in shares)</a></td>
<td class="nump">89,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan (in shares)</a></td>
<td class="nump">3,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation', window );">Reclassification of liability-classified stock-based compensation awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,276)<span></span>
</td>
<td class="num">(33,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Ending period at Dec. 31, 2021</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">250,064<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(229,929)<span></span>
</td>
<td class="nump">20,098<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Ending period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">14,529,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of common stock previously subject to repurchase (in shares)</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Vesting of share-based awards and exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Vesting of share-based awards and exercise of stock options (in shares)</a></td>
<td class="nump">44,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan (in shares)</a></td>
<td class="nump">4,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for employee taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for employee taxes (in shares)</a></td>
<td class="num">(13,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">34,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares)</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,296)<span></span>
</td>
<td class="num">(44,296)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Ending period at Dec. 31, 2022</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 288,361<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="num">$ (274,225)<span></span>
</td>
<td class="nump">$ 14,305<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Ending period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">19,165,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustments to additional paid in capital resulting from reclassification of liability-classified stock based compensation to equity classified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been vesting of common stock previously subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock vesting of common stock previously subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092567104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (44,296)<span></span>
</td>
<td class="num">$ (33,276)<span></span>
</td>
<td class="num">$ (28,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash interest expense</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_NoncashLossOnExtinguishmentOfDebt', window );">Noncash loss on extinguishment of debt</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangible assets</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities', window );">Net changes in operating lease ROU assets and liabilities</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory excess and obsolescence charge</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,989<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">2,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(2,421)<span></span>
</td>
<td class="num">(1,553)<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(6,073)<span></span>
</td>
<td class="num">(5,194)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="num">(992)<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(884)<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
<td class="num">(2,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current and long-term liabilities</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(40,748)<span></span>
</td>
<td class="num">(30,432)<span></span>
</td>
<td class="num">(24,456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from the sale and maturity of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment for intangible asset</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(872)<span></span>
</td>
<td class="num">(627)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(1,872)<span></span>
</td>
<td class="num">(627)<span></span>
</td>
<td class="nump">9,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">34,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of debt financing costs</a></td>
<td class="num">(3,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of withholding taxes related to stock-based compensation to employees</a></td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">40,852<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="nump">44,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="num">(144)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(1,912)<span></span>
</td>
<td class="num">(30,463)<span></span>
</td>
<td class="nump">29,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">43,931<span></span>
</td>
<td class="nump">74,394<span></span>
</td>
<td class="nump">45,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">42,019<span></span>
</td>
<td class="nump">43,931<span></span>
</td>
<td class="nump">74,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">3,394<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities', window );">Liability-classified stock-based compensation in accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified', window );">Reclassification of liability-classified stock-based compensation awards to equity-classified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease ROU asset exchanged for operating lease liabilities</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities', window );">Tenant improvement and deferred rent reclassified to operating lease liabilities</a></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_OperatingLeaseObligationAssumed', window );">Operating lease liabilities assumed for operating lease ROU assets</a></td>
<td class="nump">$ 1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Classified Stock-Based Compensation In Accrued Expenses And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net changes in operating lease right-of-use assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_NoncashLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Loss On Extinguishment Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_NoncashLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_OperatingLeaseObligationAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in operating lease obligation assumed on exchange of operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_OperatingLeaseObligationAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of liability-classified stock-based compensation to equity-classified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tenant improvement and deferred rent exchanged for operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095341296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1)&#160;Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">TELA Bio,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on April&#160;17, 2012 and wholly owns TELA Bio Limited, a company incorporated in the United Kingdom. The Company is commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient&#8217;s own anatomy. OviTex Reinforced Tissue Matrix (&#8220;OviTex&#8221;), the Company&#8217;s first portfolio of products, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. OviTex PRS Reinforced Tissue Matrix (&#8220;OviTex PRS&#8221;), the Company&#8217;s second portfolio of products, addresses unmet needs in plastic and reconstructive surgery. The Company&#8217;s principal corporate office and research facility is located in Malvern, Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has been directly impacted by the COVID-19 pandemic since the onset of the pandemic in 2020. To date, among other impacts on the Company&#8217;s business related to the pandemic, physicians and their patients have been required by state mandates, or have chosen to, defer elective surgery procedures in which the Company&#8217;s products otherwise would be used. There remains uncertainty and lack of visibility regarding the Company&#8217;s near-term revenue growth prospects and product development plans due to the volatility in the frequency of surgical procedures using the Company&#8217;s products, including through labor and hospital staffing shortages and the allocation of hospital resources due to financial strain experienced during the COVID-19 pandemic. Although the Company continues to monitor developments related to hospital capacity and the volume of elective procedures, there is uncertainty regarding the pace to which surgical volumes will normalize to their pre-pandemic levels and the timing to address the backlog of deferred procedures. The full extent of the impact of the COVID-19 pandemic on the Company&#8217;s business, results of operations and financial condition, including revenue, expenses, manufacturing capability, supply chain integrity, staffing availability, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751177988080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Risks and Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2)&#160;Risks and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations to date have focused on commercializing products, developing and acquiring technology and assets, business planning, raising capital and organization and staffing. The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $274.2 million as of December 31, 2022. The Company anticipates incurring additional losses until such time, if ever, it can generate sufficient revenue from its products to cover its expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2022, the Company completed an underwritten public offering in which the Company issued and sold 4,600,000 shares of its common stock at a public offering price of $8.00 per share. The Company received net proceeds of $34.4 million after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The operations of the Company are subject to certain risks and uncertainties including, among others, the uncertainty of product development, the impact of macroeconomic conditions, including the COVID-19 pandemic, general economic uncertainty, including as a result of inflationary pressures and the measures undertaken by various governments to address them, banking instability, geopolitical factors such as the war in Ukraine, technological uncertainty, commercial acceptance of any developed products, alternative competing technologies, dependence on collaborative partners, uncertainty regarding patents and proprietary rights, comprehensive government regulations, and dependence on key personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095464816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3)&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principals of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of TELA Bio,&#160;Inc. and its wholly owned subsidiary TELA Bio Limited. All intercompany accounts and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company&#8217;s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash with high-credit-quality financial institutions and primarily invests in money market funds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (&#8220;SVB&#8221;) and appointed the FDIC as receiver. On March 12, 2023, the U.S. Department of the Treasury, the Federal Reserve and the FDIC released a joint statement confirming that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, on March 10, 2023, the Bank of England (the &#8220;BOE&#8221;) announced that it intended to seek the placement of Silicon Valley Bank UK Limited (&#8220;SVBUK&#8221;), an affiliate of SVB, into a Bank Insolvency Procedure, which ultimately results in the acquisition of SVBUK by HSBC UK Bank Plc (&#8220;HSBC") on March 13, 2023. The BOE confirmed that all depositors&#8217; money with SVBUK is safe and secure as a result of the transaction, and that operations at SVBUK would continue as normal.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the course of these events, a portion of the Company&#8217;s cash was held in accounts at SVB and SVBUK, with the remainder held at another high-credit-quality financial institution. We have recently established additional redundant accounts with another high-credit-quality financial institution to mitigate liquidity risk to our cash and cash equivalents from any further instability in the financial industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As described in Note&#160;11, the Company has licensed patents and other intellectual property from Aroa Biosurgery Ltd. (&#8220;Aroa&#8221;). As part of this agreement, Aroa is also the exclusive contract manufacturer of the Company&#8217;s OviTex portfolio of products. The inability of Aroa to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with Aroa, or an adverse change in their business, could materially impact future operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers cash equivalents to be highly liquid investments with maturities of three&#160;months or less from the date of purchase. Cash equivalents consist of investments in a money market fund. The Company&#8217;s cash and cash equivalents are carried at fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory consists of finished goods and is identified and tracked by lot and stated at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. The Company periodically analyzes its inventory levels and writes down inventory that has become obsolete or that has a cost basis in excess of its expected net realizable value based on expected customer demand. As of December 31, 2022 and 2021, the Company had $2.3&#160;million and $1.7&#160;million, respectively, in finished goods consigned to others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at the aggregate cost incurred to acquire and place the asset in service. Expenditures for routine maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Depreciation is provided over the estimated useful lives of the assets using the straight-line method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and milestone payments due related to licenses or commercialization rights prior to future economic benefit being established are recorded as research and development expenses. Milestone payments due related to licenses or commercialization rights after future economic benefit is established are recorded as intangible assets. In 2022, 2021 and 2020, the Company recorded $0.8 million, $0.3 million and $0.3 million of amortization expense, respectively, related to intangible assets. At December 31, 2022, the remaining life of intangible assets was 6.6&#160;years. The Company anticipates recognizing amortization expense of $0.4&#160;<span style="-sec-ix-hidden:Hidden_N7lFaWJk4UioTzyN62omEA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span></span> in each of the <span style="-sec-ix-hidden:Hidden_KtzSWTvEJkCOw76-3Skdsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">next</span></span> <span style="-sec-ix-hidden:Hidden_M4WVaq1GFEm8sYjSSs7jbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span>&#160;<span style="-sec-ix-hidden:Hidden_BsVw2TEmt0uc2rx2gi65UA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">years</span></span> and $0.5&#160;million thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by such asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group exceeds the undiscounted cash flows, an impairment is recognized to the extent the carrying value exceeds its fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment losses were recognized during the&#160;years ended December 31, 2022, 2021 or 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Debt Issuance Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Debt issuance costs incurred in connection with debt (Note&#160;6) are amortized to interest expense over the term of the respective financing arrangement using the effective-interest method. Debt issuance costs, net of related amortization are deducted from the carrying value of the related debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i)&#160;identify the contract(s)&#160;with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Company&#8217;s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Company&#8217;s customer contracts, the only identified performance obligation is providing the product to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue is recognized at the estimated net sales price which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Payment terms with customers do not exceed one&#160;year and, therefore, the Company does not account for a financing component in its arrangements. There are no incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than one&#160;year. Fees charged to customers for shipping are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents revenue disaggregated (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,093</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex PRS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,120</p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,213</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Sales outside of the U.S. were $3.2 million or 8% of total revenue for the year ended December 31, 2022 and immaterial for the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred and consist primarily of salaries, benefits, and other related costs, including stock-based compensation for personnel serving in the research and development functions as well as costs incurred with Aroa under development agreements related to technology transfer, laboratory materials and supplies. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. Costs incurred in obtaining patent and other intellectual property licenses or milestone payments from license agreements for which there are no alternative future uses are charged to expense as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based awards in accordance with provisions of ASC Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>, under which the Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over the vesting period of the award while awards containing a performance condition are recognized as expense when the achievement of the performance criteria is considered probable. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by ASC Topic 740, <i style="font-style:italic;">Income Taxes </i>(&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ASC Subtopic 740-10, <i style="font-style:italic;">Accounting for Uncertainty of Income Taxes </i>(&#8220;ASC 740-10&#8221;), defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in consolidated financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the consolidated financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. Due to the related-party relationship of the OrbiMed Credit Facility (Note&#160;6), it was impractical to determine the fair value of the debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company follows the provisions of ASC Topic&#160;820, <i style="font-style:italic;">Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">1:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">2:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">3:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following fair value hierarchy table presents information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measurement&#160;at&#160;reporting&#160;date&#160;using</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">active&#160;markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents&#160;&#8211; money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents&#160;&#8211; money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:12pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per common share is determined by dividing net loss by the weighted-average shares of common stock outstanding during the reporting period. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share since dilutive shares are not assumed to have been issued if their effect is antidilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as they would be antidilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options (including shares subject to repurchase)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,071,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,706,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,498,390</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 311,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,472,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,958,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,586,946</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, <i style="font-style:italic;">Leases</i>, (&#8220;ASU 2016-02&#8221;) which requires a lessee to record a right-of-use (&#8220;ROU&#8221;) asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12&#160;months. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&#160;its effective date or (2)&#160;the beginning of the earliest comparative period presented in the consolidated financial statements as its date of initial application. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the transition practical expedients to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the date of application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In June 2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Measurement of Credit Losses on Financial Instruments</i>, which provides guidance for recognizing credit losses on financial instruments based on an estimate of current expected credit losses model. The standard is effective for the Company beginning January&#160;1, 2023, and the adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2020, the FASB issued ASU No.&#160;2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options</i><i style="font-style:italic;"> and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (&#8220;</i>ASU 2020-06&#8221;)<i style="font-style:italic;">.</i> ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. The adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751187227296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Asset description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated useful lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5&#160;Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,352</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5&#160;Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3&#160;Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of useful life or lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,881</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,943</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,140)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,757)</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,186</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The cost of property and equipment at both December&#160;31, 2022 and 2021 includes $0.2&#160;million of equipment located at Aroa. Depreciation expense was $0.4&#160;million, $0.2&#160;million and $0.2 million for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751096306592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,976</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party and professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,233</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amounts due to contract manufacturer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 842</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,161</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095510544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Long-term debt consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">MidCap Term Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OrbiMed Term Loan (related party)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">End of term charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unamortized end of term charge and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,084)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,509)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,491</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MidCap Term Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 26, 2022, the Company entered into the Credit and Security Agreement (the &#8220;MidCap Credit Agreement&#8221;) with MidCap Financial Trust, as agent (the &#8220;Agent&#8221;), and certain lender parties thereto. The MidCap Credit Agreement provides for up to $50.0 million in term loans (the &#8220;MidCap Term Loans&#8221;), consisting of a $40.0 million Tranche 1 (&#8220;Tranche 1&#8221;) and a $10.0 million Tranche 2 (&#8220;Tranche 2&#8221;). Upon closing, the Company borrowed $40.0 million of Tranche 1 and used a portion of the proceeds to repay borrowings under the OrbiMed Credit Facility (described below) and intends to use the remaining proceeds to fund operations and other general corporate purposes. The Company will be eligible to borrow Tranche 2 at the Company&#8217;s option upon meeting certain conditions, including, but not limited to, reaching $65.0 million of net product revenue over the preceding four quarters by fiscal year end 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the MidCap Credit Agreement, the Company provided a first priority security interest in all existing and future acquired assets, including intellectual property, owned by the Company. The MidCap Credit Agreement contains certain covenants that limit the Company&#8217;s ability to engage in certain transactions that may be in the Company&#8217;s long-term best interests, including the incurrence of additional indebtedness, effecting certain corporate changes, making certain investments, acquisitions or dispositions and paying dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The MidCap Credit Agreement also contains customary indemnification obligations and customary events of default, including, among other things, (i) non-payment, (ii) breach of warranty, (iii) non-performance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, the Company must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, the Company would be required to pay interest on principal and all other due and unpaid obligations at the current rate in effect plus 2%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The MidCap Term Loans mature on May 1, 2027 and bear interest at a rate equal to 6.25% plus the greater of one-month Term SOFR (as defined in the MidCap Credit Agreement) or 1.0%. The Company is required to make 36 monthly interest payments beginning on June 1, 2022 (the &#8220;Interest-Only Period&#8221;). If the Company is in covenant compliance at the end of the Interest-Only Period, the Company will have the option to extend the Interest-Only Period by 12 months to 48 monthly interest payments, followed by 12 months of straight-line amortization, with the entire principal payment due at maturity. If the Company is not in covenant compliance at the end of the Interest-Only Period, the Company is required to make 24 months of straight-line amortization payments, with the entire principal amount due at maturity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subject to certain limitations, the MidCap Term Loans have a prepayment fee equal to 3.0% of the prepaid principal amount for the first year following the closing date of the MidCap Term Loans, 2.0% of the prepaid principal amount for </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the second year following the closing date and 1.0% of the prepaid principal amount for the third year following the closing date and thereafter. The Company is also required to pay an exit fee at the time of maturity or prepayment event equal to 5% of all principal borrowings (the &#8220;End of Term Charge&#8221;) (or in the event of a prepayment event, the amount of principal being prepaid). Interest expense associated with the MidCap Credit Facility recorded for the year ended December 31, 2022 was $2.6 million, of which $0.4 million was related to the amortization of debt issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OrbiMed Term Loan (Related Party)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2018, the Company entered into the OrbiMed Credit Facility with OrbiMed, a related party as the lender is affiliated with a stockholder of the Company, which consisted of up to $35.0 million in term loans (the &#8220;OrbiMed Term Loans&#8221;). The OrbiMed Term Loans consisted of two tranches, a $30.0&#160;million Tranche&#160;1 (&#8220;First Tranche&#8221;) and a $5.0&#160;million Tranche&#160;2 (&#8220;Second Tranche&#8221;). In November&#160;2018, the Company borrowed $30.0&#160;million of the First Tranche. The Company elected not to borrow the Second Tranche&#160;prior to its expiration on December&#160;31, 2019. On May 26, 2022, the Company entered into the MidCap Credit Agreement and upon closing used a portion of the proceeds to repay all borrowings under the OrbiMed Credit Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The OrbiMed Term Loan bore interest at a rate equal to 7.75% plus the greater of one-month LIBOR or 2.0% until the aggregate principal, interest and End of Term Charge of $3.0 million were paid with part of the proceeds received from the MidCap Credit Agreement. As a result of these payments, a $1.2 million loss on extinguishment was recorded during the year ended December 31, 2022. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2022, was $1.5 million, of which $0.3 million was related to the amortization of debt issuance costs. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2021, was $3.6 million, of which $0.7 million was related to the amortization of debt issuance costs. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2020, was $3.6 million, of which $0.6 million was related to the amortization of debt issuance costs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095366720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7)&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Public Stock Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company sold 3,000,000 shares of its common stock at a public offering price of $16.00 per share. The Company received net proceeds of $44.7 million after deducting underwriting discounts, commissions and other offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2020, the Company entered into an Equity Distribution Agreement (the &#8220;Equity Agreement&#8221;) with Piper Sandler &amp; Co (&#8220;Piper&#8221;) in connection with the establishment of an at-the-market offering program under which it may sell up to an aggregate of $50.0 million of shares of the Company&#8217;s common stock, from time to time through Piper as sales agent. No sales were made under the Equity Agreement during the years ended December 31, 2022, 2021 or 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2022, the Company completed an underwritten public offering in which the Company issued and sold 4,600,000 shares of its common stock at a public offering price of $8.00 per share. The Company received net proceeds of $34.4 million after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company had the following warrants outstanding at December&#160;31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">dates</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2028</p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2027</p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095354704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has two equity incentive plans: the 2012 Stock Incentive Plan and the Amended and Restated 2019 Equity Incentive Plan. New awards can only be granted under the Amended and Restated 2019 Equity Incentive Plan (the &#8220;Plan&#8221;). At December 31, 2022,  1,427,772 shares of common stock were available for future issuances under the Plan. The Plan is subject to an annual increase, subject to prior approval by the Company&#8217;s board of directors, equal to the lesser of (i) 432,442 shares, (ii) 4% of the shares outstanding on the last day of the immediately preceding fiscal year and (iii) such smaller number of shares as determined by the board of directors. The Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options vest based on the terms in each award agreements and generally vest over four&#160;years and have a term of 10&#160;years. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense ratably over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations and comprehensive loss (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 961</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 696</p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,030</p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 332</p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,058</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity for the Plan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average&#160;exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual&#160;term</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price&#160;per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,420,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,783)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70,037)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,498,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (77,154)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (182,645)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,706,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (81,408)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,071,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.16</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,022,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.12</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,237,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.16</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Included in outstanding options at December 31, 2022, were 381,125 stock options granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). At December 31, 2022, the aggregate intrinsic value of outstanding options and exercisable options was $3.0 million and $2.3 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The 2012 Stock Incentive Plan provided the holders of stock options an election to early exercise prior to vesting. The Company had the right, but not the obligation, to repurchase early exercised options without transferring any appreciation to the employee if the employee terminates employment before the end of the original vesting period. The repurchase price is the lesser of the original exercise price or the then fair value of the common stock. At December&#160;31, 2022, all early exercised options had vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity relating to early exercise of stock options:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (306)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (267)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (153)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The weighted average grant-date fair value per share of options granted was $6.55, $8.66 and $8.13 for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $16,000, $0.4 million and $0.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December&#160;31, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2022, the total unrecognized compensation expense related to unvested employee and nonemployee stock option awards was $5.1&#160;million, which is expected to be recognized in expense over a weighted-average period of approximately 2.5&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Estimating Fair Value of Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected term</i>&#160;&#8211; The expected term of stock options represents the weighted average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time to vesting and the contractual life of the options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility</i>&#160;&#8211; Due to the Company&#8217;s limited operating history and lack of sufficient company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers, including the Company, whose share prices are publicly available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate</i>&#160;&#8211; The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividend</i>&#160;&#8211; The Company has not paid and does not intend to pay dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Units</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) vest based on the terms in each award agreement and generally vest over four years. The following table summarizes restricted stock units for the Plan:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194,232</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,000)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,189)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163,043</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,950</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,783)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,219)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 311,991</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Included in outstanding RSUs at December 31, 2022, were 7,500 RSUs granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). The weighted average grant-date fair value per RSU granted was $11.21 and $16.57 during the year ended December 31, 2022 and 2021, respectively. The aggregate intrinsic value of RSUs outstanding was $3.6 million and $2.1 million at December 31, 2022 and 2021, respectively. The total unrecognized compensation expense at December 31, 2022 related to RSUs was $2.6&#160;million, which is expected to be recognized in expense over a weighted-average period of approximately 2.6&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095261808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9)&#160;Employee Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">401(k) Defined Contribution Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a 401(k)&#160;defined-contribution plan covering all employees. Participants are permitted to contribute up to 100% of their eligible annual pretax compensation up to an established federal limit on aggregate participant contributions. Discretionary contributions made by the Company, if any, are determined annually by the board of directors. Effective January 1, 2020, the Company matched 50% of employees&#8217; contributions up to 6%, subject to a maximum annual amount. The Company&#8217;s contributions were $0.4 million, $0.3 million and $0.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. The match was suspended from April to August 2020 due to COVID-19. Participants are immediately vested in their own contributions to the plan and are fully vested in discretionary profit sharing made by the Company after three&#160;years of service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2019 Employee Stock Purchase</b> <b style="font-weight:bold;">Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). At December 31, 2022, 421,065 shares were available for future issuance under the ESPP. The ESPP is subject to an annual increase, subject to prior approval by the Company&#8217;s board of directors, equal to the least of (i) 107,887 shares of common stock, (ii) 1% of the shares outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares as determined by the board of directors. The ESPP provides the opportunity to purchase the Company&#8217;s common stock at a 15% discount to the market price through payroll deductions. As of December 31, 2022, 2021 and 2020, 4,523, 3,163 and 2,797 shares, respectively, have been issued under the ESPP. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091199120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10)&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred losses since inception. Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for&#160;years in which differences are expected to reverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets for federal income taxes consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,737</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 623</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,356</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,887</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (435)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (302)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (737)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax asset before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,798</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,798)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company does not have unrecognized tax benefits as of December&#160;31, 2022 and 2021. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss (&#8220;NOL&#8221;) carryforwards for federal and state income tax purposes consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NOL carryforwards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,443</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151,488</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The NOL carryforwards begin expiring in 2032 for federal purposes and in 2026 for state income tax purposes yet $100.7 million of the federal NOL carryforwards have no expiration. The Company recorded a valuation allowance on the deferred tax assets as of December&#160;31, 2022 and 2021 because of the uncertainty of their realization. The valuation allowance increased by $10.4 million and $8.1 million for the years ended December 31, 2022 and 2021, respectively, mainly due to losses incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Utilization of the net operating losses and general business tax credits carryforwards may be subject to a substantial limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, if changes in ownership of the company have occurred previously or occur in the future. Ownership changes may limit the amount of net operating losses and general business tax credits carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of 5% shareholders in the stock of a corporation by more than 50&#160;percentage points over a three-year period. If the Company experiences a Section&#160;382 ownership change, the tax benefits related to the NOL carryforwards may be further limited or lost. The Company has not performed an analysis under Section 382 and cannot predict or otherwise determine whether there would be any limitation to the amount of net operating losses and general business tax credits carryforwards that can be utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and as reflected in the consolidated financial statements is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rate reconciliation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State rate, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__Xg7yEHRTkaf1AHzKKzaFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9o4WxlJ-z0CC9U7RFAF0Vg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_B8cBHWhtUUWKXvY0U7DfHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction, various state jurisdictions and the United Kingdom. Tax years 2019 and forward remain open for examination for federal and the Company&#8217;s more significant state tax jurisdictions. Carryforward attributes from prior years may be adjusted upon examination by taxing authorities if used in an open period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many governments have enacted or are currently contemplating economic stimulus and financial aid measures. Many of these measures include deferring the due dates for tax payments, including both income tax and other taxes. The Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted on March 27, 2020 in the United States to address the economic impacts of the COVID-19 pandemic. The CARES Act includes corporate income tax, payroll tax, and other provisions. While the Company may receive financial, tax, or other benefits under the bill, this legislation did not impact the Company during the year ended December 31, 2020. During the year ended December 31, 2021, the Company claimed an employee retention payroll tax credit of $0.5 million for certain employment taxes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095400544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(11) Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be a party to various other lawsuits, claims, and other legal proceedings that arise in the ordinary course of its business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Agreements with Aroa</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2012, the Company entered into a License, Product Development, and Supply Umbrella Agreement (&#8220;Aroa Agreement&#8221;) with Aroa. The Aroa Agreement provides the Company a license to patent rights and other intellectual property related to Aroa&#8217;s products and technologies for use in certain indications and expires on the expiration of the last patent covering the products (currently March 9, 2031). The Company has the right to extend the term of the agreement by an additional 10 years following the expiration of the last patent covering the products on commercially reasonable terms to be negotiated by the parties. This agreement initially limited the Company&#8217;s license rights to the U.S. but was subsequently amended in March&#160;2013 to include certain countries in Europe including the United Kingdom and members of the European Union and certain former Union of Soviet Socialist Republic satellite nations. The Aroa Agreement required payments aggregating up to $4.0&#160;million upon the achievement of U.S. and European cumulative product sales targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company paid $1.0&#160;million to Aroa in 2018 related to one of the cumulative product sales targets and the remaining $2.0 million in 2019. The Company paid $1.0&#160;million in 2022 related to the sales milestone payments in the European territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other key terms of the amended Aroa agreement in addition to those disclosed above are as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The transfer price for product produced by Aroa is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">200%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Aroa&#8217;s cost of goods sold. The transfer price and the quarterly true-up amount continued to equal </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">27%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Company&#8217;s net sales of licensed products. Upon a change in control of the Company (as defined in the amended agreement), the annual minimum amounts will be extended for a sixth&#160;year with a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$5.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million minimum amount for the North American territory and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million minimum amount for the European territory. If a change in control of the Company occurs prior to the first product launch in the applicable territory, then the annual minimum requirements shall commence upon such change in control. If the make whole payments, if any, are not made by the Company after a notice and cure period, then the license will convert to a nonexclusive basis in the territory for which the payment was required but not made.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Provisions exist for the Company to step in and operate Aroa&#8217;s plant if a supply failure occurs and is not cured within a set timeframe. Under the amended agreement, the criteria for a supply failure was modified to mean a failure by Aroa to timely supply, during any consecutive </span><span style="-sec-ix-hidden:Hidden_aX4OvrC5tUqVcgWeJXKlnQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60-day</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period, at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">75%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the products ordered by the Company under binding purchase orders. During the period that the Company steps in and assumes manufacturing responsibility, it shall not be required to purchase product from or pay transfer prices to Aroa, the annual minimums shall be proportionately reduced to reflect the lack of supply responsibility by Aroa and the Company shall pay a royalty of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of net sales in lieu of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">27%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of net sales of the licensed products.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company expects to enter into similar milestone-based agreements with its strategic partner for both product territories and new products in order to expand and extend its product portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had $1.0 million in purchase commitments with Aroa, $20.7 million in commitments with certain other suppliers to maintain exclusivity rights over time and $2.2 million milestone payments related to certain research and development arrangements which are currently deemed not probable as the timing and likelihood of such payments are not known with certainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2021, the Company entered into an exclusive distribution agreement with Next Science, a medical technology company, granting the Company exclusive rights to sell and market Next Science&#8217;s proprietary antimicrobial surgical wash in the U.S. plastic reconstructive surgery market. To maintain exclusivity, the Company had purchase commitments and annual license fees over a ten-year period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Company entered into an exclusive development and distribution partnership for Collagen Matrix, Inc.&#8217;s proprietary fibrillar collagen pack in the U.S. To maintain exclusivity, the Company has purchase commitments of $20.7 million over the remaining nine-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company leases office and laboratory space in Malvern, Pennsylvania under a noncancelable lease (the &#8220;Malvern Lease&#8221;). The Malvern Lease, which was concluded to be an operating lease, was amended in December 2020 to extend the term of the lease from May 2021 to May&#160;2028. The Malvern Lease has annual scheduled payment increases and provides the Company a renewal option for an additional term of 60 months at the end of the lease term. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. As the Company is not reasonably certain to exercise the renewal option, the additional 60-month term has been excluded. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On January 1, 2022 and upon adoption of ASU 2016-02, the Company recorded an operating lease liability of $1.8 million and an operating lease ROU asset of $1.4 million related to the Malvern Lease. The Company also eliminated approximately $0.4<span style="white-space:pre-wrap;"> million of deferred rent and tenant allowance liabilities as of January 1, 2022 as these components are reflected as a reduction in the operating lease ROU asset.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the lease term. The tenant allowance was historically amortized over the initial, non-cancelable term of the Malvern Lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company's lease does not provide an implicit rate, and therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company used an incremental borrowing rate of 9.75% to discount the Malvern Lease payments included in the operating lease liabilities recognized upon adoption of ASU 2016-02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recognized $0.3 million of lease cost during the year ended December 31, 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $0.3 million for the year ended December 31, 2022, and this amount is included in operating activities in the consolidated statements of cash flows. As of December 31, 2022, the remaining lease term for the Malvern Lease is 5.5 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 358</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 366</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 375</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 392</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total undiscounted future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,039</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (468)</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,571</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2021, the Company&#8217;s future minimum lease payments under non-cancelable operating leases for the five years ending December 31, 2022 through 2026 and thereafter were as follows: $0.3 million, $0.4 million, $0.4 million, $0.4 million, $0.4 million and $0.5 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2022, $0.3 million representing the current portion of operating lease liabilities is included in <span style="-sec-ix-hidden:Hidden_O-RcgO7O50aNxn4SsWFhrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accrued expenses and other current liabilities</span></span> in the consolidated balance sheets and $1.2 million representing the long-term portion of operating lease liabilities is included in <span style="-sec-ix-hidden:Hidden_XxtxzYXVGkCewipeasalog;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other long-term liabilities</span></span><span style="white-space:pre-wrap;"> in the consolidated balance sheets.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092760848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(12) Related-Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November&#160;16, 2018, the Company entered into a senior secured term loan facility with OrbiMed, an entity affiliated with an owner of a material amount of the Company&#8217;s outstanding voting securities. The terms of the debt and related components are described in more detail in Note&#160;6. On May 26, 2022, the Company entered into the MidCap Credit Agreement and upon closing used a portion of the proceeds to repay all borrowings under the OrbiMed Credit Facility, and terminated the OrbiMed Credit Facility.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751086213200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principals of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principals of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of TELA Bio,&#160;Inc. and its wholly owned subsidiary TELA Bio Limited. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company&#8217;s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash with high-credit-quality financial institutions and primarily invests in money market funds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (&#8220;SVB&#8221;) and appointed the FDIC as receiver. On March 12, 2023, the U.S. Department of the Treasury, the Federal Reserve and the FDIC released a joint statement confirming that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, on March 10, 2023, the Bank of England (the &#8220;BOE&#8221;) announced that it intended to seek the placement of Silicon Valley Bank UK Limited (&#8220;SVBUK&#8221;), an affiliate of SVB, into a Bank Insolvency Procedure, which ultimately results in the acquisition of SVBUK by HSBC UK Bank Plc (&#8220;HSBC") on March 13, 2023. The BOE confirmed that all depositors&#8217; money with SVBUK is safe and secure as a result of the transaction, and that operations at SVBUK would continue as normal.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the course of these events, a portion of the Company&#8217;s cash was held in accounts at SVB and SVBUK, with the remainder held at another high-credit-quality financial institution. We have recently established additional redundant accounts with another high-credit-quality financial institution to mitigate liquidity risk to our cash and cash equivalents from any further instability in the financial industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As described in Note&#160;11, the Company has licensed patents and other intellectual property from Aroa Biosurgery Ltd. (&#8220;Aroa&#8221;). As part of this agreement, Aroa is also the exclusive contract manufacturer of the Company&#8217;s OviTex portfolio of products. The inability of Aroa to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with Aroa, or an adverse change in their business, could materially impact future operating results.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers cash equivalents to be highly liquid investments with maturities of three&#160;months or less from the date of purchase. Cash equivalents consist of investments in a money market fund. The Company&#8217;s cash and cash equivalents are carried at fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory consists of finished goods and is identified and tracked by lot and stated at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. The Company periodically analyzes its inventory levels and writes down inventory that has become obsolete or that has a cost basis in excess of its expected net realizable value based on expected customer demand. As of December 31, 2022 and 2021, the Company had $2.3&#160;million and $1.7&#160;million, respectively, in finished goods consigned to others.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at the aggregate cost incurred to acquire and place the asset in service. Expenditures for routine maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Depreciation is provided over the estimated useful lives of the assets using the straight-line method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and milestone payments due related to licenses or commercialization rights prior to future economic benefit being established are recorded as research and development expenses. Milestone payments due related to licenses or commercialization rights after future economic benefit is established are recorded as intangible assets. In 2022, 2021 and 2020, the Company recorded $0.8 million, $0.3 million and $0.3 million of amortization expense, respectively, related to intangible assets. At December 31, 2022, the remaining life of intangible assets was 6.6&#160;years. The Company anticipates recognizing amortization expense of $0.4&#160;<span style="-sec-ix-hidden:Hidden_N7lFaWJk4UioTzyN62omEA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">million</span></span> in each of the <span style="-sec-ix-hidden:Hidden_KtzSWTvEJkCOw76-3Skdsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">next</span></span> <span style="-sec-ix-hidden:Hidden_M4WVaq1GFEm8sYjSSs7jbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span>&#160;<span style="-sec-ix-hidden:Hidden_BsVw2TEmt0uc2rx2gi65UA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">years</span></span> and $0.5&#160;million thereafter.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by such asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group exceeds the undiscounted cash flows, an impairment is recognized to the extent the carrying value exceeds its fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment losses were recognized during the&#160;years ended December 31, 2022, 2021 or 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Debt Issuance Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Debt issuance costs incurred in connection with debt (Note&#160;6) are amortized to interest expense over the term of the respective financing arrangement using the effective-interest method. Debt issuance costs, net of related amortization are deducted from the carrying value of the related debt.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i)&#160;identify the contract(s)&#160;with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Company&#8217;s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Company&#8217;s customer contracts, the only identified performance obligation is providing the product to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue is recognized at the estimated net sales price which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Payment terms with customers do not exceed one&#160;year and, therefore, the Company does not account for a financing component in its arrangements. There are no incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than one&#160;year. Fees charged to customers for shipping are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents revenue disaggregated (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,093</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex PRS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,120</p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,213</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Sales outside of the U.S. were $3.2 million or 8% of total revenue for the year ended December 31, 2022 and immaterial for the years ended December 31, 2021 and 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred and consist primarily of salaries, benefits, and other related costs, including stock-based compensation for personnel serving in the research and development functions as well as costs incurred with Aroa under development agreements related to technology transfer, laboratory materials and supplies. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. Costs incurred in obtaining patent and other intellectual property licenses or milestone payments from license agreements for which there are no alternative future uses are charged to expense as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based awards in accordance with provisions of ASC Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>, under which the Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over the vesting period of the award while awards containing a performance condition are recognized as expense when the achievement of the performance criteria is considered probable. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by ASC Topic 740, <i style="font-style:italic;">Income Taxes </i>(&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ASC Subtopic 740-10, <i style="font-style:italic;">Accounting for Uncertainty of Income Taxes </i>(&#8220;ASC 740-10&#8221;), defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in consolidated financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the consolidated financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income tax expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. Due to the related-party relationship of the OrbiMed Credit Facility (Note&#160;6), it was impractical to determine the fair value of the debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company follows the provisions of ASC Topic&#160;820, <i style="font-style:italic;">Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">1:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">2:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level&#160;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">3:  </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following fair value hierarchy table presents information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measurement&#160;at&#160;reporting&#160;date&#160;using</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">active&#160;markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents&#160;&#8211; money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents&#160;&#8211; money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:12pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per common share is determined by dividing net loss by the weighted-average shares of common stock outstanding during the reporting period. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share since dilutive shares are not assumed to have been issued if their effect is antidilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as they would be antidilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options (including shares subject to repurchase)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,071,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,706,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,498,390</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 311,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,472,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,958,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,586,946</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, <i style="font-style:italic;">Leases</i>, (&#8220;ASU 2016-02&#8221;) which requires a lessee to record a right-of-use (&#8220;ROU&#8221;) asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12&#160;months. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&#160;its effective date or (2)&#160;the beginning of the earliest comparative period presented in the consolidated financial statements as its date of initial application. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the transition practical expedients to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the date of application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In June 2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Measurement of Credit Losses on Financial Instruments</i>, which provides guidance for recognizing credit losses on financial instruments based on an estimate of current expected credit losses model. The standard is effective for the Company beginning January&#160;1, 2023, and the adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2020, the FASB issued ASU No.&#160;2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options</i><i style="font-style:italic;"> and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (&#8220;</i>ASU 2020-06&#8221;)<i style="font-style:italic;">.</i> ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. The adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091063488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents revenue disaggregated (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,093</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex PRS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,120</p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,213</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value of assets and liabilities measured on recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following fair value hierarchy table presents information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measurement&#160;at&#160;reporting&#160;date&#160;using</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">active&#160;markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents&#160;&#8211; money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents&#160;&#8211; money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of dilutive securities excluded</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options (including shares subject to repurchase)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,071,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,706,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,498,390</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 311,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td></tr><tr><td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,472,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,958,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,586,946</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092760848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Asset description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated useful lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5&#160;Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,352</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5&#160;Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3&#160;Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of useful life or lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,881</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,943</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,140)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,757)</p></td></tr><tr><td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,186</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095327744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,976</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party and professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,233</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amounts due to contract manufacturer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 842</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79</p></td></tr><tr><td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,161</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095302112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Long-term debt consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">MidCap Term Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OrbiMed Term Loan (related party)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">End of term charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unamortized end of term charge and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,084)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,509)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,491</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095332560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding to purchase common stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">dates</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2028</p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2027</p></td></tr><tr><td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751093093648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock based compensation expense categories in statement of operations</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 961</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 696</p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,030</p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 332</p></td></tr><tr><td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,058</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average&#160;exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual&#160;term</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price&#160;per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,420,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,783)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (70,037)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,498,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (77,154)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (182,645)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,706,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (81,408)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,071,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.16</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,022,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.12</p></td></tr><tr><td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,237,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.16</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Schedule of activity relating to early exercise of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January&#160;1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (306)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (267)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (153)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of weighted average assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock units (RSUs)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) vest based on the terms in each award agreement and generally vest over four years. The following table summarizes restricted stock units for the Plan:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194,232</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,000)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,189)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163,043</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,950</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,783)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,219)</p></td></tr><tr><td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 311,991</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751096953680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Significant components of the Company's deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,737</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 623</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,356</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,887</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (435)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (302)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gross deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (737)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net deferred tax asset before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,798</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (60,161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,798)</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Net deferred tax asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Company's net operating loss (NOL) carryforwards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NOL carryforwards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,443</p></td></tr><tr><td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151,488</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax benefit</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rate reconciliation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State rate, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__Xg7yEHRTkaf1AHzKKzaFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9o4WxlJ-z0CC9U7RFAF0Vg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_B8cBHWhtUUWKXvY0U7DfHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751271729376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments under non-cancelable operating lease agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 358</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 366</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 375</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 383</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 392</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 165</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total undiscounted future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,039</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (468)</p></td></tr><tr><td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,571</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751086371568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (274,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (229,929)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,400<span></span>
</td>
<td class="nump">$ 44,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold (in shares)</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses</a></td>
<td class="nump">$ 34,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751095387136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segments (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract', window );"><strong>Segments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091199216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGrossAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Inventory consigned to others</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090406112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization expense related to intangible assets</a></td>
<td class="nump">$ 804<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining life of intangible assets</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Intangible assets future amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Year 1</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Year 2</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Year 3</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Year 4</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Year 5</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751096338608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Long-Lived Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091317024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue Disaggregated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 41,418<span></span>
</td>
<td class="nump">$ 29,463<span></span>
</td>
<td class="nump">$ 18,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_IncrementalCostsOfObtainingContract', window );">Incremental costs of obtaining a contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage', window );">Revenue, as a percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tela_OvitexMember', window );">OviTex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 28,879<span></span>
</td>
<td class="nump">22,990<span></span>
</td>
<td class="nump">15,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tela_OvitexPrsMember', window );">OviTex PRS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">12,431<span></span>
</td>
<td class="nump">$ 6,473<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tela_OtherCustomersMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_IncrementalCostsOfObtainingContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents incremental costs incurred in obtaining a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_IncrementalCostsOfObtainingContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customer, Including Assessed Tax, as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tela_OvitexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tela_OvitexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tela_OvitexPrsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tela_OvitexPrsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tela_OtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tela_OtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751096211776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair value of financial instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 39,010<span></span>
</td>
<td class="nump">$ 41,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090888160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net loss per share (Potentially dilutive securities) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares</a></td>
<td class="nump">2,472,395<span></span>
</td>
<td class="nump">1,958,037<span></span>
</td>
<td class="nump">1,586,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares</a></td>
<td class="nump">2,071,848<span></span>
</td>
<td class="nump">1,706,438<span></span>
</td>
<td class="nump">1,498,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares</a></td>
<td class="nump">311,991<span></span>
</td>
<td class="nump">163,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tela_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares</a></td>
<td class="nump">88,556<span></span>
</td>
<td class="nump">88,556<span></span>
</td>
<td class="nump">88,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tela_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tela_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092627584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Total</a></td>
<td class="nump">$ 5,822<span></span>
</td>
<td class="nump">$ 4,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(4,140)<span></span>
</td>
<td class="num">(3,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tela_AgreementWithAroaMember', window );">Umbrella Agreement with Aroa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Total</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tela_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Total</a></td>
<td class="nump">$ 2,635<span></span>
</td>
<td class="nump">2,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Total</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tela_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Total</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Total</a></td>
<td class="nump">$ 2,309<span></span>
</td>
<td class="nump">$ 1,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tela_AgreementWithAroaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tela_AgreementWithAroaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tela_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tela_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tela_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tela_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091047600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">$ 6,420<span></span>
</td>
<td class="nump">$ 4,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Third-party and professional fees</a></td>
<td class="nump">2,563<span></span>
</td>
<td class="nump">2,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_AccruedExpensesAmountDueToContractManufacturer', window );">Amounts due to contract manufacturer</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ResearchAndDevelopmentExpensesPayableCurrent', window );">Research and development expenses</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 10,869<span></span>
</td>
<td class="nump">$ 8,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_AccruedExpensesAmountDueToContractManufacturer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to contract manufacturer due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_AccruedExpensesAmountDueToContractManufacturer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ResearchAndDevelopmentExpensesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of current portion of obligation payable pertaining to Research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ResearchAndDevelopmentExpensesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091085392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of long term debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">End of term charge</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized end of term charge and issuance costs</a></td>
<td class="num">(2,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,509)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Longterm debt</a></td>
<td class="nump">39,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember', window );">MidCap Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long Term Debt</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_OrbimedTermLoanMember', window );">OrbiMed Term Loans (related party)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tela_OrbimedTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tela_OrbimedTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090718768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - MidCap Term Loan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember', window );">MidCap Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_EligibilityRequirementToBorrowTranche2', window );">Eligibility Requirement To Borrow Tranche 2</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_InterestPenaltyPercentage', window );">Interest due to unpaid obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_DebtInstrumentInterestPaymentTerm', window );">Number of Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_PercentageOfExitFee', window );">Exit fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember', window );">MidCap Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_AdditionalExtensionForInterestOnlyPaymentPeriod', window );">Extension for interest only payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember', window );">MidCap Term Loan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_AdditionalExtensionForInterestOnlyPaymentPeriod', window );">Extension for interest only payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember', window );">MidCap Term Loan | First year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount', window );">Percentage of prepayment penalty on prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember', window );">MidCap Term Loan | Second year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2', window );">Percentage Of Prepayment Penalty On Prepaid Principal Amount 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember', window );">MidCap Term Loan | Third year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount', window );">Percentage of prepayment penalty on prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember', window );">MidCap Term Loan | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable Interest Rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoanTrancheOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt amount</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoanTrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt amount</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_AdditionalExtensionForInterestOnlyPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional extension for interest only payment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_AdditionalExtensionForInterestOnlyPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_DebtInstrumentInterestPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of debt instrument interest payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_DebtInstrumentInterestPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_EligibilityRequirementToBorrowTranche2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue the company must generate to be eligible to borrow Tranche 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_EligibilityRequirementToBorrowTranche2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_InterestPenaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of penalty to be paid on the event of default in meeting the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_InterestPenaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_PercentageOfExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the principal amount paid as an exit fee at the time of maturity or prepayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_PercentageOfExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of penalty to be paid on principal amount of debt for the first year after closing date and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of penalty to be paid on principal amount of debt for the second year after closing date and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tela_FirstYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tela_FirstYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tela_SecondYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tela_SecondYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tela_ThirdYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tela_ThirdYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoanTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoanTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoanTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoanTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092672704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - OrbiMed Term Loan (related party) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">$ (1,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoanMember', window );">OrbiMed Term Loans (related party)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt amount</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_NumberOfTranches', window );">Number of Tranches | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate (as a percent)</a></td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_EndOfTermCharge', window );">End of Term Charge</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expenses</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoanMember', window );">OrbiMed Term Loans (related party) | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable Interest Rate (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoansTrancheOneMember', window );">OrbiMed Term Loans - Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoansTrancheTwoMember', window );">OrbiMed Term Loans - Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_EndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the principal amount paid as an exit fee at the time
 of maturity or prepayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_EndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of tranches of debt obtained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoansTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoansTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoansTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tela_OrbimedTermLoansTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090645664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Public Stock Offerings (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,400<span></span>
</td>
<td class="nump">$ 44,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold (in shares)</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses</a></td>
<td class="nump">$ 34,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tela_SecondUnderwrittenPublicOfferingMember', window );">Second Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tela_EquityDistributionAgreementMember', window );">Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement', window );">Value Of Shares Authorized To Be Sold Under Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value Of Shares Authorized To Be Sold Under Equity Distribution Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tela_SecondUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tela_SecondUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tela_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tela_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090849376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">88,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tela_CommonStockWarrantsExpiringIn2028Member', window );">Common stock warrants expiring in 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">8,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 28.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire', window );">Expiration dates</a></td>
<td class="text">2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tela_CommonStockWarrantsExpiringIn2027Member', window );">Common stock warrants expiring in 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">80,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 28.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire', window );">Expiration dates</a></td>
<td class="text">2027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Date from which Warrants or Rights Expire</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tela_CommonStockWarrantsExpiringIn2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tela_CommonStockWarrantsExpiringIn2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tela_CommonStockWarrantsExpiringIn2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tela_CommonStockWarrantsExpiringIn2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090956768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narratives (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_EquityIncentivePlansNumber', window );">Number of equity incentive plans | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Options (per share) | $ / shares</a></td>
<td class="nump">$ 6.55<span></span>
</td>
<td class="nump">$ 8.66<span></span>
</td>
<td class="nump">$ 8.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod', window );">Inducement grants | shares</a></td>
<td class="nump">381,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of unrecognized expenses</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Equity Instruments (per share) | $ / shares</a></td>
<td class="nump">$ 11.21<span></span>
</td>
<td class="nump">$ 16.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod', window );">Inducement grants | shares</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of unrecognized expenses</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tela_EquityIncentivePlan2019Member', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance | shares</a></td>
<td class="nump">1,427,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance', window );">Common Stock Capital Shares Reserved For Future Annual Issuance | shares</a></td>
<td class="nump">432,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear', window );">Common Stock Capital Shares Reserved For Future Issuance, Percentage Of Shares Outstanding Last Day Of Fiscal Year</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Vesting term</a></td>
<td class="text">10&#160;years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Annual Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance, Percentage Of Shares Outstanding Last Day Of Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_EquityIncentivePlansNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about number of equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_EquityIncentivePlansNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of inducement restricted stock units outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tela_EquityIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tela_EquityIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751086313712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 3,989<span></span>
</td>
<td class="nump">$ 3,661<span></span>
</td>
<td class="nump">$ 2,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,029<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090961792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of period</a></td>
<td class="nump">1,706,409<span></span>
</td>
<td class="nump">1,498,208<span></span>
</td>
<td class="nump">1,420,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">450,410<span></span>
</td>
<td class="nump">468,000<span></span>
</td>
<td class="nump">175,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(3,563)<span></span>
</td>
<td class="num">(77,154)<span></span>
</td>
<td class="num">(27,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled/forfeited</a></td>
<td class="num">(81,408)<span></span>
</td>
<td class="num">(182,645)<span></span>
</td>
<td class="num">(70,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of period</a></td>
<td class="nump">2,071,848<span></span>
</td>
<td class="nump">1,706,409<span></span>
</td>
<td class="nump">1,498,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at end of period</a></td>
<td class="nump">2,022,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period</a></td>
<td class="nump">1,237,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 11.88<span></span>
</td>
<td class="nump">$ 10.87<span></span>
</td>
<td class="nump">$ 10.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted ( in dollars per share)</a></td>
<td class="nump">10.24<span></span>
</td>
<td class="nump">14.80<span></span>
</td>
<td class="nump">15.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">5.51<span></span>
</td>
<td class="nump">7.08<span></span>
</td>
<td class="nump">6.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited (in dollars per share)</a></td>
<td class="nump">13.13<span></span>
</td>
<td class="nump">13.08<span></span>
</td>
<td class="nump">12.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of period (in dollars per share)</a></td>
<td class="nump">11.49<span></span>
</td>
<td class="nump">$ 11.88<span></span>
</td>
<td class="nump">$ 10.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at end of period (in dollars per share)</a></td>
<td class="nump">11.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding</a></td>
<td class="text">7 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">7 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Exercisable</a></td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751093026288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Early Exercise Of Stock Options (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Early exercised stock options, Unvested balance at beginning of period</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Early exercised stock options, Unvested balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092680880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted average assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">69.60%<span></span>
</td>
<td class="nump">63.90%<span></span>
</td>
<td class="nump">59.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.55%<span></span>
</td>
<td class="nump">0.99%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 24 days<span></span>
</td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751094683200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units (Details) - Restricted stock units - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">163,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">197,950<span></span>
</td>
<td class="nump">194,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(40,783)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled/forfeited</a></td>
<td class="num">(8,219)<span></span>
</td>
<td class="num">(19,189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period</a></td>
<td class="nump">311,991<span></span>
</td>
<td class="nump">163,043<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090329728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum contribution of participant (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of employer's contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employer's contribution to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Amount of employer's contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1', window );">Deferred Compensation Arrangement with Individual, Requisite Service Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tela_EmployeeStockPurchasePlan2019Member', window );">Employee Stock Purchase Plan 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance', window );">Increase in number of shares</a></td>
<td class="nump">107,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding', window );">Increase in percentage of shares outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock', window );">Discount on purchase of common stock</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,523<span></span>
</td>
<td class="nump">3,163<span></span>
</td>
<td class="nump">2,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the discount on purchase of common stock under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of shares outstanding on the final day of the immediately preceding calendar year, which will be the conditional annual increase to the number of shares authorized or reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of conditional annual increase to shares authorized or reserved for issuance under the share based payment arrangement plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tela_EmployeeStockPurchasePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tela_EmployeeStockPurchasePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092809744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 55,091<span></span>
</td>
<td class="nump">$ 47,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">4,425<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserve</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">60,898<span></span>
</td>
<td class="nump">49,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(435)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liability</a></td>
<td class="num">(737)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_NetDeferredTaxAssetBeforeValuationAllowance', window );">Net deferred tax asset before valuation allowance</a></td>
<td class="nump">60,161<span></span>
</td>
<td class="nump">49,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(60,161)<span></span>
</td>
<td class="num">(49,798)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to  lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to  depreciation and amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to Right of use asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_NetDeferredTaxAssetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_NetDeferredTaxAssetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751091023616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - NOL carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 212,314<span></span>
</td>
<td class="nump">$ 181,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</a></td>
<td class="nump">100,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 173,472<span></span>
</td>
<td class="nump">$ 151,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751090931136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Rate reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Rate reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State rate, net of federal benefit</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="num">(4.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">23.40%<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751086274512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narratives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Employee retention payroll tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751085768816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania | Office and laboratory space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania | Office and laboratory space | Cumulative Effect, Period of Adoption, Adjustment [Member] | ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset', window );">Deferred rent and tenant allowance netted off against right-of-use asset</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tela_AgreementWithAroaMember', window );">Umbrella Agreement with Aroa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_RevenueBasedMilestonePayment', window );">Payment for agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements', window );">Milestone payments related to research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_FixedCostOfNetSales', window );">Fixed Cost Of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder', window );">Number of days for product supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder', window );">Percentage of products ordered to be supplied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_PercentageOfRoyaltyOfNetSales', window );">Royalty percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tela_AgreementWithAroaMember', window );">Umbrella Agreement with Aroa | European territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_SalesMilestonePaymentDue', window );">Sales milestone payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_PurchaseObligationDueInSixthYear', window );">Purchase commitments due year Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tela_AgreementWithAroaMember', window );">Umbrella Agreement with Aroa | North American territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_SalesMilestonePayment', window );">Sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_TransferPriceForProductProduced', window );">Transfer Price For Product Produced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_FixedCostOfNetSales', window );">Fixed Cost Of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_PurchaseObligationDueInSixthYear', window );">Purchase commitments due year Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tela_OtherSuppliersForExclusivityRightsMember', window );">Other Suppliers for Exclusivity Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets', window );">Aggregate future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tela_NextScienceMember', window );">Next Science</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_OtherCommitmentsTermOfContract', window );">Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tela_CollagenMatrixInc.Member', window );">Collagen Matrix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Contingencies and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tela_OtherCommitmentsTermOfContract', window );">Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred rent and tenant allowance netted against operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_FixedCostOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Cost Of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_FixedCostOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments related to research and development arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_OtherCommitmentsTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of Contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_OtherCommitmentsTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_PercentageOfRoyaltyOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Royalty of net sales in lieu of 27% of net sales of the licensed products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_PercentageOfRoyaltyOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of product ordered to be supplied within specified period, in case of supply failure occurs, the Company to step in and operate Aroa's plant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days for supply of the products ordered , in case of supply failure occurs, the Company to step in and operate Aroa's plant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_PurchaseObligationDueInSixthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the sixth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_PurchaseObligationDueInSixthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_RevenueBasedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for agreement under the terms of agreement entered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_RevenueBasedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment under the terms of agreement entered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_SalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone Payment made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_SalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_SalesMilestonePaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone Payment due when cumulative product sales in the North American territory reach certain amounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_SalesMilestonePaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tela_TransferPriceForProductProduced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage increase above Counterparty's cost of good sold for product purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tela_TransferPriceForProductProduced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tela_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tela_OfficeAndLaboratorySpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tela_OfficeAndLaboratorySpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tela_AgreementWithAroaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tela_AgreementWithAroaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tela_OtherSuppliersForExclusivityRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tela_OtherSuppliersForExclusivityRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tela_NextScienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tela_NextScienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tela_CollagenMatrixInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tela_CollagenMatrixInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139751092747168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022/2023</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023/2024</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024/2025</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025/2026</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026/2027</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">2,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>tela-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:tela="http://www.telabio.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tela-20221231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__0NqwDOnU069qrqDweDq7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6jS7FaWS5k2vBIexrI3UwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cMdTTyP7gEeGyUNTqvLRNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Joj3v_81eEyOiZcwVgt7eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8Dc-5nKCK0aFZB4G6pHLtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v61EXnBz5UOMTIqvTTVxlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GnrH2KSZPUexCDzLyVUgWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N7ZqSLBpBkC2dB9n5qsheQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BALcPEf8f06_ByU0A3la0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__z1HrlyAiEeZoN2ntN1wdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mI1Et8gIm0OdOoNeRu_ZkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6I5vqtHVrke8eqs2gI250A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZbaHak272kytCiOj7lO8ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-N1PP0dpzE6v3HICXjB5NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ngCQpjdcvk-SsVBsAtLEbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w6UDjR_eTEagY1f1G_onNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_e7ixSa7Av0qDAVrov1S1Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lJzbq-J-nEOX--0ZNtWiug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:SecondUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_apjFPhUEQUmSn47rVbBhIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_YKvVJdoCfU6XG4kpRDTKPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_P49kb58aeUOwJ9BHNFx0Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_5nSnl9FMqkyjoV_-oqlcRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_0ySqKDuji0e0ER6NBbeSnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_L9eLKsRNw0CRO-mST_AJQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OvitexPrsMember_L3BIDNF6OES8ZPhVA4kbNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexPrsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OvitexMember_EdbT9Stg4kukXsfXOaqw7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OtherCustomersMember_jNrO6oj7BUi2tHp_zIcW1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tela_OvitexPrsMember_65VAhesxikuTOSd3VYTV5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexPrsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tela_OvitexMember_KoD1LsmYCUi3vu5Gf7IEhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tela_OvitexPrsMember_633JkzTN7k-JMFLDXqSR6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexPrsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tela_OvitexMember_g62SfrjEtkKrRkIEyjjV_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tela:OvitexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_CollagenMatrixInc.Member_1Pkcz42t1Ey6xw6VGMm4YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:CollagenMatrixInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_L6OtipUKj0WBTkfRIZ9BCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_hqviTa-18kW6leCDSegk5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_dMZmT2GGWEeog6Ay7w1DVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_OELAYKjFM02OmAHs-BXhFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mPjPPo5jm0CMb8H3SqPEdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_kFCoP67BGk6_GGyzDE7erQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_1rGYh_LT7ki_OPiUFup5XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_4PvHI75_kUy1koIiD7H3FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_jpLtYA4OHkmQ_qtVIb5JZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_T7ZsTtnwJUu8lL-B2AMf1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_T-vzareBQk2hQt3aejgflA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_BaYfUZMFFkC1bk-Vne9zAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lQEEIhyvLUeG6RwD_4RFTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:SecondUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IVbed4JzJkGCxrAyFbPuzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_loDUZPMImEmoouzBKpBYYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SOs1kkyXi0abe8ZkOi1Ztg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_v9zeKR1og0GICgO2UBJLYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_nh_rYZ3xKUOudm_jXKbwPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_A9GP45d3REOrEZcQtCpqQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_rkR5ymX8o0ef8OoHXSVS1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gvnas9QAp02vVM237t3iyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qV52jkzrGkyM3BjDcW7aFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__lbPSe6rPkKCFW4tp1NNww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_kMDohVy_8EGHSodUA1iG_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_8Fc2PFOc2keKSCoCf2k64w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_KxwryCVlz0irzGqrcf7T9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_1_2022_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_ijh9r7V11UmJJurC5JZr8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_pOKNe1MZo0aFsxEbEdiunQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheTwoMember_b-6HOZChpUeQzYJXQLel8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoansTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheOneMember_yI91ExdwXUG56squ0fq2vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoansTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_Kaoof9Egs0ivKLTiFF4Y9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_jCqHr9goH0iWw09Jjit7ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheTwoMember_UJdzkLGJCk6Gx_nvGHVbIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoanTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheOneMember_HRhYP45vYUW4DEuuKEzNbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoanTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_h_H8pqMUMUyTw6VdKGsnwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_tela_OrbimedTermLoanMember_pkFbA7Mc-UqsKDpK3kA_6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_BMBZkylIyUmOoB5qEBh2iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_QykfsvRGv0WxqJJfvminqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_CHZHq7ZTvEK6xqdLmH_vew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tela:CommonStockWarrantsExpiringIn2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member_TigqdE4b6kOc3r-MRIqDcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tela:CommonStockWarrantsExpiringIn2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_PGJ1GKO4r0m8-XWNlJhlug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Aei9Npet1Ea_GR9b8r2LiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_tv04xB9wqEaTQH96wyjNIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_rqhtk_S59EqxwFA-juI72g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_E9meB2rtA0C78Kyfm-g3Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tela:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_pRF4sUzZHkaM1gci9cPj_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cI7QGTXY5USeztjg0obgqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_sM9LuqJ1i0q0bgc5PtaRTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tela:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_UGImw1N6L0mZ0fnBk-7tDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_0cVBhli_GUqVg00WCdCr8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tela:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_YSX6qeqpOEafTWL95y7zgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_9qJHl78Mt0qRtojolu34eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_qb-xC0ZM6EmvUL8LzpWnCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wDi4dsqi-EqOxKJ9dizz-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_idpfOALz2UiyklGl9EYKzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_8-eGjFS6uU6hiVBVgeYbig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7uFgx_FdS0ODpYTmtHXo-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qXTrNzsEgEG6lcTM1Mz12g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_9XvGvd6jPkaCSiqkj9Sjcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZOR2THAP1EyzyW3OgaAWLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_L98p-_WvLky1L5Gl_Pz7mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_xGKYdmhTDE2zwVT9engEmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_5WQ0HWHJy0GEHABnWD88Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_DFSh0vmZ7ES3xBh8RnpMfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tela:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_bNi-UjogoEuFoyrMYtfZFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_WrQWz5vLr0aUSSjLYF2vLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_X-lkTg0yAk6A3AzjollXfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_OtherSuppliersForExclusivityRightsMember_nti7PndlCEqpmp9aOi8sDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:OtherSuppliersForExclusivityRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2012_To_8_31_2012_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_5TQp0DFf-kq_QSMl5v0gog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-08-01</startDate>
            <endDate>2012-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_EuropeMember_P4ROvIxkZ0GJPalY78p2MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_vMwv7HGAZk6VxBh2MfXhWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_SecondYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_z5Xo6mvHC0uadpbBdDSOsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tela:SecondYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_ThirdYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_LQmV-QrJjEGKWrU-HuZaaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tela:ThirdYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_FirstYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Fa-0d26vSUuUMMIob5eqFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tela:FirstYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_NextScienceMember_LkcT3sf4w0qZZyV6NqpeQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:NextScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_CollagenMatrixInc.Member_dYLoJZtTSE2udKKQ9CsaEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:CollagenMatrixInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_5UcmEJq_IkSYYQljqHnZxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tela:AgreementWithAroaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tela:OrbimedTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2019_To_11_30_2019_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_2L7PdrGMqki5LBBGmf_Rew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EmployeeStockPurchasePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="Duration_5_26_2022_To_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_7alFNq9WVkudCwmmXa7QyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_0PuV96OlxUKqwMyunu8Gaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tela:OfficeAndLaboratorySpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_pbxz9JD2tEuMD0Bp4A1EmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tela:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_SAt9gqyaqUqRNPZ9FC6LyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tela:CommonStockWarrantsExpiringIn2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member__U-R7Y6xF0uM61E9PpKfaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tela:CommonStockWarrantsExpiringIn2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_QT0qfYviYU6Qkgg2H5pTKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_pYoDsd8Lak-sf5zkcqJ-0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tela:MidcapTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_iop3vfvQHEOwxPOcSV8riA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2023_0OZ9Jh7WtUahPhIJykFOTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001561921</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item__TJFBDNbO0SDXs4XkYl9ag">
        <measure>tela:item</measure>
    </unit>
    <unit id="Unit_Standard_tranche_taD5b-wNNkeDwJocY19qDA">
        <measure>tela:tranche</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_I8CJGHwyyEWw2nQXigOSaQ">
        <measure>tela:segment</measure>
    </unit>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      id="Hidden_zB0Ls2B_l0i5ZHo4irGruQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      id="Hidden_jSt6V58rQUeFCid3YD_e2Q"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="2"
      id="Hidden_Dui_H_slDEazZiYT0YHI6Q"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">-2.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="2"
      id="Hidden_a3N_SAKM90S-ydoFe7MfqQ"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">-2.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="2"
      id="Hidden_YJBwTeTqC02MfB4Us1UtcA"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">-2.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="0"
      id="Hidden_jUVfzJ5Sc0ip__me3EABkg"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">16267678</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="0"
      id="Hidden_ybHydbmMGk2ngdR2CI-iww"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">14473213</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="0"
      id="Hidden_8VqSOiw77EycX_RI-uX-cQ"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">12934421</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Hidden__Xg7yEHRTkaf1AHzKKzaFA"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      id="Hidden_9o4WxlJ-z0CC9U7RFAF0Vg"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      id="Hidden_B8cBHWhtUUWKXvY0U7DfHQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Hidden_N7lFaWJk4UioTzyN62omEA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Hidden_KtzSWTvEJkCOw76-3Skdsg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Hidden_M4WVaq1GFEm8sYjSSs7jbA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Hidden_BsVw2TEmt0uc2rx2gi65UA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <tela:ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_vMwv7HGAZk6VxBh2MfXhWQ"
      id="Hidden_aX4OvrC5tUqVcgWeJXKlnQ">P60D</tela:ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_rKXQMDmP00aRa18PBVAa8w_2_1">0001561921</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_hzB1q1YSYEiJDEroT_bU-Q_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_5iMlW-_WEEa-Jp8pcy0Mcg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_P3vhrBSqnEuXqVS43nuKhA_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Hidden_tmVXD74xzkigULe3TP8B-Q"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Hidden_m5PUSyBzVUWzcfWCUvycBQ"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      id="Hidden_O-RcgO7O50aNxn4SsWFhrQ">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      id="Hidden_XxtxzYXVGkCewipeasalog">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_D4p_0D7tkEqfWz50dW_x_A">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_EiPPGKvZGEqrL7kRblQ2CA_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_OAsSO_D0g0-WzzFZbtVfkw">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_z8xdw1CDxkq8gXjqOYnIVA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_iGIFd_OALk2n9XKicb52EA_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_8_K1qUorrEObamIxtfzSrg">001-39130</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_wvqyyMw6-k2xQmdMxLrs3Q">TELA Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_kcnoPXK2zU2Ejed2okjPPA">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_EqryBgsORUWtHKdeahj4BA">45-5320061</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_EPQfRe2Ju0O-J_4E50F0Dw">1 Great Valley Parkway, Suite 24</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_g79tsNxr3k2eMmCgt1QypQ">Malvern</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_EU7-gKkW7kmq8pEd1evGnQ">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_P6IgoVyJDE-f3kQnCYggXA">19355</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_nyMYUr7OrE6-FZL92X-GFA">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_-Gys4a0rDUCOxyTgglFmIw">320-2930</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_g7uIua4pwEyy7KjlL9f7uw_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_YCANGCFP20WAnoLeOBeINQ_2_2">TELA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_sGe2Hj_sRkuBDkjI_nuZ4Q_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_FxnUvJvebEO_Sxer2KNUew">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_n2jcBvsWc0yKNtP6K4E6pQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_otlHf5r8lU-YdKAld9k_0w">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_kU64A6lBWka8_MBQUDBptQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_IDH56jibz0yGDLX_-doeWg">true</dei:EntitySmallBusiness>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_9xbIZ3e1TEeJHYmvDbXcoQ">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_rhq-_hN2BEyOPvULcmaczw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_O3YPqZo1A0e6UR-9YrTPQg">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_R5Yvmpi74UqlFHO-zbhnrw">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_b3p4s00BKU-6fTaKI6Di9g">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_iop3vfvQHEOwxPOcSV8riA"
      decimals="-5"
      id="Narr_gKxQVkFfBUCMrSnaD9XR6w"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">54400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_16_2023_0OZ9Jh7WtUahPhIJykFOTA"
      decimals="INF"
      id="Narr_ouQdZNFZFE2FAbMPGuQRZw"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">19216821</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_JsUCODzikkmFc_MJA1ofkQ">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_kZz3_xcgmUyWVwCiZS-hqA">Philadelphia, PA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_boMQNbGSEUCVJWpY7ODvoA">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_KQLiKS2rgE6OQW59NsCm_A_5_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">42019000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_YkTkYi6PskSAR6pMv5IaCQ_5_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">43931000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_y9WJWspkGUGjuNR6BwBeFA_6_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">6621000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc__CIgcIYYAkOAdoiXLOBZsw_6_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4234000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_S24reQo_GUWumsRJCoubTA_7_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">11792000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_6sAzQ0x_a0m8OkarLhe4ng_7_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">7658000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_fZmeiSVYmUOcMDBi7lNdfQ_8_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2015000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_CIKaEgA7XEyeVfR6TW41BQ_8_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3232000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_-KnFCNzTBUehiGwCO71Uug_9_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">62447000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_m4L2ZignCUiMJwf9N0iHbg_9_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">59055000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_X2C27JMzAkmKjHyQJcfHWA_10_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1682000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_7fL_K1QCKUSHVtyqjTzDog_10_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1186000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_jQ2vOV1twkihJ2MSmo5lRg_11_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2499000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_3BgUVjxRSkCecpcc5FLwAg_11_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2303000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_h_AdTwqu5UeeILn5Qbjt5g_12_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1227000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_XGU-CVNg7UCsK8CM9SDXrw_13_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">67855000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_rriIlLOTUUC-K_NmcmaPdA_13_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">62544000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_950cSrFmH0KLEDHhD9iIpA_17_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1534000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_FueXeNKV9UyXX4VfxR98rg_17_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2414000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_4cxIZ5htRkOqMWtes3F-nA_18_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">10869000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_lUAOweL_V0Gvb-3qqdGAdw_18_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">8161000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_G8HI3RpLA0agehXjoV5Tmg_19_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">12403000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_lwLj9UywlUO1qLZZFI5FhQ_19_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">10575000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_W-fS5lq1PE-KdCJGRYjDDA_20_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">39916000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_LIahiltWpUephmlPs6_UKw_21_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">31491000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_T3J6JmEUfE2nwglw-q5f4Q_22_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1231000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_YDs6gvveYkqtOKi9lIO58Q_22_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">380000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_wVxImSITnU2A50Gz5lg2vA_23_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">53550000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_lFVkPdUoFk2HTiz7KUqCCQ_23_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">42446000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Narr_5vV3YZN-NU2W9RXq-ZxTBQ"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Narr_0-7mOs_g1EGdCPte_obvnA"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Narr_uj8REwIHNkOagTmqDIykGw"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Narr_lEnwuIin00OP0Qw2f5QJpA"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Narr_FsCJ0BRpMkGM2B4aUfKAmw"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Narr_mqceYozI1UWI8Sopex2puw"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Narr_Lm4_BxeVFE29nqTRD4DrQg"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Narr_Juvp4Mhx7kyGyEjDHRsxpw"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Narr_nVOnWX9eO0u3qQh2ancCNA"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Narr_89B7yHYo5kOmddpCOenLYw"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Narr_QO6yHh2PWkq4V2JGBfypSw"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">19165027</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Narr_WatDQZRqAEWEa_Rb0sGEFA"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">14529606</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Narr_qnLFFx5Zz0GqbssUH4TPmA"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">19165027</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Narr_XOkgsEElKkWdooetoNKS5w"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">14529577</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_Y_tKMfnHkk-LvJGaFWZnAw_29_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">19000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_783jIxpBWEuKPcIQkcZKxQ_29_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">15000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_ASl-Hffo-EmtDhha1PibOA_30_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">288361000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_MjVXwaNfhEmAzFOqGwPQaQ_30_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">250064000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_qZFylpa0W0Kb50xTmMpmWw_31_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">150000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_AIf0K60qnEyMRqDNWKCk4A_31_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-52000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_s4A5_F8nskOuV9GZ9dd1ng_32_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-274225000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_wPbV89LCkkGWJYReqo0aog_32_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-229929000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_1996ce-S-USlrugtfoNImA_33_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">14305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc__h0rh-dqiEyjnbXR1FBB2A_33_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">20098000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_KwTmqybtZkaF_u5bjbOKNA_34_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">67855000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_v0u4XBgWg0CromTFHZcV_Q_34_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">62544000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_GB3GtgK5PESi943JKAYbrg_3_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">41418000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_XmSmOcRnpU-tf4L2_5MJ5g_3_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">29463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_PZBkhcnEP0-S12Nz2-aTnA_3_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">18213000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_KyFcL4A8wUa-gtdoK4jgOQ_4_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">13570000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_Ece-1rdrFEiB2K_LIE-Caw_4_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">10346000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_H3sCb2hWOUmouXwXn-rydA_4_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">6675000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_WFBWAOvlgUepTlUo5v_PaQ_5_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">804000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_6VwkmhCGgUijV09ALIf4EQ_5_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">304000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_MIVJj1zZGk-BPo9FrL8OzA_5_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">304000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_QhHsW5yd_kaTrmbOdabrFQ_6_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">27044000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_1gUJOOTj-0mZxyRZTWnw_g_6_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">18813000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_N85ktFx300e5uBh1LBgcPQ_6_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">11234000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_tsnkLahfpUqW8dUPmkjbaw_8_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">43252000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_0eZucfuemk6RAb4WYSKxaQ_8_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">29062000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_bESURh9L6kif9ZB-4FUzrA_8_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">22111000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_nXR1M3xBqE6QZ5zQx4TAFw_9_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">13862000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_lBnBxJ6zeESGXelDL8Yx_A_9_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">12459000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_re7JavkHD0Wj2YIlSSJ-HQ_9_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">10143000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_09BnxFoZK0Kxl4GgaLpMiA_10_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">8937000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_J8lTfV2JcUOcovnY6PAWtA_10_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">6743000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc__RKa41djQUKwd9CaagO8qg_10_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4255000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_38UcK8ApSUCZ7PsKVrwmTQ_11_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">66051000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_zRfKJSvHjESZyCpMsYhNYg_11_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">48264000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_hM67ektQR0yppY1Ts97vEA_11_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">36509000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_seng4oW-QECxJamc8qhS5A_12_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-39007000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_lCVYCip_qU-C8dYSkkgUfg_12_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-29451000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_qeLul1qNY02sZZc_PPFrBg_12_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-25275000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_bzzAIlacOEKrUMnn62xj7w_14_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4051000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_IndTef1cO0qFmkVNeKIUtQ_14_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3597000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_B-WNa_zwdUSki6Kk-Sbllw_14_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3564000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_ITnnGcIW206uKgjLeSHWuQ_15_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-1228000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_kTbEpZ3vaE2w_7E7X-QWqQ_16_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_NM3siMXDC024bwcAGC7LCg_16_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-228000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_dAw2h7zJ_0Ga3B5oI_eQDg_16_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">45000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_huV9M-u3nkuTn3y-wvHmDw_17_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-5289000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_bPDuRLorFkarOSU4Gb3NDg_17_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-3825000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_VsGeFPhlo0e2dbbpVfIoIw_17_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-3519000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc__ApBf7Y5GUCPlxyWJY6RNQ_18_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-44296000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_DUusIHluAEmsC8TuF1B31g_18_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-33276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_duTbcvCQdkqtTOP5dhratA_18_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-28794000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="2"
      id="Tc_6Cw4uwdgnECjwPN1GD4XMg_19_3"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">-2.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="2"
      id="Tc_GVv23BzlbUq3wbm_-ebR3Q_19_6"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">-2.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="2"
      id="Tc_DlbrUBcbc0uOPz6-Wrm8kQ_19_9"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">-2.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="0"
      id="Tc_NdclkHNyaU6lD4TrOSw7Gw_20_3"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">16267678</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="0"
      id="Tc_m2T_Kox13kiLY0FSXmlPDw_20_6"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">14473213</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="0"
      id="Tc_Bi9V-yudu0azeBDubAfBNw_20_9"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">12934421</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_otbjIAs6EUOEh4HuPeSQlA_22_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-44296000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_4bbjKuPoAEKTepIOk1hzZg_22_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-33276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_BLTcqxbQCkuUYie9fErhng_22_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-28794000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_qMdV-D-T4kOWz4f2EF-bBg_23_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">202000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_YfeQl7cb_UuW_SoAeer5cg_23_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_qVM3nYCAtkWrVBqnmOK3Kg_23_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-52000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_J2I89XeJPU-0P1wg5e9ViA_24_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-44094000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_Xs19Y-MUbUqJhOfLFAHe0A_24_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-33257000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_Z0TOZ9fsoU2xc6sP1Xme6g_24_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-28846000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w6UDjR_eTEagY1f1G_onNg"
      decimals="INF"
      id="Tc_PBLg2sTzSEOVBdsE-uMHBQ_5_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">11406221</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w6UDjR_eTEagY1f1G_onNg"
      decimals="-3"
      id="Tc_aNgdVbcEYECOJoCMNiT3lw_5_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mI1Et8gIm0OdOoNeRu_ZkQ"
      decimals="-3"
      id="Tc_EIBl4vO4sE-X6OAGACGIbw_5_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">198829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6I5vqtHVrke8eqs2gI250A"
      decimals="-3"
      id="Tc_enkTGqO9oE-RsjQRJ35NQQ_5_11"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__z1HrlyAiEeZoN2ntN1wdA"
      decimals="-3"
      id="Tc_dT5DeUKa2kyAcyTQDXsjQw_5_14"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-167859000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg"
      decimals="-3"
      id="Tc_frbYSs0gA0CMaKwfgKSFIw_5_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">30962000</us-gaap:StockholdersEquity>
    <tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg"
      decimals="INF"
      id="Tc_dfROwNrMRkekqRTpPtKVhA_6_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">306</tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase>
    <tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ"
      decimals="-3"
      id="Tc_x7U7vmG3Y0GVGz3KEhnpOQ_6_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3000</tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_F8T7K_V2qkee1C9qzBGkNA_6_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3000</tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg"
      decimals="INF"
      id="Tc_T9J2olmdNUm3VjYM9kuORQ_7_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">27783</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ"
      decimals="-3"
      id="Tc_729Y9o9jc06wcn2qPcrLmQ_7_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_OWaAETQHHkuJGC8xOYhFzw_7_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg"
      decimals="INF"
      id="Tc_JWbLgl7xs0G2lCI7Fl_VaQ_8_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">2797</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ"
      decimals="-3"
      id="Tc_8NvdMkAzLUqTFDB_CuGFXA_8_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">34000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_yYOUXmoGmEOUndeYg5Fb9g_8_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">34000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SOs1kkyXi0abe8ZkOi1Ztg"
      decimals="-3"
      id="Tc_OmT9azKCqkG05i9p6Oh9Cw_9_11"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-52000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_5sAPas127kaRYC0lgasZ0A_9_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-52000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ"
      decimals="-3"
      id="Tc_YtAD9JQjyUyaL9DPBBe-ZQ_10_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1976000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_8WVLcmH7nUmU2Hc0_L3EoQ_10_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1976000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg"
      decimals="INF"
      id="Tc_ry54KxUKB0e--XIK6VIm1g_11_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NGaGeEkFjU6InPPW0BXEwg"
      decimals="-3"
      id="Tc_aFgF09mMLUmYhgx98sU-MA_11_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K3C8U8_bTEGNEtnMiOUNPQ"
      decimals="-3"
      id="Tc_iTuum7c0NEi3O4dZYbJmPA_11_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">44719000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_zeZ1PM1GQkaqnmscIlYd7g_11_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">44722000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__lbPSe6rPkKCFW4tp1NNww"
      decimals="-3"
      id="Tc_7AxoIxhsS0G-klL4QJpH9w_12_14"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-28794000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_4nrmvqWcv0uKR-FCiUB29Q_12_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-28794000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ngCQpjdcvk-SsVBsAtLEbg"
      decimals="INF"
      id="Tc_EU5G3nsMBUKeqIpFF8-9Pg_13_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">14437107</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ngCQpjdcvk-SsVBsAtLEbg"
      decimals="-3"
      id="Tc_tnRwktmrZEOyVrcXGrcAAQ_13_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N7ZqSLBpBkC2dB9n5qsheQ"
      decimals="-3"
      id="Tc_1OPY9lUTck2GDLZgnE_Vcg_13_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">245736000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BALcPEf8f06_ByU0A3la0A"
      decimals="-3"
      id="Tc_7SXrzMgQhU22RUgQ8xL8Yw_13_11"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-71000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GnrH2KSZPUexCDzLyVUgWw"
      decimals="-3"
      id="Tc_o_cyfGhdH0-2YTkYs94tSA_13_14"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-196653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ"
      decimals="-3"
      id="Tc_eQGjdiwFREWpuM0eUORuzQ_13_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">49026000</us-gaap:StockholdersEquity>
    <tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew"
      decimals="INF"
      id="Tc_O-YNGUGM90CKU4AB5CYEzw_14_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">153</tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase>
    <tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA"
      decimals="-3"
      id="Tc_H_BYrTMDLE-rLkzyv5K43A_14_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000</tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_STwftRwzk0-_ZN7ZCvTz-Q_14_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000</tela:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew"
      decimals="INF"
      id="Tc_L0IJ-KjQaUSvOcmdar9-rg_15_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">89154</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew"
      decimals="-3"
      id="Tc_2yGuWANljkSytB21nyXCQA_15_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA"
      decimals="-3"
      id="Tc_Hv1V0EcwZEa5s9u7dgCpPw_15_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">546000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_h5P38bA8N0a4WMRcfr7i5g_15_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">547000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_InsdHgosGkWsL-h9hdxzew"
      decimals="INF"
      id="Tc_dcHzWjP8l0K7srcyt-5o2A_16_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">3163</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA"
      decimals="-3"
      id="Tc_WMbf0kJId0CtvsL8ADdsQw_16_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">38000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_Br2D8Cg0sEigjBUB_Znx6A_16_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">38000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_loDUZPMImEmoouzBKpBYYQ"
      decimals="-3"
      id="Tc_CywXa9av80CWyvhhsPmoUg_17_11"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_A8Mhsw97o02x07RLQRqUOQ_17_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA"
      decimals="-3"
      id="Tc_CSWeZca2HkerB2orAk626g_18_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3661000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_0g_avfBpG0adSW94RpEIQA_18_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3661000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tela:AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rdUje_OpSkOpjmPGbCfeGA"
      decimals="-3"
      id="Tc_eq_csioqwEGXzAR-uCbpSQ_19_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">82000</tela:AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation>
    <tela:AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_BKdVco8ChEaK8tgt-vBjWw_19_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">82000</tela:AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qV52jkzrGkyM3BjDcW7aFg"
      decimals="-3"
      id="Tc_hZ-ohSD0CUWVW6mMjWCp5w_20_14"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-33276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_pJTLcOgyl026Jlr7VcPBmw_20_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-33276000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-N1PP0dpzE6v3HICXjB5NQ"
      decimals="INF"
      id="Tc_5TAjAShh7kSKeoycinVLeg_21_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">14529577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-N1PP0dpzE6v3HICXjB5NQ"
      decimals="-3"
      id="Tc_z89SboXQgU2ZU25iHe6gLA_21_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8Dc-5nKCK0aFZB4G6pHLtA"
      decimals="-3"
      id="Tc_AIlKYNOp9kO192wpsG-5vQ_21_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">250064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v61EXnBz5UOMTIqvTTVxlQ"
      decimals="-3"
      id="Tc_35UusNAlCkSxOLGyNrlKbA_21_11"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Joj3v_81eEyOiZcwVgt7eA"
      decimals="-3"
      id="Tc_1r_8zBfeyk2Bh3THpgisqQ_21_14"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-229929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_asiN_uh1yUytyGu0P4vkTQ_21_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">20098000</us-gaap:StockholdersEquity>
    <tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg"
      decimals="INF"
      id="Tc_vVrxv7GvpUS_VQqzhyNppg_22_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">29</tela:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg"
      decimals="INF"
      id="Tc_2KSb6TKozE6vhTd8GY-uuw_23_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">44346</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g"
      decimals="-3"
      id="Tc_xe_RA52eUEOhYUuf2zoG3g_23_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_zQ3R0vYYO0as1MqyRA7CaA_23_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg"
      decimals="INF"
      id="Tc_Saw3akBky0qq8BvgsBRYNg_24_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">4523</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g"
      decimals="-3"
      id="Tc_onrIFjCqdUWcY3-297Obgw_24_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">50000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_2I-I0BjC00-nMZBUUcxf4g_24_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">50000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg"
      decimals="INF"
      id="Tc_-mrBGIG7-0Ollo-D0oZnRQ_25_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">13448</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g"
      decimals="-3"
      id="Tc_zEZPe2h1v06PI5YA6QU01w_25_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">157000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_pthx9wVslk-LKS2Fmzruew_25_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">157000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IVbed4JzJkGCxrAyFbPuzA"
      decimals="-3"
      id="Tc_n19WphwGaECRkQO5dXFRKg_26_11"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">202000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_I8T5f6Nm3kigKZCJ96e_Vw_26_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">202000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g"
      decimals="-3"
      id="Tc_KHiG1PAt70a16subwQDoZw_27_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3989000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_0mOxRM51MkK7rQne3hIhug_27_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3989000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg"
      decimals="INF"
      id="Tc__-VUI5k37keZ52nNByQ-Yg_28_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_51T2o_PFUEOrnWsHVwvLWg"
      decimals="-3"
      id="Tc_q058P9DdQky5ovhqofrslQ_28_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__2WtVvLf8UCNrhKrDZM92g"
      decimals="-3"
      id="Tc_ieyNxeb6GE6Dr6zADTZEgQ_28_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">34396000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_JI7NRddnbk2htJU3rVw2gQ_28_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">34400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gvnas9QAp02vVM237t3iyQ"
      decimals="-3"
      id="Tc_jpYmpTOFOE2RGyxHZxao5A_29_14"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-44296000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_NfMeb0711k-r5jdnmB4xGQ_29_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-44296000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZbaHak272kytCiOj7lO8ow"
      decimals="INF"
      id="Tc_wsUJMZOkDUalQb2-QLiwBA_30_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">19165027</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZbaHak272kytCiOj7lO8ow"
      decimals="-3"
      id="Tc_n2YsBiEDBkeOlLhigThB5Q_30_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6jS7FaWS5k2vBIexrI3UwA"
      decimals="-3"
      id="Tc_SCiV3-hqUUiBBiKINDoMKQ_30_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">288361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cMdTTyP7gEeGyUNTqvLRNg"
      decimals="-3"
      id="Tc_y93Ni2qjM0qx6_Qb0IPK_A_30_11"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__0NqwDOnU069qrqDweDq7A"
      decimals="-3"
      id="Tc_UBeBbTtDXkeMJ1-FRBfPaA_30_14"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-274225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_9rpOPseSNUmAefEw7W6Cdw_30_17"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">14305000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_05iebgxycUW1A_mIMszfow_4_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-44296000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_G76JMjOR20-yUc0OvnQ5ng_4_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-33276000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_Y_TN3UG2Lky2Yj_ZE4CQ2w_4_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-28794000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_cIvpsJA4gkizfHAdtLzaqw_6_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">383000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_3-kR8Inh10Ozv5HLcY7fQA_6_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">231000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_rx-Z0ahVIUGuVBOkTjeVgg_6_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">221000</us-gaap:Depreciation>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_61y02Jyal0O3GbDOh1jTBw_7_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">657000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_wKqndEGEkEyHT4sBQwBBNg_7_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">664000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_TR5Va2WI60Ob9Oj7mWE4PA_7_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">584000</us-gaap:PaidInKindInterest>
    <tela:NoncashLossOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_qbRmgVY6c0W1_Lx2JxnN0A_8_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1228000</tela:NoncashLossOnExtinguishmentOfDebt>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_oNAuWi3DSEey6KKcv1puBw_9_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">804000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_lrr_xQLMhUSPBe02QE-Dug_9_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">304000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_qTp7qyfFi0OIWtej9kvzcg_9_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">304000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <tela:NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_rrox9fEf906Jkc4EGQOXEg_10_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">36000</tela:NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_0tZfyOxI40m68I-u189_Qw_11_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1866000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_JjHoYygC8k6XZCTqY20Baw_11_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1439000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_8C6jThV8rkSoWGu9TciLCA_11_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1327000</us-gaap:InventoryWriteDown>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_qpeqkBB-AU-_8VHxt13q0Q_12_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3989000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_CSwPpcWfs06DdcaSGBNv5Q_12_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3661000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_kn3MSpduE0WxfolE7v-HDA_12_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2058000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_nZ0lR6SIUEi1xXXJoHh3SQ_13_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-2000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_eX3TOnkKWUieWLWqiLmNJQ_15_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2421000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_K4PVK0jvYkSDn7khISOyKQ_15_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1553000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_i5X693J79keHiMoITTwMmA_15_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-149000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_Pw3ohuPjtUea4zpFgpdZ5Q_16_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">6073000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_tg0PUW1PwEOgGrrMwgO6jA_16_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">5194000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_ZRhDzMOrckWNkyEmyesLlQ_16_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">620000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_OuRBXQVwTkyB8Au1uBDNpg_17_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-1216000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_1XmiyuqH3UenFhgOzvoyRg_17_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">992000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_yj8Fq1354UWvkzyx5CWUhw_17_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-66000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_486DJ3bwtk29snxZkt1Nwg_18_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-884000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_y6DJ6RAvFk-31aov_bx67Q_18_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1597000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_7-DJwM4Jf0OVxBhIshwEOA_18_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-2002000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_x93rFSLinUuBpJuCOzgzWA_19_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2399000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_1a7tEf8StkWXsZSaZGcRrw_19_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2673000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_GEGpuU0FdkiCYcK05AQ6_Q_19_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2321000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_e8ikf6S9jEu_b936UyzRRw_20_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-420000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_q_lRtu_PZkCCyvXoNW-sdA_20_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-12000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_XkoCzwx9mEub9YZp5uUJTw_20_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">70000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_rGhCsNkwo0ShZIWrEB2w2A_21_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-40748000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_GTUmBpkYy0OdoSQWLLZwCA_21_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-30432000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_T-1D5EcF_06dzhEB5PHRDQ_21_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-24456000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_tylGFhq7DEKky3bREK5Q9w_23_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">9289000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_ZKpQNwhUUU2ok2wyQFgpRw_24_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_8r7-F8cmgEG7f-Wg53Ax8Q_25_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">872000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_BVur8vedZ022jX8a2YNfEA_25_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">627000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_t2QIoHFjGEeu85I6-a7fNw_25_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">167000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_D0c4EcC5nU6pnbeM5qZ57A_26_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-1872000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_wbMRWJtxcUS9aUc7I9ZH9g_26_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-627000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_R9bbY_dZLEmObj1Eyni7uA_26_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">9122000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_QGM4WTEhq0iu_LBk2gG4mg_28_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">34400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_b9UIu_zBsEGiZRWq8jGBEQ_28_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">44722000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_rN2pFbpDfkGJi0EUZM0zzQ_29_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">40000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_qXcwPeh57k2ilvi9F9Jdyw_30_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">30000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_ELFFthW96kudWi4NIKzPqw_31_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3460000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_SI_QF34qHkCHxr5zQ3-eiQ_32_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">522000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_y9PuEZ1AxU-5O9oJygwFqw_33_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">19000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_3zNsb9Up9kWVBpAidFhZ8Q_33_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">547000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc__bQ3xsXUWkKoHqhTv8fOGw_33_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">175000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_oqvWoYQFw0iOSBecRxHKlw_34_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">157000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_Kwq8KaTL9km1QqPtmJfpMA_35_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">50000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_oeDvnYkHsECaUsUD_MF7WQ_35_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">38000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_A6NQ7qAl10KODn_mURvswQ_35_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">34000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_CYixyJNyqUSxf7myaDlWTQ_36_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">40852000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_pojd6AfzrUqZ78ojIK5S1A_36_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">585000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_Xp2vTgkQUEqeBiOkW2fybw_36_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">44409000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_QiEuNawLl0y54YbxSRVwKw_37_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-144000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_cnxxyh2ANkuLeeilduz9HQ_37_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">11000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_oJwEPZZiI0KDGAojlqEjyA_37_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">17000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_ArgD9_ncyUajM-rrJhW1nA_38_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-1912000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_MkoIdf9D40CUuHTxOFw9lg_38_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-30463000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_bFgz_IoqbEi_p6VkGoniYQ_38_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">29092000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_CdHn-xxVz0yIvkjpToDIeQ_39_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">43931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ"
      decimals="-3"
      id="Tc_0Hz_6LUALUKRbyA8-cSE-w_39_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">74394000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg"
      decimals="-3"
      id="Tc__BrJLAnrGU-IPIumLevDUQ_39_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">45302000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_vdD89D7qQE2XgtPnxcogcg_40_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">42019000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_-QTadml3gkKWu9yjbsM5Pw_40_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">43931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ"
      decimals="-3"
      id="Tc_TziFTePXsUOiCcfPFdrgGg_40_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">74394000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_dacsK-aOLU2FaEJ6QkIlqQ_42_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3394000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_TcanEg3OiU6-ch78-5uBgw_42_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2933000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_p3vT35U1dkKhnDp0luSCcQ_42_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2980000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_AI9qZAgw6ECEmPsFB6eleQ_44_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">7000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_si4Rmm5je0KMWZAqEv27EA_44_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">166000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_0rggLZbJaEuOOcoAWMeTFQ_44_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_kvbdQ94eiUSGXgSZtrkrOA_45_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_lqCfJphsn0S4PTUAEtU-zg_45_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3000</us-gaap:StockIssued1>
    <tela:LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_E6M9sY1Yt0q3cukP9D9h2A_46_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">82000</tela:LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities>
    <tela:ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_9RfQimk-hE2CtTmyE2QcSA_47_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">82000</tela:ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_W7nsunf9rkuMd2USdpG2Hg_48_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1376000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <tela:TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_YnxteH83JU2pOGzqBQAIwQ_49_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">380000</tela:TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities>
    <tela:OperatingLeaseObligationAssumed
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_vnePwamIdUaNu2j_UeCWRg_50_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-1756000</tela:OperatingLeaseObligationAssumed>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_ocCM_nkLpUehU9ZsbM8AkA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(1)&#160;Background&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;TELA Bio,&#160;Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware on April&#160;17, 2012 and wholly owns TELA Bio Limited, a company incorporated in the United Kingdom. The Company is commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient&#x2019;s own anatomy. OviTex Reinforced Tissue Matrix (&#x201c;OviTex&#x201d;), the Company&#x2019;s first portfolio of products, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. OviTex PRS Reinforced Tissue Matrix (&#x201c;OviTex PRS&#x201d;), the Company&#x2019;s second portfolio of products, addresses unmet needs in plastic and reconstructive surgery. The Company&#x2019;s principal corporate office and research facility is located in Malvern, Pennsylvania.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has been directly impacted by the COVID-19 pandemic since the onset of the pandemic in 2020. To date, among other impacts on the Company&#x2019;s business related to the pandemic, physicians and their patients have been required by state mandates, or have chosen to, defer elective surgery procedures in which the Company&#x2019;s products otherwise would be used. There remains uncertainty and lack of visibility regarding the Company&#x2019;s near-term revenue growth prospects and product development plans due to the volatility in the frequency of surgical procedures using the Company&#x2019;s products, including through labor and hospital staffing shortages and the allocation of hospital resources due to financial strain experienced during the COVID-19 pandemic. Although the Company continues to monitor developments related to hospital capacity and the volume of elective procedures, there is uncertainty regarding the pace to which surgical volumes will normalize to their pre-pandemic levels and the timing to address the backlog of deferred procedures. The full extent of the impact of the COVID-19 pandemic on the Company&#x2019;s business, results of operations and financial condition, including revenue, expenses, manufacturing capability, supply chain integrity, staffing availability, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_sfXXNJrCK0KRmxY1kvpSVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(2)&#160;Risks and Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operations to date have focused on commercializing products, developing and acquiring technology and assets, business planning, raising capital and organization and staffing. The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $274.2 million as of December 31, 2022. The Company anticipates incurring additional losses until such time, if ever, it can generate sufficient revenue from its products to cover its expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In August 2022, the Company completed an underwritten public offering in which the Company issued and sold 4,600,000 shares of its common stock at a public offering price of $8.00 per share. The Company received net proceeds of $34.4 million after deducting underwriting discounts, commissions and other offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The operations of the Company are subject to certain risks and uncertainties including, among others, the uncertainty of product development, the impact of macroeconomic conditions, including the COVID-19 pandemic, general economic uncertainty, including as a result of inflationary pressures and the measures undertaken by various governments to address them, banking instability, geopolitical factors such as the war in Ukraine, technological uncertainty, commercial acceptance of any developed products, alternative competing technologies, dependence on collaborative partners, uncertainty regarding patents and proprietary rights, comprehensive government regulations, and dependence on key personnel.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Narr_c-7FzdjTbUGRMT-aCaU-zA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">-274200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw"
      decimals="INF"
      id="Narr_YT0-sLIStUSpSV-5HQs3ng"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_e7ixSa7Av0qDAVrov1S1Rw"
      decimals="2"
      id="Narr_y-IHow0TY0aVsaZnUg_9-Q"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">8.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw"
      decimals="-5"
      id="Narr_-AH7eGZJUUan3vLcbaxm0A"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">34400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_uIQKdKtx-Uim8_JRTZWqLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(3)&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation and Principals of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of TELA Bio,&#160;Inc. and its wholly owned subsidiary TELA Bio Limited. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company&#x2019;s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash with high-credit-quality financial institutions and primarily invests in money market funds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (&#x201c;SVB&#x201d;) and appointed the FDIC as receiver. On March 12, 2023, the U.S. Department of the Treasury, the Federal Reserve and the FDIC released a joint statement confirming that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In addition, on March 10, 2023, the Bank of England (the &#x201c;BOE&#x201d;) announced that it intended to seek the placement of Silicon Valley Bank UK Limited (&#x201c;SVBUK&#x201d;), an affiliate of SVB, into a Bank Insolvency Procedure, which ultimately results in the acquisition of SVBUK by HSBC UK Bank Plc (&#x201c;HSBC") on March 13, 2023. The BOE confirmed that all depositors&#x2019; money with SVBUK is safe and secure as a result of the transaction, and that operations at SVBUK would continue as normal.   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the course of these events, a portion of the Company&#x2019;s cash was held in accounts at SVB and SVBUK, with the remainder held at another high-credit-quality financial institution. We have recently established additional redundant accounts with another high-credit-quality financial institution to mitigate liquidity risk to our cash and cash equivalents from any further instability in the financial industry.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As described in Note&#160;11, the Company has licensed patents and other intellectual property from Aroa Biosurgery Ltd. (&#x201c;Aroa&#x201d;). As part of this agreement, Aroa is also the exclusive contract manufacturer of the Company&#x2019;s OviTex portfolio of products. The inability of Aroa to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with Aroa, or an adverse change in their business, could materially impact future operating results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers cash equivalents to be highly liquid investments with maturities of three&#160;months or less from the date of purchase. Cash equivalents consist of investments in a money market fund. The Company&#x2019;s cash and cash equivalents are carried at fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory consists of finished goods and is identified and tracked by lot and stated at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. The Company periodically analyzes its inventory levels and writes down inventory that has become obsolete or that has a cost basis in excess of its expected net realizable value based on expected customer demand. As of December 31, 2022 and 2021, the Company had $2.3&#160;million and $1.7&#160;million, respectively, in finished goods consigned to others.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at the aggregate cost incurred to acquire and place the asset in service. Expenditures for routine maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Depreciation is provided over the estimated useful lives of the assets using the straight-line method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and milestone payments due related to licenses or commercialization rights prior to future economic benefit being established are recorded as research and development expenses. Milestone payments due related to licenses or commercialization rights after future economic benefit is established are recorded as intangible assets. In 2022, 2021 and 2020, the Company recorded $0.8 million, $0.3 million and $0.3 million of amortization expense, respectively, related to intangible assets. At December 31, 2022, the remaining life of intangible assets was 6.6&#160;years. The Company anticipates recognizing amortization expense of $0.4&#160;&lt;span style="-sec-ix-hidden:Hidden_N7lFaWJk4UioTzyN62omEA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million&lt;/span&gt;&lt;/span&gt; in each of the &lt;span style="-sec-ix-hidden:Hidden_KtzSWTvEJkCOw76-3Skdsg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;next&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_M4WVaq1GFEm8sYjSSs7jbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;&#160;&lt;span style="-sec-ix-hidden:Hidden_BsVw2TEmt0uc2rx2gi65UA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;years&lt;/span&gt;&lt;/span&gt; and $0.5&#160;million thereafter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by such asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group exceeds the undiscounted cash flows, an impairment is recognized to the extent the carrying value exceeds its fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment losses were recognized during the&#160;years ended December 31, 2022, 2021 or 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Debt Issuance Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Debt issuance costs incurred in connection with debt (Note&#160;6) are amortized to interest expense over the term of the respective financing arrangement using the effective-interest method. Debt issuance costs, net of related amortization are deducted from the carrying value of the related debt.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i)&#160;identify the contract(s)&#160;with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Company&#x2019;s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Company&#x2019;s customer contracts, the only identified performance obligation is providing the product to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Revenue is recognized at the estimated net sales price which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Payment terms with customers do not exceed one&#160;year and, therefore, the Company does not account for a financing component in its arrangements. There are no incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than one&#160;year. Fees charged to customers for shipping are recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents revenue disaggregated (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;OviTex&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,093&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;OviTex PRS&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,473&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Sales outside of the U.S. were $3.2 million or 8% of total revenue for the year ended December 31, 2022 and immaterial for the years ended December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are charged to expense as incurred and consist primarily of salaries, benefits, and other related costs, including stock-based compensation for personnel serving in the research and development functions as well as costs incurred with Aroa under development agreements related to technology transfer, laboratory materials and supplies. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. Costs incurred in obtaining patent and other intellectual property licenses or milestone payments from license agreements for which there are no alternative future uses are charged to expense as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for stock-based awards in accordance with provisions of ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt;, under which the Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over the vesting period of the award while awards containing a performance condition are recognized as expense when the achievement of the performance criteria is considered probable. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset-and-liability method as required by ASC Topic 740, &lt;i style="font-style:italic;"&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Subtopic 740-10, &lt;i style="font-style:italic;"&gt;Accounting for Uncertainty of Income Taxes &lt;/i&gt;(&#x201c;ASC 740-10&#x201d;), defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in consolidated financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the consolidated financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#x2019;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair value of financial instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. Due to the related-party relationship of the OrbiMed Credit Facility (Note&#160;6), it was impractical to determine the fair value of the debt. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the provisions of ASC Topic&#160;820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level&#160;&lt;/i&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;"&gt;1:  &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level&#160;&lt;/i&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;"&gt;2:  &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level&#160;&lt;/i&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;"&gt;3:  &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following fair value hierarchy table presents information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;measurement&#160;at&#160;reporting&#160;date&#160;using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;active&#160;markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&#160;&#x2013; money market fund&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&#160;&#x2013; money market fund&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:12pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per common share is determined by dividing net loss by the weighted-average shares of common stock outstanding during the reporting period. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share since dilutive shares are not assumed to have been issued if their effect is antidilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as they would be antidilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options (including shares subject to repurchase)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,071,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,706,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,498,390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 311,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,472,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,958,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,586,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;, (&#x201c;ASU 2016-02&#x201d;) which requires a lessee to record a right-of-use (&#x201c;ROU&#x201d;) asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12&#160;months. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&#160;its effective date or (2)&#160;the beginning of the earliest comparative period presented in the consolidated financial statements as its date of initial application. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the transition practical expedients to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the date of application.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13, &lt;i style="font-style:italic;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which provides guidance for recognizing credit losses on financial instruments based on an estimate of current expected credit losses model. The standard is effective for the Company beginning January&#160;1, 2023, and the adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In August 2020, the FASB issued ASU No.&#160;2020-06, &lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options&lt;/i&gt;&lt;i style="font-style:italic;"&gt; and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (&#x201c;&lt;/i&gt;ASU 2020-06&#x201d;)&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. The adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_NdhnL46pI0Cavk2dUjlCLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation and Principals of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of TELA Bio,&#160;Inc. and its wholly owned subsidiary TELA Bio Limited. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_3D0ep_FRx0eyDmzOwn3n-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company&#x2019;s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_K6lpGrU0fkebF8ge78YFTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="INF"
      id="Narr_4CsR91aKx0qBo3I0kLa2ag"
      unitRef="Unit_Standard_segment_I8CJGHwyyEWw2nQXigOSaQ">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_YMPUaTqSrUqIlJQvaBRqCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash with high-credit-quality financial institutions and primarily invests in money market funds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (&#x201c;SVB&#x201d;) and appointed the FDIC as receiver. On March 12, 2023, the U.S. Department of the Treasury, the Federal Reserve and the FDIC released a joint statement confirming that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In addition, on March 10, 2023, the Bank of England (the &#x201c;BOE&#x201d;) announced that it intended to seek the placement of Silicon Valley Bank UK Limited (&#x201c;SVBUK&#x201d;), an affiliate of SVB, into a Bank Insolvency Procedure, which ultimately results in the acquisition of SVBUK by HSBC UK Bank Plc (&#x201c;HSBC") on March 13, 2023. The BOE confirmed that all depositors&#x2019; money with SVBUK is safe and secure as a result of the transaction, and that operations at SVBUK would continue as normal.   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the course of these events, a portion of the Company&#x2019;s cash was held in accounts at SVB and SVBUK, with the remainder held at another high-credit-quality financial institution. We have recently established additional redundant accounts with another high-credit-quality financial institution to mitigate liquidity risk to our cash and cash equivalents from any further instability in the financial industry.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As described in Note&#160;11, the Company has licensed patents and other intellectual property from Aroa Biosurgery Ltd. (&#x201c;Aroa&#x201d;). As part of this agreement, Aroa is also the exclusive contract manufacturer of the Company&#x2019;s OviTex portfolio of products. The inability of Aroa to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with Aroa, or an adverse change in their business, could materially impact future operating results.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_gHCziumJ4karwV21ZXzVzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers cash equivalents to be highly liquid investments with maturities of three&#160;months or less from the date of purchase. Cash equivalents consist of investments in a money market fund. The Company&#x2019;s cash and cash equivalents are carried at fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_ptjRrrD5W0ioI4snh6VcdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory consists of finished goods and is identified and tracked by lot and stated at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. The Company periodically analyzes its inventory levels and writes down inventory that has become obsolete or that has a cost basis in excess of its expected net realizable value based on expected customer demand. As of December 31, 2022 and 2021, the Company had $2.3&#160;million and $1.7&#160;million, respectively, in finished goods consigned to others.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Narr_PTdvalngxkqRYctF73C9Qw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2300000</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-5"
      id="Narr_t4Qw2DkUW0aVpHs4F8PIwQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1700000</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_q5-AhCQtME2P_dDt1tvTxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at the aggregate cost incurred to acquire and place the asset in service. Expenditures for routine maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Depreciation is provided over the estimated useful lives of the assets using the straight-line method.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_XLf21lP4d0-igk5UF_x4dQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and milestone payments due related to licenses or commercialization rights prior to future economic benefit being established are recorded as research and development expenses. Milestone payments due related to licenses or commercialization rights after future economic benefit is established are recorded as intangible assets. In 2022, 2021 and 2020, the Company recorded $0.8 million, $0.3 million and $0.3 million of amortization expense, respectively, related to intangible assets. At December 31, 2022, the remaining life of intangible assets was 6.6&#160;years. The Company anticipates recognizing amortization expense of $0.4&#160;&lt;span style="-sec-ix-hidden:Hidden_N7lFaWJk4UioTzyN62omEA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;million&lt;/span&gt;&lt;/span&gt; in each of the &lt;span style="-sec-ix-hidden:Hidden_KtzSWTvEJkCOw76-3Skdsg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;next&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_M4WVaq1GFEm8sYjSSs7jbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;&#160;&lt;span style="-sec-ix-hidden:Hidden_BsVw2TEmt0uc2rx2gi65UA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;years&lt;/span&gt;&lt;/span&gt; and $0.5&#160;million thereafter.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-5"
      id="Narr_lyo1qTLgUUGr5XfKrkB6mQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">800000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-5"
      id="Narr_Vdc-4qPWIUmQ3LTFviQlYQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">300000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-5"
      id="Narr_ESp0m-5TIEmJ-dd3evkmAg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">300000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_3Rrjcl0_TEuBaiNgTc6qTw">P6Y7M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Narr_tmxXsBIVdEC3JzSPyLUa6w"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Narr_aI3FVOGjPUim43k_PvXjLw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_cBespzxVLkqHlWQ6LWvPcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by such asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group exceeds the undiscounted cash flows, an impairment is recognized to the extent the carrying value exceeds its fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment losses were recognized during the&#160;years ended December 31, 2022, 2021 or 2020.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-5"
      id="Narr_AqkUH1jEk0-J2U3Wlv4gyQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-5"
      id="Narr_lzPhqlzHqE6w2lNUcd1OAA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-5"
      id="Narr_7wT4p6EYk0SkmMnuQL12NA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_RapPcdp8Ik-B_H4QATNZSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Debt Issuance Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Debt issuance costs incurred in connection with debt (Note&#160;6) are amortized to interest expense over the term of the respective financing arrangement using the effective-interest method. Debt issuance costs, net of related amortization are deducted from the carrying value of the related debt.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_OtCFG1kXJUi9dYosDBlnXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i)&#160;identify the contract(s)&#160;with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Company&#x2019;s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Company&#x2019;s customer contracts, the only identified performance obligation is providing the product to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Revenue is recognized at the estimated net sales price which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Payment terms with customers do not exceed one&#160;year and, therefore, the Company does not account for a financing component in its arrangements. There are no incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than one&#160;year. Fees charged to customers for shipping are recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents revenue disaggregated (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;OviTex&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,093&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;OviTex PRS&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,473&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Sales outside of the U.S. were $3.2 million or 8% of total revenue for the year ended December 31, 2022 and immaterial for the years ended December 31, 2021 and 2020.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <tela:IncrementalCostsOfObtainingContract
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Narr_-nuEigRNHkqZrxtyraP6Gg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</tela:IncrementalCostsOfObtainingContract>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_bSGTtcmmSkWMVy0DXbI_vA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents revenue disaggregated (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;OviTex&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,093&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;OviTex PRS&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,473&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OvitexMember_EdbT9Stg4kukXsfXOaqw7A"
      decimals="-3"
      id="Tc_k75sSUEuIE2JXP7RoOCdzQ_3_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">28879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tela_OvitexMember_KoD1LsmYCUi3vu5Gf7IEhw"
      decimals="-3"
      id="Tc_8fngu1mqFE6Vz360wU3osg_3_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">22990000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tela_OvitexMember_g62SfrjEtkKrRkIEyjjV_w"
      decimals="-3"
      id="Tc_1sBfa7aTekij6vrPxZPpFg_3_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">15093000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OvitexPrsMember_L3BIDNF6OES8ZPhVA4kbNA"
      decimals="-3"
      id="Tc_82fUkehlQkmPd-xWD-EeCA_4_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">12431000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tela_OvitexPrsMember_65VAhesxikuTOSd3VYTV5Q"
      decimals="-3"
      id="Tc_UjOAQah8nEi00HnnujukAg_4_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">6473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tela_OvitexPrsMember_633JkzTN7k-JMFLDXqSR6g"
      decimals="-3"
      id="Tc_sjGVY2g5BUacVVaIZQayxQ_4_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tela_OtherCustomersMember_jNrO6oj7BUi2tHp_zIcW1A"
      decimals="-3"
      id="Tc_2RUtwNUg1kquTtcXsxjGTg_5_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_CJNhO_tNlkidxAYfyOu3fA_6_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">41418000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_x355mzwxP0WH4LMoLR71LA_6_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">29463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_g5jWg0OFH0uuemYLfYfMFg_6_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">18213000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_X-lkTg0yAk6A3AzjollXfg"
      decimals="-5"
      id="Narr_u6oB4p0zWkydo-loo3lo8Q"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tela:RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_X-lkTg0yAk6A3AzjollXfg"
      decimals="2"
      id="Narr_UBa6JuXnSk-HG-AzxHu8dA"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.08</tela:RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_yAFpdg3_kk-FEmgEwstfGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are charged to expense as incurred and consist primarily of salaries, benefits, and other related costs, including stock-based compensation for personnel serving in the research and development functions as well as costs incurred with Aroa under development agreements related to technology transfer, laboratory materials and supplies. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. Costs incurred in obtaining patent and other intellectual property licenses or milestone payments from license agreements for which there are no alternative future uses are charged to expense as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_2RpJv08mDUSDQJbrzWs4vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for stock-based awards in accordance with provisions of ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt;, under which the Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee board members as compensation expense on a straight-line basis over the vesting period of the award while awards containing a performance condition are recognized as expense when the achievement of the performance criteria is considered probable. The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_RlvTLlq9cEi1IRxzxN7iNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset-and-liability method as required by ASC Topic 740, &lt;i style="font-style:italic;"&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Subtopic 740-10, &lt;i style="font-style:italic;"&gt;Accounting for Uncertainty of Income Taxes &lt;/i&gt;(&#x201c;ASC 740-10&#x201d;), defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in consolidated financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the consolidated financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#x2019;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_pdBR3EV1qkuRAn4lkZLm5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair value of financial instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. Due to the related-party relationship of the OrbiMed Credit Facility (Note&#160;6), it was impractical to determine the fair value of the debt. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the provisions of ASC Topic&#160;820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level&#160;&lt;/i&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;"&gt;1:  &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level&#160;&lt;/i&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;"&gt;2:  &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level&#160;&lt;/i&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;white-space:pre-wrap;"&gt;3:  &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following fair value hierarchy table presents information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;measurement&#160;at&#160;reporting&#160;date&#160;using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;active&#160;markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&#160;&#x2013; money market fund&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&#160;&#x2013; money market fund&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_gppnzFcql0q0JSLnd0LbBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following fair value hierarchy table presents information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;measurement&#160;at&#160;reporting&#160;date&#160;using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;active&#160;markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&#160;&#x2013; money market fund&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&#160;&#x2013; money market fund&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_PGJ1GKO4r0m8-XWNlJhlug"
      decimals="-3"
      id="Tc_UqJCApn8ukaXUT5GfN34Ng_8_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">39010000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Aei9Npet1Ea_GR9b8r2LiQ"
      decimals="-3"
      id="Tc_5A1O0H8OQ06D2EFS2C2c_A_11_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">41396000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_Or1-dqMi6UWX1Qup2vDFIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:12pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per common share is determined by dividing net loss by the weighted-average shares of common stock outstanding during the reporting period. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share since dilutive shares are not assumed to have been issued if their effect is antidilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding, as they would be antidilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options (including shares subject to repurchase)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,071,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,706,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,498,390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 311,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,472,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,958,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,586,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_nZsBl7s95U-GnRnLyg3JbA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options (including shares subject to repurchase)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,071,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,706,438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,498,390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 311,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,472,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,958,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,586,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_tv04xB9wqEaTQH96wyjNIw"
      decimals="INF"
      id="Tc_7LAy9r1ddkqIZ_-w7IEobw_3_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">2071848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_pRF4sUzZHkaM1gci9cPj_g"
      decimals="INF"
      id="Tc_Zq2gb6orp0u4NxEIuayacw_3_4"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1706438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_UGImw1N6L0mZ0fnBk-7tDQ"
      decimals="INF"
      id="Tc_aCaFurlaFkGHVD3-rh0t1w_3_6"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1498390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_rqhtk_S59EqxwFA-juI72g"
      decimals="INF"
      id="Tc_ITvmeKR8lkqqeoOLBCKDqw_4_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">311991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cI7QGTXY5USeztjg0obgqA"
      decimals="INF"
      id="Tc_MhbjFiFtZ0iZKnH0kKphqg_4_4"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">163043</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_E9meB2rtA0C78Kyfm-g3Bg"
      decimals="INF"
      id="Tc_WuMeMq5gKkm9hKepSB0q-w_5_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">88556</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_sM9LuqJ1i0q0bgc5PtaRTQ"
      decimals="INF"
      id="Tc_YN85ALqVWEWz7UiUUvk_Ww_5_4"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">88556</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_tela_CommonStockWarrantsMember_0cVBhli_GUqVg00WCdCr8A"
      decimals="INF"
      id="Tc_fIZVB-cTdUKIrsFux6-olA_5_6"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">88556</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="INF"
      id="Tc_Pa5sBIxLVEym12hPZF9mZA_6_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">2472395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="INF"
      id="Tc_2bNCAo_SKUWun-O4UJT_eg_6_4"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1958037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="INF"
      id="Tc_K-p0HweGG0ameDJG_kxqRw_6_6"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1586946</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb__76EjmLUJE2g371uWEQyrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;, (&#x201c;ASU 2016-02&#x201d;) which requires a lessee to record a right-of-use (&#x201c;ROU&#x201d;) asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12&#160;months. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&#160;its effective date or (2)&#160;the beginning of the earliest comparative period presented in the consolidated financial statements as its date of initial application. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the transition practical expedients to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the date of application.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13, &lt;i style="font-style:italic;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which provides guidance for recognizing credit losses on financial instruments based on an estimate of current expected credit losses model. The standard is effective for the Company beginning January&#160;1, 2023, and the adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In August 2020, the FASB issued ASU No.&#160;2020-06, &lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options&lt;/i&gt;&lt;i style="font-style:italic;"&gt; and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (&#x201c;&lt;/i&gt;ASU 2020-06&#x201d;)&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. The adoption of this guidance is not expected to have a significant impact on the consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_ARCEjlOF_UKP2UYNNjC_Ng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(4)&#160;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated useful lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&#160;Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&#160;Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 274&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3&#160;Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of useful life or lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,140)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,757)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,682&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The cost of property and equipment at both December&#160;31, 2022 and 2021 includes $0.2&#160;million of equipment located at Aroa. Depreciation expense was $0.4&#160;million, $0.2&#160;million and $0.2 million for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_qI3MnDlZxEmCJpFXXctoWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated useful lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&#160;Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&#160;Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 274&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3&#160;Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of useful life or lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,140)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,757)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,682&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_hqviTa-18kW6leCDSegk5w"
      id="Tc_lFxcUzqNtEGMXlP8-eUBCw_3_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_kFCoP67BGk6_GGyzDE7erQ"
      decimals="-3"
      id="Tc_Ry5H81YJqEGhjG_8xc6m0A_3_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2635000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_LabEquipmentMember_T7ZsTtnwJUu8lL-B2AMf1g"
      decimals="-3"
      id="Tc_Xf3eWZLSYEKQ1mPEi7fZ2Q_3_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2352000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_L6OtipUKj0WBTkfRIZ9BCw"
      id="Narr_wO5ptA4XsEOXDLcmP8MJRg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mPjPPo5jm0CMb8H3SqPEdg"
      decimals="-3"
      id="Tc_Cj3piFsNsU-mc2fT_GZWyQ_4_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">274000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_jpLtYA4OHkmQ_qtVIb5JZQ"
      decimals="-3"
      id="Tc_JjgAlenIZUi-8uMd_KbGZA_4_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">242000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_dMZmT2GGWEeog6Ay7w1DVA"
      id="Narr_usaHov5Xfkeqe4PbyIxH2w">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_1rGYh_LT7ki_OPiUFup5XQ"
      decimals="-3"
      id="Tc_nCC1FmdSVESNzaIlbZEdYg_5_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">604000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_ComputerEquipmentAndSoftwareMember_T-vzareBQk2hQt3aejgflA"
      decimals="-3"
      id="Tc_SKhqHQJXNEiYy83OIiXSqg_5_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">468000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_OELAYKjFM02OmAHs-BXhFA"
      decimals="-3"
      id="Tc_WMwzSwvdjkO0Dh8wlCo1fg_6_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2309000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_4PvHI75_kUy1koIiD7H3FA"
      decimals="-3"
      id="Tc_cm4lT2hdzUuO4mVogY09Vw_6_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1881000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_yi1v9wCzYUaBp69Hyl6upw_7_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">5822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_-zUJoCz_s0mSv1tSXyLsUA_7_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4943000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_fMwdMGGsy0-ejxPEDJLQSA_8_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4140000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_AWvoK4kSO0ygrTsgeaVvhQ_8_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3757000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_RmuERawfpke5JkAInytURA_9_5"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1682000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_Zk1e9JLdwEKdDJjroGEClw_9_8"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1186000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_BaYfUZMFFkC1bk-Vne9zAQ"
      decimals="-5"
      id="Narr_FXfytBvdIk-iB_ut6oW4_w"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw"
      decimals="-5"
      id="Narr_p64dB5DGB0CYzGjsewAAxQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-5"
      id="Narr_4nSFzUiYkk2wRfDmG5Lqvw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-5"
      id="Narr_l0TpkhXBR02JtRHUoeDyaA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-5"
      id="Narr_CLOPmaX3K0CXVTVXJzL8cA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">200000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_gfB2Qr_n5UCoDbbc0pPEpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(5)&#160;Accrued Expenses and Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party and professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amounts due to contract manufacturer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 842&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_I7-BRo6oeUC3d1NS3m78pw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party and professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amounts due to contract manufacturer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 842&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_GM5lnUvfokyrXiXEE4MbQw_3_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">6420000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_8QpGBuLcJ0GT0HkHRlTCDQ_3_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4976000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_5QZG6cXHdkWLZ49SUHs7ag_4_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2563000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_DX7L3oubfkukN9z6qvVh8g_4_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2233000</us-gaap:AccruedProfessionalFeesCurrent>
    <tela:AccruedExpensesAmountDueToContractManufacturer
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_Tj7_XkiEY0eJprk57zeDRg_5_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1263000</tela:AccruedExpensesAmountDueToContractManufacturer>
    <tela:AccruedExpensesAmountDueToContractManufacturer
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_j8mGeXK8R0CPZVAenZtHWA_5_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">842000</tela:AccruedExpensesAmountDueToContractManufacturer>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_VRiK9AdXhUqdcIFz6rMPlA_6_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">340000</us-gaap:OperatingLeaseLiabilityCurrent>
    <tela:ResearchAndDevelopmentExpensesPayableCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_j4i7kiAjikaTo6uJkVjomA_7_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">137000</tela:ResearchAndDevelopmentExpensesPayableCurrent>
    <tela:ResearchAndDevelopmentExpensesPayableCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_vIFpwKvf8U2Q8kS8fzJ8lQ_7_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">31000</tela:ResearchAndDevelopmentExpensesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_0P8Jev8m1E-xrf7DW0znTg_8_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">146000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_5NPMMDg-Mkah6m5H7UJTAg_8_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">79000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_SomUEBFJSEqlQu9PFcF49w_9_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">10869000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_biT6OtHfakOYCOvos_YJZw_9_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">8161000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_c1ZqIlySh0mUska7FEZ6jQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(6)&#160;Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-term debt consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;MidCap Term Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;OrbiMed Term Loan (related party)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;End of term charge&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unamortized end of term charge and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,084)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,509)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term debt &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;MidCap Term Loan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On May 26, 2022, the Company entered into the Credit and Security Agreement (the &#x201c;MidCap Credit Agreement&#x201d;) with MidCap Financial Trust, as agent (the &#x201c;Agent&#x201d;), and certain lender parties thereto. The MidCap Credit Agreement provides for up to $50.0 million in term loans (the &#x201c;MidCap Term Loans&#x201d;), consisting of a $40.0 million Tranche 1 (&#x201c;Tranche 1&#x201d;) and a $10.0 million Tranche 2 (&#x201c;Tranche 2&#x201d;). Upon closing, the Company borrowed $40.0 million of Tranche 1 and used a portion of the proceeds to repay borrowings under the OrbiMed Credit Facility (described below) and intends to use the remaining proceeds to fund operations and other general corporate purposes. The Company will be eligible to borrow Tranche 2 at the Company&#x2019;s option upon meeting certain conditions, including, but not limited to, reaching $65.0 million of net product revenue over the preceding four quarters by fiscal year end 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pursuant to the MidCap Credit Agreement, the Company provided a first priority security interest in all existing and future acquired assets, including intellectual property, owned by the Company. The MidCap Credit Agreement contains certain covenants that limit the Company&#x2019;s ability to engage in certain transactions that may be in the Company&#x2019;s long-term best interests, including the incurrence of additional indebtedness, effecting certain corporate changes, making certain investments, acquisitions or dispositions and paying dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The MidCap Credit Agreement also contains customary indemnification obligations and customary events of default, including, among other things, (i) non-payment, (ii) breach of warranty, (iii) non-performance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In addition, the Company must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, the Company would be required to pay interest on principal and all other due and unpaid obligations at the current rate in effect plus 2%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The MidCap Term Loans mature on May 1, 2027 and bear interest at a rate equal to 6.25% plus the greater of one-month Term SOFR (as defined in the MidCap Credit Agreement) or 1.0%. The Company is required to make 36 monthly interest payments beginning on June 1, 2022 (the &#x201c;Interest-Only Period&#x201d;). If the Company is in covenant compliance at the end of the Interest-Only Period, the Company will have the option to extend the Interest-Only Period by 12 months to 48 monthly interest payments, followed by 12 months of straight-line amortization, with the entire principal payment due at maturity. If the Company is not in covenant compliance at the end of the Interest-Only Period, the Company is required to make 24 months of straight-line amortization payments, with the entire principal amount due at maturity. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Subject to certain limitations, the MidCap Term Loans have a prepayment fee equal to 3.0% of the prepaid principal amount for the first year following the closing date of the MidCap Term Loans, 2.0% of the prepaid principal amount for &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;the second year following the closing date and 1.0% of the prepaid principal amount for the third year following the closing date and thereafter. The Company is also required to pay an exit fee at the time of maturity or prepayment event equal to 5% of all principal borrowings (the &#x201c;End of Term Charge&#x201d;) (or in the event of a prepayment event, the amount of principal being prepaid). Interest expense associated with the MidCap Credit Facility recorded for the year ended December 31, 2022 was $2.6 million, of which $0.4 million was related to the amortization of debt issuance costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;OrbiMed Term Loan (Related Party)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2018, the Company entered into the OrbiMed Credit Facility with OrbiMed, a related party as the lender is affiliated with a stockholder of the Company, which consisted of up to $35.0 million in term loans (the &#x201c;OrbiMed Term Loans&#x201d;). The OrbiMed Term Loans consisted of two tranches, a $30.0&#160;million Tranche&#160;1 (&#x201c;First Tranche&#x201d;) and a $5.0&#160;million Tranche&#160;2 (&#x201c;Second Tranche&#x201d;). In November&#160;2018, the Company borrowed $30.0&#160;million of the First Tranche. The Company elected not to borrow the Second Tranche&#160;prior to its expiration on December&#160;31, 2019. On May 26, 2022, the Company entered into the MidCap Credit Agreement and upon closing used a portion of the proceeds to repay all borrowings under the OrbiMed Credit Facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The OrbiMed Term Loan bore interest at a rate equal to 7.75% plus the greater of one-month LIBOR or 2.0% until the aggregate principal, interest and End of Term Charge of $3.0 million were paid with part of the proceeds received from the MidCap Credit Agreement. As a result of these payments, a $1.2 million loss on extinguishment was recorded during the year ended December 31, 2022. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2022, was $1.5 million, of which $0.3 million was related to the amortization of debt issuance costs. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2021, was $3.6 million, of which $0.7 million was related to the amortization of debt issuance costs. Interest expense associated with the OrbiMed Credit Facility recorded for the year ended December 31, 2020, was $3.6 million, of which $0.6 million was related to the amortization of debt issuance costs.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_t1AZHfTnlEeoOqzxzQZFfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-term debt consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;MidCap Term Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;OrbiMed Term Loan (related party)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;End of term charge&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unamortized end of term charge and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,084)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,509)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term debt &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_jCqHr9goH0iWw09Jjit7ig"
      decimals="-3"
      id="Tc_0DjPUFhT6Uykw3ROVsLEUA_3_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">40000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_tela_OrbimedTermLoanMember_pkFbA7Mc-UqsKDpK3kA_6A"
      decimals="-3"
      id="Tc_FN58tjG7BUOBUij-UBmxrw_4_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_1ckFpIDRrk2IEwD056WHYg_5_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_zINiBms2VkCAiTQCNjgjHA_5_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_2hba7St7wUS-oSCvwmYdOQ_6_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2084000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_ZCaJZAYfaUqgjU7cNQSSNg_6_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1509000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_qjSt5jP--EKtCZzK1aHb4Q_7_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">39916000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_lsYjrssfA0C4xgPCWmIAGw_7_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">31491000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_h_H8pqMUMUyTw6VdKGsnwA"
      decimals="-5"
      id="Narr_DUys8Z_pI0KmmTZs0pYuRA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheOneMember_HRhYP45vYUW4DEuuKEzNbg"
      decimals="-5"
      id="Narr_zTlIJIbE9kSZyQ_-qTnknQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">40000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheTwoMember_UJdzkLGJCk6Gx_nvGHVbIA"
      decimals="-5"
      id="Narr_HttmDajHmkOzc7xbbTYSAQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoanTrancheOneMember_HRhYP45vYUW4DEuuKEzNbg"
      decimals="-5"
      id="Narr_cuNPk2bLkEmzKiuCq1Yo0w"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">40000000.0</us-gaap:DebtInstrumentFaceAmount>
    <tela:EligibilityRequirementToBorrowTranche2
      contextRef="Duration_5_26_2022_To_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_7alFNq9WVkudCwmmXa7QyA"
      decimals="-5"
      id="Narr_IEEK0kTH3UGksuSMQ7Miog"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">65000000.0</tela:EligibilityRequirementToBorrowTranche2>
    <tela:InterestPenaltyPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw"
      decimals="2"
      id="Narr_xCoz_1J7DEycE7M9NbIpxw"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.02</tela:InterestPenaltyPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_jCqHr9goH0iWw09Jjit7ig"
      decimals="4"
      id="Narr_HQ23RMxfN06TEkVxdx-Qkg"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_QykfsvRGv0WxqJJfvminqQ"
      decimals="3"
      id="Narr_sCQKT-92K0i-l2SFrBMYvQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <tela:DebtInstrumentInterestPaymentTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw"
      id="Narr_K12gRPLYxU-bVGMwCjFdrQ">P36M</tela:DebtInstrumentInterestPaymentTerm>
    <tela:AdditionalExtensionForInterestOnlyPaymentPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_QT0qfYviYU6Qkgg2H5pTKQ"
      id="Narr_6nSgeZPYbUy4TJetQ0SILg">P12M</tela:AdditionalExtensionForInterestOnlyPaymentPeriod>
    <tela:AdditionalExtensionForInterestOnlyPaymentPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_pYoDsd8Lak-sf5zkcqJ-0w"
      id="Narr_N79DQRZgk02bFOUbLF-t6w">P48M</tela:AdditionalExtensionForInterestOnlyPaymentPeriod>
    <tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_FirstYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Fa-0d26vSUuUMMIob5eqFg"
      decimals="3"
      id="Narr_KHMcv_t890KEuSninHv9Gg"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.030</tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount>
    <tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_SecondYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_z5Xo6mvHC0uadpbBdDSOsg"
      decimals="3"
      id="Narr_yRPEbZarH0ubcZwxmG7evw"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.020</tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2>
    <tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_tela_ThirdYearMember_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_LQmV-QrJjEGKWrU-HuZaaA"
      decimals="3"
      id="Narr_nK0nE3Fg70SDBPZLmz3FkA"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.010</tela:PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount>
    <tela:PercentageOfExitFee
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw"
      decimals="2"
      id="Narr_SNIzjiHsDEOckaIg2CRrJQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.05</tela:PercentageOfExitFee>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw"
      decimals="-5"
      id="Narr_TEhtRGXQEUSK7BWhRlVsmg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_Owp_-eMKVUGq0-Q2z81jSw"
      decimals="-5"
      id="Narr_y9NGTfWDGUCwW0MiVzyNNg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_Kaoof9Egs0ivKLTiFF4Y9Q"
      decimals="-5"
      id="Narr_xegINaV3EEib1mCqIFQeJw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">35000000.0</us-gaap:DebtInstrumentFaceAmount>
    <tela:NumberOfTranches
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA"
      decimals="INF"
      id="Narr_lfnEquQKBkqKr4T8GhVQ6Q"
      unitRef="Unit_Standard_tranche_taD5b-wNNkeDwJocY19qDA">2</tela:NumberOfTranches>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheOneMember_yI91ExdwXUG56squ0fq2vQ"
      decimals="-5"
      id="Narr_4dR4XyVtnEahQ4rDfKSMSw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheTwoMember_b-6HOZChpUeQzYJXQLel8A"
      decimals="-5"
      id="Narr_lIFeBLkowkOgOVvMJUiSuw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoansTrancheOneMember_yI91ExdwXUG56squ0fq2vQ"
      decimals="-5"
      id="Narr_Vd5R6BkBy0KID-XO0oDczQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_Kaoof9Egs0ivKLTiFF4Y9Q"
      decimals="INF"
      id="Narr_VqEP9CdSGEC08t-c8SFyaQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_BMBZkylIyUmOoB5qEBh2iA"
      decimals="3"
      id="Narr_6WvGssFxU0SbsH5Csi8g8A"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.020</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <tela:EndOfTermCharge
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA"
      decimals="-5"
      id="Narr_SGcSBm8RO0WRG2Y46_SKrg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3000000.0</tela:EndOfTermCharge>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA"
      decimals="-5"
      id="Narr_XPuZeyCGt0O-MJ7KLcdtKQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA"
      decimals="-5"
      id="Narr_PztRWeYBu0epmNZaApgk_Q"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1500000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_RS3VxypOVkWD_m6YdCAYfA"
      decimals="-5"
      id="Narr_Lur4jF0oZUWkLlKDKTAUmQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_YSX6qeqpOEafTWL95y7zgA"
      decimals="-5"
      id="Narr_ZrbRDM1ZXEKPatC9wuMJIw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3600000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_YSX6qeqpOEafTWL95y7zgA"
      decimals="-5"
      id="Narr_yV0lGZwMyES3RZ-aL6ipfQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">700000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_9qJHl78Mt0qRtojolu34eA"
      decimals="-5"
      id="Narr_v4ZE41VXL0azGJ4awk2vpA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3600000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_9qJHl78Mt0qRtojolu34eA"
      decimals="-5"
      id="Narr_xR14MJW4n0mWiV7ZMnnu2Q"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_BBMPzqNNP0GievSAdSpUew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(7)&#160;Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Public Stock Offerings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company sold 3,000,000 shares of its common stock at a public offering price of $16.00 per share. The Company received net proceeds of $44.7 million after deducting underwriting discounts, commissions and other offering expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2020, the Company entered into an Equity Distribution Agreement (the &#x201c;Equity Agreement&#x201d;) with Piper Sandler &amp;amp; Co (&#x201c;Piper&#x201d;) in connection with the establishment of an at-the-market offering program under which it may sell up to an aggregate of $50.0 million of shares of the Company&#x2019;s common stock, from time to time through Piper as sales agent. No sales were made under the Equity Agreement during the years ended December 31, 2022, 2021 or 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In August 2022, the Company completed an underwritten public offering in which the Company issued and sold 4,600,000 shares of its common stock at a public offering price of $8.00 per share. The Company received net proceeds of $34.4 million after deducting underwriting discounts, commissions and other offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had the following warrants outstanding at December&#160;31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;dates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,379&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lQEEIhyvLUeG6RwD_4RFTg"
      decimals="INF"
      id="Narr_F04Qh2L-2UaK6KYdxAHy8Q"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lJzbq-J-nEOX--0ZNtWiug"
      decimals="INF"
      id="Narr_HvjvumMycEeyfvQHLmw7-w"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">16.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lQEEIhyvLUeG6RwD_4RFTg"
      decimals="-5"
      id="Narr_agsRfIL6U0Cv0EfpON5RFw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">44700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement
      contextRef="As_Of_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_DFSh0vmZ7ES3xBh8RnpMfw"
      decimals="-5"
      id="Narr_rNEwxdR6gEiVd70zbFFRLw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">50000000.0</tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement>
    <tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement
      contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_5WQ0HWHJy0GEHABnWD88Bg"
      decimals="-5"
      id="Narr_DNrsMKzv6U-r33KIsdqwIg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement>
    <tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement
      contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_tela_EquityDistributionAgreementMember_xGKYdmhTDE2zwVT9engEmA"
      decimals="-5"
      id="Narr_EsxxnZoSCki4MLms59TfuA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</tela:ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw"
      decimals="INF"
      id="Narr_vIJH8TG72EWqRDnrQUMzWA"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_e7ixSa7Av0qDAVrov1S1Rw"
      decimals="2"
      id="Narr_UKL-8LyxOUONSNSeWX9ong"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">8.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_wn71I9xBc0G-OYVw--DEiw"
      decimals="-5"
      id="Narr_EuqZDReuXEaFroZocU_Hqg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">34400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_8YUe00RGT0W89dHq7oTn2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;dates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,379&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_CHZHq7ZTvEK6xqdLmH_vew"
      decimals="INF"
      id="Tc_4RL_ndQ5w0esuA-MXhKDwA_3_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">8379</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_CHZHq7ZTvEK6xqdLmH_vew"
      decimals="2"
      id="Tc_ekUVxgeEcUu-7ShPrney1A_3_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">28.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tela:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2028Member_SAt9gqyaqUqRNPZ9FC6LyQ"
      id="Tc_5Qra2PebFE602pQzkJvyfA_3_7">2028</tela:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member_TigqdE4b6kOc3r-MRIqDcQ"
      decimals="INF"
      id="Tc_uGhWPntOlUqJB9Gt-g-wRg_4_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">80177</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member_TigqdE4b6kOc3r-MRIqDcQ"
      decimals="2"
      id="Tc_IqR8wdLy0UGEP4p-l9PIgg_4_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">28.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tela:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_tela_CommonStockWarrantsExpiringIn2027Member__U-R7Y6xF0uM61E9PpKfaw"
      id="Tc_thDcq_-U5Eqzpcb702-R4w_4_7">2027</tela:ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Tc_DnQFXmXFYkO0yPuNfYnjxg_5_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">88556</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_cIKczxzKiECF12q-enfxKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(8)&#160;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has two equity incentive plans: the 2012 Stock Incentive Plan and the Amended and Restated 2019 Equity Incentive Plan. New awards can only be granted under the Amended and Restated 2019 Equity Incentive Plan (the &#x201c;Plan&#x201d;). At December 31, 2022,  1,427,772 shares of common stock were available for future issuances under the Plan. The Plan is subject to an annual increase, subject to prior approval by the Company&#x2019;s board of directors, equal to the lesser of (i) 432,442 shares, (ii) 4% of the shares outstanding on the last day of the immediately preceding fiscal year and (iii) such smaller number of shares as determined by the board of directors. The Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options vest based on the terms in each award agreements and generally vest over four&#160;years and have a term of 10&#160;years. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense ratably over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 961&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 696&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total stock&#x2011;based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes stock option activity for the Plan:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&#160;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&#160;term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&#160;per&#160;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at January&#160;1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,420,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,783)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (70,037)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,498,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 468,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (77,154)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (182,645)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,706,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (81,408)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,071,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,022,232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,237,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;Included in outstanding options at December 31, 2022, were 381,125 stock options granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). At December 31, 2022, the aggregate intrinsic value of outstanding options and exercisable options was $3.0 million and $2.3 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2012 Stock Incentive Plan provided the holders of stock options an election to early exercise prior to vesting. The Company had the right, but not the obligation, to repurchase early exercised options without transferring any appreciation to the employee if the employee terminates employment before the end of the original vesting period. The repurchase price is the lesser of the original exercise price or the then fair value of the common stock. At December&#160;31, 2022, all early exercised options had vested.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes activity relating to early exercise of stock options:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at January&#160;1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (306)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (153)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;The weighted average grant-date fair value per share of options granted was $6.55, $8.66 and $8.13 for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $16,000, $0.4 million and $0.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December&#160;31, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;2022, the total unrecognized compensation expense related to unvested employee and nonemployee stock option awards was $5.1&#160;million, which is expected to be recognized in expense over a weighted-average period of approximately 2.5&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Estimating Fair Value of Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected term&lt;/i&gt;&#160;&#x2013; The expected term of stock options represents the weighted average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time to vesting and the contractual life of the options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected volatility&lt;/i&gt;&#160;&#x2013; Due to the Company&#x2019;s limited operating history and lack of sufficient company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers, including the Company, whose share prices are publicly available.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-free interest rate&lt;/i&gt;&#160;&#x2013; The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s stock options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected dividend&lt;/i&gt;&#160;&#x2013; The Company has not paid and does not intend to pay dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s restricted stock units (&#x201c;RSUs&#x201d;) vest based on the terms in each award agreement and generally vest over four years. The following table summarizes restricted stock units for the Plan:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 194,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,189)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 197,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40,783)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,219)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 311,991&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Included in outstanding RSUs at December 31, 2022, were 7,500 RSUs granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). The weighted average grant-date fair value per RSU granted was $11.21 and $16.57 during the year ended December 31, 2022 and 2021, respectively. The aggregate intrinsic value of RSUs outstanding was $3.6 million and $2.1 million at December 31, 2022 and 2021, respectively. The total unrecognized compensation expense at December 31, 2022 related to RSUs was $2.6&#160;million, which is expected to be recognized in expense over a weighted-average period of approximately 2.6&#160;years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <tela:EquityIncentivePlansNumber
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Narr_jM0CFdt0LUGSjzhGp1cG7A"
      unitRef="Unit_Standard_item__TJFBDNbO0SDXs4XkYl9ag">2</tela:EquityIncentivePlansNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_pbxz9JD2tEuMD0Bp4A1EmA"
      decimals="INF"
      id="Narr_EkBxPuE1OkmPGFYpYAOBKQ"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1427772</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tela:CommonStockCapitalSharesReservedForFutureAnnualIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_pbxz9JD2tEuMD0Bp4A1EmA"
      decimals="0"
      id="Narr_BqH0Kk0U7k2l6uJQwO7xVA"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">432442</tela:CommonStockCapitalSharesReservedForFutureAnnualIssuance>
    <tela:CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_pbxz9JD2tEuMD0Bp4A1EmA"
      decimals="2"
      id="Narr_bXUyNG0PNk64gqTekXZR3A"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.04</tela:CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_L9eLKsRNw0CRO-mST_AJQw"
      id="Narr_3rH0BXJRCUCG6apRKSE8-A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EquityIncentivePlan2019Member_L9eLKsRNw0CRO-mST_AJQw"
      id="Narr_cVkHEqVfj0evXBNABwHNzA">10&#160;years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_SF4zR4CfnkizOihNSRDJIg">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 961&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 696&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total stock&#x2011;based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_qb-xC0ZM6EmvUL8LzpWnCw"
      decimals="-3"
      id="Tc_YIwrrCjkbEGDLpISMznEjg_3_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_8-eGjFS6uU6hiVBVgeYbig"
      decimals="-3"
      id="Tc_m-HFmtKphE2Y-3h5iqaTVA_3_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_9XvGvd6jPkaCSiqkj9Sjcg"
      decimals="-3"
      id="Tc_BSRabVPK3kiBgz-R85SXmQ_3_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_idpfOALz2UiyklGl9EYKzg"
      decimals="-3"
      id="Tc_9ko4CYKzSk6aBDl1ui19NA_4_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2029000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qXTrNzsEgEG6lcTM1Mz12g"
      decimals="-3"
      id="Tc_fXWsR0oUukeEabue9AfkJQ_4_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1542000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_L98p-_WvLky1L5Gl_Pz7mw"
      decimals="-3"
      id="Tc_uNQNmsyaiUaVtgdlJUBc-w_4_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1030000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wDi4dsqi-EqOxKJ9dizz-Q"
      decimals="-3"
      id="Tc_9mbA8xodxU2FjYAfzQqi4w_5_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">587000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7uFgx_FdS0ODpYTmtHXo-w"
      decimals="-3"
      id="Tc_JA-7FA3jVkWqtzD3niulsw_5_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZOR2THAP1EyzyW3OgaAWLQ"
      decimals="-3"
      id="Tc_suvbXWqbxUu37WpVWGU-Lw_5_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">332000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-3"
      id="Tc_pr9Y_j9svk60ggqypbBbEA_6_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3989000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-3"
      id="Tc_EzCslsZOL0GooBv_QAP3nQ_6_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3661000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-3"
      id="Tc_HeYXpz_Uck6o_xqV_zwdiA_6_9"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2058000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_4Sx2giwIxEKmgkW3gRetew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&#160;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&#160;term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&#160;per&#160;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at January&#160;1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,420,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,783)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (70,037)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,498,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 468,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (77,154)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (182,645)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,706,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (81,408)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,071,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,022,232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,237,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg"
      decimals="INF"
      id="Tc_6ZnepCO0FUK_j9ZJvjVoUA_6_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1420942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg"
      decimals="2"
      id="Tc_sFqTzphmGkKITDLnvqTilQ_6_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">10.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="INF"
      id="Tc_AEdjn1j-20Ku6TGMBxdl2g_7_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">175086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="2"
      id="Tc_f7uxZZ0uh0KPgJs30_Ma_A_7_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">15.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="INF"
      id="Tc_qtr8ddKH-E2sqhk5dcmIjQ_8_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">27783</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="2"
      id="Tc_TsFNmR3mtUeJMsuexpaXrA_8_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">6.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="INF"
      id="Tc_IoRb_HD7HUCws3WmLHwSeQ_9_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">70037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="2"
      id="Tc_UT25E2roVEWhkQbC9T1hAA_9_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">12.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ"
      decimals="INF"
      id="Tc_S4BKrgciX06yipfAzNXkpQ_10_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1498208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ"
      decimals="2"
      id="Tc_-FtRPSpHb0yrOqvgb_qWug_10_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">10.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="INF"
      id="Tc_hNWFopowPkqZIRUkorlbTA_11_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="2"
      id="Tc_21FjzAjf0UiEP0XIX1zEmA_11_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">14.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="INF"
      id="Tc_rGfAcF7eI0yURjnzbPcEKw_12_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">77154</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="2"
      id="Tc_5-qxU6qUHkarIi_sdhgjEA_12_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">7.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="INF"
      id="Tc_zmw4s_zAmkKn3DtZOKTP6A_13_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">182645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="2"
      id="Tc__dEm7gh_4kmFclP8UDxGmg_13_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">13.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Tc_b07Cndhuuk2vd14pLdhE2Q_14_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1706409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="2"
      id="Tc_wn7MsCmF30S0or--ea3KSg_14_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">11.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="INF"
      id="Tc_6KTH4I6QlEiFAjs_oXAxOw_15_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">450410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="2"
      id="Tc_S87fGlV-JEKlPESDb9ZNgw_15_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">10.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="INF"
      id="Tc_E8qDELzPJ02_biOut_BizQ_16_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">3563</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="2"
      id="Tc_YAqKJZgtvEOmK5kzfV7GiQ_16_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">5.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="INF"
      id="Tc_pIJVuP4B6kefgRiayneVVw_17_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">81408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="2"
      id="Tc_MPrHqYX9nkSTZ0db2gbiwA_17_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">13.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Tc_pMWrct4dlkWmawm6Wxxltw_18_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">2071848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="2"
      id="Tc_U6HVJIzP3kmBBIbA2gxfdw_18_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">11.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_nYU7wgaEIkOrnuyz2DoSfA_18_7">P7Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Tc_O8lxAVEfCESNgafTEZhGoQ_19_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">2022232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="2"
      id="Tc_LOE9YC_lm0yzsNmMNFTA3w_19_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">11.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_FctZyyRi6EafcBEMS872QQ_19_7">P7Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="INF"
      id="Tc_A4AyKRkiukWTW8dKetw79w_20_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">1237751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="2"
      id="Tc_1jHJC3KT6U2_G3RWXXVDaA_20_5"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">11.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_Kyy54Gipvka3pzXZApI0dg_20_7">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA"
      decimals="INF"
      id="Narr_sgmalzg7eEaYJydUeS71kQ"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">381125</tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA"
      decimals="-5"
      id="Narr_Bvn-Rmtzb0yq5WbLVYBFgg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA"
      decimals="-5"
      id="Narr_4cKd3gkwiUqUo1cJMKASIQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_OnFluEuLc0WM2v0VpcRvgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at January&#160;1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (306)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (267)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (153)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg"
      decimals="INF"
      id="Tc__yZ3rD8pLky758WTJQ6KNQ_3_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">755</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="INF"
      id="Tc_17AmFgEqYUG5YS026DY0wA_4_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">306</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="INF"
      id="Tc_F1SIoLQ07k-e0Sssk7j37A_5_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">267</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ"
      decimals="INF"
      id="Tc_E0UMu82CnU-JWvxZ_1tS5g_6_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">182</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="INF"
      id="Tc_OQRYVql6qkyLx-b9VweFyg_7_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">153</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="INF"
      id="Tc_cFB9XQq26U6YZ4gmM2YMvQ_8_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">29</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="INF"
      id="Tc_uv8zoIMQt0uW7Rj1g72ebw_9_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">29</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_tv04xB9wqEaTQH96wyjNIw"
      decimals="2"
      id="Narr_tnPCFOyYdEm-fbuxeTG8rg"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">6.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_pRF4sUzZHkaM1gci9cPj_g"
      decimals="2"
      id="Narr_ZMtXecU_ik2hadYSlzLBqA"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">8.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_UGImw1N6L0mZ0fnBk-7tDQ"
      decimals="2"
      id="Narr_LLhhwKL4_kmVsjoWCEdx8g"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">8.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="0"
      id="Narr_cTjJ4PZPt0qPDMSNcWKMkA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">16000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-5"
      id="Narr__mcURQQRwUatxkaY-oUpYA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2020_-jXE02H900iugRZ97Lz3HQ"
      decimals="-5"
      id="Narr_YCIX4yvqWUObtd2acp4IhA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_QWoLpmLszUq2IYt45sIsmA"
      decimals="-5"
      id="Narr_PJO7j25WeUCXbH9EasEFSg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">5100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_tv04xB9wqEaTQH96wyjNIw"
      id="Narr_7xmZK6jyzkWedC9xW9Sg-g">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_ldPvx1xuukq8QxxcbT1ogQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="2"
      id="Tc_dO_YHMkWC0CBHpUWdEpTpg_3_2"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="3"
      id="Tc_OOo2279h0Ua5J81OwgWC1A_3_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="3"
      id="Tc_hJ6aKFYcSEanaBERu5vitA_3_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="3"
      id="Tc_ksA24rshD0mbTbxJF8UT-Q_4_2"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="3"
      id="Tc_FKbLfW4zqUCwhJvO_JKLZA_4_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="3"
      id="Tc_WysmL8YQvUeqs7u71U1mEw_4_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="4"
      id="Tc_Tb3x0ijr9UyarzG7IxgMrg_5_2"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.0255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="4"
      id="Tc_x0gkPAuM4U-jLce0332Jlw_5_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.0099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="4"
      id="Tc_LLR9D0EPNkmwoUdszceiVg_5_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.0087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tc_zT3wg2aItU2MH_bZZXTrJA_6_2">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      id="Tc_MXZpv36t5ECcncuQtZYkbQ_6_4">P6Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      id="Tc_unyHHoPLkkGKwnNeQDeGRg_6_6">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_Oc73JBGjZEe3QbIOHyn8zA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s restricted stock units (&#x201c;RSUs&#x201d;) vest based on the terms in each award agreement and generally vest over four years. The following table summarizes restricted stock units for the Plan:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 194,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,189)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 197,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40,783)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,219)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 311,991&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg"
      id="Narr_mUoXkNs1N0aXpesNAElZmw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ"
      decimals="INF"
      id="Tc_dpnPyxsyg0CxID5TBn_aug_4_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">194232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ"
      decimals="INF"
      id="Tc_V3G4yRHySEK_BP_7eA3ieA_5_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ"
      decimals="INF"
      id="Tc_DT5uCT26-0mPYLD9um4PEQ_6_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">19189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_0ySqKDuji0e0ER6NBbeSnQ"
      decimals="INF"
      id="Tc_fjBnTsSxJkyYZRwg9OFmRg_7_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">163043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg"
      decimals="INF"
      id="Tc_BRgyFjKry0yt2nJcCyrnaA_8_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">197950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg"
      decimals="INF"
      id="Tc_xOKkkPfqpkKmRYVzqEzLAg_9_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">40783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg"
      decimals="INF"
      id="Tc_Y-AlUtuWuEWO_jffoWC2cQ_10_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">8219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w"
      decimals="INF"
      id="Tc_2whHoKdN0ESi5SblPsdAwQ_11_2"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">311991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w"
      decimals="INF"
      id="Narr_-LNTtJsbREyaDO2hxxbelg"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">7500</tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg"
      decimals="2"
      id="Narr__LT-VuN1mU6Dm_lA1L2fcw"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">11.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_sMN19urHnEiFF-1rVxwrXQ"
      decimals="2"
      id="Narr_ZKtTTtVUk0WxxEZKGblrEA"
      unitRef="Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw">16.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w"
      decimals="-5"
      id="Narr_QOouFJIQzUGUbzU9Dtu2qw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">3600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_0ySqKDuji0e0ER6NBbeSnQ"
      decimals="-5"
      id="Narr_39yBg9F7xU2eO8Iw_Hr1zw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_HuMTv2y4H06-9c_UqwYQ9w"
      decimals="-5"
      id="Narr_t5rwRiSDgkeP-nLPGVgK8g"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg"
      id="Narr_IXsFKd3FV0maYm_Hdoe_EQ">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_DTMUzseynkibNqDCgvXR4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(9)&#160;Employee Benefit Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;401(k) Defined Contribution Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sponsors a 401(k)&#160;defined-contribution plan covering all employees. Participants are permitted to contribute up to 100% of their eligible annual pretax compensation up to an established federal limit on aggregate participant contributions. Discretionary contributions made by the Company, if any, are determined annually by the board of directors. Effective January 1, 2020, the Company matched 50% of employees&#x2019; contributions up to 6%, subject to a maximum annual amount. The Company&#x2019;s contributions were $0.4 million, $0.3 million and $0.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. The match was suspended from April to August 2020 due to COVID-19. Participants are immediately vested in their own contributions to the plan and are fully vested in discretionary profit sharing made by the Company after three&#160;years of service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019 Employee Stock Purchase&lt;/b&gt; &lt;b style="font-weight:bold;"&gt;Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). At December 31, 2022, 421,065 shares were available for future issuance under the ESPP. The ESPP is subject to an annual increase, subject to prior approval by the Company&#x2019;s board of directors, equal to the least of (i) 107,887 shares of common stock, (ii) 1% of the shares outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares as determined by the board of directors. The ESPP provides the opportunity to purchase the Company&#x2019;s common stock at a 15% discount to the market price through payroll deductions. As of December 31, 2022, 2021 and 2020, 4,523, 3,163 and 2,797 shares, respectively, have been issued under the ESPP. &lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="INF"
      id="Narr_evx4uxp_UU22Gr9oAu-7ZQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="2"
      id="Narr_tS9PZ2cuNE-Y_fEPGx6pBQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="2"
      id="Narr_w-B6HdkdMk2KS8Two5igkg"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-5"
      id="Narr_E5hyO99SgUSN8BTAc5h6Mg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-5"
      id="Narr_X5ifbVZDxUWXpTg-fc4Sfw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="-5"
      id="Narr_Ue9MrOdvq0qsodN-srCQCw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Narr_i44BUmjsj06JE1J5hHyyRA">P3Y</us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_apjFPhUEQUmSn47rVbBhIQ"
      decimals="0"
      id="Narr_TbAiMuS6IE62_J0uQGE4Sg"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">421065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance
      contextRef="Duration_11_1_2019_To_11_30_2019_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_2L7PdrGMqki5LBBGmf_Rew"
      decimals="INF"
      id="Narr_R-25KNBX-EKsqhqoT2x4Ig"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">107887</tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance>
    <tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding
      contextRef="Duration_11_1_2019_To_11_30_2019_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_2L7PdrGMqki5LBBGmf_Rew"
      decimals="2"
      id="Narr_mMikenZ5gUeNky_-xuuiLw"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.01</tela:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding>
    <tela:EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock
      contextRef="Duration_11_1_2019_To_11_30_2019_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_2L7PdrGMqki5LBBGmf_Rew"
      decimals="2"
      id="Narr_0emqnAXEwUqK9bL4ddhLsg"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.15</tela:EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_YKvVJdoCfU6XG4kpRDTKPg"
      decimals="INF"
      id="Narr_KWilbjY6uE-VE0N-UvSqwg"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">4523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_P49kb58aeUOwJ9BHNFx0Ag"
      decimals="INF"
      id="Narr_6y4jhD-GN02YRgDQR1kAOA"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">3163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_tela_EmployeeStockPurchasePlan2019Member_5nSnl9FMqkyjoV_-oqlcRA"
      decimals="INF"
      id="Narr_OTOGQ4XU5EW-04j6ch42kQ"
      unitRef="Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ">2797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_OBs6UvZrtky2pKP9I_XsPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(10)&#160;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred losses since inception. Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for&#160;years in which differences are expected to reverse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets for federal income taxes consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,737&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Inventory reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Gross deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,887&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (435)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Gross deferred tax liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (737)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net deferred tax asset before valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (60,161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,798)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company does not have unrecognized tax benefits as of December&#160;31, 2022 and 2021. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s net operating loss (&#x201c;NOL&#x201d;) carryforwards for federal and state income tax purposes consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOL carryforwards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 212,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181,443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151,488&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The NOL carryforwards begin expiring in 2032 for federal purposes and in 2026 for state income tax purposes yet $100.7 million of the federal NOL carryforwards have no expiration. The Company recorded a valuation allowance on the deferred tax assets as of December&#160;31, 2022 and 2021 because of the uncertainty of their realization. The valuation allowance increased by $10.4 million and $8.1 million for the years ended December 31, 2022 and 2021, respectively, mainly due to losses incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Utilization of the net operating losses and general business tax credits carryforwards may be subject to a substantial limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, if changes in ownership of the company have occurred previously or occur in the future. Ownership changes may limit the amount of net operating losses and general business tax credits carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of 5% shareholders in the stock of a corporation by more than 50&#160;percentage points over a three-year period. If the Company experiences a Section&#160;382 ownership change, the tax benefits related to the NOL carryforwards may be further limited or lost. The Company has not performed an analysis under Section 382 and cannot predict or otherwise determine whether there would be any limitation to the amount of net operating losses and general business tax credits carryforwards that can be utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and as reflected in the consolidated financial statements is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rate reconciliation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State rate, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__Xg7yEHRTkaf1AHzKKzaFA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9o4WxlJ-z0CC9U7RFAF0Vg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_B8cBHWhtUUWKXvY0U7DfHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction, various state jurisdictions and the United Kingdom. Tax years 2019 and forward remain open for examination for federal and the Company&#x2019;s more significant state tax jurisdictions. Carryforward attributes from prior years may be adjusted upon examination by taxing authorities if used in an open period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Many governments have enacted or are currently contemplating economic stimulus and financial aid measures. Many of these measures include deferring the due dates for tax payments, including both income tax and other taxes. The Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted on March 27, 2020 in the United States to address the economic impacts of the COVID-19 pandemic. The CARES Act includes corporate income tax, payroll tax, and other provisions. While the Company may receive financial, tax, or other benefits under the bill, this legislation did not impact the Company during the year ended December 31, 2020. During the year ended December 31, 2021, the Company claimed an employee retention payroll tax credit of $0.5 million for certain employment taxes.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_UTPnabPOVEG3xSetzL3E3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,737&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Inventory reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Gross deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,887&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (435)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (302)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Gross deferred tax liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (737)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Net deferred tax asset before valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (60,161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,798)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net deferred tax asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_66OLbhOZb0KsLP6pDuYxAQ_4_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">55091000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_ZlZzkYDRQEOe_c6UNQMDRQ_4_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">47737000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_hOA9n_ibkUCsxTMMZpMpig_5_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">623000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_wRQ8bpPlz06ZFZuGUVnFYQ_5_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">623000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <tela:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_iVQXedWoz0SY4b6JRnfjvQ_6_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">387000</tela:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_-y-U8ZGrWEmeRit1Qgc7Zw_7_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4425000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_mDp0755SkUG8EKVz0TZjhw_7_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1356000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_mGAIl3NPhkevO9kO7bOdQg_8_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">372000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_VhmWFeh6OEq4zmTSef41bg_8_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">171000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_dNVqCveU2U-d_UOwW8ZCVA_9_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">60898000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_sOLeP34JzUGQNWZLjEAEAg_9_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">49887000</us-gaap:DeferredTaxAssetsGross>
    <tela:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_QlWmslnmn02tSCh9O4jyhQ_11_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">435000</tela:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <tela:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_-3jys51fy0m0XWIbrSqFvQ_11_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">89000</tela:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <tela:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_WSubGXSGSUWe5cW0uWQesA_12_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">302000</tela:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_-1895EPszkyrwreXdnkKfg_13_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">737000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_rwaYQu3zJkG76aF-dXo0dg_13_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">89000</us-gaap:DeferredIncomeTaxLiabilities>
    <tela:NetDeferredTaxAssetBeforeValuationAllowance
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_kKrqUWtZdkmBFDptHNtQ3Q_14_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">60161000</tela:NetDeferredTaxAssetBeforeValuationAllowance>
    <tela:NetDeferredTaxAssetBeforeValuationAllowance
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_egu_1-4QK0CF7jU_L6TcVw_14_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">49798000</tela:NetDeferredTaxAssetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_dH22NYwjHUavxt4QdPKQGw_15_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">60161000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_Li1bmJmX2kSQzmlfz9woaA_15_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">49798000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_6BvC-BNXG02Lk9hzVnVGcA_16_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Tc_bbD_p1F2uES_gRpMqNWCQw_16_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-3"
      id="Narr_xFqUQOyRe0aQzFI6cBYVZw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Narr_5V-iI9WCvUW0Y2FTtXdm1w"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_95q_Q_-oQ0COriqWLhp9BA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOL carryforwards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 212,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181,443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151,488&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_pOKNe1MZo0aFsxEbEdiunQ"
      decimals="-3"
      id="Tc_HaHwQHuhbE25G9hMnQ2vpQ_4_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">212314000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_A9GP45d3REOrEZcQtCpqQA"
      decimals="-3"
      id="Tc_8GNRsy5AdEqXBTKyDtLymg_4_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">181443000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_v9zeKR1og0GICgO2UBJLYg"
      decimals="-3"
      id="Tc_qHpqVIYhlU2nKJnjfCbvHg_5_3"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">173472000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_nh_rYZ3xKUOudm_jXKbwPA"
      decimals="-3"
      id="Tc_fbedyIQimESVQsF49K6FKg_5_6"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">151488000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_pOKNe1MZo0aFsxEbEdiunQ"
      decimals="-5"
      id="Narr_DwhlqPWJzEql7S4RHr8bsA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">100700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-5"
      id="Narr_zEErOFuUxE6zIO2qmqWqkw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">10400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-5"
      id="Narr_9fPOhKbrWUm_l2rTc8RFbw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">8100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_HKj3UCqSYkq2ReuBIqgJJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rate reconciliation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State rate, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__Xg7yEHRTkaf1AHzKKzaFA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9o4WxlJ-z0CC9U7RFAF0Vg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_B8cBHWhtUUWKXvY0U7DfHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="INF"
      id="Tc_iVNKvU0M7EmPP1Ll7iYlWw_4_2"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="INF"
      id="Tc_wSXLnoU7I0uRImtvyZfK0A_4_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="INF"
      id="Tc_OMfdTu3T-EKkhmf7ZUbyAg_4_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="3"
      id="Tc_ObR3o2Eh6kuix43CCN7YHA_5_2"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="3"
      id="Tc_hCxJMMR3MkeQ6lJudTpVUw_5_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">-0.035</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="3"
      id="Tc_TyOtLLC7pEuy_FmHzczEjQ_5_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="1"
      id="Tc_41KbQo5d7kKNNL_aP85ong_6_2"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.6</tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="1"
      id="Tc_tGdJi1MwiUiQQWI_ra1DKA_6_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.2</tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="1"
      id="Tc_xnuL-bEwIUKO1yDAoEHPZQ_6_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.6</tela:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="3"
      id="Tc_EkRTxbf-HUKHg1_PKbogPA_7_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="3"
      id="Tc_MbnR0RZ_QUqpK5rqTs841g_7_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="3"
      id="Tc_UK4Sh2iUYkyMzNkkNPCIFQ_8_2"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.234</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="3"
      id="Tc_1aEUtwidw0mgvQ6mXPV1nQ_8_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.242</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="3"
      id="Tc_o61YS5va_k23o9dqZuf3xw_8_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.240</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="3"
      id="Tc_HiSc2pVq9U2TxxAMPJY1Ww_9_2"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="3"
      id="Tc_GF9E2GIhvEulY_RmzEWsUw_9_4"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_aAfNFtpSpUSumvVC5H9Plg"
      decimals="3"
      id="Tc_5wa4HgptYkqVUU5g6oqeLQ_9_6"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="Duration_1_1_2021_To_12_31_2021_pxfLwbU5UEenixAjGrfZfw"
      decimals="-5"
      id="Narr_QcA3qApAiEyqt85l4fWP4w"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_zgUqrppuk0SLbQZyM30cmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(11) Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Legal Proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may be a party to various other lawsuits, claims, and other legal proceedings that arise in the ordinary course of its business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Agreements with Aroa&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2012, the Company entered into a License, Product Development, and Supply Umbrella Agreement (&#x201c;Aroa Agreement&#x201d;) with Aroa. The Aroa Agreement provides the Company a license to patent rights and other intellectual property related to Aroa&#x2019;s products and technologies for use in certain indications and expires on the expiration of the last patent covering the products (currently March 9, 2031). The Company has the right to extend the term of the agreement by an additional 10 years following the expiration of the last patent covering the products on commercially reasonable terms to be negotiated by the parties. This agreement initially limited the Company&#x2019;s license rights to the U.S. but was subsequently amended in March&#160;2013 to include certain countries in Europe including the United Kingdom and members of the European Union and certain former Union of Soviet Socialist Republic satellite nations. The Aroa Agreement required payments aggregating up to $4.0&#160;million upon the achievement of U.S. and European cumulative product sales targets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company paid $1.0&#160;million to Aroa in 2018 related to one of the cumulative product sales targets and the remaining $2.0 million in 2019. The Company paid $1.0&#160;million in 2022 related to the sales milestone payments in the European territory.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Other key terms of the amended Aroa agreement in addition to those disclosed above are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The transfer price for product produced by Aroa is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;200%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of Aroa&#x2019;s cost of goods sold. The transfer price and the quarterly true-up amount continued to equal &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;27%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of Company&#x2019;s net sales of licensed products. Upon a change in control of the Company (as defined in the amended agreement), the annual minimum amounts will be extended for a sixth&#160;year with a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$5.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million minimum amount for the North American territory and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million minimum amount for the European territory. If a change in control of the Company occurs prior to the first product launch in the applicable territory, then the annual minimum requirements shall commence upon such change in control. If the make whole payments, if any, are not made by the Company after a notice and cure period, then the license will convert to a nonexclusive basis in the territory for which the payment was required but not made.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Provisions exist for the Company to step in and operate Aroa&#x2019;s plant if a supply failure occurs and is not cured within a set timeframe. Under the amended agreement, the criteria for a supply failure was modified to mean a failure by Aroa to timely supply, during any consecutive &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_aX4OvrC5tUqVcgWeJXKlnQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;60-day&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; period, at least &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;75%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of the products ordered by the Company under binding purchase orders. During the period that the Company steps in and assumes manufacturing responsibility, it shall not be required to purchase product from or pay transfer prices to Aroa, the annual minimums shall be proportionately reduced to reflect the lack of supply responsibility by Aroa and the Company shall pay a royalty of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;6%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of net sales in lieu of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;27%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of net sales of the licensed products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expects to enter into similar milestone-based agreements with its strategic partner for both product territories and new products in order to expand and extend its product portfolio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the Company had $1.0 million in purchase commitments with Aroa, $20.7 million in commitments with certain other suppliers to maintain exclusivity rights over time and $2.2 million milestone payments related to certain research and development arrangements which are currently deemed not probable as the timing and likelihood of such payments are not known with certainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Other Commitments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2021, the Company entered into an exclusive distribution agreement with Next Science, a medical technology company, granting the Company exclusive rights to sell and market Next Science&#x2019;s proprietary antimicrobial surgical wash in the U.S. plastic reconstructive surgery market. To maintain exclusivity, the Company had purchase commitments and annual license fees over a ten-year period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2022, the Company entered into an exclusive development and distribution partnership for Collagen Matrix, Inc.&#x2019;s proprietary fibrillar collagen pack in the U.S. To maintain exclusivity, the Company has purchase commitments of $20.7 million over the remaining nine-year period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employment Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company leases office and laboratory space in Malvern, Pennsylvania under a noncancelable lease (the &#x201c;Malvern Lease&#x201d;). The Malvern Lease, which was concluded to be an operating lease, was amended in December 2020 to extend the term of the lease from May 2021 to May&#160;2028. The Malvern Lease has annual scheduled payment increases and provides the Company a renewal option for an additional term of 60 months at the end of the lease term. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. As the Company is not reasonably certain to exercise the renewal option, the additional 60-month term has been excluded. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On January 1, 2022 and upon adoption of ASU 2016-02, the Company recorded an operating lease liability of $1.8 million and an operating lease ROU asset of $1.4 million related to the Malvern Lease. The Company also eliminated approximately $0.4&lt;span style="white-space:pre-wrap;"&gt; million of deferred rent and tenant allowance liabilities as of January 1, 2022 as these components are reflected as a reduction in the operating lease ROU asset.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease leasehold improvements are depreciated over the lesser of the useful lives of the leasehold improvements or the lease term. The tenant allowance was historically amortized over the initial, non-cancelable term of the Malvern Lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company's lease does not provide an implicit rate, and therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company used an incremental borrowing rate of 9.75% to discount the Malvern Lease payments included in the operating lease liabilities recognized upon adoption of ASU 2016-02.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company recognized $0.3 million of lease cost during the year ended December 31, 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $0.3 million for the year ended December 31, 2022, and this amount is included in operating activities in the consolidated statements of cash flows. As of December 31, 2022, the remaining lease term for the Malvern Lease is 5.5 years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total undiscounted future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,039&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (468)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,571&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At December 31, 2021, the Company&#x2019;s future minimum lease payments under non-cancelable operating leases for the five years ending December 31, 2022 through 2026 and thereafter were as follows: $0.3 million, $0.4 million, $0.4 million, $0.4 million, $0.4 million and $0.5 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2022, $0.3 million representing the current portion of operating lease liabilities is included in &lt;span style="-sec-ix-hidden:Hidden_O-RcgO7O50aNxn4SsWFhrQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt; in the consolidated balance sheets and $1.2 million representing the long-term portion of operating lease liabilities is included in &lt;span style="-sec-ix-hidden:Hidden_XxtxzYXVGkCewipeasalog;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; in the consolidated balance sheets.  &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tela:RevenueBasedMilestonePayment
      contextRef="Duration_8_1_2012_To_8_31_2012_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_5TQp0DFf-kq_QSMl5v0gog"
      decimals="-5"
      id="Narr_1XhU1PBMnU6EIBjPHNJqlg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">4000000.0</tela:RevenueBasedMilestonePayment>
    <tela:SalesMilestonePayment
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_WrQWz5vLr0aUSSjLYF2vLg"
      decimals="-5"
      id="Narr_VxT3eszry0GIensK-eN5MA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000000.0</tela:SalesMilestonePayment>
    <tela:SalesMilestonePayment
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_bNi-UjogoEuFoyrMYtfZFQ"
      decimals="-5"
      id="Narr_09X3gf2sbEqKWjhBso2SkQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2000000.0</tela:SalesMilestonePayment>
    <tela:SalesMilestonePaymentDue
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_EuropeMember_P4ROvIxkZ0GJPalY78p2MQ"
      decimals="-5"
      id="Narr_jGqzGb0WkEKG0YEM51oOBQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000000.0</tela:SalesMilestonePaymentDue>
    <tela:TransferPriceForProductProduced
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_5UcmEJq_IkSYYQljqHnZxQ"
      decimals="2"
      id="Narr_HPbfwj4gK0KQxKZfc4ZVOQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">2</tela:TransferPriceForProductProduced>
    <tela:FixedCostOfNetSales
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_5UcmEJq_IkSYYQljqHnZxQ"
      decimals="2"
      id="Narr_r_yQOYoCS0ayieMPvdObMQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.27</tela:FixedCostOfNetSales>
    <tela:PurchaseObligationDueInSixthYear
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_NorthAmericaMember_5UcmEJq_IkSYYQljqHnZxQ"
      decimals="-5"
      id="Narr_dJA8m209KkG9SFmpCd-C0w"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">5000000.0</tela:PurchaseObligationDueInSixthYear>
    <tela:PurchaseObligationDueInSixthYear
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_srt_StatementGeographicalAxis_srt_EuropeMember_P4ROvIxkZ0GJPalY78p2MQ"
      decimals="-5"
      id="Narr_4zs2EYsjWU-aEUaTnGIqTw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000000.0</tela:PurchaseObligationDueInSixthYear>
    <tela:ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_vMwv7HGAZk6VxBh2MfXhWQ"
      decimals="2"
      id="Narr_7WN2KUMJtEWKUSPNmmk2rA"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.75</tela:ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder>
    <tela:PercentageOfRoyaltyOfNetSales
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_vMwv7HGAZk6VxBh2MfXhWQ"
      decimals="2"
      id="Narr_XOF0AFV0PE6i2BwxXxWpQQ"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.06</tela:PercentageOfRoyaltyOfNetSales>
    <tela:FixedCostOfNetSales
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw"
      decimals="2"
      id="Narr_G6XT7fTQ2UKCF5eQvrfBdw"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.27</tela:FixedCostOfNetSales>
    <us-gaap:PurchaseObligation
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw"
      decimals="-5"
      id="Narr_5SnfMoLfIU6S0pc1iq54bg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1000000.0</us-gaap:PurchaseObligation>
    <tela:RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_OtherSuppliersForExclusivityRightsMember_nti7PndlCEqpmp9aOi8sDw"
      decimals="-5"
      id="Narr_1TPRMaDWa06s7pxcrYfnNw"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">20700000</tela:RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets>
    <tela:MilestonePaymentsRelatedToResearchAndDevelopmentArrangements
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_AgreementWithAroaMember_IQ8kclPGUEG-C2bDr2p1Qw"
      decimals="-5"
      id="Narr_HISeQS6LyEeRkkHC-Z30IA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2200000</tela:MilestonePaymentsRelatedToResearchAndDevelopmentArrangements>
    <tela:OtherCommitmentsTermOfContract
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_NextScienceMember_LkcT3sf4w0qZZyV6NqpeQA"
      id="Narr_Oy5KLcEZVEi0vkcC0xCLhA">P10Y</tela:OtherCommitmentsTermOfContract>
    <us-gaap:PurchaseObligation
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_tela_CollagenMatrixInc.Member_1Pkcz42t1Ey6xw6VGMm4YA"
      decimals="-5"
      id="Narr_ADJ9VNIehUO9oAzc4b9W0A"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">20700000</us-gaap:PurchaseObligation>
    <tela:OtherCommitmentsTermOfContract
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_tela_CollagenMatrixInc.Member_dYLoJZtTSE2udKKQ9CsaEQ"
      id="Narr_k60mDcda40yGtb5gQhoNow">P9Y</tela:OtherCommitmentsTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_12_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_KxwryCVlz0irzGqrcf7T9w"
      id="Narr_hUMdPdzoI0-dgT-6qaiccA">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_kMDohVy_8EGHSodUA1iG_A"
      id="Narr_iJbcpZlwmUaK2Dofa9rVig">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_rkR5ymX8o0ef8OoHXSVS1Q"
      decimals="-5"
      id="Narr_Vbcbmbvdp0q11bb03sewbQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_rkR5ymX8o0ef8OoHXSVS1Q"
      decimals="-5"
      id="Narr_5EsIlUJRtU-lEoWY1CTJzQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <tela:DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2022_To_1_1_2022_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_srt_StatementGeographicalAxis_stpr_PA_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_0PuV96OlxUKqwMyunu8Gaw"
      decimals="-5"
      id="Narr_kJ1pl24l6U61RmaWwsKhCg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</tela:DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_1_1_2022_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_ijh9r7V11UmJJurC5JZr8A"
      decimals="4"
      id="Narr_PdhjYsgxbka_re7xWj7v5Q"
      unitRef="Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ">0.0975</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-5"
      id="Narr_-iWq7ED5S0Wov5hdqcM8IA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      decimals="-5"
      id="Narr_beGZKvb9REyk57o4_KRnKQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">300000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_stpr_PA_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tela_OfficeAndLaboratorySpaceLeaseMember_8Fc2PFOc2keKSCoCf2k64w"
      id="Narr_k3EoZIdklESjVZuz6K6VhA">P5Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_u99WfN4B-kekD48n_ZfU3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table reconciles the undiscounted future minimum lease payments (displayed in aggregate by year) under non-cancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the consolidated balance sheets as of December 31, 2022 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 392&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total undiscounted future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,039&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (468)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,571&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_q0UTg6W2D0SNQZ5kha-JFg_1_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">358000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_IpMTeOoZJ0SyG2aLeoSkzw_2_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_GU36ORVe_kK3x7YyUCu4tQ_3_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">375000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_0mp2rY1aDU-Tt0w1W11YSw_4_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">383000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_q42N4nFVT0qqHvKBe--C2A_5_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">392000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_NSWdp1BfXEyGWDh3K2Xokw_6_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">165000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_Qf30vyhVVUqsWUn-pRkB4Q_7_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">2039000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_4FzEXxhGP0iO-APfqo-Tcg_8_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">468000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-3"
      id="Tc_0l-FvnyyWEeVdlLAUMvkPA_9_2"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1571000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-5"
      id="Narr_rU91ie9yQkqV3K5Q_XWX0g"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-5"
      id="Narr_7xWFgiqZ2kuzn46HthRauQ"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-5"
      id="Narr_QVQnofTg4U-36m1ji-NnRA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-5"
      id="Narr_TQxeAXYE70ia3Jsr3HtLvg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-5"
      id="Narr_Pf7hAGZ_9E6lZmSi-BJs1A"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg"
      decimals="-5"
      id="Narr_USe9WUvV2keUwJB-x6ND9g"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Narr_rn4HV6-zF06xX30cNAknbg"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw"
      decimals="-5"
      id="Narr_flRaP3Wmt060RlQcjHqIIA"
      unitRef="Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ">1200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w"
      id="Tb_9x06qfD7PEqxRL4JZQmvPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(12) Related-Party Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On November&#160;16, 2018, the Company entered into a senior secured term loan facility with OrbiMed, an entity affiliated with an owner of a material amount of the Company&#x2019;s outstanding voting securities. The terms of the debt and related components are described in more detail in Note&#160;6. On May 26, 2022, the Company entered into the MidCap Credit Agreement and upon closing used a portion of the proceeds to repay all borrowings under the OrbiMed Credit Facility, and terminated the OrbiMed Credit Facility.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M2H9W5AGP$F%^!P  ]S$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MF_]SHC@8QO^5C+=SLS=3*P%UV[W6&:MUK]<OZ]7N[NS]ED)49H%X(=3VO[\W
M@")[(<!-_*45]'V CTEXGA OMHS_B->4"O0:!E%\V5D+L?G8Z\7NFH8D/F4;
M&L$[2\9#(F"3KWKQAE/BI45AT+,M:]@+B1]U1A?IOCD?7;!$!'Y$YQS%21@2
M_G9% [:][.#.;L>COUH+N:,WNMB0%5U0\64SY[#5VZMX?DBCV&<1XG1YV1GC
MC].^)0O23WSUZ38^>(WDI3PS]D-NW'B7'4N>$0VH*Z0$@7\O=$*#0"K!>?R3
MBW;VQY2%AZ]WZK/TXN%BGDE,)RSXYGMB?=DYZR"/+DD2B$>V_8/F%S20>BX+
MXO0OVF:?'0P[R$UBP<*\&,X@]*/L/WG-01P4]'%%@9T7V#\5X'Y%@9,7.$T+
M^GE!/R6374K*84H$&5UPMD5<?AK4Y(L49EH-E^]'\GM?" [O^E G1E/F)O U
M"D0B#UU'PA=OZ";*VI/\7KKHRV**WK_[#;U#?H3N_2" W?%%3\#!I43/S0]T
ME1W(KC@0MM$]B\0ZAJ-XU"L+]."L]Z=N[T[]RM8J3JE[BAQ\@FS+MA4G--&7
MWQ-^BO P+7<4Y5-]^9])!$>W5$<O78VS_R*<5,_Y?U^$"G@FV%<+R@'C8[PA
M+KWLP(@04_Y".Z-??\%#ZW<5+)-B4T-B)9#]/<B^3KT ^?2VH2IL^G)L=6]5
M?+15;?D8$BOQ&>SY#)KQ&4=10@+T2#>,"Q4HO8[@B0KO1%O5%I0AL1*HX1[4
ML!FH.>4^DYW20S#&*MM4C=)NI*H<JK3U;:$9$BM!^["']J%A[^,$S$%Z#ZEN
M87JM)0EB91/3EK6E94BL1.ML3^M,>X7Y.#_S XH>DO"9<A4EO89EX:YSCAU+
M14I;VI:4(;$2J?,]J?,FI![IRH\%-"V!'DBH[(IZG:?KNS&Z\MD)W%S=4Q4R
M;7U;9(;$2LBP57@[JPDTN%+&H0NF1N($+00,8HAQ-&%))/@;_/>4)&O4I]<J
M?/JBMOQ,J94!'IACW 3@$WE%-QZ,:O[2=S-?7-U;:R3[@^[ D:D,*^EIBUO3
M,Z16IF<7].PF],:>!^KQR>X%NH//H<^1NLWI)3'Z!.E6H*\D".@;FA/^8TO>
MH$TG/K1INZ]DJI5LS=206IEID1*PUCO_A^E$;D%??F);94:HD;LGP0OEJLJ)
MOK(UMF-$ EQD JQW]3]CVX^!<\Y>_,A5MT6]YGRLQ&8T*)A2*V,KH@+6>_R?
ML<U9+" R_.UOJF\:>D5\[@P&2FY&<X,IM3*W(CE@O>%/>^481JIJ3'J!_IEZ
M*#.:$TRIE2$520'K[?T=<Z$MS=<LTIG?&A&XE7;M<[7YU9>VIG6,H("+I(#U
M-O_)%Q 2V!)A^_WS;VA!W81#*U,BTRM-6!B"@UD(YOXX0>^L4T@0:$,X>B%!
M0M&&<A2O"5<F+[UT:Z3'2!2XB!2X)@MPXOG1"BW>PF<6*$G6APDE):,9PI1:
M>9*U"!&VWN;O6AJZ?G77)%K1RN15(_0P7DS'?RDG:HUF!E-J95Y%9K ;989O
M- C0;02V#/HJB6&0\]!-'"?J4:Y&\X$IL1D-"Z;4RMB*L& W"@M?60"AE/!L
M4H0K'S34*%7 ,IH"3*F5814IP&Z4 B8)YW*N+9M@2X<R\+6)&II>\3M554WT
M5:VI'2,$V$4(L!N%@)M(4)X];Y3SN62'44E-KUA%S6@&,*56IE9D +M1!DB[
M(YI ;%HQKK0=-3H/+.H2UZ4@ R)>)JBD9S0)F%(KTRN2@*TW\CF]14C@=G"5
MQ/!VK.Z?>IVJIRWZLM:PCI$(["(1V'HSG\.Z#BE?R='L$RB(-62H<$,B=9O3
M"U92,YH,3*F5J17)P&[T$.'Z]?"92_;,2HE,KU;YT$5?UYK9,:R_75A_6^_<
M;R:S1S1./%\PCL9"T%AD\[JS@*R4U/1ZU=2,1@%3:N45"D44<!H]3UBLI;?5
M],H:F4I8^KK6BQ".D0.<(@<XC7+ /'D.?!?:%2-*AZ%7:;V*PV@DR-4&J9I<
M0?8R&O1/^Q>]%Q69PNH[C:Q^>1YB(:<<8O0Y$= 5(YG+E;1,NOA)KC8\N#Y\
M;N/AF8WWUYB3.(;?=P[6!C7S^^!2.0G P7KT%=U2=>?32UF6A0=#>9E*(F:7
M 1W#[SN%WW?T[GP7CV9^+&<:OU/"M8LX:N2Z76QW'34VHX;?E%H96V'XG88+
MA ZYS6"GTK?6B%4M>-&7M29V#)/O%";?:;A2*">6+QBJ9J:7FWU7$C/J]$VI
ME8D53M_1&_,QX/(R9!6&JT:@VD,8M?:FU,J8"FOOZ,WXSJ%6S;C6E-_.[S^A
MN[NYDI-1.V]*K<RIL/..WG[O.,U\'J*;J1*57@&?*9]*ZJM:4SJ&?>\7]KVO
M]]T[2O+!6]6:XAJ)^=H/B$>#S=HG)TC]!%POT7JIK%$7WSM8*2]G&=)?',3(
ME2NALD7S^[W[7S6,T[7\O>+CV4\B[HF<I(A10)=0:IU^@'L0SWYED&T(MDG7
MW3\S(5B8OEQ3@,?E!^#])6-BMR$/L/^MQ^A?4$L#!!0    ( $J&=U9PX5!_
MEP4  #<7   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULM5AM;]LV$/XK
MA%=L*V#')/5FI8Z!-L6P AL6-.WVF99HBZ@DNB+E-/OU(V5%DJ63G'79!]NB
M?'=\[DC><\?U@RR^J(1SC;YE::YN9HG6A^OE4D4)SYBZD@>>FW]VLLB8-L-B
MOU2'@K.X4LK2)<787V9,Y+/-NGIW5VS6LM2IR/E=@5299:QX?,=3^7 S([.G
M%Q_%/M'VQ7*S/K ]O^?Z\^&N,*-E8R46&<^5D#DJ^.YF]I9<W]+ *E02?PK^
MH#K/R+JRE?*+'7R(;V;8(N(IC[0UP<S/D=_R-+66#(ZOM=%9,Z=5[#X_6?^E
M<MXXLV6*W\KT+Q'KY&:VFJ&8[UB9ZH_RX5=>.^19>Y%,5?6-'FI9/$-1J;3,
M:F6#(!/YZ9=]JP/142#NB *M%>AS%9Q:P:D</2&KW'K/--NL"_F "BMMK-F'
M*C:5MO%&Y'89[W5A_A5&3V]N9:YD*F*F>8S>L93E$4?WUIQ""_3Y_CWZ^=5K
M] J)''U*9*E8'JOU4IN9K?XRJF=Y=YJ%CLSRGD=7R"%S1#&E@/KM\]7)N?K2
M^-LX31NG:67/&7.Z+ J>:\24,GY>0_Z<#+BP 7NVKM6!1?QF9@Z/XL61SS8_
M_D!\_ ;R[H6,G?GJ-+XZ4]8WMTPER*P:BNP#_UJ*(TN-\^ JGDP%E2F; (X;
MEV(2KI?'KCN E!,ZI)$ZP^DV.-U)G&^C2)8&ELD-$3<8MRF?HYQK".;)DM\!
MX/N4]% .A5SJN#!(KP'I38+\D!]-Z&3Q"*'R!A,2$H2T!VLH%?C>"H;E-[#\
M25AW!3\P$2/^S61WQ56UWE(GO*BW. 37'P Q2^WUT Z%'.I0&&W0H TFT7Z2
MFJ4FMW7/( 0P&*XR==V@AW HY878\V"(JP;BZD) #4\6^K$*I#TS!\-<>G0_
MKH8K[Z_Z"P\(D94/XPP;G.&%_:A9OA?FK-1Q'(48#E?;#?L'&Q!RL -#)+AE
M&#P)LBH-%G*W*!6?6.[:REF *.TO]_1<WYE+28<MR3/V[H039+AI@Y77/U:0
M&/7<D>Q$6EXCSR.V5+"M2(46'&8W\J+T]E+6SIUN"8Y,,US#' ?V:&D#=-@9
M;BZOPP:U(T,IZI*Q56F9C5RDMJ+D8'J.A@L&PA^2&<$KOW]^ ;$5\4>(F;2D
M1Z99[SQA7X(*T"!U.UFDA@J(82\8R=ND94(R386_R7R_T+S(3"V_!3,A 3@M
M#(G?!S@YS_=NZI8CR31)GOMAF@*=F,HHK<KT S/4!+HV:?-?'^LAM3K$#<>V
M4\NM9)I<_ZAV?MHX>&E# <1)G7ZU!T@Y*SP"M:57,LVOIYU_">"0-CW'\W ?
MX5#,-?7,2 5 6WJE>#+GWVL9?4ED&O-"_505*_H1;FE>B#KKGN;_(&+:$C&=
M)F)3\NZX24@Q4M;_-^@5OL*8V+.!3(-3\FM$\!SCZH-4P@J;=TN=R$+\S>,W
M*)=/;X52-CM72;G4RE14L<CW8 0G,<$^(S!X_]W0>=PZG>\D&9M^/\MD/AXT
MBB>C1L(Y\;TYID$5+^+./1K.?>P#P81EO2!XDNU$&S&-3)?/LZU)#4\7!95:
M_ZWY-KH'7EW_I& :K$-PEC'Z5 G)C) /;2L1>J$2B6-A+Z=,SK#]V$+DINL^
M")-#0)A M;%:.7X_M4%R'L;^2%U"V[J$7JQ+RJP\<4I=CLC,;+C$WM(=.1*Y
M&7/T<RJ5>@UZ )0E@[P'""V\D1:2MC4)G:Y)NMACOA.1 ,F>#LN,!0U<2OL5
M.2A(PY"&(TC;BH1.5R0G#E% E@8!#ZL3XCIX !?JWG$X<H] V[*#/J<W[Q!>
M=0:?#3X8W Q!W0\D!G0_R\ZMIKU2_IT5>Y$KE/*=T<-7@5FRXG1+>QIH>:@N
M.K=2:YE5CPEG!K05,/_OI-1/ WMWVMR5;_X!4$L#!!0    ( $J&=U8&U;1I
MV (  $@*   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK59=;]HP%/TK
M5C9-K=01)Y $.HBT4DW;PR34:MNSFUR(5<?.; >Z_?K92<@(3?GHQ@/XXYYS
MS[&OL:<;(1]5!J#14\ZXFCF9UL6UZZHD@YRH@2B FYFED#G1IBM7KBHDD+0"
MY<SU,0[=G%#NQ--J;"'CJ2@UHQP6$JDRSXG\=0-,;&:.YVP'[N@JTW; C:<%
M6<$]Z&_%0IJ>V[*D- >NJ.!(PG+F?/2NYQZV@"KB.X6-VFDC:^5!B$?;^9+.
M'&P5 8-$6PIB?M8P!\8LD]'QLR%UVIP6N-O>LG^JS!LS#T3!7+ ?--79S!D[
M*(4E*9F^$YO/T!@*+%\BF*J^T::.#2('):72(F_ 1D%.>?U+GIJ%V %XHQ<
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M<1@&6.TO/:$?N^C4_-*S"<\.)TYVUVGL>Z+K#"C!]W'DN>J2VUZCT;<O*)X
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M%=I?"+9I?P;GD0G!UNW+%4WE;-0DD)\O&1-O%\TOZQQ^W.GNOU!+ P04
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M5\]9ONSOQ/,GTY5$%8%D0R54)Z,WKP;"Y\^0O(BN25?_A8NX?Z3'"E]NY%D
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M&'S,0J2JRBR.!5D90>-"YM.2-?VDE7E1M1J)6RFU;"E65'=JQ2EK(LBG!"=
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MR>,C/5;J+MIJ(W]U BBBK=;R<V42!$&^@.>+"N# 7G !_V=(7OPW4$L#!!0
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M5FH#KHZHW)ZXA=X;R'N")JVR?0X?LG?&U:YQFY!C8T2KI=.;J&%4"T=4#"4
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M!:#\6N0O1C9N%=E)0XN-^RQIDT1E&>@]E](<+E9!OYMN_P%02P,$%     @
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M<F*&,KF.61N)Q&"SA%IIG+00$J\(6&;%*R8K)NXWH(>&&I?GK$S3VH0+S[Y
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MS\*)Z27;055NZ-?V>5E5Y9J^K@2$MD("6%^49=4.\(#NWR]N_@=02P,$%
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MAB'[:O(B!Y=/S@(-+A11ANO+[U/\=DS!YDPGMP*@X1O-B4_A@+I!<99.A=4
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MT4HY3\]I7K9#FZF:J!!9>Q49BU]0NM50_R(\,HM%(F<%.A: .'$J'A6&CKJ
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MEB^Q.VML7?T%\=@,V&%CX@6$',]",@T@?\XH1!,O+82G4!3@\,K=.EDXO3C
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MS5D'+!N@3B$P\9LD_A0:MC K$20B@Z$=6:8<?L?J_CLPYMYNI]]/P0XP=AK
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MNI_GEI2\2\>*):;<LTM8AR1Y :M\-=L8T0%\^.AB8[&,POD#IU5I*&QWXQ:
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M]@!^GTN$_/7&*F@>C9._ 5!+ P04    " !*AG=64Y[!E!(#  ! !P  &0
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M"EC0AIL[N?H&ZWQ.+5\NN79?LFICHW./Y(TVLEJ#44'%1#O2E_4Y[ "&P0>
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M=B/XPI#U54LM:+&TUQNW0FM1VM<%9QF79@+\/Q-"-X+9H+WOFOX#4$L#!!0
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MH\Y*WR 8X5SC?QOPPE$+R.X!KY/F7"<)2W'2 9%!$7<TP5_3(F9?QWSNZ*K
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M<M*$2[DGQZN2XVAS:[66Q*=,'H0IX=8:DJ9&4TCT</H@M@K]V2HEWBM$I,6
M>]/C9E_ G6;PCJ$:#S^;$LO_ J1,<F2:'9C>9$<1WV!Q ?GT'+))EAW!RT?E
M><3+?TCYG]=;3XYSYJ_GM/?(L^>10QU=^584N$ZX4#RZ3YAL7KZ8+B:OC_">
MC;QGQ] W]UR79:<0; 551YW#D!=2=QH4<GY"*_:]JHY/WH&QYJ="F )5N$O@
M<G8B"!V\1>T0@_]S.H\S>6@0*JNXK@,<17B'A>43Y*0!XF6F('UA.T-8?H7M
M*7NV2NS947*UULRK%H2PW<,>A3O[)CF>RX<:('3:AP/2EC>D1ABP!B,.D(W,
MR))0_SL-)<56*DDA!8*4VLA_F!"WCQ##TKQ5LA1!S5:H0 -B[7$*Q?TX25%O
MF>8A4>%4AEC;><XQ?W8%+U\LLTG^^HM_#LKA!/+Y,@QGD"\683 ?'?++>3 L
M'@W+/!@N'PVO,N"[X1Y=\4&,YNEB#@]1]7?<R@EDYY/\%?R&WH/4;4?Q?A@7
M/8W0I[/%\FP /W:D)S ]GU].#W'/54/ZI)=I='7LV!XBV[ZMC=;Q4;CN>^&C
M>_^BO!.NEL8SCXI#)Q>7\P1<WZ7["=DV=L:M)>ZS<=CPPX8N./!Z92T=)F&#
M\:G<_ M02P,$%     @ 2H9W5I(];:7@ P  @1$  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&ULS5C1;N(X%/T5*SM:M=*T"2% Z0(2A8QVI!E-U4YG
M'U;[X"878M6),[8#G;_?:R=D@*:9(F6EY0%LQ^?X^AQS;6>R%?)))0":/*<\
M4U,GT3J_=ET5)9!2=2ERR/#)2LB4:JS*M:MR"32VH)2[ON<-W92RS)E-;-NM
MG$U$H3G+X%825:0IE3]N@(OMU.DYNX8[MDZT:7!GDYRNX1[T0WXKL>;6+#%+
M(5-,9$3":NK,>]=ASS, V^,;@ZW:*Q,SE4<AGDSE8SQU/!,1<(BTH:#XLX$%
M<&Z8,([O%:E3CVF ^^4=^P<[>9S,(U6P$/PO%NMDZEPY)(85+;B^$]L_H9K0
MP/!%@BO[3;957\\A4:&T2"LP1I"RK/RESY40>P#D:0;X%< _!@Q? ?0K0/\8
M$+P"""I \%; H +8J;OEW*UP2ZKI;"+%EDC3&]E,P:IOT:@7R\Q"N=<2GS+$
MZ=D=4T^*T"PFG]CW@L5,_R!G2]"4<75.+LC#_9*<O3LG[XA+5$(E*,(R\I Q
MK=YC(Y:_)J)02* FKL: #*T;58/?E(/[KPS>(Y]%IA-%PBR&N &_^ 7>;R%P
M48E:#G\GQXW?RC@OUI>DWWM/?,_WFP)JAR\A:H4OWP[W&N#AV^&]%C'Z]=KH
M6[[^*WP/6:$*RHE9(T1(=#T"B2LCPS7R]R?L3#YJ2-4_3<:7S$$SL\E^URJG
M$4P=3&\*Y :<V>^_]8;>'TVB=TFV[)(L[(CLP)Z@MB=H8Y_-HZA("TXUQ"8U
MLHCI)B=:24YUHB0;63*S!VUF%_XH\/W!Q-WLB]SEH&'3H/YX[(_K00_T&]3Z
M#5KUNX,(<).*28;[<2Y%!! K(E:$KC1(E#0N<!?+UJ3 Y"*WDME*S%0DBLRD
MOTBD*5-FRRPSJ- )XL1J!=+TA&?<S14TYL76R$XU9?!"GWX0>-Z1)2][!<'(
M9*G]7F%'@1T8,JP-&;8:\F4#\F+.N=!X$M'D2VZ.$DWJM=*<JEZ79,LNR<*.
MR Z\&-5>C/ZSW#_JTIXNR99=DH4=D1W8<U7;<]7Z5UE@ZL%C-AX/HR>".:C
M-&92D!(\)F=X*BO/:N=-]I3,P_U$,/3,YS 5+%HC.%7Y+LG"CL@.E!_7RH_;
MD]0NO>>216"UC@7G5)(<D[^5O5'U\8OT>W6D=^NXI^K=)5G8$=F!WCWOYPW%
M^]_NTU5HO]A;%^TS.-6[3MG"KMA*]]R]JV8*<FWO^(I8J<MK5MU:OT>8V]OS
M4?NB=[TLWP;\I"E?3GRF<LW0*@XKI/0N1W@FD>5]OZQHD=L+[:/0>#VVQ00H
M>F\ZX/.5$'I7,0/4;UUF_P)02P,$%     @ 2H9W5@921HT< @  H 0  !D
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MG]W5Z ?7>V6[0^B[S+YESTU#&4Z(ZTF#>HVD^/PI.8F_OR5[3V2O3,@&$[+
MGNTPX0/?PEOZLWWJWQ/9*_WC0?_XW8]@2DT%^-ARY\$NL1W#:6#PXW1=9&=Q
M$N?1>EO%_UGC)#L[&;*Z\J*M'O?S]8;JE?,:!)8.%X].CPGH;F9U@55-:/M[
M9=T0"<O*C7G4/L&=ETK9E\!/DN&/H_@'4$L#!!0    ( $J&=U;9JF\ J ,
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M]/N(OC-)DSX92[B)ABOZX\-B/"W&T<.A/,=!_KGOM8-"8V$GTA[7M,=&VE]
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M*"_*XZ\I+7E4)'QL"]E45:$=U\VZJYKEO=$L%WVAA4@Y"HH$)QWV_K_8>P:
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M$;@^H/XO&9/[A29H^]'D-U!+ P04    " !*AG=6\V:S@0D&   M)   &0
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M4.\A=>YAC':A:D3 P1JG+6:T=!.A=:5KK2J<C;,4C,@C.KD!QK3@#,?\@#/
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MKJO8^S:V5[LN'D+<2V\?DQQBHB#H,'LU!UW-P6#-SZ:DOIR#@V#G!TGW8-S
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M7OY%^ZKO:.B@J.""IC58OD%*LNH7O]1"G  DCQX0U("@"W@O0J\&]+J _CN
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M/8=[CK%]F6^YN)<E@$(/=<7DPBN5:LY\7V8EU$1.> -,/RFXJ(G27;'R92.
MY!945WZ(\<RO"65>,K=CUR*9\[6J*(-K@>2ZKHGX=0$5WRZ\P'L<N*&K4ID!
M/YDW9 6WH+XUUT+W_)XEIS4P23E# HJ%=QZ<I0$V !OQG<)6[K21D7+'^;WI
M7.8+#YN,H(),&0JB;QM80E49)IW'SX[4Z]]I@+OM1_9/5KP6<T<D+'GU@^:J
M7'@G'LJA(.M*W?#M9^@$30U?QBMIKVC;QL93#V5KJ7C=@74&-67MG3QT1NP
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MO'KXR-F,2_,&_?>Y$.KMB:E@??N[J_\"4$L#!!0    ( $J&=U:ANH P(P,
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M10,  ,H4   -    >&PO<W1Y;&5S+GAM;-U876_:,!3]*U&Z3JTT-4#:0%9
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( $J&=U8%JK.1H 0  ,@D   /
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 2H9W5AVRR ;M    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M2H9W5IE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !*AG=6&? 287X'  #W,0  &
M    @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M2H9W5G#A4'^7!0  -Q<  !@              ("!P \  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $J&=U8&U;1IV (  $@*   8
M          " @8T5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !*AG=6SW9GD?(%  !>&P  &               @(&;&   >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 2H9W5J^Q]O43"0  Z$D
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M965T.2YX;6Q02P$"% ,4    " !*AG=67E7_P&X#  !9"   &0
M    @('O50  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M $J&=U95Z,11 P,  ,\'   9              " @919  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 2H9W5H.*PP;8"0  ,QT  !D
M             ("!SEP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !*AG=6MRN1(QP$  "G"@  &0              @('=9@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $J&=U:/P"U1L@H
M (HA   9              " @3!K  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 2H9W5@Q+NS+U!   F@L  !D              ("!
M&78  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !*AG=6
MJ6: M' )  !+&@  &0              @(%%>P  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( $J&=U9U-<(L4PX  -<F   9
M      " @>R$  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 2H9W5LV3CT3Y @  O08  !D              ("!=I,  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !*AG=6Z;-H;>L8   P30
M&0              @(&FE@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( $J&=U8.T""WF 0  $ .   9              " @<BO  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 2H9W5E.>P902
M P  0 <  !D              ("!E[0  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !*AG=6(]C 7 X#  "I!P  &0
M@('@MP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $J&
M=U:G;8"+L0(  %D&   9              " @26[  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 2H9W5A#%G;1L @  ! 8  !D
M         ("!#;X  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !*AG=60]LU->(%  #[$@  &0              @(&PP   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $J&=U99JOUL9 0  "P-
M   9              " @<G&  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ 2H9W5I2).<HB P  -@<  !D              ("!9,L
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !*AG=6DCUM
MI> #  "!$0  &0              @(&]S@  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( $J&=U8&4D:-' (  * $   9
M  " @=32  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M2H9W5LN8\!8H @  $P4  !D              ("!)]4  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " !*AG=6>*_Y_G8#  "4#P  &0
M            @(&&UP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( $J&=U:-P+BC<P(  *4&   9              " @3/;  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 2H9W5K:LC<L9!
MMQ8  !D              ("!W=T  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " !*AG=6LW :*V4"  !$!@  &0              @($M
MX@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $J&=U;9
MJF\ J ,  !X2   9              " @<GD  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ 2H9W5G=)[U_0!   G!X  !D
M     ("!J.@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $J&=U9GJ(12\ 0  )HA   9              "
M@?#^  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 2H9W
M5L/"#-/G @  FPH  !D              ("!%P0! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " !*AG=6\V:S@0D&   M)   &0
M        @($U!P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( $J&=U:X)<UL;P,  *00   9              " @74- 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 2H9W5I],<(<2!0  _QD
M !D              ("!&Q$! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " !*AG=6W[X%.-X"  ">"0  &0              @(%D%@$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $J&=U8=M@+R
M]0(  'H)   9              " @7D9 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ 2H9W5L^J=J@1 P  L0@  !D
M ("!I1P! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !*
MAG=65\D71*L$  !4&   &0              @('M'P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( $J&=U:^%RWHLP,  ) -   9
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M970U-"YX;6Q02P$"% ,4    " !*AG=6H;J ,",#  " "@  &0
M    @($'/0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M $J&=U;^"A#Q10,  ,H4   -              "  6%  0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ 2H9W5I>*NQS     $P(   L              ( !
MT4,! %]R96QS+RYR96QS4$L! A0#%     @ 2H9W5@6JLY&@!   R"0   \
M             ( !ND0! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $J&
M=U:\ =;!X $  .P@   :              "  8=) 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $J&=U84U''DT $  *T@   3
M          "  9]+ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     _ #\
*,!$  *!- 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>140</ContextCount>
  <ElementCount>335</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Background</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureBackground</Role>
      <ShortName>Background</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureRisksAndLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureDebt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Risks and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails</Role>
      <ShortName>Risks and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureRisksAndLiquidity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Summary of Significant Accounting Policies - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Summary of Significant Accounting Policies - Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40305 - Disclosure - Summary of Significant Accounting Policies - Revenue Disaggregated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue Disaggregated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40306 - Disclosure - Summary of Significant Accounting Policies - Fair value of financial instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair value of financial instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40307 - Disclosure - Summary of Significant Accounting Policies - Net loss per share (Potentially dilutive securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net loss per share (Potentially dilutive securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Debt - Schedule of long term debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails</Role>
      <ShortName>Debt - Schedule of long term debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Debt - MidCap Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails</Role>
      <ShortName>Debt - MidCap Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Debt - OrbiMed Term Loan (related party) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails</Role>
      <ShortName>Debt - OrbiMed Term Loan (related party) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stockholders' Equity - Public Stock Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails</Role>
      <ShortName>Stockholders' Equity - Public Stock Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stockholders' Equity - Warrants outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Warrants outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stock-Based Compensation - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails</Role>
      <ShortName>Stock-Based Compensation - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Stock-Based Compensation - Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Stock-Based Compensation - Early Exercise Of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Early Exercise Of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Stock-Based Compensation - Weighted average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40806 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureEmployeeBenefitPlans</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Income Taxes - Deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Income Taxes - NOL carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails</Role>
      <ShortName>Income Taxes - NOL carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Income Taxes - Rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Income Taxes - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureIncomeTaxesNarrativesDetails</Role>
      <ShortName>Income Taxes - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="tela-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Commitments and Contingencies - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. tela-20221231x10k.htm 105</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept LondonInterbankOfferedRateLIBORMember in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. tela-20221231x10k.htm 118</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 13 fact(s) appearing in ix:hidden were eligible for transformation: tela:ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder, us-gaap:EarningsPerShareDiluted, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo, us-gaap:PreferredStockSharesOutstanding, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  tela-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="tela-20221231x10k.htm">tela-20221231x10k.htm</File>
    <File>tela-20221231.xsd</File>
    <File>tela-20221231_cal.xml</File>
    <File>tela-20221231_def.xml</File>
    <File>tela-20221231_lab.xml</File>
    <File>tela-20221231_pre.xml</File>
    <File>tela-20221231xex10d13.htm</File>
    <File>tela-20221231xex10d15.htm</File>
    <File>tela-20221231xex10d16.htm</File>
    <File>tela-20221231xex10d17.htm</File>
    <File>tela-20221231xex10d18.htm</File>
    <File>tela-20221231xex21d1.htm</File>
    <File>tela-20221231xex23d1.htm</File>
    <File>tela-20221231xex31d1.htm</File>
    <File>tela-20221231xex31d2.htm</File>
    <File>tela-20221231xex32d1.htm</File>
    <File>tela-20221231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tela-20221231x10k001.jpg</File>
    <File>tela-20221231x10k002.jpg</File>
    <File>tela-20221231x10k003.jpg</File>
    <File>tela-20221231x10k004.jpg</File>
    <File>tela-20221231x10k006.jpg</File>
    <File>tela-20221231x10k008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="612">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tela-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 612,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 140,
   "dts": {
    "calculationLink": {
     "local": [
      "tela-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tela-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tela-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tela-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tela-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tela-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 502,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 19,
    "http://www.telabio.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 24
   },
   "keyCustom": 49,
   "keyStandard": 286,
   "memberCustom": 26,
   "memberStandard": 27,
   "nsprefix": "tela",
   "nsuri": "http://www.telabio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.telabio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.telabio.com/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.telabio.com/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.telabio.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.telabio.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.telabio.com/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.telabio.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.telabio.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Related-Party Transactions",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.telabio.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.telabio.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.telabio.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.telabio.com/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.telabio.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.telabio.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Risks and Liquidity (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails",
     "shortName": "Risks and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_I8CJGHwyyEWw2nQXigOSaQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Summary of Significant Accounting Policies - Segments (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_I8CJGHwyyEWw2nQXigOSaQ",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_H8H5Cuwd6UuI95gA3JBijw",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Summary of Significant Accounting Policies - Inventory (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails",
     "shortName": "Summary of Significant Accounting Policies - Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Summary of Significant Accounting Policies - Long-Lived Assets (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40305 - Disclosure - Summary of Significant Accounting Policies - Revenue Disaggregated (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue Disaggregated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "lang": null,
      "name": "tela:IncrementalCostsOfObtainingContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_PGJ1GKO4r0m8-XWNlJhlug",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40306 - Disclosure - Summary of Significant Accounting Policies - Fair value of financial instruments (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Fair value of financial instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_PGJ1GKO4r0m8-XWNlJhlug",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40307 - Disclosure - Summary of Significant Accounting Policies - Net loss per share (Potentially dilutive securities) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Net loss per share (Potentially dilutive securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Debt - Schedule of long term debt (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails",
     "shortName": "Debt - Schedule of long term debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_h_H8pqMUMUyTw6VdKGsnwA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Debt - MidCap Term Loan (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
     "shortName": "Debt - MidCap Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_5_26_2022_To_5_26_2022_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_7alFNq9WVkudCwmmXa7QyA",
      "decimals": "-5",
      "lang": null,
      "name": "tela:EligibilityRequirementToBorrowTranche2",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Debt - OrbiMed Term Loan (related party) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails",
     "shortName": "Debt - OrbiMed Term Loan (related party) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_tela_OrbimedTermLoanMember_Kaoof9Egs0ivKLTiFF4Y9Q",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stockholders' Equity - Public Stock Offerings (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails",
     "shortName": "Stockholders' Equity - Public Stock Offerings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_6_1_2020_To_6_30_2020_us-gaap_SubsidiarySaleOfStockAxis_tela_SecondUnderwrittenPublicOfferingMember_lQEEIhyvLUeG6RwD_4RFTg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Stockholders' Equity - Warrants outstanding (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity - Warrants outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tela:EquityIncentivePlansNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item__TJFBDNbO0SDXs4XkYl9ag",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Stock-Based Compensation - Narratives (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails",
     "shortName": "Stock-Based Compensation - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tela:EquityIncentivePlansNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item__TJFBDNbO0SDXs4XkYl9ag",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Stock-Based Compensation - Expenses (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails",
     "shortName": "Stock-Based Compensation - Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_RPfZ9MGnMUqoXSzG-bXcvg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Stock-Based Compensation - Early Exercise Of Stock Options (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Early Exercise Of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_L9MBuv_DmECPht3TjqkMbg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - Stock-Based Compensation - Weighted average assumptions (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Weighted average assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_0ySqKDuji0e0ER6NBbeSnQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40806 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_RestrictedStockUnitsRSUMember_3ahxIFvaXkyxZemSvSBVOg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_5NiKCVEWCEiDvMelyhiNOQ",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w6UDjR_eTEagY1f1G_onNg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w6UDjR_eTEagY1f1G_onNg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Income Taxes - Deferred tax assets (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_pOKNe1MZo0aFsxEbEdiunQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Income Taxes - NOL carryforwards (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails",
     "shortName": "Income Taxes - NOL carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_pOKNe1MZo0aFsxEbEdiunQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Income Taxes - Rate reconciliation (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails",
     "shortName": "Income Taxes - Rate reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_DRb3ZmmAaEWLh2gfOasNyQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Income Taxes - Narratives (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.telabio.com/role/DisclosureIncomeTaxesNarrativesDetails",
     "shortName": "Income Taxes - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Commitments and Contingencies - Operating Leases (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_lGtZg6kPKkWx27v_3XLpfw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_5xJ8MBGvHEuR30A3Y0abRQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Background",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.telabio.com/role/DisclosureBackground",
     "shortName": "Background",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Risks and Liquidity",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.telabio.com/role/DisclosureRisksAndLiquidity",
     "shortName": "Risks and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tela-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_p25qxoCTIkSOCFwdz_w79w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 55,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.telabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r301",
      "r320",
      "r555",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r161",
      "r204",
      "r211",
      "r217",
      "r264",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r415",
      "r418",
      "r420",
      "r421",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r161",
      "r204",
      "r211",
      "r217",
      "r264",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r415",
      "r418",
      "r420",
      "r421",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r161",
      "r204",
      "r211",
      "r217",
      "r264",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r415",
      "r418",
      "r420",
      "r421",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "European territory"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r255",
      "r573",
      "r631",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r345",
      "r510",
      "r524",
      "r551",
      "r552",
      "r570",
      "r581",
      "r590",
      "r629",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r345",
      "r510",
      "r524",
      "r551",
      "r552",
      "r570",
      "r581",
      "r590",
      "r629",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r255",
      "r573",
      "r631",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North American territory"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r337",
      "r345",
      "r363",
      "r364",
      "r365",
      "r486",
      "r510",
      "r524",
      "r551",
      "r552",
      "r570",
      "r581",
      "r590",
      "r625",
      "r629",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r337",
      "r345",
      "r363",
      "r364",
      "r365",
      "r486",
      "r510",
      "r524",
      "r551",
      "r552",
      "r570",
      "r581",
      "r590",
      "r625",
      "r629",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r198",
      "r199",
      "r301",
      "r320",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r217",
      "r346",
      "r601",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r572",
      "r589",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r537",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r572",
      "r589",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r217",
      "r346",
      "r601",
      "r602",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_AccruedExpensesAmountDueToContractManufacturer": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to contract manufacturer due.",
        "label": "Accrued Expenses, Amount Due To Contract Manufacturer",
        "terseLabel": "Amounts due to contract manufacturer"
       }
      }
     },
     "localname": "AccruedExpensesAmountDueToContractManufacturer",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_AdditionalExtensionForInterestOnlyPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional extension for interest only payment period.",
        "label": "Additional Extension for Interest Only Payment Period",
        "terseLabel": "Extension for interest only payment period"
       }
      }
     },
     "localname": "AdditionalExtensionForInterestOnlyPaymentPeriod",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tela_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of adjustments to additional paid in capital resulting from reclassification of liability-classified stock based compensation to equity classified.",
        "label": "Adjustments to Additional Paid in Capital, Reclassification Of Liability Classified Stock Based Compensation",
        "terseLabel": "Reclassification of liability-classified stock-based compensation awards"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedStockBasedCompensation",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_AgreementWithAroaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to License, Product Development, and Supply Umbrella Agreement with Aroa.",
        "label": "Umbrella Agreement with Aroa"
       }
      }
     },
     "localname": "AgreementWithAroaMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Date from which Warrants or Rights Expire",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Expire",
        "terseLabel": "Expiration dates"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "tela_CollagenMatrixInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Collagen Matrix, Inc.",
        "label": "Collagen Matrix, Inc. [Member]",
        "terseLabel": "Collagen Matrix, Inc."
       }
      }
     },
     "localname": "CollagenMatrixInc.Member",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Capital Shares Reserved For Future Annual Issuance",
        "label": "Common Stock Capital Shares Reserved For Future Annual Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureAnnualIssuance",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tela_CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Capital Shares Reserved For Future Issuance, Percentage Of Shares Outstanding Last Day Of Fiscal Year",
        "label": "Common Stock Capital Shares Reserved For Future Issuance, Percentage Of Shares Outstanding Last Day Of Fiscal Year"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuancePercentageOfSharesOutstandingLastDayOfFiscalYear",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_CommonStockWarrantsExpiringIn2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock warrants expiring in 2027.",
        "label": "Common stock warrants expiring in 2027"
       }
      }
     },
     "localname": "CommonStockWarrantsExpiringIn2027Member",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_CommonStockWarrantsExpiringIn2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock warrants expiring in 2028.",
        "label": "Common stock warrants expiring in 2028"
       }
      }
     },
     "localname": "CommonStockWarrantsExpiringIn2028Member",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock warrants.",
        "label": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Computer equipment and software.",
        "label": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_DebtInstrumentInterestPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of debt instrument interest payment.",
        "label": "Debt Instrument Interest Payment Term",
        "terseLabel": "Number of Installment"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentTerm",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tela_DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred rent and tenant allowance netted against operating lease right-of-use asset.",
        "label": "Deferred Rent And Tenant Allowance, Netted Against Operating Lease Right-of-use Asset",
        "terseLabel": "Deferred rent and tenant allowance netted off against right-of-use asset"
       }
      }
     },
     "localname": "DeferredRentAndTenantAllowanceNettedAgainstOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to  lease liability",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to  depreciation and amortization",
        "label": "Deferred Tax Liabilities Depreciation and amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to Right of use asset",
        "label": "Deferred Tax Liabilities, Right Of Use Asset",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "tela_EligibilityRequirementToBorrowTranche2": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue the company must generate to be eligible to borrow Tranche 2.",
        "label": "Eligibility Requirement To Borrow Tranche 2"
       }
      }
     },
     "localname": "EligibilityRequirementToBorrowTranche2",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_EmployeeStockPurchasePlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan 2019"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2019Member",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the discount on purchase of common stock under the employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan, Discount On Purchase Of Common Stock",
        "terseLabel": "Discount on purchase of common stock"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanDiscountOnPurchaseOfCommonStock",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_EndOfTermCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the principal amount paid as an exit fee at the time\n of maturity or prepayment.",
        "label": "End of Term Charge"
       }
      }
     },
     "localname": "EndOfTermCharge",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Distribution Agreement [Member]",
        "label": "Equity Distribution Agreement"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_EquityIncentivePlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for 2019 Equity Incentive Plan.",
        "label": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2019Member",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_EquityIncentivePlansNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about number of equity incentive plans.",
        "label": "Equity Incentive Plans, Number",
        "terseLabel": "Number of equity incentive plans"
       }
      }
     },
     "localname": "EquityIncentivePlansNumber",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tela_FirstYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information first year of term loan.",
        "label": "First Year [Member]",
        "terseLabel": "First year"
       }
      }
     },
     "localname": "FirstYearMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_FixedCostOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Cost Of Net Sales",
        "label": "Fixed Cost Of Net Sales"
       }
      }
     },
     "localname": "FixedCostOfNetSales",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_IncrementalCostsOfObtainingContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents incremental costs incurred in obtaining a contract.",
        "label": "Incremental Costs Of Obtaining A Contract",
        "terseLabel": "Incremental costs of obtaining a contract"
       }
      }
     },
     "localname": "IncrementalCostsOfObtainingContract",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_InterestPenaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of penalty to be paid on the event of default in meeting the obligation.",
        "label": "Interest Penalty, Percentage",
        "terseLabel": "Interest due to unpaid obligation"
       }
      }
     },
     "localname": "InterestPenaltyPercentage",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Lab equipment .",
        "label": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Classified Stock-Based Compensation In Accrued Expenses And Other Current Liabilities",
        "label": "Liability Classified Stock-Based Compensation In Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Liability-classified stock-based compensation in accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "LiabilityClassifiedStockBasedCompensationInAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_MidcapTermLoanTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to MidCap term loans tranche one.",
        "label": "MidCap Term Loan Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "MidcapTermLoanTrancheOneMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_MidcapTermLoanTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to MidCap term loans tranche two\n.",
        "label": "MidCap Term Loan Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "MidcapTermLoanTrancheTwoMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_MidcapTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to MidCap Term loans.",
        "label": "MidCap Term Loan"
       }
      }
     },
     "localname": "MidcapTermLoansMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_MilestonePaymentsRelatedToResearchAndDevelopmentArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments related to research and development arrangements.",
        "label": "Milestone payments related to research and development arrangements"
       }
      }
     },
     "localname": "MilestonePaymentsRelatedToResearchAndDevelopmentArrangements",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net changes in operating lease right-of-use assets and liabilities.",
        "label": "Net Changes in Operating Lease Right-of-use Assets And Liabilities",
        "negatedLabel": "Net changes in operating lease ROU assets and liabilities"
       }
      }
     },
     "localname": "NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_NetDeferredTaxAssetBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Net Deferred Tax Asset Before Valuation Allowance",
        "totalLabel": "Net deferred tax asset before valuation allowance"
       }
      }
     },
     "localname": "NetDeferredTaxAssetBeforeValuationAllowance",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_NextScienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Next Science.",
        "label": "Next Science"
       }
      }
     },
     "localname": "NextScienceMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_NoncashLossOnExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Loss On Extinguishment Of Debt",
        "label": "Noncash Loss On Extinguishment Of Debt",
        "terseLabel": "Noncash loss on extinguishment of debt"
       }
      }
     },
     "localname": "NoncashLossOnExtinguishmentOfDebt",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_NumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of tranches of debt obtained.",
        "label": "Number Of Tranches",
        "terseLabel": "Number of Tranches"
       }
      }
     },
     "localname": "NumberOfTranches",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tela_OfficeAndLaboratorySpaceLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to office and laboratory space lease.",
        "label": "Office and laboratory space"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceLeaseMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_OperatingLeaseObligationAssumed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in operating lease obligation assumed on exchange of operating lease right-of-use assets.",
        "label": "Operating Lease Obligation Assumed",
        "negatedLabel": "Operating lease liabilities assumed for operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseObligationAssumed",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_OrbimedTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Information pertaining to OrbiMed Term Loan.",
        "label": "OrbiMed Term Loans (related party)"
       }
      }
     },
     "localname": "OrbimedTermLoanMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails",
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_OrbimedTermLoansTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Information pertaining to OrbiMed Term Loans Tranche One.",
        "label": "OrbiMed Term Loans - Tranche One"
       }
      }
     },
     "localname": "OrbimedTermLoansTrancheOneMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_OrbimedTermLoansTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Information pertaining to OrbiMed Term Loans Tranche Two.",
        "label": "OrbiMed Term Loans - Tranche Two"
       }
      }
     },
     "localname": "OrbimedTermLoansTrancheTwoMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_OtherCommitmentsTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of Contract.",
        "label": "Other Commitments, Term Of Contract",
        "terseLabel": "Term of Contract"
       }
      }
     },
     "localname": "OtherCommitmentsTermOfContract",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tela_OtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to other customers.",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCustomersMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_OtherSuppliersForExclusivityRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Other Suppliers for Exclusivity Rights.",
        "label": "Other Suppliers for Exclusivity Rights [Member]"
       }
      }
     },
     "localname": "OtherSuppliersForExclusivityRightsMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_OvitexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OviTex [Member]",
        "label": "OviTex [Member]",
        "terseLabel": "OviTex"
       }
      }
     },
     "localname": "OvitexMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_OvitexPrsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OviTex PRS [Member]",
        "label": "OviTex PRS [Member]",
        "terseLabel": "OviTex PRS"
       }
      }
     },
     "localname": "OvitexPrsMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_PercentageOfExitFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the principal amount paid as an exit fee at the time of maturity or prepayment.",
        "label": "Percentage Of Exit Fee",
        "terseLabel": "Exit fee (as a percent)"
       }
      }
     },
     "localname": "PercentageOfExitFee",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of penalty to be paid on principal amount of debt for the first year after closing date and thereafter.",
        "label": "Percentage Of Prepayment Penalty On Prepaid Principal Amount",
        "terseLabel": "Percentage of prepayment penalty on prepaid principal amount"
       }
      }
     },
     "localname": "PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of penalty to be paid on principal amount of debt for the second year after closing date and thereafter.",
        "label": "Percentage Of Prepayment Penalty On Prepaid Principal Amount 2"
       }
      }
     },
     "localname": "PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount2",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_PercentageOfRoyaltyOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Royalty of net sales in lieu of 27% of net sales of the licensed products.",
        "label": "Percentage Of Royalty Of Net Sales",
        "terseLabel": "Royalty percentage of net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOfNetSales",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of product ordered to be supplied within specified period, in case of supply failure occurs, the Company to step in and operate Aroa's plant.",
        "label": "Provision To Step In Plant In Case of Supply Failure, Percentage of product supply Under Binding Purchase Order",
        "terseLabel": "Percentage of products ordered to be supplied"
       }
      }
     },
     "localname": "ProvisionToStepInPlantInCaseOfSupplyFailurePercentageOfProductSupplyUnderBindingPurchaseOrder",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days for supply of the products ordered , in case of supply failure occurs, the Company to step in and operate Aroa's plant.",
        "label": "Provision To Step In Plant In Case Of Supply Failure Supply Period Under Binding Purchase Order",
        "terseLabel": "Number of days for product supply"
       }
      }
     },
     "localname": "ProvisionToStepInPlantInCaseOfSupplyFailureSupplyPeriodUnderBindingPurchaseOrder",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tela_PurchaseObligationDueInSixthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the sixth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Sixth Year",
        "terseLabel": "Purchase commitments due year Six"
       }
      }
     },
     "localname": "PurchaseObligationDueInSixthYear",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of liability-classified stock-based compensation to equity-classified.",
        "label": "Reclassification Of Liability Classified Stock Based Compensation To Equity Classified",
        "terseLabel": "Reclassification of liability-classified stock-based compensation awards to equity-classified"
       }
      }
     },
     "localname": "ReclassificationOfLiabilityClassifiedStockBasedCompensationToEquityClassified",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_ResearchAndDevelopmentExpensesPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of current portion of obligation payable pertaining to Research and development.",
        "label": "Research And Development Expenses Payable Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesPayableCurrent",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_RevenueBasedMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for agreement under the terms of agreement entered.",
        "label": "Revenue Based Milestone Payment",
        "terseLabel": "Payment for agreement"
       }
      }
     },
     "localname": "RevenueBasedMilestonePayment",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment under the terms of agreement entered.",
        "label": "Revenue Based Milestone Payment Upon Achievement Of Cumulative Product Sales Targets",
        "terseLabel": "Aggregate future payments"
       }
      }
     },
     "localname": "RevenueBasedMilestonePaymentUponAchievementOfCumulativeProductSalesTargets",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract with Customer, Including Assessed Tax, as a percentage.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax, as a Percentage",
        "terseLabel": "Revenue, as a percentage"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxAsPercentage",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_SalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone Payment made.",
        "label": "Sales Milestone Payment",
        "terseLabel": "Sales milestone payment"
       }
      }
     },
     "localname": "SalesMilestonePayment",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_SalesMilestonePaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone Payment due when cumulative product sales in the North American territory reach certain amounts",
        "label": "Sales Milestone Payment Due",
        "terseLabel": "Sales milestone payments due"
       }
      }
     },
     "localname": "SalesMilestonePaymentDue",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_SecondUnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Underwritten Public Offering [Member]",
        "label": "Second Underwritten Public Offering [Member]",
        "terseLabel": "Second Underwritten Public Offering"
       }
      }
     },
     "localname": "SecondUnderwrittenPublicOfferingMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_SecondYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information second year of term loan.",
        "label": "Second Year [Member]",
        "terseLabel": "Second year"
       }
      }
     },
     "localname": "SecondYearMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of shares outstanding on the final day of the immediately preceding calendar year, which will be the conditional annual increase to the number of shares authorized or reserved for issuance.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Conditional Increase, Percentage Of Shares Outstanding",
        "terseLabel": "Increase in percentage of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualConditionalIncreasePercentageOfSharesOutstanding",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of conditional annual increase to shares authorized or reserved for issuance under the share based payment arrangement plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Conditional Annual Increase To Number Of Shares Authorized Or Reserved For Issuance",
        "terseLabel": "Increase in number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConditionalAnnualIncreaseToNumberOfSharesAuthorizedOrReservedForIssuance",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of inducement restricted stock units outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Inducement Grants in Period",
        "terseLabel": "Inducement grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tela_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been vesting of common stock previously subject to repurchase.",
        "label": "Stock Issued During Period Shares Vesting Of Common Stock Previously Subject To Repurchase",
        "terseLabel": "Vesting of common stock previously subject to repurchase (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tela_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock vesting of common stock previously subject to repurchase.",
        "label": "Stock Issued During Period Value Vesting Of Common Stock Previously Subject To Repurchase",
        "terseLabel": "Vesting of common stock previously subject to repurchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tenant improvement and deferred rent exchanged for operating lease liabilities.",
        "label": "Tenant Improvements and Deferred Rent Exchanged For Operating lease Liabilities",
        "terseLabel": "Tenant improvement and deferred rent reclassified to operating lease liabilities"
       }
      }
     },
     "localname": "TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tela_ThirdYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information third year of term loan.",
        "label": "Third Year [Member]",
        "terseLabel": "Third year"
       }
      }
     },
     "localname": "ThirdYearMember",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tela_TransferPriceForProductProduced": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage increase above Counterparty's cost of good sold for product purchased.",
        "label": "Transfer Price For Product Produced"
       }
      }
     },
     "localname": "TransferPriceForProductProduced",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tela_ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value Of Shares Authorized To Be Sold Under Equity Distribution Agreement",
        "label": "Value Of Shares Authorized To Be Sold Under Equity Distribution Agreement"
       }
      }
     },
     "localname": "ValueOfSharesAuthorizedToBeSoldUnderEquityDistributionAgreement",
     "nsuri": "http://www.telabio.com/20221231",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r588"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Third-party and professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r71",
      "r170"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r173",
      "r521",
      "r532",
      "r536"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r27",
      "r121",
      "r474",
      "r527",
      "r528",
      "r605",
      "r606",
      "r607",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r588"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r616",
      "r617",
      "r618",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r205",
      "r206",
      "r207",
      "r208",
      "r217",
      "r256",
      "r257",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r371",
      "r372",
      "r373",
      "r390",
      "r391",
      "r392",
      "r393",
      "r400",
      "r401",
      "r402",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r450",
      "r451",
      "r456",
      "r457",
      "r458",
      "r459",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r514",
      "r515",
      "r516",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Shares withheld for employee taxes"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r108",
      "r109",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r31",
      "r313",
      "r453",
      "r612"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from computation of diluted weighted average shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges [Abstract]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "AssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r139",
      "r150",
      "r171",
      "r196",
      "r237",
      "r246",
      "r250",
      "r260",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r404",
      "r408",
      "r431",
      "r588",
      "r627",
      "r628",
      "r670"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r165",
      "r176",
      "r196",
      "r260",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r404",
      "r408",
      "r431",
      "r588",
      "r627",
      "r628",
      "r670"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Principals of Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment in accounts payable and accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r48",
      "r168",
      "r553"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r43",
      "r48",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r134"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r89",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r281",
      "r282",
      "r538",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r616",
      "r617",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r588"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.001 par value: 200,000,000 shares authorized; 19,165,027 and 14,529,606 shares issued and 19,165,027 and 14,529,577 shares outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r178",
      "r180",
      "r186",
      "r517",
      "r522"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r147",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Risks and Liquidity"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r608",
      "r609"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of revenue (excluding amortization of intangible assets)"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r610"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense related to intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r140",
      "r142",
      "r149",
      "r200",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r454",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable Interest Rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r136",
      "r138",
      "r298",
      "r454",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Long Term Debt",
        "verboseLabel": "Debt amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails",
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r18",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest Rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails",
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r200",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r454",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r19",
      "r84",
      "r85",
      "r86",
      "r87",
      "r135",
      "r136",
      "r138",
      "r146",
      "r200",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r454",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails",
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r137",
      "r304",
      "r315",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized end of term charge and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r135",
      "r138",
      "r630"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "End of term charge"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1": {
     "auth_ref": [
      "r91",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Deferred Compensation Arrangement with Individual, Requisite Service Period"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r5",
      "r6",
      "r141",
      "r148",
      "r383"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "tela_NetDeferredTaxAssetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "tela_NetDeferredTaxAssetBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "verboseLabel": "Amount of employer's contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percentage of employer's contribution to employees"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Percentage of employer's contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum contribution of participant (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r46",
      "r69"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r336",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r348",
      "r367",
      "r368",
      "r370",
      "r374",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r20",
      "r289",
      "r290",
      "r291",
      "r295",
      "r296",
      "r297",
      "r477",
      "r615"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due to Related Parties, Noncurrent",
        "terseLabel": "Long-term debt with related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r187",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r218",
      "r220",
      "r222",
      "r223",
      "r224",
      "r226",
      "r421",
      "r422",
      "r518",
      "r523",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r187",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r220",
      "r222",
      "r223",
      "r224",
      "r226",
      "r421",
      "r422",
      "r518",
      "r523",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r666"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total tax provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Rate reconciliation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r197",
      "r378",
      "r395"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal tax benefit at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r659",
      "r662"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r659",
      "r662"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r659",
      "r662"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State rate, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for recognition of unrecognized expenses"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r83",
      "r161",
      "r182",
      "r183",
      "r184",
      "r201",
      "r202",
      "r203",
      "r206",
      "r214",
      "r216",
      "r228",
      "r264",
      "r334",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r420",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r474",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r424",
      "r425",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value of assets and liabilities measured on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r306",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r425",
      "r483",
      "r484",
      "r485",
      "r566",
      "r567",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r306",
      "r338",
      "r343",
      "r425",
      "r483",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r306",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r483",
      "r484",
      "r485",
      "r566",
      "r567",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r428",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r314",
      "r331",
      "r410",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r564",
      "r621",
      "r622",
      "r623",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Year 1"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Year 5"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "Year 4"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Year 3"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "Year 2"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Intangible assets future amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining life of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign currency remeasurement loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r46",
      "r79",
      "r80"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r32",
      "r196",
      "r237",
      "r245",
      "r249",
      "r251",
      "r260",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r431",
      "r563",
      "r627"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r46",
      "r68",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r197",
      "r379",
      "r381",
      "r388",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r181",
      "r376",
      "r377",
      "r381",
      "r382",
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "terseLabel": "Employee retention payroll tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r611"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current and long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r63",
      "r65"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r137",
      "r145",
      "r185",
      "r236",
      "r452"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r35",
      "r311",
      "r317",
      "r568",
      "r569"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expenses"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r189",
      "r192",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Gross [Abstract]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r175",
      "r554",
      "r588"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r167",
      "r174",
      "r227",
      "r275",
      "r277",
      "r278",
      "r511",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory excess and obsolescence charge"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments under non-cancelable operating lease agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.telabio.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2022/2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026/2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025/2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024/2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2023/2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term of operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "localname": "LessorDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r196",
      "r260",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r405",
      "r408",
      "r409",
      "r431",
      "r562",
      "r627",
      "r670",
      "r671"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r143",
      "r153",
      "r588",
      "r614",
      "r624",
      "r665"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r166",
      "r196",
      "r260",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r405",
      "r408",
      "r409",
      "r431",
      "r588",
      "r627",
      "r670",
      "r671"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r142",
      "r151",
      "r305",
      "r316",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-term Debt.",
        "totalLabel": "Longterm debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "verboseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-term Purchase Commitment [Line Items]",
        "terseLabel": "Contingencies and Commitments"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r19",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r47",
      "r144",
      "r156",
      "r164",
      "r177",
      "r179",
      "r184",
      "r196",
      "r205",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r221",
      "r237",
      "r245",
      "r249",
      "r251",
      "r260",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r422",
      "r431",
      "r563",
      "r627"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r237",
      "r245",
      "r249",
      "r251",
      "r563"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r465",
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments made"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Background"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Background"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureBackground"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Inventory consigned to others"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense (income)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of debt financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of initial public offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payment of withholding taxes related to stock-based compensation to employees"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Payment for intangible asset"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r588"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common stock, net of underwriting discounts, commissions and offering costs",
        "verboseLabel": "Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Proceeds from the sale and maturity of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r106"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r164",
      "r177",
      "r179",
      "r190",
      "r196",
      "r205",
      "r215",
      "r216",
      "r237",
      "r245",
      "r249",
      "r251",
      "r260",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r403",
      "r406",
      "r407",
      "r422",
      "r431",
      "r519",
      "r563",
      "r584",
      "r585",
      "r607",
      "r627"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r70",
      "r169"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and Equipment, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r72",
      "r155",
      "r520",
      "r588"
     ],
     "calculation": {
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r154",
      "r157",
      "r588"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r111",
      "r158",
      "r678"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r88",
      "r152",
      "r531",
      "r536",
      "r588"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r161",
      "r201",
      "r202",
      "r203",
      "r206",
      "r214",
      "r216",
      "r264",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r420",
      "r527",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r234",
      "r235",
      "r244",
      "r247",
      "r248",
      "r252",
      "r253",
      "r255",
      "r335",
      "r336",
      "r512"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r467",
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease ROU asset exchanged for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of dilutive securities excluded"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Significant components of the Company's deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income tax benefit"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r104",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock based compensation expense categories in statement of operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]",
        "terseLabel": "Schedule of activity relating to early exercise of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock units (RSUs)"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r99",
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r89",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding to purchase common stock"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "verboseLabel": "Participants vesting period in share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Canceled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares issued",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails",
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Equity Instruments (per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares reserved for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, Options (per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at end of period (in dollars per share)",
        "periodStartLabel": "Balance at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award",
        "terseLabel": "Vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted ( in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of exercisable options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Early exercised stock options, Unvested balance at end of period",
        "periodStartLabel": "Early exercised stock options, Unvested balance at beginning of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Offering price (in dollar per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at Ending period (in shares)",
        "periodStartLabel": "Balance at Beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Shares withheld for employee taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r54",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNolCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r83",
      "r161",
      "r182",
      "r183",
      "r184",
      "r201",
      "r202",
      "r203",
      "r206",
      "r214",
      "r216",
      "r228",
      "r264",
      "r334",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r420",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r474",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r228",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r50",
      "r51",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock for early exercised stock options"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "netLabel": "Common stock issued and sold (in shares)",
        "verboseLabel": "Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r88",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Vesting of share-based awards and exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r83",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Sale of common stock, net of underwriting discounts, commissions and offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r83",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Vesting of share-based awards and exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Stock Options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails",
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerSharePotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r61",
      "r588",
      "r614",
      "r624",
      "r665"
     ],
     "calculation": {
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at Ending period",
        "periodStartLabel": "Balance at Beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets",
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r195",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r334",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of Company's net operating loss (NOL) carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r1",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails",
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails",
      "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r258",
      "r259",
      "r314",
      "r331",
      "r410",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r621",
      "r622",
      "r623",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r205",
      "r206",
      "r207",
      "r208",
      "r217",
      "r256",
      "r257",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r371",
      "r372",
      "r373",
      "r390",
      "r391",
      "r392",
      "r393",
      "r400",
      "r401",
      "r402",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r450",
      "r451",
      "r456",
      "r457",
      "r458",
      "r459",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r514",
      "r515",
      "r516",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r375",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual Risk or Uncertainty [Line Items]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the unusual risk or uncertainty and its financial impact or potential financial impact.",
        "label": "Unusual Risk or Uncertainty [Table]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r229",
      "r230",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureIncomeTaxesNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/DisclosureDebtMidcapTermLoanDetails",
      "http://www.telabio.com/role/DisclosureDebtOrbimedTermLoanRelatedPartyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r219",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r218",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r592": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r593": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r594": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r595": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r596": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r597": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r598": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001558370-23-004468-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-004468-xbrl.zip
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MH9[CHYB!X?1GV@+Y 662\5\&HVAK%+=4KA\<[ZVI!XCIJP'^T 9@9$HTUP'
MTI'43'C0#M0>FMS]'S[?HO;NF*+<R8V@JDBK8/L L%UD1TXA,]WV(G;DAX#A
MT.;*(7MD5#+YX"OX_01EV/@;_6E&]]KV Q4F7&_'O'6@CK.@&N[PPP@@&R.!
M./B=; ,9,<C&PPX.M@+L:\L2/K/O=UOHF1CVC%.U9N)61P74(X=\#A2,R9)&
MVSI_->@?\RTYD$!"$;I%:R$DD$(28H86W@#T.[90&+BS?8=-EX^>NYHS#%8L
MREQS?89J6#_E8<7,V-<&7+%#=8 O4<"8V)@X(%F/Y,2%CVQ.=]C E@R:@PU_
M7$O)5%F+;9*E$DV8\N;0-$R)YJK!-8R)HCM"->L!SG9P/L-0\YE9GFN!9].5
MJ,>S/$\=H)<U@")G(E*L!T ;  JSO@U7>EBB)YVNXNZ*@1*9#.:'[LJ,:DK0
M;<^@&NJ+_*@J(2*8J2:$0'HD)QQ_#<!W#SO.*(Y8UDQQJ%33&&0Z4UU \F/S
M@"3Y(<5Z +1U).)%>=;O:\^QF9 XS53[AB&)@HS5P%ZVB4TDN?\W,?P'<$O=
M]#.7OZ-_?>2@*1MT5>*-2^FJA[_C_(!)<]+N-N(U^-4F*W/^9D/%'MH/7[E\
M"5[+53!#Q!T"T$/-H#E@K_7,7IGK,\A&5RMA]DF40'HXPVKL+[4_3J_J&9&Z
MG<9"22R5A&+14(QDDA(]F,K13.6!<O%WZO@PKWW@+O2-G#H35RKA)P-6W:RF
M(>\Z _ITD %A(<@KE@+IEV$Y"(\+,IC3T<SI*U.XMC-CXF4-0ZN9IT!!H&YG
M?\<=7_%7]L(L7U2%U-Y/4)VA_7B0H4&)B(/K6C!?(!(+!</+N%C$#LI%9%2P
MOPR6US!<]\1MBVXQZO;HT;)00#EA77@N-RD,PG/ [99N";(CR&_ JR%>4['@
M&V:'.#P#-?3;,-LJ'5LVS%6'9"Z2$R")K)]@Y)" 4ACV9(O\AZ;8;&-8=M8V
M\Q?@ ?7WZ7+)!#C%4L?>*G,UT#_FIQ1%<SY<"=4R3"J)I QH=T+[5RH$Q?F[
MKW #,^[1;PQV1=XZK'/NN03K4 3Q8AD#TDV1UL<B<)\.<Z4N_5=4)PY9*EMT
M@VS5^'XN:<O!.8TD:QQF1=P'9#LC&RXFM\(UFZD.U>)66XQJM+H]8-H5TV<&
M$UINZ3@KI'^#LK7#MXI!'=;Y.7HYUK&<H%?6D@;D&R!_O]DZWIZQ&^9"&=3,
MH6X9QE6DU6A^R?OCD!D)N!'-;H"LW9KV5\^YA=YKO_3$&Q5V@QT*93GJUK-S
MKC>SGOUU^DBL).,!RL-6L]LO7S==K\ZUQ>KUZ@''4AR#0\/AO[C/%C2G]A,7
M6L%&UR# KPEE]6HE.%'$+3RGG/BI-^1J;B3!;D"KM-7=4.OWE?!\U\ZVKD1*
M%1K0AO*M*,X[J+[YNG#M@G -$,U6@@=$#ER%Z;:D4H/=9<$TO?'ZR !IJR,B
M3<Z&U,#5^%#( ,WAIP,Z'PNH ?'@\P #N)7+5$6+4#60E.SE'Q3=8AFA?K&@
M!H2&RS\#*"UCB,T"A37@M(CG#P"U"O4UB?'5@-,XN#= TR2D5Q&[JP:B[A31
MH/XN8;@6\;<:>-H&W@:\RJ,(B6T\<P&NA5I8C/SN\C*Z:J2*8@J&TTBS(DE>
M TP'AA8."S$T"C6,SR\+UHZ;;\7\(?PUQ, /17M.%TY7K(.\54A? M*Y#7MM
MD#8R!IS;19>*4:V@K,;P0Q[#LNM'!KR.%G(J!K%M]FID/^:1;7L=Q8!XDSA4
M,9B)E&J<RK8]#]KO$)PJZ?/*Z*J1^;&@?RO:NSH@U3%B58%6&6TU8I]+$"O:
MRS:@UB964@Q5GJ 2G]K+.@9,#@F@%&-4GZ$:LXL\9C6[F 80CS.!>V&KP\_Q
M9IE4@?WAL'T"2!Q(&[:R'<T*)NXK:,0396?O.G*ILX-#@CCHU0-Q@R$<T1 4
M=5?X7$+E'6F',:LSBT,B/F@6H51R/=RL=ESSP)L-'_DKLX]@'26\ZHSCPT'&
M@4)'6NI@'(?.K,RQW"W^O+84?RV_%JAU_FHC:#,#&X4'>[4<$@H:8.]^-) *
M9W^_8\+BD@7W=!GMMCPM6,^GS@SROJ#B "&*(Z$\,EVF#&/P ]T-XE?&5VL%
M?OR5";K"OM[?=+"'>C9UYI"_2*K<'$)IA!IQ> MK*&^PA9;'UNJ.@5?25J)Z
M<9YOY-FC:O\_SWOC__"AO6>V)/J5MBM\'^SG$\DW6P??C=/?UOK]/81Q%+Z:
M]@^H[NENXX0DR+_B)3H->U9#@>"0!156CDON%3E@HM?\8"!V%A;^A)P=K5J@
MTK;52J/0QTI!\VM;*<C"G+[6!QI,V_IDVMCQ:A64G"O,?AM+(2A&_@^ACA-7
M_:>S["MJP9?T:VOZK370@B<4<7-/>9:\&V<> 'WT+,W'4,LR<ORA]7D*HL+R
M58NM?W2QK 1U.?7?LF-)"E[J+"I'-ILC1"K7"/F,+L:CBT_="Y)\<;-)(706
M_"MZV1.+<8G%N+QH7HSB5TX;%B#,@)(_-I=9]E1EI146/H%ZQAPE(S:'&&7F
MQ<669J ZF4#)JZX'J &_M-1"P<.6S0H0TAOA^-IG.\%ECW\V\D41O?Y5+#EX
M>5B/!+$/^(<>C$]@E,WL.Q_OV)HQP3U;W__Y=R8Q4C-=XJI/$!F8"?;*/5\Z
M^Q=_\4]FJ;GWS+:^L-;:>V.5\!KIXS+ECH,+2U!DX</?IEO3C_5> 0L878K]
M1+$-CL= 5_X")"@?-?4WX?G;D)0#"?0O^O=6%VBN&=F^"$Y1F+2%N6S\YQ-+
M,)NK3OK3MUO*8RNP.]<*#>H[+^51]%>EJ&<8J\*P8'WMVG?LE3F>WEL6[D>:
MT3V6+]B+%*JA99[W-1/3I:A.5I*Y(?&);19,A+4L2RRL3O1X\Y6M'U-M7"$*
MJ8):*F37%<=,:25NTP;O-'599:V*Z+ZK"L[?O$853-+ULX)??2S>=!D46(85
M*OA>T:*XJ]B*B7?W&Q.0 _Y)S9A+';4'1VCAG'<5^<HJ@AH MH;VW>N N_KB
M&[2C IN7W]" PKHT(:S )"S-NU<H5O)T"5U/\(9=@,#4U9^X/8.>R^);ZEQO
M<-$GK&37S'\BF'%36U(GGFO7*^-^Q]4#8T55C9/Z6I&OGFM1N<8+NJ?N_0X'
M&3Z7:R2:+LVYZ\!3-"#\-XW9;+:HZXS-WLV)BTKFKPR/38[/+[ZDO7L=43]=
M.X;3?7 :T=Y]&#F]>$OU!D.\=/T:4?:SDH]T$94Z7:G"E'Y6XGHEF/[T*U?K
M:^'1=$W*D_M9G>"]#[VH\\0=Z+2@C0?]UK<M+B6O.9 8#W'K;W10[Q4/K]B^
MI5ZH@UL2Q4J_<!^._8_(L;\S@_OEDN'J=[P:DW\.#WJ1#77Q9C..%V$S8"Z#
MGB5R5P>SJ5#1%A>+WGM(D7X!0*:;0UEB/QN#-KZLS=[Y\>R^/+V_AEI8Z,H:
M];HZLR V,ETX?*4Q!0 F[@O?J?7_,AI97@.Z'E=2>*]<@J2Y]Z+8=N+B, :F
M%;=4[^WPMUMG_T"YHW>'X1\FS/3-M9FXX?H>]JC^PHZ;XSOP[=NLYMG;Z^G(
M\BLSG4G1D+Z(J"=3SJKNLTD7V^L1? O[2T\VS=A IQ_3R#L)Z8FA)(+(X3L,
MN9E"*4$_^]_P9AP3&0_47C+-:T3:SVKJU8#<AJUKA&BE26_V,4G0K*_QVNA;
M#PP2::ES[;H^ONX&O0E0S;TP!FA6&JY]M?8$_Q>SIP)C\>*5V0^>P(4)LR@;
M]/X]*,B_?X&CLQ9,U1.Z"+60="M&#XE'6 Y6?F>Q/7%<I4T7MZ5AR'#J1BXW
MN516V_3K\_=$ QHP_(0P2GR>=[I0X(D )CR7ASXF#I(W(>UOCS]]!:Z[S ),
M^EL_G;0IY$S(HK(G/_>S^,&]$>&%%(D[(C)+M4T(^SM1>L% B9F?O FN%'/-
M^V/APV-I\!I3]Q/36X=*< #!8 XZ5-QS?4<5>Q#>YM<UM];1FU\F3=[OMEQ$
MW?T!^2LL8(6SZ??O-/)A?6F&&A6!_YCB7==#(P-NM6ACR@M]EA)\H85%L>.B
M%8UJPGX:;.A,]MKR^)('3QWE1CT3M\75S\&2P?OP[F]/FAC)W-(MAP&!&>,E
MAM4/OL([B<R(/#/6[Y[]/4?H4=,Y2LW#0E<.A!^I!*>WQS>RI46=9,SPSQ#T
M[D/01BI]X#ML)5+EXV3%2?TH]K7]3U^:6RSFWK4=3H!FE-L8W]&0/3,K\ AF
MT^5TV=A51&.B=Q?3XXV1!U1L[IF^*J:+(Y;'9=H__04;+-A.O5@<E^C"OCG>
MI9%/.["?SJJAV8820UM:!7U]*XR'9X);##Q>$!<U_S [4:%:RD.]1'W]6@V]
M2L.B>I@+'GOBCL_'/^: :YRCCW#6%?YSZ^I^[G-US<@NONP(EYXQ"A2&2N+Y
M?0WA00M9W:I69[G0'=^N,3HH)^X4F%'<O_6(D3\]6YLNO\G@:A#]1%3FM93
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MI(^]'<PELXWVABT]P?"B"&.LX;0S'7MJGJLOX-:U^6 K-NZ@"+LL//D5AEH
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M[SQXGZ(O>PQ/IAX7*#X;4S3ZLA<@SX8*]GK=7E2]OS\&0#FWIDOB,^)AEUO
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MS&H1ES,R5X*L,C8W?TL#4<1*!N"E5-O'IPI 36^Z^</48CM.MSLNSK1]3%?
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MB:P'J8%'$R0C14EK+<RTL22O :_^$VB2UKH\5 I?#?R )Y(\E'5O^^$(?L*
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MP^G'DP\C& <X1/'LYP\I/0(T0.C#?_WG__F7G_[OT='_G#W<C$(<I L8)Z.
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M=[$8E(4165&6,;UGUA0G?":]R]RZ21_<R+7%V1JUYV[**X"(B$B;3*]0#.(
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M<H3%I/4UY$B+1]LATSD#8\DY%]VR+!:95S%A'L%#)6\@RZ,X3Y*(/:4)'(_
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MR&6Q]GY['SI(AY?!IJGF=70D@GG7IK<NXT/62LZ(5QE"99Q)P=I6]>3Y;:1
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MR&RP]!"GJE_@'=A"R-5^#:,3">3AT<<@U6L9YOT1!T4O-?I?TU +_D$Z2VV
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MZ\U:'@T&S[=A'%\X4;3?A!&@=WO:0S<2V &IAT$J*-2A/V;HZ:/&"/%3L"/
MCU08XL&968VC@'&)'P%-\M-\;BM1]^C=Y_7M-\15I;"==K794)C[T:*DXSU?
M.4.N1.!R)!:SQH[3GUXDL4/." ;3Y$=UIH<9DL90:XPH+-B3LJ(H 0E(500\
M>(7%<E'5/OPO3%H09D%/-* ;9B>U_9;R*1@MX9QRT?/YXOZ3D\!-6[/-JWZ4
MD"/4 /.HP-2##&(\&J)-[Y>Z!,^5.DT"MJMB.;9?D9PU&OBQ8:A*E9*4LZ!D
MRP*V3;?$!_YD)[?B8I(&'HU($ 9G+CS#Y N;*5,KT=IYCBBU=M_V2Y#&J>/?
ML_BW=?2%"QDE#@LRFVF,WM8'.>(8J:QB2V,'Q"AB)G??,,BH$R /-UD4!AD\
M'&'"3-L.3S'S&%]$/3C%19;S-Q9K5USZ]L@]N575ZNZ!IC%B#VZ7N3>(.\HU
M+?(KT+3DKJ5BGYTM_^=CY 0Q) Z%P66XY?&DLXU)1^P.;*Q\Q9-;>V%V:7/A
M1_)M2=6.=Z]?:02761+Q[*Q(+_A$MT\TTEBGJ3UR7VY5575A;6/$GMLN<U^'
M!<IG!>DL7PC5=/B6!?0FH5O=),*D'W+_-5;=9&I<=$+LS^:R3S)%!C9$\+$T
M\8!,BUA6)+^+F$OSXG*Z@:NA/7+7;E7U*(VUKC%B5VZ7>5"*49P5KE\10;RL
MK#C)I@\?#)Y"@SS,2?1=;S94%)'="4W?L8!XH>\[4?GVAZ6D'_H,@^,]W841
M[!Y=LMCU0ZA^N]Z(*DPWP2:,MC(A]2E,DZL@8<D^EAU@.9Y1B,^?XB3B$TZ=
M;:=@A!T@)C-N!5E&YX(9DJ93MC>628*DD&E%2JE$AH"H9J8(1AR0C$C1_AB3
M4CB22T=^S>6S=0*'UM!V<@0^I[ F41(H<FDT]FMJCQRV6E6M/'"D:XP81-IE
M[OUDD:!<30O2N>T\<3R'KK'-P+P)7CGO,-K_%(5QVRQ$VQAY2#8K67TSN*XE
MXF!L$;C_T[D96;@?!LEFM@?4J?6TLQ$K9P*9")\<;@7F^/%#NMOYC$(.\R<*
MQ=4"C\7T"YQ;7X1!S)X#P O=AN! FLA#>123539]AQ!$# SCZ-5[Q9Y-V@L4
M*018D5P$<:U $2++S%#$R,#'#N+8-6#!F+B2JBP.$8)0=F8*/X6A]Y7Y/E?\
M)DBX5HRO4N1EBW)UTS*!Z$H#.1CU,HD*/IT(( :;?GKTC8V<FP"0DE]^6TG9
M/K ]:YG7+D>FL/."(0M80F_9*SW2^9["H3<\6[:%;9%_BNT/>>W^O<:"_:DA
MQXZ!9JH\.-B/%&(\&:I1[Z<#!=\SP?@86>#J=L:<J-RSPAF67@RT9*K2%#[;
M4)G:7]C+X@7'!GM<B[Q@U1A9J=J66<M DLL%(F.#&:)1*[UE0I*Y6E/ATF>:
MK*J0E$FP(M=\GN'XY*_4B92; I;G15:->7.(4_F% 4=AB@V[:@SRF;XECU^I
M_TH_A4'RHCM*&4QTN?C5P6B&"&9 <9D8UD6QJ5"L'L! #"+E(%(0=)@UA_$$
M@+]? "R!H(]?PU&L6-(Z*1 Z,%%_[,D(G0SD'.HS+]*($./LEX O8UE*Z/QA
M*;#".>LR8?M3.SUH4<TT$%R U&G!2T4C&P # BP&8D:QEM#[AX6 S#6W^VCV
MRXB=',2H1AJ&,$#II "FHI %? '^2X&746PEM/Z7I: +;SN>^22QTT,7Q4@#
MT86W/2UT416R@2Z\SV+090Q;":W_M !T.=]P$XX*,8<43PIG:LW5'VPJY$X&
M<>JUFA=V')!A6> SKMD>7VA$A16LH)#0\F:[<U@$F8T7+T[T3-MN"K1V0HXE
M9DJK<-'< S$B& K>UWL%>5+2)QD#ZV?0$^M]&P;/&=193,8K]5MO0"(AD)3G
M?U'?NPZC+[%NLF#:%WDH=S)!Y2Z024?$@=U-_M[9%&5DAQMRY/4$6)UMPN@L
MC2V-W3;LX(,=?&$'B[EP]_25!BF]YO%P$08"UWYAR<M%&B?AED8M8[AY;^0(
MT-$,*@88=D6, ETUZ)\/*O@0,#W).9&OG!7)>34,^;.$PR6+G>?GB#Z+N?IZ
MDXG<5%6UI0MRQS=16/7VIO:(7=Q([+Y^724.V)Y[^NCU5.,H4=R8_U?IPOP_
M_O;)^7L8Y;$4UQ1/U39"ZJ;-2H%CUK= Z(HM@O9U/@4YQZV%VN)JL@AF1:':
MLJ=M;1$[7JN*N?]I&R)UPW9YAWOC@.JE"?4=X6SO/_SP7C@<_.5OZU>6T+?:
M,J1UOR-U+*TJX$Q'/UIV("]T4UBOB(&MS>8CE!-EC_2-_"K)3;/G4Q<2R]1$
MNZB=2IW10_DNBMNB66V"/Z"/%#J(Z>+W983UL;@#X^'N_L%J="]/(9,@GT*K
M,6,=ZE$4<]Z&@*]OASKJ&U0K0[^F$?KX;Y*Y__;/C@LK:B_"PZ=,*=>XD^65
MX:IP7L&$N#G[;V>&BBETE\5N;$+%9%K-MN)\X/XJ'ESZB8;/D;-[8:[C:_8X
MFMHB110C%?,5I[8ATA5GN[R]*[TH!.?> \DJ/:HB:/= FMIB]L@V%0N/U#7$
MZI&M\H[CD39?<?D<!E_J9USU+9#Z88,ZE4*YY<\(?:Y)RMX%8D/HH9U6V#PQ
MNVUY>,6@&W)O-%7<X/3L=@&OKAB+/L$IVNVP)U<T"].;P(W$G,3Q+\(XB=>;
M]5.V"LD/I^MFTF;=D#IO5\6+5:Q!'^R+VBXJC+#&924[X@(_^$L:1=3C_R!A
MSIHX4+Y3<)]YH3N'/10>1# AZPTIV)#S(@W$PI)X;OVE$W!<J_OV(^):2SH/
M%\E//2CY%L?P"K/WZ+R=QW>4VY:+^7R8YC(22<QX.)+!"JP<2 \[CHZEWH1I
M9"M22$%R,0B78T6<F ?=KA!F9LA=ONE*82P@-A+S'7F1G:M_#HM^=OPTOV,4
M>+?,>6(^2QCE"TP'Z@9[Z^">PJ0#C!)X?+T8Y?_YT8E9W)37."9]I.@_F2DK
MEP3'(HYX<3B^CKTO$'))B! %2O%F]$45<)6AU8?N"V-]W&>F@>'V.J+_2&G@
M[AN>O#?KN91@:U>_-HSTW980( ;2]W5]A3 I*(]^)-+'T>M4KCTHZ=9S*8[>
MKGZMH^N[+<'1#:0?V=%MGK34J1T7XT_C$8QAUP4ZN\X ;=Y^V&]A[JX5O_^R
M(Z-G>[I2_/-_,1IQYWC9W_(545T.1N?.2W%O(R-HYBT-/9?@XF8*#)^XDX*Z
MG+>?_XQM$A,?&Z+S=*:)QE*"H8M)6D%?1V )H=%)CVDB!,7LYR;8I4DL0.&]
MV:2GML=2_%^O;JVW'S=?@F\W2-V[\ D0LU>IW@E<YO@W09Q$XJ2C:?ZB;8W=
M1YO5/*AB5M<4LV^V2#R@^IBD2TK"-N<>CY$3Q!NX*1QX#S1Z92Y?!*PW->K'
MCUR,N/ZGQJG)R"R01\44!E5#:4SZB.-O$C7'#-K8[GSH4QC0_2<G^HTFUVG@
M-:?@:ALCCZ5F)=6HJ&^)V+];!.Z];PEDR5;0)1L@O-B#X]N6]-ZQ>2"/A4E,
M.O8A\NT"LHRGT7.,P^2L5AVLMQ612"X3"8.F\V8A6&,B\[3I,XCM^RIV-,(-
MV10#.2L'<BL(>>'$+UQS^)^K?Z2,2UC9V"G?Y=98N4M_Y,C6V10J:AEW1HQ(
MW77H73N'LQ#((?ZA,%L19>NO9&@'06:V!RUY6(&"!_>%>JE/UYOS(&$>\].$
MO=(' $2!F5=OD'-(/9F3N-VE278_YLJ)(,4;T@\?7IRHL83@Z$R0@\HT1E61
M9UP.B.%I(D7[QFPN#HSGJD"DE(CD(N59R(50T"D7"Q*-B1#,:J[>0*-^W-<3
M:-AQGI8C<F"8P=R5@OS3L4,,&7-HW?LI  UF6-R$K]<62B@V;JP;=%MD,!XK
MWAY199_%A46-Z"/[]HH #[L;UO>4+[B9FU#O(0G=W[X$+(GO'[XT[ENW]4'N
MW48J5^N\-W1 [-=F<O?/3<RIDQC(DQ3HCWB;E8]%VS 0HO_B1)'#%X+Z&G)-
MC9'ZHYF2Q=U2;4OLMT;;!1_ESKVNIIPKV&<^^C438.;;G].90%(F@C3):=LI
M!T,C]NK $%>>QMZS^+>&%4]+%Z1QVT7A2@F8AO:(1Q$CL7N7?BF((TF\*07*
M[QE#'D/C?+^ERV*\6*]PO1<?MU^$%S>(/8(7%U?KK<[JQ7"PWL%HV#B3KVN'
MW%^UJE4V@0\;(?9,O:R]MV+%9$"2M#,7&+C1=-N28S(B>>3>/K8A1]P#O5U
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M3$!DI%C[._X"\Z0GU6\'EGN<'_=EDVP+]/RK$WGB__Q,XX1K)/<)=1GI([-
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M/-?!G+VP/*RXISD 42@HF4A#1LGU:$'TZSF(7-ORE FYU6K;$J]_&(ZGXR6
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M/?/Z;^5!'K]&ENOC<\3,_7L3P&+FY+5":4&UU5OL+3=UZ49KEA5I,E+FQV>
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M D*YD-[3H^%V2&_^,_\V2#Z$?IQ\*_GM8/VU#L3U)A)PXGFW"S4\UI_!8AE
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M\E26$%F:.10,9'8OTY>)O#V3DAV[G$D,LK&KG/R$]]Z4!^K?/R+!Q15L@]!
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MOW-P$*VD&I)1JDY&<J*2RY7&_6XSO(&-_C6Z@>\O+_)H-PN9"+<G'NBC,?:
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MVD\G2WR2<@,T0$);CX B:8\T+(_^S FKZ"LDV@)_)&J&@=Q*4T2$& 8$6FB
MOZFLV::R<.&WZ:WG.]P5:T>X?FB?=$B[=QA$%]E,#4L^NA_+;7(/U;?QA%R]
MNW!@5Z)&+OHQ5U(6IDR9C0HZ&^8^D9X PA#$)5)-RL;@/AY_14)YO+?[C])C
M:ZL%#0S3?[%O8-$]A9/WIN (:#_R:)P $XVSYQQ;B' 8?[M.<3^GTQ>7-N2>
MUAPB1?$TXS\VA+5NO8O$.^@/UOM,5:0%JUC7HGLQ/6ZR;.ZZ$TGVV\)U.5F0
M,T=50EZ($CB\Y?I)W"1+Z/O*5A$38VF_#.8/ (@"D6H]QYL$\6H[Z'H,,3/
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M]4,)F5A>KGVZ_FMD6J2U[MKG<QWOZNJG PUSFI7/9- VUB8 S'+E(^^@5K\
M;*U]9B!)7I^ JYB@M1?J&B@]\OK\3(1&:Y\--VV:A4D:K;UR)BMK8\X"/P>
MJM#[F'9"IV@!^)A^G)HR9C0"AO"<L%3:O5W!X@+$B:I9^ ]E%R1=68@',Y$'
M8GAHAG5L\T!-6D/+8A\P]=)C8[!]@H6+1?4)P:+<3U,4;0:[(8]!ZX">P,!5
M-0-V#GXE]/L(Q#OF/PZCP\=@*Q:5??094;#QWN(S,9??8@[D,!K;PD(/K\#2
M,./%HQF>5,:2NF]H8^>7S@E3'HBG@RE=<EG?]@.^.,K.>08@Z4F[<IJ.(43;
MY^VO@KZBP]_[%N#:SKY/P&@C1@',(:((F*E;%WUYCJ3UAF0N@(.W%<YCM&G[
MJOOJ79->=0>"W4)\@CZ56M6(0NV;1- )]N]_99(IZ"(?G->*IVS-BGCKE/>T
M+8'"-'6@ 6*!6C ;QDA1/*4#$=H"94<FG<@=8L":9/VV7(AP&09/6$)C63Q;
MTI/[$>:22)?I/\FWMD6<"D2>"Y3O#63-QNJ#HE"U >: Y:HFRD35H%J!+((^
M9-BZH^PL%6+"( PTL;%ML: <&H,)%"_=T$0DV= =VR8S!QK%'THV7LX9HP@]
MT,GPVS!AZ[*%?X$)%JO]0+E#8#,#T"Q,6]<Q"\#:,Z9RD(<#K%4[2HJL]A6!
MZE"8%4!';N<M2R5HH\+EL9^^3X.CK$HPATP?<SMS295K+LP3C?[3:-35Y,!8
M&V 10^@P*.@"6/+CSE6K".R08("VBY$F80U5T732EES43* (4:!D -0D&ZZ-
MX]B$*D)8R8=>XZ[A#+8-?8LZ.*'UA-: 1 $7 K80 8!891;!S^#YB# +18@:
M=,8(8>48?Z];8*>Z%J[+I4^P.L'*@Q4 0Z J+*CI6!/'B#ISO ($76,LHXD=
M!8]*F(5AF\ 4%,<%1M%&1+0Q$%3YF;H'"2PU#XOX+Q-A:\T/0\9Q.W;.6^?4
MFV8;F-F>T'E"9X#I^3QN+B=#<ZRHFN \ %W7P#HB -8&\Q5+;V(SDN?J4[F-
MY@R8M]C<E36?HIHU-(')R1HHMLA8,!5+.F?^<-WQ^$O7"P]J,;Q&!5<,1K;G
M"W9T6#PE9U1'>W78\5(1 *5\*=T]^!.SP/DE'K\O#VS#YQOV'!?N,PHHOR?J
M.%''-MX=8-2;+2P".LKCUY\B0Q"VCPU!@]ZB8",3GG4)ZJ1"G&#X$@RQDJHC
M"[D::M\&9Q_AF@JXBPWG 9EX&AVT#O&(@$/G&^#L[B7'"6HGJ&V#FB .X4XH
MJ*8*$K:TX29, 1E,;'A1PUL"C VS,0/)XYYMF,02]QB;:!L&_!V0SH*Z\"X4
MW<_IM38#=R0.V!V+#"_E%W/"Z@FKVRPK=4A5V("_U">+,</S@@-\OB3GLL4'
MLTW:Y(E+GI 7L)I\!@CX* >V(F"!BQ5 '4-F"N$O"()Q!'&Q!C!JP1.V2<0Q
MMNU/,#O!;".#<^]DF+$F(84Z>ISP%I&&P*S9#F>,A<0AB1-QXZB6-SO+*RC"
M$L>Z0N0TA21<@B&M?P+A"80!7@<_<J,6J<?17%/LB!4;U.5..#KA:*ME85&W
M(L#&0,2N,)$J:X8O7LX7JN38K]CN4.0^!*_HR##!9ZB<0'8"V3:0:3W'8/74
M>?>R&']);X$=>P$+4@A)7MY%GV!U@M6+?N -:O_)DWL"TFL\N3ZO P"GMPU7
M2X5K1<DZ<P/2D1--VL>F*3Y/DUZK+5] KY"=5\ ?F]YR0NL)K1Y:)41NJ4AH
M(5(4ZJ>01>1>K<HB_0A!ALCIZO2$'1]V?,S%YRG;%I."Y^;8E2<0G4 4C$YQ
MLVB<8&62IX8@34442" I29-T8:7*$'W=@A2&M7CKLAOWS#01B$[XEY->&66C
M41H</<8,CP1?]Q#YG3!"*J2S*!+>._#Z0A83(K%7!HR"_),A$:D[$/S%<O-C
MI]S\4V[^6W/S3]SZG\BMIQH@@-@W<+_E>%M<G[$O*UW"^V""-UDT-"]9QDF/
M\S-NR4; :[V<%0$K%)[&>;;,LS$5;29I,Y5&((C(R17O"2I):H/T9,?P.F,&
M2-,U_$^2;X/!3S,?'3/*S?4A<@;S<_@-7*/@KV>"<5)/3H#?9LW[XPD"H8)>
M20F L2&8EF&3.-JUVSB0QRI-NK(,[62-G]"V(]P%&)HBF\,@W@!#BH(POFCP
MBH[W S@FUJ*IQKM^6RQ T)6BP']7_>=NR0/_131$&FJDXD/?P-OA:M>;7TPT
M+9KF!7S_A.@3HH.(IE4=G*BL99H@( H2WVGPOTBS^""%%V2[<S/HBQ[T,OI
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MGXW_?65C(H^R7/+,+;2((*ITC"P2.45V$%L!JBRXF";N_IZDC8E3?B:0&,
M@^L1-MFCO1NH*T9%?9DZ87HRH4Q"W+2Y$_$&:<H"^C<M*PFML0T\$%#4$&^8
M""\?P)6S1=BV:440*5A*,EA@U.,=74A24RX#9R)#DTS/HSO6G&/WHN: $3J!
M*4$(0!UY(E%4&@0'H<-S>4R34+ESCD8XX_DJ*_<W FGSKF!YDA,<.4BZU9 N
M6PR5\OACP9$8;FJ;YWG>V)@&&BUC;@NOIQVP:"]Y@E5+LVB'4< HT7F=,&M-
M!QJR54AX6HF[6U9#TTC]@<#J_HL[3]#E]>CROCUF M/PNSTP B+$\4$YTUJY
M0Z!NV7&BCC%?E77%BZ*G26<#V\T@ 8\KUF@EIZX7*=TZ%; 68YL$C$0,^( $
M#/WU/,;?,Q%\#UCS@(\&-OR AJ(,9<$B^HAOX',FV.C-#7_&#$=;JCIXDU9Z
M&T&K1.*0!I7(5W%*$;#0U$Q1TS%#(\J8AN6=+$:H)H&DX.M]O-G-$3#=5U4:
M33)"#PT$-<"T*?,#Q<R9#7YQ#>1F#QD4P)A_IXD A<P($JZF"+8J#N$49AJ(
MNS/:8<=8/2U\H,OWGRVW -;H[*NC!8G$P^1MJ,\#^0%@#?I40*OYS-JY>Y#1
MG1]8/EL!@=Y)>W03L4=OX>%/3T4BE^P.._6DFA>XZD:.;.2@&-[^WF&&,PER
MA0=ITOB'SAMA-@;C<'[\!PWTHF8_P$USNG)XL^K+I*\B9M)()FY!+.1MFFX2
MR,#V+="GPS@3Q/-KN@C%(*Z+EH8QC-6/:)2J/-%X! LMK.'Y>Y*2.@+J "(-
MC/$994#4,P Q<%;$(25OJA"CL_"1FH'Z^%&BWI/!<LWL;=U["G9IN2F.:'01
M)&]PQD!;:UF$) I5%6B[B2HHU:"KP@FU:)SZ7S_EW^<,W+KZWH=9F1DPJ9SM
MHN+.6\%*#*FSB7UR8EA\&0LG+\CQG+J$ZE F8]/(/QVI9P$.1<*/' Y%C21Y
M8M,HBTR40:J!-6U(+G),%#I[]S40346Z'%O!DR(Q([J&V3Y97/0\^=]N>2"'
MV6/["B]#=(=9QA.V6KXH1'(06@]L6WH.L?1_>U?49.]T37=+0S)U^L7:G,^8
M%/X9&0L\WX((ZB2HO7AJ<%--*H63G?2BQ"@M,G@R3,]596@?'=,B6M5(!?N9
M_E" JTP76U0$P2]Z^$@MC";GIL8<:R.2GI:O-PI00U#H(6B,.@8MR+*AP*N&
MS5$X2.*=7[AE!LD)>78L*$ZP5VDV\2N58!9(,,P_W5.A]$'X"Y"F8].!*4/Q
MYAF:RW XN*_ GYJ6(\C\UZSDAM_!'U1N1P)H[WU;"5AI#GU@"3VQO11S1>Y3
MY./WD"0^UR9;[J=K5;E. =/MQLG;AG:C*9$$4\ X4DV24,'?1!*%/]U!!#!)
M3&*ZN7=OF&ADB2R8BT8 PL3LH"IQQ U\N5G.L (SQ'B<H@7S!W[LIH)@(WVJ
M@#L?/ZV2Y%9Z!>(0FD>@^#^63!P]5&LEQT!D-MEF"DLR9;QA50$LK"CG::?T
M)>6RRX,$KQLS 0]Y^0H?=;I%.9P <B"!C)=J1E!64S4HJ'N P/[6VBTI$0I*
MHK2'40UI.'L:UO#L&XUK>O)<9H=MK2L"T*/CR5NJN%YW8O#8.08^J'HP<=GT
MD;Q/&\64JF!:%EQ &^X" ZZI&5$,9D@8$:6"1)O3J;@<@]YCD\:+ZRXMVE&)
MCNLB?*]%>.K*<B$!MR.4=\5_XR7U()1#C0QMC $J\;  (6H1X6\2&M.JV/ L
M<:IAG4O&G('.TPUE=_VCWO3'&LDT&U ?KK%L">PH$- Y#;X.>BCF#-'=R,DN
M-YX(H8#EZ_((+W!]W=$1L+MWV;KN6*^R=GW;NM/L3;%LP*H__XHWFJG3C>;I
M1C-$U6'K&YQ.Q/9RZAI(@8H!^UB0ONSK=^6BNB)K.1ZHZ5Z^-U$83)?C8/XP
M1(KD!G#LT1[#;7GORECHKD$TJRQFW(HC_7RF:H _K6P.LV'->"4OK #/E;;T
MV+82&^SB@$&.ENTI(>#%-LUE'I7S4E_J"#ZJLK]!)N;2!30%/R8_AW@7_\:7
M"[QGT4!E)@VS'U)7C"AUZTDH/NL^8-*O,7/"[ 75)W]@]L"S3&M+IC2U%& M
M$,<+JK]K(0A,HXJW%8,&M%O\D;I^ B2YWU_4STM,"<SB/+BS2QT8]$[+I]8&
MS?-5_79/1X<?/1_J@/H\M?;.VUEPT=,R]=BD$YR:B6 O4Y>ZTPV0;)XDDZ(\
M?2<."PKG0_82V&-@"<]08#CH^ &6/5'WEOK2\EK9T]/\;E=K:) 2$AONUTB-
M5K#G+#!Q?3=MX(,D9^XY!V8@I'VQ7XX%\__9^[;FN*UCW?=3=?X#RHEWR6>#
M-"^Z6DFJ:,EVM,N*=$0EJ3IOF)DU'%@88(P+J<FO/_UU][IA,"0E\RKA(8Y(
MS@!K]>K5UZ^[F1NX"QG)G:I@B?(_)'KP//*E#M.PGH4CMEY6A8L18M#5R">=
M;,4G.>6^OT!Z\<24:ORG]*;IKKO/+UZ_\H)TU=5-QST!*^\'^$AK-"W:-A)0
M_OW'JW^].DY^SB<D%(NL]F]]2Y8*XB5)-FFJ>B) .#8[Z9OOURN3O.)-R#_)
M9YS(\(.I?4 831(RHDT,UU,6/#N2W.A38D,B4#>3"\<T%T9I*TMBI-KHAI/J
MY=:*DG$'XP'=A^A]L>Y[.Y8#LIC$KAVB$/@?9-8EQU,IR'L?IN;?TOW^5:OW
M+,'#3P?-<CA37^>&&8J.@+XU)1=8)JY:5LJ:N/V4=4MZ+HE8T@Y2(/$%%O2^
MRE;<"UCOFUEQBPJ9B1+P4%[VK$CA:!.'H%-D2)_4B?0>HWY/Y)>6DKR8N*DD
M4M;!W)7P?K65!/9<P4_J2XAY:F.OZY%B1*,S0\%5:8HO.D8P@(@0Q45JM,IZ
M48/AWIU;.CN["CL%,,!B,:4FP1%=MX9%R,4;LY^F$B @?JSHBK7V>]&+K-A'
M3')G49VE%O/01-&\25;3:VKMM=M:_WM+0U+6#J[WU2R'*N$FDJUO-95$%H8@
M?QTXIY]3LSB.V(:,-XQ'>"20SG;A7_:[JB8/0#J5#VSJ_2H?\;%CT(G_(JJL
M$3"7:VK)$55&=-'MS(I"P$_:\17Q;1-KD.%),VPXT7<9<,!1&?LG"2W1-87.
M7&93'JQ%ZG1AS"J%4<J&'X]!LB'M,#H@-8\VS'#^P#G0.B9D, B,B8]@T.;3
MI3@TV,W$3#.-*@*9L2IPXHCWRN93P:5AR&9>+0WD@\W<<IFR]@TLO2+*ZBD\
M&78-U,P$I45\281F2MS70?V1@L\+=5I8$&O' I]5YO6*70^R<PT!$SY!CVRV
MJ0^>?&O5:VF"P(LRT"RT%&] G%PR+6CC.+'XL(I4$UU2-*5;XE!;RG7FG!"W
MZ3,?2R*3+NM.EI+* XLG#9U<0=JG[) E!E7D60[M(<'KV#ZJ:E8.MAX>L?F5
MX61T1S*$1(0W]J40Q3-LM&"1#K:Q$GHN9R(Z%.H7F*^RFJFQQ@B19%G!%D5=
M@O,%LEFU&IIRMYL<\8F_)#^2]WFXGVHVD3/[L^3Q$UT378,ZIQWF<1P.#X"&
M#\L?[21W,0$X1PA3HK3&DC6;A0:^Y,)],^RY@>-82# U,"_L:M9JLM5VG]Z;
MURGW\YR\V!U)I&B$%%BUHEH;$=GVE]+62IP!& O9E(_MPK9:'HH10?#@(D F
MZN#Q<-K@:=!:..!0[%1R11QC[2 * 0LTS)A!/-8Z 2D'K%G$>U.E9I>T-G-!
MC^EI.Z7)LQ!57Y[4V;*QH%1Q*H04KA#>6FHHU?(+\)GVP/Z:DQ7OD)JSFH%D
MBW63TX&6/6[T3]-![7$+%#*H%+0A808U[[)B3;9H=&0#=N!NDAPY-BG6'J%B
M S#>FB#MF+A)R&CH0I\)T+ ;*H0S= -L[$([@I3U3,K/]$FP3V\1(V, 9)QD
MQF.A.0O/F4+ZIL<L+ZIFE3.\2YEV-[E)0_!-V!";,_0LS0KF9Z'Y1((W+][\
MZ]7+G?UG"028(1^$[TR88=4ZZ)R;S2-5P6S=ZY6CWJ,D\W/N)85TKIV;&/3:
M92"3I0[,BSH7-DW%CR\*_+]-K]J,J0^?T.&2.,?'9X9/PEH,"M1#:Y/" 2<=
M*$L1!)&H_3=B5V=A.MB*/D>[F;=(-!.WR(HY7@*A+"*.& ]EOZUQ,&%YJ:ZH
MD<!3R* 2& 9"GA6$V;'$Y[M?-,^)0F>0 FD_L+&L2DC9WNQ3.50.,-OCK #E
MFE1U3.^FS>9S1JSS>U*W6/J;72W?^**UV165"!N]Q:X72FSGM\YEKQ(\9+A
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MF:,B76B]+L04,';OF@3$WM"A(<VM5#;E;]4:<5W8%?4P7^%<B5]%,,DQ0Q+
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MS8K.5C786M.,"3M/CM'8#&^76+)B8-=L@)+5R<VHE'R^X5C8[,$2XMQM<Q*
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M&-G)TLJ:9?6!QPV\>//V): F&:E& W54D#/6<;E*35X-JHC(#J+_F^6-X9$
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M+3/UTRQ0)/XX[V)[$[V&3BEX?:^PPR<#Q6WD\MB*VQ9^<@XPR/%46^C+.1Z
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M<";NB$4NR=!W7GB]%^'UFH77C6F&"];!&M9-7GRTO_?@PW>B[CB&QRDO-LQ
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MS2K+:Y3]N>>BW0E_,SBH.CXHK6_?3=YT=7! "1E<,_J(;7[0M%5-F\G:I*Y
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M)W<NUG>P-\;ZQEC?9\7ZKHL&@:Z >"6;JZY6M0K'#07+5_&,>UURA$J%M74
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M<]YN.*VU3A[8?R!.]OS@X ?S\/"["/MW!W1-W\>[J< 4W0:PQ3)O6PD;BZ4
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MK^.S.4/9[\2@"Y."6.E-$RZP8G-5 J\P7V"WB%46ED/?J9L)&^[&KF4$WG*
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MA68)."_!9VE003M<<GCX=5:<<MC\K2G+9EV0@,NS6VIJ%<QR/M;N1S>6E A
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M'<1'TNV';Z<E"I-HWQN7N2-MP,T[G^D@(YY,J42-VA(&(>G,>9!'<MJ<5Y%
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MEK)R%^'R- IN%S!OVN1:? ?V>J37>9A'A%]23:<ZY@<8QH$(-HXRI]N(!9&
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M!R2\(,*CZ',,GI=':#25GY;YTU_"<T0-^"I<I:EUW"2SW1S81SA2\I\6&!X
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MC'5(?I8;Y RT^VPL7P/0#'WKQ^(M),_T=1UBYB433#QY0JQXC[\@(=N%3=0
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M&C=/[A>Q--K?;\DE=L"\(N6_<."Q@FO&;)-]:[>B&'M9,BW4%7&K-,GX!NV
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M>.0!A)M/($*+(9BY);#KOYCAU@TUD $7\IO3[%L&ZOB P]M7RS=A_'S:H9Z
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M?PL:D;,ZX"2YU\CLY1K.('49>P>N5QXWUS'D6UX;&?@@WK;S)?Z(9?.#J3[
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MOMH5=61.,W5"7CM439#9MHKGUI,<*H7217.=!5]H>8FVS;41">M2[#@3?FE
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MJ^MH:)2U[M)NIUVH,/;80814/NEBD&).5Y>#"8!DF]2(ZTN/6'7B5)-WZC'
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M-;ZY0Z:/7.BSL)F1ZN<R2KVK+\$4['Q(7Z@^Y*;"HV)<CVFZ>U]';P:[+3Z
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M[D&WAUW/++2^4G#TQNXS6X:<@UJ H)E#5A@C<,<-W,[1,\ 2#WLO)H'<W@.
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MSW]\\_KM*_S\Y#D3@%BY$@8*%WI)]4D*C%]0UFDPP($Z( +ID.;[BPBQ<'/
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M$6-C-[HESSH8TV:T[F07EF :7-66&LKX,.Y8QX-N<_UH??U(?F3!>^.='A!
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MLG'GU/OU2!X7SW'QQ/SSG?IE#RRE7]T]^X"6X+'^_+NG+-^OD?HA5Y8C&<Y
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M^_+/N.8)Y'C#@[?HUY%71&T7_"#N7320U^UK_!)[=^P\J#F8G>87?/U%AV;
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MMA<[H5-U1*Z+YTCR)>9D.8B#59*6^S&'W^;$^<'_T1DF]S.LV)X&7$FU5CA
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M6+XXVFARRIX,+5P3V;7^N,%[7*@ %%KY] 18].%UWY65UBQ02MQU5P)W5;6
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MD7P.E==J$. I;>M:&'.L(E^X%!#_"24.K4=1T3>,,"R>M/A:1E586)'M+LS
MI/A/ZIMJ1[9/UW79#QZ_F=6XW0SH8U-=ZN#R16V$/DF7JXG5@DEG8A$==:-+
MCFR:(6\PH\?# :%L#T4DO6G:<W3)$D1D-S65*,>Z!-K)ZG[0ELW03Q=2]!\7
M-K9-AV&A4?P:N3/+\Y"H)*UYUAWWBM++Y(+2GZQ.*_M0Y)+7U^XR"Z_"A,X/
M2\B:Y4SAU70M@3:3IA0)%9<[MUR*6.AS]ST/BX@8I5>@E)9OZ7HD<(]!]V;
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M=%KU805UTJPE'9GH9%,.JWAF)U54@;11,G6GYX9D4CIN.\BR*9HQD+.<EO:
M?D]C%56%BF^T1'$:S&S&SC7J4^@PB422+:+L&+3P1\$G03D@(O*5$29/W4C:
MN^GSX<)?$;0GJ3SML"3%8L3+H,"SBNR7Z:'+*2,VMF$30L5N"&[(B ^". LX
MZ.SH2K0Q!Y%+TL.6>D4TSD,,Y7# \>!.WM4%+SHQ(Y)$6FW(5>DX&YR]+7Z;
M0SU577N]AW[;)T[LXEU]'>**JJX^C9_V57CG&T ;[*KFI<(\8@ZE'M?+@:Y
M^83$B_A-[D^XC18?G_8#93N^^3$3T<!QR]!OO'4B0%NTQYASHW](AG$X3;@X
MLYBB3^J3,YV^, \-B_#5XWD;UGGX:+ CA:/_ZR["Z\*[#P= ^"/YMY3(.6_"
M.NS"?^A#I 9=;X=/=>]MFYV"F(*WV^US%Y!DBBD>?R2=FDD$;BE\//B02P7K
M7IGEED1>6I>!1]L<=(]B!H?SC<X#*\!LJE66 ^1:EK&_)\;#)(KS[3,A#GF$
M!II_^3^61$-NI45+R'^&YZBZO9GJ^I=FC+@QLW<_MMB\W%\@6+EA]9>>/EX
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MP\LE-[(0"/?0+#KBQ&$1&DX\@-W &(RPTUAG45?&$B>[9'8QG,CPPO=;UP!
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MLT#VU;% =BR0/=0"F>K03<%RO#YD)&1/KI$,&E?Q.[2/Q1($4[8LP23H^\$
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M4(T'JE3_LI%#;^GS']DR_DTIC+?"2A\6" >GCE<D.RRJFA"/ Z>C.7?%I0&
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MDQUX(U4_G17+BR2C[MLFY^^29<_.8G\.$Y@Z2QT3$OC&#1T%H@NPD<:7RIQ
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M"PU5R.38;25DO6T,VUJX1(/0.!PG;X1FP]/$#NBWU4EM==*F8 <TS3$C-XI
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MO'.K(V8I2581 I8@6'C=_N(NL9&QS6XA4Z<1J>@;+Z/V,=\;9]>*XB1<,<Z
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M4N,0S;J5,KCZE$_3(XGB2X.A+H.SI Z(HMY<CJX=O'6(83=IVU]3U/-&IOE
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MS7Z6S":.8BWFQ48I<R^!8"&^G" W>&QV46YQ@P\'L.('"S$U/78[X_;5.([
M?";(SOU^=_#S0X9',9M1.Q.T$U-3IS[)Y-A1*.%5R5$0@H!%,ZS. MA521J%
MAT_6LQ&]3H_M\@D."&5-9SHKR%)(0)_\$A0V 29CHEG+8\N%:(Q"\8C1VCQ0
M87#+]<"SH,SH]=P QN8(\2J556H>)?].^BJS*=ZA*L48E:X=;#Q94$#JN_NQ
MU]GA[0UY>P\&G;<A+%-;A@M""PRP13"T+)@T\8QD(FR@@J_O!,1JC(T5VG2
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M/TB^X-44]P^]'N8WXY.:C2H&M@(=)DK/;>CG$F+F/_C31 5HZ!.LA./0R?T
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M/^ARQ:"P+J80J]-K4Z"!EHI*)<FO)R%P<9+E8FM!2:51R%&-Y@2%VHNTV,=
MZM8XN_;MZ# W!#D,<G@-UY]@.$O<G<6;HC9NCB,R7\@8%5Z#D\>TI@6#E)KB
MHV;24->I+(-HTIQI*YU(1;$YQ%= .6+D!9).Y .9>&_X(S;@C72BO^CQ!$$-
MNIK"P%2Q-J01=ES<5=&6"PS*J[H&D=6@["9AFU>P#BZF@.]2044';1'])UVU
M23IS8D:,%6.EIKZ>DU8 -4)3@^ Z8XS?H+VZ;%&*V::E3M,&(86O\,]$?/2]
MYY].AK2[&P>[#RM/I@F>. :I>?,^U]W!-^%9$X7R0:>F"6U3L")3JXBPD3/&
MVT$%:V/&6,ZN67RQ0QP"]^$D(%3P<2+."@GBJ3346#L7U\OV?$G3VKXH1LCU
M%,;+\>3Z>V9(9*H</U<8*'I@$_'&5I7EN4SM-M?%AU:DDIWC24^R)8IL^ 0P
M0AE_G?.SKCL6QU8$5<E^$#QG@L-X@# 5]4MC(QH]RU2S!!8;V"B"C*'"I.Z7
M$@I31=GV"F1(K!S_*4[M]#$[FFHAGCB<=1ZPZ)!21L=\Y=7(\&J&A9W0 'B<
M^V2< !KK[EA3]C9P$_$Q^(^TST'/EQ0HE2Y$WNZ>K*E$0$LLO:Z'/? !C-(^
MTH#W8N%H$X 2FU1!K8TE;38S#2S I?EFEE_";1$#$(YCS+$KQ[S0JYF)R9;K
M?5HO_HII,HK!>]WB[(\$I!R ;Y1?\DL>4</. !H+04C'QM?OAFI;6VM2*S&\
M)F ;4!YCP74U5S.^BJU#YG H[I037!32JE 48MFC(L9TPE_:"? I/D@BWIHJ
M/$ GIWY+JV6-T@32\!_@EY=Y@'CN4G7+7@73@H4=0LN+J08;#.T*;'V 8X"-
MP(PWI:A13I5RXUF!$^'2!CO:ITF=O0U[X)_!HI*R% XPB'T7)#,P1FMGML 0
M['@-(%A=@Z,C+]:< /7HI3H4\>O[,[0+G7+?1HT.9147<+&)Z' AL.51>J)-
MW.DHIHIT1>L,Q2Y7.]BXQSN;AJ8K@@H9E3G/1J QEIC=A&_:DNQQAF!(A&++
M//NPJ BVV-?&B. $9$KV,OQ#1#U"!2XUO?0'EUP"M-0(X.C$H3X%;%RL3V!0
MR6@KB,9\;DXA/0X"D]N@+Z$UQ288&A\:V$I=B.!B03MX3K>OTHTPT1*M=X0N
M(!ZRU++HG3O^B#=26-NNM0GYHRQVJ+:9C4#Q1^1]^,%%L9QYWL<U@+Y(LIQ+
MRN&MX#'S=:]3R_ :&5MCH"NGT^L[7?IF=[_VA0[IGF2:L->F"=LTX::D"9L6
M<ZT/A3P&#)M0<$.&6KBBPRI9+CG2%2S6Q'54L16T=JZP"]#/8ME?FBC4XSDI
M,J!N-* 84M]I.G+B2USMVU2YD^"SMJ!-*=!2O:-&(QISX,C>6AD1&22L(&RC
MB)%D-KBU<1&MAX]FU0?0VS$XW)XUT]%JXW-=QHAA/ L2:GDT<WN-!17^6<72
M#$6@B.OQ*Q>E"Q?A86MGF8O*)'>E$3N0<J?G9YQ/Z@VV]W>$[(&%.%Z.@$T\
M51L,YH9A# 3*K0$4CO3K5>LKF]OB(;EA)D'-[9LFUOZP40*>/DJS6BJT( *V
M /(<)X@P2W- @P-'3H IF>G&C6:L;AJ@SX!Q+F[#*6CHM8FU:2^I6%.3VYD[
M(H@*:,EO3V:"'FIG2QR=_79ZO-4[\%#.JDD<$@^X!9!7&6H*S3?P&9EE4B<"
MGQW7VL:$+8VW$/.(>'0\*=YD:HPC@(&T7*;"UDQ97?VH"QIMAI#&F.3X\4B1
M(:AC8])R T?.0P49PT?W5TB!;RVH\#NF9Z]=,:NEC*%=9&-O4B@W#L#@A)=@
M^$$ZU#4BN&GXXY?*B@K.K;J*@54[]KI2*$1M:>*3DYL4/S<S=Y,LQ3!" T96
M(\&.%I\D>JW4,5BG>5$&HQ'UG]*[?+-@=!MDQ>3>)J4NW1#W5RIHU\C#^I**
MY&&Q1D6]'G?7S$6$:.E4.HIL_R,8?=OUWBW\^X_] ]WS)+_VJ<Z6V28QE? F
MBE9P%EP<#R#XC[U^I]MX JQQN_>3D9*XS&6KY# ]RBF:[J:_4@23QDPAWL1V
M9[!@$X-!X]=?OXG>HDT,!G?=Q&U1.9HF;2<Q(;I6&!/#_MC?V^[TZ^5 5+]P
MA04.D^ /;/:>6<W!;%!RIX:%GY2N8RUFC-!?Z @NJ%.J%T;I[$VN4 >B1KK#
M\]UG<235U%SCQ^G3KGFQ.=/-?M%"[N.4J/K!E,"\#<(\,^W)1QIH@^6"EC-K
M5V3^#2 ?;E36_L6V\KAJ;U+;G8$1:>!++!"HKH;R*<8%,A2G<H.^+&F6&!@X
MW&Z!%BY>NX*#-*,$H^)V4A*FD,"QE\!4:,+\M3'I^$MC$LF\+O96+E6&@_>H
M*8':T^#DI?D$S32&N= (XI%X6TY F_5&9?C?XI"@F_]J S!B+)/%=TJXO**.
M1@8TQR)S&8FB%;5/-C)G_+%:JIA3FF=4:)!2CV; 84"V7W"V+0[;<DP8UVJA
M#K4%]D:]G4>K7+!JDT2EN !=]"FEH!%V7*$*=NT7V[3,651LS)]K'G74-BZ1
M!I[^3DWCUZING"AC>)B0[*)6U,4VB2_N%*<VM1J)YI<AXA.->FX#PCXB,3X*
M,JU#6H[MBS7DH:;VX%*O01 _>%H\AK"2C+ 6L49W <V;446!_C<6D(O[D],*
ML]1%3>"19<7<=<DQ#Z 6T'O-H+XW7A@]>?I$R[6/=B[W5URBHTQ/+]9VM@?T
MJTJ!;48",6"%&)[6&+4Y?AJE%$?X L)WPJI/"^A4DUWD!LX)WFO*''L?/^,I
M@<BS>1%T_+D$RC*@)%H=-X63G91BPX*M&AP2];%I&B'\2VEJB0B)!/,R%H+(
MIF5<CXBZXNIN$>7("!I;',0K@2,B+B8SJN,0MS8T7;>!F=0G+ 1'0 ,U=)^F
MU<#-&$= F+WH>\^OPN>5&J7D.]8?93(+KN(+)"M#F4F:-H$E&C(IMC'Y6_([
M6 ,G7^,U6EW"J+C>0Z=V;KX.K\U=/Z>[SH$15SN_U]H9;\>KFYZVY+;@#F.-
M[2[CIU,+ZJ!C;8ML3;=/3N?<L7S$CB8G:"])QF+="NF=*0VJ#JT):L(*OG&8
ML4MJWCMOC@,U8&?Q9(C#3G2(3'=B")J1S:M^051=1F)R%&$=<H;RM/)LV]T\
M#699+HVQ(E6I*,>Y 7 ,E)O WU\R9/P"\ZPAPX7MFK*C*>3AX53F1):?\8$-
MX5P'?X&]AZI@[DHL"X$L(/*3S"7UVUQ2FTO:U%R2U7QL#M=%6$Y%@5G.%1)8
M"-B\I=J)Y(HE;5.37R_F*UD/8+<B0B'I44Y*L;9H5H*PG<]/<:N7W#+>E3O\
M=W/O$=L\2_4\;W2D/UCW^<PXR9L2C?C ,9ZUF-+GU1!\#K);$RH4K4697)B?
M6KU;HRJ-BNZ;)2TU-7],^IP"SS(O7,D(<#*K;)[,%  [&OV:,Y"7*7I >FW.
M>"X#RD-K$X@1J4?F2G]0@&DQXH=1'('#6;AGPI8H^.-.S1>U0X[CZ=3V*.H5
M46APT>>Y#(H]Y6"!0ZDI$DK4D<A[*<D 0X*.]QH+W1"!XI)?;G4T5;;AJCA/
MX]"%0"J$-AT!2C&T$NO>! NIV(L*]<0,YCH@B3!C?*].4IFMQLEIM EJ]6Y#
MPIXPLS]CID5*XI+3<PA5Q" ?F!9PT![9C%@<L^<$-1]R/5!EPDF<3R"O1*21
M8Z"[CJN.7II-4@[9%F76]K+2J/XW28(C\4O6*1'T.S6E;"++E0;<^B,_S"46
M?>'>VA ]]274Y839L,@257))0$I5H4'T1R7% ;Z3DN:(9F,<G[X!:ZBC]G@^
M1TR./?&L?*^6#L8_Q"EK7,%>^C*-ZPBL6':!7@5!@>BJ16EM(IK0OQSD.RI.
M3#W1I$1 *JV0?LA:;6VZ1>D)SI68O*4XK6'C1-W*L9C;L)(*V[NQKAWK<J6J
M4\2>CNC:XE<Q#U"J%-]R\<%CH7&1_BHE@"W,(-_$K8=("&,[<TFG^?0V_MP<
MF7 XR?+2B5N>IJ"_+V,T9@^+0I6K-&/NOHK8KB*@5<C!&:R>H/$%B9F0YH+%
M81M)2I\BTX$F+G'%S)"G,E,;/?T:_DF7SQ$(NH%FI+3-VVQ*)(<'#A?]+EU0
M8[A)P$BM?H35!!K4BZZ;Q2#CQ,+-J^>5<<#T$C-^*.!,@['$CZD#?,IA)VD_
MD!J2/['CDB?]6 0:OI+Z#0[J>7!YB1W;-%M;BS*LE"YP!(]!4PPT8B&!(4LI
MOCPS-Z>#4 HZ7,>Q:^X:0N1G4UI:CM7BMJJ-2>?]FF,J^3WV[7"5!?_B+7UA
M;<FZ2WKIE%>![?E!$DKZ=XB1GB$5H>M:C*:0EM.^Y9*9LG]C^=%X7GD1_867
MP4OEO"^%6+DY3$#M:DOE864&"<$\^:SQ,'-=F(VNC<Z)R_DZCR%:B"3T=;\.
MII>DSWT!JKVK:)KV@#4:YD1V$5)K#=>J>7.G@$$L6S3MJK>:VT.*;6.X^=QT
M&+TU'48G$H5\0&;N+EB ;7$R85 Q"J4'7F>> VZ:B>L68*T2H-Y$0O5BINP
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MPOMP>OXO.N('8=-EQ%UBN)^!+ ^#8HQ6PU@E$1H;D2*.0JD;J0E*]B ,0<Z
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M+A!^E-<2YQ[8HK!_TD7 =<D,_J.\857 W8=/1\$,/XI$@_/RX=##I$+MX8U
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M([X0,?;;??(6!'SUB4U_V, QK/=@/8*J9#P2" J@!<D\9I!"CD0:1'D<9B[
M4.O>-GLT8A#OC514B>BBJQ-EBC@OG@/=(\'-)QTGCS^F2:(D&-]>V">GPY,
M2(XESPB*^]!WD#=2L=:F?U8+7AI@G2QY?A6+%'.T.9"D/B&CJA_-@:%-0,2'
M= YC&W\*LM$^E1YRQ%[1A@=2- !*J&O[.2WCF&/Y]BD@8("(T1:567K.7GJM
MK4.AT4*U%GY=[FA[+'$A8]J(%YZ0L^/GVQR1+(!U0*S'&(9&H.%8J 8!V<6H
MJ,=;P-2NX 8^SG)_S.PW-!TH'E/+0MI-D)]R7(N Z'L/#D!BSY@1[B?8'8K[
M.1YLI!@4MT#VVUN504[<Q +[W#>9,HS'/(S]NQ^S[__QI94?\'QD)I26(T.
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MLA#TL<55P;61B[4[?+92Y*LYH(4#!;P#E]\(;1+W09MD '<$4:BN G1 O26
M<*?%WGYI$DZ>C3;W5/@$'$](#D*DS?JJ?3PH6O(5'6 'YC@@)G,<TF-N@@K)
M^Z#"9*-5JF=+#;;Z6-^5YSA4<<FUND!E;-_.#9S\O!OX ):C,K@8!(Q?,1F
MYM-N9!XYF!05)I!!E-OJ1'-<I)D%9;='JBCLW \)[C_:!D[0JWMS\#89D11@
M\!9TL><\/P5.Q,%_H!].[%@B3HAD\&E!4,N-!7A-;_/9_%K9B>L4L_X1,Z4Y
MK'Q5M5^LI\!A '7PBQ^(G.J2;8ME1\CRN9VFZ_.\+-;*+&Z-]>:/?RN-6B%6
MK3;^\_>3/?T;_Y1-5BV_9=311O7ACA0W\F0N;'O==58;MA/3)0OP/M4,25&-
MQ523XK$&&]YP\,Q8'D*YE/OU*2> +RLI1_L?6;5F?51H<T*V6^XM!BD^M[+
M_O$T]7S+G]/*YVV)F+QAB7AO04PR"F)&0<P_*Q-%KLFNR##)=)+Y-,_DAVY]
MWTW9/=RR1WH+Q?6+I4RITS[1+2);Y')"E;L=O87Z3,^!#Y9G-?H'X,3VT/D\
MW04ZZ_"'H^AH^Y D]RGO;ZLJ&ARQV=\JV>-.3Z>VM>\S@=I,G!QC\3EW*G$2
M:K&V/%45F+GU:?$NOU@0]6,[<</[Z4VP#<]^8\'E[B<C!-E/L.66\VX4? Z
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MG?.#D_LB+W@* _B)^=_CZRAXWSX?Y(@@CYX/(\YP]M5>_.X_HP&POWRALP9
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MT*M1=*VZ)B'1G+B36HW16)Z-YB)&M_O8BBPNQH+?F#YTKO+.:\YR/7.#S2M
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MO5U:KK+5B95) 8D EH9VNZ+FY1[I-GM"K[6L*(E<3Q#*:&EXMXNR-.?5D0"
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M2/]( Q,D2<53Y 5K\K\[ T5BY%83*2_AA_A3X?'NKJ<9MBHWN'%ZC-%B9BN
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MB[[ 64Z1K:YS"RE+I:L5JMO@*DQ/@$,O\,!N5Q[V!;'>T.L*ZZE4SIO$6ZQ
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MFGU;\3EJM%$M@\NLXY4BBV:&&FH]4*DKRAT_??RI$96 *YIK6ZYHH/(85=M
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M\XV5#D#>/P#Y?_\CA7L>6E8M:*0YFOPJYN/C7+"V,Q--;8>?=)P5L@Q-I>,
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M"WN%"/]PLI)WKXO%;A.H [CGNAGD8>E0MA4J=I%O(V1BS&8G?@C,U%#Z0C2
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M8A2ZC8DQX\EB<7P5_X!K#-"C4!OV: &0"UV\Q.-*'IN$82-D7((7M0N)>M$
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M2H@HG;L0)7FZ,<@R/TX::*$'/ZIO12FVWO9H7+F'UCC(61>ZGO89HY;DX;N
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ML=6H:S]^;=.%VWMTT H/4 /W$ XZBQ'J]^J!$/PP?I3M  5!X8",AH;$082
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MG^],WS?)IVKL0?R^3&5,&3PY]G!ZY@R#"DY\!G&'LXEN+:.EF&GM2#QCET[
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MX@\JXC[T=%#E\=Z6O#E .8?Q&%HXL8:$\D<L*H(1H7*@S)#OI;SUE)MW/]9
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M+#4LI"$4'%/7G%:M,GJ-D"RRCI<+:8Y43%B91?U2S1E V!N04ZPL.X--EXG
M4$Q/BB&+56@K'0(H<+8SJ-%42-&@5HFX=M R-%-W>>832F@1#(V%$X1*X<Z1
M?W#LA-=!%DF*I[!HUKX7 6O1Q#(#!6RG;U!:1!AV(3E%]X&Q)WH2?!VH:5#"
MK V666ZF(=OD6A< 9P2G\3/BJ2@4O$,9P]I(NC]C"@$H)B@(VND<UGW3\O0
M7[I3.JA-JK77NM<5"\H]>HL7I^2WF=B^N[+HRA!B9IE5D?2&'#0\,H0\CT/7
MUYFC &C >2PV.VL\.QBAXX@-!GV0%3K@1?SFD*;((A@ 21UT<HZ(09L#J2^X
M[_[@?LO)<-#N6\>NN3,5H8 :Z$P7IYD6D@Z9=?V!XU8\&4#GY3!A';\"^>3Z
M*H]T?I)=RE!\9'_P,O:J;*L@]%8S%8F^9J9\N!VXXR4D-?1E50VQ%LG7ODOC
MOM[;M6J.Y7+]C1F:VE#<D4T1L-WGM*DJ;I$P<LX]Y=T]]_H@[N^)^B3#.6 A
M@:$I##%<]B(L$>RVU[HCHX?W@V(.9$=5=E9$]&LW>AU__^F]8KNZX]#+42!(
M+R2C:+P34#E]C7%TLIL@=O"^%_*:2K,A$RXHL;3#]Q7AXU#4]V:#H/([)>!W
M("30SGY_F:;LJ0T-*UKYOBK5)!$F$J])=0Y,K% XA/_!WBRKJ4M@F)X-:F!W
MX)Q0P-+\\NWP-?N3#PZOBH#'45T8MXE%AA(W/*>Q#\)%7\E_S%!C!;^"?@^Z
M)<]QH^<Y5AS/Q7/B+[_"([HJY+L,FFQ1@7)D :=!^@2H<$F"A8H[G"R'0+C\
MW^UC,:P\IAM<JSB5@\([GUH^ADHPL)!-Z)?AW[SS+-\=\*7P.A9.G?/3@?7<
M\8X4&B0%<$B!0T;4]]Q5;A3R.O<$3JB/5UA[>D\ QR(_#E41.3*D8B$8\5BR
M8[BP#4)S<]<9**38:2M^>=<9FJ&9M@I![PV=FBVSS\[:H=O1M/!KH^AB MS'
M8X>/":P9WEEE5_&QBW+[H=/-CK]5^N,!(X^LE2"B/$MH R,.TV>N<&?H?6^6
M2-RS6/O3TB)REJ*R:\"/9!]'),BALBHT=[+WFT.I>S%R)_N&WXG-^P[MRJ-!
MNW(0M"O_?&8O:%=^\7;E[V^:C5MX'QDIITWW.)9*L!&!(\;"A$R-8S&!&+-I
M/CIFHQS\-I;B)GSR:6-O)J[%AUW:U*2L:A"9>"DMKQG4*/VHJ3EK)7K),I>F
MF/Y,3<V(?(P$,6I,'C<+-^UP0JE,(DF"K$ZD95NK=2-+ZE1+]7 !R$VYL*$D
MDJ@7)LJFGZ@Q)UNJ,Z4)I\OM;9/(9@:#:3XY'&UQ2_6C&:DI-5ZQI.R0*;"@
M.]*'Y<62H$ZU5)_SV4UCHMH+R=YN%X9>45-CQ3VP?3@2I,-BV)K')HPBKZ?<
MLE@,#VOHGD=/'U*;N#5J]DBB4$UE*WU2D2SR9)OV9&929>0R69?$F36:5!A"
M-^KN\:_#D>5JLL_D4IND5.E)Z5*Z&D]J>NM4F_9A4P^GA(7!2 VS;Q3H\"H]
M'KEEOH<C%;G'"[3<!X12*?32/6T[7ZN4KZ'[;F1!4X8R-5B*3#:B@$F!TAMD
MJ>64'3QI>\\/^$$FTQ'IS7! =!H,2\8!-4X>WU/.V-NYG:0*1**8K6PXHT.*
ML>DX=6+D%C*P- U/I7 CI41K?,%.DZUQ^@0WE_%43DFP4:G"JFP3\%)NO%K!
MD<?<I%8U$.ZL:6)#=O/+]5HT%7T*1WK<O/3^3M/08&AF;9HR#*PHE4>K!AV9
MF3TBY?'>#M7.TG.YD1\SE2;)#.OU>79<GUYR;\=O,%_!C3ET5!_??;OXVS_U
M$3]C;B+0XPF.6W<,N0HTT;/B<"P$BU*TIN;DT9I6LF4]/QAPEM:_E! \3[4#
M8@'O=?&B0,0GS-U$ZAYYZJ>S-K%->(7YZS>FZSUB+*3. ;$03;Z"R!XT]+U5
M VPBZ.1_AWR)QH(.V'?)F$!A[I,OD4<R%?#E_OB2?HP&=NP.^1+8L?OD2V#'
M[I0OZ,T"QER,,>\\8/?J@O*FS>./TBU70EMXV:3_A21Y=1EU'UWD \&Y'$D^
MCW9#QC!]OD\??:^,PLGS1B,/WFG"3[36=PWRC8GT89)0N(B8!R9GB+@HY&PH
M%A=6K4_-VN'[\?_/-'G7^GX?Q:'=TDP>%58+MAR24856("HG[2WY47L+0^W$
MM[*W9\5,"H3$$9*(TQGP.PE)Y"P>^+Y:#U79R7X_]&P*<&>3/%LW!L]CWK0'
M_ULD^>,5 %['HF?W^#.;[D8'^\Y#4()VO[DMAV:+I=AEPY&4U$_(()OK@*D4
M7QT<"0^;@/O-VP9*KIA ?7.% 8,=>U44P.Z<MYQ?<\QV4;?H0FT@-U-AP&2R
M+CQ,W&$]PH\TCVIXOZFTWZ!?($Z*WAD9_GV6CA#1FZO[^7I ,)W<.+XNIVJ9
MPK)(V^TH046'!#MI/VD 09GCAG!NFR#ELUHSD<P4I,2X4-AL<W02& =M"</1
M=S2->/95"H9FFKMN$-&=E6AOXL549%A>T(79O#!.K;F$@JLLXZ@942)ZH49$
M@7WXSO;!W77XRPU$Y"P&HIL<F5U+7949.R57PQF2J@F1Z?4,Q$"(@OZHVAG2
ME59$:=)B4AB1+6@@4LA 1./D^=H/WL'N2-XV(.MM ^"*2 &2$YUU^@HKX*M'
M^W]E:.^-W<D)')=WI<15V&JB88DZ4YD3_4Q7$MJE41K&W1>)\NNL88Q7#4@%
M*C8PZ<8@5^649JI6;D^O%./_C0[[6RCQ:P5.W\\=GUW1E>:\V=3B<X7(UB:I
M8K2S:-+\%3US=A[5Q;Q9-YFPPI%"=UP8]3>M<0R'[LG8Y0+W0.F_J-*_6@WT
M_;3^?4'X&[1^KE>M(15K%"6E-5Y8O=(D7AY=<<%>GD\I&:BE$2.&4W:-'U<F
MA1$ZF(CB\=CYH_$[6YXZ/2^!X3NMA")U4Q.L%6N [YJ<"%+U%TS5>S*U&P '
M=UR!<K6>KXV4+EDH]&F@31/4)KF*Y'K4Y8)ZVV2+VC(^$"2P +'F9%-:%\G5
MCS_1(''_MR;FSASZ_^7)N<N8B8A1&,[&U6Y2$L>-ILCD;3T^N&)PH&:SD;S"
M=WITI[YE2_)D1//#Z3B.E@0)XH)+@CO3E<!D7&3A\)?;C \D]-]@,[KAY19A
M&;4D<M:RHBR83P69NI[-Z%1FBV*K/*C3XG"3BC9*XJ"S0#8#+BABB=2W2N_C
M#K\S3>91%S1#6_IZE7_UQ,CW3N]748=EW,1[5\(JX ; 3L]:U/GX6W#Q9H[K
MQH!UUPQ\OR,VWU5SXCLK6O(94=>;->@J-:S,\S6";"A4T0QG!K/\%;U9O[;:
M=E9+?BXUB-PLM9*S6D1 0$*XGB5*I(.T>& W/AC]!H;CDVGUEPQ'K+DLEI+Q
ML<1L(I)6$G/)8O2:AH-38G*7G/%;QF[$E)XV'1+I'H)%2B%8I%0J\GTSZ[BQ
MVSFA-^\P(_"]$NA'^O_,?,\VZ[OD:9#E"1+#%PB)Y8(UFB:D9D7JK\GD<AP=
M5/5#S,S+>J*-&%FF5]GMD&$S>B)=W,@)6U^-DRB$C3^DR)?V> ,%#Q0\2..^
M%KNVF\(H72NH-6:A#3K;0G@RX)97K-P*;YFREMV.34+I+"-69["IF@QJL(Q2
MK@_I6/2;)5U-$V&%V(KMHD@ W8"4W.-+L8H&9[!EG0X&WV Y_H63L3<*+?]*
M-_,W)$_N/^EZ-/?0SR\68E)[XYKSV5;X60;H _1)E,_$/NNO3K@JH;;B:X6"
MN2'"8+YNTKERM=6AQBD4C,8>(C'BR%7]"FQ"8!.^?$+UZD;A[%'I!8T"U5]J
ME9C4:1";J=$UIX#M+6<M:!1@_!I]2,:3+QF%[Y$L/8V<\!!20= N)$BA?AF>
MWE&&Y= ;1*$WX#4; 8O<@^N[:->,F\_\GK(SU\N_UL$IW]96;+K-K@1= O&R
M1)74C<6TJ7$:!;R1AT0JR+X&MN&:'3-N/O5[,@[72]V>-@XC*0+2Y2J_HBM\
MKCPWM *=E1$V'2X2B*02KR5N_XNQLOY<"C=W#XT*N7(@MD_U>7\E^O$64.(>
M#-D!YBA&)#8QKKU^&IN,M4((ES-TU TXA)P''HP$Q458AB_V[TN+I&E8XRP&
MPC803/6F#B5L7P%.30V "UWZHC6C#(UUZUTR[%!@1K5\7LI&)E*XIX+TECH\
M*A(__QY$PG?&+#\0-E9FR9>DL)@9VU9"Z\?&J]W1NXOY]X_1J]1*29S<+#!T
M(9PE)SF#U".MU37II2=B?":>*V2(['!;F)M@15'KUH\_Q..IF.#)%XZ80H61
M7>CNO43+&H>W1:!DH_D^AOS+=8SFK9H@M&+/+\H?A3W\(,W]\SI)X9C:R6\9
M<2A)Y*HMY)1"O+I8KA"%CX\N'1#TX>*DB1R0)C+6UT)U-6'B# U4<4W-"X8P
M$BY(&IGHZM)LD&D39-EJ%QD-Y#8L=5KX#F4-6<1+4X<XH XQ9BFAGK?TCLYT
M;&79R\:+Z:8\O1QULM5&4V$'T0J1'?2ZO4%Y6TUQSU GY!$&/AZ!6SK4VJ 3
MM2&@\E 13[N6!\>ON Z&> @9P-0!AT!/Y,WC#G;>[]5=/&?  @+$0&*<FA!@
M'(O$8^,)&R?&_"3&$@(9YSER LWN ;:MONKS_;Q.=(D%L2:,Q$ 6^WT*4?OI
M2'ED,Y4^6^\RV=Y@*XHU4*BG6W!D_.G(N02R<7L8BS)@5)EN%+)1T*V3>,X1
M.FTT #M>T1UNJPULJREP&/GYZ)YM7BG$>LW9A.DL%&;<&\VFC?GT%$JS7) '
MZ33?59G$5MBLC"0170ZF3C_2)PC5U<$JE;/35<;.-Q/+L2 -^/C*Z4EX.#(:
MCK;M02U;A0:*S<HC@LR.<B=1FJ/)4;0WS)4F=*)8V61*4H5)-TYB+UO3L:UM
M6[48S9K#XFP-ZHM(IG4*49D=C.;-<KS"2@VR%[%T@VY,4ZAD-/%T9"Y1Y"?9
M:4UA&D-ZF(AF(B.069U"5%[2$4$JK&<*W9]U(TLS-FQ;FY.(RFR7G^4SW#3"
M*-M5-ZX3+4GKG414SN3[K+Q-V;0$QOF.5!_(W6T;1:U'E.>@DIAZ?=.G*_K4
M9L7YRN[W5L[B]RJ(RA3'H<C ;+(;%"C#/PT;\%61Q=&I"$SHJAM0:0W?5WNP
MY:QM&"?A=J="AFP98S7.9+7<9,(1>I/6J>MC+C^-=W_&7=1B=Z(AVO'V)C8S
M>*(A=U(AWXRO@F;<X6: MV70$(ZYT$7,.29S*1G.M+6$!IALE(_4.U$EF=)7
M5T<U]H@)_,34,#$YEYCR?BX!VK%[DR3QF$S_G5AASZ^. Y3#OYD1D<=DP(B[
M8$1@F^Z$$X%MNA-&!+;I7AA!!)PX*R?>62'T:MQZO5G_/6"8+]/@HV"7'\?5
M(A_CMZTH? U7"SWDT^B6WT0\/JLBYY&7V^-^7EQ> DMZAZJ2.B+!O8 3?GDC
M^G4A*^],#+ZV;?PT**5K"&]:D/>/T^P:J.;^H"1> 0 ^- $J$,0S=JZ[]4QO
M46N8O(-YGZEV\$;"^FIIX)<M&J857=8V +0=A?-M?;G;<2>* PNUN*PR2T&3
M-L9 '-!TK#9IH6WKZ(\_B8<8>7Q4+E#?0'V]]-'?K+YG+^O]B/JF6GHA8U>Y
M,E'H$D6IV):[V1P"NDO@I@S)5VM[[WN=U9V)!A_&!9<XE- -30"F">?!RB$!
M?$F0NQM:GJM.\IP';Z\A>'=C6"YQTAZ5EC1]RI,'+UF5>&M42'"#(B_UJZ-8
MNL,4S20['<=04$ ^Q!,OM7H)]/ [Z^$57OYN]/ 2A]O?IX>Y0;(:U>R)(-E2
M/;U-+):]60KI80+I(1D]8\NE.TD>4 JNI SQ-@A9&N8.FEH(WL@6X ?; $:P
M /GB"Y ;S#O(-IPMJD 'GCQ3YE7^.FJ;LT%7R[HJ6_-I[ G3UITGQP-)I(<$
M*.N&%$]N0:Z- #RBZ% B><D0XR\4_[]8[8,LQ7F"F/.H_3RE%,"@DFH3V>:H
M1P%U9!7[%%1[&-&DS@D$>HMLA7?H04<-BIP#D^B\)FNAJGP'\T5^<AXB6#+=
MXY+I9@'*7V.6SI[C:'B*AN$:O-SIYOFU5:\M5M(4/Y@Q"YXKY;<)H]:4J7$"
M!2#1$QT" W4-U/6.4R%HBA'RGZ^^_F\#$[ &-\/9?AXL@:PY_0:\8W'!*B!8
M!02+_]LN_CTEI50^MU=1;U'@GH)^WO/.8V)2$JFY*+%=+6&7I=Y<4U C>;3T
MCQZWX0Q4/E#Y8.%_VX7_)U5^6<KKJ\I22#%D*R5U4L*VG));4.7ALC]Z1I"R
M6ZSZ<<.#8'7P+H-T-_W"+U"G<.O)W8T%.O\:'VG:<5^/Y\T.T4R5P3*E1.CP
MVA"2N3ZQ5;NH+PV*-&(OU48%6OPW:_$=3.YNM/CL51#OUN)XO5FKY:;AFL3.
M$DJ\F&3*70II,0P>DB]!(W_-% A&-$704^]H!Q0LD<Z_1+IY#^,KGKFX^5SO
MQMQ=JOCR39:NHRD,G<F7._1";MGI9I[+Q]*HDQV*5XB'5.*"0/"!YM^/-ESQ
MN,;-YWHWFG^I<L\W:?Y$["8:5E%@I<8PVUAJYGA8'B'-1W41#Y'$JSF2"_=H
M/W/SE N_Y-/>BN=J]^+K7\/)@#60WLW<Y^Y4"#WR$@ULGCU;3,;V:N)..!^.
MQ)ZVJ?F__^>@_\[.%* ^D)KQV]-WW\3<OC\D5OTI"#OM?5@!/OLW*Z_8C>E%
MSNG'W=GKWSN3$<5<(!ZC\?^$?)\118[(B7I,^HAVT$/2O>RPC:3WY2MMAES>
M6)K^FXP\HJ:6/KB!&/0 \0MQZXDP1O>\^1\V-#.0_?E7MY$]*9OH,]0/:&;D
M@W82[E=PB8"[>6I""%5=05DP=Z+*_CDCYL'1(?67CK<?H2+052J4$36WQ4=)
MY1[/^&KO>9,73]W7-0N8SBM:&J(G7N;C\^IY46553H2+,>A:+-S>WPS]1!Y$
M5*%=_[4_K/^B<3@4[%/RZG;<9E,"!Z) &"=BY&0<FR2BXS28Q,8$$>531#*5
M)$#TQY\G79([^0$73_4Z4A_(B>HP49U'UZU3';=C-I6PJ;D5)3K%3B326QOA
M;*)UJH]V5)O.0)QF-U*V7VZW)C,[->B=[*--LM'RF&RW,P10$Z1&0F=GQ4_V
MT>X1E%@LC4L<0Z87(Y*V(GPQ2IWJHZWD&)7GP-BD-ZMX0="*54)?G^RCW::8
M5EQGR3JQZ/<-L.RT.Z.1>_;Q<"1/:)-D?-7M,XWD,E46Q+G574]/==P>+I.J
M62N.5<F.YW/RK!SM%X<MY^33D[G+[)I6;$FF$_%14Q"5<+V8/MF;.SWK4U4N
MQ^ET/RKSZUHXOB@:JU.]N6N)PLJRPO$UO= V?"(>"Z>BY>FICMN3>C(EBE2N
M3%<*!#6Q+4(K"6@/]8B>V6+%9G6ATI(6 C4HRFE67"=0%^]K=<>N:NJT"PPE
M!R8GFEQSD=&B)&\Z,T)A3(E-YNE18NX&:EC-*.N%<6,T+'('+;$3;DML-,DK
M-[K&=#W=VMJ*4*.BT%5E&FB-Q7:];8WRPO5;6R,)"$,;K<!(>F(%K:N]J"GZ
MF/I+V\.^@MOVB1#]/-UBH[& +_?'E\AC+!7PY?[XDGXDHP%?[H\O@1V[3[X$
M=NP^^0+M&!GPY6)\>>]V_&OA\<V(<,LVKR];]"]-DET3T/A'FX"2T5O7[KS6
M!/0$0:_>+SG0J^OK5>HUBMQ+&UWB,1GY3AITUN;*@9#LA.2;R<@G.R_?WJ36
M1#[+ZB&4: ]5-5;]"O+^]?S$:RNWRY/D'-5 K^5KKE38XY_6Q:OZW'V3,=J+
ML+S=J(WNPW"'&L2Q.E(@I#^FB^ ^SRZ*1GJJ%0FQOR+2Y;EH)<6/UP2AQY94
MTS)LM)V<AZQQ>JB<.KR0FS>9_*R;8#;2*MIN],PJS5!.9^88\0!-[&6* 0.E
M_ZY*_V)RXQ9*_^FF!8[?O6GIZC&W&L9$K %^[XM#/ST(!-S)^-?9U/3.)GZ+
M$EZDFG\]&1R'?H^GG5]6]T#\ _$_FVN[>_&_=/GZZR$N\DP*X+T8UPUQ=2D_
MH9(U+LPLS$I.KT0E:IR@KA'BYNOQE#4O)#-,(\.(\S"34=;&RNEO''TMQ/UZ
M:W1:=4J>4%S S>! \"T"]O,=O;UYH'TKU_TW&:JSG[ [-#@,_!'UW]RB1NM
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MK.QH6XFPQ4FLY;24CJ8?TI$+]7H,=/K[ZC1Y!].\)YT^>Y3RBD[+YG!NF*9
M$=G8>MK,]I4255AY/:,?8NDW]T2Z>CN #ZGE17HBO>.E3U:07J)?MAJJL9L0
MF7@((4_Q@%L 9#4%4F(3PI6\@ ^)JJ4Y/\"_1 NGN3J LPU(QA U-0!NQQ+Z
MB88@8I+$/^[[NQ?LQN!?(__\"JU$:Q9R!^U;NW0-V[0>0JP98J=/[TA-?=<_
MX'?@H!EA134D Q5:!ES/(T)2H+Z<P-(>0UUX]3,O@L#+ER(/1T,-"=DZPC?]
M]T54-CXF$Y^K>IR-BRE]46-JS*:[2O3X2L%45X=;PO%S;@DG'*VOLX8QSC$;
M,S4:ZR6BHBC=D4GH0[M-_?@3A\;N2.-#4"!E1#C4. ))KHQF<4HN=G)M[CGJ
M=J) G2<T(<3>'3NZ!I32&6BHP.5+L3T;-F/QY9#IQW*T;5?H;7TRO0Y?MEVY
M5"Y-Z+34&6U:X_"BJTIJ"]6BOL07=PJA2.BGRX_=-SO-1(IUM\3OKC27^$R9
MWTK50CDK)0KKL;HL%'N3TI64HFA92HZ=%Q6IL>62Z\FD.^Q0+=05]"W$)X^(
M3WK$?PPQ.AS)R9H)U>#0&,/PQ]!6T!K?*6ON0R\XN]Z4R$E5HI5M1;2SB\A0
M(U:OZ06T-WO50 I@FP!I@0\[$K$"^@P. -Y$SL( .NLQ!?+*A%Q /@@-\TI.
M79\#WQ@''*&?T-UPACB!/TV K*T<71-10QSGGO"I^ 8&4*!;0X;0_T3!1AM.
M#K(>-)6^'M30,\)O9<A5 [XQ:\$WM>$G$YB.#_1$: 6G"Q\= C"&%5'D#._J
MS, GG*SE%SM<)9C\QX0/=F0-R:<" #;3GO^%TL3C$]+F YP.)]L\EMZ);854
M#;7&5D14;VMI#W!J+#=#UYY;BG>-G/:"W-7.X'R3K)RO+]+]GF3SV96B#-AD
M:_-^.X-Q6VA,=RP,;;"P10.'(ETM@WG@LH \*=<EFJX04K<890J2:7=JK61-
MU*8__B3BK\BU"G"LP]N<!8F_!*H-0NA0O"O0@ .(67 "MA%:V#"" H89FFQ"
M@HC>(K0!K(%W.B$1H^?L&?CI=L,7>(VF;:#<JQ5RP]UG8L=#N^P&DLA<"*)A
M(FJ+&HZ,32]$%G$<#7^"NL)"%01K-\Y!*BS8")XWQ')8(.!M3!-8?D7"E\LR
MX"P;,@0^#IH :_,0TE8JLB0;_]N\'/,B?8'Z:OH4%PH$BSHI6C/65=23VN\"
M>"+" '4*@W,T%>\N%A1<TQ$]]T8*,HUXS*F;R;M\[L0ABD.=@SFCZ^!?N$4O
MA[MKHA4]>@2D@:BB1##@56#"BX @0-H<VB//#G(S5IT".$AA)?\(45W")^(F
MD@\.Z9T6#]#.&2%>-+V6#XZ5A98>7<R+B-'05G]W/7A)AJ#)TWR"!-=K\/[&
M!O-$445!Y%C'94Z@L?-YJOU(9(2@Q$&6\D!@;=DZ<!JLHJ$% /9K%O(4D$$_
MQ5_0D:AAR ='_WZ*\)L)]B7H/BMH(:$4;_ /WEA@8*/L2L]>TK';W+\<NF;Y
MRWN5$'IS_.Q#&?L)A\QM?NI*S,\E?(HC6\[-5<O09/P]>C%6E0Q;M[B-Z^!-
M389/YS;. #A"A HA&IB>\'+/3J!76?\*20 :%:@=D.P.J>#W\&ND,'"A[,4C
M,#@!<+T$_]!E5D5#X'T-,+5EUM(@E:$[0J8<_P!_@7]"OB,H"QX:?QAG.%J#
M7Q"-.*#G;C">&-1L&$=\<Y$OJ3L#<VC>%2BW(12.8;L!.2 JMH*]JN=-903!
M!@T?P%T471\J0U-<<LP?9J)/W'V1XIL<S$JS910QP@>Z+@):811\[MP*$@(#
MZI"H(P:C]1MT,HX8\[93E62K4.+X0ZUT3+T'8(+M)9RB*QBZ;)MOS6'":!.,
M<^U)=*0H%$OWJS-R*C18L[YY+DA[IMOF1X.TQDH?AT&MTF,*"R+<(K>IR+QS
ML+]!OC5&*[E$;4)S(5N;)C#0@7;H\79A69CTQ67KK+8=1\K)'+WAZ&0M79^4
M]#5<;Y!'0=E__B*OL4_O(%N"PAO-R3-&<)HQB45R@D++G0Q#:60=&812#L48
MROBYI>^*QY!C'U[?>O+7AJ3 G:[YUT2PV"*C[=I:J!.)+BWUUOPZW)+0TN"1
MC!]+H:/82/&AM4%V'EDF305AZ'>MF<.Y3B/?#OUD362Q1!4G@%\R5[]0T/15
M3(5W78^%'@ZN@1&=\37>#SBQ#?@&=),JRM2[V6EUBCFB"<;NEQ*TX^O.BM71
M+^[M6QM),)?MPI+HKQ?ELK"$'F/1\HO&QTM',JPIFAVX9F/YANI__\AIP3"S
MK4HWG"8KA!B6R4[>R-2&2Y2F.K%D_,]AID T#[P-C)Y!Z!-=E,]MUWT$#,/H
MZ3=O&UA\#RSY:;UJ.C$D>I*/5)4(.6TWJ\,U$Y[T"K55=I[G#4BJ:.+I5E (
M/TCV>5\W*H6K9@"-(4[;0/DOVRIPS1UYD 'W7B3<4.%=H'*+&K_/_Y6$ ]\/
M^>!;IL$/BBZ+.*9UO;=7A P_GKKQDT@"Y7]F[-+),KD9';2D6Z,4U+,W06O,
M3S#?-*QQ&X7*F-OHKYH313W1R/<*1ZM++(3A4APR"6COIF0QKG<KK9/"@3K^
MF4 ]$ ]JMYZDT?11*)W7#&_^:/JNJ#A$\ E+0NU,P:@YG#";6+<,K!;1*56A
MP8V0CG"81S*S=V9G(B"[/@,!]:&6,_E4E97"IA#?2MRB'";>JET?)U\]F<ZU
MVJ.I1)"3?(.95/-A*X%2M*FWZ]J#VZ;<28#L"(]74W#%@JQS6(:N*^06V[%.
M8(]W'1VUL:!M\T7-[HV=>-ERHA880YU22)32/*-2GC*U9.Q-$_*1X_F9L3A9
M?CRQ;QZ-=NS)'*UC($EWV\0HO>6M^JV3T2HVCBS*BWH"(8 +1J1OT?P=W$D'
M1H'0Z6M[M<ZC?.,0AM&?- 1Y-DSP9&+986RF5BMIDSA8Y*?O#5JP6=@'JPVA
MN:.BNYAJJ/@KD6]ZTOED)^<@?*D4:]QR;*721(6V.]"O%I?I C2ST5/ARWZ+
M!C_@6/[1-C^&-\ Y6IS6WB,=X'6PL^D60G SWMV.!.3AWD0 1JN:RI]!!K;Q
M@990EL4L8;.\/LGPN4[#O*(,D*>%8--NTI,1:Q0)>\*-5FNED 1+M+[^L!"<
MK._Y>HAB\0!1# 2(8N<M1PL0Q2Z"* 9MC7M7)VI[$6S)!5&Z2$R$;*.)'<:K
M#A EZ.[,U75GHG$.3U=M*;UPRRC/Z4*E;S#AHCUB6>K6T8Y:(50ZFI\FB4XN
MTQQ5E6TT+U'/)&O>'.U8B&9O8C8NFL2V_R@3A+?\GFX^0*,&UJ(3'[O+'@M*
MHKM]Y.Q[PY?P1=+./LC-8ND[V%OPBPL-B9<'SZ1T._72=BX6S1S=X"2V-"6S
M;:/<^O'G5#X7[07*LD\$?#5)_KR3V^\&Q[)9?%Q]5_+W4S.\%.]NLXH]8IVS
M9G(%#([P/1$XM4I8&%$2RUNN@S7:I 2HID&#EA99W=U"]3"9O"N2,J!],E Y
MA2?"7@4*_,IKP!Z*>HFU%6M>KI+HZH+TKK(XC\BT0^.#NGU_Y5"7GEGMPJ!%
M,YU*,M.?M>6>J4Q1!'U\#,<K''K N^HSD9O]K=2E?&F6AK#; \"',D^2>9.N
M%[I"/U=@LJL^41-[VTV]#LE,/!Z?Z-[59R'Q];I1NC5'!_D=O&D\L9[TE/B&
M&XGO.!EQHJ%GVR5A<]_0\](HBB4U5->6/C@(DHBD7CD]\5Q=*#:)[H\/:!?4
MWY\4'89 %[MG') [%@1XW=Z8LG"J&B?-(-F<W3S?2SRX6GR \GC)TPXG-/EP
M'^:U_G<55M.$-#TU"7%9J7;%?#XV3+>N4SR\!M-2G>U%:5J<1)3LHI1O@?+J
MQY_HBT66SQ]V.!)5<[_1T_4)A"\!><"H-W+(<@I'QQ:;BT_"JWI= KE56>.&
MD?0B1WW,_+Z/:>U.M+?>Z(V>U,^-E<20SU)#X2"D+M7SQQL+D'.G=F;J-KII
M0W +8O?VEO#Q2A94>F&W*AEI43%BW51AUFLE8(ADK;1C5KD40K5^=R?WYE']
M_*:4CM!K?C5@"O&$N; )84$NKZ0",;X=&VQZEDJSLU;,R F53JV#5.!4_;QC
M^9Z<;W"^W)\PP4GJ_8]7.&7R>5[LCYE,PHEB8Y2=Z0QH;8?E0:L*Y-25CIG(
MI3S(5"5M)36FC=ZR5F;$C@UY<<H:O<"*_7D3)UG\E!>X4.TU9W;ATR??17UZ
M?+R=R$B9#5$IY<*#!J'EN&WK3>KC.NX#=3E<B@-4 PY9@#8@]R<WT$5/&8ON
MB\O0T3C1,M%"3#3<F%+=K:-V0%9P,15)/X;>=QCTV0IA5&[H.\;TYL,T:!G[
MG@,U%XN#3_IF]&K@/NK5SAU1/77.EZU7ZRWH9CK+=PITEDA982[5R6]8J"/)
MQ^3[Z]6JI4RC?<OZL_?QXM7J,[CLY345$Q65D3<$ 2D=&H9GZMXF4\N,I(U<
MVC!*0\O$%W1F1HKO3F&>I\HLT5\63#._9HC.Q"S&LZ:8FD(/^<P.'32<HNPL
M=*>0H5-\6,U+)#WXU L:D>.,%?KS5@F)<T?$[S@VIO(P&(;W=XAPTO%T"EPG
MHZ3:#:+?+I##6&+<J1C/;);OTP\ 58J@!#)>2*+UYI%U1B?$Q"7*QQF:\I+=
M?PQ1)EZ\FO@<!;Z-"7PE*N</]^Z:=9YV%=!!F:IFFL!LJ/0:'52R17.&WJ0A
M/)NU&S3M$=AD"Q;1"-?*R4J5XZT*KMT\KBS?\1/Z6Q/Y=W#P%#?+Y*95>=OP
M]@!>RJR^,8G[7$KC75G<AYNF<6\J'&]-XC:W5KL/AAF; +I2'[&4/I7&6!R.
M7>8=)7%O2MMWIW"KMA&;YPEMQ/2EJES)5;H4H[10"C=Z]A3N]=0K<AWUBAR(
M0.2#(C#L#!(+L- ;-"MT^]5T?)/<3B^O7B-CTL[5(J,!76FR5C:]LFOE$LIZ
MW,<>R5W2]OT[)#U"+HQ6M0W=B;9'8;::$'4!JU?R"ZL7<1WU(@Y$@/B@"*07
MY:*<3-4L8M&VM+DFV]$8N+QZ+6,C.A;I#:H$NRV48^Q*(I<Z=3?J=9>T?;=Z
MK=N16*W<CZF$TA=[R5%-56T2J]?S1/[4!N1_G]0U77Y+\K 2$^W&O15S\N.'
M+W0ROEAKV6Y)ZC2R^16_':^2Z=53;G7V.W FO;#AZZ#",]3@%\;DM@&Z\'$9
M&8[YX55_93*UYG91KS>)@@B6'8KOZ Q8.8**Z\\HZX5Q;I58"$!!T-$ZT;#!
MV6K&WK$9^S/YRTDB^@G@-GH(.80X]RZQ4SXI6JPL<B^\6=.>P $A_%XAG$9!
M2<5K[0WCTU^.=_#G4$U(H+=FJDRXV ?F.%X7*]D>W<_28FY9 _)F)M8;SQFT
MA,^@)<91XM">=>R)*?(B:VPZT'HT!$R;IZ7D#,JZK@S1LH#JT- CGFOGY!9-
MEV:;994!A41[E1O'VOGN]./I1/P6J.DUX'-X;>H<DNG@Z4-VX)].[P'FB5AK
M1E;#),-6$I4AOZ:*FU3+A2(Y"4<2<JB*[!I*BW.:HFBJLW_N9'1U1VPT=\XH
M-\6])>V4P[U!L MR&5=,%>-9>\4G&+N4CD^I:#DCSE>G,KP7XU1Y.UF$RV&5
M;@S"86)4M_JB_1E.X8DYK&HBND!.X>].,J>XG"]MI;;A:+ 1EJUB55DEPS"F
MCB0>3S%&AR$5IMSAGL<N_>3V,7*24I=, ]Z'#KTK5FBZ=,D;FN*UCV\(62S<
M^ 5/!@SLU&P+I6J"(;)+@A;T1CW>SJ-S>+&7 G)<(@I?%#64PIL[WER=#CE.
M1WOS :L6C!K$PTYE.[URP_)+-18Y89)W@?NQ63[8VH+AAN.X0M!]6X8XL;%X
MG6YSZHY\IK]I4T12W8'3E^&__X]5]'_@,W?;L?CGW15.'S45.-*\/\]GHKZY
M7BH/%69"'EAA^%,83E<"EM]6:5.#5=R-,R=V%IUF3":09;?N!UV_2[U?0)&>
M[%J]674<4OIIOJ.JJS6Y?&=&+)51$BX@UYE9JJWJ->'])7XXI]YC91N] S9I
ME&W-- -!,G2U#.A )XTU^(4W.JE01IU>K?EV8DJ+/3Y);"?Y?+NZ>JU7*CKA
MN7-*I]IE^9W4@YN&1Y76*%['_\X,S9YZT@8#>A.^F=M!]_%J.*>?YFZ\WR**
M_6)Y0Q3H(I51^[E4*O.237RIA.@2[,W5#;-6V2X33-B(1BLEDU^L2M,??ZY5
M$/%I"J\+,$929MT<36Y7O6X:J%-:>6F%>FT*T^9ZK8ZT3E828[6J8L;37<&F
MT"&>$\W%CR([+/5X2TMA>> K'WAJI)_N@9C/;TP@$4>[R\B07>[(-/1.E#U%
MC::.RR[PZ7* UN>LNG>V,+ X"E6A W%L_N'I<A2M80]\Z<5'RK> 3KU#>KT1
MJ*\*)<L:;LO7P,TI7,%=J<E(*;W.<$0AW!CV5N%PCA97-UER+$OE8JI;2))T
M?]'.J4:+J6W[4$1C#XFOM.0X+W] 4EQWV"2U)!8YJF=HRT@GTG[W$9F/+3.8
M2C6<JF[6#:91[]0[H#](:RJTRJG[7F7<4EFNL+:@[<4HUP;V@&;AA2.-8\;%
M!2I'B+UT'.+<:XOO=T[B^=<XSHU]$.KBZQV%3P1'X8.C\,%1^*]P%)[U\(2J
MPD*95PKC*1VNK)=RQ1XG(FH+.L7X#X>WNY'-I#2RYM4X3=@$F8N%R:U!LVAD
M\NG(I6K9(X8G5Q+()]F%-+,':XH:DV/RZ<A6;;/JLE&28L+3;(.8R+JY&J.1
M1T^/98>I=2<1SQ"@L2X,-*YAQD93./+HZ2S5G%*%%9%E^CE>J*4G:2H>;XVC
M8^+IR)0N3BC:'I>8#5#T!)->*S.%@B-C3T>6,O'D(LKJ)K$ D3Z;EDO)>F8Z
MCNWN^4QK@1<WC2[CB\3G'=&//WVG03-JC'8=;W@CIWQD&7PQYHQU.NSMS^&[
M;:MAH&E;)HHD<4MXZV1Y/DG^OLY&)C>#X=<NYCS:TO0XV3#:R+:8QQN;J2$#
M"*)=Z!+]5)HO+I):5R5;%]JJ]+DXXO$M 1*ZDGC[OC'&+-L%$@X '0PB9*B2
MX+?WP?]2R.^Z+X3L(>=XK4,O[P.H<UW\<2!E&=Y3W;M%G!E]&$,O$7^,OHCC
MZC/JOD<BJ @!RJM')>_O,+KU;R=,0NFA5\,3-V;$#_:&LA/H@FP+7",L>1ZI
MT7?=VP7#%VU^&K<R$O#EAGS!4TP])@,FW)H)Y",9\.#^#!1<3+X(K!OPY39\
M"6S6??(E,&-WR1:H+O& +Q?C"\9XQO]=;(5RI7S:*Y3RGIN%]Y@8(GQ.$<A+
M@&:*GLFJ9OCHP:EW$/:BBXF;B5;J5)+UK"1YDT_\[O-_Q?=\X^E_-'J]!4GN
MVH1<7(52[S?"+VUKT&M@<*()]GL4EXS>_D(->BUPNC^!\'K='(K$VR.4:X8C
M7TH4+AY>I%ZCR$N,=_9+CO]_)LO@&$9W$\ [@Z:O0W@;->05%7P=/6GL=YV^
MDNW\;/Q^%_'(C:4H4+'KJ!@NY?PBRG7G<A'_3G*!JF[,<T0G^]JVW__B.  $
MX:8!2]9?W+PK;SA;X'%GL_5$_%QF[_JS\XDT+D3P3S?Z=+H7.#OP[%F7K,R:
M9D-PJTW<8I/]61=?^;%7D(*C?DB@D@IOE')KH;/%47&1''67="6Q7O!5I3A>
M@D\<'#CY6KXXZFF%.BH@:U?'*M^*KPA@VE2X-IA5<BM4[$7^^)-ZB";3)XZV
MG,=7W)D\O1R:73/VNB\K\N_ @'S^/,LM3<A[SK:<?"DO@X4/N^Q^W)7814Y8
M%2 QO?44T!QCAY.=6=-0P2:"K$K\QQ\R]9@X[@KWA:W*M7QP_/Y5Z P8W&?2
MBPYEI:>+#;M@%NUZ<Y3.9Q-5U$/7=T3TY)-R,/1%9XGZZ*CB4U''3P([*8^W
M#)9L@DF>3A"DWMI*Y>5&0%*>A%(.7^7X[,K7S?5=.'3^+CIZV_3 MPZ:DZYF
M=\7I@J=CDX34X*)&N-8N+7+<)_J%?R!HM@NS?A..E9E%.9,N6.%I>-5&YQY0
MT$P\1)+'#4J^0(;EZX3(W\A:?"5K<%\1\-OMP2TBX-*BG5KQU0W!%.AF3 _+
MZ69IBDS$Q2/@[Z(<E]W4_8JQK2?Q8R;<3@X3ZSQAUQ(1.MW4*P*[.F]L:\UR
MW&(<9N+T8JMSDR1!AMNQ%91?)[9-GCNVO;-UV_4]VU^:0CZ,EJ,P6N8U&QUJ
M^VO#9;E@C:8)J5F1^FLRN1Q'!U5=N&Y2.*>V\@-ED!]*#6+3M.O"4)VOI^,X
MCF]3#_'X<<O>+YR_^1(A[YT9ANN3X68YY/LBPSTF.6\B#+?)AEZ$##AB^B\^
MR_WG**ZZ3F,>[WC%QUN87[[=^E$WD4^?$G$:68S9=(3CDB Z9ME$>AP3.#!.
MIQ.3,1^- S[))4A>X)^VON@M4O&&I?2FC-@QA$:<+'?C&PJ%_T]'=L15<]8<
ME8<,R=;I#=%/;&;&Z;8?&K]9&HT%230F\[DDTWQQSJU.M?W0\HF!1>E92MI0
M*[8Z(V36FJ%[IIZ.G.F5?K27:(M$Q8H3T8'=56K&ZE3;C]C2DCK-UCPM@0WH
M9N14+<D++6<G^' D(".1W&1&;FDPCO-R5THD,\N6L[MS.)+4I;2N2#PE%9JE
M]E):@4Y-1R./WI,UQXO)NM6M2ME2HDQ3O; 2+;9\K41V([E\+EUKM>8RT<CG
MXV0C/M+2= L&)\<C2_G*C)8I70J7Y^(XUDC-&^/6.'$\,LG,DM%H/%YBE#HW
M6$X3964]1"./YJ[1H#;+4'9!JBRD82R1H)O+]!2./)I[>[A@\E&[G&+"3&S(
M&[)8YV0TTIO[I7ME[-O[XX9HJ.D8OJL+1XZA&G#CN@QK K[I J$==\S@2A5N
MN]Y61#J;CY"+,%"%=:5U# 5P>MS=0 &D_%  83SGD)\L-^BX8KYU/0'=H#(>
M=\OY3*X^:1"=W,",#:2AG&:G9U]-O-15U6FT4E)1@9FX!$V954T'#OMD\\-Y
MC<CF>8NH,H7.?#LKZ!&ND*2> <$&3AM4T;MY2$=W_XV;TI!$A'2Q$G8/#Z&G
MX_YZ: 2E.$U2T=]MU)0:]8U"L+%>>]7#ZQXQ-]D5)*X9XE@$.RMO0A.$X@D7
M2?#2?7O6=][YH/\V^F*/8TQ9IWJX7G,+!KU/';+S:5O> XZBN;F9)GVRWJ;+
M.=*B[5J.R.@Q*O*D)>\[UZ+[#%>6U5'_):>;)J0K,): SVM&WK:@Q?):.9X4
M*UK*K)LV'6E(2K.0'^I#JI'!X(,/,3+YD$R>@"#<-SD]:'"*V_&R2U:4<2,=
MA*<DX.?O$&7\.+^.X'3=3W!(R+0G<\!97M]R5450NU""#0#-RX/_9P?NF-5U
M0UO",9/-R5[:$PUR&J/:B :\4#/,ASU^+[I !J;I8,S^%']];<DAWMH+_<U"
M0V'ZOR@ZF461J$@$DY1(.6&76ZM&<MU#_7&CY$,L]JS@/$!ROYW>GT=0/C^U
MW[('\CYJ>W3>XRE[[;9]R:4J:UHY=H,0HA WAH#=>XH#F-[)@-G4"T2S+B5B
MTT472(-1.XH8<P*DUVU$[^FTKSL9Y G6$OC4$,]NO)&BH@ >@:M!&Z^C9KIX
ML(!?R0%/0\8=LACRV+2Y6<B$5$&8""KV;;X>^-!E\\ "AB*JT NX6GRLM3XK
M@11>Y.&E'E@;]C"XW?+.;SC&2,-M<J&LP=DBG1<%$?!/?T-X9C!<M':_.#[L
MQ ](.''_V?]JAC=61[,7G5Y\.->%X<V!HLO:!B Q]]F=?>=:'1@F?OC)V;]N
MPPZ:&>_&'4PLM$1@>!,<E+E,1,\Q4==PP$*.X&F&6*]'NM-8=PI48$!.;9S+
M4?.#T!FV:=ZK?=4TJ%;,=GU%9-N-L-+ICBEH68Z#*MXVG@15!SVE<4CJCT@I
ME+&=XOEF-D>1.H4H@O_7@Y/?=0F/^)0J:A2)S*#<SC+90H+5VY4.G0I#I1(T
MV^W>A_O+/\TY8-K.6"B8+.8"8N8=D?5,I$/X>&9#P)]]-.-Z4I%>](0Y 9:#
M3)WZ_^Q]:7/B2K+V]QLQ_T'1=\X;W1&&T<+:9^Z)$%@L9E_$]D4AI$((M( 6
MME__5I4$!H.W-AAA*V*FCXT+J:HR\ZG,K%PRRT)U _>,(E_8L<-RW8@<.DJA
M0!PP BI"2]0C7G10OQ-4_EF"#+Q4-8TP)<GUT$>4)RXTR'8-(1%<0,1#9__^
M4U1/.&:8UKCQ_-I[R&6J2;]DO^A0R<%SVN('7@?<E=WO6,0CGE3[NC;< PR
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M^D]EAR*C:?HKR0[RSI^IWMAK:O(7JV08,M,I9J)NBIENF752R2_&.N0Y3NF
M95^@3M3>%2L<-04.+AM[IN,X8$N]1@X:LO\#M@WGJ$SF.0(#EG3XQVFG[V[S
M_DK$3M&03!WL>NZ6_1B @T[O+:!I<'=80ZYLY8[S@B;\,)[Y,++*DH-*@M,7
M?#E5WLRZ1O:PX3OSCA!B/Q0!R*<C%?QW[X(,F5U2:[^XM*SL9#KD\O?E6;%5
MV1C<1!$8@4&1PTR2N41.JW>X!HR_0D ) >6R@$(=  IU7D!)14!^DFLE7#XQ
M5CN9C@+Z0U7Y?$#1(X6<[I1F8X[N1YAQ7)V+[0XJ_Y;X\4\Z085P$L+)&>#D
M2L51 @4GY &<D.>%DW1OD5_(B4E]*F9;ZGPZ2;<FTA7@)--JBL-.O<1,U8RR
MB313\59/1[FRZ1__)-(O5=RX/2]KW@O<]P.?==50;<?"-TRWX$(-K('V)4H%
MO1:;\07Q[2/VER]*$-_8 T$Z!#E5GHUJ;'E#\^IZJN6U--<O;:X <NFI&<O"
M5[>F"3%SKU&N2J6KK!!#1AA]1](7*3?_Z>[RX*I((4+<)D)\Q*!Z&T+,>VVK
MNK$YA<LG-*E=H2H;BKX"0HQZ7;M)FKP[!9PX=$&:'4T?4"&0!'+3Q$_DZ(8(
M$2+$.^.BOB!"?,1&>AM"E-.I643H+LK3-56.YS6AODGJ5W#DNM5&5;?7HLJ+
M'4>1M0<^(T50:=(T0@B2(<]N*@7,L8!2\44+)45#\TD&"Z"9,T3;\+[KXOZD
M:Q?W_T3]*H"K#Q3@?L1HVTHP1-S[1_D]A-OEO1J3[;D:X>:U5>DA+:N;3:1Q
M!9--'[*IE2FO>#HWZ;.C36.NQI9"')EL\=1%.AV$;NX0ED)8^GQ+\2VPE'1S
MRDK(R2VR=C_KMW6GT#,C5] "']A(,L<RD\ZT.W<V]XRANIJ-8 G;B50\%0)3
M"$R?:6T&</6! J:/&*AO :9!K4FW"VR=XM:;=9>I*2+;+5]!7[+=Q;#7G0]7
MO,LDN[-.-\]'R@B8H'G*,"^YKV[I'@^7AO[Q3]MT1(W =74PJ*3_/JZN$U[I
M?013K]T?XY,"IJZ]S$!!Y5MK.GTVM,VL=%^8I.W%-$$JRGP]&V:&'"LDD"G(
MW*53X>U=" 8A&%S8H)NM1N7ED(_S'##4%3O)6Z/!Z I@P&VRMF8/:F4R;YJ9
MA=!@ZXR!:N8G$!@D+AD &8+!]P #YJB=[G<'@Z=&E,B.JCEGUIKQ+5=?=++Q
M0KJN7>'6O@#ZO=E&X*5IPA16\XZP6<HJT@S2.*[G16_,B^UOCG['U1GV:E!(
M&K0,$2^-GS2O81!%+E&$XME</#JV%84=/^0B5/)I;8E__<]!#8V=VP!5LC2M
MWUN^WEN87[N#QBRN@(A7HD,<P7?_%K6EN+;]A2:AS&Q%YO=.--!.$!099>)_
M$7L_HQTYVDY4)7-OTPX*9?I?.ZR5N?WPE5(A/FT<<_:;IJ*H+*<.?_47%H.P
M'K\0M9Z@%/-(F_^*Q-A"0O:_[5KV9!8J^AER'Q0>[2 3U?\(FK^X'JDY(K(F
M+BQJ[T!>_.>,]7B/LCA?30?=+]G+E5DBHYI^@8:B(9VS5/![9O)B6FK5=(#M
M3=$QT7X^%M3-J89H2*JH$:W'TKH_=X5D?SUFL[X(#H>,?8I?=[U[N!R5G$M3
M(S=-3$1I RJC57*L0 A._OCGL,O/L#!M)E@G(D_GY0>6SX'VM%Q'G9B.1G:9
M)9BWA'MEFIU+ R6S!.F8B-)%8D]'&NPH>T^Q69+L#@VME>O&4FV 1AX]L]#K
M:#6AP57)Q'+FFA'&%+.KI=>(_'#DZ&'&#JOUC<)GQT.%'96J8F^#1AZ]?<[&
M%F):*]]S":I<:D@Y4RAE&U[GU\.15K(7Z?0FHDFN:]EXRJI'(AO>;Q/YI N5
MK@V<=)$2>%KNR&60DV?](NK9=/3V2(UNB -FU"+SML$I36:Q7I=9./+H[9EU
M:M!3;'0!P&@I)J(,(YTI>[*[$TCH&9!UYU,Z4QBTRK4I$"4T\OCM=&IE4DVK
MPK=BQ;3=R]H=SE:$Y/$S&P.R=I_>E$BNUK+B\<%XS%BII9 ZT5>KGRUEM'4O
MRW4KJ75/XS-FN[ 4TL<C.PD);&)Q-<MW-8MJ=?G"2A<@UY''0S=\;&J8 VY
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M\_W=O)U'$N4+%#QRX+.DLUAK>Y(1L8'T6W:M-1"MDW(Q?%TNAN^6BR;01=6
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M"G#?00*_G<)_8&5=B;YO,=(^1MV=^V5+XRUU?0-.5+;U_>U3-TP'9IU>4:?
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M$F:K47DYY.,\!PQUQ4[RUF@PNO+NI4?UVK@TM+J\+FBTU992S=P0[EXJ>EQ
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M\\(XW(:5NE OSWTU#)=^?AZS?U+4+V)O!["\'^S!)5MF/S^O,E @Z-<M4P(
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M G\5_;5J6O ;&/>W7^I:C>XFOBA;I,BW6I-R/T<ORG]X*+;08?.FT["S:C/
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M-;IL4.O3J2G&N?O<EKOE8O=A**9?&]+C=7^J[:/TE[&ET%(-W,53#T'N56V
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MC? ATE3 B<&HD?=49?U<_\P$SE11WZ4.1_!Z+&MI$I%V.RW@@!%IC\R@^4D
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M/$R3_[9-2QOA_W3<GO'[_P!02P,$%     @ 2H9W5F">P0N +0$ UC<! !@
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MTN>>X3WZWE=A!?F[!@^0,''.KL4?E\]%\]@V7I4V9EA;<=%J/3VBZSHD"S!
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M\43 UG8U(1<KKC<OBSE@XUN8=@_0X6VP/EMZD<7D<?E0:B!%/@FRD?G!D_:
MHP8'))L@L7@-K>[GT4?:/I .-\/\='Y/KV/:!^@/]/::E6\%KDG;=(R2D=WG
M;J9+RLE_>\I&8)B\A*"LLU56T@ ^3XQ.0$#LYLYB?^BI6>)HW$5 DE/_+9=P
M,&!@P^2T$?FBMS5$IR4$_/P$IJ_CZE;><C VSEL=:5Y(V(R!+*I9C613=%O'
M*F#6E>&5*.2R;;"=.UUBB47)U,$X]GB0_R[QHLZ'[$^.\R52VK,YJFD%1!K2
M;!M"<\VI8=P5_)6]DI*@])O; *E<X_[_R<FT%JW)M97#=X,H_WK4-9F /_C'
MU<EF[A@-LRG06P?;6AXG#TO>"W_Z$ A.6ZF'/41/=CYDE"W,*9/1,;O)G7WG
MG2R=*IHIJ/FM7I+YW?-DP:Z' T^B>&/BR5*!*Y9'Q15DI4P13R*NF_ %I4V
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M7.SO1%@2Y8L4_'G7[\B8[U;X0AF@)VNDMQSHJ*1 *?69J9JY*%M0[5R=9:6
M5W# _HCB[4"^5E-F0!3;'6,-=7F<2+V%WM][ <A61K8+(6"A,GK\"2EIFM\\
M%H4J5VIG>%E(C-FZAMB^DP_&ARYJ$ #*A 30R5;*E38VG<1WU2ALNAV$K:[<
MD^B'Z]#H_ (B)#0Q,3'+F^E,<LI,:OHVR*WBJU/[4.W+:CLGT_:S;Z2Q;\$U
M]N>^N>.1^QH'[(L,:/6;:'"@>[F]E].$*7S[V!1A]';\X-O;3M40>7V>T6D;
MVZ[O&N&]2%H+=) FR?:51UI2[:Y41VW6EFH5G8X2-6)$J,/&1ONMJKAP!O_Q
M'<67Q!YI@74Z_5(FKQ(5Z.(?_28?"B=^+S%@&MRQ%MQ/&Q]X&WYT7>4WN)FA
MW56;_"5:HVS3AEX<?\"N;OA8G"O1QN4'O$<=5)8BME%JOAMFH^=>?C]FW#B2
MUK=;/%S?OM1WB3\*#9M#J/1^1(NO/HQ?FQ/@][#REOU:6V?AG#"CG),Z/<].
M]9 @J%]1__%[EB]_B3!Q=S]ZI^  YVREJK23O;ZQL81I1LW'6Q=&;-*2( $-
M3::T)O>\.7.-Q#$;%]'=6J>:-V7=CL[FRF/D)Y2OQXS7G()$_J5!P_?KRWDT
M9^MC7AQ2VHF%Q4M'_6RX<Z*SP<I)#_0_BEL<4?$]2N]^-UC4:W.35[ZPP^CF
MT/#7WCA@EF(F^A.'M &I2-_,DXAE?)]?%'&FJ#W&PJCRN8X(NQ<E!+UB0V_$
M142##+WZ[MUO)."2>"<L48:\&R"&.@P5_5);/7Z*\+5NB)TY<'1\MH(QU$6<
M?)8D3@S1U-EQ%+S6_YNL(N9U1)1]S6:E$*5O<6H4,,:7_Y[C1"3D$=X;>?$#
MYD% ?AD'?(.R\*+C2K;M[2%%]N=PV?+ENJDR%KB+L$K1+3$79-"NK@0R[LL#
M1R^9S:'+^P0],U[GQNWA13L-R4C1^TO&_;RN1W$_!!^[]C,W;NL7C(M>3G1)
MBF+LJ3MGU,1\=,MK?R?I1UNM/S$L9B/$5WKEF!V^&AL%^L9_VDA]Y5&7M-P\
ME5L37P;>4%@X:D7#2>-:W>LUAY2=>9*/-/N&GU]352Y]Y#P>TPY52=&9+)RJ
MNWP:>\ !EYF#%E/\JO-ENL],0O]>F3AG)XA^0JQ%ND562:T65M?BF;SZZ.=#
MA=2I9_KO%>\!42&^CPR8[_ 4!;=*I;&G/45#U,U8M!G5*&N4UH7H.Y_'Y,>4
MAL9V_S4 %?E<[&7Q'\F&E7RBAC,;CZE/QC_!2H(_)-H_9BG[X^;#_#S <JVA
M;KHNBH]SA6QW]5$@CY92U$%X@\@>86R!.5M\AG6<UDM&*"M9ZQ/?(KCAV$H@
MBZ.:.M(N>._IQ]4%-X2\*7E_XH[?9MT9DLR>Y5E-Y*3!Q-Z9B?*":M72RT3N
M*D)\ GR\3C:V:K:F,G_0-[C>;(357SBYZNBF?A)?86M5,CU_FE#J0RX;O&_
M=XD% N%U?(5L O2A*CH\G]S@#>8M7/=W'-A?K+:;>4CX#N5#U#T!B5&AK%2F
MOW?ZT@N-/YY7P^?@\E9.Z0WRX/LQ=%Q< '!'A6LAK46!!M#Z'U*]9ABT-@:N
M0O6BXN C_K1!<Y.:<I:*%/?!$[\,/]*-@^N/*4+[DUKK@2VM_5^CU28W;)EX
MW"<Y:Q@[990VD/PYYS]<$OP_VO" V0A"V$T?LKL)*C-_$S-M0->);,$Z2TK<
MU_*;H"<>^48KB);15+,/3CC Z^5==F\"B:LCH]IY4T=AWYAB=5]+*1Q0HN+5
M?0U]?]KW29;R:;DO#IB7LU9[M- ^E@ ?P[3=86,G6JM\[*J.$<AVA>ZS6L&'
MALD;:-.G!-D*_?:!M38N]OIO;N+Y]<=SX<[9A8A^*W>6,=F&,CG]PY_G"WG0
M#W,78CDT!K 6Q%.35^4G;-BC5'_+X(X]W[$B8^7XO=8^PQ4UV\O4R0WPXDD6
MY:SD[VKS7L]-L6B(W'ZYN.!^?S6K^/)=N7HZMZEQ#F:J N)$1Z:LP)9<@:54
M'.#;LK, W8J,G5DY2X>(JS;..^T>FX,.:=,E5AX1$TQ]E\4K-)DSE<?,KV,G
MFJ+<^<^HP&/O[QC$ILI<C&C^-C=F=[UI%K],U0IZ-=*8)6C 51D0O)"A;6X<
M7O$M>Z^2)AXZ/[&%&3T\<3X#0D!/A8PF=E[L^[(_'(<AV/3LE) T#OEKDIWZ
M,BP URRP6>1_+^I27--U'<%_YBCJ*NK^?-F%W=IO7YOX@W*IR=*S\_IF=IX+
MK\!%V%LR;83K?%N= N7>;M%E);L:#DA->Z8E4P!7%.QF![DG=YP3VF;SW12$
M)]<<UGK!JU]E]^X!0]E=I3PXP$$)JAJ_M[)X8II+V9;U4DF;$C-',"GFMS2[
M9VX[=W%9?O(V#M.W5D)<^9?U5^$I\@!;1[1Q$:] >X8#1D 'X';]8YV-="_W
M,!L.Y>WCX#%)B=7\I'+174F.+-&)'(O6[6_3@<>MUI@3O:7SQ4KVR/XMF%F[
M ]O/\Y*#^4?^'IV<99V%"PI<V>Y/+1;Z6X8N99+T));QOFNR^D1?X8T\<OG5
M)O;4KBU+MB&[*=QK-FWKT.G @'GLP\NM!%F;R!D>B)#^XCABTQX64=VG1J%R
MA672.3S@VVMMLH.F<F)IWO#^Z:]"9/]!267H/*U-7MO,6EO' =D?+38L2@%Z
M;.C<Q.PXY1M,#25TF-=<,>E3RH70=;DH4M2U:H?=NN_1S7>1/6Z/B?W5IEBC
M_:7-#:-4?HM-1%8W/5P:+QJ35;=MOM2%O*B^206%#P:6H_%"-*L&BQ5Z]]?]
MP?EJHI=!_C\6V00@*8]+]H15F)7W=;/!)#6[33SFN2I/X::![1M>.""/+>SC
MR<U:WSAR4U8*_Z,9QX%,TYG$Q+%-MZ\@#BB-";]X_7YK(?L7K6RKB@V3U[!+
M.ZT%#.8>)'GY,]M<PZ%T(;#TYI%ZX[&9-WLMZ+IZ 'N_(^QV<5)\DKZB@353
MJMM<0$SBIEWX>/?7'4<P7&;9MJG>9:EKSA3R8QH^9ZNM]_J1U:RA 9[G4?L2
MD"Z.$I43;GM51H1<S /FIC'MK\35.T'A#35@.=DJIWC$9K+=I75\]53\5/8O
MYC#N@IL]+5,E1J.6I1>'/&B]3Z!(^<R\FY7!97Q'TCI[@SCV-<@N2M;TCGWL
MD(._$X>!^J4LZ^]I4)K<PQD<8 .)9B7GNUZD,VR8=GJ YJN(A,H2)SWFR9K3
M#BSEMJ"\#IS03 (%'QZHX@!&0W9D&3@2<S73N=&(>7M!XBX*;F;'TKL)ND93
M:X*$&+:B=2_HM$SZ-Y>4:ET6/&[6Q/]2IG/])9L1S-&/:PFOE+A\;G\A\H_;
ME9G7T?W/\;6L/42TI$ @(P^K?'VASK4V?3E/_/EP!80,%!^^,:LV3N/:FS^"
MKHK_3,LJ ><:\H!3]L5SO*IV9(KQN%B^!!]:>,+A[96NFX-L!5F+I;8XH!>[
M\/ES1VRP>^RZ77#AT)$25SJ3W*WE[AN7@2>]4C]*]4SK=T?-36?>C*^2R5&;
M7@89A1=PG"=)#_J)0Q<"^E%;Y]2H\#"NV*U> SJYYZT6V8,X0,NFY6:: XDE
M_.0?>47=6>8A[7,:\U1"FW[66O_A.+LKHLCI:X<>5_1:XJZF"E*K=M&JO6L^
M-7%?X,39XO#793#A*=]G)8D^$>>E(1Z?=4=PHG3 'QS0,W)PZY3QYD@GDEF2
MF8VIH&?3.*!3QK1?\H](1,D:C^357MO3LI3!^X;;I9:;IF./"M9AHI64(]";
MKP159WV:$$<Z@VICQ/4LB0@.(.-/S[<])15*W(_S*_6$G%,NR#,A[5TN/\1M
M<F.JUS_+:L@6-TPN7+HO.4U5TD(6]<Z.^Z4#24:5#\T>829DP'7?=DU(M%>E
MAP>0^^DOREZ,81I/9H$UKD+-98E=V]759]D>T/NY BC38K.B'0C_#^B#7D?6
M=-Y$$W;'$P@U#F"[X2XOTUQEX-M*%L40@C=[XB[R75;<)!_Y?_8=I2!B?5CY
M'JV7O$YE-%RF=I[^\\"RZE&"-.C23E#67.% EB8XFMH]/FIUB:=_84E]R&F^
M>M)E>,'/2K9:GQ3<N"F9 \\.E#O\IPGZ:KMH"G%P8)U'F;/E%J5+XX!A!5-4
MJP=7EO(_"LG-4H.&+W5Y[5!N^%Q@J2Y&/=_=?B9YHDXC&7E\W,WL%_#K*)KI
M)#1R.E2O.795$1QG6WI\:,&OZ'0R=<JRS#0U<ZYB1Q=/FSV?8]%R;H>XI. N
MWRS& :VUM4L7O-G'Q^'#,7XN'URS_ D2$3.EJ8,(-U]=VG->>SG>R;.H_H:0
MMW^R_7/,%O\*<JB167]6(:C@"6HTP0&4B(HXYEJ3@M6 WTMO"YG_^+7K4M-G
M>5NSZBS5BH)=WJ'ZOX&J#LPX&[(XLV:.5^;3':S^Q!H)OY88E0>L/=>IO72G
M)C]M3UY=1P>6E0QR1P7!4JXEM^MT'\X^]Z1+?Q3^>A*L:<ALJ4#SCIAGK5',
MI/39_IX'N4#/#/6!VHBT=O;0@L0S Z%F04*F4KRYT#X*\6YD&,_*#:4R8ZG*
M39X-^W$O^=>;CKIZI=3UV$4=M[((ZL88-:XGQ*2 %L)T1S_9X&'R+-TGQ,)B
M=23\>3[I9..KC7</DI_H_0Q._,KU2\SKLXQ:-PX@O[9T71XC1XL80,=/]XG5
MLI9,AH<=Y_FYV@PYJ?L9%3_(T]O%B O9/O%^1IC9[;UZ&'(&H96A_NBG5S5M
MU>!3%B#/4L*1M)3)XWW))F<MPR-J_;WWDV[(W>W;X"Q2CG;:8S=]%^R,V$M&
MJ?D<7,9YMOH@I>X K:_9+B)),Z(?I&W/O/F@9\$+F_DL@^QF83V"A J(R7+#
MD>JP"4]RQ4 %3^^FCX70D[%4P8\R-<Q?"E\U?B)-(GZD(F,;@7+IU5DR6G*H
M,N0LN!,%*31W<-N!TKDC%]295#GP\N[1*,2GO\<TO0,(B/^1YI4XS##*)HUL
MW.RW?<VL.<S:W-2+E4B9_OF=QC_Q)8M6Q37]M.>(#()OHZ"V,@PLVI@1YFG2
MXMLS9/1)A,KFG:(\&QM^ZBH2']V_RM<.]2TQLO?C6_U'YR>7:46^N\ [L2"C
MR9Z@OE$Q-=*J^NNY3.U]"=K]VY&-1.?=QL71-I,ROK_^S:2]G9'CCC](QAZ?
M*\,'UT,D-F+R#.-20UDVWG>' 9]I'IY://3Q6C.=EGGN3AC_U-ZO$E%$F=$<
MF+;*RX^WY3'DV]$A<TI<D/M9QE$![;E:[ $A0;^ZXA.3 :V4#OO.&H2MP/T;
MP1K@O_)5=]<Y/BPA!KK:_WK'M$&[8??,T)H=+_R8%ZK:%NYQBW1F"VS&_[1Z
MS!(M;6"AZU&N,6EZ2^')Y5;XG9Q7C9;31(X'HH7OGC_>_"R3N[L"BP"?@O"V
MS<T:H 7;4E+V%W"7\Q\-6F(39:I0HGB29#&29W,=@<N?-(2"EQ?I>D$4 48Y
M_QB=4_-WZ<Y9R.OKFS2A*F#2 2@U,)[X()%>DOBQ('V'S*U3SCU.^8.L<^E;
M7#S:?LG"3-<!=M'\N]90/\W+"0M]6W.\<<N5D['D;Y#,0W@\]Y2]4&I$LB0$
MLK O=2[4INA#K2/^-DO+ @6Y5)>B3CM'OPMA'B7>T=$]*X7.$UW@5Q8)UW=B
M&_XB&Y=B$R,U7S*#%-)#HMJA4O;?/Y?TW)/O-;F]E%@0B8YL><FBQ!HLH\82
MO@HB:,O\LL0PPS&ENJOB=[302;XVS%82/ORD0"EU2O 3Z5<NXL?+19V+^B>=
M5Z.9<L&6]I60#R-%"(?7ILU-D?:FS\#Q0T6#,=?U7 D&P2=67$O%ORB?'A%W
M(ZG,'*XV2VV($O_ 9]++C1 CG_1LC]\K%W[]]KJZ*EJO2I[##1AAO]VW]0(#
M;RJ+E0I[?4&1^YZ%M0V-7H9@[5'I#V&O0@-"[9T!XE]LY7YG-'@K[0QHH]6"
MH_"P,[ SN9S_"/?.@<F( UC#,2H**4R29\%)'?SX[5#^+XEW@B+1V>]0=T)=
M5RSP?=P56SP2=M4G^?8V?&HW:ONI2]@>,]GX#!##Z\%GC]1VHP;X*E:R_%4(
M#81>/ZU]M4';U4C,W<ML2! :IO,WLF8TOK\IMI=UZ1?)?]]]4>-A!.1!JRPJ
MI6N6\?#;H4)Y!H17BVN$K_L\EGWG3Z 47H(R$"_\PY+NN30[6#'FK8+R>![=
M<Y7Y_X64]XIJJOO"O8.@J(@4I=<7 BA5>@=1:2*@5"$"*KV$T"&T6 &I @)*
M%>DUTA)*(#1IH4B'! B]]Q(((>'XO_O&=W7&.!?K?N^YGCV?WS/V6E.HS&-C
MU_-MS0>KU12!:'G)/4&P.762OAI W7U-*EH3J?L>Q00DJ%PQ7*(WDOI&COL4
M$!VVRA]Q"7AWC7>QY3GY9[CFQ>.SX05UWT[W0CMLJ/J(HW:80@<9)*MD?D>_
M.YW(GWAJ6DEKLO<^FWN?+0[F8LQP%CRD.^X?=ZWKSY[ N%,?SBW-)7JY)_\J
M8V<@OWF/.%J:_[TM=U6=-T,:_:_=\W.I(\WG>1U6 8:&$X/YFV;Z2",&O6G;
MT1S8O:U)\Y)-L8,U0MQ9VU&0Z;]V.V7M@0YP#_F/<^?D:->(8?SAN6524,R?
M'#;<GVS@_C@^_J3I$G!G_;FVOW_!2[O^_KX5'0'I=[&89H-[@H"#3.ZPL+)0
MRQ&4(61)>Y]0TG():&<N<W.)MR>:TR5(O&_CL"E2\^K3H0^'A6H<3)3MHY><
M<J4Z8V!G^L(VVG4\().1@J-*JU3UO]I-_% QD=1^%.#1!R]I4\L;??\8R_,4
MA,5+YNS?1J'5,V>U/[2.%/Y,-DA.-W8^4#\^#LZ#IW79,5](E>L6NO&J3=;R
MF/OU^KONP.5!GTDR_!(K/8$LS#*';"T/@;RB"9&:[CF\^1;!GRC #!/$[&$'
M'/2%%7+Z'E#/\P5(O6?56/3Q(N0 _G)27IVZ_?SD8A*_83(S\Z?.@@WV[<J9
MQ1+WE2".#=L.;Y)D4&#[):#F$A!Q\?A P0!#]\^SRK>@A1LO?YA+2LIR]7Y0
M,O'14VI3=[^W,%-$&5RYC46/'5=9S=[T>M[O,E*^DI< ]*R$%Z"._V%')![I
M^;U:ERU.34HAS:<,N7.NRB%(Z)=\+(6XT?WZ:IC( ORN2PY3+6R'1_!ES5CM
M-,4\3,%N3LS^ZT"'6,*S*YK6%ZBS,/>B+0VUI+#@0W#(TP\OP1:XG6NL2?=7
MF'0EM^E+"U(:G5=MI6V1I4&*?V#7PA\$_=+\+...34%&+.K[<V2/^KD5T?SA
M9[<:NW+;C#KVZ[4;E5BT#28_5<A70L%M\WR[%C91%&DJVE/3H!+$NC_>I(]\
M:ER=/"&Y RGL%0Y_3\[:%HQ[/4UP)%%\<V2+: -]=V=(8WP0@Q*UXHK9U82S
MW>?EL$_?.V"M^J=_H+3;)-)#EQPNCV5$MN[O S,FSS3='Q<]P!<3H-!#RW%]
M<92S8/+V'I3P\J*$ *O^>M'?ISF]=0;0#APINSEL^K&!V*5*]04CAJ&+B03F
M-<+RL$-Y4V\W>"V_C_02NDE]:4HX/A+*^T19X^3M)N&>^.FKKDN  GZF@RD#
MS@ZXHG?:2EWRQ\Q2'[P$4C]WD[FHO 2(1W<7[7ZW5UNC3W@D.EM1-A4ZW)6F
M*+-CY02;[156S98^N\7P=((\R*"58U^?JBE*E[ ]9F'38@0D7E.)H)$,]L[\
M%[X,F*S)\?J<UQ?(2YXI1 N(#W2H".C]'#\W+?0'98+;0SF1)W=C0J<T.ZGH
MNJ! V--X,;HO2_%6>XH7:/GJ-S_).DL)OA]G7HS^%A/Y=<,S*>0+*QT,+WH)
MZ,843ET"]A9/-%K)WD^L?<F$^I#3V>;PT00)V&SK?+"SR%PY$>X,(4T-,\'6
M$D[#O[.?WQI7M0A[JHX-A;V.,'<Z0K"OSH00GS# ^ZDTLM8M9SVH]_8D)C'1
MAXJ!8#3PGH-G$(7O.P,A"A HD+C8W)BDCKP!=FY(?0F;T,-\''[/I;Q\HK3T
ML:<*XD"P"W3L'ZAS_'' G63?T-I&>/%.QCNZPM_?E:7[6U73)HBK+_*-S1RN
MJC9,?V-JU.:KQJ$D:!N)/-08JF9/6YD^DCK1--'5J#,4,2A>1OS=8U+8M?)\
MT8FA#F8!KC20&@"!K:TRPFF!F@-A L]RQ(2J0\MX53W9I8:*J;'E!N(6! JX
M'^:D_:\J,):UHH(;!:OT=KW,?^Y8]S8JC3A#DJR05Y,W?2?7KQ-8;"D$_$[X
M$XOU\V1!-7T9%O,7L:FAC'E*ZSXAU/&"!C%-.-A96N]RGD"MI>*754]3O--C
M9[ZY;J 7E,5G8I*DHBEZ_31/5E85TX#D]?&=W,BD:@7<>H&H9CV7B-HY3@-]
MD2RHAQ9"3D#[PQU=MP<5;YTJ X_GO0W\O;[J4GYP:@X<"H0?U!^_<LCYJ50L
MU(QD8]9RYL5T88=.EQ(@@*16,/!V3&;.FY[TN;8=AR/;A3W)<,>CRN=BHCGS
M-C\!FE>,?;SN'7V5'!8%,I1>7TG5KRC'!9YS750(9$O?>Y-R"?#7TR@JKA#"
M0[B]RUV7X7TE#+/F!!Y-:WBI+0@[O=N2<*HIM<_!%A#4"LBDL%B ;M1E0.[G
MD^2S]])Y@4?)I#AR:\AGY=.[D):8<U*'-J(\U%)?$U/437!P"AO5L#>'. JN
MK8U2SXQCZ*Z->B#*<SQ^M+@ZA>J,:J@DY7$?S[^^1?6(LH7YN'T):#"GW *_
M\N,R5E>QE]???=M83QD:E=3HVBP?:0RMN$)H3Q'55WM]O/PUV-1Z_1-YUO82
M,/$'5U: )(8/[OE*S3XQQ)^.,C2J#ZHWWT_EM$LD37NJ;7413]%[K!K*3&LT
M4ILAY^;U%;:#ZE]I B$_9@_+YY;?^< 8/*]JP4)3#T%_)#+Z#Q7&GV@)P$.S
M-_.:F+IY:Y,WF(@]H!*3B4&=EC@>C2T/BO@^@)96Y"=U4A!+-D:R +R2G^S*
M.EA6Q\<;V,CB4?I!22VY=]W+;8;UACABSQ?:XCB# =/MQ 06FR;I;1L;_;Q9
M)X9A&YPS3D:NX@\O 5'=*]IC?J 8*S<";YD$RKN<J:,JH'+0TNUX"9#P<VG+
M"INRER$R-9] %FHYQ@7JWCP%EM#P:8WE>(PI,@^4AB\.#=9$4JSG!%-LT-OV
M_R5XS%-M65OLAV6K(^:,AE!X8?R8O\;R"T_S -4&%P0%P>5<^,<9LF(UXT$A
M7 +F9!5+>F>,QT:E5@R4+J:7=(U/VQ%['J>$ =D7C<C?"4/9 [.GHO!DMN\S
MF;=S%*T]+-C8+!D-U+$"#_NW/+XG@D@%,?33/%[7.79=GI[W6"*;>/I"G,8%
MDX<2CW'J^$TGXVQMGD#/'G/UW[[Q015?7A^%HF<[9&"P\+DLZ3;*V^PYR*S+
M\"B%2&8XF_ L"$]%,N&TN0KZ28B3N*!- X 9 QRX?Y5M=?AFW\W#MUN*"33A
M3WC]%&4NJCR(B#7T(P"/OB"+VR!^&W'01INTCH:1E\8.LO77"K2<WTADAD.P
MS(<K+<>CPOA6%FXJ7()OLNDKJ%UP2" 1%G<G\' U8KL\(CGX=W,C<F1G.?7E
MW%USTG[EWE_?<W,PI]CGI,-5JSN##8[3=#]GBJ]=\XXWTN?_H..=')WK-+1(
M]X7'D^EX2@C[>WMV526QM^?6E<18AS7XT^82XW]> *R)6,&M3A/><TFIZW@%
M$4K#]YK&8HY"9E7NGN@[DIXEE0?PK??AD!B@C^=)#Y5>=[&F]8H:K6/%K*T;
MYP2\&GL)> Z;M2KHVBB7L/Q/5_2QK+/OZ_<]/*7CY.W&A"_BQZKN_R+^R^S-
M YZ+7E:A5C.:.+PL;\/Z]2'YY(.<Q4O A:A=Y"G;7TB&[1A'A5^9<@6A=_58
M7-?"O$=CN9ACP+]!1:[! R[5@M^_!'R.5_IC4380Z$*>1*[GK :V,!^DQ*,7
M88PN!).P@F,[8;$2\U/1_H4,#._FSSOK(!ZMRCY4#,'MS JZW]&:!'/O.PJ*
MM,HAZ3Z?"Y3S;'US8_?A)@P%XG[;'-!@_/!_F+R$LBD=LE_<NP+27B%:-L9U
MFD*B9,&LEK<5DF2*?&(3/^CH/G(?#&6I#"I=,SX++':S%4>- 0\<,WNAU^N0
MT?>XMN%J/@]I',I*GO'\Z? $Q@-XQWV+L',STT/J*%]#E]670'_,HQ6.&Z93
M*4ZOXCOC3ZSQ'=;F*2UI-)QAM0\V8!))P(<2OZ=,3V&SQ!NVJLSWJ-=47??\
MACZD6C])VRL&Z>\W;AX--D1+*2DF7S>_%846B."7"K_1"Y@T6+Q_DG KZ..2
M<Y3<K,^!E+C<2\=_X26:#1'_PEU09R7T]S9+A)==YE??+O5@.YKU.QN7@#=A
M OW3EP!G1/(R\3&?PVNJC]/7 >"-UF+)%MX@3]+SD-[C&&BE0PUE, 4O,H!L
MXP7%+K3>:O6DB1N(+^+GM3R0LCV@_5Q;X8/3/A")\H\+>3AB9]Z8*% 5/:(H
MH!L[(Y<8FSOU,%KR40GP@WEI1%Y@B:O=?OV%]K4JG]W?U@8LG_LM#D$Z \YW
M&+[]J5]2HOH>RZLU/PD_BUG(^1P**L[8<7]<,U;)R5"CW!#C@V%3TF?;[?E9
MP\C.2,=M+UR .@M9:-HQ6J4LZ2)25U?'7@[V_[#*Y6&:W/W-P<]\ ["O#8#"
MHM1L%H7_::>3@;UM47?4^//>+C_B;^CWN-H2S[O?UV8B'@.)?2G^6&!4L=H>
M+"I4=_$[UY_S8UM@.KN?%+/UE-6&*^0Z,FFVI4M(_\NC7>,<87:9%%7O3.YS
MH[S]R0Y.9-32)%S.0#7+0D&79% TYW<)L-A6D179K[EB24WSVB(SFV.D4F*/
M/]D($01Q9K.\-TQ?\U1A82KPS4J12,ZWX.>T]P\4+1I(GHFY&VF-8RIUAP,J
M.!<QC^K>NR'4>H>O[K]<LDAZX'W$W <0%*B'4 ?E_;%C7MG/BAOZ(CQLLM:1
MA+?32(%XC@SXI8DQ>@OFE<:SIYCS)SUXR*Y1MPBA7K>5#E&<\.N!S W_^!G8
M5QORF]V!,0!QS6S?2^;V->$1-:%?9Z&X+-FG-:/:M7P.'[>'Q=_>"_0\' -<
MJ=P-B)=]R&L^GW,G*&$QM%&]G"*8\8AUCF/TQ/V+W-1_1U*2GM:.XJ%C7E5%
MTT,]/QUZ/WC]Y*+<F4S^E[-J$CZLA3TZQ+H>9RE,W*C%!:TTI+LRRVE_>75W
M9GF>E4O'1P^0OGVB^3F<>0)<VR.EINDLI^)AJUWJ@5OI]/[>\LI)]OTW9=/W
M7[W$'IVV!?/F+GR_T-1(<3L'>G??#;C!^#+/K"V6GWVZMC1%\*H>#=/[A[S2
MSDM2''DS9V$G!@.2JYHLTZY?H.&I:8IEKA+I@SUSUD30J2=V"GBE@3X>XI9]
M?S)4DZ?KB^\BO<GJ( .+9+)P&=@A>=/.$:SLV6H6+\#Q*:XNRQZH0\=X75)=
M5_\L;"'K)C"^XTD-DLX'F9'T7T,EB\(-JP0)?KLT;^!2LR_LK@8KK/T-.4<H
M+CO#Y[>;)E8QW9^R_@L-J_G.@GW9YNAGTP2B>>.E^PB@)'5FB+*<SV' ;0:G
M_)DK@_+^6%0WHIG8$8A>?5DQ)^O$81^M$.,78O4-T%DU0T5E"?KWE45K</46
M$7E%C%E;*GYMLN4<R.C]%Z$:$^(M.J-C;SY-]98I)8:J18:=.W6KA>-"UI@6
M]ZJWN* 6*3.#D:A 20'_N@[K)9:!VD>2<"_;>>J?VWS_S'T3-/11@Z]F?R]*
M/%3^C?,"AFS1!6)IB<#W'S*];Q=-_AQ[)T?B*?PG-R/52IJ&PD%$<M&KS7-/
M^&*%@6'3QZ<U7TZ:1>=Z<YN;FICZ#W3%'RR7>^1?@TB\*EVI?HBO'PN%%1H4
M;9AL<F8GOBEVMTB=P,:7L<2>4DRU5%_IDI*&]]_&EOWND6R-N$F%GL>_=RUR
M(YW02^F.'!MOKXT6#<M-KS4@T/B:'TFO[XI>_<_LOJ9JZ%2/QL>\4+7]O<B=
MQ0_=!A%RT<NV__DX.'Z__YR4F?PU__T08/XY;=*FK>R!Q8]2[?EU>7I+<ZB:
MMG<1S TGE(ZO:W0]F(UZG^:@\48F93:6Z%T%0+QZ.5;'$-7HE.@,+;\$0$ N
MJ0S!D[ZNL#?)9M*T.HATEW=!LQ::RC9OB=\__V?T-,%R(I3^9]"'D5W<\Q%P
MY9NF!E#O8^$)UW%SBU>QC LO'K[6HM*5SPC9CVD[C_N<E37X'BQ?]TO-6W"7
M%(_+8E^3+)^IKN+/UI.CZK3;FA,XD+.^F&/-=L=<]\<YI1R_A[!L3S 4@GJ_
M<SH>3O=7ESGN/_4TY]]IO] 9^Y?^J5XWC9X,F-,@4U_4;>'^L,R=M,0K,[_$
M2I1N+J1\X^^0I,T]5@<M[$7Z8P(_'.DA_%W_3"SW>PHQ17V,,&%GXBQU8#I\
MI^)M 6IKO!-D1V&";S=I;O,);N.GYYX?HM#/PANVLH./'O+:E&V&"Z:HP0)I
M8W?]T&>/!5Y6O$V?FTU=2.I33:U']4,=O_:8,A%?BWN812CSUBS,OCB!,VRD
M?T+L.<NOU)K6U>8$"SO<>DZ*G2>+73E=X/M8QR&>W[1/+AA+3<QGDFOM&>!4
M6-:7@06Q5+=J;#/K+:=OK__?W54KL7$+2/6PL!KFT=G):('T-4!18(G^/9;/
M.=AO"FH]CCHV17E)7M)CKQU(S^ONN'JZ!V'^8"W?H:2+W<\'VK&NZ:&&XI5A
MM ]I T0 5+W VR?[%HE%9Q\)8V=PS2CY)=^B(!'#M+[H.9%+@$ED(H1IW?%-
M1.*^EW2\0G0SR>@,WLEW5T/4]1)P\[CB\<Y]GA&UC<'Q>L$ H%#\RI<;]JV
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M4\ Y]^F72P#SC;F!Q%&_ >JX?;#(.S;QAC:EY]=4)O\&<#Y1L<E)=&ZY.S-
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M2T""1PC<8HC+1WKL>,5=0H&>%6[2>7H)F/8F&HK@)*VL?B$6E?.['7D8<D4
M_D!S*X_%\8N&D^(1=G,3\U%/"V76&UJSJ-\]XDI=-P"Q'XP%5B+2)!,AB!N\
M%#!:;G*OT57UB)_O)SOO-]* R5S[H+X_?:I7Z<5<X#D:EE&TEE @M[,?/7GV
M);3H2-"EDN<.*0<*.EH.TRIEX^QO<9[^B0P,F$&[/M.G$==<RZ5A&J+R3@I:
MJI!9'%PRBW^"2 +SXE8<&A!O5O4WK\BDF'<I"P)Y'WBY_</$3@3>P^(2T& W
MCS"<-19Q69M)S#'5_A8X%MQ<^R2 4QMEH@M=59V#VIH^BP\@+:JEV(9=\VX3
MKOU%>J1_Y!$$^^C<AX]2"]?=+XV!0,23C)K4=IH"B_IP89> '('B-O5=.#!1
M5T C847-4*$[.B!TZ=29'TRM_)IJ\('W "?&JS$^*IL0 F.<TR\4S]E4(%?Q
M"E14O6^_MD23O:D/X)Y/M$YT=7=TY*G(CQAD'W4 :3B:\RAYK/&N_G#WAD H
M7U90]Z_ SY=%4>?2"PG<AT;!)X48EM0T[K1L4.$>:G_E1S/@16;.PVN&]-NI
M[08[#\;@.0:(V15RP25@Y=N#W_'Z7,./&67"Z\_-Q6)405,7L\[+QBFI;$0+
M!=YRAG[?O82';N[T*ION0TA;O>2K_W3PTBE*#/2Q39F#F/#WM??,^!#"XXC5
M %KQ3UI<1;NX=2W-2M$6ODC8UC^W>??TM"ZU,RF_Q9;D_LGX=+3?[N_'\W&P
MJ04%@SQR1(;D[ HA.'7LI^X+:F:9CTM1AKC=[?FP$!%';3W'FY@AR1"P;5%\
MEG)K0<UPP>_X.2L'RC@Z#D067J,340^8!]LJS5/'YQ^9)%5[%(F$/#&@%_B[
MQ>SFVWW3S03^+?[+2B^W38#S!R.H2)%GEE^VV.?DY7JB9H,,[$7"LAMKEE "
M>*"IB!R@A3Q:-G<GOAF1(__5N03,O@2W.#D= T[(ZB[@WGS6V#MOW=)C)_B<
M8[8ALD.BG2T&$>8]:K^!/'DM5!KC+)6Q2;T0<62"W/#%W%/EEXK!Q"?96=5!
M6\8UHW#;HYWTR*E=8?-IYL=,<;FFDZOB/L;4_%0[%L*I?9N/60;0@TT@12:6
MO2ZN(KO'Z?#/UD!<AN7IG=WZ:.-4.1AAF+!SP7 V 8F2 HO+$7E!"54#2 ^C
M0Z+X8# @F-F8^N.QO.^+-)+*H$%*_:&)_"QI649JXRC<JM3:)JL[#7A>D:[>
MF=#D(.X8]SQL1BQL--Z8)V3__B--UT^X,XN5+"Z#^E$_$FQ.?6#I28O'I%2C
M#N11*U6;R$]J;!E^TP1^?K8Z:BM,S.D[RG4D )TW']*80IRC-Y4HW:>G% )?
M+9<K2_@G7\H&M4;=H'NZ?%<-Q#O?->E5>VR+&6EF)XYA#KOP$=(-\+GF$U21
M>QMJ&QP>P0+<:/]K2=:QJTN+DC>4V($SL[].VS&4"=_EX,IW:5UFUA^\3F,/
MEU_3K,WI;-H1,:XY\UV "Z_]H?SG& W[+3D1SS9_BP"EY5"_*ZU$8_GFP'CQ
M<T+K$#6YZ13OD1B.*70Y\L .:J[DMO9HD_JUVN9O&WI= JH5VW<>FZ%09V6+
M0RIK5N-6V+;=<$(7:70)L7!8O,[HW7;7+#WE%^)QGG'284C-5 OMQ7^C%/H@
M 9PN8EKBHC[M.4H;MS80[[W^\5=\QTSZL?6]\L%W_P^C@*FIC?85(^7"K&TL
M.AZ.>IS<IV-%(>KBA,#=$D< AGZHVF'P!/GN<RKM_^^R0*$BVJG%X56L*'0G
MK_JX4WW*ZW@N=:86\PEAXIL$Q/7!1=_A*+I,7Z/[O=-,]XO%:NK'+MSS7=\N
M#39_OL4GWH1SR[-7$BGTGG*8% X%%9\EV9R;[8=%F%F\&[AAYD\1S,+%J]ZZ
MC<IVB_^R !R1TA@E#.U(R:ZFNG?+ZJ-K2C1%XZ>>7Y,^FYZ4F^4%8:#_^$)G
M[!?XKWI-2D8@J51G8?,Z_^FO?6L(&6:W+&98UJP)WUH;B['81Q,*_F0B4_?Q
M1/HCX C*_>3FM1&M-JH:4V._=+GP\"+/9"!#X_W<F/Y$,^_3AQ+UOGWQND5R
M4_)AALOUH"W-[3)';!D4I;_J7 ((:U7GRH'8@.4E>#45)IYD4#($=YTN8$5N
M0S_6\ZVCFQ<?I5D&'G1+9&-<0*O.&60GO",'X!* "CH>D"((Y;T*J\$8(W<.
M6Z;6U78:!F7C?^R,8G/'"D9W((+OT;XPD0%FD/.@A[\2S\.];!6GTH())$MG
MCBM)'I&!I&B\P1@WJ=]<<HN%,8IDMQ?9U>0:PNO@)V38#\F"4H.?N%Z)M?.W
MH?TE'I&#CMM7EG<U,+$$EJ.<G8%2@Y#]G([M*J+"R&8?CD],>*^FY^'KAU@=
M*&WFY(@U3VK.71\#>Q%L:-?,*+3%5S9P381/ZYW*6Y0(8?GOR-'\;,O/J@N"
M2EV3[#\MM_VE/$GP?J5$4I,;F>N>](IMD)T!YA^O&>PUVL4E/#D+O"+U+Q+1
MXK2Y?L$<L+L_U!=MK_I5 5]8=2^'G>!.-4Z"AMHUOV _70+H+D16@L(/C_I&
MF1E4N'>27T\9WPQF.N/<3%XL__TJ%,O3!_N]J^AY$2F_LU"-<K1^D/F?WTA(
M1?J)AI3\P/[+5^$"*6ZIWYR!QZF;AAJ1H1DK\<K6ZLFA \N-#,WXA*=KH8[S
MZG<6%2.7_U[H%N#<&H$[1Z!7N410MEFLC,SRPK</,CKN=RS.%A-6X 3U?M5P
M"_(F["0N2*'!?Y'NG]%PPF(6#ZZ2<R)_.LR^W@TWHUY-<.G+ZF[8,+<4ZS:U
M] ,=UUQ$M:TVA$$5JJ0_)[LV55CTNM0Y]]O=":=SA]7\^=-2M BCP[E9@V<K
ML&WHD,?@^VF8S\N.0H$LV$=5;29F'WSC/Q+"<EI;^";5V,HV*.+&-X*RA]-V
MOBQRY?$4# WV!)3?O/61.VJJ]/6'SOFU=1O:)<W(%=19@^OB@+=\W/TZ^>SK
M$+EA5:TBU$,,9^=U(9A?Z74U:<M6X"1&IJW :HN7;5*-;H&D?I_2(;YS.__0
M=B?[/C?@/^5>JK>ONT7[?=^_$VOW"_LXNHLH<SR\F.C>V.\:XC,L'<2%]&)E
MC"0-8,((HRW3/3IUKHY_#!=.NY7.C>3T;,XKMS0E)VQ7N?[6J\[5L.SQ4I1E
M?(70#W4  ,X$0#$)-X/L'J?I34K)X2",VDB[FF>&(30'/:#3D)>*J2Q>/S.3
MLSH*@B?_,'P)%SI@^'"LKE7KUY!A-TUC$7@?N>.S=/KNB=?35&ZF[#QL/0^H
M'=EHD_/Y!,2^@Q*"75W2(KC_"#U35!Q:"YL ]T^;LBF9T]BG3UC7L=N>6\_*
M[\WA?[2EB3QE3A7*SY\==;<U.Q=#QY3:,%B3LU%O A=5-5G=V+"K93"H^M@+
M ^<2:3)&E%N)&SR7[ZC[J*B8?S(?5G$) !VU[#6<HF\N^1L*FAY0$A#GAZMM
MT^8K#;^18JM*FP^!/.5A;=S!EGE!EK:C:F(%TSCC@DWK;W\?5LECB&XC#RBR
M25#YK1<8Z2%C!W+ Q="G[C6HC7YC*<K4<Z8,!$RR+G ^M3,T0K=G<Y*<4P>.
M.@Z10V3\NON(7\XMK'4O0BJ1Z^($+EUWE@MQOP3P8M7[8%6K14N9_A48N]@H
MM&Q0./@2$$C1N$+Y7@G?C@W!IBVB^P^S0U(KMJ0:+@&)2YKTX@)(<K.:OL?!
MGG;(Q"7 'Y7BD?"((9ATG[\^VA#CO2:,/Y'EO^BX#;M"'_J"I.9^?Q&-[>CB
MO7?$C#NUK/[U#-=R_(7=Z(%^5_#MZ2ZQK2V+^LF*9;"S<<931'3 8:Z^ ;2/
MH6\;\X&E<8>?VVN&VQ+C>! ^"-X9$#SQE/YF(47/4,=Y-_FD)IA,-N##3;)5
MVUKA0 -.!X7CZ!],/V=@:S]Z;ULV'@S11 _'/*F%2NR)7 *>H>,"))9[U/X,
MT;JRX[(7O,_&]N7SJ[J7/8+"=SN[YE2]NQ>LL-\0Z4]2MVC/Y28E$/?>&,[9
M)^8TC<YDQE+UPHU.1U3XKKJ+84S&Q]#3WKUBMJ$Y[6E*Y-NR0RUNZ7:;G$7?
MJZUFUE,Q2++0+$?^OQI6#F^^I!ZBKH]N;S\11.:\.O07.YO^88L57&G;J&-/
M8K]-=T5_C9V6I<8]A!X_<#=GP I&_?'<=$3CC;-Z  5=\:FNNO;E)<";,Q0/
M':8X04PZDL(+?Z7DZ".3[&HAACCTB-WD;_[PAQ]"G'ZBTHQ'EA,\8$ZH)DC:
M]G#XH6ZW%ZW:[8K6[A?F8+_91XO&M9N7 ">4GLC1]D*$1,4UVMNMR0U=1C>_
M7@NB.7ID.?Z[N58OK&*G"P[TG=/U_?68"WG./9A1N$W'TD-WH:5%<TI=X*[M
MZ%)%691[ OEABULA)H3"[>!R./6G>),$/V8(MC_'"]Y_^SK_NZ#UH-*T0]P&
MS!F!B'=(#\#=5>@]/.X5EZXS"WP+V!E[9PBJMKCJ4#G;C=HK[.;F<R$Y#)R:
M>(C''6,!2N?!#F,!=B[9Q@@W[^:/EP#ZCXURWO/[*Q&/I7G/J&.=T^6R%/:,
MD$>0?$,+,E)L#OA(&&OTZ-[ZW5M^_)D.1Y85D+>-"610^\YI[@^%'O0+BLZ]
M@+@=^ ^QN9I@* -)5/&\A$=SYA)P6^NB-#6O!.9X"<"@<<*7@-3G.!7Q"MSG
MMU3=OE]I0\T"#5DSO"'.]I[[ \*K_VA :[DKK^1UT(LA;H?LJ[+Z-4TUR/BP
MQ[UC=>86^A")7X<4$]_/%B)NQSTTR['94\R;TX;'>M%;.C&V1X+C 6KB?1AP
MOT?]6AJ-K._@M6M*RM<0:F51Z#$/8L!%<BA:JHJOB,8LX/2%7;< ,43CD"C[
MQ+Q^*<_^B)NWH5C^OB,RH:>6*.E@<9@XVA\7AOOZZ..N[%\?5[&^X2EF@SF1
MQG&)XR:H2,N_Q_P<?G2(.7<FFJO+&D93]DAVR\9ICCE)>W7/CU EQ$"^5PZW
M962T#9P=)H8(3<4MX[ :^QF08]A^J7&?)K.QCQNVKOD")N<9CV\EQFM3GM%;
M))[I(V6;2#$&A(+DE20V8\+?LG![P>/2X,)ZK.;TJ>MILMIAN0%![DYH=\,R
M8UY#%ZWI'[8T_5\@8O4<]/XA_-QXH"$!X/PQ*3P__:-.M)V"X:/S(<=E=".1
MN[KT2L \-U/B$:_LH.I-?9&R*9\PQEE!_9B='$]4_/1)A$7,8(241(KLUX]G
MS;*]-+'[#\1,0%;HE<]=0^?;3<CP)TSGY/L:PT6;P[U@T@\$8M)XT>*41ZM8
MWB!BM.)46W#/Z>4O76)*9B;5YK60M6CPD>J5I]*-4U)[DP:U2:#O^+<7^ ;R
MVL9IPF] \DBUG %=""EA)R">'2)D\]4#SQU#M7SC[K$/5)F#^[9R!9>$Y$M;
MU;*>A8:Q@&W77Z2RF<\T^[*[QB5EFA[5C?5)T\O&RN96__NIH6FW>@\MZ@:<
M[BV2J@_ 1.4G>$1MD+N-,_8%SZ.+2MTGTH4RDS=AZP&8TT)8NJ91GD;S@:FQ
M9[HV*JG;:[^]Z0=J34:4XLP?KG2E2B ;[+.HO)) $?HM@[D[,6CEZ<,@Y*7Q
M',KC\U#@V]ML^-L"X5I0JOAQP@ZH9Z\@<0?UQ>JGWJMRG_OL# +<)1J97E"6
M ,HF 7/*J/]&'A,VUI#6"VZI7_.B_1OM@)Y.)N,Z$1FD_3Y!1_M-S5SN"9T:
M?V]WR"7@SLMCW)FIK_BH9FI3TYNH_XP;NM5OBVE#:W-F_S%A,GD&=/&45^*
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MC,R(NB0UR#*U_B\!ZT:3;JQQ/@KRC8;=-#1JSW&X0=VA! _-;\Z:@.!SU^B
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M;G)CU-OMH)JD6[LB'6,TY?*1!D'/!34VZPU)U>0%I9_>;$.\D@]OS*-0$IS
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MIMK=1?J/QDG#RV[4CJMFD6/;F#ZL.['-<:;<GJFGX<.-,VF!T2<I[TT]INB
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MJKF?9:MKQ:F6%6<(9X.P ]^6D'K:\T]4?/&:NTJO21$+O6JA,':<!U[Q!91
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MW2-GHW3*4:B8>^)#_&CO^6,K7#KM&./A?&1ZFDZ!8Y\:D*VHQ3TZX-,SI_E
M?0D<_E]NCC\7!3V=82$7$!V$R9SS<&UO+\D[!U^3NX;N/Y*\ANI-;__@&9/,
MF%+(ME'-%?<2=0G^MLH'^YZUKWA ;VN^9NO):N,+_T6JZ/AKU##/HF.A1]&@
M^7M5:*J&'E<-0Z$7]Z;.;'S=""A1#'5(2CJ49+=T3O30_]U-3;WRLO\!!BEN
M['T<_I;D]?M$+F'ADM HM+-V*,<XL5]U"YP.[?,6&D2-\U^5TZD8D=&!RUGO
M&7G*8D%.JK8#LV]I=X7R!27T%(K%HEC$:,KV9-Y2,F]"4^'P7O-*X8RE-TN
M+1)Q>'2]1'I3IS0YZY@.:$**P>P8QQN-K:R^WL6]9U/IT4![K!@.P7&:PC2U
MGW)XL^NLVTV3LKC%ZF>H75LMBM38'X>Q]PV>_G>3LS8%[V07$E?_),AI(H[M
MI_F+IEE>/U:_\-TXG<QD&'FXQNJ*6!2+BE)*5?HIVC(55"H]P(6OP;,+!4U'
MLVF)9-Q8J6<YM+7,#F2%F4P>PVSN(YTBQ"D(<=5^E&,_4N(?5C#!2%>R)]Z+
MB^LA)=5$P.8?'8 3(31?^)[#[5SY0N-Q3/GH'Z1&I(50XOV[%=[@7J++*]>9
M/[U'YIZ#D05%FW("@L/;$DX5@:1W^L>>G6FSS9>XE7=#,*]\<C=G[R2URGKH
MJ"9Y^J.6C/^T1??I 9BT%-:/C7ELD\2W?[D7X*R5N[#*45?GLT*X5V]>J;!W
M$@X.CCD8&DZQ8IMM^#.-;"'N6EA-/^Y<FI[N&3?,6O6HL(L6T/C7(<_-R%GH
M[L#9.8LXI0@8U]1,?8R+2%4D4:6\<Y\.8-@K:@Q@[3K,SXQ<:)$G=AVM%:*.
M!I0Q)4\ R+]!KE;U[ZL$C.,%E:S-->M[R>\DCU0M9*F* ND=?PYT-7#M >%$
MY(ENN:52,V=5SXU)Y"^/;(\+#[/MO6\7;J0<)GTY1) TBTN54P^Q*B/W$U+D
M/3S\^6]0LK@W0(565KZH&):*O#BTZ%U, BP=&0K\6S)6>D)YU21G?P!,?M!D
M7(9/5-O'/)LJ>)$[;>Z?_F)I_%Y?_])T$[ZIYZ\]B^[DR3"MAXC>Q7^@ PX[
M(,EPU2R%0[67W>A=:TOO]L8THN]]?X]^#JMKE>\G,(]9$C3.- L'>.='QO_C
MZ6X'B5^2I)A<+5YN2O_7?Y7:@_H>DVH6S4[&U.-B/ *9ZK-<X';#BY$6 GN.
M0%P?B;KH'K\^'/V&1=WD0/<.'DPAKPO05DS! Z2I?+VG@-. PKWA'J_;2+[S
M<Z9!YS?<05<)ML&_^)[4K&2"EJI<Y1M5!88]".V'N<!;V6==2AT$4W,UY=+0
M>^T2Y]Q1>GU,N^OMGK1[NP$N/,I)<@%!_3U/>]!K@<IKDS$ ;+UR//9FS(<7
M5NBZT<H;E,,XL"EV![;,ILT5_,]/_. <LMA#]?(_B0;_?'@+2)4$'3$9*B[Q
M[20Z,%[0^/))KFS+,WB8N]_;(+?6YB7BQ1$.M4H'G%LH-34S7A?IHRW5TP%6
MC=+3N&$OCII1(3!(/V7%46/OYVTQ,,\<=3YX/[;YG9;*QW5K")Y[-[US#AU"
M!Y1Y*; )L@'_]CHQ!6UJ!7#_";#+#!DA,]A&+"($+:'B!/Z5QE(M!-&!Z0\6
MBG9.HT[$*^_!;\7Y<>X)-L/#ZSKQ"KOZKW<AD4U!;%/>B23/<C.^3A=NVMR-
M:<87<WN3)?[:(P%;/D^9+C\;I0/L)#^59JQ[^)&M47"\S4OQ%(]7JGYXS%VC
M=-\>?XP->H<5:&3\Z/FWCMB.8"&#*A,_)L:W1J]?&[S@^/O_'.O:,D:13IDM
MG:]?^3D?Q+.[P\EY9E_'2O?"\!K@1[6F-T.CAZT\2=]WH1AN-+)5-7%0*R,N
M0K[MF]@LX8AZ8J^$__GC8G+# J_H?'4>H%0UX07 OP-)&#8GC/T2;A+<E?]3
M4:\#1%G9F%^.&VKE^'#\I_IP;W(A4N9-\_CR.8!G\FV2WC=7'N^^@#3DVKAE
M56]6"V\?UY!R],<E\$3?PP\>9\YYQJYYO6;\#H1>B[.14'F,:6.;LD"'&;7*
M(==^Y<0):[#VLC.>E3L_\>W9IXLW;O2_\"0H+AJ@1F'8A8OOTG=>H8:+[8:]
M*JLK*_:<I(2*E";2FN3N0Z\]E%T:+S%X(O#?'(Y2PZ@VKI0&GHY48K%1=Y*1
MSL\;.KP#7\J._SC:_&/G<R\P?<P2JP582HVGR#6.0/US2"%&8^(E1MKI_EMC
M_-+/?,NU9I0C)!A^[IZYI716PN)UW,M]W+\G?"Q?FK@D:MT7%!9&!:8639%Z
M:=<_*K:,Q3V(ZE!_T_[!GW%P+.BHA1=;2'TJKZQ%3.'<1D%*NM\DOASV_]=]
M)4Q-ODS 2!F0</&&VTW5AV*#7GB-<6.4R]8R>UMY[QFOK74AH5*5UBR&;5$\
MP+\(?4GB@??E(*-GX_UAI9!\X$S1N&RF'X\8BD6FOH/_TNMN]@M7+MY3_*2.
M)81_U ^C2.:[<*5D3Q6EA/;/C(YBG\=*R9RR+*=9*(,/H]''Q]K=<E#VA5*2
M+E0%4M29-[->G?1&!T3$2/:E7S@39RW$_RNXR[25><ZK)/*C,AW0@KZR[25_
M(%F]Z7@"%M%$OO@$ L$KI)ZNX$#(GVB_S&F'L#,/M P^BOW\UW1&YVVNN<N1
MZDW-BN&#P$:!*5X5625PK^)ME;:\0*Y4UD_FG(8Z;!FQ,4=M30K#%#%W8:Z"
M#QB!9-]"5%PPVO.]'1MSUHJJQYSOJO"[ZDIRS>%5U:EM\5GCW:*"^AWPVU@D
MS)GA1PU!.%-7=%5_=+:%K#-T=R@CM4N;P_^K&W0H+P11@4B2OX40 HQ=#R78
M2#=Z;<HIIJE!XLVB3!/Y9;LL+:5R*JLI+QJ[?-BO.SW0X53_>[;Q?)6.^:'\
MP:+BY8[0/'-XU+MOV2<?+#0731JD%B[#.?T\=<:*0G+2<T#\2Y<?XX-B?H4]
M$6%DC(W'!  6*$*$."!C.S79Y;<%.GQ!.[,ZM#+':N*=]RT[N3-_'5[-L05_
M8>*.Z%8R [+<KB,90EFHOSROJ$U>SJ8V/7@PP7J1TN>%X1;ZM6[SE>/,$IZ@
M844Z9,&KN D>U//JJBJ!)76M=$#.<S52+!(J6Y/O/GBT 2X EO@QW-"'B/:D
MNM ]5T^7D\^[IU!W2)%/H/6J_&P;;I=@8;[\RN3['.<Y>R>AAJ) (*OEK%^2
MP3^A6<D'XOAMAVGDW>Y7OQYZ=O=)ILLOEO@!.@B($&\5KK:4V?K"35"1*T_V
M];'E6Q77_SSYEOSRL\W =/*/N(%.E8</&>U><  ,C,%52E:]];W.(F:UY=[:
M@_!>68<K9TX*&!&6C?^?9Q_Y5B,HO+FD=#8G1$\]MDHBGG=\8C6,>\M#K).B
M/\]+!URVAN=@C\=PK3#DQO%B6OJE[1O[U)5YT)IBF'G<@ER,L9G&L86UFQ')
MN"97":FVKGJK<0A/^=+D!W,P!ZY@:>L=9C%:'8S>ZMW*D@3R4W\)&9O'\W1
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MW6O!UYX6;(:+I<QP\BFHK@Q]NV?XX17K9ZF(H-34U0;0Q;2+^+5%D@E[/KR
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MT:9DGE$S=/1K 0;A_KGF1C]T?U4S8H%_[<SC;-Q1"SLW,:CIM P67IW9.T%
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M/' K6EQC,EOSQGVE<?!E=>4?E\QMPE386.;,UFWZAN;*$4U16,FG5UA.Z$7
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M(O;#M@-X \:X6JJ6$%<V^.[ Z,&.V,@M*,N7HS=N7GE: @?L2KE WMXKNV:
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MW=Q=C^#]O4] +_[*B0H[&^O=+%%;)*?X./NK/9%7;E5^4O:\C0+<SZN"+0R
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MMXOJS_EI^I1>TO;IT T53[#<&J. KXS_I.5,J6F%B;=]SR>L57UJ:)("XO<
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MOWNQ4=.P%B%-@Z M]0WT@J0,EO!+%UB"?)F\($<A'-\WM-#OR\K\7'1U T<
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M/_1UAM9HVGXF2CV2!"?E6VXAY)NE577J=0U3SL='SNM14W/8&6S<>;*QE&P
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M36!L!B7+V->,L62.^:$A/_ !Z GXZ5;_%S=6_C\3^N/"_P)02P,$%     @
M2H9W5E3#+E:7RP  >-4  !@   !T96QA+3(P,C(Q,C,Q>#$P:S P,BYJ<&?L
MNV587$VT)MH$=W</&C2X6P@>(+A+< ENC5N 0'""NSL$M\:">W!HO'%I7!J?
M?.?.G'OOR)ES[OTQ\V/6KO?/KE55ZZU=3ZVUGJK]NO2Z"<!1E%60!<"] 0#@
M_CZ UQ6 - #^S9M_RE]!^%L041 1$1 0T9"1D5 PT# PT-'0T3&Q\' PL7"Q
MT-%QB'!P\0D("0DQL(E)B A(\ @("?[I! [^;QL$1%1$1%0"3'1,@O^PO/8
M<%'@6M^TP<.]!;S!A8/'A7OM!U#_M1,1[E\$\)\%[LU?&Y&045#1T/\J-.$
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M1+>,]AV1 :-C!"TXVW[KFM$!TMEYT1AH5JF;4"?%F2>FBMZM:@V5\_% O%=
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M=_EO)P+?4I9,&&D OQS!2(:ZS=[=GD*=R,<M-%F*D[.(HJ,MB"BH VS>3%2
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MLEJ2\RDH6DH\,'%JT#->JOH@ Z0O/+35RWYIIS&"DTRT]N:,@R![..!T1F'
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M#-I\]X:%\D2Z&6^(M*3_QU#YY(EQUG;UM,C?N^9A[S3G893BZ2/4VJ&'Y?\
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M2UX@%TGFGT!F^-?/A_;+T;$XO86K9WS"TFUIXI=D6=[CIOQ9*6..C13.*_\
M.5&-8=;1FT*A9?RF<@HY@RJUX81>E2:C;QMS7K<2V1U*C&2QFF3[I36SCS:(
M.AB/.["K$&/SRUYE0F:T=5%^+C>^NZG39'L0 JO+&4XD?4J,ARQ.[XC!WP[^
MJ-FEQJ-. 2XX-P60LOD[3&JR4E1MF6L+]&LZBJ)M'&JO(,E+:L6)V>MAC0O/
MGFI^CP%]Q_[WB"@YV""(1E@@W-VIX4X"TSU?318^95PI[WPW5UJQ7,XOQ2[
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M$)UU9O&BAOI:'F%%ZS 978YA.NXCF,?)[(P5R:/#),>UAYJKC[A'@:]K]#U
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MY^6J[V(ZK*T8&(FG(8(BL[NS=Q-;^ B(_6Z>\C/J,N3;J]-&&U"4^W\$_3V
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M+C@#0ZCPI2N1+9*#B:VU:#2^O [**SQ\(R#P-8W6DH6M1)TJTC VC4D8A1M
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M+OG";[5F(0XEG5Y=*6JS15>]%!LE_%!Q]F%F.!J"QI(GLDJ<#_[@&PER:=J
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MI1/L9]Z6[;(Z+F^"-KGS?('O6Z@SCRWQ-Z<EX]A$P9;4D\WY.#A2,I@X%A>
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MEE>'>"%*TKM>DSO0\,Z9.,[$4O)8^AE5"XAT7\NI^)+K*NYZF#[A^ZAGMF2
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M&W_OCZO!PU-8Q#UDNQ62.X,M[5EV%LHJQ*$TP/V7#GE&+7E&(KS<?F0JO_>
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M5?,2AAH"[%I?)(%^<_KSX^9_@C@I#H>)Q:U1P;M*F+-*F%PRX&/%M4B')D!
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M"KPYAK"DG RIJ]H>&Q0826GSG_=[:]\,%SW9PKNU62@4"(D$!.J$%85$[W.
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M/_)C5RS&5@C4DM;T[T?;>%?6N<9^.;C9_)O.CG8>'@,S2#5(V-ILV5GJ7@\
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M.(T$=PTR>;]GOGOO,\_],3/[U/Y35:MJK[-.G=K[;>5M"_!.65Y)'@ '#P#
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M1M$VS84L?)#$EIRF.LO75HW6W! YEEV]#Z8A">?1YMX%PS%X[7P-*?JC6S?
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MD#C1$!V_BZ7YI*%@"FMIDIFW=:IL%4#CK"P%0!R].S8(7<G)1X1HP^@WON0
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M79K6[_;Y< Y8,.;  ,;P+?##Q9@@^73V&[VK2_%9#7CWQ7BT-"+9H[[A(;'
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MCS84&58NQO(25\YP+(8T&_QS&D\+HB_N=V;"NYGM_OW:I9;P/Q'Q/"J<RNU
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MUDESH)\/.0M6Z4Y:HXC!7C;;;X A(/JS_D4G%<,%I!:YZ8>1XFSU+BETNJA
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M@IQ-R1HF1W$9ZP:(?K"@!8!VQ.-+\\HG>HMUR_15O3EG+U/0*E,.]1PS_QB
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MP$:/AWQ@HN2"F@&B-2@OJ;#31 KJ6N2':N WML0L%WEW>P@G[&.5*XC)"5W
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M8GF3 8N%]O-G=\ KJJ%L_';T#;\_9GH)8_GT8O@=B-Y-&"F..EY[H<BR1;G
M^"9:K:L\!.SJH29' K+&"+W7H76?Z7?.8YF51?H%A(LZW QM"!=8S:WO#9-6
M<[E(NY[H5?[*<:ML#=@8J+HFU!OZSS@*7O=1H8<B:P389C_)((XQ4FBF;^QS
MP=P2IJ#C0<.E^AFZ[EZM]/5?K_VG#+T.L2280RYR_.3)*Z]+ >?2W4+G\"E3
M)7QQ& (I*;5]>0,_[-G.YG_$C2? ?=L-?MF$@PQ"W1^TH@SET5;/601_P_WJ
MV8S-W7$R=HG*K>>Y34<JIVEIF[[@?4KJ$CUJQIN7N]-F[B,+5CS3H:%!GZLC
MF.U@K6)LM<$HR[HF:L<5.N29A16UM"6.'6)DJDST,5"Y9)F_)0-:N]7PMYJE
M 71.\3B#OC^"F,V3.K[G'U%P_+WPEZC0S5;ZU@ZU9G>8VQ1TS*VEJI8\9D'?
MFOKS#D!_89NI=M_ M+[6E?'A:DLO:K4!_:1"\"/; 3 B4"1/+W6X&6VP97>V
MSND5"( *$Z&43/X>(KY(M-"O-,IML6?2Z-X>1,03"4IEY(7AP1@#_.PB\)R2
M0\;*9#-0MMO/(Z.O7Q=!''R(,YA%,'E><3=C@[[F3WU,RQT@1XFU(5KQ9,M_
M;V+(:DU1(N32N[:X55TGNDH#]@IT(J[\L2@2ZOHFMFW,>3^:W7H&C10.1,E+
M8IF9++WB688BO9RHFB^QFR7S>#1PRIUT>QK2")'1KEY:$:CP<OY4#E^6@^O@
M79'X*81H00@)%WKZ546=$Q,=UP.D)BO(SRR&AKRV>JDVP\:ZKCSQ2V=181HT
M!ZI@B8_ZNIB<I3=T*9Z:-TJU:.)J6O)$#,1"1$0CYO6O^_G '.]9)\<L7A<6
MN<Q>Q+NUA&">J1FP&T4J]CG;!0-_>8^<7JCB\*3KD,L!Z("(KSK535#Z)!U^
M*UE%4GRY_&;\M"1F7/Q82$3Q!:[XIXYWU1YTU51W/O@''0BWQ FAA*'T=K\C
ML<\$[@7_\F%[OWLG&EWD8.'N$RTV<0H*\:"Y=Y=Z2]U*[Z%;,(]QE2OB/;C/
M[T-%3X^37O9HP!X59>ISK\NKK;=R?X,"E$#YD\%\QG?VUTVK7 1:(DH_<N:Y
MC"^-D,I096G8NI!"Z#:0&+O6@/N\=Q-+>$XI=\6(-++.!Z>-:5^N/G[ZK.=)
MI-IEN$+8H="3Q*-2&Z==NBZ$,IVE;?,F^ZP%TM5D4=PVAM\,=5C]N,@V<O;R
MB00?JXQP$H,P@6@YOD"?S+\P+I5<:E*^Z6NJYX-( JXFJ1)!:W Y19;YU8FJ
MV?06!#X7GES-PN>!"N^N<DP;+"9&/>/P(QN?*+_QM#U33,#!'ZOC)BKIO]61
M:L%SBB/9SQR3"]=PHGM_#EY;#3'ULJU5H(W0B4DV'QYA1EXW7A;JK> 7KH3B
MK0TXV5C==R=] [:N:MT?8*Q(W0XAT"*3S6_RD-2AT5'QIAVPQ1YT,0>/I:K/
MW#ZC1W30H OJ3,:OQJU130D"!WVJ5[8&*C_*G=F1N:S4JD&,_U:VF*&@??UW
M.^#JY!HO;JXK!9:5Q:N%6WK]S\%+I"YT,OPAX #FP^AZT"-(=ZGN)EWN:F00
M"(YOW!6V!B8871\$W":9;%I?]\7*YF^18_]/OJJA5EN3E-#??:,](OA7''SD
M7+4;=O/3'EYP$W0S3.:G8Z#I\1MS_N??8*Q;VAS]P4:Q(B&9UBHF5V6%*W26
M%1&+Z\&J^Z,$ ]H)!&M#J[T1(4"-;U.)RL._D.L[$9/3GN"S/MXN2Y_[09X!
MV0\36<;4'1][@+AYZ+:'VJS5Z+4[X,!O.;+X-:8.?-EWN_FR!#SAJ'9DS-+B
M@6[M70'";B8D\]GME,I^U6;A:]V_7E@^/$32I]M_[1%?]+_^6('K*L1@_=_R
M"-_$)O9VV]:&B,H6VB'HS9SM6\3*)]2AAP9>4P!-KW=*D(4.\*NV,>6_+=C?
ML2%KSCKRH=NM>,;: 6WHIA7)PG*9N6:%R"L0MJ!A'1*7LWTIXF277;\\"FW
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M8&3WG -;)GB]52;TNY4QO"@HUCNP$E:WU=*':A9C]6Z/I\S7U,-W &W"_#O
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M\ X@>H3V+W3CO#!G$*3:2M4E4W'E\/)C^$%QJ):4' % _-.,EEABA_XX6S[
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M0!XO7 -6Y6PX3&^#<P*&ZT:&4E[<LK9@1AJ"00-V -5'D:M9I+Q9]DP]#LX
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M <N^UG#*V@*7B3QH:4@DQMQ]7W6JY(#P/,&?K>DELP"7H'4V4ULA:%QWF 1
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M+$]<Y!\"7G%TKQ5XGX/5.6N?L]L2@64'%V^5K<@.\ZA&SD3,Z6?-;G6#VZ'
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M@9@00^YSKA$[MCR"_/M+A5+P#!K?X!I<'?J$.RD,#\Y<ZIJE=CW_T8 <Z>H
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MBS*=_"O XH+_^>X[QL"!#-5"\0'R!SO?JI\FU&D[2QKPRQ*A%9DP!:\$%YC
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M+")4SITLG7^]55H7?%*R593<$G@W)9JL=(<;%69;592-D!V047&VWR+4#7%
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M-RD;09M?WB&7C.5.(>435?K18:*,>M(0A<PW=7I':UT;/%Z8(&'!@6*W?0%
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M"7*SD@"! Z_Y8.'<C*])J<':G^=ZMQ^F$7)&[]B%ZJB^70M4I%T8KML<BV5
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MW*#C.T?'%-D/2"#_P-"X#X<(*"URH'REY6D(7$#3P?(TK3#9ZR9Z^&K>.GA
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M/.?0G@+&?9R)\<6J*&U5E/9$>W@>JJS*\W?N4=(V)I]M-=B:'2/6*Z@*<(#
M"Z\"+U0G09'>NA7OVT 2,!H^HO?6H9)&*^07J*B)\,I]?63W-5H"]_6S,$-%
M]44^T[18?LF#=PB\%"G;"K=1T%37[I(P.BL/+=95L^X+:C4QHQQWZ8H8-P^S
ME-/!?IXUZSG6P-FX/W.I,=CC-Q3=#55<@(%CC68E04C#P=WE\U4=>[K%LNW"
MRM6-VQ7:0]<A$<OCC/;>(3J"G4DZ=NWIDV+/[]O?^0#._E#2XI&*S7<'K$N&
MJ7]<4J$#=JTL-(FH+$PAUW;S([$(5;OZ4BVW 9(.VK0W9XT(?2X"V!HX\0B'
M\1@,9F1KW2;VJ#RCUNW3G;*>O?F2FJK^7$\[0)9]<5SS""[ZO4S0SS5.9'&8
MNW5YD\QH]S$1H<CL40/02F12D_L*RQ)RC5=SZVB6H!+>;PK5\KQ%2G]UVR>6
MP/9=@.3B40T/LWQW.G1H#FL%=F ^QD/,_!"7D=(X*#3>(B<:^+I1.K_@3F*#
M!_4_5&,!9G:>[BE7@+)8&% <-D]3,/ED]PE8U2)+G6O)W1PT*X!7XO78XM5?
M O&Z! $!G\P=,9 \4,PJ M6L6@ULD0 FM5"':Q3'@A5]9(-@0P&\R0QW<UBO
MSQ404M1DH?SB5I7'4>6L7>#;:ZGB MG%)\9\' !K#W)_6</]X9 G T&GDZ,'
MX-Q0>PQU.:+W"BOZ<4!]K48N7:SLSY&*@%6GBV>]-PW*8X36BF$T35%@7#O(
MH4C0%D5CE;OQ)%E#>9"&=021U2K5E+0 2OH\1' #/Z'W&LLRN_<-0S_$(XN]
MU2X3S$5L,(OD^CX$G#+7<2T\@"Y&_*MPKC^F?^&Q!6UCL/;0CMQYIY:+^*!G
MAQ]=.VS+QN'D^X,6DR%=A/%BJW+$JZ++1U97NTM0='D&5^@E/'T!CB*!>]]8
M<UE16? 04$)I+*(!J:T,3V[!WX:3%$&B$"':@ UDGWX:1P>R*#JOL*(*G0B@
M!S/N) I) IPJ)$G3M8ISX'@MXXGU+ZH7D,=3CQ%!#XZ="VPJL+_:XO^>RY=B
MZ<;$G9 U)BT$'G3HST(!@D"S]_*5,'P'8=A; F$X);B28NC+FD)=(&]?18<*
MK6SK^IQ*SIJ 2U%\XN_#G90AZFJ_6\O7]U-5%UKNV^R&-__E[=;>KU/^0I;C
MPX^S<BIJ;&M;<BPNH'C?'KF/!3#DQ?.!+7D&2O!K:QX9'HH$PPJP19^L1L9M
M01N8O,0!2-C6(E552?+ 0(L]W%26OD5I*&%.0Z'I**4"&LD":^L,_XJ'N0<-
MNPD7\!;9EZB9X%,L8+11YLNZ9(+%5X6)M0H$/H//D@6^)JND!5V.AL?A36[@
M/+HP)\U'!%*1AGM2<YM<P2KX(HHLUS-<%%AX6TE:,^%9W88_0\SQ%]=;;Y9
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MW(R%,<&4P*9:H<F% NN5!/6%0NZ7%IGD*R50)A,_K FIQ8Y*=,,S).Y &?0
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M#$ =#]=:0[>!3Y"H$:WGD^G.HBJ:E *BUF_]GM2,?8!ZKMKFZ1<\.0RK F#
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M5&S"ANDS@$'T.'$H:ZC+):O(&N3(GF<#D(:N++2(1.-+>,JN,,Q"ORJ!(]R
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MD43(3=Y2C.0(#$AD N;S:2[9B?=@(-17*KTHC_NLYJ TX5NLBS^2.QM2O=^
MG$<K7E$?I)-TZ!'%&<L?3EBLU9W$F@[0!)-+?8[YM)[57LS++NHLQI(-4[EO
M@!5*(=:0Y$K)J.)"Z7R=2-G=*I$&=&M!E1P>N';P6&) 7A8*E#9?1(=C?<*Q
MUJNE ?)#*=)L5IOLTA4:8256: $/BVGLY"V6NT0XW[[ JQ436Z?F49JYQO,9
MRE.-LYZM]FSM?6'+;.RHOH3ESH#M@56)^92*-$JK4QC1,?(;^-GLBNLOPFP_
M(-H2<_L[T%E?0^Y]N=4*%+.DO[E2\>*-P(H/XA.AFOO>+I55='.5%KFJ=7<E
M7[1>+H>/^2U@)=BL+PT.YDGW>#CAT\0!X_%Q<V__YQ-;0N,JV-NE,O?763R?
M&:!5MQ86-/=W'J80+7+T34:D&K)0M85"TSDZJ2AJW6MWWK"^K1B[C+!X&V'N
M)@1M=_65-@R=5WS.,,O5F<6A=3LBAJ5WI&X+_DJ-$ 1;4OEHL8Z.C;0:VP(Y
M+$^$3XL0FRXPM.0B:VLAXBY"G06I!<1PA1 ^!O%+;4&2 4^3?;(P)Y,DM6N4
MA]DYQ(U2+*.]@_5Q2Y5&\)C1TL,+R[&RR<YP/3)TKH;>@BE;P9!50/,89!9I
M):"W!8BNL#0G)K&+#FER9IF'!\9$AN-4)RF/R.[FC0YAMK,*F:4ORAG.P[P]
M48E5D#"?=$2)4B9I" RA] ]#F03+I*]@T-!Q\,+4MTD;]+P3&!CXU9RNQ;8R
M$]F#P"($9]I>J4X0H?"CTS[F7T2!OSS?5/7IP@L(*KQ=]."8GVJB8Z97PQ"
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MR^_O=_H[BZ+ M77M;Q3<#QGL+R.._@=02P,$%     @ 2H9W5J@([74+"0
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M>;AMHOS=W6CY:[?CK(9:^WKI821HNOQZ%:+;[I'<5HH6+QB%LL5(I1?9Q#8
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M071UAAJ&$BZ@--,,79>, *38<(;]\&AK/8E* 04"K)G?0]W+H&(W+CBGWG"
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M>8XS=$&$H(RA4T'C!4'HN.\>])W^\9%EC4>@:E*MX5F ?-N#;\?SD3,(O(/
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M.".%=7G/R!J=1%+->([C/4JH/32T":$R1Y"_2BJ(SLZ0PU#"!:1FFJ'KDA&
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M]X@?)6$VKC;IYE8?XNC]0G HH@_>NS1>*K4GJFNCBA15=:WJL],*"_/BJO6
MHC6T>4N6XP6QS 43)Y*( -]Q*-<F# :#OG>PR=UFS-$OULS;-_TZ;_P/4$L!
M A0#%     @ 2H9W5E9F/Z $$P  G<,  !$              ( !     '1E
M;&$M,C R,C$R,S$N>'-D4$L! A0#%     @ 2H9W5K7*/GVA$   ..T  !4
M             ( !,Q,  '1E;&$M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( $J&=U8]335$E"H  $Q] @ 5              "  0<D  !T96QA+3(P
M,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !*AG=6P= 2,D%X   ]W < %0
M            @ '.3@  =&5L82TR,#(R,3(S,5]L86(N>&UL4$L! A0#%
M  @ 2H9W5B3$=\:-2P  ='0% !4              ( !0L<  '1E;&$M,C R
M,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( $J&=U9W ")'Q\ # "BJ(  5
M          "  0(3 0!T96QA+3(P,C(Q,C,Q>#$P:RYH=&U02P$"% ,4
M" !*AG=68)[!"X M 0#6-P$ &               @ '\TP0 =&5L82TR,#(R
M,3(S,7@Q,&LP,#$N:G!G4$L! A0#%     @ 2H9W5E3#+E:7RP  >-4  !@
M             ( !L@$& '1E;&$M,C R,C$R,S%X,3!K,# R+FIP9U!+ 0(4
M Q0    ( $J&=U;<2!<!4@<   D(   8              "  7_-!@!T96QA
M+3(P,C(Q,C,Q>#$P:S P,RYJ<&=02P$"% ,4    " !*AG=6/6Q!<AL'  "\
M!P  &               @ $'U08 =&5L82TR,#(R,3(S,7@Q,&LP,#0N:G!G
M4$L! A0#%     @ 2H9W5KIC:9>?"P  /PP  !@              ( !6-P&
M '1E;&$M,C R,C$R,S%X,3!K,# V+FIP9U!+ 0(4 Q0    ( $J&=U;T4C>.
MW[8  />Z   8              "  2WH!@!T96QA+3(P,C(Q,C,Q>#$P:S P
M."YJ<&=02P$"% ,4    " !*AG=6*KKF[+L4  "-D0  &0
M@ %"GP< =&5L82TR,#(R,3(S,7AE>#$P9#$S+FAT;5!+ 0(4 Q0    ( $J&
M=U:&K *Y\ D  !<X   9              "  32T!P!T96QA+3(P,C(Q,C,Q
M>&5X,3!D,34N:'1M4$L! A0#%     @ 2H9W5OQ?4#[0%   M(P  !D
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M,2YH=&U02P$"% ,4    " !*AG=6[:^#^AD)  #M,0  &
M@ $5_ < =&5L82TR,#(R,3(S,7AE>#,Q9#$N:'1M4$L! A0#%     @ 2H9W
M5J@([74+"0  XC$  !@              ( !9 4( '1E;&$M,C R,C$R,S%X
M97@S,60R+FAT;5!+ 0(4 Q0    ( $J&=U;ET+$VK@4  - ;   8
M      "  :4." !T96QA+3(P,C(Q,C,Q>&5X,S)D,2YH=&U02P$"% ,4
M" !*AG=67/L%(] %  "B'   &               @ &)% @ =&5L82TR,#(R
E,3(S,7AE>#,R9#(N:'1M4$L%!@     7 !< .08  (\:"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
